| (51) International Patent Classification $^6$ : | (11) International Publication Number: | **WO 99/32644** |
|---|---|---|
| C12N 15/85, 9/10, C07K 16/30, 16/40, C12Q 1/68, A01K 67/027 **A2** | (43) International Publication Date: | 1 July 1999 (01.07.99) |

(21) International Application Number: PCT/IB98/02133

(22) International Filing Date: 22 December 1998 (22.12.98)

(30) Priority Data:
08/996,306    22 December 1997 (22.12.97)    US
60/099,658    9 September 1998 (09.09.98)    US

(71) Applicant (for all designated States except US): GENSET [FR/FR]; 24, rue Royale, F–75008 Paris (FR).

(72) Inventors; and
(75) Inventors/Applicants (for US only): COHEN, Daniel [FR/FR]; 5, avenue Odette, F–94210 Fontenay–sous–Bois (FR). BLUMENFELD, Marta [FR/FR]; 5, rue Tagore, F–75013 Paris (FR). CHUMAKOV, Ilya [FR/FR]; 196, rue des Chèvrefeuilles, F–77000–Vaux–le–Pénil (FR). BOUGUEL-ERET, Lydie [FR/FR]; 108, avenue Victor–Hugo, F–92170 Vanves (FR).

(74) Agents: MARTIN, Jean–Jacques et al.; Cabinet Regimbeau, 26, avenue Kléber, F–75116 Paris (FR).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(54) Title: PROSTATE CANCER GENE

(57) Abstract

The present invention relates to PG1, a gene associated with prostate cancer. The invention provides polynucleotides including biallelic markers derived from PG1 and from flanking genomic regions. Primers hybridizing to these biallelic markers and regions flanking are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and prostate cancer and between a haplotype and prostate cancer. The invention also relates to diagnostic methods of determining whether an individual is at risk for developing prostate cancer, and whether an individual suffers from prostate concer as a result of a mutation in the PG1 gene.

# PROSTATE CANCER GENE

## Background of the Invention

5        A cancer is a clonal proliferation of cells produced as a consequence of cumulative genetic damage that finally results in unrestrained cell growth, tissue invasion and metastasis (cell transformation). Regardless of the type of cancer, transformed cells carry damaged DNA in many forms: as gross chromosomal translocations or, more subtly, as DNA amplification, rearrangement or even point mutations.

10        Some oncogenic mutations is inherited in the germline, thus predisposing the mutation carrier to an increased risk of cancer. However, in a majority of cases, cancer does not occur as a simple monogenic disease with clear Mendelian inheritance. There is only a two- or threefold increased risk of cancer among first-degree relatives for many cancers (Mulvihill JJ, Miller RW & Fraumeni JF, 1977, Genetics of human cancer Vol 3, New York Raven Press). Alternatively, DNA damage is 15   acquired somatically, probably induced by exposure to environmental carcinogens. Somatic mutations are generally responsible for the vast majority of cancer cases.

       Studies of the age dependence of cancer have suggested that several successive mutations are needed to convert a normal cell into an invasive carcinoma. Since human mutation rates are typically $10^{-6}$/gene/cell, the chance of a single cell undergoing many independent mutations is very low (Loeb 20   LA, Cancer Res 1991, 51: 3075-3079). Cancer nevertheless happens because of a combination of two mechanisms. Some mutations enhance cell proliferation, increasing the target population of cells for the next mutation. Other mutations affect the stability of the entire genome, increasing the overall mutation rate, as in the case of mismatch repair proteins (reviewed in Arnheim N & Shibata D, Curr. Op. Genetics & Development, 1997, 7:364-370).

25        An intricate process known as the cell cycle drives normal proliferation of cells in an organism. Regulation of the extent of cell cycle activity and the orderly execution of sequential steps within the cycle ensure the normal development and homeostasis of the organism. Conversely, many of the properties of cancer cells - uncontrolled proliferation, increased mutation rate, abnormal translocations and gene amplifications - can be attributed directly to perturbations of the normal 30   regulation or progression of the cycle. In fact, many of the genes that have been identified over the past several decades as being involved in cancer, can now be appreciated in terms of their direct or indirect role in either regulating entry into the cell cycle or coordinating events within the cell cycle.

       Recent studies have identified three groups of genes which are frequently mutated in cancer. The first group of genes, called oncogenes, are genes whose products activate cell proliferation. The 35   normal non-mutant versions are called protooncogenes. The mutated forms are excessively or inappropriately active in promoting cell proliferation, and act in the cell in a dominant way in that a

single mutant allele is enough to affect the cell phenotype. Activated oncogenes are rarely transmitted as germline mutations since they may probably be lethal when expressed in all the cells. Therefore oncogenes can only be investigated in tumor tissues.

5      Oncogenes and protooncogenes can be classified into several different categories according to their function.   This classification includes genes that code for proteins involved in signal transduction such as: growth factors (i.e., sis, int-2); receptor and non-receptor protein-tyrosine kinases (i.e., erbB, src, bcr-abl, met, trk); membrane-associated G proteins (i.e., ras); cytoplasmic protein kinases (i.e., mitogen-activated protein kinase –MAPK- family, raf, mos, pak), or nuclear transcription factors (i.e., myc, myb, fos, jun, rel) (for review see Hunter T, 1991 Cell 64:249; Fanger

10    GR et al., 1997 Curr.Op.Genet.Dev.7:67-74; Weiss FU et al., ibid. 80-86).

The second group of genes which are frequently mutated in cancer, called tumor suppressor genes, are genes whose products inhibit cell growth. Mutant versions in cancer cells have lost their normal function, and act in the cell in a recessive way in that both copies of the gene must be inactivated in order to change the cell phenotype. Most importantly, the tumor phenotype can be

15    rescued by the wild type allele, as shown by cell fusion experiments first described by Harris and colleagues (Harris H et al.,1969,Nature 223:363-368). Germline mutations of tumor suppressor genes is transmitted and thus studied in both constitutional and tumor DNA from familial or sporadic cases. The current family of tumor suppressors includes DNA-binding transcription factors (i.e., p53, WT1), transcription regulators (i.e., RB, APC, probably BRCA1), protein kinase inhibitors (i.e., p16), among

20    others (for review, see Haber D & Harlow E, 1997, Nature Genet. 16:320-322).

The third group of genes which are frequently mutated in cancer, called mutator genes, are responsible for maintaining genome integrity and/or low mutation rates. Loss of function of both alleles increase cell mutation rates, and as consequence, proto-oncogenes and tumor suppressor genes is mutated. Mutator genes can also be classified as tumor suppressor genes, except for the fact that

25    tumorigenesis caused by this class of genes cannot be suppressed simply by restoration of a wild-type allele, as described above.   Genes whose inactivation may lead to a mutator phenotype include mismatch repair genes (i.e., MLH1, MSH2), DNA helicases (i.e., BLM, WRN) or other genes involved in DNA repair and genomic stability (i.e., p53, possibly BRCA1 and BRCA2) (For review see Haber D & Harlow E, 1997, Nature Genet. 16:320-322; Fishel R & Wilson T. 1997,

30    Curr.Op.Genet.Dev.7: 105-113; Ellis NA,1997 ibid.354-363).

The recent development of sophisticated techniques for genetic mapping has resulted in an ever expanding list of genes associated with particular types of human cancers. The human haploid genome contains an estimated 80,000 to 100,000 genes scattered on a $3 \times 10^9$ base-long double-stranded DNA. Each human being is diploid. i.e., possesses two haploid genomes, one from paternal

35    origin, the other from maternal origin. The sequence of a given genetic locus may vary between individuals in a population or between the two copies of the locus on the chromosomes of a single

individual. Genetic mapping techniques often exploit these differences, which are called polymorphisms, to map the location of genes associated with human phenotypes.

One mapping technique, called the loss of heterozygosity (LOH) technique, is often employed to detect genes in which a loss of function results in a cancer, such as the tumor suppressor genes

5 described above. Tumor suppressor genes often produce cancer via a two hit mechanism in which a first mutation, such as a point mutation (or a small deletion or insertion) inactivates one allele of the tumor suppressor gene. Often, this first mutation is inherited from generation to generation.

A second mutation, often a spontaneous somatic mutation such as a deletion which deletes all or part of the chromosome carrying the other copy of the tumor suppressor gene, results in a cell in

10 which both copies of the tumor suppressor gene are inactive.

As a consequence of the deletion in the tumor suppressor gene, one allele is lost for any genetic marker located close to the tumor suppressor gene. Thus, if the patient is heterozygous for a marker, the tumor tissue loses heterozygosity, becoming homozygous or hemizygous. This loss of heterozygosity generally provides strong evidence for the existence of a tumor suppressor gene in the

15 lost region.

By genotyping pairs of blood and tumor samples from affected individuals with a set of highly polymorphic genetic markers, such as microsatellites, covering the whole genome, one can discover candidate locations for tumor suppressor genes. Due to the presence of contaminant non-tumor tissue in most pathological tumor samples, a decreased relative intensity rather than total loss of

20 heterozygosity of informative microsatellites is observed in the tumor samples. Therefore, classic LOH analysis generally requires quantitative PCR analysis, often limiting the power of detection of this technique. Another limitation of LOH studies resides on the fact that they only allow the definition of rather large candidate regions, typically spanning over several megabases. Refinement of such candidate regions requires the definition of the minimally overlapping portion of LOH regions

25 identified in tumor tissues from several hundreds of affected patients.

Another approach to genetic mapping, called linkage analysis, is based upon establishing a correlation between the transmission of genetic markers and that of a specific trait throughout generations within a family. In this approach, all members of a series of affected families are genotyped with a few hundred markers, typically microsatellite markers, which are distributed at

30 an average density of one every 10 Mb. By comparing genotypes in all family members, one can attribute sets of alleles to parental haploid genomes (haplotyping or phase determination). The origin of recombined fragments is then determined in the offspring of all families. Those that co-segregate with the trait are tracked. After pooling data from all families, statistical methods are used to determine the likelihood that the marker and the trait are segregating independently in all families. As

35 a result of the statistical analysis, one or several regions are selected as candidates, based on their high probability to carry a trait causing allele. The result of linkage analysis is considered as significant

when the chance of independent segregation is lower than 1 in 1000 (expressed as a LOD score > 3). Identification of recombinant individuals using additional markers allows further delineation of the candidate linked region, which most usually ranges from 2 to 20 Mb.

Linkage analysis studies have generally relied on the use of microsatellite markers (also called simple tandem repeat polymorphisms, or simple sequence length polymorphisms). These include small arrays of tandem repeats of simple sequences (di- tri- tetra- nucleotide repeats), which exhibit a high degree of length polymorphism, and thus a high level of informativeness. To date, only just more than 5,000 microsatellites have been ordered along the human genome (Dib et al., Nature 1996, 380: 152), thus limiting the maximum attainable resolution of linkage analysis to ca. 600 kb on average.

Linkage analysis has been successfully applied to map simple genetic traits that show clear Mendelian inheritance patterns. About 100 pathological trait-causing genes were discovered by linkage analysis over the last 10 years.

However, linkage analysis approaches have proven difficult for complex genetic traits, those probably due to the combined action of multiple genes and/or environmental factors. In such cases, too large an effort and cost are needed to recruit the adequate number of affected families required for applying linkage analysis to these situations, as recently discussed by Risch, N. and Merikangas, K. (Science 1996, 273: 1516-1517). Finally, linkage analysis cannot be applied to the study of traits for which no available large informative families are available. Typically, this will be the case in any attempt to identify trait-causing alleles involved in sporadic cases.

The incidence of prostate cancer has dramatically increased over the last decades. It averages 30-50/100,000 males both in Western European countries as well as within the US White male population. In these countries, it has recently become the most commonly diagnosed malignancy, being one of every four cancers diagnosed in American males. Prostate cancer's incidence is very much population specific, since it varies from 2/100,000 in China, to over 80/100,000 among African-American males.

In France, the incidence of prostate cancer is 35/100,000 males and it is increasing by 10/100,000 per decade. Mortality due to prostate cancer is also growing accordingly. It is the second cause of cancer death among French males, and the first one among French males aged over 70. This makes prostate cancer a serious burden in terms of public health, especially in view of the aging of populations.

An average 40% reduction in life expectancy affects males with prostate cancer. If completely localized, prostate cancer can be cured by surgery, with however an average success rate of only ca. 50%. If diagnosed after metastasis from the prostate, prostate cancer is a fatal disease for which there is no curative treatment.

Early-stage diagnosis relies on Prostate Specific Antigen (PSA) dosage, and would allow the

detection of prostate cancer seven years before clinical symptoms become apparent. The effectiveness of PSA dosage diagnosis is however limited, due to its inability to discriminate between malignant and non-malignant affections of the organ.

Therefore, there is a strong need for both a reliable diagnostic procedure which would enable

5   early-stage prostate cancer prognosis, and for preventive and curative treatments of the disease. The present invention relates to the PG1 gene, a gene associated with prostate cancer, as well as diagnostic methods and reagents for detecting alleles of the gene which may cause prostate cancer, and therapies for treating prostate cancer.

10      Summary of the Invention

The present invention relates to the identification of a gene associated with prostate cancer, identified as the PG1 gene, and reagents, diagnostics, and therapies related thereto. The present invention is also based on the discovery of a novel set of PG1-related biallelic markers. See the definition of PG1-related biallelic markers in the Detailed Description Section. These markers are

15   located in the coding regions as well as non-coding regions adjacent to the PG1 gene. The position of these markers and knowledge of the surrounding sequence has been used to design polynucleotide compositions which are useful in determining the identity of nucleotides at the marker position, as well as more complex association and haplotyping studies which are useful in determining the genetic basis for diseases including cancer and prostate cancer. In addition, the compositions and methods of

20   the invention find use in the identification of the targets for the development of pharmaceutical agents and diagnostic methods, as well as the characterization of the differential efficacious responses to and side effects from pharmaceutical agents acting on diseases including cancer and prostate cancer.

A first embodiment of the invention is a recombinant, purified or isolated polynucleotide comprising, or consisting of a mammalian genomic sequence, gene, or fragments thereof. In one

25   aspect the sequence is derived from a human, mouse or other mammal. In a preferred aspect, the genomic sequence is the human genomic sequence of SEQ ID NO: 179 or the complement thereto. In a second preferred aspect, the genomic sequence is selected from one of the two mouse genomic fragments of SEQ ID NO: 182 and 183. In yet another aspect of this embodiment, the nucleic acid comprises nucleotides 1629 through 1870 of the sequence of SEQ ID NO: 179. Optionally, said

30   polynucleotide consists of, consists essentially of, or comprises a contiguous span of nucleotides of a mammalian genomic sequence, preferably a sequence selected the following SEQ ID NOs: 179, 182, and 183, wherein said contiguous span is at least 6, 8, 10, 12, 15, 20, 25, 30, 50, 100, 200, or 500 nucleotides in length.

A second embodiment of the present invention is a recombinant, purified or isolated

35   polynucleotide comprising, or consisting of a mammalian cDNA sequence, or fragments thereof. In one aspect the sequence is derived from a human, mouse or other mammal. In a preferred aspect, the

cDNA sequence is selected from the human cDNA sequences of SEQ ID NO: 3, 69, 112-124 or the complement thereto. In a second preferred aspect, the cDNA sequence is the mouse cDNA sequence of SEQ ID NO: 184. Optionally, said polynucleotide consists of, consists essentially of, or comprises a contiguous span of nucleotides of a mammalian genomic sequence, preferably a sequence selected the following SEQ ID NOs: 3, 69, 112-124 and 184, wherein said contiguous span is at least 6, 8, 10, 12, 15, 20, 25, 30, 50, 100, 200, or 500 nucleotides in length.

A third embodiment of the present invention is a recombinant, purified or isolated polynucleotide, or the complement thereof, encoding a mammalian PG1 protein, or a fragment thereof. In one aspect the PG1 protein sequence is from a human, mouse or other mammal. In a preferred aspect, the PG1 protein sequence is selected from the human PG1 protein sequences of SEQ ID NO: 4, 5, 70, and 125-136. In a second preferred aspect, the PG1 protein sequence is the mouse PG1 protein sequences of SEQ ID NO: 74. Optionally, said fragment of PG1 polypeptide consists of, consists essentially of, or comprises a contiguous stretch of at least 8, 10, 12, 15, 20, 25, 30, 50, 100 or 200 amino acids from SEQ ID NOs: 4, 5, 70, 74, and 125-136, as well as any other human, mouse or mammalian PG1 polypeptide.

A fourth embodiment of the invention are the polynucleotide primers and probes disclosed herein

A fifth embodiment of the present invention is a recombinant, purified or isolated polypeptide comprising or consisting of a mammalian PG1 protein, or a fragment thereof. In one aspect the PG1 protein sequence is from a human, mouse or other mammal. In a preferred aspect, the PG1 protein sequence is selected from the human PG1 protein sequences of SEQ ID NO: 4, 5, 70, and 125-136. In a second preferred aspect, the PG1 protein sequence is the mouse PG1 protein sequences of SEQ ID NO: 74. Optionally, said fragment of PG1 polypeptide consists of, consists essentially of, or comprises a contiguous stretch of at least 8, 10, 12, 15, 20, 25, 30, 50, 100 or 200 amino acids from SEQ ID NOs: 4, 5, 70, 74, and 125-136, as well as any other human, mouse or mammalian PG1 polypeptide.

A sixth embodiment of the present invention is an antibody composition capable of specifically binding to a polypeptide of the invention. Optionally, said antibody is polyclonal or monoclonal. Optionally, said polypeptide is an epitope-containing fragment of at least 8, 10, 12, 15, 20, 25, or 30 amino acids of a human, mouse, or mammalian PG1 protein, preferably a sequence selected from SEQ ID NOs: 4, 5, 70, 74, or 125-136.

A seventh embodiment of the present invention is a vector comprising any polynucleotide of the invention. Optionally, said vector is an expression vector, gene therapy vector, amplification vector, gene targeting vector, or knock-out vector.

An eighth embodiment of the present invention is a host cell comprising any vector of the invention.

A ninth embodiment of the present invention is a mammalian host cell comprising a PG1 gene disrupted by homologous recombination with a knock out vector.

A tenth embodiment of the present invention is a nonhuman host mammal or animal comprising a vector of the invention.

A further embodiment of the present invention is a nonhuman host mammal comprising a PG1 gene disrupted by homologous recombination with a knock out vector.

Another embodiment of the present invention is a method of determining whether an individual is at risk of developing cancer or prostate cancer at a later date or whether the individual suffers from cancer or prostate cancer as a result of a mutation in the PG1 gene comprising obtaining a nucleic acid sample from the individual; and determining whether the nucleotides present at one or more of the PG1-related biallelic markers of the invention are indicative of a risk of developing prostate cancer at a later date or indicative of prostate cancer resulting from a mutation in the PG1 gene. Optionally, said PG1-related biallelic is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622, 4-77, 4-71, 4-73, 99-598, 99-576, and 4-66.

Another embodiment of the present invention is a method of determining whether an individual is at risk of developing prostate cancer at a later date or whether the individual suffers from prostate cancer as a result of a mutation in the PG1 gene comprising obtaining a nucleic acid sample from the individual and determining whether the nucleotides present at one or more of the polymorphic bases in a PG1-related biallelic marker. Optionally, said PG1-related biallelic is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622, 4-77, 4-71, 4-73, 99-598, 99-576 , and 4-66.

Another embodiment of the present invention is a method of obtaining an allele of the PG1 gene which is associated with a detectable phenotype comprising obtaining a nucleic acid sample from an individual expressing the detectable phenotype, contacting the nucleic acid sample with an agent capable of specifically detecting a nucleic acid encoding the PG1 protein, and isolating the nucleic acid encoding the PG1 protein. In one aspect of this method, the contacting step comprises contacting the nucleic acid sample with at least one nucleic acid probe capable of specifically hybridizing to said nucleic acid encoding the PG1 protein. In another aspect of this embodiment, the contacting step comprises contacting the nucleic acid sample with an antibody capable of specifically

8

binding to the PG1 protein. In another aspect of this embodiment, the step of obtaining a nucleic acid sample from an individual expressing a detectable phenotype comprises obtaining a nucleic acid sample from an individual suffering from prostate cancer.

Another embodiment of the present invention is a method of obtaining an allele of the PG1
5   gene which is associated with a detectable phenotype comprising obtaining a nucleic acid sample from an individual expressing the detectable phenotype, contacting the nucleic acid sample with an agent capable of specifically detecting a sequence within the 8p23 region of the human genome, identifying a nucleic acid encoding the PG1 protein in the nucleic acid sample, and isolating the nucleic acid encoding the PG1 protein. In one aspect of this embodiment, the nucleic acid sample is
10  obtained from an individual suffering from cancer or prostate cancer.

Another embodiment of the present invention is a method of categorizing the risk of prostate cancer in an individual comprising the step of assaying a sample taken from the individual to determine whether the individual carries an allelic variant of PG1 associated with an increased risk of prostate cancer. In one aspect of this embodiment, the sample is a nucleic acid sample. In another
15  aspect a nucleic acid sample is assayed by determining the frequency of the PG1 transcripts present. In another aspect of this embodiment, the sample is a protein sample. In another aspect of this embodiment, the method further comprises determining whether the PG1 protein in the sample binds an antibody specific for a PG1 isoform associated with prostate cancer.

Another embodiment of the present invention is a method of categorizing the risk of prostate
20  cancer in an individual comprising the step of determining whether the identities of the polymorphic bases of one or more biallelic markers which are in linkage disequilibrium with the PG1 gene are indicative of an increased risk of prostate cancer.

Another embodiment of the present invention comprises a method of identifying molecules which specifically bind to a PG1 protein, preferably the protein of SEQ ID NO:4 or a portion thereof:
25  comprising the steps of introducing a nucleic a nucleic acid encoding the protein of SEQ ID NO:4 or a portion thereof into a cell such that the protein of SEQ ID NO:4 or a portion thereof contacts proteins expressed in the cell and identifying those proteins expressed in the cell which specifically interact with the protein of SEQ ID NO:4 or a portion thereof.

Another embodiment of the present invention is a method of identifying molecules which
30  specifically bind to the protein of SEQ ID NO: 4 or a portion thereof. One step of the method comprises linking a first nucleic acid encoding the protein of SEQ ID NO:4 or a portion thereof to a first indicator nucleic acid encoding a first indicator polypeptide to generate a first chimeric nucleic acid encoding a first fusion protein. The first fusion protein comprises the protein of SEQ ID NO:4 or a portion thereof and the first indicator polypeptide. Another step of the method comprises linking a
35  second nucleic acid nucleic acid encoding a test polypeptide to a second indicator nucleic acid encoding a second indicator polypeptide to generate a second chimeric nucleic acid encoding a second

fusion protein. The second fusion protein comprises the test polypeptide and the second indicator polypeptide. Association between the first indicator protein and the second indicator protein produces a detectable result. Another step of the method comprises introducing the first chimeric nucleic acid and the second chimeric nucleic acid into a cell. Another step comprises detecting the detectable

5   result.

A further embodiment of the invention is a purified or isolated mammalian PG1 gene or cDNA sequence.

Further embodiments of the present invention include the nucleic acid and amino acid sequences of mutant or low frequency PG1 alleles derived from prostate cancer patients, tissues or

10  cell lines. The present invention also encompasses methods which utilize detection of these mutant PG1 sequences in an individual or tissue sample to diagnosis prostate cancer, assess the risk of developing prostate cancer or assess the likely severity of a particular prostate tumor.

Another embodiment of the invention encompasses any polynucleotide of the invention attached to a solid support. In addition, the polynucleotides of the invention which are attached to a

15  solid support encompass polynucleotides with any further limitation described in this disclosure, or those following: Optionally, said polynucleotides is specified as attached individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the inventions to a single solid support. Optionally, polynucleotides other than those of the invention may attached to the same solid support as polynucleotides of the invention. Optionally, when multiple polynucleotides are attached to a solid

20  support they are attached at random locations, or in an ordered array. Optionally, said ordered array is addressable.

An additional embodiment of the invention encompasses the use of any polynucleotide for, or any polynucleotide for use in, determining the identity of an allele at a PG1-related biallelic marker. In addition, the polynucleotides of the invention for use in determining the identity of an allele at a

25  PG1-related biallelic marker encompass polynucleotides with any further limitation described in this disclosure, or those following: Optionally, said PG1-related biallelic marker is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-

30  61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622, 4-77, 4-71, 4-73, 99-598, 99-576, and 4-66. Optionally, said polynucleotide may comprise a sequence disclosed in the present specification. Optionally, said polynucleotide may consist of, or consist essentially of any polynucleotide described in the present specification. Optionally, said determining is performed in a hybridization assay, sequencing assay,

35  microsequencing assay, or allele-specific amplification assay. Optionally, said polynucleotide is attached to a solid support, array, or addressable array. Optionally, said polynucleotide is labeled.

Another embodiment of the invention encompasses the use of any polynucleotide for, or any polynucleotide for use in, amplifying a segment of nucleotides comprising an PG1-related biallelic marker. In addition, the polynucleotides of the invention for use in amplifying a segment of nucleotides comprising a PG1-related biallelic marker encompass polynucleotides with any further

5    limitation described in this disclosure, or those following: Optionally, said PG1-related biallelic marker is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic

10   marker selected from the group consisting of 99-622 , 4-77 , 4-71 , 4-73 , 99-598 , 99-576 , and 4-66. Optionally, said polynucleotide may comprise a sequence disclosed in the present specification. Optionally, said polynucleotide may consist of, or consist essentially of any polynucleotide described in the present specification. Optionally, said amplifying is performed by a PCR or LCR. Optionally, said polynucleotide is attached to a solid support, array, or addressable array. Optionally, said

15   polynucleotide is labeled.

A further embodiment of the invention encompasses methods of genotyping a biological sample comprising determining the identity of an allele at an PG1-related biallelic marker. In addition, the genotyping methods of the invention encompass methods with any further limitation described in this disclosure, or those following: Optionally, said PG1-related biallelic marker is a PG1-related

20   biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622 , 4-77 , 4-71 , 4-73 , 99-598 , 99-576 , and 4-66. Optionally, said method further

25   comprises determining the identity of a second allele at said biallelic marker, wherein said first allele and second allele are not base paired (by Watson & Crick base pairing) to one another. Optionally, said biological sample is derived from a single individual or subject. Optionally, said method is performed in vitro. Optionally, said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome. Optionally, said biological sample is derived from

30   multiple subjects or individuals. Optionally, said method further comprises amplifying a portion of said sequence comprising the biallelic marker prior to said determining step. Optionally, wherein said amplifying is performed by PCR, LCR, or replication of a recombinant vector comprising an origin of replication and said portion in a host cell. Optionally, wherein said determining is performed by a hybridization assay, sequencing assay, microsequencing assay, or allele-specific amplification assay.

35       An additional embodiment of the invention comprises methods of estimating the frequency of an allele in a population comprising determining the proportional representation of an allele at a PG1-

related biallelic marker in said population. In addition, the methods of estimating the frequency of an allele in a population of the invention encompass methods with any further limitation described in this disclosure, or those following: Optionally, said PG1-related biallelic marker is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group

5    consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622 , 4-77 , 4-71 , 4-73 , 99-598 , 99-576 , and 4-66. Optionally, determining the proportional representation of an allele at a PG1-related biallelic marker is accomplished by determining the

10   identity of the alleles for both copies of said biallelic marker present in the genome of each individual in said population and calculating the proportional representation of said allele at said PG1-related biallelic marker for the population. Optionally, determining the proportional representation is accomplished by performing a genotyping method of the invention on a pooled biological sample derived from a representative number of individuals, or each individual, in said population, and

15   calculating the proportional amount of said nucleotide compared with the total.

A further embodiment of the invention comprises methods of detecting an association between a genotype and a phenotype, comprising the steps of a) genotyping at least one PG1-related biallelic marker in a trait positive population according to a genotyping method of the invention; b) genotyping said PG1-related biallelic marker in a control population according to a genotyping

20   method of the invention; and c) determining whether a statistically significant association exists between said genotype and said phenotype. In addition, the methods of detecting an association between a genotype and a phenotype of the invention encompass methods with any further limitation described in this disclosure, or those following: Optionally, said PG1-related biallelic marker is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected

25   from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622 , 4-77 , 4-71 , 4-73 , 99-598 , 99-576 , and 4-66. Optionally, said control population is a trait negative population, or a random population. Optionally, each of said

30   genotyping steps a) and b) is performed on a single pooled biological sample derived from each of said populations. Optionally, each of said genotyping of steps a) and b) is performed separately on biological samples derived from each individual in said population or a subsample thereof. Optionally, said phenotype is a disease, cancer or prostate cancer; a response to an anti-cancer agent or an anti-prostate cancer agent; or a side effect to an anti-cancer or anti-prostate cancer agent.

35   Optionally, said method comprises the additional steps of determining the phenotype in said trait positive and said control populations prior to step c).

An additional embodiment of the present invention encompasses methods of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising the steps of: a) genotyping at least one PG1-related biallelic marker for both copies of said set of biallelic marker present in the genome of each individual in said population or a subsample thereof, according to a 5 genotyping method of the invention; b) genotyping a second biallelic marker by determining the identity of the allele at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population or said subsample, according to a genotyping method of the invention; and c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency. In 10 addition, the methods of estimating the frequency of a haplotype of the invention encompass methods with any further limitation described in this disclosure, or those following: Optionally, said PG1-related biallelic marker is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250. 99-609/225, 4-90/283, 99-602/258, 99-15 600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622, 4-77 , 4-71 , 4-73 , 99-598 , 99-576 , and 4-66. Optionally, said second biallelic marker is a PG1-related biallelic marker; a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-20 73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622, 4-77 , 4-71 , 4-73 , 99-598 , 99-576 , and 4-66. Optionally, said PG1-related biallelic marker and said second biallelic marker are 4-77/151 and 4-66/145. Optionally, said haplotype determination method is an expectation-maximization algorithm.

25     An additional embodiment of the present invention encompasses methods of detecting an association between a haplotype and a phenotype, comprising the steps of:  a) estimating the frequency of at least one haplotype in a trait positive population, according to a method of the invention for estimating the frequency of a haplotype; b) estimating the frequency of said haplotype in a control population, according to a method of the invention for estimating the frequency of a 30 haplotype; and c) determining whether a statistically significant association exists between said haplotype and said phenotype. In addition, the methods of detecting an association between a haplotype and a phenotype of the invention encompass methods with any further limitation described in this disclosure, or those following: Optionally, said PG1-related biallelic is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group 35 consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-

61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622, 4-77 , 4-71 , 4-73 , 99-598 , 99-576 , and 4-66. Optionally, said PG1-related biallelic marker and said second biallelic marker are 4-77/151 and 4-66/145. Optionally, said haplotype exhibits a p-value of $< 1\text{x } 10^{-3}$ in an association with a trait positive population with cancer, preferably prostate

5    cancer. Optionally, said control population is a trait negative population, or a random population. Optionally, said phenotype is a disease, cancer or prostate cancer; a response to an anti-cancer agent or an anti-prostate cancer agent, or a side effects to an anti-cancer or anti-prostate cancer agent. Optionally, said method comprises the additional steps of determining the phenotype in said trait positive and said control populations prior to step c).

10    Additional embodiments and aspects of the present invention are set forth in the Detailed Description of the Invention and the Examples.


Brief Description of the Drawings

Figure 1 is a diagram showing the BAC contig containing the PG1 gene and the positions of

15    biallelic markers along the contig.

Figure 2 is a graph showing the results of the first screening of a prostate cancer association study and the significance of various biallelic markers as measured by their chi squared and p-values for a low density set of markers.

Figure 3 is a graph showing the results of the first screening of a prostate cancer association

20    study and the significance of various biallelic markers as measured by their chi squared and p-values for a higher density set of markers.

Figure 4 is a table demonstrating the results of an haplotype analysis. Among all the theoretical potential different haplotypes based on 2 to 9 markers, 11 haplotypes showing a strong association with prostate cancer were selected, and their haplotype analysis results are shown here.

25    Figure 5 is a bar graph demonstrating the results of an experiment evaluating the significance (p-values) of the haplotype analysis shown in Figure 4.

Figure 6A is a table listing the biallelic markers used in the haplotype analysis of Figure 4. Figure 6B is a table listing additional biallelic markers in linkage disequilibrium with the PG1 gene.

Figure 7 is a table listing the positions of exons, splice sites, a stop codon, and a poly A site in

30    the PG1 gene.

Figure 8A is a diagram showing the genomic structure of PG1 in comparison with its most abundant mRNA transcript. Figure 8B is a more detailed diagram showing the genomic structure of PG1, including exons and introns.

Figure 9 is a table listing some of the homologies between the PG1 protein and known

35    proteins.

Figure 10 is a half-tome reproduction of a fluorescence micrograph of the perinuclear/nuclear

expression of PG1 in tumoral (PC3) and normal prostatic cell lines (PNT2). Vector "PG1": includes all the coding exons from exon 1 to 8. For PC3 (upper panel) and PNT2 (lower panel), the nucleus was labelled with Propidium iodide (IP, left panel). Note that EGFP fluorescence was detected in and around the nucleus (GFP, middle panel), as shown when the two pictures were overlapped (right

5  panel).

Figure 11 is a half-tome reproduction of a fluorescence micrograph of the perinuclear/nuclear expression of PG1/1-4 in tumoral (PC3) and normal prostatic cell lines (PNT2). Vector "PG1/1-4" corresponds to an alternative messenger which is due to an alternative splicing, joining exon 1 to exon 4, and resulting in the absence of exons 2 and 3. For PC3 (upper panel) and PNT2 (lower panel),

10  the nucleus was labelled with Propidium iodide (IP, left panel). Note that EGFP fluorescence was detected in and around the nucleus (GFP, middle panel), as shown when the two pictures were overlapped (right panel).

Figure 12 is a half-tome reproduction of a fluorescence micrograph of the perinuclear/nuclear expression of PG1/1-5 in tumoral prostatic cell line (PC3) and cytoplasmic expression of PG1/1-5 in

15  normal prostatic cell line (PNT2). Vector "PG1/1-5" corresponds to an alternative messenger which is due to an alternative splicing, joining exon 1 to exon 5, and resulting in the absence of exons 2, 3 and 4. For PC3 (upper panel) and PNT2 (lower panels), the nucleus was labelled with Propidium iodide (IP). Note that in PC3 cells, EGFP fluorescence was detected in and around the nucleus (GFP, upper middle panel), as shown when the two picture were overlapped (upper right panel). In PNT2A cells,

20  EGFP fluorescence was detected in the cytoplasm (GFP, lower left panel), as shown when the two pictures were overlapped (lower right panel).

Figure 13 is a half-tome reproduction of a fluorescence micrograph of the perinuclear/nuclear expression of a mutated form PG1 (PG1mut229) in normal prostatic cell line (PNT2). Vector "PG1/1-7" includes exons 1 to 6, and corresponds to the mutated form identified in genomic DNA of

25  the prostatic tumoural cell line LNCaP. The nucleus was labelled with Propidium iodide (IP, left panel). EGFP fluorescence was detected in the cytoplasm (GFP, middle panel), as shown when the two pictures were overlapped (lower right panel).

Figure 14 is a diagram of the structure of the 14 alternative splice species found for human PG1 by the exons present. An * indicates that there is a stop codon in frame at that location. An

30  arrow to the right at the right-hand side of a splice species indicates that the open-reading frame continues off of the chart. a space between exons indicates that the exon(s) is missing from that particular alternative splice species. An up arrow indicates that either exon 1bis, 3bis, or 5bis has been inserted depending upon which is indicated. A bracket notation in exon 6, over an exon 6bis notation indicates that the first 60 bases is missing from exon 6, and exon 6bis is therefor present as a

35  truncated form of exon 6.

Figure 15 is a table listing the results of a series of RT-PCR experiments that were performed

on RNA of normal prostate, normal prostatic cell lines (PNT1A, PNT1B and PNT2), and tumoral prostatic cell lines (LnCaPFCG, LnCaPJMB, CaHPV, Du145, PC3, and prostate tumors (ECP5 to ECP24) using all the possible combinations of primers (SEQ ID NOs: 137-178) specific to all of the possible splice junctions or exon borders in human PG1. An NT indicates that the experiment was

5    not performed. An [+] indicates the use of an alternative splice species with exons 1, 3, 4, 7, and 8.

Figure 16 is a graph showing the results of association studies using markers spanning the 650 kb region of the 8p23 locus around PG1, using both single point analysis and haplotyping studies.

Figure 17 is a graph showing an enlarged view of the single point association results within a 160 kb region comprising the PG1 gene.

10         Figure 18A is a graph showing an enlarged view of the single point association results of 40 kb within the PG1 gene. Figure 18B is a table listing the location of markers within PG1 gene, the two possible alleles at each site. For each marker, the disease-associated allele is indicated first; its frequencies in cases and controls as well as the difference between both are shown; the odd-ratio and the p-value of each individual marker association are also shown.

15         Figure 19A is a table showing the results of a haplotype analysis study using 4 markers (marker Nos. 4-14, 99-217, 4-66 and 99-221) ) within the 160 kb region shown in Figure 17. Figure 19B is a table showing the segmented haplotyping results according to the subject's age, and whether the prostate cancer cases were sporadic or familial, using the same markers 4 markers and the same individuals as were used to generate the results in Figure 19A.

20         Figure 20 is a table listing the haplotyping results and odd ratios for combinations of the 7 markers (99-622 ; 4-77 ; 4-71 ; 4-73 ; 99-598 ; 99-576 ; 4-66) within PG1 gene that were shown in Figure 18 to have p-values more significant than $1.10^{-2}$. All of the 2-, 3-, 4-, 5-, 6- and 7-marker haplotypes were tested.

Figure 21 is a graph showing the distribution of statistical significance, as measured by Chi-

25    square values, for each series of possible x-marker haplotypes, (x =2, 3 or 4) using all of the 19 markers listed in Figure 18B.

Detailed Description of the Preferred Embodiment

The practice of the present invention encompasses conventional techniques of chemistry,

30    immunology, molecular biology, biochemistry, protein chemistry, and recombinant DNA technology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Oligonucleotide Synthesis (M. Gait ed. 1984); Nucleic Acid Hybridization (B. Hames & S. Higgins, eds., 1984); Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989); PCR Technology (H.A. Erlich ed., Stockton Press); R. Scope, Protein Purification

35    Principles and Practice (Springer-Verlag); and the series Methods in Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.).

<u>Definitions</u>

As used interchangeably herein, the terms "nucleic acid" "oligonucleotide", and "polynucleotides" include RNA, DNA, or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form. The term "nucleotide" as used herein as an adjective to

5 describe molecules comprising RNA, DNA, or RNA/DNA hybrid sequences of any length in single-stranded or duplex form. The term "nucleotide" is also used herein as a noun to refer to individual nucleotides or varieties of nucleotides, meaning a molecule, or individual unit in a larger nucleic acid molecule, comprising a purine or pyrimidine, a ribose or deoxyribose sugar moiety, and a phosphate group, or phosphodiester linkage in the case of nucleotides within an oligonucleotide or

10 polynucleotide. Although the term "nucleotide" is also used herein to encompass "modified nucleotides" which comprise at least one modifications (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar, for examples of analogous linking groups, purine, pyrimidines, and sugars see for example PCT publication No. WO 95/04064. However, the polynucleotides of the invention are preferably

15 comprised of greater than 50% conventional deoxyribose nucleotides, and most preferably greater than 90% conventional deoxyribose nucleotides. The polynucleotide sequences of the invention is prepared by any known method, including synthetic, recombinant, ex vivo generation, or a combination thereof, as well as utilizing any purification methods known in the art.

As used herein, the term "purified" does not require absolute purity; rather, it is intended as a

20 relative definition Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

The term "purified" is used herein to describe a polynucleotide or polynucleotide vector of the invention which has been separated from other compounds including, but not limited to other

25 nucleic acids, charbohydrates, lipids and proteins (such as the enzymes used in the synthesis of the polynucleotide), or the separation of covalently closed polynucleotides from linear polynucleotides. A polynucleotide is substantially pure when at least about 50 %, preferably 60 to 75% of a sample exhibits a single polynucleotide sequence and conformation (linear versus covalently close). A substantially pure polynucleotide typically comprises about 50 %, preferably 60 to 90%

30 weight/weight of a nucleic acid sample, more usually about 95%, and preferably is over about 99% pure. Polynucleotide purity or homogeneity is indicated by a number of means well known in the art, such as agarose or polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polynucleotide band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.

35 The term "polypeptide" refers to a polymer of amino without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide.

This term also does not specify or exclude prost-expression modifications of polypeptides, for example, polypeptides which include the covalent attachment of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like are expressly encompassed by the term polypeptide. Also included within the definition are polypeptides which contain one or more analogs of an amino acid

5    (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

As used herein, the term "isolated" requires that the material be removed from its original

10   environment (e.g., the natural environment if it is naturally occurring).

The term "purified" is used herein to describe a polypeptide of the invention which has been separated from other compounds including, but not limited to nucleic acids, lipids, charbohydates and other proteins. A polypeptide is substantially pure when at least about 50 %, preferably 60 to 75% of a sample exhibits a single polypeptide sequence. A substantially pure polypeptide typically comprises

15   about 50 %, preferably 60 to 90% weight/weight of a protein sample, more usually about 95%, and preferably is over about 99% pure. Polypeptide purity or homogeneity is indicated by a number of means well known in the art, such as agarose or polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polypeptide band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.

20   As used herein, the term "non-human animal" refers to any non-human vertebrate, birds and more usually mammals, preferably primates, farm animals such as swine, goats, sheep, donkeys, and horses, rabbits or rodents, more preferably rats or mice. As used herein, the term "animal" is used to refer to any vertebrate, preferable a mammal. Both the terms "animal" and "mammal" expressly embrace human subjects unless preceded with the term "non-human".

25   As used herein, the term "antibody" refers to a polypeptide or group of polypeptides which are comprised of at least one binding domain, where an antibody binding domain is formed from the folding of variable domains of an antibody molecule to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an antigenic determinant of an antigen., which allows an immunological reaction with the antigen. Antibodies

30   include recombinant proteins comprising the binding domains, as wells as fragments, including Fab, Fab', F(ab)$_2$, and F(ab')$_2$ fragments.

As used herein, an "antigenic determinant" is the portion of an antigen molecule, in this case an PG1 polypeptide, that determines the specificity of the antigen-antibody reaction. An "epitope" refers to an antigenic determinant of a polypeptide. An epitope can comprise as few as 3 amino acids

35   in a spatial conformation which is unique to the epitope. Generally an epitope consists of at least 6 such amino acids, and more usually at least 8-10 such amino acids. Methods for determining the

amino acids which make up an epitope include x-ray crystallography, 2-dimensional nuclear magnetic resonance, and epitope mapping e.g. the Pepscan method described by H. Mario Geysen et al. 1984. Proc. Natl. Acad. Sci. U.S.A. 81:3998-4002; PCT Publication No. WO 84/03564; and PCT Publication No. WO 84/03506.

5        The term "DNA construct" and "vector" are used herein to mean a purified or isolated polynucleotide that has been artificially designed and which comprises at least two nucleotide sequences that are not found as contiguous nucleotide sequences in their natural environment.

The terms "trait" and "phenotype" are used interchangeably herein and refer to any visible, detectable or otherwise measurable property of an organism such as symptoms of, or susceptibility to

10    a disease for example. Typically the terms "trait" or "phenotype" are used herein to refer to symptoms of, or susceptibility to cancer or prostate cancer; or to refer to an individual's response to an anti-cancer agent or an anti-prostate cancer agent; or to refer to symptoms of, or susceptibility to side effects to an anticancer agent or an anti-prostate cancer agent.

The term "allele" is used herein to refer to variants of a nucleotide sequence. A biallelic

15    polymorphism has two forms. Typically the first identified allele is designated as the original allele whereas other alleles are designated as alternative alleles. Diploid organisms is homozygous or heterozygous for an allelic form.

The term "heterozygosity rate" is used herein to refer to the incidence of individuals in a population, which are heterozygous at a particular allele. In a biallelic system the heterozygosity rate

20    is on average equal to $2P_a(1-P_a)$, where $P_a$ is the frequency of the least common allele. In order to be useful in genetic studies a genetic marker should have an adequate level of heterozygosity to allow a reasonable probability that a randomly selected person will be heterozygous.

The term "genotype" as used herein refers the identity of the alleles present in an individual or a sample. In the context of the present invention a genotype preferably refers to the description of the

25    biallelic marker alleles present in an individual or a sample. The term "genotyping" a sample or an individual for a biallelic marker consists of determining the specific allele or the specific nucleotide carried by an individual at a biallelic marker.

The term "mutation" as used herein refers to a difference in DNA sequence between or among different genomes or individuals which has a frequency below 1%.

30    The term "haplotype" refers to a combination of alleles present in an individual or a sample. In the context of the present invention a haplotype preferably refers to a combination of biallelic marker alleles found in a given individual and which is associated with a phenotype.

The term "polymorphism" as used herein refers to the occurrence of two or more alternative genomic sequences or alleles between or among different genomes or individuals. "Polymorphic"

35    refers to the condition in which two or m .. variants of a specific genomic sequence can be found in a population. A "polymorphic site" is the locus at which the variation occurs. A single nucleotide

polymorphism is a single base pair change. Typically a single nucleotide polymorphism is the replacement of one nucleotide by another nucleotide at the polymorphic site. Deletion of a single nucleotide or insertion of a single nucleotide, also give rise to single nucleotide polymorphisms. In the context of the present invention "single nucleotide polymorphism" preferably refers to a single

5   nucleotide substitution. Typically, between different genomes or between different individuals, the polymorphic site is occupied by two different nucleotides.

The terms "biallelic polymorphism" and "biallelic marker" are used interchangeably herein to refer to a nucleotide polymorphism having two alleles at a fairly high frequency in the population. A "biallelic marker allele" refers to the nucleotide variants present at a biallelic marker site. Usually a

10  biallelic marker is a single nucleotide polymorphism. However, less commonly there are also insertions and deletions of up to 5 nucleotides which constitute biallelic markers for the purposes of the present invention. Typically the frequency of the less common allele of the biallelic markers of the present invention has been validated to be greater than 1%, preferably the frequency is greater than 10%, more preferably the frequency is at least 20% (i.e. heterozygosity rate of at least 0.32),

15  even more preferably the frequency is at least 30% (i.e. heterozygosity rate of at least 0.42). A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a "high quality biallelic marker."

The location of nucleotides in a polynucleotide with respect to the center of the polynucleotide are described herein in the following manner. When a polynucleotide has an odd

20  number of nucleotides, the nucleotide at an equal distance from the 3' and 5' ends of the polynucleotide is considered to be "at the center" of the polynucleotide, and any nucleotide immediately adjacent to the nucleotide at the center, or the nucleotide at the center itself is considered to be "within 1 nucleotide of the center." With an odd number of nucleotides in a polynucleotide any of the five nucleotides positions in the middle of the polynucleotide would be considered to be within

25  2 nucleotides of the center, and so on. When a polynucleotide has an even number of nucleotides, there would be a bond and not a nucleotide at the center of the polynucleotide. Thus, either of the two central nucleotides would be considered to be "within 1 nucleotide of the center" and any of the four nucleotides in the middle of the polynucleotide would be considered to be "within 2 nucleotides of the center", and so on.

30  The term "upstream" is used herein to refer to a location which is toward the 5' end of the polynucleotide from a specific reference point.

The terms "base paired" and "Watson & Crick base paired" are used interchangeably herein to refer to nucleotides which can be hydrogen bonded to one another be virtue of their sequence identities in a manner like that found in double-helical DNA with thymine or uracil residues linked to

35  adenine residues by two hydrogen bonds and cytosine and guanine residues linked by three hydrogen bonds (See Stryer, L., *Biochemistry*, 4th edition, 1995).

The terms "complementary" or "complement thereof" are used herein to refer to the sequences of polynucleotides which is capable of forming Watson & Crick base pairing with another specified polynucleotide throughout the entirety of the complementary region. This term is applied to pairs of polynucleotides based solely upon their sequences and not any particular set of conditions

5   under which the two polynucleotides would actually bind.

As used herein the term "PG1-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with PG1. The term PG1-related biallelic marker includes all of the biallelic markers used in the initial association studies shown below in Section I.D., including those biallelic markers contained in SEQ ID NOs: 21-38 and 57-62. The term PG1-related biallelic marker

10  encompasses all of the following polymorphisms positioned in SEQ ID 179, and listed by internal reference number, including: 5-63-169 G or C in position 2159;

5-63-453 C or T in position 2443; 99-622-95 T or C in position 4452;

99-621-215 T or C in position 5733; 99-619-141 G or A in position 8438;

4-76-222 deletion of GT in position 11843; 4-76-361 C or T in position 11983;

15  4-77-151 G or C in position 12080; 4-77-294 A or G in position 12221;

4-71-33 G or T in position 12947; 4-71-233 A or G in position 13147;

4-71-280 G or A in position 13194; 4-71-396 G or C in position 13310;

4-72-127 A or G in position 13342; 4-72-152 A or G in position 13367;

4-72-380 deletion of A in position 13594; 4-73-134 G or C in position 13680;

20  4-73-356 G or C in position 13902; 99-610-250 T or C in position 16231;

99-610-93 A or T in position 16388; 99-609-225 A or T in position 17608;

4-90-27 A or C in position 18034; 4-90-283 A or C in position 18290;

99-607-397 T or C in position 18786; 99-602-295 deletion of A in position 22835;

99-602-258 T or C in position 22872;

25  99-600-492 deletion of TATTG in position 25183;

99-600-483 T or G in position 25192; 5-23-288 A or G in position 25614;

99-598-130 T or C in position 26911; 99-592-139 A or T in position 32703;

99-217-277 C or T in position 34491; 5-47-284 A or G in position 34756;

99-589-267 T or G in position 34934; 99-589-41 G or C in position 35160;

30  99-12899-307 C or T in position 39897; 4-12-68 A or G in position 40598;

99-582-263 T or C in position 40816; 99-582-132 T or C in position 40947;

99-576-421 G or C in position 45783; 4-13-51 C or T in position 47929;

4-13-328 A or T in position 48206; 4-13-329 G or C in position 48207;

99-12903-381 C or T in position 49282; 5-56-208 A or G in position 50037;

35  5-56-225 A or G in position 50054; 5-56-272 A or G in position 50101;

5-56-391 G or T in position 50220; 4-61-269 A or G in position 50440;

4-61-391 A or G in position 50562; 4-63-99 A or G in position 50653;

4-62-120 A or G in position 50660; 4-62-205 A or G in position 50745;

4-64-113 A or T in position 50885; 4-65-104 A or G in position 51249;

5-28-300 A or G in position 51333; 5-50-269 C or T in position 51435;

5 4-65-324 C or T in position 51468; 5-71-129 G or C in position 51515;

5-50-391 G or C in position 51557; 5-71-180 A or G in position 51566;

4-67-40 C or T in position 51632; 5-71-280 A or C in position 51666;

5-58-167 A or G in position 52016; 5-30-325 C or T in position 52096;

5-58-302 A or T in position 52151; 5-31-178 A or G in position 52282;

10 5-31-244 A or G in position 52348; 5-31-306 deletion of A in position 52410;

5-32-190 C or T in position 52524; 5-32-246 C or T in position 52580;

5-32-378 deletion of A in position 52712; 5-53-266 G or C in position 52772;

5-60-158 C or T in position 52860; 5-60-390 A or G in position 53092;

5-68-272 G or C in position 53272; 5-68-385 A or T in position 53389;

15 5-66-53 deletion of GA in position 53511; 5-66-142 G or C in position 53600;

5-66-207 A or G in position 53665; 5-37-294 A or G in position 53815;

5-62-163 insertion of A in position 54365; 5-62-340 A or T in position 54541; and the compliments

thereof. The term PG1-related biallelic marker also includes all of the following biallelic markers

listed by internal reference number, and two SEQ ID NOs each of which contains a 47-mers with one

20 of the two alternative bases at position 24:

4-14-107 of SEQ ID NOs 185 and 262; 4-14-317 of SEQ ID NOs 186 and 263;          4-14-35 of

SEQ ID NOs 187 and 264; 4-20-149 of SEQ ID NOs 188 and 265;

4-20-77 of SEQ ID NOs 189and 266; 4-22-174 of SEQ ID NOs 190 and 267;

4-22-176 of SEQ ID NOs 191 and 268; 4-26-60 of SEQ ID NOs 192 and 269;

25 4-26-72 of SEQ ID NOs 193 and 270; 4-3-130 of SEQ ID NOs 194 and 271;

4-38-63 of SEQ ID NOs 195 and 272;

4-38-83 of SEQ ID NOs 196 and 273; 4-4-152 of SEQ ID NOs 197 and 274;

4-4-187 of SEQ ID NOs 198 and 275; 4-4-288 of SEQ ID NOs 199 and 276;

4-42-304 of SEQ ID NOs 200 and 277; 4-42-401 of SEQ ID NOs 201 and 278;

30 4-43-328 of SEQ ID NOs 202 and 279; 4-43-70 of SEQ ID NOs 203 and 280;

4-50-209 of SEQ ID NOs 204 and 281; 4-50-293 of SEQ ID NOs 205 and 282;

4-50-323 of SEQ ID NOs 206 and 283; 4-50-329 of SEQ ID NOs 207 and 284;

4-50-330 of SEQ ID NOs 208 and 285; 4-52-163 of SEQ ID NOs 209 and 286;

4-52-88 of SEQ ID NOs 210 and 287; 4-53-258 of SEQ ID NOs 211 and 288;

35 4-54-283 of SEQ ID NOs 212 and 289; 4-54-388 of SEQ ID NOs 213 and 290;

4-55-70 of SEQ ID NOs 214 and 291; 4-55-95 of SEQ ID NOs 215 and 292;

4-56-159 of SEQ ID NOs 216 and 293; 4-56-213 of SEQ ID NOs 217 and 294;

4-58-289 of SEQ ID NOs 218 and 295; 4-58-318 of SEQ ID NOs 219 and 296;

4-60-266 of SEQ ID NOs 220 and 297; 4-60-293 of SEQ ID NOs 221 and 298;

4-84-241 of SEQ ID NOs 222 and 299; 4-84-262 of SEQ ID NOs 223 and 300;

5   4-86-206 of SEQ ID NOs 224 and 301; 4-86-309 of SEQ ID NOs 225 and 302;

4-88-349 of SEQ ID NOs 226 and 303; 4-89-87 of SEQ ID NOs 227 and 304;

99-123-184 of SEQ ID NOs 228 and 305; 99-128-202 of SEQ ID NOs 229 and 306;

99-128-275 of SEQ ID NOs 230 and 307; 99-128-313 of SEQ ID NOs 231 and 308;      99-128-60 of

SEQ ID NOs 232 and 309; 99-12907-295 of SEQ ID NOs 233 and 310; 99-130-58 of SEQ ID NOs

10   234 and 311; 99-134-362 of SEQ ID NOs 235 and 312;

99-140-130 of SEQ ID NOs 236 and 313; 99-1462-238 of SEQ ID NOs 237 and 314; 99-147-181 of

SEQ ID NOs 238 and 315; 99-1474-156 of SEQ ID NOs 239 and 316;      99-1474-359 of SEQ ID

NOs 240 and 317; 99-1479-158 of SEQ ID NOs 241 and 318; 99-1479-379 of SEQ ID NOs 242 and

319; 99-148-129 of SEQ ID NOs 243 and 320; 99-148-132 of SEQ ID NOs 244 and 321; 99-148-139

15   of SEQ ID NOs 245 and 322;

99-148-140 of SEQ ID NOs 246 and 323; 99-148-182 of SEQ ID NOs 247 and 324;

99-148-366 of SEQ ID NOs 248 and 325; 99-148-76 of SEQ ID NOs 249 and 326;

99-1480-290 of SEQ ID NOs 250 and 327; 99-1481-285 of SEQ ID NOs 251 and 328; 99-1484-101 of

SEQ ID NOs 252 and 329; 99-1484-328 of SEQ ID NOs 253 and 330; 99-1485-251 of SEQ ID NOs

20   254 and 331; 99-1490-381 of SEQ ID NOs 255 and 332;      99-1493-280 of SEQ ID NOs 256 and

333; 99-151-94 of SEQ ID NOs 257 and 334;

99-211-291 of SEQ ID NOs 258 and 335; 99-213-37 of SEQ ID NOs 259 and 336;

99-221-442 of SEQ ID NOs 260 and 337; 99-222-109 of SEQ ID NOs 261 and 338; and the

compliments thereof.

25      The term "non-genic" is used herein to describe PG1-related biallelic markers, as well as

polynucleotides and primers which do not occur in the human PG1 genomic sequence of SEQ ID NO:

179.   The term "genic" is used herein to describe PG1-related biallelic markers as well as

polynucleotides and primers which do occur in the human PG1 genomic sequence of SEQ ID NO:

179.

30      The terms "an anti-cancer agent" refers to a drug or a compound that is capable of reducing

the growth rate, rate of metastasis, or viability of tumor cells in a mammal, is capable of reducing the

size or eliminating tumors in a mammal, or is capable of increasing the average life span of a mammal

or human with cancer. Anti-cancer agents also include compounds which are able to reduce the risk

of cancer developing in a population, particularly a high risk population. The terms "an anti-prostate

35   cancer agent" is an anti-cancer agent that has these effects on cells or tumors that are derived from

prostate cancer cells.

The terms "response to an anti-cancer agent" and "response to an anti- prostate cancer agent" refer to drug efficacy, including but not limited to ability to metabolize a compound, to the ability to convert a pro-drug to an active drug, and to the pharmacokinetics (absorption, distribution, elimination) and the pharmacodynamics (receptor-related) of a drug in an individual.

5        The terms "side effects to an anti-cancer agent" and "side effects to an anti-prostate cancer agent" refer to adverse effects of therapy resulting from extensions of the principal pharmacological action of the drug or to idiosyncratic adverse reactions resulting from an interaction of the drug with unique host factors. These side effects include, but are not limited to, adverse reactions such as dermatological, hematological or hepatological toxicities and further includes gastric and intestinal

10   ulceration, disturbance in platelet function, renal injury, nephritis, vasomotor rhinitis with profuse watery secretions, angioneurotic edema, generalized urticaria, and bronchial asthma to laryngeal edema and bronchoconstriction, hypotension, sexual dysfunction, and shock.

As used herein the term "homology" refers to comparisons between protein and/or nucleic acid sequences and is evaluated using any of the variety of sequence comparison algorithms and

15   programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85(8):2444-2448; Altschul et al., 1990, J. Mol. Biol. 215(3):403-410; Thompson et al., 1994, Nucleic Acids Res. 22(2):4673-4680; Higgins et al., 1996, Methods Enzymol. 266:383-402; Altschul et al., 1990, J. Mol. Biol. 215(3):403-410; Altschul et al., 1993, Nature Genetics 3:266-272).

20   In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST") which is well known in the art (see, e.g., Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268; Altschul et al., 1990, J. Mol. Biol. 215:403-410; Altschul et al., 1993, Nature Genetics 3:266-272; Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402). In particular, five specific BLAST programs are used to perform the following

25   task:

(1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;

(2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;

30                  (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database;

(4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and

(5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

The BLAST programs identify homologous sequences by identifying similar segments, which are

5 referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992, Science 256:1443-1445; Henikoff and Henikoff, 1993, Proteins 17:49-61). Less

10 preferably, the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation). The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified threshold of significance, such as a user-specified percent

15 homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (see, e.g., Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268).

## I. ISOLATION AND CHARACTERIZATION OF THE PG1 GENE AND PROTEINS

### I.A. The 8p23 Region- LOH Studies: Implications of 8p23 Region in Distinct Cancer Types

20 Substantial amounts of LOH data support the hypothesis that genes associated with distinct cancer types are located within 8p23 region of the human genome. Emi et al., demonstrated the implication of 8p23.1-8p21.3 region in cases of hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer. (Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, Maeda Y, Tsuruta K, Miyaki M, Nakamura Y, Cancer Res. 1992 Oct 1; 52(19): 5368-5372) Yaremko, et al.,

25 showed the existence of two major regions of LOH for chromosome 8 markers in a sample of 87 colorectal carcinomas. The most prominent loss was found for 8p23.1-pter, where 45% of informative cases demonstrated loss of alleles. (Yaremko ML, Wasylyshyn ML, Paulus KL, Michelassi F, Westbrook CA, Genes Chromosomes Cancer 1994 May;10(1):1-6). Scholnick et al. demonstrated the existence of three distinct regions of LOH for the markers of chromosome 8 in cases

30 of squamous cell carcinoma of the supraglottic larynx. They showed that the allelic loss of 8p23 marker D8S264 serves as a statistically significant, independent predictor of poor prognosis for patients with supraglottic squamous cell carcinoma. (Scholnick SB, Haughey BH, Sunwoo JB, el-Mofty SK, Baty JD, Piccirillo JF, Zequeira MR, J. Natl. Cancer Inst. 1996 Nov 20; 88(22): 1676-1682 and Sunwoo JB, Holt MS, Radford DM, Deeker C, Scholnick S, Genes Chromosomes Cancer 1996

35 Jul; 16(3):164-169).

In other studies, Nagai et al. demonstrated the highest loss of heterozygosity in the specific region of 8p23 by genome wide scanning of LOH in 120 cases of hepatocellular carcinoma (HCC). (Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A, Oncogene 1997 Jun 19; 14(24): 2927-2933). Gronwald et al. demonstrated 8p23-pter loss in renal clear cell carcinomas. (Gronwald J, Storkel S,

5    Holtgreve-Grez H, Hadaczek P, Brinkschmidt C, Jauch A, Lubinski J, Cremer, Cancer Res. 1997 Feb 1; 57(3): 481-487).

The same region is involved in specific cases of prostate cancer. Matsuyama et al. showed the specific deletion of the 8p23 band in prostate cancer cases, as monitored by FISH with D8S7 probe. (Matsuyama H, Pan Y, Skoog L, Tribukait B, Naito K, Ekman P, Lichter P, Bergerheim US

10   Oncogene 1994 Oct; 9(10): 3071-3076). They were able to document a substantial number of cases with deletions of 8p23 but retention of the 8p22 marker LPL. Moreover, Ichikawa et al. deduced the existence of a prostate cancer metastasis suppressor gene and localized it to 8p23-q12 by studies of metastasis suppression in highly metastatic rat prostate cells after transfer of human chromosomes. (Ichikawa T. Nihei N, Kuramochi H, Kawana Y, Killary AM, Rinker-Schaeffer CW, Barrett JC,

15   Isaacs JT, Kugoh H, Oshimura M, Shimazaki J, Prostate Suppl. 1996; 6: 31-35).

Recently Washbum et al. were able to find substantial numbers of tumors with the allelic loss specific to 8p23 by LOH studies of 31 cases of human prostate cancer. (Washbum J, Woino K, and Macoska J, Proceedings of American Association for Cancer Research, March 1997; 38). In these samples they were able to define the minimal overlapping region with deletions covering genetic

20   interval D8S262-D8S277.

### Linkage Analysis Studies: Search for Prostate Cancer

### Linked Regions on Chromosome 8

Microsatellite markers mapping to chromosome 8 were used by the inventors to perform linkage analysis studies on 194 individuals issued from 47 families affected with prostate cancer.

25   While multiple point analysis led to weak linkage results, two point lod score analysis led to non significant results, as shown below.

*Two point lod (parametric analysis)*

| MARKER | Distance (cM) | Z(lod) scores |
|--------|---------------|---------------|
| D8S1742 |              | -0.13 |
| D8S561 | 0.8 | -0.07 |

| | |
|---|---|
| # of families analyzed | 47 |
| Total # of individuals genotyped | 194 |
| Total # of affected individuals genotyped | 122 |

In view of the non-significant results obtained with linkage analysis, a new mapping approach based on linkage disequilibrium of biallelic markers was utilised to identify genes responsible for sporadic cases of prostate cancer.

## I.B. Linkage Disequilibrium Using Biallelic Markers To Identify Candidate Loci Responsible For Disease

### Linkage Disequilibrium

Once a chromosomal region has been identified as potentially harboring a candidate gene associated with a sporadic trait, an excellent approach to refine the candidate gene's location within the identified region is to look for statistical associations between the trait and some marker genotype when comparing an affected (trait $^{+}$) and a control (trait $^{-}$) population.

Association studies have most usually relied on the use of biallelic markers. Biallelic markers are genome-derived polynucleotides that exhibit biallelic polymorphism at one single base position. By definition, the lowest allele frequency of a biallelic polymorphism is 1%; sequence variants that show allele frequencies below 1% are called rare mutations. There are potentially more than $10^{7}$ biallelic markers lying along the human genome.

Association studies seek to establish correlations between traits and genetic markers and are based on the phenomenon of linkage disequilibrium (LD). LD is defined as the trend for alleles at nearby loci on haploid genomes to correlate in the population. If two genetic loci lie on the same chromosome, then sets of alleles on the same chromosomal segment (i.e., haplotypes) tend to be transmitted as a block from generation to generation. When not broken up by recombination, haplotypes can be tracked not only through pedigrees but also through populations. The resulting phenomenon at the population level is that the occurrence of pairs of specific alleles at different loci on the same chromosome is not random, and the deviation from random is called linkage disequilibrium.

Since results generated by association studies are essentially based on the quantitative calculation of allele frequencies, they best apply to the analysis of germline mutations. This is mainly due to the fact that allelic frequencies are difficult to quantify within tumor tissue samples because of the usual presence of normal cells within the studied tumor samples. Association studies applied to cancer genetics will therefore be best suited to the identification of tumor suppressor genes.

### Trait Localization by Linkage Disequilibrium Mapping

Any gene responsible or partly responsible for a given trait will be in LD with some flanking markers. To map such a gene, specific alleles of these flanking markers which are associated with the gene or genes responsible for the trait are identified. Although the following discussion of techniques for finding the gene or genes associated with a particular trait using linkage disequilibrium mapping, refers to locating a single gene which is responsible for the trait, it will be appreciated that the same techniques may also be used to identify genes which are partially responsible for the trait.

Association studies is conducted within the general population (as opposed to the linkage analysis techniques discussed above which are limited to studies performed on related individuals in one or several affected families).

Association between a biallelic marker A and a trait T may primarily occur as a result of three

5    possible relationships between the biallelic marker and the trait. First, allele *a* of biallelic marker A is directly responsible for trait T (e.g., Apo E e4 allele and Alzheimer's disease). However, since the majority of the biallelic markers used in genetic mapping studies are selected randomly, they mainly map outside of genes. Thus, the likelihood of allele *a* being a functional mutation directly related to trait T is therefore very low.

10    An association between a biallelic marker A and a trait T may also occur when the biallelic marker is very closely linked to the trait locus. In other words, an association occurs when allele *a* is in linkage disequilibrium with the trait-causing allele. When the biallelic marker is in close proximity to a gene responsible for the trait, more extensive genetic mapping will ultimately allow a gene to be discovered near the marker locus which carries mutations in people with trait T (i.e. the gene

15    responsible for the trait or one of the genes responsible for the trait). As will be further exemplified below using a group of biallelic markers which are in close proximity to the gene responsible for the trait, the location of the causal gene can be deduced from the profile of the association curve between the biallelic markers and the trait. The causal gene will be found in the vicinity of the marker showing the highest association with the trait.

20    Finally, an association between a biallelic marker and a trait may occur when people with the trait and people without the trait correspond to genetically different subsets of the population who, coincidentally, also differ in the frequency of allele *a* (population stratification). This phenomenon is avoided by using large heterogeneous samples.

Association studies are particularly suited to the efficient identification of susceptibility genes

25    that present common polymorphisms, and are involved in multifactorial traits whose frequency is relatively higher than that of diseases with monofactorial inheritance.

<u>Application of Linkage Disequilibrium Mapping</u>

<u>to Candidate Gene Identification</u>

The general strategy of association studies using a set of biallelic markers, is to scan two

30    pools of individuals (affected individuals and unaffected controls) characterized by a well defined phenotype in order to measure the allele frequencies for a number of the chosen markers in each of these pools. If a positive association with a trait is identified using an array of biallelic markers having a high enough density, the causal gene will be physically located in the vicinity of the associated markers, since the markers showing positive association to the trait are in linkage

35    disequilibrium with the trait locus. Regions harboring a gene responsible for a particular trait which

are identified through association studies using high density sets of biallelic markers will, on average, be 20 - 40 times shorter in length than those identified by linkage analysis.

Once a positive association is confirmed as described above, BACs (bacterial artificial chromosomes) obtained from human genomic libraries, constructed as described below, harboring the
5   markers identified in the association analysis are completely sequenced.

Once a candidate region has been sequenced and analyzed, the functional sequences within the candidate region (exons and promoters, and other potential regulatory regions) are scanned for mutations which are responsible for the trait by comparing the sequences of a selected number of controls and affected individuals using appropriate software. Candidate mutations are further
10  confirmed by screening a larger number of affected individuals and controls using the microsequencing techniques described below.

Candidate mutations are identified as follows. A pair of oligonucleotide primers is designed in order to amplify the sequences of every predicted functional region. PCR amplification of each predicted functional sequence is carried out on genomic DNA samples from affected patients and
15  unaffected controls. Amplification products from genomic PCR are subjected to automated dideoxy terminator sequencing reactions and electrophoresed on ABI 377 sequencers. Following gel image analysis and DNA sequence extraction, the sequence data are automatically analyzed to detect the presence of sequence variations among affected cases and unaffected controls. Sequences are systematically verified by comparing the sequences of both DNA strands of each individual.

20  Polymorphisms are then verified by screening a larger population of affected individuals and controls using the microsequencing technique described below in an individual test format. Polymorphisms are considered as candidate mutations when present in affected individuals and controls at frequencies compatible with the expected association results.

Association Studies: Statistical Analysis and Haplotyping

25  As mentioned above, linkage analysis typically localizes a disease gene to a chromosomal region of several megabases. Further refinement in location requires the analysis of additional families in order to increase the number of recombinants. However, this approach becomes unfeasible because recombination is rarely observed even within large pedigrees (Boehnke, M, 1994, Am. J. Hum. Genet. 55: 379-390).

30  Linkage disequilibrium, the nonrandom association of alleles at linked loci, may offer an alternative method of obtaining additional recombinants. When a chromosome carrying a mutant allele of a gene responsible for a given trait is first introduced into a population as a result of either mutation or migration, the mutant allele necessarily resides on a chromosome having a unique set of linked markers (haplotype). Consequently, there is complete disequilibrium between these markers
35  and the disease mutation: the disease mutation is present only linked to a specific set of marker alleles. Through subsequent generations, recombinations occur between the disease mutation and

these marker polymorphisms, resulting in a gradual disappearance of disequilibrium. The degree of disequilibrium dissipation depends on the recombination frequency, so the markers closest to the disease gene will tend to show higher levels of disequilibrium than those that are farther away (Jorde LB, 1995, Am. J. Hum. Genet. 56: 11-14). Because linkage disequilibrium patterns in a present-day

5    population reflect the action of recombination through many past generations, disequilibrium analysis effectively increases the sample of recombinants. Thus the mapping resolution achieved through the analysis of linkage disequilibrium patterns is much higher than that of linkage analysis.

In practice, in order to define the regions bearing a candidate gene, the affected and control populations are genotyped using an appropriate number of biallelic markers (at a density of 1 marker

10   every 50-150 kilobases). Then, a marker/trait association study is performed that compares the genotype frequency of each biallelic marker in the affected and control populations by means of a chi square statistical test (one degree of freedom).

After the first screening, additional markers within the region showing positive association are genotyped in the affected and control populations. Two types of complementary analysis are then

15   performed. First, a marker/trait association study (as described above) is performed to refine the location of the gene responsible for the trait. In addition, a haplotype association analysis is performed to define the frequency and the type of the ancestral/preferential carrier haplotype. Haplotype analysis, by combining the informativeness of a set of biallelic markers increases the power of the association analysis, allowing false positive and/or negative data that may result from the

20   single marker studies to be eliminated.

The haplotype analysis is performed by estimating the frequencies of all possible haplotypes for a given set of biallelic markers in the case and control populations, and comparing these frequencies by means of a chi square statistical test (one degree of freedom). Haplotype estimations are performed by applying the Expectation-Maximization (EM) algorithm (Excoffier L & Slatkin M,

25   1995, Mol. Biol. Evol. 12: 921-927), using the EM-HAPLO program (Hawley ME, Pakstis AJ & Kidd KK, 1994, Am. J. Phys. Anthropol. 18: 104). The EM algorithm is used to estimate haplotype frequencies in the case when only genotype data from unrelated individuals are available. The EM algorithm is a generalized iterative maximum likelihood approach to estimation that is useful when data are ambiguous and/or incomplete.

30   The application of biallelic marker based linkage disequilibrium analysis to the 8p23 region to identify a gene associated with prostate dancer is described below.

**I.C. Application of Linkage Disequilibrium Mapping to the 8p23 Region**

### YAC Contig Construction in 8p23 Region

First, a YAC contig which contains the 8p23 region was constructed as follows. The CEPH-

35   Genethon YAC map for the entire human genome (Chumakov I.M. et al. A YAC contig map of the human genome, Nature, 377 Supp.: 175-297, 1995) was used for detailed contig building in the region

around D8S262 and D8S277 genetic markers. Screening data available for regional genetic markers D8S1706, D8S277, D8S1742, D8S518, D8S262, D8S1798, D8S1140, D8S561 and D8S1819 were used to select the following set of CEPH YACs, localized within this region: 832_g_12, 787_c_11, 920_h_7, 807_a_1, 842_b_1, 745_a_3, 910_d_3, 879_f_11, 918_c_6, 764_c_7, 910_f_12, 967_c_11,

5   856_d_8, 792_a_6, 812_h_4, 873_c_8, 930_a_2, 807_a_1, 852_d_10. This set of YACs was tested by PCR with the above mentioned genetic markers as well as with other publicly available markers supposedly located within the 8p23 region. As a result of these studies, a YAC STS contig map was generated around genetic markers D8S262 and D8S277. The two CEPH YACs, 920_h_7 (1170 kb insert size) and 910_f_12 (1480 kb insert size) constitute a minimal tiling path in this region, with an

10  estimated size of ca. 2 Megabases.

During this mapping effort, the following publicly known STS markers were precisely located within the contig: WI-14718, WI-3831, D8S1413E, WI-8327, WI-3823, ND4.

<u>BAC Contig Construction Covering D8S262-D8S277</u>

<u>Fragment Within 8p23 Region of the Human Genome</u>

15        Following construction of the YAC contig, a BAC contig was constructed as follows. BAC libraries were obtained as described in Woo et al. Nucleic Acids Res., 1994, 22, 4922-4931. Briefly, two different whole human genome libraries were produced by cloning BamHI or HindIII partially digested DNA from a lymphoblastoid cell line (derived from individual N°8445, CEPH families) into the pBeloBAC11 vector (Kim et al. Genomics, 1996, 34, 213-218). The library produced with the

20  BamHI partial digestion contained 110,000 clones with an average insert size of 150 kb, which corresponds to 5 human haploid genome equivalents. The library prepared with the HindIII partial digestion corresponds to 3 human genome equivalents with an average insert size of 150 kb.

<u>BAC Screening</u>

The human genomic BAC libraries obtained as described above were screened with all of the

25  above mentioned STSs. DNA from the clones in both libraries was isolated and pooled in a three dimensional format ready for PCR screening with the above mentioned STSs using high throughput PCR methods (Chumakov et al., Nature 1995, 377: 175-298). Briefly, three dimensional pooling consists in rearranging the samples to be tested in a manner which allows the number of PCR reactions required to screen the clones with STSs to be reduced by at least 100 fold, as compared to

30  screening each clone individually. PCR amplification products were detected by conventional agarose gel electrophoresis combined with automated image capturing and processing.

In a final step, STS-positive clones were checked individually. Subchromosomal localization of BACs was systematically verified by fluorescence in situ hybridization (FISH), performed on metaphasic chromosomes as described by Cherif et al. Proc. Natl. Acad. Sci. USA 1990, 87: 6639-

35  6643.

BAC insert size was determined by Pulsed Field Gel Electrophoresis after digestion with restriction enzyme NotI.

### BAC Contig Analysis

The ordered BACs selected by STS screening and verified by FISH, were assembled into

5   contigs and new markers were generated by partial sequencing of insert ends from some of them. These markers were used to fill the gaps in the contig of BAC clones covering the chromosomal region around D8S277, having an estimated size of 2 megabases. Selected BAC clones from the contig were subcloned and sequenced.

### BAC Subcloning

10   Each BAC human DNA was first extracted using the alkaline lysis procedure and then sheared by sonication. The obtained DNA fragments were end-repaired and electrophoresed on preparative agarose gels. The fragments in the desired size range were isolated from the gel, purified and ligated to a linearized, dephosphorylated, blunt-ended plasmid cloning vector (pBluescript II Sk (+)). Example 1 describes the BAC subcloning procedure.

15                                          ### Example 1

The cells obtained from three liters overnight culture of each BAC clone were treated by alkaline lysis using conventional techniques to obtain the BAC DNA containing the genomic DNA inserts. After centrifugation of the BAC DNA in a cesium chloride gradient, ca. 50μg of BAC DNA was purified. 5-10μg of BAC DNA was sonicated using three distinct conditions, to obtain fragments

20   of the desired size. The fragments were treated in a 50 μl volume with two units of Vent polymerase for 20 min at 70°C, in the presence of the four deoxytriphosphates (100μM). The resulting blunt-ended fragments were separated by electrophoresis on low-melting point 1% agarose gels (60 Volts for 3 hours). The fragments were excised from the gel and treated with agarase. After chloroform extraction and dialysis on Microcon 100 columns, DNA in solution was adjusted to a 100 ng/μl

25   concentration. A ligation was performed overnight by adding 100 ng of BAC fragmented DNA to 20 ng of pBluescript II Sk (+) vector DNA linearized by enzymatic digestion, and treated by alkaline phosphatase. The ligation reaction was performed in a 10 μl final volume in the presence of 40 units/μl T4 DNA ligase (Epicentre). The ligated products were electroporated into the appropriate cells (ElectroMAX E.coli DH10B cells). IPTG and X-gal were added to the cell mixture, which was

30   then spread on the surface of an ampicillin-containing agar plate. After overnight incubation at 37°C, recombinant (white) colonies were randomly picked and arrayed in 96 well microplates for storage and sequencing.

### Partial Sequencing of BACs

At least 30 of the obtained BAC clones were sequenced by the end pair-wise method (500 bp

35   sequence from each end) using a dye-primer cycle sequencing procedure. Pair-wise sequencing was performed until a map allowing the relative positioning of selected markers along the corresponding

DNA region was established. Example 2 describes the sequencing and ordering of the BAC inserts.

Example 2

The subclone inserts were amplified by PCR on overnight bacterial cultures, using vector primers flanking the insertions. The insert extremity sequences (on average 500 bases at each end)
5  were determined by fluorescent automated sequencing on ABI 377 sequencers, with a ABI Prism DNA Sequencing Analysis software (2.1.2 version).

The sequence fragments from BAC subclones were assembled using Gap4 software from R. Staden (Bonfield et al. 1995). This software allows the reconstruction of a single sequence from sequence fragments. The sequence deduced from the alignment of different fragments is called the
10  consensus sequence. We used directed sequencing techniques (primer walking) to complete sequences and link contigs.

Figure 1 shows the overlapping BAC subclones (labeled BAC) which make up the assembled contig and the positions of the publicly known STS markers along the contig.

Identification of Biallelic Markers Lying Along the BAC Contig

15  Following assembly of the BAC contig, biallelic markers lying along the contig were then identified. Given that the assessed distribution of informative biallelic markers in the human genome (biallelic polymorphisms with a heterozygosity rate higher than 42%) is one in 2.5 to 3 kb, six 500 bp genomic fragments have to be screened in order to identify 1 biallelic marker. Six pairs of primers per potential marker, each one defining a ca. 500 bp amplification fragment, were derived from the
20  above mentioned BAC partial sequences. All primers contained a common upstream oligonucleotide tail enabling the easy systematic sequencing of the resulting amplification fragments. Amplification of each BAC-derived sequence was carried out on pools of DNA from ca. 100 individuals. The conditions used for the polymerase chain reaction were optimized so as to obtain more than 95% of PCR products giving 500bp-sequence reads.

25  The amplification products from genomic PCR using the oligonucleotides derived from the BAC subclones were subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Following gel image analysis and DNA sequence extraction, sequence data were automatically processed with appropriate software to assess sequence quality and to detect the presence of biallelic sites among the pooled amplified fragments. Biallelic sites were
30  systematically verified by comparing the sequences of both strands of each pool.

The detection limit for the frequency of biallelic polymorphisms detected by sequencing pools of 100 individuals is 0.3 +/- 0.05 for the minor allele, as verified by sequencing pools of known allelic frequencies. Thus, the biallelic markers selected by this method will be "informative biallelic markers" since they have a frequency of 0.3 to 0.5 for the minor allele and 0.5 to 0.7 for the major
35  allele, therefore an average heterozygosity rate higher than 42%.

Example 3 describes the preparation of genomic DNA samples from the individuals screened

to identify biallelic markers.

## Example 3

The population used in order to generate biallelic markers in the region of interest consisted of ca. 100 unrelated individuals corresponding to a French heterogeneous population.

5      DNA was extracted from peripheral venous blood of each donor as follows.

30 ml of blood were taken in the presence of EDTA. Cells (pellet) were collected after centrifugation for 10 minutes at 2000 rpm. Red cells were lysed by a lysis solution (50 ml final volume : 10 mM Tris pH7.6; 5 mM MgCl₂; 10 mM NaCl). The solution was centrifuged (10 minutes, 2000 rpm) as many times as necessary to eliminate the residual red cells present in the supernatant,

10    after resuspension of the pellet in the lysis solution.

The pellet of white cells was lysed overnight at 42°C with 3.7 ml of lysis solution composed of:

- 3 ml TE 10-2 (Tris-HCl 10 mM, EDTA 2 mM) / NaCl 0.4 M

- 200 µl SDS 10%

15    - 500 µl K-proteinase (2 mg K-proteinase in TE 10-2 /   NaCl 0.4 M).

For the extraction of proteins, 1 ml saturated NaCl (6M) (1/3.5 v/v) was added. After vigorous agitation, the solution was centrifuged for 20 minutes at 10000 rpm.

For the precipitation of DNA, 2 to 3 volumes of 100% ethanol were added to the previous supernatant, and the solution was centrifuged for 30 minutes at 2000 rpm. The DNA solution was

20    rinsed three times with 70% ethanol to eliminate salts, and centrifuged for 20 minutes at 2000 rpm. The pellet was dried at 37°C, and resuspended in 1 ml TE 10-1 or 1 ml water. The DNA concentration was evaluated by measuring the OD at 260 nm (1 unit OD = 50 µg/ml DNA).

To determine the presence of proteins in the DNA solution, the OD 260 / OD 280 ratio was determined. Only DNA preparations having a OD 260 / OD 280 ratio between 1.8 and 2 were used in

25    the subsequent steps described below.

## DNA Amplification

Once each BAC was isolated, pairs of primers, each one defining a 500 bp-amplification fragment, were designed. Each of the primers contained a common oligonucleotide tail upstream of the specific bases targeted for amplification, allowing the amplification products from each set of

30    primers to be sequenced using the common sequence as a sequencing primer. The primers used for the genomic amplification of sequences derived from BACs were defined with the OSP software (Hillier L. and Green P. Methods Appl., 1991, 1: 124-8). The synthesis of primers was performed following the phosphoramidite method, on a GENSET UFPS 24.1 synthesizer.

Example 4 provides the procedures used in the amplification reactions.

35                              ## Example 4

The amplification of each sequence was performed by PCR (Polymerase Chain Reaction) as follows:

| | |
|---|---|
| - final volume | 50 µl |
| - genomic DNA | 100 ng |
| - MgCl₂ | 2 mM |
| - dNTP (each) | 200 µM |
| - primer (each) | 7.5 pmoles |
| - Ampli Taq Gold DNA polymerase (Perkin) | 1 unit |

- PCR buffer (10X=0.1 M Tris HCl pH 8.3, 0.5 M KCl)  1X.

The amplification was performed on a Perkin Elmer 9600 Thermocycler or MJ Research PTC200 with heating lid. After heating at 94°C for 10 minutes, 35 cycles were performed. Each cycle comprised: 30 sec at 94°C, 1 minute at 55°C, and 30 sec at 72°C. For final elongation, 7 minutes at 72°C ended the amplification.

The obtained quantity of amplification products was determined on 96-well microtiter plates, using a fluorimeter and Picogreen as intercalating agent (Molecular Probes).

The sequences of the amplification products were determined for each of the approximately 100 individuals from whom genomic DNA was obtained. Those amplification products which contained biallelic markers were identified.

Figure 1 shows the locations of the biallelic markers along the 8p23 BAC contig. This first set of markers corresponds to a medium density map of the candidate locus, with an inter-marker distance averaging 50kb-150kb.

A second set of biallelic markers was then generated as described above in order to provide a very high-density map of the region identified using the first set of markers which can be used to conduct association studies, as explained below. The high density map has markers spaced on average every 2-50kb.

The biallelic markers were then used in association studies as described below.

Collection of DNA samples from affected and non-affected individuals

Prostate cancer patients were recruited according to clinical inclusion criteria based on pathological or radical prostatectomy records. Control cases included in this study were both ethnically- and age-matched to the affected cases; they were checked for both the absence of all clinical and biological criteria defining the presence or the risk of prostate cancer, and for the absence of related familial prostate cancer cases. Both affected and control individuals corresponded to unrelated cases.

The two following pools of independent individuals were used in the association studies. The first pool, comprising individuals suffering from prostate cancer, contained 185 individuals. Of these

35

185 cases of prostate cancer, 45 cases were sporadic and 140 cases were familial. The second pool, the control pool, contained 104 non-diseased individuals.

Haplotype analysis was conducted using additional diseased (total samples: 281) and control samples (total samples: 130), from individuals recruited according to similar criteria.

5                              Genotyping Affected and Control Individuals

The general strategy to perform the association studies was to individually scan the DNA samples from all individuals in each of the two populations described above in order to establish the allele frequencies of the above described biallelic markers in each of these populations.

Allelic frequencies of the above-described biallelic markers in each population were 10 determined by performing microsequencing reactions on amplified fragments obtained by genomic PCR performed on the DNA samples from each individual.

DNA samples and amplification products from genomic PCR were obtained in similar conditions as those described above for the generation of biallelic markers, and subjected to automated microsequencing reactions using fluorescent ddNTPs (specific fluorescence for each 15 ddNTP) and the appropriate oligonucleotide microsequencing primers which hybridized just upstream of the polymorphic base. Once specifically extended at the 3' end by a DNA polymerase using the complementary fluorescent dideoxynucleotide analog (thermal cycling), the primer was precipitated to remove the unincorporated fluorescent ddNTPs. The reaction products were analyzed by electrophoresis on ABI 377 sequencing machines.

20        Example 5 describes one microsequencing procedure.

Example 5

5 µl of PCR products in a microtiter plate were added to 5 µl purification mix {2U SAP (Amersham) ; 2U Exonuclease I (Amersham) ; 1 µl SAP10X buffer : 400mM Tris-HCl pH8, 100 mM MgCl2 ; H2O final volume 5 µl}. The reaction mixture was incubated 30 minutes at 37°C, and 25 denatured 10 minutes at 94°C. After 10 sec centrifugation, the microsequencing reaction was performed on line with the whole purified reaction mixture (10 µl) in the microplate using 10 pmol microsequencing oligonucleotide (23mers, GENSET, crude synthesis, 5 OD), 0.5 U Thermosequenase (Amersham), 1.25 µl Thermosequenase 16X buffer (Amersham), both of the fluorescent ddNTPs (Perkin Elmer) corresponding to the polymorphism {0.025 µl ddTTP and ddCTP, 0.05 µl ddATP and 30 ddGTP}, H2O to a final volume of 20 µl. A PCR program on a GeneAmp 9600 thermocycler was carried out as follows: 4 minutes at 94°C ; 5 sec at 55°C / 10 sec at 94°C for 20 cycles. The reaction product was incubated at 4°C until precipitation. The microtiter plate was centrifuged 10 sec at 1500 rpm. 19 µl MgCl2 2mM and 55 µl 100 % ethanol were added in each well. After 15 minute incubation at room temperature, the microtiter plate was centrifuged at 3300 rpm 15 minutes at 4°C. 35 Supernatants were discarded by inverting the microtitre plate on a box folded to proper size and by centrifugation at 300 rpm 2 minutes at 4°C afterwards. The microplate was then dried 5 minutes in a

vacuum drier. The pellets were resuspended in 2.5 µl formamide EDTA loading buffer (0.7µl of 9 µg/µl dextran blue in 25 mM EDTA and 1.8 µl formamide). A 10% polyacrylamide gel / 12 cm / 64 wells was pre-run for 5 minutes on a 377 ABI 377 sequencer. After 5 minutes denaturation at 100°C, 0.8 µl of each microsequencing reaction product was loaded in each well of the gel. After migration

5    (2 h 30 for 2 microtiter plates of PCR products per gel), the fluorescent signals emitted by the incorporated ddNTPs were analyzed on the ABI 377 sequencer using the GENESCAN software (Perkin Elmer).Following gel analysis, data were automatically processed with a software that allowed the determination of the alleles of biallelic markers present in each amplified fragment.

## I.D. Initial Association Studies

10    Association studies were run in two successive steps. In a first step, a rough localization of the candidate gene was achieved by determining the frequencies of the biallelic markers of Figure 1 in the affected and unaffected populations. The results of this rough localization are shown in Figure 2. This analysis indicated that a gene responsible for prostate cancer was located near the biallelic marker designated 4-67.

15    In a second phase of the analysis, the position of the gene responsible for prostate cancer was further refined using the very high density set of markers described above. The results of this localization are shown in Figure 3.

As shown in Figure 3, the second phase of the analysis confirmed that the gene responsible for prostate cancer was near the biallelic marker designated 4-67, most probably within a ca. 150kb

20    region comprising the marker.

### Haplotype analysis

The allelic frequencies of each of the alleles of biallelic markers 99-123, 4-26, 4-14, 4-77, 99-217, 4-67, 99-213, 99-221, and 99-135 (SEQ ID NOs: 21-38) were determined in the affected and unaffected populations. Table 1 lists the internal identification numbers of the markers used in the

25    haplotype analysis (SEQ ID NOs: 21-38), the alleles of each marker, the most frequent allele in both unaffected individuals and individuals suffering from prostate cancer, the least frequent allele in both unaffected individuals and individuals suffering from prostate cancer, and the frequencies of these alleles in each population.

Among all the theoretical potential different haplotypes based on 2 to 9 markers, 11

30    haplotypes showing a strong association with prostate cancer were selected. The results of these haplotype analyses are shown in Figure 4.

Figures 2, 3, and 4 aggregate linkage analysis results with sequencing results which permitted the physical order and/or the distance between markers to be estimated.

The significance of the values obtained in Figure 4 are underscored by the following results

35    of computer simulations. For the computer simulations, the data from the affected individuals and the unaffected controls were pooled and randomly allocated to two groups which contained the same

number of individuals as the affected and unaffected groups used to compile the data summarized in Figure 4. A haplotype analysis was run on these artificial groups for the six markers included in haplotype 5 of Figure 4. This experiment was reiterated 100 times and the results are shown in Figure 5. Among 100 iterations, only 5% of the obtained haplotypes are present with a p-value below $1X10^{-4}$

5  as compared to the p-value of $9X10^{-7}$ for haplotype 5 of Figure 4. Furthermore, for haplotype 5 of Figure 4, only 6% of the obtained haplotypes have a significance level below $5X10^{-3}$, while none of them show a significance level below $5X10^{-5}$.

Thus, using the data of Figure 4 and evaluating the associations for single maker alleles or for haplotypes will permit estimation of the risk a corresponding carrier has to develop prostate cancer.

10  Significance thresholds of relative risks will be adapted to the reference sample population used.

The diagnostic techniques may employ a variety of methodologies to determine whether a test subject has a biallelic marker pattern associated with an increased risk of developing prostate cancer or suffers from prostate cancer resulting from a mutant PG1 allele. These include any method enabling the analysis of individual chromosomes for haplotyping, such as family studies, single sperm

15  DNA analysis or somatic hybrids.

In each of these methods, a nucleic acid sample is obtained from the test subject and the biallelic marker pattern for one or more of the biallelic markers listed in Figures 4, 6A and 6B is determined. The biallelic markers listed in Figure 6A are those which were used in the haplotype analysis of Figure 4. The first column of Figure 6A lists the BAC clones in which the biallelic

20  markers lie. The second column of Figure 6A lists the internal identification number of the marker. The third column of Figure 6A lists the sequence identification number for a first allele of the biallelic markers. The fourth column of Figure 6A lists the sequence identification number for a second allele of the biallelic markers. For example, the first allele of the biallelic marker 99-123 has the sequence of SEQ ID NO:21 and the second allele of the biallelic marker has the sequence of SEQ ID NO: 30.

25  The fifth column of Figure 6A lists the sequences of upstream primers which is used to generate amplification products containing the polymorphic bases of the biallelic markers. The sixth column of Figure 6A lists the sequence identification numbers for the upstream primers.

The seventh column of Figure 6A lists the sequences of downstream primers which is used to generate amplification products containing the polymorphic bases of the biallelic markers. The eighth

30  column of Figure 6A lists the sequence identification numbers for the downstream primers.

The ninth column of Figure 6A lists the position of the polymorphic base in the amplification products generated using the upstream and downstream primers. The tenth column lists the identities of the polymorphic bases found at the polymorphic positions in the biallelic markers. The eleventh and twelfth columns list the locations of microsequencing primers in the biallelic markers which can

35  be used to determine the identities of the polymorphic bases.

In addition to the biallelic markers of SEQ ID NOs: 21-38, other biallelic markers (designated
99-1482, 4-73, 4-65) have been identified which are closely linked to one or more of the biallelic
markers of SEQ ID NOs: 21-38, SEQ ID NOs: 57-62, and the PG1 gene. These biallelic markers
include the markers of SEQ ID NOs: 57-62, which are listed in Figure 6B. The columns in Figure 6B
5    are identical to the corresponding columns in Figure 6A. SEQ ID NOs: 58, 59, 61, and 62 lie within
the PG1 gene of SEQ ID NO:1 at the positions indicated in the accompanying Sequence Listing.

Genetic analysis of these additional biallelic markers is performed as follows. Nucleic acid
samples are obtained from individuals suffering from prostate cancer and unaffected individuals. The
frequencies at which each of the two alleles occur in the affected and unaffected populations is
10   determined using the methodologies described above. Association values are calculated to determine
the correlation between the presence of a particular allele or spectrum of alleles and prostate cancer.
The markers of SEQ ID NOs: 21-38 may also be included in the analysis used to calculate the risk
factors. The markers of SEQ ID NOs: 21-38 and SEQ ID NOs: 57-62 is used in diagnostic
techniques, such as those described below, to determine whether an individual is at risk for
15   developing prostate cancer or suffers from prostate cancer as a result of a mutation in the PG1 gene.

Example 6 describes methods for determining the biallelic marker pattern.

## Example 6

A nucleic acid sample is obtained from an individual to be tested for susceptibility to prostate
cancer or PG1 mediated prostate cancer. The nucleic acid sample is an RNA sample or a DNA
20   sample.

A PCR amplification is conducted using primer pairs which generate amplification products
containing the polymorphic nucleotides of one or more biallelic markers associated with prostate
cancer-related forms of PG1, such as the biallelic markers of SEQ ID NOs: 21-38, SEQ ID NOs: 57-
62, biallelic markers which are in linkage disequilibrium with the biallelic markers of SEQ ID NOs:
25   21-38, SEQ ID NOs: 57-62, biallelic markers in linkage disequilibrium with the PG1 gene, or
combinations thereof. In some embodiments, the PCR amplification is conducted using primer pairs
which generate amplification products containing the polymorphic nucleotides of several biallelic
markers . For example, in one embodiment, amplification products containing the polymorphic bases
of several biallelic markers selected from the group consisting of SEQ ID NOs: 21-38, SEQ ID NOs:
30   57-62, and biallelic markers which are in linkage disequilibrium with the biallelic markers of SEQ ID
NOs: 21-38, SEQ ID NOs: 57-62 or with the PG1 gene is generated. In another embodiment,
amplification products containing the polymorphic bases of two or more biallelic markers selected
from the group consisting of SEQ ID NOs: 21-38, SEQ ID NOs: 57-62, and biallelic markers which
are in linkage disequilibrium with the biallelic markers of SEQ ID NOs: 21-38, SEQ ID NOs: 57-62
35   or with the PG1 gene is generated. In another embodiment, amplification products containing the
polymorphic bases of five or more biallelic markers selected from the group consisting of SEQ ID

NOs: 21-38, SEQ ID NOs: 57-62, and biallelic markers which are in linkage disequilibrium with the biallelic markers of SEQ ID NOs: 21-38, SEQ ID NOs: 57-62 or with the PG1 gene is generated. In another embodiment, amplification products containing the polymorphic bases of more than five of the biallelic markers selected from the group consisting of SEQ ID NOs: 21-38, SEQ ID NOs: 57-62,

5    and biallelic markers which are in linkage disequilibrium with the biallelic markers of SEQ ID NOs: 21-38, SEQ ID NOs: 57-62 or with the PG1 gene is generated.

For example, the primers used to generate the amplification products may comprise the primers listed in Figure 6A or 6B (SEQ ID NOs: 39-56 and SEQ ID NOs: 63-68). Figures 6A and Figure 6B provide exemplary primers which is used in the amplification reactions and the identities

10    and locations of the polymorphic bases in the amplification products which are produced with the exemplary primers. The sequences of each of the alleles of the biallelic markers resulting from amplification using the primers in Figures 6A and 6B are listed in the accompanying Sequence Listing as SEQ ID NOs:21-38 and 57-62.

The PCR primers is oligonucleotides of 10, 15, 20 or more bases in length which enable the

15    amplification of the polymorphic site in the markers. In some embodiments, the amplification product produced using these primers is at least 100 bases in length (i.e. 50 nucleotides on each side of the polymorphic base). In other embodiments, the amplification product produced using these primers is at least 500 bases in length (i.e. 250 nucleotides on each side of the polymorphic base). In still further embodiments, the amplification product produced using these primers is at least 1000 bases in length

20    (i.e. 500 nucleotides on each side of the polymorphic base).

It will be appreciated that the primers listed in Figure 6A and 6B are merely exemplary and that any other set of primers which produce amplification products containing the polymorphic nucleotides of one or more of the biallelic markers of SEQ ID NOs. 21-38 and SEQ ID NOs: 57-62 or biallelic markers in linkage disequilibrium with the sequences of SEQ ID NOs. 21-38 and SEQ ID

25    NOs: 57-62 or with the PG1 gene, or a combination thereof is used in the diagnostic methods.

Following the PCR amplification, the identities of the polymorphic bases of one or more of the biallelic markers of SEQ ID NOs: 21-38 and SEQ ID NOs: 57-62, or biallelic markers in linkage disequilibrium with the sequences of SEQ ID NOs. 21-38 and SEQ ID NOs: 57-62 or with the PG1 gene, or a combination thereof, are determined. The identities of the polymorphic bases is determined

30    using the microsequencing procedures described in Example 5 above and the microsequencing primers listed as features in the sequences of SEQ ID NOs: 21-38 and SEQ ID NOs: 57-62. It will be appreciated that the microsequencing primers listed as features in the sequences of SEQ ID NOs: 21-38 and SEQ ID NOs: 57-62 are merely exemplary and that any primer having a 3Nend near the polymorphic nucleotide, and preferably immediately adjacent to the polymorphic nucleotide, is used.

35    Alternatively, the microsequencing analy.is is performed as described in Pastinen et al., Genome Research 7:606-614 (1997), which is described in more detail below.

Alternatively, the PCR product is completely sequenced to determine the identities of the polymorphic bases in the biallelic markers. In another method, the identities of the polymorphic bases in the biallelic markers is determined by hybridizing the amplification products to microarrays containing allele specific oligonucleotides specific for the polymorphic bases in the biallelic markers.

5   The use of microarrays comprising allele specific oligonucleotides is described in more detail below.

It will be appreciated that the identities of the polymorphic bases in the biallelic markers is determined using techniques other than those listed above, such as conventional dot blot analyses.

Nucleic acids used in the above diagnostic procedures may comprise at least 10 consecutive nucleotides in the biallelic markers of SEQ ID NOs: 21-38 and SEQ ID NOs: 57-62 or the sequences

10  complementary thereto. Alternatively, the nucleic acids used in the above diagnostic procedures may comprise at least 15 consecutive nucleotides in the biallelic markers of SEQ ID NOs: 21-38 and SEQ ID NOs: 57-62 or the sequences complementary thereto In some embodiments, the nucleic acids used in the above diagnostic procedures may comprise at least 20 consecutive nucleotides in the biallelic markers of SEQ ID NOs: 21-38 and SEQ ID NOs: 57-62 or the sequences complementary thereto. In

15  still other embodiments, the nucleic acids used in the above diagnostic procedures may comprise at least 30 consecutive nucleotides in the biallelic markers of SEQ ID NOs: 21-38 and SEQ ID NOs: 57-62 or the sequences complementary thereto. In further embodiments, the nucleic acids used in the above diagnostic procedures may comprise more than 30 consecutive nucleotides in the biallelic markers of SEQ ID NOs: 21-38 and SEQ ID NOs: 57-62 or the sequences complementary thereto. In

20  still further embodiments, the nucleic acids used in the above diagnostic procedures may comprise the entire sequence of the biallelic markers of SEQ ID NOs: 21-38 and SEQ ID NOs: 57-62 or the sequences complementary thereto.

## I.E.  Identification and Sequencing, of the PG1 Gene, and Localization of the PG1 Protein

The above haplotype analysis indicated that 171kb of genomic DNA between biallelic

25  markers 4-14 and 99-221 totally or partially contains a gene responsible for prostate cancer. Therefore, the protein coding sequences lying within this region were characterized to locate the gene associated with prostate cancer. This analysis, described in further detail below, revealed a single protein coding sequence in the 171 kb, which was designated as the PG1 gene.

Template DNA for sequencing the PG1 gene was obtained as follows. BACs 189EO8 and

30  463FO1 were subcloned as previously described  Plasmid inserts were first amplified by PCR on PE 9600 thermocyclers (Perkin-Elmer), usirlg appropriate primers, AmpliTaqGold (Perkin-Elmer), dNTPs (Boehringer), buffer and cycling conditions as recommended by the Perkin-Elmer Corporation.

PCR products were then sequenced using automatic ABI Prism 377 sequencers (Perkin Elmer, Applied Biosystems Division, Foster City, CA). Sequencing reactions were performed using PE 9600

35  thermocyclers (Perkin Elmer) with standard dye-primer chemistry and ThermoSequenase (Amersham Life Science). The primers were labeled with the JOE, FAM, ROX and TAMRA dyes. The dNTPs and

ddNTPs used in the sequencing reactions were purchased from Boehringer. Sequencing buffer, reagent concentrations and cycling conditions were as recommended by Amersham.

Following the sequencing reaction, the samples were precipitated with EtOH, resuspended in formamide loading buffer, and loaded on a standard 4% acrylamide gel. Electrophoresis was performed

5      for 2.5 hours at 3000V on an ABI 377 sequencer, and the sequence data were collected and analyzed using the ABI Prism DNA Sequencing Analysis Software, version 2.1.2.

The sequence data obtained as described above were transferred to a proprietary database, where quality control and validation steps were performed. A proprietary base-caller ("Trace"), working using a Unix system automatically flagged suspect peaks, taking into account the shape of the peaks, the inter-

10     peak resolution, and the noise level. The proprietary base-caller also performed an automatic trimming. Any stretch of 25 or fewer bases having more than 4 suspect peaks was considered unreliable and was discarded. Sequences corresponding to cloning vector oligonucleotides were automatically removed from the sequence. However, the resulting sequence may contain 1 to 5 bases belonging to the vector sequences at their 5• end. If needed, these can easily be removed on a case by case basis.

15     The genomic sequence of the PG1 gene is provided in the accompanying Sequence Listing and is designated as SEQ ID NO: 1.

Potential exons in BAC-derived human genomic sequences were located by homology searches on protein, nucleic acid and EST (Expressed Sequence Tags) public databases. Main public databases were locally reconstructed. The protein database, NRPU (Non-redundant Protein Unique) is formed by a

20     non-redundant fusion of the Genpept (Benson D.A. et al., Nucleic Acids Res. 24: 1-5 (1996), Swissprot (Bairoch, A. and Apweiler, R, Nucleic Acids Res. 24: 21-25 (1996) and PIR/NBRF (George, D.G. et al., Nucleic Acids Res. 24:17-20 (1996) databases. Redundant data were eliminated by using the NRDB software (Benson et al., supra) and internal repeats were masked with the XNU software (Benson et al., supra). Homologies found using the NRPU database allowed the identification of sequences

25     corresponding to potential coding exons related to known proteins.

The EST local database is composed by the gbest section (1-9) of GenBank (Benson et al., supra), and thus contains all publicly available transcript fragments. Homologies found with this database allowed the localization of potentially transcribed regions.

The local nucleic acid database contained all sections of GenBank and EMBL (Rodriguez-

30     Tome, P. et al., Nucleic Acids Res. 24: 6-12 (1996) except the EST sections. Redundant data were eliminated as previously described.

Similarity searches in protein or nucleic acid databases were performed using the BLAS software (Altschul, S.F. et al., J. Mol. Biol. 215: 403-410 (1990). Alignments were refined using the Fasta software, and multiple alignments used Clustal W. Homology thresholds were adjusted for each

35     analysis based on the length and the complexity of the tested region, as well as on the size of the reference database.

Potential exon sequences identified as above were used as probes to screen cDNA libraries. Extremities of positive clones were sequenced and the sequence stretches were positioned on the genomic sequence of SEQ ID NO:1. Primers were then designed using the results from these alignments in order to enable the PG1 cloning procedure described below.

5                                      Cloning PG1 cDNA

PG1 cDNA was obtained as follows. 4:1 of ethanol suspension containing 1mg of human prostate total RNA (Clontech laboratories, Inc., Palo Alto, USA; catalogue N. 64038-1, lot 7040869) was centrifuged, and the resulting pellet was air dried for 30 minutes at room temperature.

First strand cDNA synthesis was performed using the AdvantageTM RT-for-PCR kit

10   (Clontech laboratories, Inc., Palo Alto, USA; catalogue N. K1402-1). 1:1 of 20mM solution of primer PGRT32: TTTTTTTTTTTTTTTTTTTTGAAAT (SEQ ID NO:10) was added to 12.5 :1 of RNA solution in water, heated at 74°C for two and a half minutes and rapidly quenched in an ice bath. 10:1 of 5xRT buffer (50mM Tris-HCl, pH 8.3, 75mM KCl, 3 mM MgCl2), 2.5 :1 of dNTP mix (10mM each), 1.25:1 of human recombinant placental RNA inhibitor were mixed with 1 ml of MMLV reverse

15   transcriptase (200 units). 6.5:1 of this solution were added to RNA-primer mix and incubated at 42°C for one hour. 80:1 of water were added and the solution was incubated at 94°C for 5 minutes.

5:1 of the resulting solution were used in a Long Range PCR reaction with hot start, in 50 :1 final volume, using 2 units of rtTHXL, 20 pmol/µl of each of GC1.5p.1: CTGTCCCTGGTGCTCCACACGTACTC      (SEQ      ID      NO:6)      or      GC1.5p2

20   TGGTGCTCCACACGTACTCCATGCGC      (SEQ      ID      NO:      7)      and      GC1.3p: CTTGCCTGCTGGAGACACAGAATTTCGATAGCAC (SEQ ID NO:9) primers with 35 cycles of elongation for 6 minutes at 67°C in thermocycler.

The sequence of the PG1 cDNA obtained as described above (SEQ ID NO 3) is provided in the accompanying Sequence Listing. Results of Northern blot analysis of prostate mRNAs support the

25   existence of a major PG1 cDNA having a 5-6kb length.

                              Characterization of the PG1 Gene

The intron/exon structure of the gene was deduced by aligning the mRNA sequence from the cDNA of SEQ ID NO:3 and the genomic DNA sequence of SEQ ID NO: 1.

The positions of the introns and exons in the PG1 genomic DNA are provided in Figures 7

30   and 8. Figure 7 lists positions of the start and end nucleotides defining each of the at least 8 exons (labeled Exons A-H) in the sequence of SEQ ID NO: 1, the locations and phases of the 5' and 3' splice sites in the sequence of SEQ ID NO: 1, the position of the stop codon in the sequence of SEQ ID NO: 1, and the position of the polyadenylation site in the sequence of SEQ ID NO: 1. Figure 8 shows the positions of the exons within the PG1 genomic DNA and the PG1 mRNA, the location of a

35   tyrosine phosphatase retro-pseudogene in the PG1 genomic DNA, the positions of the coding region in the mRNA, and the locations of the polyadenylation signal and polyA stretch in the mRNA.

43

As indicated in Figures 7 and 8, the PG1 gene comprises at least 8 exons, and spans more than 52kb. The first intron contains a tyrosine phosphatase retropseudogene. A G/C rich putative promoter region lies between nucleotide 1629 and 1870 of SEQ ID NO: 1. A CCAAT box is present at nucleotide 1661 of SEQ ID NO: 1. The promoter region was identified as described in Prestridge,

5    D.S., Predicting Pol II Promoter Sequences Using Transcription Factor Binding Sites, J. Mol. Biol. 249:923-932 (1995).

It is possible that the methionine listed as being the initiating methionine in the PG1 protein sequence of SEQ ID NO: 4 (based on the cDNA sequence of SEQ ID NO: 3) may actually be downstream but in phase with another methionine which acts as the initiating methionine. The

10   genomic DNA sequence of SEQ ID NO: 1 contains a methionine upstream from the methionine at position number 1 of the protein sequence of SEQ ID NO: 4 . If the upstream methionine is in fact the authentic initiation site, the sequence of the PG1 protein would be that of SEQ ID NO: 5. This possibility is investigated by determining the exact position of the 5N end of the PG1 mRNA as follows.

15   One way to determine the exact position of the 5N end of the PG1 mRNA is to perform a 5NRACE reaction using the Marathon-Ready human prostate cDNA kit from Clontech (Catalog. No. PT1156-1). For example, the RACE reaction may employ the PG1 primers PG15RACE196 CAATATCTGGACCCCGGTGTAATTCTC (SEQ ID NO: 8) as the first primer. The second primer in    the    RACE    reaction    is    PG15RACE130n    having    the    sequence

20   GGTCGTCCAGCGCTTGGTAGAAG (SEQ ID NO: 2). The sequence analysis of the resulting PCR product, or the product obtained with other PG1 specific primers, will give the exact sequence of the initiation point of the PG1 transcript.

Alternatively, the 5Nsequence of the PG1 transcript can be determined by conducting a PCR amplification with a series of primers extending from the 5Nend of the presently identified coding

25   region. In any event, the present invention contemplates use of PG1 nucleic acids and/or polypeptides coding for or corresponding to either SEQ ID NO:4 or SEQ ID NO:5 or fragments thereof.

It is also possible that alternative splicing of the PG1 gene may result in additional translation products not described above. It is also possible that there are sequences upstream or downstream of the genomic sequence of SEQ ID NO: 1 which contribute to the translation products of the gene.

30   Finally, alternative promoters may result in PG1derived transcripts other than those described herein.

The promoter activity of the region between nucleotides 1629 and 1870 can be verified as described below. Alternatively, should this region lack promoter activity, the promoter responsible for driving expression of the PG1 gene is identified as described below.

Genomic sequences lying upstream of the PG1 gene are cloned into a suitable promoter reporter

35   vector, such as the pSEAP-Basic, pSEAP-Enhancer, pβgal-Basic, pβgal-Enhancer, or pEGFP-1 Promoter Reporter vectors available from Clontech. Briefly, each of these promoter reporter vectors

include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline phosphatase, β galactosidase, or green fluorescent protein. The sequences upstream of the PG1 coding region are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The level of reporter protein is

5  assayed and compared to the level obtained from a vector which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect to the control vector indicates the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for augmenting transcription levels from weak promoter sequences. A significant level of expression above that observed with the vector lacking an insert

10  indicates that a promoter sequence is present in the inserted upstream sequence.

Promoter sequences within the upstream genomic DNA is further defined by constructing nested deletions in the upstream DNA using conventional techniques such as Exonuclease III digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity. In this way, the boundaries of the promoters is

15  defined. If desired, potential individual regulatory sites within the promoter is identified using site directed mutagenesis or linker scanning to obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels is determined by inserting the mutations into the cloning sites in the promoter reporter vectors.

Sequences within the PG1 promoter region which are likely to bind transcription factors is

20  identified by homology to known transcription factor binding sites or through conventional mutagenesis or deletion analyses of reporter plasmids containing the promoter sequence. For example, deletions is made in a reporter plasmid containing the promoter sequence of interest operably linked to an assayable reporter gene. The reporter plasmids carrying various deletions within the promoter region are transfected into an appropriate host cell and the effects of the deletions on expression levels is assessed.

25  Transcription factor binding sites within the regions in which deletions reduce expression levels is further localized using site directed mutagenesis, linker scanning analysis, or other techniques familiar to those skilled in the art.

The promoters and other regulatory sequences located upstream of the PG1 gene is used to design expression vectors capable of directing the expression of an inserted gene in a desired spatial,

30  temporal, developmental, or quantitative manner. For example, since the PG1 promoter is presumably active in the prostate, it can be used to construct expression vectors for directing gene expression in the prostate.

Preferably, in such expression vectors, the PG1 promoter is placed near multiple restriction sites to facilitate the cloning of an insert encoding a protein for which expression is desired downstream of the

35  promoter, such that the promoter is able to drive expression of the inserted gene. The promoter is inserted in conventional nucleic acid backbones designed for extrachromosomal replication, integration

into the host chromosomes or transient expression. Suitable backbones for the present expression vectors include retroviral backbones, backbones from eukaryotic episomes such as SV40 or Bovine Papilloma Virus, backbones from bacterial episomes, or artificial chromosomes.

Preferably, the expression vectors also include a polyA signal downstream of the multiple
5  restriction sites for directing the polyadenylation of mRNA transcribed from the gene inserted into the expression vector.

Nucleic acids encoding proteins which interact with sequences in the PG1 promoter is identified using one-hybrid systems such as those described in the manual accompanying the Matchmaker One-Hybrid System kit available from Clontech (Catalog No. K1603-1). Briefly, the Matchmaker One-
10  hybrid system is used as follows. The target sequence for which it is desired to identify binding proteins is cloned upstream of a selectable reporter gene and integrated into the yeast genome. Preferably, multiple copies of the target sequences are inserted into the reporter plasmid in tandem.

A library comprised of fusions between cDNAs to be evaluated for the ability to bind to the promoter and the activation domain of a yeast transcription factor, such as GAL4, is transformed into the
15  yeast strain containing the integrated reporter sequence. The yeast are plated on selective media to select cells expressing the selectable marker linked to the promoter sequence. The colonies which grow on the selective media contain genes encoding proteins which bind the target sequence. The inserts in the genes encoding the fusion proteins are further characterized by sequencing. In addition, the inserts is inserted into expression vectors or in vitro transcription vectors. Binding of the polypeptides encoded by the
20  inserts to the promoter DNA is confirmed by techniques familiar to those skilled in the art, such as gel shift analysis or DNAse protection analysis.

<u>Analysis of PG1 Protein Sequence</u>

The PG1 cDNA of SEQ ID NO: 3 encodes a 353 amino-acid protein (SEQ ID NO:4). As indicated in the accompanying Sequence Listing, a Prosite analysis indicated that the PG1 protein has
25  a leucine zipper motif, a potential glycosylation site, 3 potential casein kinase II phosphorylation sites, a potential cAMP dependent protein kinase phosphorylation site, 2 potential tyrosine kinase phosphorylation sites, 4 potential protein kinase C phosphorylation sites, 5 potential N-myristoylation sites, 1 potential tyrosine sulfation site, and one potential amidation site.

A search for membrane associated domains was conducted according to the methods
30  described in Argos, P. et al., Structural Prediction of Membrane-bound Proteins, Elur. J. Biochem. 128:565-575 (1982); Klein et al., Biochimica & Biophysica Acta 815:468-476 (1985); and Eisenberg et al., J. Mol. Biol. 179:125-142 (1984). The search revealed 5 potential transmembrane domains predicted to be integral membrane domains. These results suggest that the PG1 protein is likely to be membrane-associated and is an integral membrane protein.

35  A homology search was conducted to identify proteins homologous to the PG1 protein. Several proteins were identified which share homology with the PG1 protein. Figure 9 lists the

accession numbers of several proteins which share homology with the PG1 protein in three regions designated box1, box2 and box3.

It will be appreciated that each of the motifs described above is also present in the protein of SEQ ID NO: 5, which would be produced if by translation initiation translated from the potential

5  upstream methionine in the nucleic acid of SEQ ID NO: 1.

As indicated in Figure 9, a distinctive pattern of homology to box 1, box 2 (SEQ ID NOs: 11-14) and box 3 (SEQ ID NOs: 15-20) is found amongst acyl glyerol transferases. For example, the plsC protein from E. coli ( Accession Number P26647) shares homology with the box1 and box2 sequences, but not the box 3 sequence, of the PG1 protein. The product of this gene transfers acyl

10  from acyl-coenzymeA to the sn2 position of 1-Acyl-sn-glycerol-3-phosphate (lysophosphatidic acid, LPA)(Coleman J., Mol Gen Genet. 1992 Mar 1; 232(2): 295-303).

Box1 and box2 homologies, but not box 3 homologies, are also found in the SLCI gene product from baker's yeast (Accession Number P33333) and the mouse gene AB005623. Each of these genes are able to complement in vivo mutations in the bacterial plsC gene. (Nagiec MM, Wells

15  GB, Lester RL, Dickson RC, J. Biol. Chem., 1993 Oct 15; 268(29): 22156-22163, A suppressor gene that enables Saccharomyces cerevisiae to grow without making sphingolipids encodes a protein that resembles an Escherichia coli fatty acyltransferase; and Kume K, Shimizu T, Biochem. Biophys. Res. Commun. 1997, Aug. 28; 237(3): 663-666, cDNA cloning and expression of murine 1-acyl-sn-glycerol-3-phosphate acyltransferase).

20  Recently two different human homologues of the mouse AB005623 gene, Accession Numbers U89336 and U56417 were cloned and found to be localized to human chromosomes 6 and 9 (Eberhardt. C., Gray, P.W. and Tjoelker,L.W., J. Biol. Chem. 1997; 272, 20299-20305, Human lysophosphatidic acid acyltransferase cDNA cloning, expression, and localization to chromosome 9q34.3; and West, J., Tompkins, C.K., Balantac, N., Nudelman, E., Meengs, B., White, T., Bursten,

25  S., Coleman, J., Kumar, A., Singer, J.W. and Leung, D.W, DNA Cell Biol. 6, 691-701 (1997), Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine induced signaling responses in cells).

The enzymatic acylation of LPA results in 1,2-diacyl-sn-glycerol 3-phosphate, an intermediate to the biosynthesis of both glycerophospholipids and triacylglycerol. Several important signaling

30  messengers participating in the transduction of mitogenic signals, induction of apoptosis, transmission of nerve impulses and other cellular responses mediated by membrane bound receptors belong to this metabolic pathway.

LPA itself is a potent regulator of mammalian cell proliferation. In fact, LPA is one of the major mitogens found in blood serum. (For a review: Durieux ME, Lynch KR, Trends Pharmacol.

35  Sci. 1993 Jun; 14(6):249-254, Signaling properties of lysophosphatidic acid. LPA can act as a survival factor to inhibit apoptosis of primary cells; and Levine JS, Koh JS, Triaca V, Lieberthal W,

Am. J. Physiol. 1997 Oct; 273(4Pt2): F575-F585, Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells). This function of LPA is mediated by the lipid kinase phosphatidylinositol 3-kinase.

Phosphatidylinositol and its derivatives present another class of messengers emerging from
5   the 1-acyl-sn-glycerol-3-phosphate acyltransferase pathway. (Toker A, Cantley LC, Nature 1997 Jun 12; 387(6634): 673-676, Signaling through the lipid products of phosphoinositide-3-OH kinase; Martin TF, Curr. Opin. Neurobiol. 1997 Jun; 7(3):331-338, Phosphoinositides as spatial regulators of membrane traffic; and Hsuan JJ, et al., Int. J. Biochem. Cell Biol. 1997 Mar 1st; 29(3): 415-435, Growth factor-dependent phosphoinositide signaling).

10        Cell growth, differentiation and apoptosis can be affected and modified by enzymes involved in this metabolic pathway. Consequently, alteration of this pathway could facilitate cancer cell progression. Modulation of the activity of enzymes in this pathway using agents such as enzymatic inhibitors could be a way to restore a normal phenotype to cancerous cells.

Ashagbley A, Samadder P, Bittman R, Erukulla RK, Byun HS, Arthur G have recently shown
15   that        ether-linked        analogue        of        lysophosphatidic        acid:        4-O-hexadecyl-3(S)-O-methoxybutanephosphonate can effectively inhibit the proliferation of several human cancerous cell lines, including DU145 line of prostate cancer origin. (Anticancer Res 1996 Jul; 16(4A): 1813-1818, Synthesis of ether-linked analogues of lysophosphatidate and their effect on the proliferation of human epithelial cancer cells in vitro).

20        Structural differences between the PG1 family of cellular proteins and the functionally confirmed 1-acyl-sn-glycerol-3-phosphate acyltransferase family, evidenced by the existence of a different pattern of homology to box3, could point to unique substrate specificity in the phospholipid metabolic pathway, to specific interaction with other cellular components or to both.

Further analysis of the function of the PG1 gene can be conducted, for example, by
25   constructing knockout mutations in the yeast homologues of the PG1 gene in order to elucidate the potential function of this protein family, and to test potential substrate analogs in order to revert the malignant phenotype of human prostate cancer cells as described in Section VIII, below.

<u>Example 7</u>

<u>Analysis of the Intracellular Localisation of the PG1 Isoforms</u>

30        To study the intracellular localisation of PG1 protein, different isoforms of PG1 were cloned in the expression vector pEGFP-N1(Clbntech), transfected and expressed in normal (PNT2A) or adenocarcinoma (PC3) prostatic cell line.

First, to generate cDNA inserts, 5' and 3' primers were synthesised allowing to amplify different regions of the PG1 open reading frame. Respectively, these primers were designed with an
35   internal EcoRI or BamHI site which allowed the insertion of the amplified product into the EcoRI and BamHI sites of the expression vector. The restriction sites were introduced into the primer so that

after cloning into pEGFP-N1, the PG1 open reading frame would be fused in frame, to the EGFP open reading frame. The translated protein would be a fusion between PG1 and EGFP. EGFP being a variant form of the GFP protein (Green Fluorescent Protein), it is possible to detect the intracellular localisation of the different PG1 isoforms by examining the fluorescence emitted by the EGFP fused

5   protein.

The different forms that were analysed correspond either to different messengers identified by RT-PCR performed on total normal human prostatic RNA or to a truncated form resulting from a non sense mutation identified in a tumoural prostatic cell line LnCaP. The different PG1 constructions were transfected using the lipofectine technique and EGFP expression was examined 20 hours post

10  transfection.

<u>Name and description of the different forms transfected are listed below :</u>

A) <u>PG1</u> includes all the coding exons from exon 1 to 8.

B) <u>PG1/1-4</u> corresponds to an alternative messenger which is due to an alternative splicing, joining exon 1 to exon 4, and resulting in the absence of exons 2 and 3.

15         C) <u>PG1/1-5</u> corresponds to an alternative messenger which is due to an alternative splicing, joining exon 1 to exon 5, and resulting in the absence of exons 2, 3 and 4.

D) <u>PG1/1-7</u> includes exons 1 to 6, and corresponds to the mutated form identified in genomic DNA of the prostatic tumoural cell line LNCaP.

<u>Cloning of the PG1 cDNA inserts in the EGFP-N1 expression vector</u>

20         cDNAs from human prostate were obtained by RT-PCR using the Advantage RT-for-PCR Kit (CLONTECH ref K1402-2). First, 1μl of oligodT-containing PG1 specific primer PGRT32 TTTTTTTTTTTTTTTTTTTTGAAAT (20pmoles) and 11.5 μl of DEPC treated $H_2O$ were added to 1μl of total mRNA (1μg) extracted from human prostate (CLONTECH ref 64038-1). The mRNA was heat denaturated for 2.5 min at 74°C and then quickly chilled on ice. A mix containing 4μl of 5X

25  buffer, 1μl of dNTPs (10mM each), 0.5μl of recombinant RNase inhibitor (20U) and 1μl of MoMuLV Reverse Transcriptase (200U) was added to the denaturated mRNA. Reverse transcription was performed for 60 min. at 42°C. Enzymes were heat denaturated for 5 min. at 94°C. Then, 80μl of DEPC treated $H_2O$ were added to the reaction mix and the cDNA mix was stored at -20°C. Primers PG15Eco3   (5'   CCT<u>GAATTC</u>CGCCGAGCTGAGAAGATGC   3'),   and   PG13Bam2   (5'

30  CCT<u>GGATCC</u>GCTTTAATAGTAACCCACAGGCAG 3') were used for PCR amplification of the different PG1 cDNAs. A 50μl PCR reaction mix containing 5μl of the previously prepared prostate cDNA mix, 15μl of 3.3X PCR buffer, 4μl of dNTPs (2.5mM each), 20pmoles of primer PG15Eco3, 20pmoles of primer PG13Bam2, 1μl of RtthXL enzyme, 2.2μl Mg(OAc)$_2$ (Hot Start) was set up and amplification was performed for 35 cycles of 30 sec at 94°C, 10 min. at 72°C, 4 min. at 67°C after an

35  initial denaturation step of 10 min. at 94°C. Size and integrity of the PCR product was assessed by migration on a 1% agarose gel. 2μg of the amplification product were digested with 2.4 units of

EcoRI (PROMEGA ref R601A) and 2.0 units of BamHI (PROMEGA ref R602A) in 50μl of 1X Multicore buffer for 2 hours at 37°C. Enzymes were then heat inactivated for 20 min, at 68°C, DNA was phenol/chloroform extracted and ethanol-precipitated and its concentration was estimated by migration on a 1% agarose gel.

5      To prepare the vector, 2μg of pEGFP-N1 vector (CLONTECH ref 6085-1) were digested with 2.4 units of EcoRI (PROMEGA ref R601A) and 2.0 units of BamHI (PROMEGA ref R602A) in 50μl of 1X multicore buffer for 2 hours at 37°C. Enzymes were then heat inactivated for 20 min, at 68°C, DNA was phenol/chloroform extracted and ethanol-precipitated and its concentration and integrity were estimated by migration on a 1% agarose gel. 20ng of the BamHI and EcoRI digested pEGFP-N1

10    vector were added to 50ng of BamHI-EcoRI digested PG1 cDNAs. Ligation was performed over night at 13°C using 0.5units of T4 DNA ligase (BOEHRINGER ref 84333623) in a final volume of 20μl containing 1X ligase buffer. The ligation reaction mix was desalted by dialysis against water (MILLIPORE ref VSWP01300) for 30min. at room temperature. One fifth of the desalted ligation reaction was electroporated in 25μl of competent cells ElectroMAX DH10B (GIBCO BRL ref

15    18290-015) using a resistance of 126 Ohms, capacitance of 50μF, and voltage of 2.5KV. Bacteria were then incubated in 500μl of SOB medium for 30min at 37°C. One fifth was plated on LB AGAR containing 40μg/μl KANAMYCINE (SIGMA ref K4000) and incubated over night at 37°C.

Plasmid DNA was prepared from an overnight liquid culture of individual colonies and sequenced. Among the different forms identified 3 were used :

20    A) PG1 which includes all the coding exons from exon 1 to 8.

B) PG1/1-4 which corresponds to an alternative messenger which is due to an alternative splicing, joining exon 1 to exon 4, and resulting in the absence of exons 2 and 3.

C) PG1/1-5 which corresponds to an alternative messenger which is due to an alternative splicing, joining exon 1 to exon 5, and resulting in the absence of exons 2, 3 and 4.

25    D) Vector PG1/1-7 : A cDNA insert encoding for a truncated protein was synthesized by PCR amplification, using primers PG15Eco3 and PG1mut29Bam (5' CCTGGATCCCCTCCATCGTCTTTCCCTT 3') and vector PG1 as a template. The resulting PCR product was cloned following the same protocol as described above.

Transfection of the PG1 expression vectors in human prostate cell lines.

30    The DNA/lipofectin solution was prepared as followed: 1.5μl of lipofectin (GIBCO BRL ref 18292-011) was diluted in 100μl of OPTI-MEM medium (GIBCO BRL ref 31985-018), and incubated for 30min. at room temperature before being mixed to 0.5μg of vector diluted in 100μl of OPTI-MEM medium and incubated for 15 min. at room temperature. Cells were inoculated in RPMI1640 medium (Gibco BRL ref 61870-010) containing 5% fetal calf serum (Dutscher ref P30-

35    3302) on slides (NUNC Lab-Tek ref 177402A) and grown at 37°C in 5%$CO_2$. Cells reaching 40-60% confluency were rinsed with 300μl OPTI-MEM medium and incubated with the DNA/lipofectin

solution for 6 hours at 37°C. The medium containing DNA was replaced by medium supplemented in fetal calf serum and cells were incubated for at least 36 hours at 37°C. Slides were rinsed in PBS and cells were fixed in ethanol, treated with Propidium iodide, and examined with a fluorescence microscope using a double-pass filter set for FITC/PI .

After transfection of PG1 and PG1/1-4 in both the normal and tumoural prostatic cell line, green fluorescence was detected into and around the nucleus (Figures 10 and 11). This result shows that the PG1 protein is localised in the nucleus and/or the nuclear membrane. Furthermore, it suggests that exons 2 and 3 are dispensable for translocation of PG1 to the nucleus. In addition, no difference in the intracellular localisation of these two forms was detected between the tumoral and the normal prostatic cell line.

On the contrary, transfection experiments using PG1/1-5 show that this form is cytoplasmic in the normal prostatic cell line PNT2A. It suggests that exon 4 might be important for the regulation of the translocation to the nucleus. Interestingly, similar transfection experiments in the tumoral cell line PC3 show that PG1/1-5 remains nuclear and or perinuclear (Figure 12). This result shows that there is an abnormality in the regulation of the intracellular localization of the PG1 isoforms in this tumoral cell line. Furthermore, it indicates that the normal function of PG1 can be altered indirectly in prostatic tumors by an abnormality in the regulation of its intracellular location.

Finally, a non-sense mutation has been identified in the prostatic tumoural cell line LNCaP, in exon 6 of PG1 (SEQ ID NO: 69). This mutation is responsible for the production of a truncated protein (SEQ ID NO: 70). To determine the intracellular location of this truncated protein, PG1/1-7 and PG1 were transfected in the normal prostatic cell line PNT2A. Comparison of the fluorescence detected in both sets of experiments clearly showed that the truncated form was localised in the cytoplasm as the non-truncated protein was located in and/or around the nucleus (Figure 13). This result indicates that this mutated PG1 is translated in a truncated protein which is unable to reach the nucleus. It also suggests that exons 7 and 8 may play an important role in the regulation of the intracellular localisation of PG1. Furthermore, it supports the previous hypothesis that an altered regulation of PG1 intracellular localisation might be involved in prostate tumorigenesis.

|  | pEGFP N1 | PG1 | PG11-4 | PG11-5 | PG11-7 |
|---|---|---|---|---|---|
| Transfection PNT2 06/17/98 | NA | nuclear | nuclear | ND | ND |

| Transfection PNT2 06/30/98 | cytoplasmic | nuclear | nuclear | ND | ND |

| Transfection PNT2 07/16/98 | cytoplasmic | NA | NA | cytoplasmic | ND |
|---|---|---|---|---|---|
| Transfection PC3 07/16/98 | NA | nuclear | nuclear | nuclear | ND |
| Transfection PC3 07/16/98 bis | cytoplasmic | nuclear | NA | NA | ND |

| Transfection PC3 08/27/98 | cytoplasmic | nuclear | nuclear | nuclear | NA |
|---|---|---|---|---|---|
| Transfection PNT2 08/28/98 | cytoplasmic | nuclear | NA | cytoplasmic | cytoplasmic |
| | All exons | X2-3 Spliced out | X2-3-4Spliced out | mut aa229 | |

NA : Not assessable

ND : Not done

5       Nuclear : localized in and around the nucleus (nuclear and perinuclear localization).

Alternative Splice Species

Alternative splicing is a common natural tool for the inhibition of function of full length gene products. Alternative splicing is known to result in enzyme isoforms, possesing different kinetic characteristics (pyruvate kinase: M1 and M2 Yamada K, Noguchi T, Biochem J. 1999 Jan1;337(Pt

10   1):1-11. Estrogen receptor (ER) gene is known to possess variant splicing yelding the deletions of exon 3, 5, or 7. The truncated ER protein induced from variant mRNA could mainly be exhibited as a repressor through dominant negative effects on normal ER protein (Iwase H, Omoto Y, Iwata H, Hara Y, Ando Y, Kobayashi S, Oncology 1998 Dec;55 Suppl S1:11-16 )'Yu et al ( Yu JJ, Mu C, Dabholkar M, Guo Y, Bostick-Bruton F, Reed E,Int J Mol Med 1998 Mar;1(3):617-620 ) demonstrated that there

15   is an association between alternative splicing of ERCC1, and reduction in cellular capability to repair cisplatin-DNA adduct. Munoz-Sanjuan et al (Munoz-Sanjuan I, Simandl BK, Fallon JF, Nathans J, Development 1998 Dec 14;126(Pt 2):409-421) demonstrated existence of two differentially spliced isoforms of fibroblast growth factor(FGF) type two genes that are present in non-overlapping spatial

52

distributions in the neural tube and adjacent structures in developing chiken embryo. One of these forms is secreted and activates the expression of HoxD13, HoxD11, Fgf-4 and BMP-2 ectopically, consistent with cFHF-2 playing a role in anterior-posterior patterning of the limb.

The CD44 is a cell adhesion molecule that is present as numerous isoforms created by mRNA

5    alternative splicing. Expression of variant isoforms of CD44 is associated with tumor growth and metastasis.(Shibuya Y, Okabayashi T, Oda K, Tanaka N,Jpn J Clin Oncol 1998 Oct;28(10):609-14) they showed that ratio of two particular isoforms is a useful indicator of prognosis in gastric and colorectal carcinoma. Zhang YF et al (Zhang YF, Jeffery S, Burchill SA, Berry PA, Kaski JC, Carter ND, Br J Cancer 1998 Nov;78(9):1141-6 ° showed that human endothelin receptor A is the subject to

10   alternative spicing giving at least two isoforms. The truncated receptor was expressed in all tissues and cells examined, but the level of expression varied. In melanoma cell lines and melanoma tissues, the truncated receptor gene was the major species, whereas the wild-type ETA was predominant in other tissues. Zhang et al. conclude that the function and biological significance of this truncated ETA receptor is not clear, but it may have regulatory roles for cell responses to ETs.

15                                      Example 8

                         Identification of PG1 Alternative Splice Species

The PG1 cDNA was first cloned by screening of a human prostate cDNA library. Sequence analysis of about 400 cDNA clones showed that at least 14 isoforms were present in this cDNA library. Comparison of their sequences to the genomic sequence showed that these isoforms resulted

20   from a complex set of different alternative splicing events between numerous exons (Figure 14).

To rule out the possibility of a cloning artefact generated during the cDNA library construction and to systematically identify all existing alternative splice junctions, RT-PCR experiments were performed on RNA of normal prostate as well as normal prostatic cell lines PNT1A, PNT1B and PNT2 using all the possible combinations of primers specific to the different

25   exon borders SEQ ID NOs: 137-178. The presence of multiple PCR bands in each reaction was assessed by migration in an agarose gel. Each band was analysed by sequencing, and the presence or absence of specific splicing events, as seen in the sequence by a specific splice junction, was scored as plus or minus in Figure 15.

Furthermore, to identify aberrant splicing event in prostate tumors, similar experiments were

30   performed on RNA extracted from tumoral prostatic cell lines LnCaP (obtained from two different sources and named FCG and JMB), CaHPV, Du145 and PC3 as well as on RNA obtained from prostate tumors (ECP5 to ECP24).

As shown in the first five columns, all isoforms identified in the cDNA library were detected in RNA of normal prostate, normal prostatic cell lines or prostate tumors. In addition to the different

35   splice junctions detected in the cDNA library, 19 other splice junctions were detected in normal prostate or in normal prostatic cell lines. Two types of exon junctions (exons 3-7, exons 3b-8) were

never detected in either normal prostate, normal prostatic cell lines, prostate tumors or prostatic tumoral cell lines. Comparison between normal and tumoral samples showed the presence of 2 additional exon junctions ( exons 3-8, exons 5-8) in the tumoral samples that were not detected previously in the normal samples. This result demonstrate that during tumorigenesis, the complex

5 regulation of the PG1 splicing has been altered, resulting in an abnormal ratio of the different isoforms. It is of a specific interest since it has been shown in patients with a genetic predisposition to Wilms tumor, that an imbalance between different RNA isoforms might be involved in tumorigenesis (Bickmore et al., Science 1992, 257:325-7; Little et al, Hum Mol Genet 1995, 4:351-8).

Interestingly, comparison between normal and tumoral samples, also showed that some exon

10 junctions are present in all normal samples, but are absent in numerous tumoral samples. It further indicates that the normal function of PG1 can be altered by an abnormality in the regulation of PG1 splicing and further support the previous hypothesis.

Furthermore, comparison between the different types of normal samples (Col.2 versus Col. 3, 4 and 5) also showed differences in the presence or absence of some exon junctions. It indicates that

15 the transformation process necessary to the generation of these normal prostatic cell lines might result in similar alteration which further support the previous hypothesis.

Example 9

Determining the Tumor Suppressor Activity of the PG1 Gene Product, Mutants and Other PG1

Polypeptides

20      PG1 variants which results from either alternate splicing of the PG1 mRNA or from mutation of PG1 that introduce a stop codon (nucleotide of SEQ ID NO: 69 and protein of SEQ ID NO: 70) can no longer perform its role of tumor suppressor. It is possible and even likely that PG1 tumor suppressor role extends beyond prostate cancer to other form of malignancies. PG1 therefore represent a prime candidate for gene therapy of cancer by creating a targeting vector which knocks out

25 the mutant and/or introduces a wild-type PG1 gene (e.g. SEQ ID NO 3 or 179) or a fragment thereof.

To validate this model, PG1 and its alternatively spliced or mutated variants are stably transfected in tumor cell line using methods described in Section VIII. The efficiency of transfection is determined by northern and western blotting; the latter is performed using antibodies prepared against PG1 synthetic peptides designed to distinguish the product of the most abundant PG1 mRNA

30 from the alternatively spliced variants, the truncated variant, or other functional mutants. The production of synthetic peptides and of polyclonal antibodies is performed using the methods described herein in Sections III and VII.. After demonstrating that PG1 and its variant are efficiently expressed in various tumor cell line preferably derived from human prostate cancer, hepatocarcinoma, lung and colon carcinoma; we the effect of this gene on the rate of cell division, DNA synthesis,

35 ability to grow in soft agar and ability to induce tumor progression and metastasis when injected in immunologically deficient nude mice are determined.

Alternatively the PG1 gene and its variant are inserted in adenoviruses that are used to obtain a high level of expression of these genes. This method is preferred to test the effect of PG1 expression in animal that are spontaneously developing tumor. The production of specific adenoviruses is obtained using methods familiar to those with normal skills in cell and molecular

5    biology.

## II. POLYNUCLEOTIDES:

The present invention encompasses polynucleotides in the form of PG1 genomic or cDNA as well as polynucleotides for use as primers and probes in the methods of the invention. These polynucleotides may consist of, consist essentially of, or comprise a contiguous span of nucleotides of

10    a sequence from any sequence in the Sequence Listing as well as sequences which are complementary thereto ("complements thereof"). Preferably said sequence is selected from SEQ ID NOs: 3, 112-125, 179, 182-184. The "contiguous span" is at least 6, 8, 10, 12, 15, 20, 25, 30, 50, 100, 200, or 500 nucleotides in length. It should be noted that the polynucleotides of the present invention are not limited to having the exact flanking sequences surrounding the polymorphic bases which are

15    enumerated in Sequence Listing. Rather, it will be appreciated that the flanking sequences surrounding the biallelic markers, or any of the primers of probes of the invention which are more distant from a biallelic markers, is lengthened or shortened to any extent compatible with their intended use and the present invention specifically contemplates such sequences. It will be appreciated that the polynucleotides referred to in the Sequence Listing is of any length compatible

20    with their intended use. Also the flanking regions outside of the contiguous span need not be homologous to native flanking sequences which actually occur in humans. The addition of any nucleotide sequence, which is compatible with the nucleotides intended use is specifically contemplated. The contiguous span may optionally include the PG1-related biallelic marker in said sequence. Optionally either allele of the biallelic markers described above in the definition of PG1-

25    related biallelic marker is specified as being present at the PG1-related biallelic marker.

The invention also relates to polynucleotides that hybridize, under conditions of high or intermediate stringency, to a polynucleotide of a sequence from any sequence in the Sequence Listing as well as sequences, which are complementary thereto. Preferably said sequence is selected from SEQ ID NOs: 3, 112-125, 179, 182-184. Preferably such polynucleotides is at least 6, 8, 10, 12, 15,

30    20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 200, or 500 nucleotides in length. Preferred polynucleotides comprise an PG1-related biallelic marker. Optionally either allele of the biallelic markers described above in the definition of PG1-related biallelic marker is specified as being present at the biallelic marker site. Conditions of high and intermediate stringency are further described in Section X.C.4, below.

35    The invention embodies polynucleotides which encode an entire human, mouse or mammalian PG1 protein, or fragments thereof. Generally the polynucleotides of the invention

comprise the naturally occurring nucleotide sequence of the PG1. However, any naturally occurring

silent codon variation or other silent codon variation can be employed to encode the PG1 amino acids

sequence. As for those amino acids which are changed or added to the PG1 gene for any embodiment

of the invention which requires the expression of a nucleotide sequence, the nucleic acid sequences

5   generally will be chosen to optimize expression in the specific human or non-human animal system in

which the polynucleotide is intended to be used, making use of known codon preferences. The PG1

polynucleotides of the invention can be the native nucleotide sequence which encodes a human,

mouse, or mammalian PG1 protein, preferably the PG1 polynucleotide sequence of SEQ ID NOs: 3,

112-125, 179, 182-184, and the compliments thereof. The polynucleotides of the invention include

10  those which encode PG1 polypeptides with a contiguous stretch of at least 8, 10, 12, 15, 20, 25, 30,

50, 100 or 200 amino acids from SEQ ID NOs: 4, 5, 70, 74, and 125-136, as well as any other human,

mouse or mammalian PG1 polypeptide.   In addition the present invention encompasses

polynucleotides which comprise a contiguous stretch of at least 8, 10, 12, 15, 20, 25, 30, 50, 100, 200,

500 nucleotides of a human, mouse or mammalian PG1 genomic sequence as well as complete human,

15  mouse, or mammalian PG1 genes, preferably of SEQ ID NOs: 179, 182, 183, and the compliments

thereof.

The present invention encompasses polynucleotides which consist of, consist essentially of,

or comprise a contiguous stretch of at least 8, 10, 12, 15, 20, 25, 30, 50, 100, 200, or 500 nucleotides

of a human, mouse or mammalian PG1 cDNA sequences as well as an entire human, mouse, or

20  mammalian PG1 cDNA.   The cDNA species and polynucleotide fragments comprised by the

polynucleotides of the invention include the predominant species derived from any human, mouse or

mammal source, preferably SEQ ID NOs: 3, 184, and the compliments thereof.   In addition, the

polynucleotides of the invention comprise cDNA species, and fragments thereof, that result from the

alternative splicing of PG1 transcripts in any human, mouse or other mammal, preferably the cDNA

25  species of SEQ ID NOs: 112-124, and compliments thereof. Moreover, the invention encompasses

cDNA species and other polynucleotides which consist of or comprise the polynucleotides which span

a splice junction, preferably including any one of SEQ ID NOs: 137 to 178, and the compliments

thereof; more preferably any one of SEQ ID NOs: 137 to 149, 151 to 169, 171 to 178, and the

compliments thereof.   The polynucleotides of the invention also include cDNA and other

30  polynucleotides which comprise two covalently linked PG1 exons, derived from a single human,

mouse or mammalian species, immediately adjacent to one another in the order shown, and selected

from the following pairs of PG1 exons: 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:4,

3:5, 3:6, 3:7, 3:8, 4:5, 4:6, 4:7, 4:8, 5:6, 5:7, 5:8, 6:7, 6:8, 7:8, 1:1bis, 1bis:2, 1bis:3, 1bis:4, 1bis:5,

1bis:6, 1bis:7, 1bis:8, 3:3bis, 3bis:4, 3bis:5, 3bis:6, 3bis:7, 3bis:8, 5:5bis, 5bis:6, 5bis:7, 5bis:8,

35  1:6bis, 2:6bis, 3:6bis, 4:6bis, 5:6bis, 6bis:7, 6bis:8, and the compliments thereof.   In a preferred

embodiment the sequences of the PG1 exons in each of the pairs of exons is selected as follows:

exon 1 – SEQ ID NO: 100; exon 2 – SEQ ID NO: 101; exon 3 – SEQ ID NO: 102;

exon 4 – SEQ ID NO: 103; exon 5 – SEQ ID NO: 104; exon 6 – SEQ ID NO: 105;

exon 7 – SEQ ID NO: 106; exon 8 – SEQ ID NO: 107; exon 1bis – SEQ ID NO: 108;

exon 3bis – SEQ ID NO: 109; exon 5bis – SEQ ID NO: 110; and

5     exon 6bis – SEQ ID NO: 111. Because of the 8 different polyadenylation sites in exon 8, any cDNA or polynucleotide of the invention comprising a human cDNA fragment encompassing exon 8 is truncated such that only the first 330 nucleotides, 699 nucleotides, 833 nucleotides, 1826 nucleotides, 2485 nucleotides, 2805 nucleotides, 4269 nucleotides or 4315 nucleotides of exon 8 shown in SEQ ID NO: 107 are present.

10     The primers of the present invention is designed from the disclosed sequences for any method known in the art. A preferred set of primers is fashioned such that the 3' end of the contiguous span of identity with the sequences of the Sequence Listing is present at the 3' end of the primer. Such a configuration allows the 3' end of the primer to hybridize to a selected nucleic acid sequence and dramatically increases the efficiency of the primer for amplification or sequencing reactions. Allele

15     specific primers is designed such that a biallelic marker is at the 3' end of the contiguous span and the contiguous span is present at the 3' end of the primer. Such allele specific primers tend to selectively prime an amplification or sequencing reaction so long as they are used with a nucleic acid sample that contains one of the two alleles present at a biallelic marker. The 3' end of primer of the invention is located within or at least 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 50, 100, 250, 500, or 1000 nucleotides

20     upstream of an PG1-related biallelic marker in said sequence or at any other location which is appropriate for their intended use in sequencing, amplification or the location of novel sequences or markers.

Preferred amplification primers include the polynucleotides disclosed in SEQ ID NOs: 39-56, and 63-68. Additional preferred amplification primers for particular non-genic PG1-related biallelic

25     markers are listed as follows by the internal reference number for the marker and the SEQ ID NOs for the PU and RP amplification primers respectively:

4-14-107 use SEQ ID NOs 339 and 382; 4-14-317 use SEQ ID NOs 339 and 382;

4-14-35 use SEQ ID NOs 339 and 382; 4-20-149 use SEQ ID NOs 340 and 383;

4-22-174 use SEQ ID NOs 341 and 384; 4-22-176 use SEQ ID NOs 341 and 384;

30     4-26-60 use SEQ ID NOs 342 and 385; 4-26-72 use SEQ ID NOs 342 and 385;

4-3-130 use SEQ ID NOs 343 and 386; 4-38-63 use SEQ ID NOs 344 and 387;

4-38-83 use SEQ ID NOs 344 and 387; 4-4-152 use SEQ ID NOs 345 and 388;          4-4-187 use

SEQ ID NOs 345 and 388; 4-4-288 use SEQ ID NOs 345 and 388;

4-42-304 use SEQ ID NOs 346 and 389; 4-42-401 use SEQ ID NOs 346 and 389;

35     4-43-328 use SEQ ID NOs 347 and 390; 4-43-70 use SEQ ID NOs 347 and 390;

4-50-209 use SEQ ID NOs 348 and 391; 4-50-293 use SEQ ID NOs 348 and 391;

4-50-323 use SEQ ID NOs 348 and 391; 4-50-329 use SEQ ID NOs 348 and 391;

4-50-330 use SEQ ID NOs 348 and 391; 4-52-163 use SEQ ID NOs 349 and 392;

4-52-88 use SEQ ID NOs 349 and 392;   4-53-258 use SEQ ID NOs 350 and 393;

4-54-283 use SEQ ID NOs 351 and 394; 4-54-388 use SEQ ID NOs 351 and 394;

5   4-55-70 use SEQ ID NOs 352 and 395; 4-55-95 use SEQ ID NOs 352 and 395;

4-56-159 use SEQ ID NOs 353 and 396; 4-56-213 use SEQ ID NOs 353 and 396;

4-58-289 use SEQ ID NOs 354 and 397; 4-58-318 use SEQ ID NOs 354 and 397;

4-60-266 use SEQ ID NOs 355 and 398; 4-60-293 use SEQ ID NOs 355 and 398;

4-84-241 use SEQ ID NOs 356 and 399; 4-84-262 use SEQ ID NOs 356 and 399;

10   4-86-206 use SEQ ID NOs 357 and 400; 4-86-309 use SEQ ID NOs 357 and 400;

4-88-349 use SEQ ID NOs 358 and 401; 4-89-87 use SEQ ID NOs 359 and 402;

99-123-184 use SEQ ID NOs 360 and 403; 99-128-202 use SEQ ID NOs 361 and 404;       99-128-

275 use SEQ ID NOs 361 and 404; 99-128-313 use SEQ ID NOs 361 and 404;

99-128-60 use SEQ ID NOs 361 and 404; 99-12907-295 use SEQ ID NOs 362 and 405;       99-

15   130-58 use SEQ ID NOs 363 and 406; 99-134-362 use SEQ ID NOs 364 and 407;       99-140-130

use SEQ ID NOs 365 and 408; 99-1462-238 use SEQ ID NOs 366 and 409;       99-147-181 use

SEQ ID NOs 367 and 410; 99-1474-156 use SEQ ID NOs 368 and 411;       99-1474-359 use SEQ

ID NOs 368 and 411;

99-1479-158 use SEQ ID NOs 369 and 412;

20   99-1479-379 use SEQ ID NOs 369 and 412; 99-148-129 use SEQ ID NOs 370 and 413;

99-148-132 use SEQ ID NOs 370 and 413; 99-148-139 use SEQ ID NOs 370 and 413;

99-148-140 use SEQ ID NOs 370 and 413; 99-148-182 use SEQ ID NOs 370 and 413;

99-148-366 use SEQ ID NOs 370 and 413; 99-148-76 use SEQ ID NOs 370 and 413;       99-1480-

290 use SEQ ID NOs 371 and 414;

25   99-1481-285 use SEQ ID NOs 372 and 415;

99-1484-101 use SEQ ID NOs 373 and 416;

99-1484-328 use SEQ ID NOs 373 and 416;

99-1485-251 use SEQ ID NOs 374 and 417;

99-1490-381 use SEQ ID NOs 375 and 418;

30   99-1493-280 use SEQ ID NOs 376 and 419; 99-151-94 use SEQ ID NOs 377 and 420;

99-211-291 use SEQ ID NOs 378 and 421; 99-213-37 use SEQ ID NOs 379 and 422;

99-221-442 use SEQ ID NOs 380 and 423; 99-222-109 use SEQ ID NOs 381 and 424; and the

compliments thereof.

Primers with their 3' ends located 1 nucleotide upstream or downstream of a PG1-related

35   biallelic marker have a special utility in microsequencing assays. Preferred microsequencing primers

include the polynucleotides from position 1 to position 23 and from position 25 to position 47 of SEQ

ID NOs: 21-38, and as well as the compliments thereof. Additional preferred microsequencing primers for particular non-genic PG1-related biallelic markers are listed as follows by the internal reference number for the marker and the SEQ ID NOs of the two preferred microsequencing primers:

4-14-107 of SEQ ID NOs 425 and 502*; 4-14-317 of SEQ ID NOs 426 and 503*;

5  4-14-35 of SEQ ID NOs 427 and 504*; 4-20-149 of SEQ ID NOs 428* and 505;

4-20-77 of SEQ ID NOs 429 and 506; 4-22-174 of SEQ ID NOs 430* and 507;

4-22-176 of SEQ ID NOs 431 and 508; 4-26-60 of SEQ ID NOs 432 and 509*;

4-26-72 of SEQ ID NOs 433 and 510; 4-3-130 of SEQ ID NOs 434 and 511*;

4-38-63 of SEQ ID NOs 435 and 512; 4-38-83 of SEQ ID NOs 436 and 513*;

10  4-4-152 of SEQ ID NOs 437 and 514; 4-4-187 of SEQ ID NOs 438* and 515;

4-4-288 of SEQ ID NOs 439 and 516; 4-42-304 of SEQ ID NOs 440 and 517;

4-42-401 of SEQ ID NOs 441* and 518; 4-43-328 of SEQ ID NOs 442 and 519;

4-43-70 of SEQ ID NOs 443* and 520; 4-50-209 of SEQ ID NOs 444* and 521;

4-50-293 of SEQ ID NOs 445* and 522; 4-50-323 of SEQ ID NOs 446* and 523;

15  4-50-329 of SEQ ID NOs 447* and 524; 4-50-330 of SEQ ID NOs 448 and 525;

4-52-163 of SEQ ID NOs 449* and 526; 4-52-88 of SEQ ID NOs 450* and 527;

4-53-258 of SEQ ID NOs 451 and 528*;4-54-283 of SEQ ID NOs 452* and 529;

4-54-388 of SEQ ID NOs 453 and 530; 4-55-70 of SEQ ID NOs 454 and 531*;

4-55-95 of SEQ ID NOs 455* and 532; 4-56-159 of SEQ ID NOs 456* and 533;

20  4-56-213 of SEQ ID NOs 457 and 534; 4-58-289 of SEQ ID NOs 458* and 535;

4-58-318 of SEQ ID NOs 459* and 536; 4-60-266 of SEQ ID NOs 460* and 537;

4-60-293 of SEQ ID NOs 461* and 538; 4-84-241 of SEQ ID NOs 462 and 539*;

4-84-262 of SEQ ID NOs 463 and 540; 4-86-206 of SEQ ID NOs 464 and 541*;

4-86-309 of SEQ ID NOs 465 and 542; 4-88-349 of SEQ ID NOs 466 and 543.;

25  4-89-87 of SEQ ID NOs 467* and 544.; 99-123-184 of SEQ ID NOs 468 and 545;

99-128-202 of SEQ ID NOs 469 and 546; 99-128-275 of SEQ ID NOs 470 and 547;

99-128-313 of SEQ ID NOs 471 and 548; 99-128-60 of SEQ ID NOs 472* and 549;

99-12907-295 of SEQ ID NOs 473 and 550*;

99-130-58 of SEQ ID NOs 474* and 551*;

30  99-134-362 of SEQ ID NOs 475 and 552*; 99-140-130 of SEQ ID NOs 476* and 553*;

99-1462-238 of SEQ ID NOs 477* and 554; 99-147-181 of SEQ ID NOs 478 and 555*;

99-1474-156 of SEQ ID NOs 479 and 556*; 99-1474-359 of SEQ ID NOs 480 and 557;

99-1479-158 of SEQ ID NOs 481* and 558; 99-1479-379 of SEQ ID NOs 482 and 559;

99-148-129 of SEQ ID NOs 483 and 560; 99-148-132 of SEQ ID NOs 484 and 561;

35  99-148-139 of SEQ ID NOs 485 and 562; 99-148-140 of SEQ ID NOs 486 and 563;

99-148-182 of SEQ ID NOs 487 and 564*; 99-148-366 of SEQ ID NOs 488 and 565;

99-148-76 of SEQ ID NOs 489 and 566; 99-1480-290 of SEQ ID NOs 490 and 567*;

99-1481-285 of SEQ ID NOs 491 and 568*; 99-1484-101 of SEQ ID NOs 492 and 569;

99-1484-328 of SEQ ID NOs 493* and 570;

99-1485-251 of SEQ ID NOs 494 and 571*;

5    99-1490-381 of SEQ ID NOs 495* and 572;

99-1493-280 of SEQ ID NOs 496 and 573*;

99-151-94 of SEQ ID NOs 497 and 574*; 99-211-291 of SEQ ID NOs 498* and 575;

99-213-37 of SEQ ID NOs 499 and 576; 99-221-442 of SEQ ID 500 and 577;

99-222-109 of SEQ ID NOs 501* and 578; and compliments thereof.

10        Additional preferred microsequencing primers for particular genic PG1-related biallelic markers include a polynucleotide selected from the group consisting of the nucleotide sequences from position N-X to position N-1 of SEQ ID NO:179, nucleotide sequences from position N+1 to position N+X of SEQ ID NO:179, and the compliments thereof, wherein X is equal to 15, 18, 20, 25, 30, or a range of 15 to 30, and N is equal to one of the following values: 2159; 2443; 4452; 5733; 8438;

15   11843; 1983; 12080; 12221; 12947; 13147; 13194; 13310; 13342; 13367; 13594; 13680; 13902; 16231; 16388; 17608; 18034; 18290; 18786; 22835; 22872; 25183; 25192; 25614; 26911; 32703; 34491; 34756; 34934; 5160; 39897; 40598; 40816; 40947; 45783; 47929; 48206; 48207; 49282; 50037; 50054; 50101; 50220; 50440; 50562; 50653; 50660; 50745; 50885; 51249; 51333; 51435; 51468; 51515; 51557; 51566; 51632; 51666; 52016; 52096; 52151; 52282; 52348; 52410; 52580;

20   52712; 52772; 52860; 53092; 53272; 53389; 53511; 53600; 53665; 53815; 54365; and 54541.

        The probes of the present invention is designed from the disclosed sequences for any method known in the art, particularly methods which allow for testing if a particular sequence or marker disclosed herein is present. A preferred set of probes is designed for use in the hybridization assays of the invention in any manner known in the art such that they selectively bind to one allele of a biallelic

25   marker, but not the other under any particular set of assay conditions. Preferred hybridization probes may consists of, consist essentially of, or comprise a contiguous span which ranges in length from 8, 10, 12, 15, 18 or 20 to 25, 35, 40, 50, 60, 70, or 80 nucleotides, or be specified as being 12, 15, 18, 20, 25, 35, 40, or 50 nucleotides in length and including a PG1-related biallelic marker of said sequence. Optionally either of the two alleles specified in the definition of PG1-realted biallelic marker is

30   specified as being present at the biallelic marker site. Optionally, said biallelic marker is within 6, 5, 4, 3, 2, or 1 nucleotides of the center of the hybridization probe or at the center of said probe. A preferred set of hybridization probes is disclosed in SEQ ID NOs: 21-38, 57-62, 185-338, and the compliments thereof. Another particularly preferred set of hybridization probes includes the polynucleotides from position X to position Y of any one of SEQ ID NOs: 21-38, 57-62, 185-338, or

35   the compliments thereof, wherein X is equal to 5, 8, 10, 12, 14, 16, 18 or a range of 5 to 18, and Y is equal to 30, 32, 34, 36, 38, 40, 43 or a range of 30 to 43; preferably X equals 12 and Y equals 36.

Additional preferred hybridization probes for particular genic PG1-related biallelic markers include a polynucleotide selected from the group consisting of the nucleotide sequences from position N-X to position N+Y of SEQ ID NO:179, and the compliments thereof, wherein X is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30, Y is equal to 8, 10, 12, 15, 20, 25, or a range of 8 to 30, and N is equal to

5    one of the following values: 2159; 2443; 4452; 5733; 8438; 11843; 1983; 12080; 12221; 12947; 13147; 13194; 13310; 13342; 13367; 13594; 13680; 13902; 16231; 16388; 17608; 18034; 18290; 18786; 22835; 22872; 25183; 25192; 25614; 26911; 32703; 34491; 34756; 34934; 5160; 39897; 40598; 40816; 40947; 45783; 47929; 48206; 48207; 49282; 50037; 50054; 50101; 50220; 50440; 50562; 50653; 50660; 50745; 50885; 51249; 51333; 51435; 51468; 51515; 51557; 51566; 51632;

10   51666; 52016; 52096; 52151; 52282; 52348; 52410; 52580; 52712; 52772; 52860; 53092; 53272; 53389; 53511; 53600; 53665; 53815; 54365; and 54541; wherein the nucleotide at position N is selected from one of the two alleles specified in the definition of PG1-realted biallelic marker at the biallelic marker site at position N.

        Any of the polynucleotides of the present invention can be labeled, if desired, by

15   incorporating a label detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive substances, fluorescent dyes or biotin. Preferably, polynucleotides are labeled at their 3' and 5' ends. A label can also be used to capture the primer, so as to facilitate the immobilization of either the primer or a primer extension product, such as amplified DNA, on a solid support. A capture label is attached to the primers or

20   probes and can be a specific binding member which forms a binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin). Therefore depending upon the type of label carried by a polynucleotide or a probe, it is employed to capture or to detect the target DNA. Further, it will be understood that the polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For example, in the case where a solid phase reagent's binding

25   member is a nucleic acid sequence, it is selected such that it binds a complementary portion of a primer or probe to thereby immobilize the primer or probe to the solid phase. In cases where a polynucleotide probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a sequence or "tail" that is not complementary to the target. In the case where a polynucleotide primer itself serves as the capture label, at least a portion of the primer will be free to

30   hybridize with a nucleic acid on a solid phase. DNA Labeling techniques are well known to the skilled technician.
        Any of the polynucleotides, primers and probes of the present invention can be conveniently immobilized on a solid support. Solid supports are known to those skilled in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic beads, nitrocellulose strips,

35   membranes, microparticles such as latex particles, sheep (or other animal) red blood cells, duracytes® and others. The solid support is not critical and can be selected by one skilled in the art. Thus, latex

particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and duracytes are all suitable examples. Suitable methods for immobilizing nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers

5   to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent. Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to

10   the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid support and which has the ability to immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the performance of the assay. The solid phase thus can be a plastic, derivatized

15   plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, duracytes® and other configurations known to those of ordinary skill in the art. The polynucleotides of the invention can be attached to or immobilized on a solid support individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the inventions to a single solid support. In addition,

20   polynucleotides other than those of the invention may attached to the same solid support as one or more polynucleotides of the invention.

Any polynucleotide provided herein is attached in overlapping areas or at random locations on the solid support. Alternatively the polynucleotides of the invention is attached in an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not

25   overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be "addressable" where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. The knowledge of the precise location of each polynucleotides location makes these

30   "addressable" arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as the Genechips™, and has been generally described in US Patent 5,143,854; PCT publications WO 90/15070 and 92/10092. These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods, which

35   incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., Science, 251:767-777, 1991). The immobilization of arrays of oligonucleotides on solid

supports has been rendered possible by the development of a technology generally identified as "Very Large Scale Immobilized Polymer Synthesis" (VLSIPS™) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPS™ technologies are provided in US Patents 5,143,854 and 5,412,087 and in PCT Publications WO 90/15070, WO

5   92/10092 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis techniques. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence information. Examples of such presentation strategies are disclosed in PCT

10  Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256.

Oligonucleotide arrays may comprise at least one of the sequences selected from the group consisting of SEQ ID NOs: 3, 21-38, 57-62, 100-124, 179, 185-338, the preferred hybridization probes for genic PG1-related biallelic markers described above; and the sequences complementary thereto; or a fragment thereof of at least 15 consecutive nucleotides for determining whether a sample

15  contains one or more alleles of the biallelic markers of the present invention. Oligonucleotide arrays may also comprise at least one of the sequences selected from the group consisting of SEQ ID NOs: 179, 339-424; and the sequences complementary thereto or a fragment thereof of at least 15 consecutive nucleotides for amplifying one or more alleles of the PG1-realted biallelic markers. In other embodiments, arrays may also comprise at least one of the sequences selected from the group

20  consisting of SEQ ID 425-578, the preferred microsequencing primers for genic PG1-related biallelic markers described above; and the sequences complementary thereto or a fragment thereof of at least 15 consecutive nucleotides for conducting microsequencing analyses to determine whether a sample contains one or more alleles of PG1-related biallelic marker.

The present invention further encompasses polynucleotide sequences that hybridize to any

25  one of SEQ ID NOs: 3, 69, 100-112, or 179-184 under conditions of high or intermediate stringency as described below:

(i) By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll,

30  0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10^6 cpm of ^32P-labeled probe. Alternatively, the hybridization step can be performed at 65°C in the presence of SSC buffer, 1 x SSC corresponding to 0.15M NaCl and 0.05 M Na citrate. Subsequently, filter washes can be done at 37°C for 1 h in a solution containing

35  2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1X SSC at 50°C for 45 min. Alternatively, filter washes can be performed in a solution containing 2 x SSC and 0.1% SDS,

or 0.5 x SSC and 0.1% SDS, or 0.1 x SSC and 0.1% SDS at 68°C for 15 minute intervals. Following the wash steps, the hybridized probes are detectable by autoradiography. Other conditions of high stringency which is used are well known in the art and as cited in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., pp. 9.47-9.57; and

5   Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. Preferably, such sequences encode a homolog of a polypeptide encoded by one of ORF2 to ORF1297. In one embodiment, such sequences encode a mammalian PG1 polypeptide.

(ii)   By way of example and not limitation, procedures using conditions of intermediate stringency are as follows: Filters containing DNA are prehybridized, and then hybridized at a

10   temperature of 60°C in the presence of a 5 x SSC buffer and labeled probe. Subsequently, filters washes are performed in a solution containing 2x SSC at 50°C and the hybridized probes are detectable by autoradiography. Other conditions of intermediate stringency which is used are well known in the art and as cited in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., pp. 9.47-9.57; and Ausubel et al., 1989, Current

15   Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. Preferably, such sequences encode a homolog of a polypeptide encoded by one of SEQ ID NOs: 3, 69, 100-112, or 179-184. In one embodiment, such sequences encode a mammalian PG1 polypeptide.

The present invention also encompasses diagnostic kits comprising one or more polynucleotides of the invention with a portion or all of the necessary reagents and instructions for

20   genotyping a test subject by determining the identity of a nucleotide at a PG1-related biallelic marker. The polynucleotides of a kit may optionally be attached to a solid support, or be part of an array or addressable array of polynucleotides. The kit may provide for the determination of the identity of the nucleotide at a marker position by any method known in the art including, but not limited to, a sequencing assay method, a microsequencing assay method, a hybridization assay method, or an allele

25   specific amplification method. Optionally such a kit may include instructions for scoring the results of the determination with respect to the test subjects' risk of contracting a cancer or prostate cancer, or likely response to an anti-cancer agent or anti-prostate cancer agent, or chances of suffering from side effects to an anti-cancer agent or anti-prostate cancer agent.

Use of PG1 Nucleic Acids as Reagents

30   The PG1 genomic DNA of SEQ ID NO: 179, the PG1 cDNA of SEQ ID NO: 3, 112-124 and PG1 alleles responsible for a detectable phenotype (such as those obtainable by the methods of Example 12, and SEQ ID NO:69) can be used to prepare PCR primers for use in diagnostic techniques or genetic engineering methods such as those described above. Example 10 describes the use of the PG1 genomic DNA of SEQ ID NO: 179, the PG1 cDNA of SEQ ID NO: 3, 112-124 and PG1 alleles responsible for a

35   detectable phenotype (such as those obtainable by the methods of Example 12) in PCR amplification procedures.

Example 10

The PG1 genomic DNA of SEQ ID NO: 179, the PG1 cDNA of SEQ ID NO: 3, and PG1 alleles

responsible for a detectable phenotype (such as those obtainable by the methods of Example 12) is used

to prepare PCR primers for a variety of applications, including isolation procedures for cloning nucleic

5    acids capable of hybridizing to such sequences, diagnostic techniques and forensic techniques. The PCR

primers comprise at least 10 consecutive bases of the PG1 genomic DNA of SEQ ID NO: 179, the PG1

cDNA of SEQ ID NO: 3, 112-124 and PG1 alleles responsible for a detectable phenotype (such as those

obtainable by the methods of Example 12) or the sequences complementary thereto. Preferably, the PCR

primers comprise at least 12, 15, or 17 consecutive bases of these sequences. More preferably, the PCR

10   primers comprise at least 20-30 consecutive bases of the PG1 genomic DNA of SEQ ID NO: 179, the

PG1 cDNA of SEQ ID NO: 3, 112-124 and PG1 alleles responsible for a detectable phenotype (such as

those obtainable by the methods of Example 12) or the sequences complementary thereto. In some

embodiments, the PCR primers may comprise more than 30 consecutive bases of the PG1 genomic DNA

of SEQ ID NO: 179, the PG1 cDNA of SEQ ID NO: 3, 112-124 and PG1 alleles responsible for a

15   detectable phenotype (such as those obtainable by the methods of Example 12) or the sequences

complementary thereto. It is preferred that the primer pairs to be used together in a PCR amplification

have approximately the same G/C ratio, so that melting temperatures are approximately the same.

A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR

technology, see Molecular Cloning to Genetic Engineering White, B.A. Ed. in Methods in Molecular

20   Biology 67: Humana Press, Totowa 1997. In each of these PCR procedures, PCR primers on either side

of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along

with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent

polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized

to complementary nucleic acid sequences in the sample. The hybridized primers are extended.

25   Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are

repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between

the primer sites.

The polynucleotides of the Invention also encompass vectors and DNA constructs as well as

other forms of primers and probes. For a thorough description of these embodiments please see

30   Sections VIII, X, and XI below.

**III. POLYPEPTIDES**

PG1 Proteins and Polypeptide Fragments

The term "PG1 polypeptides" is used herein to embrace all of the proteins and polypeptides of

the present invention. Also forming part of the invention are polypeptides encoded by the

35   polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. The

invention embodies PG1 proteins from human (SEQ ID NOs: 4, and 5), and mouse (SEQ ID NO: 74).

However, PG1 species from other varieties of mammals are expressly contemplated and is isolated using the antibodies of the present invention in conjunction with standard affinity chromatography methods as well as being expressed from the PG1 genes isolated from other mammalian sources using human and mouse PG1 nucleic acid sequences as primers and probes as well as the methods described

5   herein.

The invention also embodies PG1 proteins translated from less common alternative splice species, including SEQ ID NOs: 125-136, and PG1 proteins which result from naturally occurring mutant, particularly functional mutants of PG1, including SEQ ID NO: 70, which is identified and obtained by the described herein. The present invention also embodies polypeptides comprising a

10  contiguous stretch of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 50, or 100 amino acids of a PG1 protein. In a preferred embodiment the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition, swap or truncation of the amino acids in the PG1 protein sequence. For instance, polypeptides that contain either the Arg and His residues at amino acid position 184, and polypeptides

15  that contain either the Arg or Ile residue at amino acid position 293 of the SEQ ID NO: 4 in said contiguous stretch are particularly preferred embodiments of the invention and useful in the manufacture of antibodies to detect the presence and absence of these mutations. Similarly, polypeptides with a carboxy terminus at position 228 is a particularly preferred embodiment of the invention and useful in the manufacture of antibodies to detect the presence and absence of the

20  mutation shown in SEQ ID NOs: 69 and 70.

Similarly, polypeptides that that contain an peptide sequences of 8, 10, 12, 15, or 25 amino acids encoded over a naturally-occurring splice junction (the point at which two human PG1 exon (SEQ ID NOs: 100-111) are covalently linked) in said contiguous stretch are particularly preferred embodiments and useful in the manufacture of antibodies to detect the presence, localization, and

25  quantity of the various protein products of the PG1 alternative splice species.

PG1 proteins are preferably isolated from human, mouse or mammalian tissue samples or expressed from human, mouse or mammalian genes.

The PG1 polypeptides of the invention can be made using routine expression methods known in the art, see, for instance, Example 11, below. The polynucleotide encoding the desired

30  polypeptide, is ligated into an expression vector suitable for any convenient host. Both eukaryotic and prokaryotic host systems is used in forming recombinant polypeptides, and a summary of some of the more common systems are included in Sections II and VIII. The polypeptide is then isolated from lysed cells or from the culture medium and purified to the extent needed for its intended use. Purification is by any technique known in the art, for example, differential extraction, salt

35  fractionation, chromatography, centrifugation, and the like. See, for example, *Methods in Enzymology* for a variety of methods for purifying proteins.

In addition, shorter protein fragments is produced by chemical synthesis. Alternatively the proteins of the invention is extracted from cells or tissues of humans or non-human animals. Methods for purifying proteins are known in the art, and include the use of detergents or chaotropic agents to disrupt particles followed by differential extraction and separation of the polypeptides by ion

5    exchange chromatography, affinity chromatography, sedimentation according to density, and gel electrophoresis.

Expression of the PG1 Protein

Any PG1 cDNA, including SEQ ID NO: 3, 69, 112-124, or 184 or synthetic DNAs is use as described in Example 11 below to express PG1 proteins and polypeptides.

10                                  Example 11

The nucleic acid encoding the PG1 protein or polypeptide to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The PG1 insert in the expression vector may comprise the full coding sequence for the PG1 protein or a portion thereof. For example, the PG1 derived insert may encode a polypeptide comprising at least 10 consecutive amino

15   acids of the PG1 proteins of SEQ ID NO: 4.

The expression vector is any of the mammalian yeast, insect or bacterial expression systems known in the art, see for example Section VIII. Commercially available vectors and expression systems are available from a variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to

20   enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence is optimized for the particular expression organism in which the expression vector is introduced, as explained by Hatfield, et al., U.S. Patent No. 5,082,767.

The following is provided as one exemplary method to express the PG1 protein or a portion thereof. In one embodiment, the entire coding sequence of the PG1 cDNA through the poly A signal of

25   the cDNA are operably linked to a promoter in the expression vector. Alternatively, if the nucleic acid encoding a portion of the PG1 protein lacks a methionine to serve as the initiation site, an initiating methionine can be introduced next to the first codon of the nucleic acid using conventional techniques. Similarly, if the insert from the PG1 cDNA lacks a poly A signal, this sequence can be added to the construct by, for example, splicing out the Poly A signal from pSG5 (Stratagene) using BglI and SalI

30   restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXT1 (Stratagene). pXT1 contains the LTRs and a portion of the gag gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene. The nucleic acid encoding the PG1 protein or a portion thereof is obtained by PCR from a bacterial vector containing the

35   PG1 cDNA of SEQ ID NO: 3 using oligonucleotide primers complementary to the PG1 cDNA or portion thereof and containing restriction endonuclease sequences for Pst I incorporated into the 5• primer and

BglII at the 5• end of the corresponding cDNA 3• primer, taking care to ensure that the sequence encoding the PG1 protein or a portion thereof is positioned properly with respect to the poly A signal. The purified fragment obtained from the resulting PCR reaction is digested with PstI, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXT1, now containing a poly A signal and

5　digested with BglII.

The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, New York) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600ug/ml G418 (Sigma, St. Louis, Missouri).

10　Alternatively, the nucleic acids encoding the PG1 protein or a portion thereof is cloned into pED6dpc2 (Genetics Institute, Cambridge, MA). The resulting pED6dpc2 constructs is transfected into a suitable host cell, such as COS 1 cells. Methotrexate resistant cells are selected and expanded.

The above procedures may also be used to express a mutant PG1 protein responsible for a detectable phenotype or a portion thereof.

15　The expressed proteins is purified using conventional purification techniques such as ammonium sulfate precipitation or chromatographic separation based on size or charge. The protein encoded by the nucleic acid insert may also be purified using standard immunochromatography techniques. In such procedures, a solution containing the expressed PG1 protein or portion thereof, such as a cell extract, is applied to a column having antibodies against the PG1 protein or portion thereof is attached to the

20　chromatography matrix. The expressed protein is allowed to bind the immunochromatography column. Thereafter, the column is washed to remove non-specifically bound proteins. The specifically bound expressed protein is then released from the column and recovered using standard techniques.

To confirm expression of the PG1 protein or a portion thereof, the proteins expressed from host cells containing an expression vector containing an insert encoding the PG1 protein or a portion thereof

25　can be compared to the proteins expressed in host cells containing the expression vector without an insert. The presence of a band in samples from cells containing the expression vector with an insert which is absent in samples from cells containing the expression vector without an insert indicates that the PG1 protein or a portion thereof is being expressed. Generally, the band will have the mobility expected for the PG1 protein or portion thereof. However, the band may have a mobility different than

30　that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

Antibodies capable of specifically recognizing the expressed PG1 protein or a portion thereof is generated as described below in Section VII.

If antibody production is not possible, the nucleic acids encoding the PG1 protein or a portion thereof is incorporated into expression vectors designed for use in purification schemes employing

35　chimeric polypeptides. In such strategies the nucleic acid encoding the PG1 protein or a portion thereof is inserted in frame with the gene encoding the other half of the chimera. The other half of the chimera

is β-globin or a nickel binding polypeptide encoding sequence. A chromatography matrix having antibody to β-globin or nickel attached thereto is then used to purify the chimeric protein. Protease cleavage sites is engineered between the β-globin gene or the nickel binding polypeptide and the PG1 protein or portion thereof. Thus, the two polypeptides of the chimera is separated from one another by

5    protease digestion.

One useful expression vector for generating β-globin chimerics is pSG5 (Stratagene), which encodes rabbit β-globin. Intron II of the rabbit β-globin gene facilitates splicing of the expressed transcript, and the polyadenylation signal incorporated into the construct increases the level of expression. These techniques are well known to those skilled in the art of molecular biology. Standard methods are

10   published in methods texts such as Davis et al., (Basic Methods in Molecular Biology, L.G. Davis, M.D. Dibner, and J.F. Battey, ed., Elsevier Press, NY, 1986) and many of the methods are available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from the construct using in vitro translation systems such as the In vitro Express™ Translation Kit (Stratagene).

## IV. IDENTIFICATION OF MUTATIONS IN THE PG1 GENE WHICH ARE ASSOCIATED

15   ## WITH A DETECTABLE PHENOTYPE

Mutations in the PG1 gene which are responsible for a detectable phenotype is identified by comparing the sequences of the PG1 genes from affected and unaffected individuals as described in Example 12, below. The detectable phenotype may comprise a variety of manifestations of altered PG1 function, including prostate cancer, hepatocellular carcinoma, colorectal cancer, non-small cell

20   lung cancer, squamous cell carcinoma, or other conditions. The mutations may comprise point mutations, deletions, or insertions of the PG1 gene. The mutations may lie within the coding sequence for the PG1 protein or within regulatory regions in the PG1 gene.

### Example 12

Oligonucleotide primers are designed to amplify the sequences of each of the exons or the

25   promoter region of the PG1 gene. The oligonucleotide primers may comprise at least 10 consecutive nucleotides of the PG1 genomic DNA of SEQ ID NO:179 or the PG1 cDNA of SEQ ID NO: 3 or the sequences complementary thereto. Preferably, the oligonucleotides comprise at least 15 consecutive nucleotides of the PG1 genomic DNA of SEQ ID NO:179 or the PG1 cDNA of SEQ ID NO: 3 or the sequences complementary thereto. In some embodiments, the oligonucleotides may comprise at least

30   20 consecutive nucleotides of the PG1 genomic DNA of SEQ ID NO: 179 or the PG1 cDNA of SEQ ID NO:3 or the sequences complementary thereto. In other embodiments, the oligonucleotides may comprise 25 or more consecutive nucleotides of the PG1 genomic DNA of SEQ ID NO: 179 or the PG1 cDNA of SEQ ID NO: 3 or the sequences complementary thereto.

Each primer pair is used to amplify the exon or promoter region from which it is derived.

35   Amplification is carried out on genomic DNA samples from affected patients and unaffected controls using the PCR conditions described above. Amplification products from the genomic PCRs are

subjected to automated dideoxy terminator sequencing reactions and electrophoresed on ABI 377

sequencers. Following gel image analysis and DNA sequence extraction, ABI sequence data are

automatically analyzed to detect the presence of sequence variations among affected and unaffected

individuals. Sequences are verified by determining the sequences of both DNA strands for each

5    individual. Preferably, these candidate mutations are detected by comparing individuals homozygous

for haplotype 5 of Figure 4 and controls not carrying haplotype 5 or related haplotypes.

Candidate polymorphisms suspected of being responsible for the detectable phenotype, such

as prostate cancer or other conditions, are then verified by screening a larger population of affected

and unaffected individuals using the microsequencing technique described above. Polymorphisms

10   which exhibit a statistically significant correlation with the detectable phenotype are deemed

responsible for the detectable phenotype.

Other techniques may also be used to detect polymorphisms associated with a detectable

phenotype such as prostate cancer or other conditions. For example, polymorphisms is detected using

single stranded conformation analyses such as those described in Orita et al., Proc. Natl. Acad. Sci.

15   U.S.A. 86: 2776-2770 (1989). In this approach, polymorphisms are detected through altered

migration on SSCA gels.

Alternatively, polymorphisms is identified using clamped denaturing gel electrophoresis,

heteroduplex analysis, chemical mismatch cleavage, and other conventional techniques as described

in Sheffield; V.C. et al, Proc. Natl. Acad. Sci. U.S.A 49:699-706 (1991); White, M.B. et al.,

20   Genomics 12:301-306 (1992); Grompe, M. et al., Proc. Natl. Acad. Sci. U.S.A 86:5855-5892 (1989);

and Grompe, M. Nature Genetics 5:111-117 (1993).

The PG1 genes from individuals carrying PG1 mutations responsible for the detectable

phenotype, or cDNAs derived therefrom, is cloned as follows. Nucleic acid samples are obtained

from individuals having a PG1 mutation associated with the detectable phenotype. The nucleic acid

25   samples are contacted with a probe derived from the PG1 genomic DNA of SEQ ID NO: 179 or the

PG1 cDNA of SEQ ID NO:3. Nucleic acids containing the mutant PG1 allele are identified using

conventional techniques. For example, the mutant PG1 gene, or a cDNA derived therefrom, is

obtained by conducting an amplification reaction using primers derived from the PG1 genomic DNA

of SEQ ID NO: 179 or the PG1 cDNA of SEQ ID NO:3. Alternatively, the mutant PG1 gene, or a

30   cDNA derived therefrom, is identified by hybridizing a genomic library or a cDNA library obtained

from an individual having a mutant PG1 gene with a detectable probe derived from the PG1 genomic

DNA of SEQ ID NO: 179 or the PG1 cDNA of SEQ ID NO: 3. Alternatively, the mutant PG1 allele

is obtained by contacting an expression library from an individual carrying a PG1 mutation with a

detectable antibody against the PG1 proteins of SEQ ID NO: 4 or SEQ ID NO: 5 which has been

35   prepared as described below. Those skilled in the art will appreciate that the PG1 genomic DNA of

SEQ ID NO: 179, the PG1 cDNA of SEQ ID NO: 3 and the PG1 proteins of SEQ ID NOs: 4 and 5 is used in a variety of other conventional techniques to obtain the mutant PG1 gene.

In another embodiment the mutant PG1 allele which causes a detectable phenotype can be isolated by obtaining a nucleic acid sample such as a genomic library or a cDNA library from an

5    individual expressing the detectable phenotype. The nucleic acid sample can be contacted with one or more probes lying in the 8p23 region of the human genome. Nucleic acids in the sample which contain the PG1 gene can be identified by conducting sequencing reactions on the nucleic acids which hybridize to the markers from the 8p23 region of the human genome.

The region of the PG1 gene containing the mutation responsible for the detectable phenotype

10   may also be used in diagnostic techniques such as those described below.  For example, oligonucleotides containing the mutation responsible for the detectable phenotype is used in amplification or hybridization based diagnostics, such as those described herein, for detecting individuals suffering from the detectable phenotype or individuals at risk of developing the detectable phenotype at a subsequent time. In addition, the PG1 allele responsible for the detectable phenotype

15   is used in gene therapy as described herein. The PG1 allele responsible for the detectable phenotype may also be cloned into an expression vector to express the mutant PG1 protein a described herein.

During the search for biallelic markers associated with prostate cancer, a number of polymorphic bases were discovered which lie within the PG1 gene. The identities and positions of these polymorphic bases are listed as features in the accompanying Sequence Listing for the PG1

20   genomic DNA of SEQ ID NO: 179. The polymorphic bases is used in the above-described diagnostic techniques for determining whether an individual is at risk for developing prostate cancer at a subsequent date or suffers from prostate cancer as a result of a PG1 mutation. The identities of the nucleotides present at the polymorphic positions in a nucleic acid sample is determined using the techniques, such as microsequencing analysis, which are described above.

25       It is possible that one or more of these polymorphisms (or other polymorphic bases) is mutations which are associated with prostate cancer. To determine whether a polymorphism is responsible for prostate cancer, the frequency of each of the alleles in individuals suffering from prostate cancer and unaffected individuals is measured as described in the haplotype analysis above. Those mutations which occur at a statistically significant frequency in the affected population are

30   deemed to be responsible for prostate cancer.

cDNAs containing the identified mutant PG1 gene is prepared as described above and cloned into expression vectors as described below. The proteins expressed from the expression vectors is used to generate antibodies specific for the mutant PG1 proteins as described below. In addition, allele specific probes containing the PG1 mutation responsible for prostate cancer is used in the

35   diagnostic techniques described below.

Genes sharing homology to the PG1 gene is identified as follows.

<u>Example 13</u>

Alternatively, a cDNA library or genomic DNA library to be screened for genes sharing homology to the PG1 gene is obtained from a commercial source or made using techniques familiar to those skilled in the art. The cDNA library or genomic DNA library is hybridized to a detectable probe

5   comprising at least 10 consecutive nucleotides from the PG1 cDNA of SEQ ID NO:3, the PG1 genomic DNA of SEQ ID NO: 179, or the sequences complementary thereto, using conventional techniques. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the PG1 cDNA of SEQ ID NO:3, the PG1 genomic DNA of SEQ ID NO: 179, or the sequences complementary thereto. More preferably, the probe comprises at least 20-30 consecutive nucleotides from the PG1 cDNA of

10   SEQ ID NO:3, the PG1 genomic DNA of SEQ ID NO: 179, or the sequences complementary thereto. In some embodiments, the probe comprises more than 30 nucleotides from the PG1 cDNA of SEQ ID NO:3, the PG1 genomic DNA of SEQ ID NO: 179, or the sequences complementary thereto.

Techniques for identifying cDNA clones in a cDNA library which hybridize to a given probe sequence are disclosed in Sambrook et al., Molecular Cloning: A Laboratory Manual 2d Ed., Cold

15   Spring Harbor Laboratory Press, 1989. The same techniques is used to isolate genomic DNAs sharing homology with the PG1 gene.

Briefly, cDNA or genomic DNA clones which hybridize to the detectable probe are identified and isolated for further manipulation as follows. A probe comprising at least 10 consecutive nucleotides from the PG1 cDNA of SEQ ID NO:3, the PG1 genomic DNA of SEQ ID NO: 179, or the sequences

20   complementary thereto, is labeled with a detectable label such as a radioisotope or a fluorescent molecule. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the PG1 cDNA of SEQ ID NO:3, the PG1 genomic DNA of SEQ ID NO: 179, or the sequences complementary thereto. More preferably, the probe comprises 20-30 consecutive nucleotides from the PG1 cDNA of SEQ ID NO:3, the PG1 genomic DNA of SEQ ID NO: 179, or the sequences complementary thereto. In

25   some embodiments, the probe comprises more than 30 nucleotides from the PG1 cDNA of SEQ ID NO:3, the PG1 genomic DNA of SEQ ID NO: 179, or the sequences complementary thereto.

Techniques for labeling the probe are well known and include phosphorylation with polynucleotide kinase, nick translation, in vitro transcription, and non-radioactive techniques. The cDNAs or genomic DNAs in the library are transferred to a nitrocellulose or nylon filter and denatured.

30   After incubation of the filter with a blocking solution, the filter is contacted with the labeled probe and incubated for a sufficient amount of time for the probe to hybridize to cDNAs or genomic DNAs containing a sequence capable of hybridizing to the probe.

By varying the stringency of the hybridization conditions used to identify cDNAs or genomic DNAs which hybridize to the detectable probe, cDNAs or genomic DNAs having different levels of

35   homology to the probe can be identified and isolated. To identify cDNAs or genomic DNAs having a

high degree of homology to the probe sequence, the melting temperature of the probe is calculated using the following formulas:

For probes between 14 and 70 nucleotides in length the melting temperature TM is calculated using the formula: Tm=81.5+16.6(log (Na+))+0.41(fraction G+C)-(600/N) where N is the length of the

5   probe.

If the hybridization is carried out in a solution containing formamide, the melting temperature is calculated using the equation Tm=81.5+16.6(log (Na+))+0.41(fraction G+C)-(0.63% formamide)-(600/N) where N is the length of the probe.

Prehybridization is carried out in 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100• g denatured

10  fragmented salmon sperm DNA or 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100• g denatured fragmented salmon sperm DNA, 50% formamide. The formulas for SSC and Denhardt's solutions are listed in Sambrook et al., supra.

Hybridization is conducted by adding the detectable probe to the prehybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured before addition to the

15  hybridization solution. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to cDNAs or genomic DNAs containing sequences complementary thereto or homologous thereto. For probes over 200 nucleotides in length, the hybridization is carried out at 15-25• C below the Tm. For shorter probes, such as oligonucleotide probes, the hybridization is conducted at 15-25• C below the Tm. Preferably, for hybridizations in 6X SSC, the hybridization is

20  conducted at approximately 68• C. Preferably, for hybridizations in 50% formamide containing solutions, the hybridization is conducted at approximately 42• C.

All of the foregoing hybridizations would be considered to be under "stringent" conditions.

Following hybridization, the filter is washed in 2X SSC, 0.1% SDS at room temperature for 15 minutes. The filter is then washed with 0.1X SSC, 0.5% SDS at room temperature for 30 minutes to 1

25  hour. Thereafter, the solution is washed at the hybridization temperature in 0.1X SSC, 0.5% SDS. A final wash is conducted in 0.1X SSC at room temperature.

cDNAs or genomic DNAs homologous to the PG1 gene which have hybridized to the probe are identified by autoradiography or other conventional techniques.

The above procedure is modified to identify cDNAs or genomic DNAs having decreasing levels

30  of homology to the probe sequence. For example, to obtain cDNAs or genomic DNAs of decreasing homology to the detectable probe, less stringent conditions is used. For example, the hybridization temperature is decreased in increments of 5• C from 68• C to 42• C in a hybridization buffer having a Na+ concentration of approximately 1M. Following hybridization, the filter is washed with 2X SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be "moderate"

35  conditions above 50• C and "low" conditions below 50• C.

Alternatively, the hybridization is carried out in buffers, such as 6X SSC, containing formamide at a temperature of 42• C. In this case, the concentration of formamide in the hybridization buffer is reduced in 5% increments from 50% to 0% to identify clones having decreasing levels of homology to the probe. Following hybridization, the filter is washed with 6X SSC, 0.5% SDS at 50• C. These

5    conditions are considered to be "moderate" conditions above 25% formamide and "low" conditions below 25% formamide.

cDNAs or genomic DNAs which have hybridized to the probe are identified by autoradiography.

If it is desired to obtain nucleic acids homologous to the PG1 gene, such as allelic variants thereof or nucleic acids encoding proteins related to the PG1 protein, the level of homology between the

10   hybridized nucleic acid and the PG1 gene may readily be determined. To determine the level of homology between the hybridized nucleic acid and the PG1 gene, the nucleotide sequences of the hybridized nucleic acid and the PG1 gene are compared. For example, using the above methods, nucleic acids having at least 95% nucleic acid homology to the PG1 gene is obtained and identified. Similarly, by using progressively less stringent hybridization conditions one can obtain and identify nucleic acids

15   having at least 90%, at least 85%, at least 80% or at least 75% homology to the PG1 gene.

To determine whether a clone encodes a protein having a given amount of homology to the PG1 protein, the amino acid sequence of the PG1 protein is compared to the amino acid sequence encoded by the hybridizing nucleic acid. Homology is determined to exist when an amino acid sequence in the PG1 protein is closely related to an amino acid sequence in the hybridizing nucleic acid. A sequence is

20   closely related when it is identical to that of the PG1 sequence or when it contains one or more amino acid substitutions therein in which amino acids having similar characteristics have been substituted for one another. Using the above methods, one can obtain nucleic acids encoding proteins having at least 95%, at least 90%, at least 85%, at least 80% or at least 75% homology to the proteins encoded by the PG1 probe.

25   Isolation and Use of Mutant or Low Frequency PG1 Alleles from Mammalian Prostate Tumor Tissues
and Cell lines

A single mutant PG1 gene was isolated from a human prostate cancer cell line. The nucleic acid sequence and amino acid sequence of this mutant PG1 are disclosed in SEQ IN NOs: 69 and 70, respectively. This mutant was found to contain a stop codon at codon position number 229, and

30   therefore results in a truncated gene product of only 228 amino acids. The present invention encompasses purified or isolated nucleic acids comprising at least 8, 10, 12, 15, 20, or 25 consecutive nucleotides of SEQ ID NO: 69, preferably containing the mutation in codon number 229. A preferred embodiment of the present invention encompasses purified or isolated nucleic acids comprising at least 8, 10, 12, 15, 20, or 25 consecutive nucleotides of SEQ ID NO: 71.

35   The present invention is also directed to methods of determining whether an individual is at risk of developing prostate cancer at a later date or whether said individual suffers from prostate

cancer as a result of a mutation in the PG1 gene comprising: obtaining a nucleic acid sample from said individual; and determining whether the nucleotides present at one or more of the polymorphic bases in the sequences selected from the group consisting of SEQ ID NOs: 69 and 71 are indicative of a risk of developing prostate cancer at a later date or indicative of prostate cancer resulting from a

5     mutation in the PG1 gene. The present invention also includes purified or isolated nucleic acids encoding at least 4, 8, 10, 12, 15, or 20 consecutive amino acids of the polypeptide of SEQ ID NO: 70, preferably including the carboxy terminus of said polypeptide. The isolated or purified polypeptides of the invention include polypeptides comprising at least 4, 8, 10, 12, 15, or 20 consecutive amino acids of the polypeptide of SEQ ID NO: 70, preferably including the carboxy

10    terminus of said polypeptide.

## V. DIAGNOSIS OF INDIVIDUALS AT RISK FOR DEVELOPING PROSTATE CANCER OR INDIVIDUALS SUFFERING FROM PROSTATE CANCER AS A RESULT OF A MUTATION IN THE PG1 GENE

        Individuals may then be screened for the presence of polymorphisms in the PG1 gene or

15    protein which are associated with a detectable phenotype such as cancer, prostate cancer or other conditions as described in Example 13, below. The individuals is screened while they are asymptomatic to determine their risk of developing cancer, prostate cancer or other conditions at a subsequent time. Alternatively, individuals suffering from cancer, prostate cancer or other conditions is screened for the presence of polymorphisms in the PG1 gene or protein in order to determine

20    whether therapies which target the PG1 gene or protein should be applied.

### Example 14

        Nucleic acid samples are obtained from a symptomatic or asymptomatic individual. The nucleic acid samples is obtained from blood cells as described above or is obtained from other tissues or organs. For individuals suffering from prostate cancer, the nucleic acid sample is obtained from

25    the tumor. The nucleic acid sample may comprise DNA, RNA, or both. The nucleotides at positions in the PG1 gene where mutations lead to prostate cancer or other detectable phenotypes are determined for the nucleic acid sample.

        In one embodiment, a PCR amplification is conducted on the nucleic acid sample as described above to amplify regions in which polymorphisms associated with prostate cancer or other detectable

30    phenotypes have been identified. The amplification products are sequenced to determine whether the individual possesses one or more PG1 polymorphisms associated with prostate cancer or other detectable phenotypes.

        Alternatively, the nucleic acid sample is subjected to microsequencing reactions as described above to determine whether the individual possesses one or more PG1 polymorphisms associated with

35    prostate cancer or another detectable phenotype resulting from a mutation in the PG1 gene.

In another embodiment, the nucleic acid sample is contacted with one or more allele specific oligonucleotides which specifically hybridize to one or more PG1 alleles associated with prostate cancer or another detectable phenotype. The nucleic acid sample is also contacted with a second PG1 oligonucleotide capable of producing an amplification product when used with the allele specific

5 oligonucleotide in an amplification reaction. The presence of an amplification product in the amplification reaction indicates that the individual possesses one or more PG1 alleles associated with prostate cancer or another detectable phenotype.

## Determination of PG1 Expression Levels

As discussed above, PG1 polymorphisms associated with cancer, prostate cancer or other

10 detectable phenotypes may exert their effects by increasing, decreasing, or eliminating PG1 expression, or in altering the frequency of various transcription species. Accordingly, PG1 expression levels in individuals suffering from cancer, prostate cancer or other detectable phenotypes is compared to those of unaffected individuals to determine whether over-expression, under-expression, loss of expression, or changes in the relative frequency of transcription species of PG1 causes cancer,

15 prostate cancer or another detectable phenotype. Individuals is tested to determine whether they are at risk of developing cancer, or prostate cancer at a subsequent time or whether they suffer from prostate cancer resulting from a mutation in the PG1 gene by determining whether they exhibit a level of PG1 expression associated with prostate cancer. Similarly, individuals is tested to determine whether they suffer from another PG1 mediated detectable phenotype or whether they are at risk of suffering from

20 such a condition at a subsequent time.

Expression levels in nucleic acid samples from affected and unaffected individuals is determined by performing Northern blots using detectable probes derived from the PG1 gene or the PG1 cDNA. A variety of conventional Northern blotting procedures is used to detect and quantitate PG1 expression and the frequencies of the various transcription species of PG1, including those

25 disclosed in Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. 1997 and Sambrook et al. Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989.

Alternatively, PG1 expression levels is determined as described in Example 15, below.

## Example 15

30 Expression levels and patterns of PG1 is analyzed by solution hybridization with long probes as described in International Patent Application No. WO 97/05277. Briefly, the PG1 cDNA or the PG1 genomic DNA described above, or fragments thereof, is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the PG1 insert comprises at least 100 or more consecutive nucleotides of the genomic DNA

35 sequence of SEQ ID NO: 1 or the cDNA sequences of SEQ ID NO: 3. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and

DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridizations are performed under standard stringent conditions (40-50• C for 16 hours in an 80% formamide, 0.4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M,

5    U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

Quantitative analysis of PG1 gene expression may also be performed using arrays as described in Sections II and X,. As used here, the term array means an arrangement of a plurality of nucleic acids

10   of sufficient length to permit specific detection of expression of PG1 mRNAs capable of hybridizing thereto. For example, the arrays may contain a plurality of nucleic acids derived from genes whose expression levels are to be assessed. The arrays may include the PG1 genomic DNA of SEQ ID NO:179, the PG1 cDNA of SEQ ID NO:3 or the sequences complementary thereto or fragments thereof. The array may contain some or all of the known alternative splice or transcription species of PG1,

15   including the species in SEQ ID NOs: 3, and 112-124 to determine the relative frequency of particular transcription species. Alternatively, the array may contain polynucleotides which overlap all of the potential splice junctions, including, for  example SEQ ID NOs: 137-178, so that the frequency of particular splice junctions can be determined and correlated with traits or used in diagnostics just as expressions levels are. Preferably, the fragments are at least 15 nucleotides in length. In other

20   embodiments, the fragments are at least 25 nucleotides in length. In some embodiments, the fragments are at least 50 nucleotides in length. More preferably, the fragments are at least 100 nucleotides in length. In another preferred embodiment, the fragments are more than 100 nucleotides in length. In some embodiments the fragments is more than 500 nucleotides in length.

For example, quantitative analysis of PG1 gene expression is performed with a complementary

25   DNA microarray as described by Schena et al. (Science 270:467-470, 1995; Proc. Natl. Acad. Sci. U.S.A. 93:10614-10619, 1996). Full length PG1 cDNAs or fragments thereof are amplified by PCR and arrayed from a 96-well microtiter plate onto silylated microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 min, twice in water for 1 min and once for 5 min in sodium borohydride

30   solution. The arrays are submerged in water for 2 min at 95• C, transferred into 0.2% SDS for 1 min, rinsed twice with water, air dried and stored in the dark at 25• C.

Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by a single round of reverse transcription. Probes are hybridized to 1 cm$^2$ microarrays under a 14 x 14 mm glass coverslip for 6-12 hours at 60• C. Arrays are washed for 5 min at 25• C in low stringency wash buffer

35   (1 x SSC/0.2% SDS), then for 10 min at room temperature in high stringency wash buffer (0.1 x SSC/0.2% SDS). Arrays are scanned in 0.1 x SSC using a fluorescence laser scanning device fitted with

a custom filter set. Accurate differential expression measurements are obtained by taking the average of the ratios of two independent hybridizations.

Quantitative analysis of PG1 gene expression may also be performed with full length PG1 cDNAs or fragments thereof in complementary DNA arrays as described by Pietu et al. (Genome

5    Research 6:492-503, 1996). The full length PG1 cDNA or fragments thereof is PCR amplified and spotted on membranes. Then, mRNAs originating from various tissues or cells are labeled with radioactive nucleotides. After hybridization and washing in controlled conditions, the hybridized mRNAs are detected by phospho-imaging or autoradiography. Duplicate experiments are performed and a quantitative analysis of differentially expressed mRNAs is then performed.

10    Alternatively, expression analysis using the PG1 genomic DNA, the PG1 cDNA, or fragments thereof can be done through high density nucleotide arrays as described by Lockhart et al. (Nature Biotechnology 14: 1675-1680, 1996) and Sosnowsky et al. (Proc. Natl. Acad. Sci. 94:1119-1123, 1997). Oligonucleotides of 15-50 nucleotides from the sequences of the PG1 genomic DNA of SEQ ID NO: 179, the PG1 cDNA of SEQ ID NO: 3, 112-124 or the sequences complementary thereto, are synthesized

15    directly on the chip (Lockhart et al., supra) or synthesized and then addressed to the chip (Sosnowski et al., supra).

PG1 cDNA probes labeled with an appropriate compound, such as biotin, digoxigenin or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After

20    washing as described in Lockhart et al., supra and application of different electric fields (Sosnowsky et al., Proc. Natl. Acad. Sci. 94:1119-1123)., the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed. Comparative analysis of the intensity of the signal originating from cDNA probes on the same target oligonucleotide in different cDNA samples indicates a differential expression of PG1 mRNA.

25    The above methods may also be used to determine whether an individual exhibits a PG1 expression pattern associated with cancer, prostate cancer or other diseases. In such methods, nucleic acid samples from the individual are assayed for PG1 expression as described above. If a PG1 expression pattern associated with cancer, prostate cancer, or another disease is observed, an appropriate diagnosis is rendered and appropriate therapeutic techniques which target the PG1 gene or protein is

30    applied.

The above methods may also be applied using allele specific probes to determine whether an individual possesses a PG1 allele associated with cancer, prostate cancer, or another disease. In such approaches, one or more allele specific oligonucleotides containing polymorphic nucleotides in the PG1 gene which are associated with prostate cancer are fixed to a microarray. The array is contacted with a

35    nucleic acid sample from the individual being tested under conditions which permit allele specific hybridization of the sample nucleic acid to the allele specific PG1 probes. Hybridization of the sample

nucleic acid to one or more of the allele specific PG1 probes indicates that the individual suffers from prostate cancer caused by the PG1 gene or that the individual is at risk for developing prostate cancer at a subsequent time. Alternatively, any of the genotyping methods described in Section X is utilized..

## Use of the Biallelic Markers Of The Invention In Diagnostics

5        The biallelic markers of the present invention can also be used to develop diagnostics tests capable of identifying individuals who express a detectable trait as the result of a specific genotype or individuals whose genotype places them at risk of developing a detectable trait at a subsequent time.

The diagnostic techniques of the present invention may employ a variety of methodologies to determine whether a test subject has a biallelic marker pattern associated with an increased risk of 10  developing a detectable trait or whether the individual suffers from a detectable trait as a result of a particular mutation, including methods which enable the analysis of individual chromosomes for haplotyping, such as family studies, single sperm DNA analysis or somatic hybrids. The trait analyzed using the present diagnostics is any detectable trait, cancer, prostate cancer or another disease, a response to an anti-cancer, or anti-prostate cancer, or side effects to an anti-cancer or anti- 15  prostate cancer agent. Diagnostics, which analyze and predict response to a drug or side effects to a drug, is used to determine whether an individual should be treated with a particular drug. For example, if the diagnostic indicates a likelihood that an individual will respond positively to treatment with a particular drug, the drug is administered to the individual. Conversely, if the diagnostic indicates that an individual is likely to respond negatively to treatment with a particular drug, an 20  alternative course of treatment is prescribed. A negative response is defined as either the absence of an efficacious response or the presence of toxic side effects.

Clinical drug trials represent another application for the markers of the present invention. One or more markers indicative of response to an anti-cancer or anti-prostate cancer agent or to side effects to an anti-cancer or anti-prostate cancer agent is identified using the methods described in 25  Section XI, below. Thereafter, potential participants in clinical trials of such an agent is screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment is measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety 30  problems. Preferably, in such diagnostic methods, a nucleic acid sample is obtained from the individual and this sample is genotyped using methods described in Section X.

Another aspect of the present invention relates to a method of determining whether an individual is at risk of developing a trait or whether an individual expresses a trait as a consequence of possessing a particular trait-causing allele. The present invention relates to a method of determining 35  whether an individual is at risk of developing a plurality of traits or whether an individual expresses a plurality of traits as a result of possessing a particular trait-causing allele. These methods involve

obtaining a nucleic acid sample from the individual and determining whether the nucleic acid sample contains one or more alleles of one or more biallelic markers indicative of a risk of developing the trait or indicative that the individual expresses the trait as a result of possessing a particular trait-causing allele.

5       As described herein, the diagnostics is based on a single biallelic marker or a group of biallelic markers.

## VI.   ASSAYING THE PG1 PROTEIN FOR INVOLVEMENT IN RECEPTOR/LIGAND INTERACTIONS

The expressed PG1 protein or portion thereof is evaluated for involvement in receptor/ligand
10   interactions as described in Example 16 below.

### Example 16

The proteins encoded by the PG1 gene or a portion thereof may also be evaluated for their involvement in receptor/ligand interactions. Numerous assays for such involvement are familiar to those skilled in the art, including the assays disclosed in the following references: Chapter 7.28 (Measurement
15   of Cellular Adhesion under Static Conditions 7.28.1-7.28.22) in Current Protocols in Immunology, J.E. Coligan et al. Eds. Greene Publishing Associates and Wiley-Interscience; Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160, 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995; Gyuris et al., Cell 75:791-803, 1993.

20       For example, the proteins of the present invention may demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as sclectins, integrins and their
25   ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

30       The PG1 protein or portions thereof described above is used in drug screening procedures to identify molecules which are agonists, antagonists, or inhibitors of PG1 activity. The PG1 protein or portion thereof used in such analyses is free in solution or linked to a solid support. Alternatively, PG1 protein or portions thereof can be expressed on a cell surface. The cell may naturally express the PG1 protein or portion thereof or, alternatively, the cell may express the PG1 protein or portion thereof from
35   an expression vector such as those described below.

In one method of drug screening, eukaryotic or prokaryotic host cells which are stably transformed with recombinant polynucleotides in order to express the PG1 protein or a portion thereof are used in conventional competitive binding assays or standard direct binding assays. For example, the formation of a complex between the PG1 protein or a portion thereof and the agent being tested is measured in

5    direct binding assays. Alternatively, the ability of a test agent to prevent formation of a complex between the PG1 protein or a portion thereof and a known ligand is measured.

Alternatively, the high throughput screening techniques disclosed in the published PCT application WO 84/03564, is used. In such techniques, large numbers of small peptides to be tested for PG1 binding activity are synthesized on a surface and affixed thereto. The test peptides are contacted

10   with the PG1 protein or a portion thereof, followed by a wash step. The amount of PG1 protein or portion thereof which binds to the test compound is quantitated using conventional techniques.

In some methods, PG1 protein or a portion thereof is fixed to a surface and contacted with a test compound. After a washing step, the amount of test compound which binds to the PG1 protein or portion thereof is measured.

15   In another approach, the three dimensional structure of the PG1 protein or a portion thereof may be determined and used for rational drug design.

Alternatively, the PG1 protein or a portion thereof is expressed in a host cell using expression vectors such as those described herein. The PG1 protein or portion thereof is an isotype which is associated with prostate cancer or an isotype which is not associated with prostate cancer. The cells

20   expressing the PG1 protein or portion thereof are contacted with a series of test agents and the effects of the test agents on PG1 activity are measured. Test agents which modify PG1 activity is employed in therapeutic treatments.

The above procedures may also be applied to evaluate mutant PG1 proteins responsible for a detectable phenotype.

25                    Identification of Proteins which Interact with the PG1 Protein

Proteins which interact with the PG1 protein is identified as described in Example 17, below.

Example 17

Proteins which interact with the PG1 protein or a portion thereof, is identified using two hybrid systems such as the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech). As described

30   in the manual accompanying the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech), nucleic acids encoding the PG1 protein or a portion thereof, are inserted into an expression vector such that they are in frame with DNA encoding the DNA binding domain of the yeast transcriptional activator GAL4. cDNAs in a cDNA library which encode proteins which might interact with the polypeptides encoded by the nucleic acids encoding the PG1 protein or a portion thereof are inserted into a second

35   expression vector such that they are in frame with DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into yeast and the yeast are plated on selection medium which

selects for expression of selectable markers on each of the expression vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the histidine selection and the lacZ assay contain plasmids encoding proteins which interact with the polypeptide

5    encoded by the nucleic acid inserts.

Alternatively, the system described in Lustig et al., Methods in Enzymology 283: 83-99 (1997), is used for identifying molecules which interact with the PG1 protein or a portion thereof. In such systems, in vitro transcription reactions are performed on vectors containing an insert encoded the PG1 protein or a portion thereof cloned downstream of a promoter which drives in vitro transcription. The

10   resulting mRNA is introduced into Xenopus laevis oocytes. The oocytes are then assayed for a desired activity.

Alternatively, the in vitro transcription products produced as described above is translated in vitro. The in vitro translation products can be assayed for a desired activity or for interaction with a known polypeptide.

15   The system described in U.S. Patent No. 5,654,150 may also be used to identify molecules which interact with the PG1 protein or a portion thereof. In this system, pools of cDNAs are transcribed and translated in vitro and the reaction products are assayed for interaction with a known polypeptide or antibody.

Proteins or other molecules interacting with the PG1 protein or portions thereof can be found

20   by a variety of additional techniques. In one method, affinity columns containing the PG1 protein or a portion thereof can be constructed. In some versions of this method the affinity column contains chimeric proteins in which the PG1 protein or a portion thereof is fused to glutathione S-transferase. A mixture of cellular proteins or pool of expressed proteins as described above is applied to the affinity column. Proteins interacting with the polypeptide attached to the column can then be isolated

25   and analyzed on 2-D electrophoresis gel as described in Ramunsen et al. Electrophoresis, 18, 588-598 (1997). Alternatively, the proteins retained on the affinity column can be purified by electrophoresis based methods and sequenced. The same method can be used to isolate antibodies, to screen phage display products, or to screen phage display human antibodies.

Proteins interacting with the PG1 protein or portions thereof can also be screened by using an

30   Optical Biosensor as described in Edwards et Leatherbarrow, Analytical Biochemistry, 246, 1-6 (1997). The main advantage of the method is that it allows the determination of the association rate between the protein and other interacting molecules. Thus, it is possible to specifically select interacting molecules with a high or low association rate. Typically a target molecule is linked to the sensor surface (through a carboxymethl dextran matrix) and a sample of test molecules is placed in

35   contact with the target molecules. The binding of a test molecule to the target molecule causes a change in the refractive index and/ or thickness. This change is detected by the Biosensor provided it

occurs in the evanescent field (which extend a few hundred nanometers from the sensor surface). In these screening assays, the target molecule can be the PG1 protein or a portion thereof and the test sample can be a collection of proteins extracted from tissues or cells, a pool of expressed proteins, combinatorial peptide and/ or chemical libraries, or phage displayed peptides. The tissues or cells

5    from which the test proteins are extracted can originate from any species.

In other methods, a target protein is immobilized and the test population is the PG1 protein or a portion thereof.

To study the interaction of the PG1 protein or a portion thereof with drugs, the microdialysis coupled to HPLC method described by Wang et al., Chromatographia, 44, 205-208(1997) or the

10   affinity capillary electrophoresis method described by Busch et al., J. Chromatogr. 777:311-328 (1997).

The above procedures may also be applied to evaluate mutant PG1 proteins responsible for a detectable phenotype.

## VII. PRODUCTION OF ANTIBODIES AGAINST PG1 POLYPEPTIDES

15          Any PG1 polypeptide or whole protein (SEQ ID NOs: 4, 5, 70, 74, 125-136) whether human, mouse or mammalian is used to generate antibodies capable of specifically binding to expressed PG1 protein or fragments thereof as described in Example 16, below. The antibodies is capable of binding the full length PG1 protein. PG1 proteins which result from naturally occurring mutant, particularly functional mutants of PG1, including SEQ ID NO: 70, which may used in the

20   production of antibodies. The present invention also contemplates the use of polypeptides comprising a contiguous stretch of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 50, or 100 amino acids of any PG1 protein in the manufacture of antibodies. In a preferred embodiment the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition, swap or truncation of the amino acids in the PG1

25   protein sequence. For instance, polypeptides that contain either the Arg and His residues at amino acid position 184, and polypeptides that contain either the Arg or Ile residue at amino acid position 293 of the SEQ ID NO: 4 in said contiguous stretch are particularly preferred embodiments of the invention and useful in the manufacture of antibodies to detect the presence and absence of these mutations. Similarly, polypeptides with a carboxy terminus at position 228 is a particularly preferred

30   embodiment of the invention and useful in the manufacture of antibodies to detect the presence and absence of the mutation shown in SEQ ID NOs: 69 and 70. Similarly, polypeptides that that contain an peptide sequences of 8, 10, 12, 15, or 25 amino acids encoded over a naturally-occurring splice junction (the point at which two human PG1 exon (SEQ ID NOs: 100-111) are covalently linked) in said contiguous stretch are particularly preferred embodiments and useful in the manufacture of

35   antibodies to detect the presence, localization, and quantity of the various protein products of the PG1 alternative splice species.

Alternatively, the antibodies is screened so as to isolate those which are capable of binding an epitope-containing fragment of at least 8, 10, 12, 15, 20, 25, or 30 amino acids of a human, mouse, or mammalian PG1 protein, preferably a sequence selected from SEQ ID NOs: 4, 5, 70, 74, or 125-136.

Antibodies may also be generated which are capable of specifically binding to a given isoform
5   of the PG1 protein. For example, the antibodies is capable of specifically binding to an isoform of the PG1 protein which causes prostate cancer or another detectable phenotype which has been obtained as described above and expressed from an expression vector as described above. Alternatively, the antibodies is capable of binding to an isoform of the PG1 protein which does not cause prostate cancer. Such antibodies is used in diagnostic assays in which protein samples from an individual are evaluated
10  for the presence of an isoform of the PG1 protein which causes cancer or another detectable phenotype using techniques such as Western blotting or ELISA assays.

Non-human animals or mammals, whether wild-type or transgenic, which express a different species of PG1 than the one to which antibody binding is desired, and animals which do not express PG1 (i.e. an PG1 knock out animal as described in Section VIII.) are particularly useful for preparing
15  antibodies. PG1 knock out animals will recognize all or most of the exposed regions of PG1 as foreign antigens, and therefore produce antibodies with a wider array of PG1 epitopes. The humoral immune system of animals which produce a species of PG1 that resembles the antigenic sequence will preferentially recognize the differences between the animal's native PG1 species and the antigen sequence, and produce antibodies to these unique sites in the antigen sequence.

20                                                  Example 18

Substantially pure protein or polypeptide is isolated from transfected or transformed cells containing an expression vector encoding the PG1 protein or a portion thereof as described in Example 11. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the
25  protein can then be prepared as follows:

A. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes in the PG1 protein or a portion thereof can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., Nature 256:495 (1975) or derivative methods thereof. Also see Harlow, E., and D. Lane. 1988. Antibodies A
30  Laboratory Manual. Cold Spring Harbor Laboratory. pp. 53-242.

Briefly, a mouse is repetitively inoculated with a few micrograms of the PG1 protein or a portion thereof over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising
35  aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are

identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, E., Meth. Enzymol. 70:419 (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et

5    al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2.

B. Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogeneous epitopes in the PG1 protein or a portion thereof can be prepared by immunizing suitable non-human animal with the PG1 protein or a portion thereof, which can be unmodified or modified to enhance immunogenicity. A suitable non-

10   human animal is preferably a non-human mammal is selected, usually a mouse, rat, rabbit, goat, or horse. Alternatively, a crude preparation which has been enriched for PG1 concentration can be used to generate antibodies. Such proteins, fragments or preparations are introduced into the non-human mammal in the presence of an appropriate adjuvant (e.g. aluminum hydroxide, RIBI, etc.) which is known in the art. In addition the protein, fragment or preparation can be pretreated with an agent

15   which will increase antigenicity, such agents are known in the art and include, for example, methylated bovine serum albumin (mBSA), bovine serum albumin (BSA), Hepatitis B surface antigen, and keyhole limpet hemocyanin (KLH). Serum from the immunized animal is collected, treated and tested according to known procedures. If the serum contains polyclonal antibodies to undesired epitopes, the polyclonal antibodies can be purified by immunoaffinity chromatography.

20   Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and

25   Walker (1987). An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33:988-991 (1971).

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., Chap. 19

30   in: Handbook of Experimental Immunology D. Wier (ed) Blackwell (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 • M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).

35   Antibody preparations prepared according to either the monoclonal or the polyclonal protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances

in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

## VIII.  VECTORS AND THE USES OF POLYNUCLEOTIDES IN CELLS, ANIMALS, AND

5  **HUMANS**

The nucleic acids of the invention include expression vectors, amplification vectors, PCR-suitable polynucleotide primers, and vectors which are suitable for the introduction of a polynucleotide of the invention into an embryonic stem cells for the production of transgenic non-human animals. In addition, vectors which are suitable for the introduction of a polynucleotide of the

10  invention into cells, organs and individuals, including human individuals, for the purposes of gene therapy to reduce the severity of or prevent genetic diseases associated with functional mutations in PG1 genes are encompassed by the present invention. Functional mutations in PG1 genes which are suitable as targets for the gene therapy and transgenic vectors and methods of the invention include, but are not limited to, mutations in the coding region of the PG1 gene which affect the amino acid

15  sequence of the PG1 gene's product, mutations in the promoter or other regulatory regions which affect the levels of PG1 expression, mutations in the PG1 splice sites which affect length of the PG1 gene product or the relative frequency of PG1 alternative splicing species, and any other mutation which in any way affects the level or quality of PG1 expression or activity.  The gene therapy methods can be achieved by targeting vectors and method for changing a mutant PG1 gene into a

20  wild-type PG1 gene in a embryonic stem cell or somatic cell. Alternatively, the present invention also encompasses methods and vectors for introducing the expression of wild-type PG1 sequences without the disruption of any mutant PG1 which already reside in the cell, organ or individual.

The invention also embodies amplification vectors, which comprise a polynucleotide of the invention, and an origin of replication.  Preferably, such amplification vectors further comprise

25  restriction endonuclease sites flanking the polynucleotide, so as to facilitate cleavage and purification of the polynucleotides from the remainder of the amplification vector, and a selectable marker, so as to facilitate amplification of the amplification vector.  Most preferably, the restriction endonuclease sites in the amplification vector are situated such that cleavage at those site would result in no other amplification vector fragments of a similar size.

30  Thus, such an amplification vector is transfected into a host cell compatible with the origin of replication of said amplification vector, wherein the host cell is a prokaryotic or eukaryotic cell, preferably a mammalian, insect, yeast, or bacterial cell, most preferably an Escherichia coli cell. The resulting transfected host cells is grown by culture methods known in the art, preferably under selection compatible with the selectable marker (e.g., antibiotics). The amplification vectors can be

35  isolated and purified by methods known in the art (e.g., standard plasmid prep procedures).  The polynucleotide of the invention can be cleaved with restriction enzymes that specifically cleave at the

restriction endonuclease sites flanking the polynucleotide, and the double-stranded polynucleotide fragment purified by techniques known in the art, including gel electrophoresis.

Alternatively linear polynucleotides comprising a polynucleotide of the invention is amplified by PCR. The PCR method is well known in the art and described in, e.g., U.S. Patent Nos. 4,683,195

5   and 4,683,202 and Saiki, R et al. 1988. Science 239:487-491, and European patent applications 86302298.4, 86302299.2 and 87300203.4, as well as Methods in Enzymology 1987 155:335-350.

The polynucleotides of the invention can also be derivatized in various ways, including those appropriate for facilitating transfection and/or gene therapy. The polynucleotides can be derivatized by attaching a nuclear localization signal to it to improve targeted delivery to the nucleus. One well-

10  characterized nuclear localization signal is the heptapeptide PKKKRKV (pro-lys-lys-lys-arg-lys-val). Preferably, in the case of polynucleotides in the form of a closed circle, the nuclear localization signal is attached via a modified loop nucleotide or spacer that forms a branching structure.

If it is to be used in vivo, the polynucleotide of the invention is derivatized to include ligands and/or delivery vehicles which provide dispersion through the blood, targeting to specific cell types,

15  or permit easier transit of cellular barriers. Thus, the polynucleotides of the invention is linked or combined with any targeting or delivery agent known in the art, including but not limited to, cell penetration enhancers, lipofectin, liposomes, dendrimers, DNA intercalators, and nanoparticles. In particular, nanoparticles for use in the delivery of the polynucleotides of the invention are particles of less than about 50 nanometers diameter, nontoxic, non-antigenic, and comprised of albumin and

20  surfactant, or iron as in the nanoparticle particle technology of SynGenix. In general the delivery vehicles used to target the polynucleotides of the invention may further comprise any cell specific or general targeting agents known in the art, and will have a specific trapping efficiency to the target cells or organs of from about 5 to about 35%.

The polynucleotides of the invention is used ex vivo in a gene therapy method for obtaining

25  cells or organs which produce wild-type PG1 or PG1 proteins which have been selectively mutated. The cells are created by incubation of the target cell with one or more of the above-described polynucleotides under standard conditions for uptake of nucleic acids, including electroporation or lipofection. In practicing an ex vivo method of treating cells or organs, the concentration of polynucleotides of the invention in a solution prepare to treat target cells or organs is from about 0.1

30  to about 100 µM, preferably 0.5 to 50 µM, most preferably from 1 to 10 µM.

Alternatively, the oligonucleotides can be modified or co-administered for targeted delivery to the nucleus. Improved oligonucleotide stability is expected in the nucleus due to: (1) lower levels of DNases and RNases; and (2) higher oligonucleotide concentrations due to lower total volume.

Alternatively, the polynucleotides of the invention can be covalently bonded to biotin to form

35  a biotin-polynucleotide prodrug by methods known in the art, and co-administered with a receptor ligand bound to avidin or receptor specific antibody bound to avidin, wherein the receptor is capable

of causing uptake of the resulting polynucleotide-biotin-avidin complex into the cells. Receptors that cause uptake are known to those of skill in the art.

The invention encompasses vectors which are suitable for the introduction of a polynucleotide of the invention into an embryonic stem cell for the production of transgenic non-human animals,

5    which in turn result in the expression of recombinant PG1 in the transgenic animal. Any appropriate vector system can be used for the introduction and expression of PG1 in transgenic animals, including for example yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), bacteriophage P1, and other vectors known in the art which are able to accommodate sufficiently large inserts to encode the PG1 protein or desired fragments thereof. Selected alterations, additions

10   and deletions in the PG1 gene may optionally be achieved by site-directed mutagenesis. Once an appropriate vector system is chosen, the site-directed mutagenesis process may then be conducted by techniques well known in the art , and the fragment be returned and ligated to the larger vector from which it was cleaved. For site directed mutagenesis methods see, for example, Kunkel, T. 1985. Proc. Natl. Acad. Sci. U.S.A. 82:488; Bandeyar, M. et al. 1988. Gene 65: 129-133; Nelson, M., and M.

15   McClelland 1992. Methods Enzymol. 216:279-303; Weiner, M. 1994. Gene 151: 119-123; Costa, G. and M. Weiner. 1994. Nucleic Acids Res. 22: 2423; Hu, G. 1993. DNA and Cell Biology 12:763-770; and Deng, W. and J. Nickoff. 1992. Anal. Biochem. 200:81.

Briefly, the transgenic technology used herein involves the inactivation, addition or replacement of a portion of the PG1 gene or the entire gene. For example the present technology

20   includes the addition of PG1 genes with or without the inactivation of the non-human animal's native PG1 genes, as described in the preceding two paragraphs and in the Examples. The invention also encompasses the use of vectors, and the vectors themselves which target and modify an existing human PG1 gene in a stem cell, whether it is contained in a non-human animal cell where it was previously introduced into the germ line by transgenic technology or it is a native PG1 gene in a

25   human pluripotent or somatic cell. This transgene technology usually relies on homologous recombination in a pluripotent cell that is capable of differentiating into germ cell tissue. A DNA construct that encodes an altered region of the non-human animal's PG1 gene that contains, for instance a stop codon to destroy expression, is introduced into the nuclei of embryonic stem cells. Preferably mice are used for this transgenic work. In a portion of the cells, the introduced DNA

30   recombines with the endogenous copy of the cell's gene, replacing it with the altered copy. Cells containing the newly engineered genetic alteration are injected in a host embryo of the same species as the stem cell, and the embryo is reimplanted into a recipient female. Some of these embryos develop into chimeric individuals that posses germ cells entirely derived from the mutant cell line. Therefore, by breeding the chimeric progeny it is possible to obtain a new strain containing the

35   introduced genetic alteration. See Capecchi 1989. Science. 244:1288-1292 for a review of this procedure.

The present invention encompasses the polynucleotides described herein, as well as the methods for making these polynucleotides including the method for creating a mutation in a human PG1 gene. In addition, the present invention encompasses cells which comprise the polynucleotides of the invention, including but not limited to amplification host cells comprising amplification vectors

5    of the invention. Furthermore the present invention comprises the embryonic stem cells and transgenic non-human animals and mammals described herein which comprise a gene encoding a human PG1 protein.

<u>DNA construct that enables directing temporal and spatial gene expression in recombinant host cells and in transgenic animals</u>

10    In order to study the physiological and phenotype consequences of a lack of synthesis of the PG1 protein, both at the cellular level and at the multi-cellular organism level, in particular as regards to disorders related to abnormal cell proliferation, notably cancers, the invention also encompasses DNA constructs and recombinant vectors enabling a conditional expression of a specific allele of the PG1 genomic sequence or cDNA and also of a copy of this genomic sequence or cDNA harboring

15    substitutions, deletions, or additions of one or more bases as regards to the PG1 nucleotide sequence of SEQ ID NOs: 3, 112-125, 179, 182-184, or a fragment thereof, these base substitutions, deletions or additions being located either in an exon, an intron or a regulatory sequence, but preferably in a 5'-regulatory sequence of a mammalian PG1 gene, more preferably SEQ ID NO: 180 or in an exon of the PG1 genomic sequence or within the PG1 cDNA of SEQ ID NOs 3, 112-125, or 184.

20    A first preferred DNA construct is based on the tetracycline resistance operon tet from E. coli transposon Tn110 for controlling the PG1 gene expression, such as described by Gossen M. et al., 1992, Proc. Natl. Acad. Sci. USA, 89: 5547-5551; Gossen M. et al., 1995, Science, 268: 1766-1769; and Furth P.A. et al., 1994, Proc. Natl Acad. Sci USA, 91: 9302-9306. Such a DNA construct contains seven tet operator sequences from Tn10 (tetop) that are fused to either a minimal promoter or

25    a 5'-regulatory sequence of the PG1 gene, said minimal promoter or said PG1 regulatory sequence being operably linked to a polynucleotide of interest that codes either for a sense or an antisense oligonucleotide or for a polypeptide, including a PG1 polypeptide or a peptide fragment thereof. This DNA construct is functional as a conditional expression system for the nucleotide sequence of interest when the same cell also comprises a nucleotide sequence coding for either the wild type (tTA) or the

30    mutant (rTA) repressor fused to the activating domain of viral protein VP16 of herpes simplex virus, placed under the control of a promoter, such as the HCMVIE1 enhancer/promoter or the MMTV-LTR. Indeed, a preferred DNA construct of the invention will comprise both the polynucleotide containing the tet operator sequences and the polynucleotide containing a sequence coding for the tTA or the rTA repressor.

In the specific embodiment wherein the conditional expression DNA construct contains the sequence encoding the mutant tetracycline repressor rTA, the expression of the polynucleotide of interest is silent in the absence of tetracycline and induced in its presence.

### DNA constructs allowing homologous recombination : replacement vectors

5       A second preferred DNA construct will comprise, from 5'-end to 3'-end : (a) a first nucleotide sequence that is comprised of a PG1 sequence preferably a PG1 genomic sequence; (b) a nucleotide sequence comprising a positive selection marker, such as the marker for neomycin resistance (neo); and (c) a second nucleotide sequence that comprised of a PG1 sequence preferably a PG1 genomic sequence, and is located on the genome downstream the first PG1 nucleotide sequence (a).

10      In a preferred embodiment, this DNA construct also comprises a negative selection marker located upstream the nucleotide sequence (a) or downstream the nucleotide sequence (b). Preferably, the negative selection marker consists of the thymidine kinase (tk) gene (Thomas K.R. et al., 1986, Cell, 44: 419-428), the hygromycin beta gene (Te Riele et al., 1990, Nature, 348: 649-651), the hprt gene (Van der Lugt et al., 1991, Gene, 105: 263-267; and Reid L.H. et al., 1990, Proc. Natl. Acad. Sci.

15      USA, 87: 4299-4303) or the Diphteria toxin A fragment (Dt-A) gene (Nada S. et al., 1993, Cell, 73: 1125-1135; Yagi T. et al., 1990, Proc. Natl. Acad. Sci. USA, 87: 9918-9922). Preferably, the positive selection marker is located within a PG1 exon sequence so as to interrupt the sequence encoding a PG1 protein.

These replacement vectors are described for example by Thomas K.R. et al., 1986, Cell, 44:

20      419-428; Thomas K.R. et al., 1987, Cell, 51: 503-512; Mansour S.L. et al., 1988, Nature, 336: 348-352; and Koller et al., 1992, Annu. Rev. Immunol., 10: 705-30.

The first and second nucleotide sequences (a) and (c) is located at any point within a PG1 regulatory sequence, an intronic sequence, an exon sequence or a sequence containing both regulatory and/or intronic and/or exon sequences. The length of nucleotide sequences (a) and (c) is determined

25      empirically by one of ordinary skill in the art. Nucleotide sequences (a) and (c) or any length are specifically contemplated in the present invention, however, lengths ranging from 1 kb to 50 kb, preferably from 1 kb to 10 kb, more preferably from 2 kb to 6 kb and most preferably from 2 kb to 4 kb are normally used.

### DNA constructs allowing homologous recombination : Cre-loxP system.

30      These new DNA constructs make use of the site-specific recombination system of the P1 phage. The P1 phage possesses a recombinase called Cre which interacts specifically with a 34 base pairs loxP site. The loxP site is composed of two palindromic sequences of 13 bp separated by a 8 bp conserved sequence (Hoess et al., 1986, Nucleic Acids Res., 14: 2287-2300). The recombination by the Cre enzyme between two loxP sites having an identical orientation leads to the deletion of the

35      DNA fragment.

The Cre-loxP system used in combination with a homologous recombination technique has been first described by Gu H. et al., 1993, Cell, 73: 1155-1164 ; and Gu H. et al., 1994, Science, 265: 103-106. Briefly, a nucleotide sequence of interest to be inserted in a targeted location of the genome harbors at least two loxP sites in the same orientation and located at the respective ends of a

5    nucleotide sequence to be excised from the recombinant genome. The excision event requires the presence of the recombinase (Cre) enzyme within the nucleus of the recombinant host cell. The recombinase enzyme is brought at the desired time either by (a) incubating the recombinant host cells in a culture medium containing this enzyme, by injecting the Cre enzyme directly into the desired cell, such as described by Araki K. et al., 1995, Proc. Natl. Acad. Sci. USA, 92: 160-164 ; or by lipofection

10   of the enzyme into the cells, such as described by Baubonis et al., 1993, Nucleic Acids Res., 21: 2025-2029; (b) transfecting the cell host with a vector comprising the Cre coding sequence operably linked to a promoter functional in the recombinant cell host, which promoter being optionally inducible, said vector being introduced in the recombinant cell host, such as described by Gu H. et al., 1993, Cell, 73: 1155-1164; and Sauer B. et al., 1988, Proc. Natl. Acad. Sci. USA, 85: 5166-5170; (c) introducing in

15   the genome of the host cell a polynucleotide comprising the Cre coding sequence operably linked to a promoter functional in the recombinant cell host, which promoter is optionally inducible, and said polynucleotide being inserted in the genome of the cell host either by a random insertion event or an homologous recombination event, such as described by Gu H. et al., 1994, Science, 265: 103-106.

In the specific embodiment wherein the vector containing the sequence to be inserted in the

20   PG1 gene by homologous recombination is constructed in such a way that selectable markers are flanked by loxP sites of the same orientation, it is possible, by treatment by the Cre enzyme, to eliminate the selectable markers while leaving the PG1 sequences of interest that have been inserted by an homologous recombination event. Again, two selectable markers are needed: a positive selection marker to select for the recombination event and a negative selection marker to select for the

25   homologous recombination event. Vectors and methods using the Cre-loxP system are described by Zou Y.R. et al., 1994, Curr. Biol., 4: 1099-1103.

Thus, a third preferred DNA construct of the invention comprises, from 5'-end to 3'-end: (a) a first nucleotide sequence that is comprised of a PG1 sequence, preferably a PG1 genomic sequence; (b) a nucleotide sequence comprising a polynucleotide encoding a positive selection marker, such as

30   the marker for neomycin resistance (neo), said nucleotide sequence comprising additionally two sequences defining a site recognized by a recombinase, such as a loxP site, the two sites being placed in the same orientation; and (c) a second nucleotide sequence that is comprised of a PG1 sequence, preferably a PG1 genomic sequence, and is located on the genome downstream of the first PG1 nucleotide sequence (a).

35   The sequences defining a site recognized by a recombinase, such as a loxP site, are preferably located within the nucleotide sequence (b) at suitable locations bordering the nucleotide sequence for

which the conditional excision is sought. In one specific embodiment, two loxP sites are located at each side of the positive selection marker sequence, in order to allow its excision at a desired time after the occurrence of the homologous recombination event.

5      In a preferred embodiment of a method using the third DNA construct described above, the excision of the polynucleotide fragment bordered by the two sites recognized by a recombinase, preferably two loxP sites, is performed at a desired time, due to the presence within the genome of the recombinant host cell of a sequence encoding the Cre enzyme operably linked to a promoter sequence, preferably an inducible promoter, more preferably a tissue-specific promoter sequence and most preferably a promoter sequence which is both inducible and tissue-specific, such as described by Gu
10    H. et al., 1994, Science, 265: 103-106.

The presence of the Cre enzyme within the genome of the recombinant cell host may result of the breeding of two transgenic animals, the first transgenic animal bearing the PG1-derived sequence of interest containing the loxP sites as described above and the second transgenic animal bearing the Cre coding sequence operably linked to a suitable promoter sequence, such as described by Gu H. et
15    al., 1994, Science, 265: 103-106. Spatio-temporal control of the Cre enzyme expression may also be achieved with an adenovirus based vector that contains the Cre gene thus allowing infection of cells, or in vivo infection of organs, for delivery of the Cre enzyme, such as described by Anton M. et al., 1995, J. Virol., 69: 4600-4606; and Kanegae Y. et al., 1995, Nucl. Acids Res., 23: 3816-3821.

The DNA constructs described above is used to introduce a desired nucleotide sequence of
20    the invention, preferably a PG1 genomic sequence or a PG1 cDNA sequence, and most preferably an altered copy of a PG1 genomic or cDNA sequence, within a predetermined location of the targeted genome, leading either to the generation of an altered copy of a targeted gene (knock-out homologous recombination) or to the replacement of a copy of the targeted gene by another copy sufficiently homologous to allow an homologous recombination event to occur (knock-in homologous
25    recombination).

## Nuclear antisense DNA constructs

Preferably, the antisense polynucleotides of the invention have a 3' polyadenylation signal that has been replaced with a self-cleaving ribozyme sequence, such that RNA polymerase II transcripts are produced without poly(A) at their 3' ends, these antisense polynucleotides being
30    incapable of export from the nucleus, such as described by Liu Z. et al., 1994, Proc. Natl. Acad. Sci. USA, 91: 4528-4262. In a preferred embodiment, these PG1 antisense polynucleotides also comprise, within the ribozyme cassette, a histone stem-loop structure to stabilize cleaved transcripts against 3'-5' exonucleolytic degradation , such as described by Eckner R. et al., 1991, EMBO J., 10: 3513-3522.

## Expression Vectors

35    The polynucleotides of the invention also include expression vectors. Expression vector systems, control sequences and compatible host are known in the art. For a review of these systems

see, for example, U.S. Patent No. 5,350,671, columns 45-48. Any of the standard methods known to those skilled in the art for the insertion of DNA fragments into a vector is used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and

5　synthetic techniques and in vivo recombinants (genetic recombination).

Expression of a polypeptide, peptide or derivative, or analogs thereof encoded by a polynucleotide sequence in SEQ ID NOs: 3, 69, 100-112, or 179-184 is regulated by a second nucleic acid sequence so that the protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a protein or peptide is controlled by any

10　promoter/enhancer element known in the art. Promoters which is used to control expression include, but are not limited to, the CMV promoter, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the

15　metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the beta-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; plant expression vectors comprising the nopaline synthetase promoter region (Herrera-Estrella et al., 1983,

20　Nature 303:209-213) or the cauliflower mosaic virus 35S RNA promoter (Gardner, et al., 1981, Nucl. Acids Res. 9:2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, Nature 310:115-120); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions,

25　which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et

30　al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer

35　et al., 1987, Science 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in

myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

Other suitable vectors, particularly for the expression of genes in mammalian cells, is selected from the group of vectors consisting of P1 bacteriophages, and bacterial artificial chromosomes (BACs). These types of vectors may contain large inserts ranging from about 80-90 kb (P1 bacteriophage) to about 300 kb (BACs).

10                                        P1 bacteriophage

The construction of P1 bacteriophage vectors such as p158 or p158/neo8 are notably described by Sternberg N.L., 1992, Trends Genet., 8: 1-16; and Sternberg N.L., 1994, Mamm. Genome, 5: 397-404. Recombinant P1 clones comprising PG1 nucleotide sequences is designed for inserting large polynucleotides of more than 40 kb (Linton M.F. et al., 1993, J. Clin. Invest., 92: 3029-3037). To generate P1 DNA for transgenic experiments, a preferred protocol is the protocol described by McCormick et al., 1994, Genet. Anal. Tech. Appl., 11: 158-164. Briefly, E. coli (preferably strain NS3529) harboring the P1 plasmid are grown overnight in a suitable broth medium containing 25 μg/ml of kanamycin. The P1 DNA is prepared from the E. coli by alkaline lysis using the Qiagen Plasmid Maxi kit (Qiagen, Chatsworth, CA, USA), according to the manufacturer's instructions. The P1 DNA is purified from the bacterial lysate on two Qiagen-tip 500 columns, using the washing and elution buffers contained in the kit. A phenol/chloroform extraction is then performed before precipitating the DNA with 70% ethanol. After solubilizing the DNA in TE (10 mM Tris-HCl, pH 7.4, 1 mM EDTA), the concentration of the DNA is assessed by spectrophotometry.

When the goal is to express a P1 clone comprising PG1 nucleotide sequences in a transgenic animal, typically in transgenic mice, it is desirable to remove vector sequences from the P1 DNA fragment, for example by cleaving the P1 DNA at rare-cutting sites within the P1 polylinker (SfiI, NotI or SalI). The P1 insert is then purified from vector sequences on a pulsed-field agarose gel, using methods similar using methods similar to those originally reported for the isolation of DNA from YACs (Schedl A. et al., 1993, Nature, 362: 258-261; and Peterson et al., 1993, Proc. Natl. Acad. Sci. USA, 90: 7593-7597). At this stage, the resulting purified insert DNA can be concentrated, if necessary, on a Millipore Ultrafree-MC Filter Unit (Millipore, Bedford, MA, USA – 30,000 molecular weight limit) and then dialyzed against microinjection buffer (10 mM Tris-HCl, pH 7.4; 250 μM EDTA) containing 100 mM NaCl, 30 μM spermine, 70 μM spermidine on a microdyalisis membrane (type VS, 0.025 μM from Millipore). The intactness of the purified P1 DNA insert is assessed by electrophoresis on 1% agarose (Sea Kem GTG; FMC Bio-products) pulse-field gel and staining with ethidium bromide.

## Bacterial Artificial Chromosomes (BACs)

The bacterial artificial chromosome (BAC) cloning system (Shizuya et al., 1992, Proc. Natl. Acad. Sci. USA, 89: 8794-8797) has been developed to stably maintain large fragments of genomic DNA (100-300 kb) in E. coli. A preferred BAC vector consists of pBeloBAC11 vector that has been

5    described Kim U. J., et al., 1996, Genomics, 34: 213-218. BAC libraries are prepared with this vector using size-selected genomic DNA that has been partially digested using enzymes that permit ligation into either the Bam HI or Hind III sites in the vector. Flanking these cloning sites are T7 and SP6 RNA polymerase transcription initiation sites that can be used to generate end probes by either RNA transcription or PCR methods. After the construction of a BAC library in E. coli, BAC DNA is

10   purified from the host cell as a supercoiled circle. Converting these circular molecules into a linear form precedes both size determination and introduction of the BACs into recipient cells. The cloning site is flanked by two Not I sites, permitting cloned segments to be excised from the vector by Not I digestion. Alternatively, the DNA insert contained in the pBeloBAC11 vector is linearized by treatment of the BAC vector with the commercially available enzyme lambda terminase that leads to

15   the cleavage at the unique cosN site, but this cleavage method results in a full length BAC clone containing both the insert DNA and the BAC sequences.

## Host Cells

The PG1 gene expression in human cells is rendered defective, or alternatively it is proceeded with the insertion of a PG1 genomic or cDNA sequence with the replacement of the PG1 gene

20   counterpart in the genome of an animal cell by a PG1 polynucleotide according to the invention. These genetic alterations is generated by homologous recombination events using specific DNA constructs that have been previously described.

One kind of host cell that is used are mammal zygotes, such as murine zygotes. For example, murine zygotes may undergo microinjection with a purified DNA molecule of interest, for example a

25   purified DNA molecule that has previously been adjusted to a concentration range from 1 ng/ml –for BAC inserts- 3 ng/μl –for P1 bacteriophage inserts- in 10 mM Tris-HCl, pH 7.4, 250 μM EDTA containing 100 mM NaCl, 30 μM spermine, and 70 μM spermidine. When the DNA to be microinjected has a large size, polyamines and high salt concentrations can be used in order to avoid mechanical breakage of this DNA, as described by Schedl et al., 1993, Nucleic Acids Res., 21: 4783-

30   4787.

Anyone of the polynucleotides of the invention, including the DNA constructs described herein, is introduced in an embryonic stem (ES) cell line, preferably a mouse ES cell line. ES cell lines are derived from pluripotent, uncommitted cells of the inner cell mass of pre-implantation blastocysts. Preferred ES cell lines are the following : ES-E14TG2a (ATCC No. CRL-1821), ES-D3

35   (ATCC No. CRL1934 and No. CRL-11632), YS001 (ATCC No. CRL-11776), 36.5 (ATCC No. CRL-11116). To maintain ES cells in an uncommitted state, they are cultured in the presence of growth

inhibited feeder cells which provide the appropriate signals to preserve this embryonic phenotype and serve as a matrix for ES cell adherence. Preferred feeder cells consist of primary embryonic fibroblasts that are established from tissue of day 13- day 14 embiyos of virtually any mouse strain, that are maintained in culture, such as described by Abbondanzo SJ et al., 1993, Methods in

5  Enzymology, Academic Press, New York, pp. 803-823; and are inhibited in growth by irradiation, such as described by Robertson E., 1987, Embryo-derived stem cell lines. E.J. Robertson Ed. Teratocarcinomas and embrionic stem cells: a practical approach. IRL Press, Oxford, pp. 71, or by the presence of an inhibitory concentration of LIF, such as described by Pease S. and William R.S., 1990, Exp. Cell. Res., 190: 209-211.

10                                              Transgenic Animals

The terms "transgenic animals" or "host animals" are used herein designate non-human animals that have their genome genetically and artificially manipulated so as to include one of the nucleic acids according to the invention. Preferred animals are non-human mammals and include those belonging to a genus selected from Mus (e.g. mice), Rattus (e.g. rats) and Oryctogaius (e.g.

15  rabbits) which have their genome artificially and genetically altered by the insertion of a nucleic acid according to the invention.

The transgenic animals of the invention all include within a plurality of their cells a cloned recombinant or synthetic DNA sequence, more specifically one of the purified or isolated nucleic acids comprising a PG1 coding sequence, a PG1 regulatory polynucleotide or a DNA sequence

20  encoding an antisense polynucleotide such as described in the present specification.

Preferred transgenic animals according to the invention contains in their somatic cells and/or in their germ line cells a polynucleotide selected from the following group of polynucleotides:

a) non-native, purified or isolated nucleic acid encoding a PG1 polypeptide, or a polypeptide fragment or variant thereof.

25  b) a non-native, purified or isolated nucleic comprising at least 8 consecutive nucleotides of the nucleotide sequence SEQ ID NOs: 179, 182, or 183, a nucleotide sequence complementary; in some embodiments, the length of the fragments can range from at least 8, 10, 15, 20 or 30 to 200 nucleotides, preferably from at least 10 to 50 nucleotides, more preferably from at least 40 to 50 nucleotides of SEQ ID NOs: 179, 182, or 183, or the sequence complementary thereto. In some

30  embodiments, the fragments may comprise more than 200 nucleotides of SEQ ID NOs: 179, 182, or 183, or the sequence complementary thereto.

c) a non-native, purified or isolated nucleic acid comprising at least 8 consecutive nucleotides of the nucleotide sequence SEQ ID NOs: 3, 69, 112-125 or 184, a sequence complementary thereto or a variant thereof; In some embodiments, the length of the fragments can range from at least 8, 10, 15,

35  20 or 30 to 200 nucleotides, preferably from at least 10 to 50 nucleotides, more preferably from at least 40 to 50 nucleotides of SEQ ID NOs: 3, 69, 112-125 or 184, or the sequence complementary

thereto. In some embodiments, the fragments may comprise more than 200 nucleotides of SEQ ID NOs: 3, 69, 112-125 or 184, or the sequence complementary thereto.

d) a non-native, purified or isolated nucleic acid comprising a nucleotide sequence selected from the group of SEQ ID NOs: 100 to 111, a sequence complementary thereto or a fragment or a

5    variant thereof.

e) a non-native, purified or isolated nucleic acid comprising a combination of at least two polynucleotides selected from the group consisting of SEQ ID NOs: 100 to 111, or the sequences complementary thereto wherein the polynucleotides are arranged within the nucleic acid, from the 5' end to the 3'end of said nucleic acid, in the same order than in SEQ NOs: 179, 182, or 183.

10    f) a non-native, purified or isolated nucleic acid comprising the nucleotide sequence SEQ ID NO: 180, or the sequences complementary thereto or a biologically active fragment or variant of the nucleotide sequence of SEQ ID NO: 180, or the sequence complementary thereto.

g) a non-native, purified or isolated nucleic acid comprising the nucleotide sequence SEQ ID NO: 181, or the sequence complementary thereto or a biologically active fragment or variant of the

15    nucleotide sequence of SEQ ID NO: 181 or the sequence complementary thereto.

h) a polynucleotide consisting of :

(1) a nucleic acid comprising a regulatory polynucleotide of SEQ ID NO: 180 or the sequences complementary thereto or a biologically active fragment or variant thereof

(2) a polynucleotide encoding a desired polypeptide or nucleic acid.

20    (3) Optionally, a nucleic acid comprising a regulatory polynucleotide of SEQ NO: 181, or the sequence complementary thereto or a biologically active fragment or variant thereof.

i) a DNA construct as described previously in the present specification.

The transgenic animals of the invention thus contain specific sequences of exogenous genetic material or "non-native" such as the nucleotide sequences described above in detail.

25    In a first preferred embodiment, these transgenic animals is good experimental models in order to study the diverse pathologies related to cell differentiation, in particular concerning the transgenic animals within the genome of which has been inserted one or several copies of a polynucleotide encoding a native PG1 protein, or alternatively a mutant PG1 protein.

In a second preferred embodiment, these transgenic animals may express a desired

30    polypeptide of interest under the control of the regulatory polynucleotides of the PG1 gene, leading to good yields in the synthesis of this protein of interest, and eventually a tissue specific expression of this protein of interest.

The design of the transgenic animals of the invention is made according to the conventional techniques well known from the one skilled in the art. For more details regarding the production of

35    transgenic animals, and specifically transgenic mice, it is referred to Sandou et al. (1994) and also to US Patents Nos 4,873,191, issued Oct.10, 1989, 5,464,764 issued Nov 7, 1995 and 5,789,215, issued

Aug 4, 1998.

Transgenic animals of the present invention are produced by the application of procedures which result in an animal with a genome that has incorporated exogenous genetic material. The procedure involves obtaining the genetic material, or a portion thereof, which encodes either a PG1

5 coding sequence, a PG1 regulatory polynucleotide or a DNA sequence encoding a PG1 antisense polynucleotide such as described in the present specification.

A recombinant polynucleotide of the invention is inserted into an embryonic or ES stem cell line. The insertion is preferably made using electroporation, such as described by Thomas K.R. et al., 1987, Cell, 51: 503-512. The cells subjected to electroporation are screened (e.g. by selection via

10 selectable markers, by PCR or by Southern blot analysis) to find positive cells which have integrated the exogenous recombinant polynucleotide into their genome, preferably via an homologous recombination event. An illustrative positive-negative selection procedure that is used according to the invention is described by Mansour S.L. et al., 1988, Nature, 336: 348-352.

Then, the positive cells are isolated, cloned and injected into 3.5 days old blastocysts from

15 mice, such as described by Bradley A., 1987, Production and analysis of chimaeric mice. In : E.J. Robertson (Ed.), Teratocarcinomas and embryonic stem cells : A practical approach. IRL Press, Oxford, pp.113. The blastocysts are then inserted into a female host animal and allowed to grow to term.

Alternatively, the positive ES cells are brought into contact with embryos at the 2.5 days old

20 8-16 cell stage (morulae) such as described by Wood S.A. et al., 1993, Proc. Natl. Acad. Sci. USA, 90: 4582-4585; or by Nagy A. et al., 1993, Proc. Natl. Acad. Sci. USA, 90: 8424-8428. The ES cells being internalized to colonize extensively the blastocyst including the cells which will give rise to the germ line. The offspring of the female host are tested to determine which animals are transgenic e.g. include the inserted exogenous DNA sequence and which are wild-type.

25 Thus, the present invention also concerns a transgenic animal containing a nucleic acid, a recombinant expression vector or a recombinant host cell according to the invention.

Recombinant cell lines derived from the transgenic animals of the invention.

A further object of the invention consists of recombinant host cells obtained from a transgenic animal described herein.

30 Recombinant cell lines is established in vitro from cells obtained from any tissue of a transgenic animal according to the invention, for example by transfection of primary cell cultures with vectors expressing onc-genes such as SV40 large T antigen, as described by Chou J.Y., 1989, Mol. Endocrinol., 3: 1511-1514 ; and Shay J.W. et al., 1991, Biochem. Biophys. Acta, 1072: 1-7.

Functional Analysis of the PG1 Poplypeptides In Transgenic Animals

Using different BACs that contain the PG1 gene, we performed FISH experiment on the adenocarcinoma prostatic cell line PC3. Only one signal could be detected showing that this region of chromosome 8 is hemizygous in this tumoral cell line.

5        To study the function of PG1, it is inactivate by homologous recombination in the remaining allele of PG1 in the PC3 cell line. To inactivate the remaining PG1 allele, a knock-out targeting vector is generated by inserting two genomic DNA fragments of 3.0 and 4.3 kb (that correspond to a sequence upstream of the PG1 promoter and to part of intron 1, respectively) in the pKO Scrambler Neo TK vector (Lexicon ref V1901). Since the targeting vector contains the neomycine resistance

10     gene as well as the Tk gene, homologous recombination is selected by adding geneticin and FIAU to the medium. The promoter, the transcriptional start site, and the first ATG contained in exon 1 on the recombinant allele is deleted by homologous recombination between the targeting vector and the remaining PG1 allele. Accordingly, no coding transcripts is initiated from the recombinant allele. The parental PC3 cells as well as cells hemizygous for the null allele are assessed for their phenotype,

15     their growth rate in liquid culture, their ability to grow in agar (anchorage-independent growth) as well as their ability to form tumors and metastasis when injected subcutaneously in nude mice.

To determine the function of PG1 in the animal, and to generate an animal model for prostate tumorigenesis, mice in which tissue specific inactivation of the PG1 alleles can be induced are generated. For this purpose, the Cre-loxP system is utilized as described above to allow chromosome

20     engineering to be perform directly in the animal.

First, to generate mice with a conditional null allele, two loxP sites are introduced in the murine genome, the first one 5' to the PG1 promoter and the second one 3' to the PG1 exon 1. Alternatively, to generate subtle mutations or to specifically mutate some isoforms, the loxP sites are introduced so that they flank any of the given exons or any potential set of exons. It is important to

25     note that a functional PG1 messenger can be transcribed from these alleles until a recombination is triggered between the loxP sites by the Cre enzyme.

Second, to generate the inducer mice, the Cre gene is introduced in the mouse genome under the control of a tissue specific promoter, for example under the control of the PSA (prostate specific antigen) promoter.

30     Finally, tissue specific inactivation of the PG1 gene are induced by generating mice containing the Cre transgene that are homozygous for the recombinant PG1 allele.

Gene Therapy

The present invention also comprises the use of the PG1 genomic DNA sequence of SEQ ID NO: 179, the PG1 cDNA of SEQ ID NO: 3, or nucleic acid encoding a mutant PG1 protein responsible

35     for a detectable phenotype in gene therapy strategies, including antisense and triple helix strategies as described in Examples 19 and 20, below. In antisense approaches, nucleic acid sequences

complementary to an mRNA are hybridized to the mRNA intracellularly, thereby blocking the expression of the protein encoded by the mRNA. The antisense sequences may prevent gene expression through a variety of mechanisms. For example, the antisense sequences may inhibit the ability of ribosomes to translate the mRNA. Alternatively, the antisense sequences may block transport of the

5   mRNA from the nucleus to the cytoplasm, thereby limiting the amount of mRNA available for translation. Another mechanism through which antisense sequences may inhibit gene expression is by interfering with mRNA splicing. In yet another strategy, the antisense nucleic acid is incorporated in a ribozyme capable of specifically cleaving the target mRNA.

Example 19

10   Preparation and Use of Antisense Oligonucleotides

The antisense nucleic acid molecules to be used in gene therapy is either DNA or RNA sequences. They may comprise a sequence complementary to the sequence of the PG1 genomic DNA of SEQ ID NO: 179, the PG1 cDNA of SEQ ID NO: 3, or a nucleic acid encoding a PG1 protein responsible for a detectable phenoytpe. The antisense nucleic acids should have a length and melting

15   temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the PG1 mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., Ann. Rev. Biochem. 55:569-597 (1986) and Izant and Weintraub, Cell 36:1007-1015 (1984).

In some strategies, antisense molecules are obtained by reversing the orientation of the PG1

20   coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules is transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach involves transcription of PG1 antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in an expression vector.

25   Alternatively, oligonucleotides which are complementary to the strand of the PG1 gene normally transcribed in the cell is synthesized in vitro. Thus, the antisense PG1 nucleic acids are complementary to the PG1 mRNA and are capable of hybridizing to the mRNA to create a duplex. In some embodiments, the PG1 antisense sequences may contain modified sugar phosphate backbones to increase stability and make them less sensitive to RNase activity. Examples of modifications suitable for use in

30   antisense strategies are described by Rossi et al., Pharmacol. Ther. 50(2):245-254, (1991).

Various types of antisense oligonucleotides complementary to the sequence of the PG1 genomic DNA of SEQ ID NO: 179, the PG1 cDNA of SEQ ID NO: 3, or a nucleic acid encoding a PG1 protein responsible for a detectable phenoytpe is used. In one preferred embodiment, stable and semi-stable antisense oligonucleotides as described in International Application No. PCT WO94/23026, are used to

35   inhibit the expression of the PG1 gene. In these molecules, the 3• end or both the 3• and 5• ends are engaged in intramolecular hydrogen bonding between complementary base pairs. These molecules are

better able to withstand exonuclease attacks and exhibit increased stability compared to conventional antisense oligonucleotides.

In another preferred embodiment, the antisense oligodeoxynucleotides described in International Application No. WO 95/04141, are used to inhibit expression of the PG1 gene.

5      In yet another preferred embodiment, the covalently cross-linked antisense oligonucleotides described in International Application No. WO 96/31523, are used to inhibit expression of the PG1 gene. These double- or single-stranded oligonucleotides comprise one or more, respectively, inter- or intra-oligonucleotide covalent cross-linkages, wherein the linkage consists of an amide bond between a primary amine group of one strand and a carboxyl group of the other strand or of the same strand,

10     respectively, the primary amine group being directly substituted in the 2' position of the strand nucleotide monosaccharide ring, and the carboxyl group being carried by an aliphatic spacer group substituted on a nucleotide or nucleotide analog of the other strand or the same strand, respectively.

The antisense oligodeoxynucleotides and oligonucleotides disclosed in International Application No. WO 92/18522, may also be used to inhibit the expression of the PG1 gene. These molecules are

15     stable to degradation and contain at least one transcription control recognition sequence which binds to control proteins and are effective as decoys therefor. These molecules may contain "hairpin" structures, "dumbbell" structures, "modified dumbbell" structures, "cross-linked" decoy structures and "loop" structures.

In another preferred embodiment, the cyclic double-stranded oligonucleotides described in

20     European Patent Application No. 0 572 287 A2, are used to inhibit the expression of the PG1 gene. These ligated oligonucleotide "dumbbells" contain the binding site for a transcription factor which binds to the PG1 promoter and inhibits expression of the gene under control of the transcription factor by sequestering the factor.

Use of the closed antisense oligonucleotides disclosed in International Application No. WO

25     92/19732, is also contemplated. Because these molecules have no free ends, they are more resistant to degradation by exonucleases than are conventional oligonucleotides. These oligonucleotides is multifunctional, interacting with several regions which are not adjacent to the target mRNA.

The appropriate level of antisense nucleic acids required to inhibit PG1 gene expression is determined using in vitro expression analysis. The antisense molecule is introduced into the cells by

30     diffusion, injection, infection or transfection using procedures known in the art. For example, the antisense nucleic acids can be introduced into the body as a bare or naked oligonucleotide, oligonucleotide encapsulated in lipid, oligonucleotide sequence encapsidated by viral protein, or as an oligonucleotide operably linked to a promoter contained in an expression vector. The expression vector is any of a variety of expression vectors known in the art, including retroviral or viral vectors, vectors

35     capable of extrachromosomal replication, or integrating vectors. The vectors is DNA or RNA.

The PG1 antisense molecules are introduced onto cell samples at a number of different concentrations preferably between 1x10^{-10}M to 1x10^{-4}M. Once the minimum concentration that can adequately control gene expression is identified, the optimized dose is translated into a dosage suitable for use in vivo. For example, an inhibiting concentration in culture of 1x10^{-7} translates into a dose of approximately 0.6 mg/kg bodyweight. Levels of oligonucleotide approaching 100 mg/kg bodyweight or higher is possible after testing the toxicity of the oligonucleotide in laboratory animals. It is additionally contemplated that cells from the vertebrate are removed, treated with the antisense oligonucleotide, and reintroduced into the vertebrate.

It is further contemplated that the PG1 antisense oligonucleotide sequence is incorporated into a ribozyme sequence to enable the antisense to specifically bind and cleave its target mRNA. For technical applications of ribozyme and antisense oligonucleotides see Rossi et al., supra.

In a preferred application of this invention, antibody-mediated tests such as RIAs and ELISA, functional assays, or radiolabeling are used to determine the effectiveness of antisense inhibition on PG1 expression.

The PG1 cDNA, the PG1 genomic DNA, and the PG1 alleles of the present invention may also be used in gene therapy approaches based on intracellular triple helix formation. Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity as it is associated with a particular gene. The PG1 cDNA, PG1 genomic DNA, or PG1 allele of the present invention or, more preferably, a portion of those sequences, can be used to inhibit gene expression in individuals suffering from prostate cancer or another detectable phenotype or individuals at risk for developing prostate cancer or another detectable phenotype at a later date as a result of their PG1 genotype. Similarly, a portion of the PG1 cDNA, the PG1 genomic DNA, or the PG1 alleles can be used to study the effect of inhibiting PG1 transcription within a cell. Traditionally, homopurine sequences were considered the most useful for triple helix strategies, such as those described in Example 20, below. However, homopyrimidine sequences can also inhibit gene expression. Such homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. Thus, both types of sequences from the PG1 cDNA, the PG1 genomic DNA, and the PG1 alleles are contemplated within the scope of this invention.

<u>Example 20</u>

The sequences of the PG1 cDNA, the PG1 genomic DNA, and the PG1 alleles are scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches which could be used in triple-helix based strategies for inhibiting PG1 expression. Following identification of candidate homopyrimidine or homopurine stretches, their efficiency in inhibiting PG1 expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into tissue culture cells which express the PG1 gene. The oligonucleotides is prepared on an oligonucleotide synthesizer or they is purchased

commercially from a company specializing in custom oligonucleotide synthesis, such as GENSET, Paris, France.

The oligonucleotides is introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran,

5  electroporation, liposome-mediated transfection or native uptake.

Treated cells are monitored for altered cell function or reduced PG1 expression using techniques such as Northern blotting, RNase protection assays, or PCR based strategies to monitor the transcription levels of the PG1 gene in cells which have been treated with the oligonucleotide.

The oligonucleotides which are effective in inhibiting gene expression in tissue culture cells

10  may then be introduced in vivo using the techniques described above and in Example 19 at a dosage calculated based on the in vitro results, as described in Example 19.

In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to

15  stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin et al. (Science 245:967-971 (1989).

Alternatively, the PG1 cDNA, the PG1 genomic DNA, and the PG1 alleles of the present invention is used in gene therapy approaches in which expression of the PG1 protein is beneficial, as described in Example 21 below.

20                                    Example 21

The PG1 cDNA, the PG1 genomic DNA, and the PG1 alleles of the present invention may also be used to express the PG1 protein or a portion thereof in a host organism to produce a beneficial effect. In such procedures, the PG1 protein is transiently expressed in the host organism or stably expressed in the host organism. The expressed PG1 protein is used to treat conditions resulting from a lack of PG1

25  expression or conditions in which augmentation of existing levels of PG1 expression is beneficial.

A nucleic acid encoding the PG1 proteins of SEQ ID NO: 4, SEQ ID NO:5, or a PG1 allele is introduced into the host organism. The nucleic acid is introduced into the host organism using a variety of techniques known to those of skill in the art. For example, the nucleic acid is injected into the host organism as naked DNA such that the encoded PG1 protein is expressed in the host organism, thereby

30  producing a beneficial effect.

Alternatively, the nucleic acid encoding the PG1 proteins of SEQ ID NO: 4, SEQ ID NO: 5, or a PG1 allele is cloned into an expression vector downstream of a promoter which is active in the host organism. The expression vector is any of the expression vectors designed for use in gene therapy, including viral or retroviral vectors.

35      The expression vector is directly introduced into the host organism such that the PG1 protein is expressed in the host organism to produce a beneficial effect. In another approach, the expression vector

is introduced into cells in vitro. Cells containing the expression vector are thereafter selected and introduced into the host organism, where they express the PG1 protein to produce a beneficial effect.

## IX. ISOLATION OF PG1 cDNA FROM NONHUMAN MAMMALS

The present invention encompasses mammalian PG1 sequences including genomic and cDNA

5    sequences, as well as polypeptide sequences. The present invention also encompasses the use of PG1 genomic and cDNA sequences of the invention, including SEQ ID NOs: 179, 3, 182, and 183, in methods of isolating and characterizing PG1 nucleotide sequences derived from nonhuman mammals, in addition to sequences derived from human sequences. The human and mouse PG1 nucleic acid sequences of the invention can be used to construct primers and probes for amplifying and identifying

10   PG1 genes in other nonhuman animals particularly mammals. The primers and probes used to identify nonhuman PG1 sequences is selected and used for the isolation of nonhuman PG1 utilizing the same techniques described above in Examples 4, 5, 6, 12 and 13.

In addition, sequence analysis of other homologous proteins is used to optimize the sequences of these primers and probes. As described above in the Analysis of the PG1 Protein Sequence, three boxes

15   of homology were identified in the structure of the PG1 protein product when compared to proteins from a diverse range of organisms. See Figure 9. Using the assumption that the nucleotide sequences for these homologous proteins also show a high degree of homology, it is possible to construct primers that are specific for the PCR amplification of PG1 cDNA in nonhuman mammals.

### Example 22

20   The primers BOXIed: AATCATCAAAGCACAGTTGACTGGAT (SEQ ID NO: 77) and BOXIIIer: ATAAACCACCGTAACATCATAAATTGCATCTAA (SEQ ID NO: 78) were designed as PCR primers from the human PG1 sequences after comparison with the sequence homologies of Figure 9. The BOXIed (SEQ ID NO: 77) and BOXIIIer (SEQ ID NO: 78) primers were used to amplify a mouse PG1 cDNA sequence from mouse liver marathon-ready cDNA (Clontech) under the conditions

25   described above in Example 4. This PCR reaction yielded a product of approximately 400 base pairs, the boxI-boxIII fragment, which was subjected to automated dideoxy terminator sequencing and electrophoresed on ABI 377 sequencers as described above. Sequence analysis confirmed very high homology to human PG1 both at the nucleic acid and protein levels.

Primers were designed for RACE analysis using the 400 base pair boxI-boxIII fragment. Further

30   sequence information was obtained using 5' and 3' RACE reactions on mouse liver marathon cDNA using two sets of these nested PCR primers: moPG1RACE5.350: AATCAAAAGCAACGTGAGTGGC (SEQ ID NO: 94) and moPG1RACE5.276: GCAAATGCCTGACTGGCTGA (SEQ ID NO: 93) for the 5' RACE reaction and moPG1RACE3.18: CTGCCAGACAGGATGCCCTA (SEQ ID NO: 90) and moPG1RACE3.63: ACAAGTTAAAATGGCTTCCGCTG (SEQ ID NO: 91) for the 3' RACE reaction.

35   The PCR products of the RACE reactions were sequenced by primer walking using the following primers:

| moPGrace3S473: | GAGATAAAAG ATAGGTTGCT CA | (SEQ ID NO: 79); |
| moPGrace3S526: | AAGAAACAAA TTTCCTGGG | (SEQ ID NO: 80); |
| moPGrace3S597: | TCTTGGGGAG TTTGACTG | (SEQ ID NO: 81); |
| moPGrace5R323: | GACCCCGGTG TAGTTCTC | (SEQ ID NO: 82); |
| moPGrace5R372: | CAGTAAAGCC GGTCGTC | (SEQ ID NO: 83); |
| moPGrace5R444: | CAGGCCAGCA GGTAGGT | (SEQ ID NO: 84); |
| moPGrace5R492: | AGCAGGTAGC GCATAGAGT | (SEQ ID NO: 85). |

Again a high degree of homology between the mouse sequence obtained from the primer walking and the human PG1 sequence was observed. An additional pair of nested primers were designed and utilized to further extend the 3' mouse PG1 sequence in yet another RACE reaction, moPG3RACE2: TGGGCACCTG GTTGTATGGA (SEQ ID NO: 95) and moPG3RACE2n: TCCTTGGCTG CCTGTGGTTT (SEQ ID NO:96). The PCR product of this final RACE reaction was also sequenced by primer walking using the following primers:

| moPG1RACE3R94: | CAAATGCATG TTGGCTGT | (SEQ ID NO: 92); |
| moPG3RACES20: | GATGGCTACA CATTGTATCA C | (SEQ ID NO: 97); |
| moPG3RACES5: | TCCTGAATTA AATAAGGAGT TTTC | (SEQ ID NO: 98); |
| moPG3RACES90: | GTTTGTTATT AAAGCATAAG CAAG | (SEQ ID NO: 99). |

The overlap in the 5' RACE, boxI-boxIII, and 3' RACE fragments allowed a single contiguous coding sequence for the mouse PG1 ortholog to be generated alignment of the three fragments. Primers were chosen from near the 5' and 3' ends of this predicted contiguous sequence (contig) in order to confirm the existence of such a transcript. PCR amplification was performed again on mouse liver marathon-ready cDNA (Clontech) with the chosen primers, moPG15: TGGCGAGCCGAGAGGATG (SEQ ID NO: 87) and moPG13LR2: GGAAACAATGTGATACAATGTGTAGCC (SEQ ID NO: 86) under the PCR conditions described above in Example 4. The resulting PCR product was a roughly 1.2 kb DNA molecule and was shown to have an identical sequence to that of the deduced contig. Finally modified versions of the moPG15 and moPG13LR2 primers with the addition of EcoRI and BamHI sites, moPG15EcoRI: CGTGAATTCTGGCGAGCCGAGAGGATG (SEQ ID NO: 89) and moPG15Baml: CGTGGATCCGGAAACAATGTGATACAATGTGTAGCC (SEQ ID NO: 88) were used to obtain a PCR product that could be cloned into a pSKBluescript plasmid (Stratagene) cleaved with EcoRI and BamHI restriction enzymes. The mouse PG1 cDNA in the resulting construct was subjected to automated dideoxy terminator sequencing and electrophoresed on ABI 377 sequencers as described above. The sequence for mouse PG1 cDNA is reported in SEQ ID NO: 72, and the deduced amino acid sequence corresponding to the cDNA is reported in SEQ ID NO: 74.

## Example 23

A mouse BAC library was constructed by the cloning of BamHI partially digested DNA of pluripotent embryonic stem cells, cell line ES-E14TG2a (ATCC CRL-1821) into pBeloBACII vector

plasmid. Approximately fifty-six thousand clones with an average inset size of 120 kb were picked individually and pooled for PCR screening as described above for human BAC library screening. These pools were screened with STS g34292 derived from the region of the mouse PG1 transcript corresponding to exon6 of the human gene. The upstream and downstream primers defining this STS are: upstream amplification primer for g34292: ATTAAAACAC GTACTGACAC CA (SEQ ID NO: 75), and downstream amplification primer for g34292: AGTCATGGAT GGTGGATTT (SEQ ID NO: 76). BAC C0281H06 tested positive for hybridizing to g34292. This BAC was isolated and sequenced by sub-cloning into pGenDel sequencing vector. The resulting partial genomic sequence for mouse PG1 is reported in SEQ ID NO: 73. This process was repeated and the resulting partial genomic sequences for mouse PG1 is reported in SEQ ID NOs: 182 and 183.

Other mammalian PG1 cDNA and genomic sequences can be isolated by the methods of the present invention. PG1 genes in mammalian species have a region of at least 100, preferably 200, more preferably 500 nucleotides in each mammal's most abundant transcription species which has at least 75%, preferably 85%, more preferably 95% sequence homology to the most abundant human or mouse cDNA species (SEQ ID NO: 3). PG1 proteins in mammalian species have a region of at least 40, preferably 90, more preferably 160 amino acids in the deduced amino acid sequence of the most abundant PG1 transcirption species which has at least 75%, preferably 85%, more preferably 95% sequence homology to the deduced amino acid sequence of the most abundant human or mouse translations species (SEQ ID NO: 4 or 74).

## X. METHODS FOR GENOTYPING AN INDIVIDUAL FOR BIALLELIC MARKERS

Methods are provided to genotype a biological sample for one or more biallelic markers of the present invention, all of which is performed in vitro. Such methods of genotyping comprise determining the identity of a nucleotide at an PG1-related biallelic marker by any method known in the art. These methods find use in genotyping case-control populations in association studies as well as individuals in the context of detection of alleles of biallelic markers which, are known to be associated with a given trait, in which case both copies of the biallelic marker present in individual's genome are determined so that an individual is classified as homozygous or heterozygous for a particular allele.

These genotyping methods can be performed nucleic acid samples derived from a single individual or pooled DNA samples.

Genotyping can be performed using similar methods as those described above for the identification of the biallelic markers, or using other genotyping methods such as those further described below. In preferred embodiments, the comparison of sequences of amplified genomic fragments from different individuals is used to identify new biallelic markers whereas microsequencing is used for genotyping known biallelic markers in diagnostic and association study applications.

## X.A. Source of DNA for genotyping

Any source of nucleic acids, in purified or non-purified form, can be utilized as the starting nucleic acid, provided it contains or is suspected of containing the specific nucleic acid sequence desired. DNA or RNA is extracted from cells, tissues, body fluids. As for the source of genomic

5　DNA to be subjected to analysis, any test sample can be foreseen without any particular limitation. These test samples include biological samples, which can be tested by the methods of the present invention described herein, and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like;

10　biological fluids such as cell culture supernatants; fixed tissue specimens including tumor and non-tumor tissue and lymph node tissues; bone marrow aspirates and fixed cell specimens. The preferred source of genomic DNA used in the present invention is from peripheral venous blood of each donor. Techniques to prepare genomic DNA from biological samples are well known to the skilled technician. While nucleic acids for use in the genotyping methods of the invention can be derived

15　from any mammalian source, the test subjects and individuals from which nucleic acid samples are taken are generally understood to be human.

## X.B. Amplification Of DNA Fragments Comprising Biallelic Markers

Methods and polynucleotides are provided to amplify a segment of nucleotides comprising one or more biallelic marker of the present invention. It will be appreciated that amplification of

20　DNA fragments comprising biallelic markers is used in various methods and for various purposes and is not restricted to genotyping. Nevertheless, many genotyping methods, although not all, require the previous amplification of the DNA region carrying the biallelic marker of interest. Such methods specifically increase the concentration or total number of sequences that span the biallelic marker or include that site and sequences located either distal or proximal to it. Diagnostic assays may also rely

25　on amplification of DNA segments carrying a biallelic marker of the present invention.

Amplification of DNA is achieved by any method known in the art. The established PCR (polymerase chain reaction) method or by developments thereof or alternatives. Amplification methods which can be utilized herein include but are not limited to Ligase Chain Reaction (LCR) as described in EP A 320 308 and EP A 439 182, Gap LCR (Wolcott, M.J., Clin. Mcrobiol. Rev. 5:370-

30　386), the so-called "NASBA" or "3SR" technique described in Guatelli J.C. et al. (*Proc. Natl. Acad. Sci. USA* 87:1874-1878, 1990) and in Cómpton J. (*Nature* 350:91-92, 1991), Q-beta amplification as described in European Patent Application no 4544610, strand displacement amplification as described in Walker et al. (*Clin. Chem.* 42:9-13, 1996) and EP A 684 315 and, target mediated amplification as described in PCT Publication WO 9322461.

35　LCR and Gap LCR are exponential amplification techniques, both depend on DNA ligase to join adjacent primers annealed to a DNA molecule. In Ligase Chain Reaction (LCR), probe pairs are

used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5' phosphate-
5   3'hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded, the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from
10   the target strand, it will hybridize with the third and fourth probes which can be ligated to form a complementary, secondary ligated product. It is important to realize that the ligated products are functionally equivalent to either the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. A method for multiplex LCR has also been described (WO 9320227). Gap LCR (GLCR) is a version of LCR where the probes are not adjacent
15   but are separated by 2 to 3 bases.

       For amplification of mRNAs, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Patent No. 5,322,770 or, to use Asymmetric Gap LCR (RT-AGLCR) as described by Marshall R.L. et al. (*PCR Methods and Applications* 4:80-84, 1994).
20   AGLCR is a modification of GLCR that allows the amplification of RNA.

       Some of these amplification methods are particularly suited for the detection of single nucleotide polymorphisms and allow the simultaneous amplification of a target sequence and the identification of the polymorphic nucleotide as it is further described in X.C.

       The PCR technology is the preferred amplification technique used in the present invention. A
25   variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see Molecular Cloning to Genetic Engineering White, B.A. Ed. in *Methods in Molecular Biology* 67: Humana Press, Totowa (1997) and the publication entitled "PCR Methods and Applications" (1991, Cold Spring Harbor Laboratory Press). In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along
30   with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between
35   the primer sites. PCR has further been described in several patents including US Patents 4,683,195, 4,683,202 and 4,965,188.

The identification of biallelic markers as described above allows the design of appropriate oligonucleotides, which can be used as primers to amplify DNA fragments comprising the biallelic markers of the present invention. Amplification can be performed using the primers initially used to discover new biallelic markers which are described herein or any set of primers allowing the

5   amplification of a DNA fragment comprising a biallelic marker of the present invention. Primers can be prepared by any suitable method. As for example, direct chemical synthesis by a method such as the phosphodiester method of Narang S.A. et al. (*Methods Enzymol.* 68:90-98, 1979), the phosphodiester method of Brown E.L. et al. (*Methods Enzymol.* 68:109-151, 1979), the diethylphosphoramidite method of Beaucage et al. (*Tetrahedron Lett.* 22:1859-1862, 1981) and the

10  solid support method described in EP 0 707 592.

In some embodiments the present invention provides primers for amplifying a DNA fragment containing one or more biallelic markers of the present invention. It will be appreciated that the amplification primers listed in the present specification are merely exemplary and that any other set of primers which produce amplification products containing one or more biallelic markers of the present

15  invention.

The primers are selected to be substantially complementary to the different strands of each specific sequence to be amplified. The length of the primers of the present invention can range from 8 to 100 nucleotides, preferably from 8 to 50, 8 to 30 or more preferably 8 to 25 nucleotides. Shorter primers tend to lack specificity for a target nucleic acid sequence and generally require cooler

20  temperatures to form sufficiently stable hybrid complexes with the template. Longer primers are expensive to produce and can sometimes self-hybridize to form hairpin structures. The formation of stable hybrids depends on the melting temperature ™ of the DNA. The Tm depends on the length of the primer, the ionic strength of the solution and the G+C content. The higher the G+C content of the primer, the higher is the melting temperature because G:C pairs are held by three H bonds whereas

25  A:T pairs have only two. The G+C content of the amplification primers of the present invention preferably ranges between 10 and 75 %, more preferably between 35 and 60 %, and most preferably between 40 and 55 %. The appropriate length for primers under a particular set of assay conditions is empirically determined by one of skill in the art.

The spacing of the primers determines the length of the segment to be amplified. In the

30  context of the present invention amplified segments carrying biallelic markers can range in size from at least about 25 bp to 35 kbp. Amplification fragments from 25-3000 bp are typical, fragments from 50-1000 bp are preferred and fragments from 100-600 bp are highly preferred. It will be appreciated that amplification primers for the biallelic markers is any sequence which allow the specific amplification of any DNA fragment carrying the markers. Amplification primers is labeled or

35  immobilized on a solid support as described in Section II.

**X.C. Methods of Genotyping DNA samples for Biallelic Markers**

Any method known in the art can be used to identify the nucleotide present at a biallelic marker site. Since the biallelic marker allele to be detected has been identified and specified in the present invention, detection will prove routine for one of ordinary skill in the art by employing any of a number of techniques. Many genotyping methods require the previous amplification of the DNA

5 region carrying the biallelic marker of interest. While the amplification of target or signal is often preferred at present, ultrasensitive detection methods which do not require amplification are also encompassed by the present genotyping methods. Methods well-known to those skilled in the art that can be used to detect biallelic polymorphisms include methods such as, conventional dot blot analyzes, single strand conformational polymorphism analysis (SSCP) described by Orita et al. (*Proc.*

10 *Natl. Acad. Sci. U.S.A* 86:27776-2770, 1989), denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis, mismatch cleavage detection, and other conventional techniques as described in Sheffield, V.C. et al. (*Proc. Natl. Acad. Sci. USA* 49:699-706, 1991), White et al. (*Genomics* 12:301-306, 1992), Grompe, M. et al. (*Proc. Natl. Acad. Sci. USA* 86:5855-5892, 1989) and Grompe, M. (*Nature Genetics* 5:111-117, 1993). Another method for determining the identity of the nucleotide

15 present at a particular polymorphic site employs a specialized exonuclease-resistant nucleotide derivative as described in US patent 4,656,127.

Preferred methods involve directly determining the identity of the nucleotide present at a biallelic marker site by sequencing assay, allele-specific amplification assay, or hybridization assay. The following is a description of some preferred methods. A highly preferred method is the

20 microsequencing technique. The term "sequencing assay" is used herein to refer to polymerase extension of duplex primer/template complexes and includes both traditional sequencing and microsequencing.

## 1) Sequencing assays

The nucleotide present at a polymorphic site can be determined by sequencing methods. In a

25 preferred embodiment, DNA samples are subjected to PCR amplification before sequencing as described above. Methods for sequencing DNA using either the dideoxy-mediated method (Sanger method) or the Maxam-Gilbert method are widely known to those of ordinary skill in the art. Such methods are for example disclosed in Maniatis et al. (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Second Edition, 1989). Alternative approaches include hybridization to high-

30 density DNA probe arrays as described in Chee et al. (Science 274, 610, 1996).

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. The products of the sequencing reactions are run on sequencing gels and the sequences are determined using gel image analysis.

The polymorphism detection in a pooled sample is based on the presence of superimposed

35 peaks in the electrophoresis pattern resulting from different bases occurring at the same position. Because each dideoxy terminator is labeled with a different fluorescent molecule, the two peaks

corresponding to a biallelic site present distinct colors corresponding to two different nucleotides at the same position on the sequence. However, the presence of two peaks can be an artifact due to background noise. To exclude such an artifact, the two DNA strands are sequenced and a comparison between the peaks is carried out. In order to be registered as a polymorphic sequence, the polymorphism has to be detected on both strands.

The above procedure permits those amplification products, which contain biallelic markers to be identified. The detection limit for the frequency of biallelic polymorphisms detected by sequencing pools of 100 individuals is approximately 0.1 for the minor allele, as verified by sequencing pools of known allelic frequencies.

**Microsequencing assays**

In microsequencing methods, the nucleotide at a polymorphic site in a target DNA is detected by a single nucleotide primer extension reaction. This method involves appropriate microsequencing primers which, hybridize just upstream of the polymorphic base of interest in the target nucleic acid. A polymerase is used to specifically extend the 3' end of the primer with one single ddNTP (chain terminator) complementary to the nucleotide at the polymorphic site. Next the identity of the incorporated nucleotide is determined in any suitable way.

Typically, microsequencing reactions are carried out using fluorescent ddNTPs and the extended microsequencing primers are analyzed by electrophoresis on ABI 377 sequencing machines to determine the identity of the incorporated nucleotide as described in EP 412 883. Alternatively capillary electrophoresis can be used in order to process a higher number of assays simultaneously.

Different approaches can be used to detect the nucleotide added to the microsequencing primer. A homogeneous phase detection method based on fluorescence resonance energy transfer has been described by Chen and Kwok (*Nucleic Acids Research* 25:347-353 1997) and Chen et al. (*Proc. Natl. Acad. Sci. USA* 94/20 10756-10761,1997). In this method amplified genomic DNA fragments containing polymorphic sites are incubated with a 5'-fluorescein–labeled primer in the presence of allelic dye-labeled dideoxyribonucleoside triphosphates and a modified Taq polymerase. The dye-labeled primer is extended one base by the dye-terminator specific for the allele present on the template. At the end of the genotyping reaction, the fluorescence intensities of the two dyes in the reaction mixture are analyzed directly without separation or purification. All these steps can be performed in the same tube and the fluorescence changes can be monitored in real time. Alternatively, the extended primer is analyzed by MALDI-TOF Mass Spectrometry. The base at the polymorphic site is identified by the mass added onto the microsequencing primer (see Haff L.A. and Smirnov I.P., *Genome Research*, 7:378-388, 1997).

Microsequencing is achieved by the established microsequencing method or by developments or derivatives thereof. Alternative methods include several solid-phase microsequencing techniques. The basic microsequencing protocol is the same as described previously, except that the method is

conducted as a heterogenous phase assay, in which the primer or the target molecule is immobilized or captured onto a solid support. To simplify the primer separation and the terminal nucleotide addition analysis, oligonucleotides are attached to solid supports or are modified in such ways that permit affinity separation as well as polymerase extension. The 5' ends and internal nucleotides of

5   synthetic oligonucleotides can be modified in a number of different ways to permit different affinity separation approaches, e.g., biotinylation. If a single affinity group is used on the oligonucleotides, the oligonucleotides can be separated from the incorporated terminator regent. This eliminates the need of physical or size separation. More than one oligonucleotide can be separated from the terminator reagent and analyzed simultaneously if more than one affinity group is used. This permits

10  the analysis of several nucleic acid species or more nucleic acid sequence information per extension reaction. The affinity group need not be on the priming oligonucleotide but could alternatively be present on the template. For example, immobilization can be carried out via an interaction between biotinylated DNA and streptavidin-coated microtitration wells or avidin-coated polystyrene particles. In the same manner oligonucleotides or templates is attached to a solid support in a high-density

15  format. In such solid phase microsequencing reactions, incorporated ddNTPs can be radiolabeled (Syvänen, *Clinica Chimica Acta* 226:225-236, 1994) or linked to fluorescein (Livak and Hainer, *Human Mutation* 3:379-385,1994). The detection of radiolabeled ddNTPs can be achieved through scintillation-based techniques. The detection of fluorescein-linked ddNTPs can be based on the binding of antifluorescein antibody conjugated with alkaline phosphatase, followed by incubation

20  with a chromogenic substrate (such as *p*-nitrophenyl phosphate). Other possible reporter-detection pairs include: ddNTP linked to dinitrophenyl (DNP) and anti-DNP alkaline phosphatase conjugate (Harju et al., *Clin. Chem.* 39/11 2282-2287, 1993) or biotinylated ddNTP and horseradish peroxidase-conjugated streptavidin with *o*-phenylenediamine as a substrate (WO 92/15712). As yet another alternative solid-phase microsequencing procedure, Nyren et al. (*Analytical Biochemistry* 208:171-

25  175, 1993) described a method relying on the detection of DNA polymerase activity by an enzymatic luminometric inorganic pyrophosphate detection assay (ELIDA).

Pastinen et al. (*Genome research* 7:606-614, 1997) describe a method for multiplex detection of single nucleotide polymorphism in which the solid phase minisequencing principle is applied to an oligonucleotide array format. High-density arrays of DNA probes attached to a solid support (DNA

30  chips) are further described in X.C.5.

In one aspect the present invention provides polynucleotides and methods to genotype one or more biallelic markers of the present invention by performing a microsequencing assay. It will be appreciated that any primer having a 3' end immediately adjacent to the polymorphic nucleotide is used. However, polynucleotides comprising at least 8, 12, 15, 20, 25, or 30 consecutive nucleotides of

35  the sequence immediately adjacent to the biallelic marker and having a 3' terminus immediately

upstream of the corresponding biallelic marker are well suited for determining the identity of a nucleotide at biallelic marker site.

Similarly, it will be appreciated that microsequencing analysis is performed for any biallelic marker or any combination of biallelic markers of the present invention.

## 5  Mismatch detection assays based on polymerases and ligases

In one aspect the present invention provides polynucleotides and methods to determine the allele of one or more biallelic markers of the present invention in a biological sample, by mismatch detection assays based on polymerases and/or ligases. These assays are based on the specificity of polymerases and ligases. Polymerization reactions places particularly stringent requirements on 10 correct base pairing of the 3' end of the amplification primer and the joining of two oligonucleotides hybridized to a target DNA sequence is quite sensitive to mismatches close to the ligation site, especially at the 3' end. Methods, primers and various parameters to amplify DNA fragments comprising biallelic markers of the present invention are further described above in X.B.

**Allele specific amplification**

15       Discrimination between the two alleles of a biallelic marker can also be achieved by allele specific amplification, a selective strategy, whereby one of the alleles is amplified without amplification of the other allele. This is accomplished by placing the polymorphic base at the 3' end of one of the amplification primers. Because the extension forms from the 3'end of the primer, a mismatch at or near this position has an inhibitory effect on amplification. Therefore, under 20 appropriate amplification conditions, these primers only direct amplification on their complementary allele. Designing the appropriate allele-specific primer and the corresponding assay conditions are well with the ordinary skill in the art.

**Ligation/amplification based methods**

The "Oligonucleotide Ligation Assay" (OLA) uses two oligonucleotides which are designed 25 to be capable of hybridizing to abutting sequences of a single strand of a target molecules. One of the oligonucleotides is biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate that can be captured and detected. OLA is capable of detecting single nucleotide polymorphisms and is advantageously combined with PCR as described by 30 Nickerson D.A. et al. (*Proc. Natl. Acad. Sci. U.S.A.* 87:8923-8927, 1990). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

Other methods which are particularly suited for the detection of single nucleotide polymorphism include LCR (ligase chain reaction), Gap LCR (GLCR) which are described above in X.B. As mentioned above LCR uses two pairs of probes to exponentially amplify a specific target. 35 The sequences of each pair of oligonucleotides, is selected to permit the pair to hybridize to abutting sequences of the same strand of the target. Such hybridization forms a substrate for a template-

113

dependant ligase. In accordance with the present invention, LCR can be performed with
oligonucleotides having the proximal and distal sequences of the same strand of a biallelic marker
site. In one embodiment, either oligonucleotide will be designed to include the biallelic marker site.
In such an embodiment, the reaction conditions are selected such that the oligonucleotides can be
5   ligated together only if the target molecule either contains or lacks the specific nucleotide that is
complementary to the biallelic marker on the oligonucleotide. In an alternative embodiment, the
oligonucleotides will not include the biallelic marker, such that when they hybridize to the target
molecule, a "gap" is created as described in WO 90/01069. This gap is then "filled" with
complementary dNTPs (as mediated by DNA polymerase), or by an additional pair of
10  oligonucleotides. Thus at the end of each cycle, each single strand has a complement capable of
serving as a target during the next cycle and exponential allele-specific amplification of the desired
sequence is obtained.

Ligase/Polymerase-mediated Genetic Bit Analysis$^{TM}$ is another method for determining the
identity of a nucleotide at a preselected site in a nucleic acid molecule (WO 95/21271). This method
15  involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide
present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation to
a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the
reaction's solid phase or by detection in solution.

**2) Hybridization assay methods**

20  A preferred method of determining the identity of the nucleotide present at a biallelic marker
site involves nucleic acid hybridization. The hybridization probes, which can be conveniently used in
such reactions, preferably include the probes defined herein. Any hybridization assay is used
including Southern hybridization, Northern hybridization, dot blot hybridization and solid-phase
hybridization (see Sambrook et al., Molecular Cloning – A Laboratory Manual, Second Edition, Cold
25  Spring Harbor Press, N.Y., 1989).

Hybridization refers to the formation of a duplex structure by two single stranded nucleic
acids due to complementary base pairing. Hybridization can occur between exactly complementary
nucleic acid strands or between nucleic acid strands that contain minor regions of mismatch. Specific
probes can be designed that hybridize to one form of a biallelic marker and not to the other and
30  therefore are able to discriminate between different allelic forms. Allele-specific probes are often
used in pairs, one member of a pair showing perfect match to a target sequence containing the original
allele and the other showing a perfect match to the target sequence containing the alternative allele.
Hybridization conditions should be sufficiently stringent that there is a significant difference in
hybridization intensity between alleles, and preferably an essentially binary response, whereby a
35  probe hybridizes to only one of the alleles. Stringent, sequence specific hybridization conditions,
under which a probe will hybridize only to the exactly complementary target sequence are well known

in the art (Sambrook et al., Molecular Cloning – A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., 1989). Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point ™ for the specific sequence at a defined ionic strength and pH. By way of

5    example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 µg/ml denatured

10   salmon sperm DNA and 5-20 X $10^6$ cpm of $^{32}$P-labeled probe. Alternatively, the hybridization step can be performed at 65°C in the presence of SSC buffer, 1 x SSC corresponding to 0.15M NaCl and 0.05 M Na citrate. Subsequently, filter washes can be done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1X SSC at 50°C for 45 min. Alternatively, filter washes can be performed in a solution containing 2 x SSC and 0.1% SDS,

15   or 0.5 x SSC and 0.1% SDS, or 0.1 x SSC and 0.1% SDS at 68°C for 15 minute intervals. Following the wash steps, the hybridized probes are detectable by autoradiography. By way of example and not limitation, procedures using conditions of intermediate stringency are as follows: Filters containing DNA are prehybridized, and then hybridized at a temperature of 60°C in the presence of a 5 x SSC buffer and labeled probe. Subsequently, filters washes are performed in a solution containing 2x SSC

20   at 50°C and the hybridized probes are detectable by autoradiography. Other conditions of high and intermediate stringency which is used are well known in the art and as cited in Sambrook et al. (Molecular Cloning - A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., 1989) and Ausubel et al. (Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y., 1989).

25          Although such hybridizations can be performed in solution, it is preferred to employ a solid-phase hybridization assay. The target DNA comprising a biallelic marker of the present invention is amplified prior to the hybridization reaction.   The presence of a specific allele in the sample is determined by detecting the presence or the absence of stable hybrid duplexes formed between the probe and the target DNA. The detection of hybrid duplexes can be carried out by a number of

30   methods. Various detection assay formats are well known which utilize detectable labels bound to either the target or the probe to enable detection of the hybrid duplexes. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Those skilled in the art will recognize that wash steps is employed to wash away excess target DNA or probe. Standard heterogeneous assay formats are suitable for detecting the hybrids

35   using the labels present on the primers and probes.

Two recently developed assays allow hybridization-based allele discrimination with no need for separations or washes (see Landegren U. et al., *Genome Research*, 8:769-776,1998). The TaqMan assay takes advantage of the 5' nuclease activity of Taq DNA polymerase to digest a DNA probe annealed specifically to the accumulating amplification product. TaqMan probes are labeled with a

5      donor-acceptor dye pair that interacts via fluorescence energy transfer. Cleavage of the TaqMan probe by the advancing polymerase during amplification dissociates the donor dye from the quenching acceptor dye, greatly increasing the donor fluorescence. All reagents necessary to detect two allelic variants can be assembled at the beginning of the reaction and the results are monitored in real time (see Livak et al., *Nature Genetics*, 9:341-342, 1995). In an alternative homogeneous hybridization

10     based procedure, molecular beacons are used for allele discriminations. Molecular beacons are hairpin-shaped oligonucleotide probes that report the presence of specific nucleic acids in homogeneous solutions. When they bind to their targets they undergo a conformational reorganization that restores the fluorescence of an internally quenched fluorophore (Tyagi et al., *Nature Biotechnology*, 16:49-53, 1998).

15     The polynucleotides provided herein can be used in hybridization assays for the detection of biallelic marker alleles in biological samples. These probes are characterized in that they preferably comprise between 8 and 50 nucleotides, and in that they are sufficiently complementary to a sequence comprising a biallelic marker of the present invention to hybridize thereto and preferably sufficiently specific to be able to discriminate the targeted sequence for only one nucleotide variation. The GC

20     content in the probes of the invention usually ranges between 10 and 75 %, preferably between 35 and 60 %, and more preferably between 40 and 55 %. The length of these probes can range from 10, 15, 20, or 30 to at least 100 nucleotides, preferably from 10 to 50, more preferably from 18 to 35 nucleotides. A particularly preferred probe is 25 nucleotides in length. Preferably the biallelic marker is within 4 nucleotides of the center of the polynucleotide probe. In particularly preferred

25     probes the biallelic marker is at the center of said polynucleotide. Shorter probes may lack specificity for a target nucleic acid sequence and generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. Longer probes are expensive to produce and can sometimes self-hybridize to form hairpin structures. Methods for the synthesis of oligonucleotide probes have been described above and can be applied to the probes of the present invention.

30     Preferably the probes of the present invention are labeled or immobilized on a solid support. Labels and solid supports are further described in II. Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example peptide nucleic acids which are disclosed in International Patent Application WO 92/20702, morpholino analogs which are described in U.S. Patents Numbered 5,185,444; 5,034,506 and 5,142,047. The probe may have to be rendered

35     "non-extendable" in that additional dNTPs cannot be added to the probe. In and of themselves analogs usually are non-extendable and nucleic acid probes can be rendered non-extendable by

116

modifying the 3' end of the probe such that the hydroxyl group is no longer capable of participating in elongation. For example, the 3' end of the probe can be functionalized with the capture or detection label to thereby consume or otherwise block the hydroxyl group. Alternatively, the 3' hydroxyl group simply can be cleaved, replaced or modified, U.S. Patent Application Serial No. 07/049,061 filed

5    April 19, 1993 describes modifications, which can be used to render a probe non-extendable.

The probes of the present invention are useful for a number of purposes. They can be used in Southern hybridization to genomic DNA or Northern hybridization to mRNA. The probes can also be used to detect PCR amplification products. By assaying the hybridization to an allele specific probe, one can detect the presence or absence of a biallelic marker allele in a given sample.

10    High-Throughput parallel hybridizations in array format are specifically encompassed within "hybridization assays" and are described below.

**Hybridization to addressable arrays of oligonucleotides**

Hybridization assays based on oligonucleotide arrays rely on the differences in hybridization stability of short oligonucleotides to perfectly matched and mismatched target sequence variants.

15    Efficient access to polymorphism information is obtained through a basic structure comprising high-density arrays of oligonucleotide probes attached to a solid support (the chip) at selected positions. Each DNA chip can contain thousands to millions of individual synthetic DNA probes arranged in a grid-like pattern and miniaturized to the size of a dime.

The chip technology has already been applied with success in numerous cases. For example,

20    the screening of mutations has been undertaken in the BRCA1 gene, in *S. cerevisiae* mutant strains, and in the protease gene of HIV-1 virus (Hacia et al., *Nature Genetics*, 14(4):441-447, 1996; Shoemaker et al., *Nature Genetics*, 14(4):450-456, 1996; Kozal et al., *Nature Medicine*, 2:753-759, 1996). Chips of various formats for use in detecting biallelic polymorphisms can be produced on a customized basis by Affymetrix (GeneChip™), Hyseq (HyChip and HyGnostics), and Protogene

25    Laboratories.

In general, these methods employ arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from an individual which, target sequences include a polymorphic marker. EP785280 describes a tiling strategy for the detection of single nucleotide polymorphisms. Briefly, arrays may generally be "tiled" for a large number of specific

30    polymorphisms. By "tiling" is generally meant the synthesis of a defined set of oligonucleotide probes which is made up of a sequence complementary to the target sequence of interest, as well as preselected variations of that sequence, e.g., substitution of one or more given positions with one or more members of the basis set of monomers, i.e. nucleotides. Tiling strategies are further described in PCT application No. WO 95/11995. In a particular aspect, arrays are tiled for a number of specific,

35    identified biallelic marker sequences. In particular the array is tiled to include a number of detection blocks, each detection block being specific for a specific biallelic marker or a set of biallelic markers.

For example, a detection block is tiled to include a number of probes, which span the sequence segment that includes a specific polymorphism. To ensure probes that are complementary to each allele, the probes are synthesized in pairs differing at the biallelic marker. In addition to the probes differing at the polymorphic base, monosubstituted probes are also generally tiled within the detection

5   block. These monosubstituted probes have bases at and up to a certain number of bases in either direction from the polymorphism, substituted with the remaining nucleotides (selected from A, T, G, C and U). Typically the probes in a tiled detection block will include substitutions of the sequence positions up to and including those that are 5 bases away from the biallelic marker. The monosubstituted probes provide internal controls for the tiled array, to distinguish actual hybridization

10  from artefactual cross-hybridization. Upon completion of hybridization with the target sequence and washing of the array, the array is scanned to determine the position on the array to which the target sequence hybridizes. The hybridization data from the scanned array is then analyzed to identify which allele or alleles of the biallelic marker are present in the sample. Hybridization and scanning is carried out as described in PCT application No. WO 92/10092 and WO 95/11995 and US patent No.

15  5,424,186.

### 5) Integrated Systems

Another technique, which is used to analyze polymorphisms, includes multicomponent integrated systems, which miniaturize and compartmentalize processes such as PCR and capillary electrophoresis reactions in a single functional device. An example of such technique is disclosed in

20  US patent 5,589,136, which describes the integration of PCR amplification and capillary electrophoresis in chips.

Integrated systems can be envisaged mainly when microfluidic systems are used. These systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip. The movements of the samples are controlled by electric, electroosmotic or

25  hydrostatic forces applied across different areas of the microchip to create functional microscopic valves and pumps with no moving parts. Varying the voltage controls the liquid flow at intersections between the micro-machined channels and changes the liquid flow rate for pumping across different sections of the microchip.

For genotyping biallelic markers, the microfluidic system may integrate nucleic acid

30  amplification, microsequencing, capillary electrophoresis and a detection method such as laser-induced fluorescence detection.

### XI. METHODS OF GENETIC ANALYSIS USING THE BIALLELIC MARKERS OF THE PRESENT INVENTION

The methods available for the genetic analysis of complex traits fall into different categories

35  (see Lander and Schork, *Science*, 265, 2037-2048, 1994). In general, the biallelic markers of the present invention find use in any method known in the art to demonstrate a statistically significant

correlation between a genotype and a phenotype. The biallelic markers is used in linkage analysis and in allele-sharing methods. Preferably, the biallelic markers of the present invention are used to identify genes associated with detectable traits using association studies, an approach which does not require the use of affected families and which permits the identification of genes associated with

5   complex and sporadic traits.

The genetic analysis using the biallelic markers of the present invention is conducted on any scale. The whole set of biallelic markers of the present invention or any subset of biallelic markers of the present invention is used. In some embodiments, any additional set of genetic markers including a biallelic marker of the present invention is used. As mentioned above, it should be noted that the

10  biallelic markers of the present invention is included in any complete or partial genetic map of the human genome. These different uses are specifically contemplated in the present invention and claims.

## XI.A.  Linkage Analysis

Until recently, the identification of genes linked with detectable traits has mainly relied on a

15  statistical approach called linkage analysis. Linkage analysis involves proposing a model to explain the inheritance pattern of phenotypes and genotypes observed in a pedigree. Linkage analysis is based upon establishing a correlation between the transmission of genetic markers and that of a specific trait throughout generations within a family. In this approach, all members of a series of affected families are genotyped with a few hundred markers, typically microsatellite markers, which

20  are distributed at an average density of one every 10 Mb. By comparing genotypes in all family members, one can attribute sets of alleles to parental haploid genomes (haplotyping or phase determination). The origin of recombined fragments is then determined in the offspring of all families. Those that co-segregate with the trait are tracked. After pooling data from all families, statistical methods are used to determine the likelihood that the marker and the trait are segregating

25  independently in all families. As a result of the statistical analysis, one or several regions having a high probability of harboring a gene linked to the trait are selected as candidates for further analysis. The result of linkage analysis is considered as significant (i.e. there is a high probability that the region contains a gene involved in a detectable trait) when the chance of independent segregation of the marker and the trait is lower than 1 in 1000 (expressed as a LOD score > 3). Generally, the length

30  of the candidate region identified as having a LOD score of greater than 3 using linkage analysis is between 2 and 20Mb. Once a candidate region is identified as described above, analysis of recombinant individuals using additional markers allows further delineation of the candidate region. Linkage analysis studies have generally relied on the use of a maximum of 5,000 microsatellite markers, thus limiting the maximum theoretical attainable resolution of linkage analysis to about 600

35  kb on average.

Linkage analysis has been successfully applied to map simple genetic traits that show clear Mendelian inheritance patterns and which have a high penetrance (i.e., the ratio between the number of trait positive carriers of allele $a$ and the total number of $a$ carriers in the population). About 100 pathological trait-causing genes were discovered using linkage analysis over the last 10 years. In

5   most of these cases, the majority of affected individuals had affected relatives and the detectable trait was rare in the general population (frequencies less than 0.1%). In about 10 cases, such as Alzheimer's Disease, breast cancer, and Type II diabetes, the detectable trait was more common but the allele associated with the detectable trait was rare in the affected population. Thus, the alleles associated with these traits were not responsible for the trait in all sporadic cases.

10   Linkage analysis suffers from a variety of drawbacks. First, linkage analysis is limited by its reliance on the choice of a genetic model suitable for each studied trait. Furthermore, as already mentioned, the resolution attainable using linkage analysis is limited, and complementary studies are required to refine the analysis of the typical 2Mb to 20Mb regions initially identified through linkage analysis. In addition, linkage analysis approaches have proven difficult when applied to complex

15   genetic traits, such as those due to the combined action of multiple genes and/or environmental factors. In such cases, too large an effort and cost are needed to recruit the adequate number of affected families required for applying linkage analysis to these situations, as recently discussed by Risch, N. and Merikangas, K. (*Science*, 273:1516-1517, 1996). Finally, linkage analysis cannot be applied to the study of traits for which no large informative families are available. Typically, this will

20   be the case in any attempt to identify trait-causing alleles involved in sporadic cases, such as alleles associated with positive or negative responses to drug treatment.

**XI.B. Allele-Sharing methods**

Whereas linkage analysis involves proposing a model to explain the inheritance pattern of phenotypes and genotypes in a pedigree, allele-sharing methods are not based on constructing a

25   model, but rather on rejecting a model (see Lander and Schork, *Science*, 265, 2037-2048, 1994). More specifically, one tries to prove that the inheritance pattern of a chromosomal region is not consistent with random Mendelian segregation by showing that affected relatives inherit identical copies of the region more often than expected by chance. Because allele-sharing methods are nonparametric (that is, assume no model for the inheritance of the trait), they tend to be more useful

30   for the analysis of complex traits than linkage analysis. Affected relatives should show excess allele sharing even in the presence of incomplete penetrance and polygenic inheritance. Allele-Sharing methods involve studying affected relatives in a pedigree to determine how often a particular copy of a chromosomal region is shared identical-by-descent (IBD), that is, is inherited from a common ancestor within the pedigree. The frequency of IBD sharing at a locus can then be compared with

35   random expectation. Affected sib pair analysis is a well-known special case and is the simplest form of this method.

However, as allele-sharing methods analyze affected relatives, they tend to be of limited value in the genetic analysis of drug responses or in the analysis of side effects to treatments. This type of analysis is impractical in such cases due to the lack of availability of familial cases. In fact, the likelihood of having more than one individual in a family being exposed to the same drug at the same

5    time is very low.

### XI.C. Association Studies

The present invention comprises methods for identifying one or several genes among a set of candidate genes that are associated with a detectable trait using the biallelic markers of the present invention. In one embodiment the present invention comprises methods to detect an association

10   between a biallelic marker allele or a biallelic marker haplotype and a trait. Further, the invention comprises methods to identify a trait causing allele in linkage disequilibrium with any biallelic marker allele of the present invention.

As described above, alternative approaches can be employed to perform association studies: genome-wide association studies, candidate region association studies and candidate gene association

15   studies. In a preferred embodiment, the biallelic markers of the present invention are used to perform candidate gene association studies. The candidate gene analysis clearly provides a short-cut approach to the identification of genes and gene polymorphisms related to a particular trait when some information concerning the biology of the trait is available. Further, the biallelic markers of the present invention is incorporated in any map of genetic markers of the human genome in order to

20   perform genome-wide association studies. Methods to generate a high-density map of biallelic markers has been described in US Provisional Patent application serial number 60/082,614. The biallelic markers of the present invention may further be incorporated in any map of a specific candidate region of the genome (a specific chromosome or a specific chromosomal region for example).

25   As mentioned above, association studies is conducted within the general population and are not limited to studies performed on related individuals in affected families. Linkage disequilibrium and association studies are extremely valuable as they permit the analysis of sporadic or multifactor traits. Moreover, association studies represent a powerful method for fine-scale mapping enabling much finer mapping of trait causing alleles than linkage studies. Studies based on pedigrees often

30   only narrow the location of the trait causing allele. Association studies and Linkage Disequilibrium mapping methods using the biallelic markers of the present invention can therefore be used to refine the location of a trait causing allele in a candidate region identified by Linkage Analysis or by Allele-Sharing methods. Moreover, once a chromosome segment of interest has been identified, the presence of a candidate gene such as a candidate gene of the present invention, in the region of

35   interest can provide a shortcut to the identification of the trait causing allele. Biallelic markers of the

present invention can be used to demonstrate that a candidate gene is associated with a trait. Such uses are specifically contemplated in the present invention and claims.

### 1) Case-control populations (inclusion criteria)

Association studies do not concern familial inheritance and do not involve the analysis of

5    large family pedigrees but compare the prevalence of a particular genetic marker, or a set of markers, in case-control populations. They are case-control studies based on comparison of unrelated case (affected or trait positive) individuals and unrelated control (random or unaffected or trait negative) individuals. The control group is composed of individuals chosen randomly or of unaffected (trait negative) individuals, preferably the control group is composed of unaffected or trait negative

10   individuals. Further, the control group is preferably both ethnically- and age-matched to the case population. In the following "trait positive population", "case population" and "affected population" are used interchangeably.

An important step in the dissection of complex traits using association studies is the choice of case-control populations (see Lander and Schork, *Science*, 265, 2037-2048, 1994). Narrowing the

15   definition of the disease and restricting the patient population to extreme phenotypes allows one to work with a trait that is more nearly Mendelian in its inheritance pattern and more likely to be homogeneous (patients suffer from the disease for the same genetic reasons). Therefore, a major step in the choice of case-control populations is the clinical definition of a given trait or phenotype. Four criteria are often useful: clinical phenotype, age at onset, family history and severity. Preferably, in

20   order to perform efficient and significant association studies, such as those described herein, the trait under study should preferably follow a bimodal distribution in the population under study, presenting two clear non-overlapping phenotypes (trait positive and trait negative). Nevertheless, even in the absence of such bimodal distribution (as may in fact be the case for more complex genetic traits), any genetic trait may still be analyzed by the association method proposed here by carefully selecting the

25   individuals to be included in the trait positive and trait negative phenotypic groups. The selection procedure involves selecting individuals at opposite ends of the non-bimodal phenotype spectra of the trait under study, so as to include in these trait positive and trait negative populations individuals which clearly represent extreme, preferably non-overlapping phenotypes. This is particularly useful for continuous or quantitative traits (such as blood pressure for example). Selection of individuals at

30   extreme ends of the trait distribution increases the ability to analyze these complex traits. The definition of the inclusion criteria for the case-control populations is an important aspect of association studies. The selection of those drastically different but relatively uniform phenotypes enables efficient comparisons in association studies and the possible detection of marked differences at the genetic level, provided that the sample sizes of the populations under study are significant

35   enough.

Preferably, case-control populations to be included in association studies such as those proposed in the present invention consist of phenotypically homogeneous populations of individuals each representing 100% of the corresponding phenotype if the trait distribution is bimodal. If the trait distribution is non-bimodal, trait positive and trait negative populations consist of phenotypically

5   uniform populations of individuals representing each between 1 and 98%, preferably between 1 and 80%, more preferably between 1 and 50%, and more preferably between 1 and 30%, most preferably between 1 and 20% of the total population under study, and selected among individuals exhibiting non-overlapping phenotypes. In some embodiments, the trait positive and trait negative groups consist of individuals exhibiting the extreme phenotypes within the studied population. The clearer

10  the difference between the two trait phenotypes, the greater the probability of detecting an association with biallelic markers.

In preferred embodiments, a first group of between 50 and 300 trait positive individuals, preferably about 100 individuals, are recruited according to their phenotypes. A similar number of trait negative individuals are included in such studies.

15  In the present invention, typical examples of inclusion criteria include a diagnosis of cancer or prostate cancer or the evaluation of the response to anti-cancer or anti-prostate cancer agent or side effects to treatment with anti-cancer or anti-prostate cancer agents.

Suitable examples of association studies using biallelic markers including the biallelic markers of the present invention, are studies involving the following populations:

20  a case population suffering from a form of cancer and a healthy unaffected control population, or

a case population suffering from a form of prostate cancer and a healthy unaffected control population, or

a case population treated with anticancer agents suffering from side-effects resulting from the treatment and a control population treated with the same agents showing no side-effects, or

25  a case population treated with anti-prostate cancer agents suffering from side-effects resulting from the treatment and a control population treated with the same agents showing no side-effects, or

a case population treated with anti-cancer agents showing a beneficial response and a control population treated with same agents showing no beneficial response, or

a case population treated with anti-prostate cancer agents showing a beneficial response and a control

30  population treated with same agents showing no beneficial response.

**2) Determining the frequency of an allele in case-control populations**

Allelic frequencies of the biallelic markers in each of the populations can be determined using one of the methods described above under the in Section X. under the heading "Methods for genotyping an individual for biallelic markers", or any genotyping procedure suitable for this intended

35  purpose. The frequency of a biallelic marker allele in a population can be determined by genotyping pooled samples or individual samples. One way to reduce the number of genotypings required is to

use pooled samples. A major obstacle in using pooled samples is in terms of accuracy and reproducibility for determining accurate DNA concentrations in setting up the pools. Genotyping individual samples provides higher sensitivity, reproducibility and accuracy and; is the preferred method used in the present invention. Preferably, each individual is genotyped separately and simple

5    gene counting is applied to determine the frequency of an allele of a biallelic marker or of a genotype in a given population.

**3) Determining the frequency of a haplotype in case-control populations**

The gametic phase of haplotypes is usually unknown when diploid individuals are heterozygous at more than one locus. Different strategies for inferring haplotypes is used to partially

10   overcome this difficulty (see Excoffier L. and Slatkin M., *Mol. Biol. Evol.*, 12(5): 921-927, 1995). One possibility is that the multiple-site heterozygous diploids can be eliminated from the analysis, keeping only the homozygotes and the single-site heterozygote individuals, but this approach might lead to a possible bias in the sample composition and the underestimation of low-frequency haplotypes. Another possibility is that single chromosomes can be studied independently, for

15   example, by asymmetric PCR amplification (see Newton et al., *Nucleic Acids Res.*, 17:2503-2516, 1989; Wu et al., *Proc. Natl. Acad. Sci. USA*, 86:2757, 1989) or by isolation of single chromosome by limit dilution followed by PCR amplification (see Ruano et al., *Proc. Natl. Acad. Sci. USA*, 87:6296-6300, 1990). Further, multiple haplotypes can sometimes be inferred using genealogical information in families (Perlin et al., *Am. J. Hum. Genet.*, 55:777-787, 1994). A sample is haplotyped for

20   sufficiently close biallelic markers by double PCR amplification of specific alleles (Sarkar, G. and Sommer S.S., *Biotechniques*, 1991). These approaches are not entirely satisfying either because of their technical complexity, the additional cost they entail, their lack of generalization at a large scale, or the possible biases they introduce. To overcome these difficulties, an algorithm based on Hardy-Weinberg equilibrium (random mating) to infer the phase of PCR-amplified DNA genotypes

25   introduced by Clark A.G. (*Mol. Biol. Evol.*, 7:111-122, 1990) is used. Briefly, the principle is to start filling a preliminary list of haplotypes present in the sample by examining unambiguous individuals, that is, the complete homozygotes and the single-site heterozygotes. Then other individuals in the same sample are screened for the possible occurrence of previously recognized haplotypes. For each positive identification, the complementary haplotype is added to the list of recognized haplotypes,

30   until the phase information for all individuals is either resolved or identified as unresolved. This method assigns a single haplotype to each multiheterozygous individual, whereas several haplotypes are possible when there are more than one heterozygous site. Any other method known in the art to determine the frequency of a haplotype in a population is used. Preferably, an expectation-maximization (EM) algorithm (Dempster et al., *J. R. Stat. Soc.*, 39B:1-38, 1977) leading to maximum-

35   likelihood estimates of haplotype frequencies under the assumption of Hardy-Weinberg proportions is used (see Excoffier L. and Slatkin M., *Mol. Biol. Evol.*, 12(5): 921-927, 1995). The EM algorithm is

used to estimate haplotype frequencies in the case when only genotype data from unrelated individuals are available. The EM algorithm is a generalized iterative maximum-likelihood approach to estimation that is useful when data are ambiguous and/or incomplete. The EM algorithm is used to resolve heterozygotes into haplotypes. Haplotype estimations are further described below under the

5    heading "Statistical methods".

### 4) Genetic Analysis based on Linkage Disequilibrium

Linkage disequilibrium is the non-random association of alleles at two or more loci and represents a powerful tool for genetic mapping of complex traits (see Jorde L.B., *Am. J. Hum. Genet.*, 56:11-14, 1995). Biallelic markers, because they are densely spaced in the human genome and can be

10   genotyped in large numbers, are particularly useful in genetic analysis based on linkage disequilibrium.

When a disease mutation is first introduced into a population (by a new mutation or the immigration of a mutation carrier), it necessarily resides on a single chromosome and thus on a single "background" or "ancestral" haplotype of linked markers. Consequently, there is complete

15   disequilibrium between these markers and the disease mutation: one finds the disease mutation only in the presence of a specific set of marker alleles. Through subsequent generations recombinations occur between the disease mutation and these marker polymorphisms, and the disequilibrium gradually dissipates. The pace of this dissipation is a function of the recombination frequency, so the markers closest to the disease gene will manifest higher levels of disequilibrium than those that are

20   further away. When not broken up by recombination, "ancestral" haplotypes and linkage disequilibrium between marker alleles at different loci can be tracked not only through pedigrees but also through populations.

The pattern or curve of disequilibrium between disease and marker loci will exhibit a single maximum that occurs at the disease locus. Consequently, the amount of linkage disequilibrium

25   between a disease allele and closely linked genetic markers may yield valuable information regarding the location of the disease gene. For fine-scale mapping of a disease locus, it is useful to have some knowledge of the patterns of linkage disequilibrium that exist between markers in the studied region. As mentioned above the mapping resolution achieved through the analysis of linkage disequilibrium is much higher than that of linkage studies. The high density of biallelic markers combined with

30   linkage disequilibrium analysis provide powerful tools for fine-scale mapping. Different methods to calculate linkage disequilibrium are described below under the heading "Statistical Methods". Moreover, association studies as a method of mapping genetic traits rely on the phenomenon of linkage disequilibrium.

### 3) Association studies

35   As mentioned above, the occurrence of pairs of specific alleles at different loci on the same chromosome is not random, and the deviation from random is called linkage disequilibrium. If a

specific allele in a given gene is directly involved in causing a particular trait, its frequency will be statistically increased in an affected (trait positive) population when compared to the frequency in a trait negative population or in a random control population. As a consequence of the existence of linkage disequilibrium, the frequency of all other alleles present in the haplotype carrying the trait-

5      causing allele will also be increased in trait positive individuals compared to trait negative individuals or random controls. Therefore, association between the trait and any allele (specifically a biallelic marker allele) in linkage disequilibrium with the trait-causing allele will suffice to suggest the presence of a trait-related gene in that particular allele's region. Association studies focus on population frequencies. Case-control populations can be genotyped for biallelic markers to identify

10     associations that narrowly locate a trait causing allele. Moreover, any marker in linkage disequilibrium with one given marker associated with a trait will be associated with the trait. Linkage disequilibrium allows the relative frequencies in case-control populations of a limited number of genetic polymorphisms (specifically biallelic markers) to be analyzed as an alternative to screening all possible functional polymorphisms in order to find trait-causing alleles. Association studies compare

15     the frequency of marker alleles in unrelated case-control populations, and represent powerful tools for the dissection of complex traits.

**Association analysis**

The general strategy to perform association studies using biallelic markers derived from a candidate gene is to scan two groups of individuals (case-control populations) in order to measure and

20     statistically compare the allele frequencies of the biallelic markers of the present invention in both groups.

If a statistically significant association with a trait is identified for at least one or more of the analyzed biallelic markers, one can assume that: either the associated allele is directly responsible for causing the trait (the associated allele is the trait causing allele), or more likely the associated allele is

25     in linkage disequilibrium with the trait causing allele. The specific characteristics of the associated allele with respect to the candidate gene function usually gives further insight into the relationship between the associated allele and the trait (causal or in linkage disequilibrium). If the evidence indicates that the associated allele within the candidate gene is most probably not the trait causing allele but is in linkage disequilibrium with the real trait causing allele, then the trait causing allele can

30     be found by sequencing the vicinity of the associated marker.

Association studies are usually run in two successive steps. In a first phase, the frequencies of a reduced number of biallelic markers from one or several candidate genes are determined in the trait positive and trait negative populations. In a second phase of the analysis, the identity of the candidate gene and the position of the genetic loci responsible for the given trait is further refined using a higher

35     density of markers from the relevant gene  However, if the candidate gene under study is relatively

small in length, as it is the case for many of the candidate genes analyzed included in the present invention, a single phase is sufficient to establish significant associations.

**Haplotype analysis**

As described above, when a chromosome carrying a disease allele first appears in a
5 population as a result of either mutation or migration, the mutant allele necessarily resides on a chromosome having a unique set of linked markers: the ancestral haplotype. This haplotype can be tracked through populations and its statistical association with a given trait can be analyzed. The statistical power of association studies is increased by complementing single point (allelic) association studies with multi-point association studies also called haplotype studies. Thus, a
10 haplotype association study allows one to define the frequency and the type of the ancestral carrier haplotype. A haplotype analysis is important in that it increases the statistical significance of an analysis involving individual markers. Indeed, by performing an association study with a set of biallelic markers, it increases the value of the results obtained through the study, allowing false positive and/or negative data that may result from the single marker studies to be eliminated.

15 In a first stage of a haplotype frequency analysis, the frequency of the possible haplotypes based on various combinations of the identified biallelic markers of the invention is determined. The haplotype frequency is then compared for distinct populations of trait positive and control individuals. The number of trait positive individuals which should be subjected to this analysis to obtain statistically significant results usually ranges between 30 and 300, with a preferred number of
20 individuals ranging between 50 and 150. The same considerations apply to the number of random control or unaffected individuals used in the study. The results of this first analysis provide haplotype frequencies in case-control populations, the relative risk for an individual carrying a given haplotype of being affected with the given trait under study and the estimated p value for each evaluated haplotype.

25 **Interaction Analysis**

The biallelic markers of the present invention may also be used to identify patterns of biallelic markers associated with detectable traits resulting from polygenic interactions. The analysis of genetic interaction between alleles at unlinked loci requires individual genotyping using the techniques described herein. The analysis of allelic interaction among a selected set of biallelic
30 markers with appropriate level of statistical significance can be considered as a haplotype analysis, similar to those described in further details within the present invention. Preferably, genotyping typing is performed using the microsequencing technique.

Methods to test for association between a trait and a biallelic marker allele or a haplotype of biallelic marker alleles are described below.

35 **XI.D. Statistical methods**

In general, any method known in the art to test whether a trait and a genotype show a statistically significant correlation is used.

**Methods to estimate haplotype frequencies in a population**

As described above, when genotypes are scored, it is often not possible to distinguish

5   heterozygotes so that haplotype frequencies cannot be easily inferred. When the gametic phase is not known, haplotype frequencies can be estimated from the multilocus genotypic data. Any method known to person skilled in the art can be used to estimate haplotype frequencies (see Lange K., *Mathematical and Statistical Methods for Genetic Analysis, Springer, New York,* 1997; Weir, B.S., *Genetic data Analysis II: Methods for Discrete population genetic Data, Sinauer Assoc., Inc.,*

10  *Sunderland, MA, USA,* 1996) Preferably, maximum-likelihood haplotype frequencies are computed using an Expectation- Maximization (EM) algorithm (see Dempster et al., *J. R. Stat. Soc.,* 39B:1-38, 1977; Excoffier L. and Slatkin M., *Mol. Biol. Evol.,* 12(5): 921-927, 1995). This procedure is an iterative process aiming at obtaining maximum-likelihood estimates of haplotype frequencies from multi-locus genotype data when the gametic phase is unknown. Haplotype estimations are usually

15  performed by applying the EM algorithm using for example the EM-HAPLO program (Hawley M.E. et al., *Am. J. Phys. Anthropol.,* 18:104, 1994) or the Arlequin program (Schneider et al., *Arlequin: a software for population genetics data analysis,* University of Geneva, 1997). The EM algorithm is a generalized iterative maximum likelihood approach to estimation and is briefly described below.

In the following part of this text, phenotypes will refer to multi-locus genotypes with

20  unknown phase. Genotypes will refer to known-phase multi-locus genotypes.

Suppose a sample of N unrelated individuals typed for K markers. The data observed are the unknown-phase K-locus phenotypes that can categorized in F different phenotypes. Suppose that we have H underlying possible haplotypes (in case of K biallelic markers, $H=2^K$).

For phenotype j, suppose that cj genotypes are possible. We thus have the following equation

25   $$P_j = \sum_{i=1}^{c_j} pr(genotype_i) = \sum_{i=1}^{c_j} pr(h_k, h_l)$$   <u>Equation 1</u>

where $P_j$ is the probability of the phenotype *j*, *hk* and *hl* are the two haplotypes constituent the genotype *i*. Under the Hardy-Weinberg equilibrium, *pr(hk,hl)* becomes :

$$pr(h_k, h_l) = pr(h_k)^2 \text{ if } h_k = h_l, \ pr(h_k, h_l) = 2pr(h_k).pr(h_l) \text{ if } h_k \neq h_l.$$   <u>Equation 2</u>

The successive steps of the E-M algorithm can be described as follows:

30   Starting with initial values of the of haplotypes frequencies, noted, $p_1^{(0)}, p_2^{(0)}, \ldots p_T^{(0)}$.

these initial values serve to estimate the genotype frequencies (Expectation step) and then estimate another set of haplotype frequencies (Maximization step): $p_1^{(1)}, p_2^{(1)}, \ldots p_T^{(1)}$.

these two steps are iterated until change in the sets of haplotypes frequency are very small.

A stop criterion can be that the maximum difference between haplotype frequencies between two iterations is less than $10^{-7}$. These values can be adjusted according to the desired precision of estimations.

In detail, at a given iteration s, the Expectation step consists in calculating the genotypes
5  frequencies by the following equation:

$$pr(genotype_i)^{(s)} = pr(phenotype_j).pr(genotype_i|phenotype_j)^{(s)}$$

$$= \frac{n_j}{N} \cdot \frac{pr(h_k,h_l)^{(s)}}{P_j^{(s)}} \qquad \text{\underline{Equation 3}}$$

where genotype $i$ occurs in phenotype $j$, and where $hk$ and $hl$ constitute genotype $i$. Each probability are derived according to equations 1 and 2 above.

Then the Maximization step simply estimates another set of haplotype frequencies given the
10  genotypes frequencies. This approach is also known as gene-counting method (Smith, *Ann. Hum. Genet.*, 21:254-276, 1957).

$$p_t^{(s+1)} = \frac{1}{2} \sum_{j=1}^{F} \sum_{i=1}^{c_j} \delta_{it} \cdot pr(genotype_i)^{(s)} \qquad \text{\underline{Equation 4}}$$

where $\delta_{it}$ is an indicator variable which count the number of time haplotype $t$ in genotype $i$. It takes the values of 0, 1 or 2.

15      To ensure that the estimation finally obtained are the maximum-likelihood estimations several values of departures are required. The estimations obtained are compared and if they differ the estimations leading to the best likelihood are kept. The term "haplotype determination method" is used to refer to all methods for determinin haplotypes known in the art including expectation-maximization algorithms.

20  **Methods to calculate linkage disequilibrium between markers**

A number of methods can be used to calculate linkage disequilibrium between any two genetic positions, in practice, linkage disequilibrium is measured by applying a statistical association test to haplotype data taken from a population.

Linkage disequilibrium between any pair of biallelic markers comprising at least one of the biallelic
25  markers of the present invention ($M_i,M_j$) can be calculated for every allele combination ($M_{i1},M_{j1}$ ; $M_{i1},M_{j2}$ ; $M_{i2},M_{j1}$ and $M_{i2},M_{j2}$), according to the Piazza formula :

$\Delta M_{ik},M_{jl}= \sqrt{\theta 4} - \sqrt{(\theta 4 + \theta 3)(\theta 4 + \theta 2)}$, where :

$\theta 4 = - - =$ frequency of genotypes not having allele k at $M_i$ and not having allele l at $M_j$

$\theta 3 = - + =$ frequency of genotypes not having allele k at $M_i$ and having allele l at $M_j$

30  $\theta 2 = + - =$ frequency of genotypes having allele k at $M_i$ and not having allele l at $M_j$

Linkage disequilibrium (LD) between pairs of biallelic markers (Mi, Mj) can also be calculated for every allele combination ($M_{i1},M_{j1}; M_{i1},M_{j2}; M_{i2},M_{j1}$ and $M_{i2},M_{j2}$), according to the maximum-likelihood estimate (MLE) for delta (the composite linkage disequilibrium coefficient), as described by Weir (B.S. Weir, *Genetic Data Analysis*, Sinauer Ass. Eds, 1996). This formula allows linkage

5   disequilibrium between alleles to be estimated when only genotype, and not haplotype, data are available. This LD composite test makes no assumption for random mating in the sampled population, and thus seems to be more appropriate than other LD tests for genotypic data.

Another means of calculating the linkage disequilibrium between markers is as follows. For a couple of biallelic markers, *Mi* ($a_i/b_i$) and *Mj* ($a_j/b_j$), fitting the Hardy-Weinberg equilibrium, one can

10   estimate the four possible haplotype frequencies in a given population according to the approach described above.

The estimation of gametic disequilibrium between *ai* and *aj* is simply:

$$D_{aiaj} = pr(haplotype(a_i,a_j)) - pr(a_i).pr(a_j).$$

Where *pr(ai)* is the probability of allele *ai* and *aj* is the probability of allele *aj*. and where

15   *pr(haplotype (ai, aj))* is estimated as in <u>Equation 3</u> above.

For a couple of biallelic marker only one measure of disequilibrium is necessary to describe the association between *Mi* and *Mj*.

Then a normalized value of the above is calculated as follows:

**D'aiaj = Daiaj / max ( pr(ai).pr(aj),pr(bi).(bj) )        with Daiaj<0**

20   **D'aiaj = Daiaj / max ( pr(bi).pr(aj),pr(ai).(bj) )        with Daiaj>0**

The skilled person will readily appreciate that other LD calculation methods can be used without undue experimentation.

Linkage disequilibrium among a set of biallelic markers having an adequate heterozygosity rate can be determined by genotyping between 50 and 1000 unrelated individuals, preferably between

25   75 and 200, more preferably around 100.

**Testing for association**

Methods for determining the statistical significance of a correlation between a phenotype and a genotype, in this case an allele at a biallelic marker or a haplotype made up of such alleles, is determined by any statistical test known in the art and with any accepted threshold of statistical

30   significance being required. The application of particular methods and thresholds of significance are well with in the skill of the ordinary practitioner of the art.

Testing for association is performed by determining the frequency of a biallelic marker allele in case and control populations and comparing these frequencies with a statistical test to determine if their is a statistically significant difference in frequency which would indicate a correlation between

35   the trait and the biallelic marker allele under study. Similarly, a haplotype analysis is performed by estimating the frequencies of all possible haplotypes for a given set of biallelic markers in case and

control populations, and comparing these frequencies with a statistical test to determine if their is a statistically significant correlation between the haplotype and the phenotype (trait) under study. Any statistical tool useful to test for a statistically significant association between a genotype and a phenotype is used. Preferably the statistical test employed is a chi square test with one degree of

5    freedom. A P-value is calculated (the P-value is the probability that a statistic as large or larger than the observed one would occur by chance).

**Statistical significance**

In preferred embodiments, significance for diagnosis purposes, either as a positive basis for further diagnostic tests or as a preliminary starting point for early preventive therapy, the p value

10   related to a biallelic marker association is preferably about 1 x 10-2 or less, more preferably about 1 x 10-4 or less, for a single biallelic marker analysis and about 1 x 10-3 or less, still more preferably 1 x 10-6 or less and most preferably of about 1 x 10-8 or less, for a haplotype analysis involving several markers. These values are believed to be applicable to any association studies involving single or multiple marker combinations.

15   The skilled person can use the range of values set forth above as a starting point in order to carry out association studies with biallelic markers of the present invention. In doing so, significant associations between the biallelic markers of the present invention and cancer and prostate cancer can be revealed and used for diagnosis and drug screening purposes.

Using the method described above and evaluating the associations for single marker alleles or

20   for haplotypes permits an estimation of the risk a corresponding carrier has to develop a given trait, and particularly in the context of the present invention, a disease, preferably cancer, more preferably prostate cancer. Significance thresholds of relative risks are to be adapted to the reference sample population used.

In this regard, among all the possible marker combinations or haplotypes which are evaluated

25   to determine the significance of their association with a given trait, for example a form of cancer or prostate cancer, a response to treatment with anti-cancer or anti-prostate cancer agents or side effects related to treatment with anti-cancer or anti-prostate cancer agents, it is believed that those displaying a coefficient of relative risk above 1, preferably about 5 or more, preferably of about 7 or more are indicative of a "significant risk" for the individuals carrying the identified haplotype to develop the

30   given trait. It is difficult to evaluate accurately quantified boundaries for the so-called "significant risk". Indeed, and as it has been demonstrated previously, several traits observed in a given population are multifactorial in that they are not only the result of a single genetic predisposition but also of other factors such as environmental factors or the presence of further, apparently unrelated, haplotype associations. Thus, the evaluation of a significant risk must take these parameters into

35   consideration in order to, in a certain manner, weigh the potential importance of external parameters in the developm nt of a given trait. Without wishing to be bound to any invariable model or theory

based on the above statistical analyses, the inventors believe that a "significant risk" to develop a given trait is evaluated differently depending on the trait under consideration.

It will of course be understood by practitioners skilled in the treatment or diagnosis of cancer and prostate cancer that the present invention does not intend to provide an absolute identification of individuals who could be at risk of developing a particular form of cancer or who will or will not respond or exhibit side effects to treatment with anti-cancer or anti-prostate cancer agents but rather to indicate a certain degree or likelihood of developing a disease or of observing in a given individual a response or a side effect to treatment with a particular agent or set of agents.

However, this information is extremely valuable as it can, in certain circumstances, be used to initiate preventive treatments or to allow an individual carrying a significant haplotype to foresee warning signs such as minor symptoms. In the case of cancer, the knowledge of a potential predisposition, even if this predisposition is not absolute, might contribute in a very significant manner to treatment, or allow for suggestions in changes in diet or the reduction of risky behaviors, e.g. smoking. Similarly, a diagnosed predisposition to a potential side effect could immediately direct the physician toward a treatment, for which such side effects have not been observed during clinical trials.

**Phenotypic randomization**

In order to confirm the statistical significance of the first stage haplotype analysis described above, it might be suitable to perform further analyses in which genotyping data from case-control individuals are pooled and randomized with respect to the trait phenotype. Each individual genotyping data is randomly allocated to two groups which contain the same number of individuals as the case-control populations used to compile the data obtained in the first stage. A second stage haplotype analysis is preferably run on these artificial groups, preferably for the markers included in the haplotype of the first stage analysis showing the highest relative risk coefficient. This experiment is reiterated between 50 and 200 times, preferably between 75 and 125 times. The repeated iterations allow the determination of the percentage of obtained haplotypes with a significant p-value level below about $1 \times 10^{-3}$.

Example 24

Detailed Association Studies

The initial association studies between the 8p23 locus and prostate cancer described in Section I.D. were repeated at a higher level of sophistication.

Collection of DNA samples from affected and non-affected individuals

Prostate cancer patients were recruited according to clinical inclusion criteria based on pathological or radical prostatectomy records as described above in Section I. However, the pool of individuals suffering from prostate cancer described in Section I was augmented from the original 185 individuals to a range of between 275 and 491 individuals depending on the marker tested. Similarly,

the control pool of non-diseased individuals described in Section I was augmented from the original

104 individuals to a range of between 130 and 313 individuals depending on the marker tested.

## Genotyping Affected and Control Individuals

As for Section I.D., allelic frequencies of the biallelic markers in each population were

5    determined by performing microsequencing reactions on amplified fragments obtained by genomic

PCR performed on the DNA samples from each individual as described in Example 5.

## Association Studies

Association results were obtained using markers spanning a 650 kb region of the 8p28 locus

around PG1 both using single point analysis and haplotyping studies.  See Figure 16.  As compared

10   with the earlier representation of the initial association results for this region shown in Figure 2,

Figure 16 is to scale, since the entire region has now been sequenced.  In addition, more markers were

generated around the association peak in the area of PG1; each of which has been tested in single

point analysis (hence the density of data within this subregion).  The haplotyping curve in Figure 16

represents, for each marker considered, the maximum p-value for haplotypes obtained using this

15   marker and any number from all markers harbored by the same BAC and being in Hardy Weindeberg

Disequilibrium with said marker.

The data presented in Figure 16 shows a strong association between this specific region

within 8p23 locus, especially in the area that has been identified as being the PG1 gene, and prostate

cancer. The maximum p-value in single point analysis, for the PG1 sub-region, is $3.10^{-3}$, while outside

20   of the PG1 subregion, most of the p-values obtained for single point associations are less significant

than $1.10^{-1}$. The maximum p-value obtained for haplotyping studies is the one obtained for a marker

inside PG1's BAC, and equals $3.10^{-6}$.

Figure 17 is a graph showing an enlarged view of the single point association results within a

160 kb region comprising the PG1 gene.  Markers involved in this enlargement were all located on

25   BAC B0463F01 (see Figure 16), except marker 4-14, which lies in very close proximity, on BAC

B0189E08.  Figure 17 shows all of the markers which made up the maximum haplotype shown in

Figure 16.  Some of these markers were later revealed to lie within the promoter, exonic or intronic

regions of the PG1 gene. The markers outside the gene were all informative biallelic markers with a

least frequent allele present at a frequency of more than 20%, while markers within the gene were a

30   mix of such informative markers and markers whose least frequent allele's frequency is less than

20%. These data confirm and narrow the previous peak of association values seen in Figure 16, to a

40 kb harboring the PG1 gene.  Significant associations are obtained for markers starting at the

promoter site with marker No. 99-1485, and ending at the 3' UTR site with marker No. 5-66.

Figure 18A is a graph showing an enlarged view of the single point association results of 40

35   kb within the PG1 gene. These data confirm that seven markers within the PG1 gene have one allele

associated with prostate cancer, with p-values all similar and more significant than $1.10^{-2}$ , specifically

markers 99-622 ; 4-77 ; 4-71 ; 4-73 ; 99-598 ; 99-576 ; 4-66. Figure 18B is a table listing the location of markers within PG1 gene, the two possible alleles at each site. For each marker, the disease-associated allele is indicated first ; its frequencies in cases and controls as well as the difference between both are shown ; the odd-ratio and the p-value of each individual marker association are also

5    shown.

The data in Figures 17, 18A, and 18B demonstrate that the markers in the PG1 gene have an association with prostate cancer that is valid, and exhibits similar significance values, regardless whether the considered cases are sporadic or familial cases. Therefore, some PG1 alleles must be general risk factors for any type of prostate cancer, whether familial or sporadic. The fact that several

10   p-values for associated alleles are around $1.10^{-2}$ suggests that all these markers are in linkage disequilibrium to one another, and can all be used individually to assess PG1 associated prostate cancer susceptibility risk. The prostate cancer associated alleles of the 7 markers discussed above, all exhibit an odd-ratio of about 1.5, which means for each of them that an individual carrying such allele has 1.5 more chances to be susceptible to prostate cancer than not.

15   In order to confirm the significance of the association results found for markers on the BAC harboring PG1, we a novel statistical method was performed as described in provisional patent application serial no. 60/107,986, filed November 10, 1998.

<u>Haplotype analysis</u>

The results of a haplotype analysis study using 4 markers (marker Nos. 4-14, 99-217, 4-66 and

20   99-221) ) within the 160 kb region shown in Figure 17 are shown in Figure 19A. These 4 markers have each been shown to be strongly associated with prostate cancer, i.e. with p-values more significant than $1.10^{-3}$ on approximately 150 cases and 130 controls. All haplotypes using 2, 3, or 4 markers among the 4 above cited were analyzed using 491 case patients and 317 control individuals. Figure 19A shows the most significant haplotypes obtained, as well as the individual odd-ratios for

25   each. Haplotype 11 is the most significant (p-value of ca. $3.10^{-6}$), and is related to haplotype 5, shown in Figure 4 in that three of the four marker alleles (4-14 C, 99-217 T and 99-221 A) are common to both haplotypes, and both cover a similar region. Differences in p-values are explained both by the addition of markers and of more case or control individuals. Haplotype 11 has an highly informative odd-ratio (of above 3) ; it is present in 3% of the controls and almost 10% of the cases.

30   Figure 19B is a table showing the segmented haplotyping results according to the age of the subjects, and whether the prostate cancer cases were sporadic or familial, using the same markers 4 markers and the same individuals as were used to generate the results in Figure 19A. Figure 19B shows equivalent results for all segments of the population analyzed, demonstrating that the PG1 associated alleles are general risk factors for prostate cancer, regardless of the age of onset of the

35   disease.

The haplotyping results and odd ratios for all of the combinations of the 7 markers (99-622; 4-77; 4-71; 4-7 ; 99-598; 99-576; and 4-66) within PG1 gene that were shown in Figure 18 to have p-values more significant than $1 \times 10^{-2}$ were computed. A portion of these data are shown in Figure 20. All of the 2-, 3-, 4-, 5-, 6- and 7-marker haplotypes were tested. Figure 20 identifies for each x-marker haplotype category, the most significant haplotype. Among all these, the most significant haplotype is the two-marker haplotype 1, which shows a p-value of approximately $6.10^{-5}$, with an odd ratio of 2. The frequency of haplotype 1 among the control individuals is 15%, while it is 26% among the case patients. It is worth noting that these frequencies are very similar for all haplotypes presented on Figure 20. It will thus be sufficient to test this two marker haplotype for prognosis/diagnosis on risk patients, as opposed to having a more complex test of a haplotype comprising 3 or more makers.

Finally, Figure 21 is a graph showing the distribution of statistical significance, as measured by Chi-square values, for each series of possible x-marker haplotypes, (x =2, 3 or 4) using all of the 19 markers found in PG1 gene. These data confirm that testing 2-marker haplotypes within PG1 is sufficient because the testing 3- or 4-marker haplotypes does not increase the statistical relevance of the analysis.

<div align="center">Example 25

Attributable Risk</div>

Attributable risk describes the proportion of individuals in a population exhibiting a phenotype due to exposure to a particular factor. For further discussion of attributable risk values, see *Holland, Bart K., Probability without Equations – Concepts for Clinicians*; The Johns Hopkins University Press, pp. 88-90. In the present case the phenotype examined was prostate cancer, and the exposure was either one single allele of an individual PG1-related marker, or a haplotype thereof in an individual's genome.

The formula used for calculating attributable risk values in the present study was the following:

$$AR = P_E (RR-1) / [P_E (RR-1)+1], \text{ where:}$$

AR was the attributable risk of allele or haplotype ;

$P_E$ was the frequency of exposure to allele or haplotype within the population at large, in the present study a random male Caucasian population ; and

RR was the relative risk, in the present study relative risk is approximated with the odd-ratio, because of the relatively low incidence of prostate cancer in populations at large (values for the odd ratios are found in Figures 18B and 20).

In this case, $P_E$ was estimated using a dominant transmission model for prostate cancer:

$$P_E = (N_{AA} + N_{AB}) / N, \text{ where:}$$

$N_{AA}$ was the number of homozygous individuals harboring the disease associated allele or haplotype within a given random population, and $N_{AB}$ was the number of heterozygous individuals is said random population. $N_{AA}$ and $N_{AB}$ were calculated using the allele frequencies in the random

population as indicated in Figures 18B and 20, and N was the number of individuals in total random population.

We calculated the attributable risks of disease-associated alleles for markers within PG1 gene and presented these results in Figure 18B. In Figure 20, the attributable risk for the two-marker 5   haplotypes present in the figure as shown as well. These data demonstrate that disease-associated alleles of PG1 are present in approximately 20% of prostate cancer patients in the Caucasian population at large, and therefor represent prognostic tools of significant value.


### SEQUENCE LISTING FREE TEXT

10   The following free text appears in the accompanying Sequence Listing:

      identification method Proscan

      potential start codon

      exon1

      Tyr phos

15      upstream amplification primer

      polymorphic fragment

      polymorphic base

      downstream amplification primer

      complement

20      upstream amplification primer 99-217-PU, extracted from SEQ ID1 34216 34234

      Klein, Kanehisa and DeLisi identification method, potential helix

      Eisenberg, Schwarz, Komarony, Wall identification method, potential helix

      Prosite match

      potential Tyrosine kinase site, Prosite match

25      potential caseine kinase II site, Prosite match

      potential Leucine zipper site, Prosite match

      potential site, Prosite match

      potential protein kinase C, Prosite match

      potential cAMP and cGMP dependant protein kinase site, Prosite match

30      primer oligonucleotide

      box2 from SEQID4, present in AF003136, P33333, P26647, U89336, U56417, AB005623

      box2 from Z72511

      box3 from SEQID4, present in AF003136

35      potential microsequencing oligo

      complement potential microsequencing oligo

polymorphic fragment 4-77, extracted from SEQ ID1 12057 12103

polymorphic fragment 99-123, variant version of SEQ ID21

base A ; G in SEQ ID22

downstream amplification primer 99-217-RP, extracted from SEQ ID1 34625 34645

5    complement

polymorphic base C in PG1 (13680) SEQ ID1

stop codon

potential

amplification oligonucleotide

10    sequencing oligonucleotide

Box II

Box III

Box I

upstream amplification primer for SEQ 188, SEQ 265, SEQ 189, SEQ 266

15    downstream amplification primer for SEQ 185, SEQ 262, SEQ 186, SEQ 263, SEQ 187, SEQ

264

microsequencing oligo for 4-20-149.mis1


Although this invention has been described in terms of certain preferred embodiments, other

20    embodiments which will be apparent to those of ordinary skill in the art in view of the disclosure

herein are also within the scope of this invention. Accordingly, the scope of the invention is intended

to be defined only by reference to the appended claims.

Table 1

| marker | polymorphism | most frequent | less frequent | cases | | controls | |
|---|---|---|---|---|---|---|---|
| | | | | p* | q** | p* | q** |
| 99-123 | C/T | C | T | 0,65 | 0,35 | 0,7 | 0,3 |
| 4-26 | A/G | A | G | 0,61 | 0,39 | 0,55 | 0,45 |
| 4-14 | C/T | C | T | 0,65 | 0,35 | 0,59 | 0,41 |
| 4-77 | C/G | C | G | 0,67 | 0,33 | 0,76 | 0,24 |
| 99-217 | C/T | C | T | 0,69 | 0,31 | 0,77 | 0,23 |
| 4-67 | C/T | C | T | 0,74 | 0,26 | 0,84 | 0,16 |
| 99-213 | A/G | A | G | 0,55 | 0,45 | 0,62 | 0,38 |
| 99-221 | C/A | C | A | 0,43 | 0,57 | 0,43 | 0,57 |
| 99-135 | A/G | A | G | 0,75 | 0,25 | 0,7 | 0,3 |

*: frequency of most frequent base within each sub-population
**: frequency of least frequent base within each sub-population (p+q=1)
        standard deviations ~0,023 to 0,031 for controls
        standard deviations ~0,018 to 0,021for cases

WHAT IS CLAIMED IS:

1.    A recombinant, purified or isolated polynucleotide comprising a mammalian PG1 gene, cDNA, complement thereof, or fragment thereof having at least 10 nucleotides in length.

2.    The polynucleotide according to claim 1, wherein said mammalian PG1 gene or cDNA is human or mouse.

3.    The polynucleotide according to claim 2, wherein the polynucleotide is selected from SEQ ID NOs: 3, 69, 112-124, 179, and 182-184.

4.    A polynucleotide selected from SEQ ID NOs: 185-578.

5.    A purified or isolated polypeptide comprising a mammalian PG1 protein, or fragment thereof having at least 8 amino acids in length.

6.    The polypeptide according to claim 5, wherein said mammalian PG1 protein is human or mouse.

7.    The polypeptide according to claim 6, wherein said polypeptide is selected from SEQ ID NOs: 4, 5, 70, 74, and 125-136.

8.    The polypeptide according to claim 5, wherein said polypeptide consists of said mammalian PG1 protein, or fragment thereof having at least 8 amino acids in length.

9.    A polynucleotide comprising a nucleic acid sequence encoding a polypeptide according to claim 8.

10.    An antibody composition capable of selectively binding to an epitope-containing fragment of a polypeptide according to claim 8, wherein said antibody is either polyclonal or monoclonal.

11.    A vector comprising a polynucleotide according to any one of claims 1, 4, and 9.

12.    A host cell comprising a polynucleotide according to claim 11.

13      A nonhuman host animal or mammal comprising a vector according to claim 11.

14.     A mammalian host cell comprising a PG1 gene disrupted by homologous recombination with a knock out vector.

15.     A nonhuman host mammal comprising a PG1 gene disrupted by homologous recombination with a knock out vector.

16.     A polynucleotide according to any one of claims 1, 4, and 9, further comprising a label.

17.     A polynucleotide according to any one of claims 1, 4, and 9, attached to a solid support.

18.     A random or addressable array of polynucleotides comprising at least one polynucleotide according to any one of claims 1, 4, and 9.

19.     A method of determining whether an individual is at risk of developing cancer or prostate cancer, or whether said individual suffers from cancer or prostate cancer as a result of a mutation in the PG1 gene comprising:
          obtaining a nucleic acid sample from said individual; and
          determining whether the nucleotides present at one or more PG1-related biallelic marker are indicative of a risk of developing cancer or prostate cancer or indicative of cancer or prostate cancer resulting from a mutation in the PG1 gene.

20.     A method of determining whether an individual is at risk of developing cancer or prostate cancer or whether said individual suffers from cancer or prostate cancer as a result of a mutation in the PG1 gene comprising:
          obtaining a nucleic acid sample from said individual; and
          determining whether the nucleotides present at one or more PG1-related biallelic marker are indicative of a risk of developing cancer or prostate cancer or indicative of cancer or prostate cancer resulting from a mutation in the PG1 gene.

21.     A method according to either one of claims 19 and 20, wherein said PG1-related biallelic is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-

77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622, 4-77, 4-71, 4-73, 99-598, 99-576 , and 4-66.

5       22.     A method of obtaining an allele of the PG1 gene which is associated with a detectable phenotype comprising:

        obtaining a nucleic acid sample from an individual expressing said detectable phenotype;

        contacting said nucleic acid sample with an agent capable of specifically detecting a nucleic acid encoding the PG1 protein; and

10      isolating said nucleic acid encoding the PG1 protein.

        23.     A method of obtaining an allele of the PG1 gene which is associated with a detectable phenotype comprising:

        obtaining a nucleic acid sample from an individual expressing said detectable phenotype;

15      contacting said nucleic acid sample with an agent capable of specifically detecting a sequence within the 8p23 region of the human genome;

        identifying a nucleic acid encoding the PG1 protein in said nucleic acid sample; and

        isolating said nucleic acid encoding the PG1 protein.

20      24.     A method of categorizing the risk of prostate cancer in an individual comprising the step of assaying a sample taken from the individual to determine whether the individual carries an allelic variant of PG1 associated with an increased risk of prostate cancer.

        25.     The method of Claim 24 wherein said sample is a nucleic acid sample.

25

        26.     The method of Claim 24 wherein said sample is a protein sample.

        27.     The method of Claim 26, further comprising determining whether the PG1 protein in said sample binds an antibody that binds specifically to a PG1 isoform associated with prostate

30      cancer.

        28.     A method of genotyping comprising determining the identity of a nucleotide at a PG1-related biallelic marker in a biological sample.

29. A method of estimating the frequency of an allele in a population comprising determining the proportional representation of a nucleotide at a PG1-related biallelic marker in a pooled biological sample derived from said population.

5      30. A method of detecting an association between a genotype and a phenotype, comprising the steps of:

a) genotyping at least one PG1-related biallelic marker in a trait positive population;

b) genotyping said PG1-related biallelic marker in a control population; and

c) determining whether a statistically significant association exists between said genotype and

10  said phenotype.

31. A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:

a) genotyping at least one PG1-related biallelic marker;

15      b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and

c) applying an haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.

20

32. A method of detecting an association between a haplotype and a phenotype, comprising the steps of:

a) estimating the frequency of at least one haplotype in a trait positive population according to the method of claim 31;

25      b) estimating the frequency of said haplotype in a control population according to the method of claim 31; and

c) determining whether a statistically significant association exists between said haplotype and said phenotype.

30      33. A method according to claim 31, wherein said PG1-related biallelic marker and said second biallelic marker are 4-77/151 and 4-66/145,

34. A method according to claim 32, wherein said haplotype exhibits a p-value of $< 1x$ $10^{-3}$ in an association with a trait positive population with cancer, or prostate cancer.

35

35.     A method according to any one of claims 29 to 31, wherein said PG1-related biallelic is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622, 4-77, 4-71, 4-73, 99-598, 99-576 , and 4-66.

36.     A method according to either one of claims 30 and 32, wherein said control population is a trait negative population or a random population.

37.     A method according to any one of claims 22, 23, 30, and 32, wherein said phenotype is a disease, cancer or prostate cancer; a response to an anti-cancer agent or an anti-prostate cancer agent; or a side effect to an anti-cancer or anti-prostate cancer agent.

38.     A polynucleotide for use in a hybridization assay for determining the identity of the nucleotide at an PG1-related biallelic marker; for use in a sequencing assay for determining the identity of the nucleotide at an PG1-related biallelic marker; for use in a allele-specific amplification assay for determining the identity of the nucleotide at an PG1-related biallelic marker; or for use in amplifying a segment of nucleotides comprising an PG1-related biallelic marker.

39.     The polynucleotide according to claim 38, wherein said PG1-related biallelic is a PG1-related biallelic markers positioned in SEQ ID NO: 179; a PG1-related biallelic marker selected from the group consisting of 99-1485/251, 99-622/95, 99-619/141, 4-76/222, 4-77/151, 4-71/233, 4-72/127, 4-73/134, 99-610/250, 99-609/225, 4-90/283, 99-602/258, 99-600/492, 99-598/130, 99-217/277, 99-576/421, 4-61/269, 4-66/145, and 4-67/40; or a PG1-related biallelic marker selected from the group consisting of 99-622, 4-77, 4-71, 4-73, 99-598, 99-576 , and 4-66.

Figure 1

Figure 2

# ASSOCIATION STUDIES (FIRST SCREENING)

| | AFFECTED | NON AFFECTED |
|---|---|---|
| Population<br>Sample size | CASES = 112 | CONTROLS=76 |
| Population<br>Characteristics | 35 sporadic cases<br>+ 77 familial cases | > 65 years<br>PSA<4 |

ASSOCIATION STUDIES (ZOOM)

| characteristics of populations | AFFECTED CASES (185) | UNAFFECTED CONTROLS (104) |
|---|---|---|
| | 47 sporadic cases<br>+ 138 familial cases | > 65 years<br>PSA<4 |

Figure 3

# HAPLOTYPE FREQUENCY ANALYSIS

Figure 4

**POPULATIONS**

| characteristics of populations | AFFECTED CASES 2 (281) | UNAFFECTED CONTROLS 3 (130) |
|---|---|---|
| | 143 sporadic cases + 138 familial cases | > 65 years PSA<4 |

| markers | 99-123 | 4-26 | 4-14 | 4-77 | 99-217 | 4-67 | 99-213 | 99-221 | 99-135 | haplotype frequencies | | relative risk | pvalue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| bacs | H0287B09 | B0189E08 | | | | B0463F01 | | | B0725B12 | cases ·(2) | controls ·(3) | | |
| contigs | | | | 11453 | | | | | | | | | |
| genes | | | | ←——————PG1——————→ | | | | | | | | | |
| p value | 2,00E-01 · | 1,00E-01 · | 1,00E-01 · | 2,00E-02 ·· | 2,00E-02 ·· | 6,00E-04 ··· | 9,00E-02 · | 7,00E-01 · | 2,00E-01 · | | | | |
| distance between markers (kb) | <18kb> | <15kb> | <15kb> | <88kb> | <22kb> | <17kb> | <15kb> | <29kb> | >100kb< | | | | |
| haplotype 8 >304kb< | C | A | C | G | T | T | G | A | A | 0,075 | 0,018 | 4,42 | 9,00E-04 *** |
| haplotype 7 >286kb< | | A | C | G | T | T | G | A | A | 0,095 | 0,016 | 6,46 | 6,00E-05 **** |
| haplotype 6 <186kb> | | A | C | G | T | T | G | A | | 0,116 | 0,019 | 6,78 | 1,00E-05 ***** |
| haplotype 5 <171kb> | | | C | G | T | T | G | A | | 0,117 | 0,013 | 10,06 | 9,00E-07 ****** |
| haplotype 4 <83kb> | | | | G | T | T | G | A | | 0,117 | 0,025 | 5,17 | 2,00E-05 ***** |
| haplotype 3.1 <54kb> | | | | | T | T | G | A | | 0,117 | 0,027 | 4,78 | 2,00E-05 ***** |
| haplotype 3.2 <54kb> | | | | G | T | T | G | | | 0,222 | 0,109 | 2,33 | 4,00E-05 ***** |
| haplotype 2.2 <54kb> | | | | G | T | T | | | | 0,251 | 0,134 | 2,17 | 2,00E-04 **** |
| haplotype 2.2 <39kb> | | | | | T | T | G | | | 0,226 | 0,112 | 2,32 | 1,00E-04 *** |
| haplotype 2 <32kb> | | | | | T | T | | | | 0,256 | 0,146 | 2,01 | 3,00E-04 **** |
| haplotype 1.1 <17 kb> | | | | | | T | G | | | 0,233 | 0,129 | 2,05 | 6,00E-04 *** |
| haplotype 1.2 <15 kb> | | | | | | T | | | | | | | |

Figure 5

HAPLOTYPE SIMULATIONS (100 ITERATIONS)

| markers | 4-14 | 4-77 | 99-217 | 4-67 | 99-213 | 99-221 | haplotype frequencies | | relativ risk | pvalue |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | cases | controls | | |
| haplotype | C | G | T | T | G | A | 0,117 | 0,013 | 10,06 | 9,00E-07 |



pvalue max of haplotypes for 100 simulations



pvalue of haplotype CGTTGA for 100 simulations

Figure 6A

| BAC | Marker | SEQ ID N° | SEQ ID N° (mut) | PU sequence | SEQ ID N° | RP sequence | SEQ ID N° | Polymorphism position* | Base | Microseq. oligos positions* | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 228 | 99-123 | 21 | 30 | AAAGCCAGGACTAGAAGG | 39 | TATTCAGAAAGGAGTGGG | 48 | 24 | C/T | 1-23 | 25-47 (complementary) |
| 189 | 4-26 | 22 | 31 | TACAGCCCTGTAAGACAC | 40 | TGAGGACTGCTAGGAAAG | 49 | 24 | A/G | 1-22 | 25-47 (complementary) |
| 228/189 | 4-14 | 23 | 32 | TCTAACCTCTCATCCAAC | 41 | GACTGTATCCTTTGATGCAC | 50 | 24 | C/T | 1-23 | 25-47 (complementary) |
| 189/463 | 4-77 | 24 | 33 | TGTTGATTTACAGGCGGC | 42 | GGAAAGGTACTCATTCATAG | 51 | 24 | G/C | 1-23 | 25-47 (complementary) |
| | | 25 | 34 | GGTGGGAATTTACTATATG | 43 | GTTTATTTGTGTGAGCTTTG | 52 | 24 | C/T | 1-23 | 25-47 (complementary) |
| 463 | 99-217 | 26 | 35 | AAGTTCACCTTCTCAAGC | 44 | TGAAAGAGTTTATTCTCTGG | 53 | 24 | C/T | 1-23 | 25-47 (complementary) |
| 189/463 | 4-67 | 27 | 36 | ATACTGGCAGCGTGTGCTTC | 45 | TTATTGCCCCACATGCTGAG | 54 | 24 | A/C | 1-23 | 25-47 (complementary) |
| 463 | 99-213 | 28 | 37 | CCCTTTTCTTCACTGTTC | 46 | TCATTCGTCTGGCTAGGTC | 55 | 24 | A/G | 1-23 | 25-47 (complementary) |
| 725 | 99-135 | 29 | 38 | TGGAAGTTGTTATTGCCC | 47 | AAACACCTCCCATTGTGC | 56 | 24 | | 1-23 | 25-47 (complementary) |

Figure 6B

| BAC | Marker | SEQ ID N° | SEQ ID N° (mut) | PU sequence | SEQ ID N° | RP sequence | SEQ ID N° | Polymorphism position* | Base | Microseq. oligos positions* | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 189/463 | 99-1482 | 57 | 60 | ATCAAATCAGTGAAGTCTGAG | 63 | ACAAATCTATATAAGGCTGG | 66 | 24 | A/C | 1-23 | 25-47 (complementary) |
| 463 | 4-73 | 58 | 61 | ATCGCTGGAACATTCTGG | 64 | CTCTTGGTTAAACAGCAGTG | 67 | 24 | G/C | 1-23 | 25-47 (complementary) |
| 463 | 4-65 | 59 | 62 | GATTTAAGCTACGCTATTAG | 65 | TGGCTCTGCATTCTTCC | 68 | 24 | C/T | 1-23 | 25-47 (complementary) |

*: positions are given relative to the sequence of the corresponding marker (i.e. SEQ ID N° 21-38 and 57-62)

## Figure 7

| EXON Phase | START | END | 5' SPsite | PHASE | 3' SPsite |
|---|---|---|---|---|---|
| Ex1 +0 | 2001 | 2216 | | | GTGAGC |
| Ex2      GTTTGTA +1 | 18196 | 18265 | TAG | +0 | |
| Ex3 +0 | 23717 | 23832 | CAG | +2 | GTAACT |
| Ex4      GTAAGA +0 | 25571 | 25660 | CAG | +0 | |
| Ex5 GTAAGT +2 | 34669 | 34759 | CAG | +0 | |
| Ex6 +1 | 40688 | 40846 | TAG | +1 | GTAAGT |
| Ex7 +2 | 48070 | 48193 | TAG | +2 | GTGAGT |
| Ex8 | 50182 | 54523 | TAG | +1 | |
| ATG codon | 2031 | 2033 | | | |
| STOP codon | 50405 | 50407 | | | |
| POLY Ad site | 54445 | 54450 | | | |

Figure 8A



PG1 genome structure and cDNAs

Figure 8B

Prostate Gene 1

| | | box1 | box2 | box3 |
|---|---|---|---|---|
| PG1 | Hs | **NHQ** *81-83* | **FPEGTR** *160-165* | **LDAIYDVTV** *211-219* |
| AF003136 (Genbank) | Ce | NHQ *630-632* | FPEGTR *712-717* | LDAIYDVTV *762-770* |
| Z72511 (Genbank) | Ce | 48 NHR 50 | FPEGTD *129-134* | VEYIYDITI *204-212* |
| P38226 (Swissprot) | Sc | 111 NHQ 113 | FPEGTN *223-228* | IESLYDITI *271-279* |
| P33333 (Swissprot) | Sc | 81 NHQ 83 | FPEGTR *154-159* | - |
| Z49770 (Genbank) | Sc | 116 NHQ 118 | FPEGTN *215-220* | LDAIYDVTI *265-273* |
| P26647 (Swissprot) | Ec | 72 NHQ 74 | FPEGTR *145-150* | - |
| Z49860 (Genbank) | Bn | - | FVEGTR *90-95* | VPAIYDMTV *138-146* |
| U89336 (Genbank) | Hs | 95 NHQ 97 | FPEGTR *168-173* | - |
| U56417 (Genbank) | Hs | 103 NHQ 105 | FPEGTR *176-181* | - |
| AB005623 (Genbank) | Mm | 100 NHQ 102 | FPEGTR *173-178* | - |
| Z29518 (Genbank) | Zm | 91 NHR 93 | FVEGTR *170-175* | VPAIYDTTV *218-226* |

Hs = Homo sapiens, Ce = Caenorabibtis elegans, Ec = Escherichia coli; Sc = Saccharomyces cerevisiae , Bn = Brassica napus, Zm = Zea maize, Mm = Mus musculus

- = pattern absent from protein sequence

Note :      Functional acyl glycerol transferases all contain boxes 1 and 2 and not box 3. Proteins most related to PG1 contain the 3 boxes with a high degree of conservation.

**Figure 9**

Figure 10

Figure 11

Figure 12

PNT2 PG1 mut229

Figure 13

Figure 14



Alternative splicing

**Figure 15**

**Combinations of exons of PG1 gene discovered by PCR with primers specific for exon borders**

| Primer | Clones | prostate | PNT1A | PNT1B | PNT2 | LnCaPFCG | LNCaPJMB | CoHPV | Du145 | PC3 | ECP5 | ECP6 | ECP7 | ECP8 | ECP9 | ECP10 | ECP11 | ECP12 | ECP13 | ECP14 | ECP15 | ECP16 | ECP17 | ECP18 | ECP19 | ECP20 | ECP21 | ECP22 | ECP23 | ECP24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PG1exon13 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon14 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon15 | + | - | - | - | - | - | - | NT | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PG1exon16 | - | + | - | + | + | - | - | NT | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - |
| PG1exon17 | + | + | + | + | + | + | + | NT | + | + | - | - | + | - | - | - | + | + | + | + | + | + | + | - | - | + | + | - | + | + |
| PG1exon18 | + | + | + | + | + | - | - | NT | + | + | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - |
| PG1exon24 | - | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon25 | + | + | - | + | + | - | - | NT | + | - | - | - | - | - | - | - | + | - | - | - | + | - | - | - | - | - | - | - | + | + |
| PG1exon26 | - | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon27 | - | - | - | + | + | - | - | NT | + | - | - | - | - | - | - | - | - | + | - | - | + | - | - | - | - | - | - | - | + | + |
| PG1exon28 | - | - | + | - | - | - | - | NT | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PG1exon35 | - | + | + | + | + | + | + | NT | + | + | - | - | - | - | - | - | - | + | + | - | + | + | + | - | + | + | + | + | - | - |
| PG1exon36 | - | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon37 | - | - | - | - | - | - | - | NT | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PG1exon38 | - | - | - | - | - | - | - | NT | - | + | - | - | - | - | - | - | - | - | - | + | - | - | - | + | - | - | - | - | - | - |
| PG1exon46 | - | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon47 | + | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | - | + | + | + | + | + | + | + | + | + | + |
| PG1exon48 | - | - | - | - | + | - | - | NT | - | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PG1exon57 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon58 | - | - | - | - | - | + | + | NT | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - |
| PG1exon68 | - | + | + | - | + | + | + | NT | + | + | - | - | - | - | + | + | - | - | + | + | - | - | + | - | - | - | + | - | + | + |
| PG1exon11b | + | + | + | + | + | + | + | NT | + | + | - | + | - | + | + | + | + | + | + | + | - | + | - | - | + | + | + | - | + |
| PG1exon1b2 | + | + | + | + | + | + | + | NT | + | + | - | + | - | + | + | + | + | + | + | + | - | + | - | - | + | + | + | - | + |
| PG1exon1b3 | - | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon1b4 | - | + | - | + | + | + | + | + | + | + | - | + | - | + | - | + | - | + | + | + | + | - | + | - | + | + | - | + | - |
| PG1exon1b5 | - | + | - | + | + | + | + | NT | + | + | - | + | - | + | + | - | + | - | - | + | - | + | - | + | + | + | - | + | - |
| PG1exon1b6 | - | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon1b7 | - | + | - | + | + | + | + | NT | + | + | + | + | - | - | + | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - |
| PG1exon1b8 | - | - | - | + | - | + | - | NT | - | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PG1exon3b4 | + | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon3b5 | - | - | - | + | + | - | - | NT | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PG1exon3b6 | - | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon3b7 | - | + | - | + | + | - | + | NT | - | + | - | + | - | + | - | - | - | - | - | + | + | - | - | + | - | - | - | - | - | - |
| PG1exon3b8 | - | - | - | - | - | - | - | NT | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PG1exon5b6 | + | + | - | - | - | - | + | NT | - | + | - | + | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - |
| PG1exon5b7 | - | + | - | + | + | + | + | NT | + | - | - | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - |
| PG1exon5b8 | - | - | - | - | + | + | - | NT | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PG1exon56b | + | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon46b | - | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon36b | - | + | + | + | + | + | + | NT | + | + | + | + | + | + | - | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon26b | - | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| PG1exon16b | - | + | + | + | + | + | + | NT | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |

[+] alternative splicing form with combination of exons 13478 instead of 1345678

## ASSOCIATION STUDIES

### HAPLOTYPE FREQUENCY ANALYSIS (chrom 8p23)

Figure 16

18/24

Figure 17

ASSOCIATION STUDIES
PG1 (8p23)

# ASSOCIATION STUDIES
## PG1 (8p23)

**Figure 18A**

**Figure 18B**

| name of markers | PG1 | Polym. | Freq(cas) | Freq(controls) | abs diff % (fq(cases) - (fq(controls)) | Odd Ratio | Pvalue | Freq(randoms) | Attributable Risk |
|---|---|---|---|---|---|---|---|---|---|
| 99-14R5/251 | prom | G*/T | 0,32 | 0,24 | 7,4 | 1,44 | 2,53E-02 | 0,29 | 17,58 |
| 99-622/95 | in1 | G/T | 0,52 | 0,42 | 10,1 | 1,51 | 9,64E-03 | ND $ | ND |
| 99-619/141 | in1 | C/T | 0,28 | 0,22 | 5,8 | 1,37 | 6,93E-02 | ND | ND |
| 4-76/222 | in1 | G/A | 0,43 | 0,38 | 5 | 1,23 | 1,57E-01 | 0,41 | 13,15 |
| 4-77/151 | in1 | G/C | 0,34 | 0,26 | 7,4 | 1,43 | 1,35E-02 | 0,31 | 18,16 |
| 4-71/233 | in1 | A/G | 0,34 | 0,26 | 8,3 | 1,49 | 1,43E-02 | 0,28 | 18,64 |
| 4-72/127 | in1 | A/G | 0,36 | 0,30 | 5,7 | 1,29 | 9,43E-02 | 0,31 | 13,25 |
| 4-73/134 | in1 | G/C | 0,52 | 0,42 | 9,7 | 1,48 | 7,29E-03 | 0,52 | 26,76 |
| 99-610/250 | in1 | G/A | 0,43 | 0,37 | 6,2 | 1,30 | 8,33E-02 | ND | ND |
| 99-609/225 | in1 | A/T | 0,37 | 0,30 | 7 | 1,36 | 4,83E-02 | ND | ND |
| 4-90/283 | in2 | A/C | 0,29 | 0,25 | 4,4 | 1,25 | 1,68E-01 | 0,28 | 9,32 |
| 99-602/258 | in2 | A/G | 0,33 | 0,25 | 7,4 | 1,44 | 2,69E-02 | ND | ND |
| 99-600/492 | in3 | T/A | 0,34 | 0,34 | 0,3 | 1,01 | 7,52E-01 | ND | ND |
| 99-598/130 | in4 | G/A | 0,35 | 0,25 | 9,2 | 1,55 | 7,29E-03 | ND | ND |
| 99-217/277 | in4 | T/C | 0,31 | 0,28 | 3,8 | 1,20 | 1,07E-01 | 0,28 | 8,46 |
| 99-576/421 | in6 | G/C | 0,27 | 0,17 | 9,2 | 1,72 | 3,18E-03 | 0,24 | 18,40 |
| 4-61/269 | 3'UTR | G/A | 0,01 | 0,00 | 0,3 | 1,76 | 0,527 § | ND | ND |
| 4-66/145 | 3'UTR | C/T | 0,25 | 0,19 | 6,2 | 1,43 | 4,68E-03 | 0,24 | 13,16 |
| 4-67/40 | 3'UTR | T/C | 0,25 | 0,20 | 4,9 | 1,33 | 2,39E-02 | 0,24 | 10,97 |

§ Test Fisher - $ ND: Not done - * disease associated allele / not associated allele

Figure 19A

# HAPLOTYPE FREQUENCY ANALYSIS

| POPULATIONS | AFFECTED | | UNAFFECTED |
|---|---|---|---|
| sample sizes | CASES (n=491) | | CONTROLS (n=317) |
| characteristics of populations | 294 sporadic cases<br>+ 197 familial cases | | 28 unaffected ( 65 years or older)<br>+ 289 controls (65 years or older with PSA<4) |

| PG1 (8p23) | | 4-14/240 | 99-217/277 | 4-66/145 | 99-221/377 | haplotype frequencies | | Odd ratio | Chi-S | Pvalue | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | In4 | 3'UTR | | cases | controls | | | | |
| distance between mks | | | <100kb> | <17kb> | <43kb> | | | | | | |
| size (cases vs controls) | | 481 vs 305 | 481 vs 302 | 481 vs 300 | 481 vs 303 | | | | | | |
| frequency % (cases / controls) | | 65.7/62.1 (C) | 31.3/27.5 (T) | 25.1/19 (C) | 42.7/42.91 (A) | | | | | | |
| abs diff freq. all (cases-controls) | | 3,6 | 3,8 | 6,2 | 0 | | | | | | |
| pvalue | | 1,47E-01 | 1,07E-01 | 4,68E-03 | 7,52E-01 | | | | | | |
| Hardy Weinberg Disequilibrium | cases | 5,84E-01 | 6,55E-01 | 2,54E-01 | 5,84E-01 | | | | | | |
| | controls | 4,80E-01 | 2,21E-01 | 3,71E-01 | 2,54E-01 | | | | | | |
| HAP 1 <43kb> | 451 vs 297 | C | | | A | 0.116 | 0.067 | 1.83 | 9.85 | (1.7e-03) | *** |
| HAP 2 <17kb> | 451 vs 296 | | T | C | | 0.243 | 0.183 | 1.43 | 7.49 | (6.2e-03) | ** |
| HAP 3 <117kb> | 452 vs 299 | C | | C | | 0.182 | 0.130 | 1.49 | 7.18 | (7.3e-03) | ** |
| HAP 4 <100kb> | 479 vs 302 | C | T | | | 0.217 | 0.188 | 1.20 | 1.88 | (1.7e-01) | * |
| HAP 5 <60kb> | 476 vs 300 | | T | | A | 0.155 | 0.132 | 1.20 | 1.54 | (2.1e-01) | * |
| HAP 6 <160kb> | 476 vs 303 | C | | | C | 0.373 | 0.346 | 1.12 | 1.16 | (2.7e-01) | * |
| PT2 HAP 7 <160kb> | 447 vs 297 | C | | C | A | 0.095 | 0.042 | 2.39 | 14.62 | (1.3e-04) | **** |
| HAP 8 <60kb> | 446 vs 294 | | T | C | A | 0.117 | 0.065 | 1.93 | 11.33 | (7.3e-04) | *** |
| HAP 9 <117kb> | 450 vs 296 | C | T | C | | 0.178 | 0.125 | 1.53 | 7.80 | (5.2e-03) | ** |
| PT3 HAP 10 <160kb> | 474 vs 300 | C | T | | A | 0.114 | 0.089 | 1.32 | 2.44 | (1.1e-01) | * |
| PT4 HAP 11 <160kb> | 445 vs 294 | C | T | C | A | 0.095 | 0.032 | 3.18 | 21.59 | (3.4e-06) | ***** |

Figure 19-B

# HAPLOTYPE FREQUENCY ANALYSIS
## PG1 (8p23)

| markers of haplotype Max | 4-14/240 | 99-217/277 In4 | 4-66/145 3'UTR | 99-221/377 |
|---|---|---|---|---|
| | C | T | C | A |
| distance between mks | | <100kb> | <17kb> | <43kb> |

| PG1 | sample sizes cases vs controls | haplotype frequencies cases | haplotype frequencies controls | odd ratio | chi-S | P value | |
|---|---|---|---|---|---|---|---|
| cases vs controls | 445 vs 294 | 0,095 | 0,032 | 3,18 | 21,59 | 3,40E-06 | ****** |
| cases (<=65 years) vs controls | 171 vs 294 | 0,105 | 0,032 | 3,56 | 20,91 | 4,60E-06 | ****** |
| cases (>65 years) vs controls | 271 vs 294 | 0,079 | 0,032 | 2,60 | 12,13 | 4,80E-04 | **** |
| sporadic cases vs controls | 266 vs 294 | 0,096 | 0,032 | 3,23 | 19,73 | 8,60E-06 | ***** |
| sporadic cases (<=65 years) vs controls | 85 vs 294 | 0,095 | 0,032 | 3,20 | 12,04 | 5,00E-04 | **** |
| sporadic cases (>65 years) vs controls | 178 vs 294 | 0,085 | 0,032 | 2,82 | 12,75 | 3,50E-04 | **** |
| informative sporadic cases vs controls | 67 vs 294 | 0,062 | 0,032 | 2,00 | 2,70 | 9,40E-02 | ** |
| familial cases vs controls | 179 vs 294 | 0,098 | 0,032 | 3,32 | 18,33 | 1,80E-05 | **** |
| familial cases (<=65 years) vs controls | 86 vs 294 | 0,112 | 0,032 | 3,83 | 17,98 | 2,20E-05 | ***** |
| familial cases (>65 years) vs controls | 93 vs 294 | 0,075 | 0,032 | 2,48 | 6,59 | 1,00E-02 | ** |
| familial cases (>=3 caP) vs controls | 79 vs 294 | 0,123 | 0,032 | 4,26 | 21,33 | 3,70E-06 | ****** |

Figure 20

# HAPLOTYPE FREQUENCY ANALYSIS (PG1)

| Markers in PG1 | 99-622/95 | 4-77/151 | 4-71/233 | 4-73/134 | 99-598/130 | 99-576/421 | 4-66/145 |
|---|---|---|---|---|---|---|---|
| | G/T | C/G | A/G | C/G | A/G | C/G | C/T |
| | In1 | | | | In4 | In6 | 3'UTR |
| size (cases vs controls) | 336 vs 108 | 363 vs 173 | 336 vs 130 | 352 vs 129 | 347 vs 126 | 355 vs 129 | 456 vs 306 |
| allelic frequency % (cases / controls) | 52/42 (G) | 34/26 (G) | 34/26 (A) | 52/42 (G) | 35/25 (G) | 27/17 (G) | 25/19 (C) |
| allelic frequency % (randoms) | ND | 31 (G) | 28 (A) | 52 (G) | ND | 24 (G) | 24 (C) |
| diff freq. all. % (cases-controls) | 10,1 | 7.4 | 8.3 | 9.7 | 9.2 | 9.2 | 6.2 |
| pvalue (cases vs controls) | 9,64E-03 | 1,35E-02 | 1,43E-02 | 7,29E-03 | 7,29E-03 | 3,18E-03 | 4,68E-03 |
| Odd Ratio | ... | ... | ... | ... | ... | ... | ... |
| | 1,51 | 1,43 | 1,49 | 1,48 | 1,55 | 1,72 | 1,43 |
| Attributable Risk % | ND | 18.16 | 18.64 | 26.76 | ND | 8.46 | 13.16 |
| Hardy Weinberg Disequilibrium | 7,52E-01 | 7,52E-01 | 5,84E-01 | 7,52E-01 | 7,52E-01 | 7,52E-01 | 3,43E-01 |
| | 4,39E-01 | 4,03E-01 | 1,21E-01 | 7,52E-01 | 6,52E-02 | 7,52E-01 | 1,29E-01 |

| | cases / controls | 99-622/95 | 4-77/151 | 4-71/233 | 4-73/134 | 99-598/130 | 99-576/421 | 4-66/145 |
|---|---|---|---|---|---|---|---|---|
| haplotype 1 | 2 MKS 339 vs 167 | | G | | | G | G | C |
| haplotype 2 | 3 MKS 330 vs 122 | | | A | | G | G | C |
| haplotype 3 | 4 MKS 312 vs 122 | | | A | G | G | G | C |
| haplotype 4 | 5 MKS 311 vs 121 | | G | A | G | G | G | C |
| haplotype 5 | 6 MKS 309 vs 121 | G | G | A | G | G | G | C |
| haplotype 6 | 7 MKS 290 vs 99 | G | G | | | G | G | C |

haplotype frequencies

| | cases | controls | Odd Ratio | Attributable Risk % | Pvalue (cases vs controls) |
|---|---|---|---|---|---|
| haplotype 1 | 0,263 | 0,152 | 1,99 | 18,55 | (6.7e-05) |
| haplotype 2 | 0,259 | 0,147 | 2,02 | ND | (3.9e-04) |
| haplotype 3 | 0,259 | 0,147 | 2,02 | ND | (4.1e-04) |
| haplotype 4 | 0,26 | 0,148 | 2,01 | ND | (4.8e-04) |
| haplotype 5 | 0,258 | 0,149 | 2 | ND | (5.3e-04) |
| haplotype 6 | 0,255 | 0,146 | 2 | ND | (1.6e-03) |

ND: Not Done

Figure 21

## Comparison of Pvalue between nb of mks for haplotype
## (19 mks of PG1)

| GENE | # of markers | # of 2 mks combinations | # of 3 mks combinations | # of 4 mks combinations |
|---|---|---|---|---|
| PG1 | 19 | 171 | 969 | 3876 |

CUMULATIVE FREQUENCY HISTOGRAM OF Chi-square statistics (Chi-S) for PG1



— ■ — 2 mks combinations     - ● - 3 mks combinations     — ◆ — 4 mks combinations

```
<110> Cohen, Daniel
      Blumenfeld , Marta
      Chumakov, Ilya
      Bougueleret, Lydie
<120> Prostate cancer gene
<130> PG1
<150> 08/996,306
<151> 1997-12-22
<150> 60/099,658
<151> 1998/09/09
<160> 578
<170> Patent.pm
<210> 1
<211> 56516
<212> DNA
<213> Homo sapiens
<220>
<221> promoter
<222> 1629..1870
<223> identification  method  Proscan
<221> misc_feature
<222> 1998..2000
<223> potential  ATG
<221> exon
<222> 2001..2216
<223> exon1
<221> misc_feature
<222> 2031..2033
<223> ATG
<221> misc_feature
<222> 11694..14332
<223> Tyr  Phos
<221> primer_bind
<222> 11930..11947
<223> upstream  amplification  primer  4-77  SEQ  ID42
<221> allele
<222> 12057..12103
<223> polymorphic  fragment  4-77  SEQ  ID24
<221> primer_bind
<222> 12339..12358
<223> downstream  amplification  primer  4-77  SEQ  ID51,  complement
<221> primer_bind
<222> 13547..13564
<223> upstream  amplification  primer  4-73  SEQ  ID64
<221> allele
<222> 13657..13703
<223> polymorphic  fragment  4-73  SEQ  ID58
<221> primer_bind
<222> 13962..13981
<223> downstream  amplification  primer  4-73  SEQ  ID67,  complement
<221> exon
<222> 18196..18265
<223> exon  2
<221> exon
<222> 23717..23832
<223> exon  3
<221> exon
<222> 25571..25660
<223> exon  4
<221> primer_bind
<222> 34216..34234
```

2

```
<223> upstream  amplification  primer  99-217  SEQ  ID43
<221> allele
<222> 34469..34515
<223> polymorphic  fragment  99-217  SEQ  ID25
<221> primer_bind
<222> 34625..34645
<223> downstream  amplification  primer  99-217  SEQ  ID52,  complement
<221> exon
<222> 34669..34759
<223> exon  5
<221> exon
<222> 40688..40846
<223> exon  6
<221> exon
<222> 48070..48193
<223> exon  7
<221> exon
<222> 50182..54523
<223> exon  8
<221> primer_bind
<222> 51149..51168
<223> upstream  amplification  primer  4-65  SEQ  ID65
<221> allele
<222> 51448..51494
<223> polymorphic  fragment  4-65  SEQ  ID59
<221> primer_bind
<222> 51482..51499
<223> downstream  amplification  primer  4-65  SEQ  ID68,  complement
<221> primer_bind
<222> 51596..51613
<223> upstream  amplification  primer  4-67  SEQ  ID44
<221> allele
<222> 51612..51658
<223> polymorphic  fragment  4-67  SEQ  ID26
<221> primer_bind
<222> 51996..52015
<223> downstream  amplification  primer  4-67  SEQ  ID53,  complement
<221> polyA_signal
<222> 54445..54450
<223> AATAAA
<400> 1
gtggatctgt gactgttcgc aggaagagag gagcgggagc aggacagaca ataactgata   60
gtcaggagct gggtttggag ataaagaggg aacaagagaa agttaagttc tgtgttttca  120
tggcaaacat tgcacaaaag tttacaactt cgtgactaac agtaatctgg ggtgattcac  180
aacaaattta cacataaaca catatttact gactttatac acagcaatcc taacgtgaac  240
acagaacctg ctttatcttt tcgcacactg ttctagtgta gagatgtctg gtctcagtta  300
aagaaagcat aaggagcatt agttgtgcac actgtccaca cccgtgactt ttttccacca  360
gtactaaacc tagtgcttct tacagtacag ggcaatgaca gccacagaaa gagagaagct  420
ccttttactg tgtaatgctt cctgctggcc ttcaaatact tgttacttga gagatctcca  480
ttcacctggc tttgtcccca aaggtcatca tctaccaatg atgttgttat ttgatgttaa  540
tcatgtataa agaaagtagc taccatcctg ccctgatta gaacttccca ctgaaatacc  600
gtcctgccta aaggtagcac aggtttccat tatggtggtg gtggggaggg ggcgggaata  660
tatatatata tatatatata tatatatatg gtaaagcatt cggcattctt ttaaagtaca  720
actatccttg aaaagggtta catattaaac cattttttacc acagccaaag gggaggagaa  780
agatccaaaa gtcctgtgga tctgctttaa catcaataaa acagttatcc acccttcgta  840
gcttttagtg aaggctacaa aagtatgctt tttatggatt acacatgtgc acgcaactac  900
tttaattact acagaaaaaa acgaggctcc ttattaaaaa aaaatcagaa acaagtccaa  960
cagactctga ggaaatgaag caagagtgaa ttctgaaaag gtctaataaa cagtatggaa 1020
atatccttgt gggattgttc ttcagctatg cataaacatg taattatcat cattactgtg 1080
atggggaaaa acacggaccc taattctgaa acaccctggt agcgagagac gggcaggagg 1140
ggctgctgcg cactcagagc ggaggctgag gaggcggcgt ccccttgcaa aggactggca 1200
```

```
gtgagcagat gggyacactc gagctgcccc gcgacctggg ccgagctgcc tacaacctgg   1260
gcccaggtgc ctgcaagaat tagacctccg ataacgttaa cacccacttt ctcactgctc   1320
taattgtgtg catcccggcg cccagggget tgtgagcagc aggtgcgcgt tccaggcagc   1380
tccagcgacc cttaaacctg accgcgcgca cgtccggccc gagggagcag aacaagaggc   1440
acccggaccc tcctccggcc agcacccacc ttcacccagt tccgtcagtc gccaccacct   1500
cccttcccgc gtccgcagcc ggcccagctg gggagcatgc gcagtggccg gagccgggtt   1560
gcccgcgcca cagcaggtag ctgtactgca actgtcggcc caaaccaacc aatcaagaga   1620
cgtgttattg ccgccgaggt ggaactatgg caacgggcga ccaatcagaa ggcgcgttgt   1680
tgccgcggag cccctgccc cggcaggggg atgtggcgat gggtgagggt catggggtgt   1740
gagcatccct gagccatcga tccgggaggg ccgcgggttc ccttgctttg ccgccgggag   1800
cggcgcacgc agccccgcac tcgcctaccc ggccccgggc ggcggcgcgg cccatgcggc   1860
tgggggcgga ggctgggagc gggtggcggg cgcggcggcc cgggcccggg cggtgattgg   1920
ccgcctgctg gccgcgactg aggcccggga ggcgggcggg gagcgcaggc ggagctcgct   1980
gccgccgagc tgagaagatg ctgctgtccc tggtgctcca cacgtactcc atgcgctacc   2040
tgctgcccag cgtcgtgctc ctgggcacgg cgcccaccta cgtgttggcc tgggggggtct   2100
ggcggctgct ctccgccttc ctgcccgccc gcttctacca agcgctggac gaccggctgt   2160
actgcgtcta ccagagcatg gtgctcttct tcttcgagaa ttacaccggg gtccaggtga   2220
gccgcctccc gctcccgggt ctcggcgtcc acccgagctc ccggggggcgc ggacctctcc   2280
gctcccccac agctggcgag ggtcacccgg ccggcccggc ggacccagca cggagagcac   2340
gtgccgcctc cccgccttcc tctccgcatg cttcctgccg ttctgccgag atcgctctct   2400
aggaagctgt ggctgcgtcg tcctgaggct acgagtggga cccgccgccc ctttccccgc   2460
ccctcgcctg ggtctgatgc tgcttagcaa agtgggtgca gatgcacgtt ttaaataata   2520
gggcacgcgt ttagcagttt ctggcctttg gtccaaagag gtggtcatgt tggaacagat   2580
cggagacgtc tacactccga agtgcgcttt tacagtgacc tcttgaaaca gaagtacaat   2640
tcggtcttgt gttctttccc ctggacaagt gaaagctggg cgaagaaatg aatacatttg   2700
ttaaccgtag aagcctaact agatacaatt cttgccaact ttaactgggc ttgaatgtgt   2760
gggtgatctg ttgtctgatt actttctttc tgttactgtt tctctgtaga gattggattc   2820
gtagattaaa cttgagaaac aaaccataaa agtggaaggc cctctttaac agtaggtatt   2880
tgaagtgtta taaaaaaaaa aaaggtgaat ttttctttta tttctcagtt tgaaagaaca   2940
gctttattct tggttattcc taatgtccac ctagtcctct tttacttttc ttggtagggt   3000
tagggtggca tggggaaatg ggacggtatc attttgtctt tttaactttt tttttttcca   3060
cctacagcag ctgtttttac cctgtggtca gtcaggtact atatttagtt tgcagttgca   3120
ctgctgatcg acccttgatg gccccagttg gaagttgttt gggggggaagg aactaggaga   3180
ggccagggcc tccatttaaa ccagtgtctg taagtgtctc cttggaagga aaaaaagata   3240
ctgttccagg tcatggtttc ctggtagttg acgtttaaaa tgggcctcat ttaaaaattt   3300
caataattca ggctaatttt ttcccttttat atggtaactc caccaagttt gtctaaatgt   3360
atgattttta tcatgattaa gttttttactt ccacatcatg tgacaactgg cctgggatgg   3420
gatataagct cagaacacaa agtcattcac ctgttaaaaa aataattcta tctgtggcgg   3480
gttatgttat ttttgttcaa agaggacaca atatgatgca gaatacacca ttgaaggatt   3540
ttttggtttg gcaagttctt attttttttaa atggctgtaa aacctagcag tgtttctgaa   3600
attgcatacc ttacctgatg ttcagagatc cgatttactt cttgatttcc cagcaagtga   3660
ttttgaaaac atttaatcta atcattcccc ccaccgtctg ttcaaatcaa aggaagtggc   3720
atccagcact aatttttcatg catttatgaa aggatgcctg aggacccctta agtataattc   3780
aaaattttgt ttaatgtgtg ttccttgatg aagttcttta ggagtcgtag aacgaactga   3840
ttgcccactg atcatcaaat gcaagttatg aacatttaat aaaaatttaa aaccaagagt   3900
ttcttgttcc tgcattttta tttttattgt atggagggga caaataatta ttttctgttt   3960
agtaacagag cagggtattt tgaatttatt agggtctttt tctgcagtcg gggtttcctg   4020
tgtacacaaa gctacctttc aatatttttt attgtttctg ttaagattaa atcaatagag   4080
gaataaatag ctatcttcaa acataagacc caaaggaaaa agatttatag tgatgttctg   4140
tcaccttatt ttttacctgt gactttgtac cattaacttt gtcactgaga tgttttgatt   4200
aaaatttta gcttgctttt cttgttttgt taggacactc tttttttctt gaattgtttt   4260
tatcagcttt cgtttgcaag gctagtgatg attctcttgt tctgtataaa gtattgttga   4320
ctcatttctg aagggagttt tagtaattta agaggttata agttttttaaa taaaaggttt   4380
attaattttat atatattaaa gaggcatttt aaaataaaat ttttttttaaa tgacatttttt   4440
acacctttca actctaggtt taaaaaataa gtggttcaca gtagttcttg cagaagaata   4500
ttttcttttta catagaattt ttaagctgaa gagaagtagt agtaggtcca tgagatttat   4560
gatctgtgct tggcaggtaa acctgcttcc aacaaattta gttggatttt cttggattc   4620
tgggtaaata ccttttttctt ccccagtttc ac:actttat tttcatatgt atctctgaga   4680
tagagaaata tttcagtcag tgctgctaaa attgttcctt ataactcgtt tatccttttta   4740
ggtccttcca gaatctctca ttggtactga aactcaaatg ggtactttct tcaccattta   4800
tttctttaga ataagtaata agaattttat aagctttttt atatttcacg taatttgaga   4860
```

```
ctattgaaaa tccagttaag tctctctact gtgttgagag gcattgattc aagtacctgt    4920
gttactttcc tgtgctgcca aaacagatca cctcaaacta agcggcttaa aataatagaa    4980
cttaagttct cgtgattctg gaggccagca ctttgaaatc aaggtgtagg ctcaattta     5040
ctccctctgg aggccctagg gggaatctgt tcttgtgggt ttcaacttct ggtgactggt    5100
ggcattcctt ggcttggggc cccatcactt caacctctgc cttacagtcc ttgctgccac    5160
ctcttctgtc tcacatctca ctctcccttt ctcttagaag gatgcttgtc attgggttta    5220
gagcccacct ggatattccg ggatgatctc ttcatctcaa gatccttaat tataactgca    5280
aagagccttt ttccaaataa gaaaacattc acaggttcca gggcttagga tgtggacaca    5340
ttttttgagg ggctgccctt cattcccca caacaatgaa ctccatagtt ctgcctattc     5400
agtattttgt agttatttcg tagtttaact tgccttattt ctttaggtat ttacgtatta    5460
aagcattttg gtctctgctt tctttaacag agaacctggt tttctgtaat aagtttactt    5520
actttcccat aatcttttag tttcttattt acagatttac cttcacatat cccttaagta    5580
gaacatttga ttaactgttt tattttcgga acaaatctgc attctgtata ataaccaact    5640
tattcatatt tcggtattct tttaattctt atctgattct gaaattacca tcttgtgatt    5700
atatatatat atatatggaa ataactgaaa tcttgataaa ttaaaggtga tataacttct    5760
aagacaatta attatgtatg atgtggtgaa tatactggtg tttggtttgt ttgccactta    5820
aaagccctat ctataggata ggaagtaact tgaatgtgga atgcttagag actcagagta    5880
agaggccgta tatatatcct tgagctggag tttaaggaaa acttatggga aattaaaagg    5940
aaagttggag tactgacaga ggattgcgta ggactcatga aaaaggaatg aagttacctt    6000
aaattctatc atcgtgagtt aacgtgaaac tagatttatg ttagtttata gcctagaatt    6060
ctatcctagg aatctagata tatcctaaat gttgagatag ctgcataaac aataactgta    6120
atcgttatga taaataatga caaatctttt tagcatgttt tgtgaagctg ataaatgtta    6180
ataggatgtc ttcaaatgtc agaattcttt tttctttgct tcttttttaa aaaatttctt    6240
ttcccccatt cctatgcaat acactgaaaa ctgatcattg aaatttgtag gccaaaaat     6300
taatcaacac gtaatagatt ggggtttggg ttttttttgag tcaggtgtctt cttctgtcac    6360
ccaggctctg gtgcggtggc accatcatgg ctcattgcag ccttgaatgc ctgggttcaa    6420
gtgatcctcc ggagtagctg ccgtgccatt atttctagct aatttttaaa agttttttgta    6480
gaaatggggt ctttctgtgt tgcccaggct ggtcttgaat tcctggcctc aggtgatcct    6540
tctgccttgg cctcccaaag tgctgggatt acaggtgtga gccaccatgc ctagcccta     6600
ataaatattc taattaccga tttatcttgc ttaaatcagt tggtaacact tggaatttac    6660
ttcagaatat attttacatt agtggctctg actgctaatt ccccttctc caaatgctaa     6720
tgtaatataa caataaaatg cacagttctt aagtttatat aaaataaaca ggttttcagt    6780
tgacctgctt taagtgtaaa atagtgtgaa aaacacaaga aagaagataa agaatttaag    6840
attttgacat ttctctaata tgcccttaac ttctccaagg attcatactt ttttttgtaa    6900
gacagaatct cacactgttg cccaaaccag aggtgcagtg gtgcagtctc cactcactgc    6960
aacctctgcc cccgggctca agcggtcctc ccacctcagc ctcctgagta gctgggacta    7020
caggtacaca gcaccatgcc cagctaattt tttttttttgg tattttttag tgggggtaga    7080
gacgagattt tgccatattg cccagtctgg ttttgagctc ctgggctcaa gtgatccgtc    7140
cttgatccac catgcttagc tgattcatac tcttaactga aacattgttc caagtttctc    7200
agaaacagtc aaggctttt atctagagaa catttataac tggatctttc tttgtgtagc     7260
actgattcat caaactaatc ctaaactcct aatgagttaa atttatattc tgaatcttgc    7320
tgtaaaagca gccattcatt agaatgaaac atgtttactt agaattggag aagggagctt    7380
ataagtcatc tagtctactc cctttatga cacttctaca ttctttctgc acttctgcca    7440
aaatgttgcc cagcgtcgtc tctgatacct atagtcctaa caagaatatg aatcatacct    7500
tgtatcctta attttactct tctctgctta tttgccattc atgtgaagac cttaaataga    7560
tcttaaattg cttccttcac tttagctgag agtgacagga ctgtgtaggt gtgggtgtgt    7620
ttctgcattt gcttatttaa gcaggataat aaaaacttttt actataggaa attaaacatt    7680
tcccaatcaa atacaattcc agtctaacac aattaaattc tggttaggga actgcttaac    7740
ttactagact tataggaaaa tactaaaaaa atgtaactag aactctattt ttacactta     7800
taaatataaa cctctgtgaa caaccagtt atttcaggtt gcatttgtgt atagtttttt     7860
aatgcctgat ttttctattt taaaatcaca gatgcaatta tacattcaaa cactgccaca    7920
atactttgag aaagttaaag tttcccctac tcctacactg cgtacacctt tcctaggtac    7980
atcccagttt ggtgtgtaac tttagatttc ttccaagagc ttttgagtaa gtgtttgaat    8040
tgtgggaagg ttctttagtt aaatgaactt cttacagatc agtttttttag tacagtagca    8100
cgaaatatac ctgcatacct atggggatac ctctgtgcca ttacgatgga aggcacggga    8160
aaacagcact ccgtatatac ctagtttact ttccctcttt tgtatatttg tctgattttg    8220
tggagctgat gcttctcaag tggaatcaga agttaacttt tcctttacta ttttctcatt    8280
ttattatggt ttcttaacta gaggttgatg ttagtggttg gaccattcaa tagtaagtaa    8340
tgacttttca gtaagggatc tctagaaccc agatccctta attcctgcaa tattcccgtg    8400
tgtacattgt tccaggtgct gtcctgggta ccaagggata caatgtttga tagacaatgt    8460
acctgccatt atggaggtca cattctagtg tgggaagaca aacaataaca agaaaatgaa    8520
```

```
aatttactgt gccatgccag gttgtttagc ctggtgggtg agaggtaggg gtttggaaaa    8580
tcttactgag caagtgacat ttgtgtggag ctctgtaaaa gggccagctt ggaaggtaat    8640
gtagtcatcc aggtgagaaa tgatggttag gggagtggaa agagtggatg ttaagattga    8700
aaagaattcc aaatctattt tagtggtagc tgatagggct ttgtgattga atgtggagga    8760
aaaagaagag ggtgggttag taacacactc agtcgcagtt agtgagtgct gctgtgtgca    8820
agtattgttc tattatgtaa ataattccat ctttacaaag taggcaccat tcttcctctt    8880
ttacagacaa ggaaaaggga acacccatgg ttcacatctg tagtagccta gccaggagtt    8940
tcaggcactt attttctgaa gatgctctgc ctggcaatgt ggttatattg gttgaaatga    9000
gaccccctac tttcaaggta ttcatctagg aaagacatga actgccaatt acaatatagg    9060
ataacactga aattagagac gtgtttatta actttgccat acagaggtaa agtaactctt    9120
taaagtaact ctttgcttgg gttagtggag aaggctataa aaattacttg gagtttttac    9180
tttgaacatg cgtaattaac atggaatgtt tagggaaaag aggttttcaa ttgataacat    9240
aataaacatg aggagtttga agcatggcat tcaaggtttt ctaaattctg ccccggttaa    9300
cttttccatt cgttggtttc attctagtct agcttttcct tctgggccgc ccctccccac    9360
attagaccgc tcctctctgg aattccaact caagcccttg cttttctcca tctgtccatga    9420
tgttacccca tctcattgtc agggtaactt ttatgtaata ttaacatata taatactgat    9480
ataacattag catattttaa tgtatggatc atctcctctg caacattgta acctcttgga    9540
gatggcaata atgggaagaa tgacttgatt ttacttttc ttttaacaaa aatggtggag    9600
tagtctgggc acggtgtggc tcatgcctgt aatcccagca ttttgggagg ccaaggaggg    9660
tggatcactt gaggtcaggc attcgagacc agtctggcca acattgtgaa accccatctc    9720
taccaaaaaa atacaaacac ttactgggca tggtggtgtg tgcctgtagt cctagctact    9780
caggaggctg aggtgggaga atcacttgaa catgggaggt agaggctcca gcttgggcga    9840
cagagtgaga ccctgtctca aaagaaaaaa aaggtaaaag ggccaggtgc ggaggctcac     9900
gctggtaatc caagcacttt gggaggctga ggcaatggat cacctgaggt cgggagttcg    9960
agatcagcct gaccaacatg gagaaacccc ttctctacta aaaatacaaa attagccggg   10020
cgtggtggtg cctgcctgta atctaagcta catgggaggc tgaggcagga gaatcacttg   10080
aacccaggag acagaggttg tggtgagcca agatggcacc attgcactcc cgactgggca   10140
acaagagcga aattccgtct caaaacaaac aaacaaacaa aacaaaacag agagaaaagg   10200
cagagtactc tagggaattc tagtctgtgt ttctgtggaa atgtatatga atctcacttt   10260
taagggatgg agatttttga atggcataac tagttgataa gtttttgctct aacagggtac   10320
ccaagtctag tgagtccgat tcattctttc cttaaataga tgaaggagga agaaacatga   10380
ctccaccctc aagagtaagg cagaatgagc aaagtcagag aagttaaaaa agaattctca   10440
cgcagccagc agtgcagaga aaccttggtt tagttgtgaa tcaaaaccag tactttttgt   10500
aattttttgag cctatgcaat tctccaaggt tttatgttgt ttcttctgtt tctctgtagg   10560
caccagaaat caaaaccccca aataagaaag tgttacttga agatttttaga gtacttattt   10620
gtgtataagt gtaagtgata tttggaagac gactttactg cgctcctcca gcttggcatg   10680
agaattccag gggcggaaag aaaggagggt gatggtacct ggaaaggaga gtcatgttaa   10740
gtcccagcca catattaagt gctaaccacc tactgttaaa aggtgtaatg ttctagactg   10800
acaaaataca tagtctctac cgtaaagtaa cacataattt agcagtgcag aaagatgtca   10860
cttaaaagaa aacttgaata tatgctgaga tagttcacaa attaaagaaa tgaacaaaga   10920
actgaggaaa taaaggagga atacaactgt gtccaaatga atacttaact gggtgggagc   10980
tgttgcatat gtaagcaggt ggttcaccta aaagttggat gtaacgtagt taacgccagc   11040
tcttggtgca cttacatatt gcattgcttc cgggcttaat ttgtgttcat ataggaataa   11100
attttttgtt ggttttttaat tttactcctt gtaattccgt ggttgatatt caaagtgaaa   11160
aaaattacat aagcttctaa tatatgagaa gtcttctcac ttgacatttt ttatttggaa   11220
ttttttgcaga gagtagtttt gtcacagtca aaagattttg ggatcttgca gtgagaaacc   11280
taggtgtaat tcctatttct ctgccattcc gtatgtcatc tggattaagt gtcaacttct   11340
cagtctcaag attctcgtcc ttaaatggaa tactttttgt catgctattt tgaagacaaa   11400
atgagataat acgtgaaact gcctagctca gtgaatggta catcatagat actcagaaaa   11460
aacacaccct ctaaaataag aacagtacca aaagacagga tgtaaaataa gggcagtacc   11520
aaaagacaca tgcatgctga gtgtatgaga aagaactttg tggccttctt gggtggcaca   11580
ggccatggca gttccacagc atgacgtggt tgctgtgggt ggtagagcag acatgccgct   11640
ccccgtcact gcctggcttt gatgcttgct ttcttcagct gagaggacgc agctgtgata   11700
tgaaggtctt gtgtgtacag tcgtgacctc acatttccaa tttcctgctg gcagaaccca   11760
cagtctacaa cgtacgagca ccagagttga cgtgagacag acagcataca gaggcttgta   11820
acatccttct ggaaaacact gtgtaagctt tcagtgcgaa taaacatgat cagtggcaag   11880
ttctgttaga tgtagtctgc aagcatcctg attttactgg gcaagactat gttgatttac   11940
aggcggctga tgattccatg gatagcccac tactagtatt ttcacaaatt tcacaagaca   12000
ttcttactgg aagattgccc tgttcttatg atactgctgc cctttttagct tcatttgctg   12060
ttcagactaa acttggagac tacagtcagt cagagaactt gctaggccac ctctcaggtt   12120
attctttcat tcttgatcat cctcaaaatt ttgaaaaaga aattgtaaaa attacatcag   12180
```

```
caacatatag gcttatgtcc ttgagaagca gcagttaatt acctaaacac agcaagtacc 12240
ttagaactct gtggagttga attgcactat gcaagggatc aagtaacaat aaaattatga 12300
ttggaatgat gtcaagagga attctgattt ataacaggct atgaatgagt acctttccat 12360
ggtcgaagat tgtaaaaatt tgtttttaagt gcaaacagtt ttttattcag ctttgaaaat 12420
gacttgcata aatctggaga aagattatca ggatttaata tggtgaatta tatggcatgt 12480
aaacatttgt ggaaagcaag tttagaacat cacatattct tctgtttgga cagaccactt 12540
ccaactagaa agaatttttt tgcacattat tttacattag gttcaaaatt cctaatgcat 12600
ggtgggagaa ctgaagttca gttagttcag tatggcaaag aaaaggcaaa taaagacaga 12660
ctacttgcag gatcctcaag taagccattg acgtggaaat taatagtttg ggaagtagta 12720
ggcaggaatt caatatctga tgaaaagatt agaaacataa agccttccat cacaattccc 12780
acccggaaca ggaattccta ctcatcaaaa ttctgcattc atacaagagg gaacctgatt 12840
atgaccatct tctgttggtc atttggtaga ttatgtggtt cacacttctt ccaaatattt 12900
gcaaatcaga catcaccatt atcagcacaa gctaatagca tcattctgga atcatcacta 12960
ttacaggaca cccctggaga tgggtagcct ccagctttac cacccaaaca agctaagaaa 13020
aactgttgga accaaattca ttatttacat tttcaacaag atctggaaga tcatattaat 13080
gaaacgttga tgttctatct tctcttaaaa aatctgctcc taatggtggt attctacatg 13140
ataatcgtgt tctaatccga gtgaacctga cgaaaatgga aggtttggag tcaatgcaaa 13200
gggggatatg atcagaagat gtctgtgatc gtgtcctgag aagcaccagg aacacctttg 13260
acctcagtga ctctcgattg aagagaagac caagttgtat tgatcagtgg ttgggacttt 13320
acagaacaca cccatgattg ggttgtcctg cttttttaaag ccaactgtga gagacattct 13380
ggggaactca tgcttctagt tctacctatg ctgcatatga tgtagtggaa gaagtgctag 13440
aaaatgagac agacttccag tacattctgg agaaagcccc actagatagt gtccaccagg 13500
atgaccatgt gctgtgggag tcagtgatcc agctaaccga gggcttatcg ctggaacatt 13560
ctggacacaa tttgatcaac ttatcaaaaa aaaacttgga atgacaattt ctggtgccag 13620
attaccttag aacctttgca aaaatagata gagatagttt tccttatgat gttacatggc 13680
ttattttttaa aggtaatgaa aactacatca gtgtaattcc agcatcataa gtcagaacag 13740
tgcttgtcaa ggggcgttac cacacacttg aacagatttt tggcagatga cttgggaaca 13800
aggctcctcc atgtttgtaa tgttgaccac acaagttgaa tgtggcagag ttaaatgacc 13860
ccaatattgg ccagaaccca caggaagttc atcctatgga tgctaccaag ccttctgcca 13920
ctgagaagaa ggaagcactg tctttatctt caggaagatc acactgctgt ttaaccaaga 13980
gaaaaattag agagtcatca atcacgcaga tccagtacag agggtggcct gaccatggag 14040
accctgatga ttcagtgact ttctggattt tgtttttcat atgcaaaata agagggctag 14100
caaggaaaaa cccccttgttg tttcttgcag tgctggagtt ggaagaacca gcgttcttaa 14160
tactatggaa acagccatgt gtctcattga tctcattgaa tgcagtcagc cagtttattc 14220
actagacatg gtaagaacaa tgagagagca gtgagccgtg atggtccaaa cacctagtca 14280
ttacagtttt gcgtgtgaag tactattttg aaagcttatg aagaaggctt tgctgaagaa 14340
agcaaaagga aaaaaagaac tttgtcatct gttaggttcc atttattgca tgataattgt 14400
gtttgtattg attattgggc aagtagctgt ttgctatttt gatcttattt cagaagggca 14460
taataatttt actattcaat gaaacgtttt aaacggggta gaaaaagact agttttgta 14520
tgctttacag cagaaatctt ataatgatta actggtaata tatttcgttg gcataaaaat 14580
acatttaaaa gttcaagtaa ttataaacat tgtaaattgt atatgtaatc atattgaaat 14640
tgaaattctt tatagctgta cttctgtgta atcaaagact ggggagagat agactagcta 14700
gctctttctc ttatccatta atcacttaac agagttttga ataaaaagtt ccattcatg 14760
ggataagaat aatgacaggt taacctattt tagttggtta ctatgttcta ggtgttgtat 14820
gaagtagttt acatagtttc actgatttca ctacaatccc aggaggagta gttactatta 14880
ttacactcat tttacaggca aagaaatagg tttggagggg ttgggtgttt tgcccaagtt 14940
ctcatcgtaa aatgacagat gaggattcaa attcaagtct taattgaagt ccattacttt 15000
agaacctacc tcttagtggc tcttatgtta cagtataagg gagagcagac tgttcctta 15060
cccttgtagg gtagctaggg cttgtgaatt aagagactga ttaacaggag aagaggcata 15120
cacattttat tgacgttagt attttttacat gcacagggaa ggagggtttt attttttattt 15180
ttattttttat cttttatttta aagagacagg ggtcttgctg tgttgccagg ctggactca 15240
aactcctgaa gccaagcgat tcttctgctt gagattcctg agtagcaggg actataggtg 15300
tgctcctctg tgcttggcta aagaaggggt ttgtatgtga tttttaacaa aggctgataa 15360
attgtgaaga agtgactagt caaaggagaa gaggattca gctcccaggg gtggtaaatt 15420
gtgggaagat gactaggaaa tgtatagtaa taaggtttgc tatgcaggtt tattttgcca 15480
gtttctggtc tcctaataag ggacagggaa acacctttac agatggaaat tcatatcacc 15540
tttccacagg gaaatttatg tcctgcctta ggcagttagg ggaagggcag agaattcttc 15600
ctgtatctgc tgtgtctcag gtgccttcag ctcaaaataa tccttatgcc aaagtagcat 15660
atttgggtgt ggcatattct ctgatctctt tcaacagcat catctatact taacaacagc 15720
aaaagttttt tttaaaaaat catgtttcaa gatttgcatg tggaagacaa atggacatga 15780
ttgagataaa tgaagaatat atatttttta acaaagaatg ctgtatattt atgtctctgt 15840
```

```
gacattgtgt  tatggaggct  aaggtgttaa  gcatgtgatt  actttagatg  ccgtatgact  15900
acctgttttt  aagattaaaa  aagaatcaat  aggcagttta  tatgcatggg  agcaagttaa  15960
aaacaacaca  gatgtgatga  aggcgaggtg  aaactggtcc  gcatctaatt  caggccttct  16020
cctgaaagcc  agtgtgtgca  agataaataa  gtttgtttga  cgaaagcaga  ataactagtt  16080
tgtcctttgt  gatgaagata  gttattcaga  aatcattttt  attggctacc  tctgaattaa  16140
taaatgaaaa  gagaaatttt  tttttctgta  ggggatgtct  gatgagttct  taaaaagtgg  16200
atgaacctga  aattatcatg  aacaagcaat  tataatgaac  ttaaaattac  ttaaagagtt  16260
atgaaaaaca  aaaagaaaag  ccgtatgttt  tcttgtgcct  tattttgaag  tgacaaatta  16320
tttgcagggt  acatttgtag  acggaactaa  tgtgatttaa  aaaatgagta  ctagatttac  16380
agaatgatgc  ctttaaaaag  tcactggtgc  actttaatta  ttttatttat  gtttattctg  16440
aaactacctt  tattttgaaa  atgaggtata  gctttgccta  ctggtgacaa  aagtgtaaat  16500
aattcagtaa  acatctgtta  aaaaccagct  tggtgctagg  ctcttggggt  agaaaactga  16560
tcaggccatt  gaggagctca  tagtccctaa  ggggctgggg  acttgtcatt  aggtgtgcag  16620
tgtgttctgg  atgctcctga  aggagtgtgg  gcaggtgcgc  accaccatgc  ctggctaatc  16680
tttttataat  tatgtagaga  cagggtctgg  ctgtgctgcc  catgctgggt  ttgaacttct  16740
gggcttaaga  gatcttccct  ccctgcccct  accgaccccg  cccgcccact  ccacctcagc  16800
ctccccaaag  cactgggatt  gcaggcatgg  gccactatgc  ctgggctgtg  caaaactttt  16860
aaatcagtgc  atactcaatg  gtcttgatgc  aattctggct  tgttggtaag  agaatgggga  16920
tttactcaca  agccacgatg  tcactttaa  ctctgaacag  atcaagctat  tggtattact  16980
catttatgtc  atcgataaac  tttatgaata  aaaactcatt  gtgcaaatat  ttaaacatac  17040
tacatacata  gcactgtgca  gtttctaagg  aaagtaatgg  aaacctttgt  cacatccctg  17100
gcttccagaa  ctttatgtta  tctaagtgca  tttgtctgca  aagttgttgg  gttaattgcc  17160
cctttctttc  ttctcttttt  aagatattaa  taaatagtgt  catgaccaaa  agataatcct  17220
tatggacaag  atagatctaa  aaagccttag  ctaatttata  atcttgcata  atccatgatg  17280
acaagatgca  gaaacaaaaa  tgcccagaat  aaaaacttag  caccattagc  agccatttcc  17340
ttttaagtct  ttacaagtat  actcccagtt  tcttgaaaaa  tttattctaa  aatatgtaag  17400
acacacaaaa  cagcagaagg  actaatacag  gtacatcgaa  cacctgtgtg  cctaccgccc  17460
agtttaaaaa  taaactggaa  tgatgtttct  ctcatactta  cagaataaag  ttttaatctt  17520
tagcatggaa  ttcaaagac  ttctgccatt  ccagttcaga  gccatcctat  tggtctcctt  17580
gctcctcagc  cgcgcacactg  cccatgtacc  caacaggcct  ccagggttac  tgcttccatt  17640
cgttcttatt  ctcatgaaca  ttttccttca  tctcatctgc  cagaatccta  cctaataata  17700
ctcctgctct  gcagtttaca  gttctttaaa  attaaaaaag  gttgtgtacc  ctttagtgtc  17760
ctgaaaaaag  aaaaaacaaa  tttaaaacct  taaaaggta  ccatatttc  atagtatttg  17820
cgttatgtct  cattacagtt  cctgtggaca  tgtctgtctc  ttttactaga  ttgattgtgg  17880
gctctttgaa  ggaagatata  tcttatgaac  agtgttttat  atattgttag  caatcaatga  17940
atgcttgcta  tattttctc  atgaggatat  tgattattct  attttaattt  attaccnnnn  18000
nnntgtacta  tacataactg  ctttctgtac  ctgagctatt  tatgatctct  gaggctcctg  18060
tgagaaatct  aatttttgtt  aatcatggat  ggaaatattc  acaacatcat  tcgtcagttt  18120
cttcacattg  tcttcctttg  tatattcag  atgtttttaaa  atatcaaagt  aatgtttttt  18180
tgttttatct  tttagatatt  gctatatgga  gatttgccaa  aaaataaaga  aaatataata  18240
tatttagcaa  atcatcaaag  cacaggtttg  tatttcattt  gcatgaaacc  taggtttttc  18300
tacagatggc  acatgggcat  tcaaaatacc  gttcttatat  ttaaatgaag  tgggtttttt  18360
aaaacagcaa  ttttctgtgc  agatattaca  cctgttcttg  tattttgtg  attttacttt  18420
ttggaaagtc  agaaacttga  aagctatgaa  ttttcctaaa  cttaccttct  ccctctgttg  18480
gatgtaagta  agctatcttc  ttacttgctt  gctttgtttt  tcctttgtgt  agctctttaa  18540
agagtgtatt  cattctttt  gtaagtgatg  tttctagaag  tagcattggt  gggtcgaagt  18600
gtgtatacat  tttactatgt  tgattgctaa  gctgcagaaa  agctgtattg  gtatgtaagt  18660
actcgtttcc  ttactatgct  cgtcattct  agtgtctgct  cttcctttcc  ttcttcaaat  18720
gggtttggtt  taattctagt  tgctactgtt  ccatcagagg  aattgcagag  aactggtctt  18780
caaaacagtg  cagtatatac  tttaggtgaa  gatacttcta  aaaccttttg  tattttgagg  18840
taattctaga  gtcccaagaa  tttgcaaaaa  gagtacattg  tcagcaatat  ttttcccaat  18900
ggtgacatct  taatataact  gtagcacagt  agcagaatca  ggaaattgtc  attgggtaag  18960
gtacttttta  attctccaaa  taattcagcc  ctccaaaaaa  atcccacttc  ttatgttttc  19020
aaacctgtag  ctacttttga  tgcgtacttc  ctaaattgca  tttttattac  tttaaaaaat  19080
ataataccta  gaagctcaaa  gctggaaaca  gcctgatcaa  tatagtactc  ttaagctaaa  19140
aacaacctga  tcaatatagt  actcttaggg  aaatcactta  tgcctgtggc  tttttttaaa  19200
ttttcttcct  gtcagctgtc  tcttcatgat  tttgtggttt  ttattactgc  ttataccata  19260
gatgaggtat  agaaagtaaa  agaagttaaa  atgcattttt  ctcaatttag  tgaattaatg  19320
attacattca  gatttatagg  acaagggttg  aagctancaa  ggggttgata  ggaatcttga  19380
tgtatctgag  tattttcccc  aactttatta  catgactggt  tcagactatt  ttatctaatt  19440
acatttcact  cttggcagaa  atagcaaaac  agtcaaccaa  tggtcaatgc  tgctgagaac  19500
```

8

```
tctggcctgt gcagacatat tggctgtttt acttctaata ccattctgct tttcctgtcc 19560
tgctgctgat ggatgtttct tccaggtttt aaatatcaaa caaaagggat ctgtgggccc 19620
agtacaggga atggctcttg atagatttga ttttcctgca tttcctttat tttgatccag 19680
tgttaatttc atgtagagtt gtctgtttaa caggattctc ttaaaattcc ttcttcagtt 19740
tacctgccag cttttctttg tccaggtttc agtatgaact ccactcgatt aatagagctc 19800
tctagtagtg acttgtggag tgggttctct gaacatttct ggaagtgttg ctgatagtga 19860
taatattgat cactagtact gttaatttgt gtgcttacta catgttggct tttatatgta 19920
ttccttcaga ttaaggactt ctagaaaaca tccatgaaaa aacagattaa aaaaaacaat 19980
tctgcatgta tttgggacta gaaggtacta tgggaaggat aatcttcata ctcagaccat 20040
actgacctga atttcattta tcagtttaga gaaccacttc cccttccctt caccctacct 20100
ccgagtgcct gtgactttgt atcaccgctc tggcaccaca tcctcatccc agcaggattt 20160
gggaaggctg ctttttgaaa gccttttaaa attctgtaag ttgagaaaat actaggggaa 20220
tgattttaaa tttctttaga attacaggct ttagtcagta tatgacagag ccttttccta 20280
gaaaaatgtg catataaaaa tttgcatgta gttttagggt ttcagagacc cctaaagcct 20340
atccatagac gtggttcatt gtctgattgt gtttaggtac ccttctaaaa cccttttgag 20400
atgttaggaa tcacaacaga gtatctctga aaatgtaatt agcggaaaga acatttcaaa 20460
gactgttgtt ctgcttagac tttctagttt gtcttctgcc aggcttgccg gaataaatga 20520
gtttcctggc ctgatactca aaagaattga catttaaatt agtctctctc ttcccttgtt 20580
ttcgcttgac acatccttgt ctctacattc tgtctctgtc tctgttagct tatttctctc 20640
tcgagtcagc aggatatagt ggctgttatt tcttcccctt atccttcaac gatctacttt 20700
tgacaacact ttgccttttt ttttttgaga tggagtttca ctcttgttgc ccaggctggg 20760
tgtaatggtg caatctcagc tcactgcaac ctttgcctcc cgggttcaag ccattttcct 20820
gcctcagcct cccgagtagc tgggattaca gacatgcacc accacgcctg gctaattttg 20880
tattttcagt agagatgggg tttcaccatg ttggtcaggc tggtcttgaa ctcctgacct 20940
caggtgatct gcctgcctcg gcctcccaaa gtgcagggat tacaggcgtg agccactgtg 21000
ccctgcctgc tatttgcctt tttaatctca tgaaatgttc tcttttcttg gctgaagtgt 21060
cacttttctt gttgaacagc atgcgtggtg agtagaatgt tataaaaagg gatggacttt 21120
ggagttagag agacccaggt tcctgttcgg cattgcagaa atgctgttct gcaataggct 21180
gtgtgtcagt gggcaaatta cttatctctc agagccttat tggtaaggtg tgagtgatag 21240
ctcctttcag gcaccttaca gaggctgtct cctaatcctg gtagcgtacc tggctcatag 21300
atggcattta aaagtggttg tgatgacagt catagctcac cattagcata gcgctggatc 21360
catggcaggg aagcgctgca catgcagtat ctcttggact acacagggcc ctcatgaatt 21420
aggaactgct gtttcatgag gatagggatg aggaaattag acttgctgcc cctcactgcc 21480
ttccactcct ctcctccaag ttaatgggaa ctatgactct gctttggctt gattgccatg 21540
gaagattctc acacagccaa atttattgct atcttagtta aattatgcca gaacacaaaa 21600
tatgaagtta ttgtcaaagt aatataatct cagctgtaac tgagatagtc agaaactgtc 21660
tgtaatctga tgtcctatct gaaaggtagc tgagaataaa caagaaataa agagaattca 21720
gtagcaaata ttggtgacac aaagctttta tattttgact agttaagcta gttcttaaat 21780
gtttccacta aaatattcaa gtttaagggc atagcccagg gcagcttatt atgaacatga 21840
tgtattttgg aaatcttaca ctttctctta aaagttcttg ggaggggcat gtgaggccat 21900
aatataacca taaaaccatt tgttttaaaa taaaacccat ttttaaaatt cttccaaata 21960
aaaaaattat tgcaggaaaa aatgctaaac ctggttttta actttgtacg ccaactatat 22020
ttccaagatg tgctgtagcc tggtaaccat acagaaccat acagaattag ttctcagaat 22080
ttattgtctg cttacttttg catttggtac aggtataaca gggtcgatta tatggtttct 22140
aagacatgac tagaaagaaa tatgtttatc agttattatt tcttccatct aaattagaag 22200
gggctaggga gagggcttca acaggaattt atatacttta gagaaaagtg atcattgata 22260
gcccaatagt atagatatct caacccaata acacaggttg tgtctgtctc tgggatcata 22320
cactgtaggg gagaatcttt gcaagcaaca ttctacttat agggagccat aacaaaagtt 22380
tcatatgtat aataattata agtcttaagt catcaagaaa aagttaactt gtgaatgata 22440
atccctgatt aaaaagagag atgtataata atggataaga gatttttctt ggttaatttt 22500
tagtattaaa atggctgaaa cttctttggg atattctgac tagtatggtg cattgtctaa 22560
tagatttccc atagctgaga gctaatcatc ttgtaatctg tggaaaactg tcctctttgg 22620
ctaaaacttt attgtaattc ctctaaatcc tcagctttta ttttctacag actttttttt 22680
tttttaaca tttccttcct ctgactcact qcttttgttc tcattttcat ggcctgagaa 22740
catgggtgat gatagaatta ttcttttcac agattaacag ttttcttttc gagtatcgtt 22800
gagctcatgt gtgtattaac tagagaagtc tccttacat ttcattttta tgttttcttt 22860
ctcatcagga gatagtttgt agccatttac tttcaaatcc aagtttctgc ggttcttaag 22920
acctgtatca tttgtctcct gaatttcact tcattcctc tttaaaccat gtcctctgtt 22980
tcccatcttc tgcacccact ttgccacttc ctgtttgttt aattggcaag ggccactctc 23040
tgtgttggaa attttttctt tttgaaagct caactaacaa cttctaggaa gttttttatt 23100
gctactgtta tcaattcata ccatcttacc cttgtttttg caacccttg ttaataacat 23160
```

```
atttatttaa ctatagttat tagcagtctg agatcatttt acttggttac ataaggagca  23220
catatatcta cccagcatca ttgtaaggca tgtgagacct ttgtttgatt gctgtcctaa  23280
cctagtaccg agtcctaaaa actcattagt agaagatgaa gtgtccttgc cttttgctga  23340
acatatatat acacactgaa tatttagtgg caattcatag ttgcatttgg ccattttttg  23400
tttataattt cccctttctc attaaaaaaa ctttgttttc tagactttag gatttagaga  23460
agctcatttt gttccataca catgctgctg ttggattatt taggtatttt gtgactgtat  23520
tttatctttg aaataaaaag cctttcaaga aatgcaaaaa aaaaaagctc aaaaacaga   23580
aaatgtatat tttttaaata tctcagatag atttaaagaa attttaaaca tcctaatcat  23640
agtacttttg aagcccattc atagtacaac ctgtgaagag cctcatgtac gcgctaactg  23700
ggtcctgtct ctgcagttga ctggattgtt gctgacatct tggccatcag gcagaatgcg  23760
ctaggacatg tgcgctacgt gctgaaagaa gggttaaaat ggctgccatt gtatgggtgt  23820
tactttgctc aggtaacttg tttccatgct tttctctcta tatatgtagt ttataaattt  23880
tttttttttt ttttggagac agtctcactt tattgctcag gctgagtgca gtggtgtgaa  23940
cacagctcac tgcagccttg acctctgggg ctcaagtgaa cctcctgcct ctgcctccca  24000
agtagttggg accgtagtgc ccaccatcat gcccggctaa attttctatt ttttgtagag  24060
atgggggtct cgctgtgttg cccaggctgg tcttggactc aagcaatctg cctgtctcag  24120
cctaccaaaa tgctggatta taggtgtgaa ctgccatacc caaccctata aaaatgttat  24180
attttaaaat ttaacaatat acttcatgtg aatgtatggt ttttaaaatg ggtttaatag  24240
tttattctca gttgaagtaa ttttgtttgg catttttagt ggtgtgtatt tatatacgtc  24300
tgattatcca tatgcggttt tccttcagca tctgtgggga ttggtttag aaccaccaca   24360
gataccaaaa tctaaggtgt tcaagaccct catatagaat gggatagtat ttgcatataa  24420
cctgtgcact actttaaatc atctctagat tacttataat atctaataca ttataaatgc  24480
catgtaaatg gttgttatac tttattttttt atttgtatta ttttaattgt tatattattt  24540
ttaatttttta tttgttcaca tatttttgat ctgtgatttg ttgaatctgc agatgtggaa  24600
ctcatggatg tgaagggcca gctgcagtaa aatgaaagag caaaaatgca aatgtacaaa  24660
gttcaaacaa ataggaaatt taaaggcata gaatttgata ggcaattaca ttaaactgtt  24720
gataacagta attagtgatc tgtatgatat taaaaaaaaa aagcaaactg tatatataaa  24780
acttactttc tccagttctg gaggctagac atccaagatc aaggtgttga cagggttagt  24840
ttctcccaag gcctctctcc caggcttgca gacagcatcc ttcttcctgt gtcctcaggt  24900
ggtttttttc cctgtgccca agcacccctg gcactgcttc ctcttcttag aaggactagt  24960
tacactggat gactaatcct tctacagaga ctgctaaggt cccactctga ggccctttt   25020
taaccttaat taccacctct aagtccctct ctctgaatac agtcacagtg ggaactatta  25080
gggctttagt agactgattt gggggaacac acttctgtcc gtaacagtgc cacataaata  25140
tctttagcag gattgatttt ttaaaatccc taaagatcgt gagtattgac atgttaagga  25200
cgcttttttag tgactctgta ataagtgggt ggaagaattg ggagttaaat ccatctgatg  25260
gatcaggttt tttattttta aaaatgtgta tttaagaaag aaagcatttt cattttaact  25320
gccaacaaaa ctaaacttca tgtgttttcc aatacagtgt cacatgcagt ttttttgaat  25380
tatgttgaga caaggcaatt ttcagctaaa tgttctttag aagctaatgt ttgaagatat  25440
taaatataga ttaaattctg aaatgtagtt ttcattctgt acttttgca agagaagttg   25500
cctttttgat gactctggcc aattgttatt ttaaaagtaa atgctctttc tcccgatttg  25560
attgtggcag catggaggaa tctatgtaaa gcgcagtgcc aaatttaacg agaaagagat  25620
gcgaaacaag ttgcagagct acgtggacgc aggaactcca gtaagagcct acccgttttt  25680
attttttctta ccagctctca gtttctaaat ttaagaatta aattaaaatc taagaattgt  25740
tttgacaatg tatttttccca tgtgtaatta ctaattcagg gttatgctga ggtaacagaa  25800
accctctatg tacaggtagg caggtttttc agccatcaga aagattgctg taaacaacta  25860
ggtcctttgc tggtcagtgg accttaaaga ggaataaaaa gagcatttgg tgtcgttcag  25920
agtctataaa tagaactaac tgcattttaa cctgacattt aagctagttt acaagctcat  25980
cttacttctt gtcttctta gtatcagatt tggttttaga agcagcaact gttttctgtt   26040
agtgcaaatt ttgaatgtct tacatgtaca gaaaaaccaa aaaaggatga atctctacaa  26100
atgttaaatc attcagtgta aataatattt tataaaactt tattccacaa aagtggggag  26160
agttcaatct gctttgtata gaatgctgat tgctgccaaa ggctttccc ctggttccct   26220
ccggagacaa agcaccatga tcaccggggc gacttgggct ttctctttca gtacatgaca  26280
tgtgctcaga agcttagctc gtgtgcacag gctttccctt tcctttctgg ctccctccct  26340
ctgtcttccc tcctctcctc ttgccctccc ctcaccaggg gtcctgggca gcagctggag  26400
ctcatggtga aggaagaatt cttcatggtc agctggcgaa gtgcctggtg tgagcattgt  26460
ttattcacat gcctcttcta ggtgttttta cattagaaca ttgcatctgt tttgggcatg  26520
tgttgggtga cagaagcaga atggaatgag atgaacagtg acccttatc ctgttatagc   26580
taacccttga gaaccaagct tggtgtcttc aaagggtctg tttagtctga aacagtgtgg  26640
tgaatttggg cagaattgtg gtcattgcat gtaggtctcc aaaagacaga ataagttggt  26700
aatatggttt atcgactttt tacaaaaaaa atttaaaaat catgaattta taccttaaaa  26760
tgtccatccc acttctctcc cagctgtcca gtcacccag caatggatga ctgctgtgga   26820
```

```
gttccttctg tgtcctgctg tgggcattgt atatatgaag caaatgaaga tagctgcctt 26880
ttgggtgatg ttggcatcct atgcacagtg gtcccttgct tttttgcccc catgaatata 26940
gctgccagtg gcgctagggc tgaaaaaatc agctctttac acttgtcatg tgtcttgttt 27000
atgtggctgc cttcgtgagt ttcttcttgt ttttggtttg cagcagttta agtatcatat 27060
atctgagtgt catttaaaaa ttttaccctg gattggtcct ctgagcttgg atctatgatt 27120
tggtgtctgt tattaatttt ggaaatttct ttgctcttat ttccttaaat attattccta 27180
ccccagtctt tcttctccag ttatgtttgt gttggttcat ttctcgctgt tctttagttc 27240
ttagatgcat tattcgtttt ttgttggttt ttttttaaat tttttttttt acgccccctc 27300
ccttttttct ttttgtgtta cattttggat aatttctgtt gacccacctt tgagttcatg 27360
gattcttcct ttggctgtgt tgagtctact ggtgagccag tttaaggcac tcttcatctc 27420
tgctactgcg tgtttcattc ctcacatttc cctttgaccc tgtttcatag tttccatctc 27480
tgtgctagtg tatctatctg atcataaagc ttagtcacgt tttccagttg aacctttatc 27540
attttattat acttgcagtt ctcttaaatt ccctgcttga taattccaac atctgggcca 27600
tatctgagtc tgcaaatttt gattacttta tctcttcaga ttgtgcttta tcttgccttt 27660
gtcatacttc ctaagatttt gcctaacgct gggccttttt tgtaagacag gagaaatgga 27720
ggcaagttgt cttgatacct ggaaatggat agacttgtct ttctgcttgg cttttagtgt 27780
tgaggagtgg agtcagtcca ctgaggaggt gcactgcatt tgggtttttgc tcatgtgctt 27840
tttctcacag cttcaggttt ctgtagaact cattactttg tttgtaggtt ggggatgtcc 27900
tcccgctaga gcttttcctc agtgtctatt tcacactcag cgttttcaca tagcaccttg 27960
gagtggctct cttctttatg cctttcccca ctatacttct tggatacttg ttactgaact 28020
ctcgctagtt tggtggtaga aggagaggga agggaagtgt cttttcattc ttagggagaa 28080
tctcaggggt ggagccttct ctgatcctgc cttgcttctg gctgtaagtc tgtgcccagt 28140
atgtattcct gcctttacta agagtttttc cctgttctct tcacccagcc tcatcgagta 28200
ttcatccgtg ccccatgggt agcagggttt tgttgcccct gttcatcagt ttcaggctgc 28260
tgttccatag gaaaggtaga aagaaggatg tgggctgggc cctgagccct tcccacaggg 28320
ctgctttttcc ctcccacaag cctacatcca gtcttccctg accgcagtgt gtttttctttt 28380
ttcttttgtct tgtgagtaca caggaggtct gtgggtcgag cctgtgaaat gtgctgcatt 28440
ctccttgtgt ctgtagccca ggggttcgtc tgttccactg gctcatactt ggctttctgc 28500
aaaattgata aaatttttag ctaaattctt tttactggta tctgttacat tggcccccaa 28560
ctaaacaacc acttgcatct tgtttctcct ttgagttttc catctttcct tagactttg 28620
ggttagttgg ttgccttgca accttgcagc tctctgaagg gtctaagaaa agtcatgaat 28680
ctacagcttg tcagtgttgt tgttgttgta gggttggcag tagtattcct tcagcattct 28740
acatacttaa tggaagccgc ctcccatttt tggttaataa atttcaaaac ttggaacaat 28800
gttagattta caaaaacgtc agaaagaaca gagtgttcct gtttattctt tatatagctt 28860
tttttttttt tttttttttt gagttggagt ctcggtctgt cacccaggct ggagtgcagt 28920
ggcacgatct tggctcactg caacctctgc ctcacgggtt caagcaatct cctgcctcag 28980
cctcctgagt agctgggatt acaggcgtgc accgccatgc ccggctaatt tttgtatttt 29040
tagtagagac agggtttcac catgttggcc aggctggtct cgaactcctg acctcttgat 29100
ccgcccgcct cggccccca cagtgctggg attataggtg tgagccacca cgcccagcct 29160
tcttcatcta gctttaacat ctaatgttga catcttacat aacatggtat atatttgtca 29220
aaactaagaa ataaacattg gtaccacact attaattgta ctacagattt ttattcagac 29280
tttaccaggt tttccactaa tgtccttttt ctgttctaaa atacaatcca gaatagatac 29340
aaatccattc aacttcagtg ttttaaatta ttgttttca ttatatgaag tgctgtgtgg 29400
tttttgtcaa atctgttatt ttggtttaa tcttcaagct tgtctttgtt tctttaagtg 29460
ataaaggcat aatttaaaag gtgtgttggg ttatttcagt gcctaaagtc ttgtctgagt 29520
cacttgtttt ctgctgttct tgcttatggt actttctttc cttgtttgct ttgttatctt 29580
cctttgctgc tggctgtgtt tggttaagtt atttgtggaa atcagttgaa gcctcaggtg 29640
ggagtgtctt tctccggaga acatttctac ctgtttagc tgggcccctt aaggctcctc 29700
tagcgtgggc cccacccaaa cgagattctg agttgaaggt gaactgagcc attcaggcag 29760
tgcagccagg gttgcagatg cacgtgagac ctgctcacct ctcatttact ttcaccctga 29820
gagtagagcc tttggtgttt cgttcacttg tctgattctc tcttcacagt tctattagaa 29880
ggtccatggg tttggtttc tgtgcccttc atcttatgag tcttgtaaat caaagttctg 29940
ttttatgctt acttctgctt tactgtgttt gcttaatttc agtcttaaca tcttgccaac 30000
tcttgggtac ttttaaaata atgttatatc cagctttta agttgttttc agtaggaagg 30060
ttgattcaaa taacctagtc tggttatggg ctacgagaat agcctccctg ttttttgtgg 30120
gcaaaattcc agccttttat gttcctagcg cagtgtggat aacagactgg caggttcaag 30180
aggccgtgct gagcagcttt cactgtaagg tcactgtccc aggtcgggtt tctaagaatc 30240
tggatggttg tttcatttct taatatgtac gccctgtgag agcggataca tcttgctcag 30300
gttcttatga ttcttttgtt tctgaaggtg aattaagtaa gtgacatggt agaatatgtt 30360
aagtcaactt tcgtgtggct tactagttct catgaatcta ttccatgatt gtatcagttc 30420
ttattcagta ttagtatttta agaaatgcag aatttgttt caaaaaatat atttgtatta 30480
```

```
taagttgtga agaaatacat ctccataatt attgctggga caatacagta ttttcttaag   30540
gaacttattg gttgtggatg caaatgaagc atatttgtga taaaaataac taatagaagt   30600
cattttgtta gactatgagc tagtaaaact tatggcacaa acatggagac ttaacacttt   30660
ttcttccagc tttcacttaa gttccttttc agataggagg cagcctggtg gataagagta   30720
ttggttttga aattagattc aggtttaaat cccagatctt ctgtttaatc tttattttat   30780
ttcaggtaga ttttctggat aacttgctat agcttatacg tcagtacttg ccacttcaat   30840
tttatgttat ggagagacgg cttcttttcct taaacctcac gaaccaacct ctgctagctt   30900
ctaagttttt tcctgccact tctttacctc tctcagcctt cagagaatta aagggagtta   30960
gggccttgct ctggattagg atttgcttta agggagtgtt gtggctggtt tgatgtttta   31020
tctagagcac tcaaactttc tccatatcag caataaggct gttttgcttt ctaatcattc   31080
atgtgttcag tgaagtagca cttttaattc tctttaagaa cttttccttt gcatccgcaa   31140
cttggctgtt tagtggaaag gacctagctt ttgacctacc ttggctttca acatacctttc   31200
ctcactaagc catttctagc tattgatgta aagtgagaga catgcaacc ttcctttcac   31260
tggaacgctt agcagccatt gtagggttat taattggcct aatttcaata ttgttgtgtc   31320
tcagggaata gggaaaccca aggggcggta gagagaaaga gagacaggag aacaggccat   31380
cattggagca gtcagaacac acacgacatt tatcaattaa atttgtcatc ttatatgggt   31440
gcaattcatg gcacccccaa acaattacaa tagtaacatc agagatcaca gatcacaata   31500
acagatataa taatatgaaa tattgtgaga ttaccgaaat atgacacaga gacgtgaggt   31560
gagcacatac tgttggaaaa atggcaccaa tagacttgct cgatgcaggg ttgtcataaa   31620
ccttcaatgg gaaaaaaatg caatttccgt gaagctcagt aaagcgaagc atgataaaat   31680
gagatgagcc tgtcactcct aagaatgttc ctgtacaagt ttttgcatc tgttacttac   31740
cttttcctat ttgtgaatag tatctttttt gagtacgtgt gtttttttat ttttatacat   31800
ttatatgtat cttttgaaga acatactttt aagcttaatt tattgatttt ttttctctca·  31860
taatttccac ttttttgtatc ctatttaaga agtccttgcc aaacttaagg ttgctaagat   31920
tttctccttt gttttcttct ggaaatttta gagttttgct tttacattta gttctaggat   31980
ttatttataa ttaatgtttt catatggtgt aagatcgaag ttcatatttt tttaatatag   32040
gtaaccatca ctatagaaaa gattatttcc ccccaatgtt tgaaataagt agactgaata   32100
tagatgggtc tgttatccct agatcaatgg agcatttgtt ctgttatatt gatctatata   32160
tatatatcct tatgccaata ccatactgtc ttaataatgc ttgctttgca gtaagttttt   32220
aaatagtgta gttgtcttct aaatttgttc tttctttttca aagttgtttt ggctatttta   32280
ggtttttttgc atttctgtgt gaattataga attagctcga caattctac ccaaagtttg   32340
tgggcttttc attttgattg tattgaagat atagatgaat ttgggaagaa ttgatataac   32400
aggattgaat ctttggattc atgaacgtag cctgcatttg tttacttagg tcttctttat   32460
ttatctcagt gtgttttgta gtttaatgta cagatttgca catcttttgc cagatatatc   32520
cctaagaatt tcagtttttg atactattgt agatgacatt taaaaaaatt tcaagttttt   32580
gtttgttgac ctaggcatat atttgacttt ttaatatact aaccttgcta aacttatttta   32640
tcatctagta acttacaaaa tatattcctt aggatttcct acataaacaa tcatgtcatt   32700
gttttagaaa taacagtttt actttgtcct ttttaatctt gatggctttt atttctttt   32760
cttgctaaat tttctggcta gacctcctag tacagccttg actagaactg gtgtgaggga   32820
aatcctttcc atattcctca tctttaggga aaagcactca ttcttttatc cattctttag   32880
ttcctagccc cattgccctt cctaaatttt ttctcatcat tttccttcat cacaccttgt   32940
tcttttttctt tgcaatcata tcatgatatg taacgacatg ttttttatttta tctgtttaat   33000
gtatttcttt tcctcacttg tccatgaagg gaaggaccat atgtgttgtt atcctttgtg   33060
cagttcctgg aacataataa gtatataaga aatagtttct gaattagctg tgaatgaatt   33120
catgccttcc tgctgtctgt caatgttctt ttaaattaaa catctaagac agcaaataat   33180
accacatgag ttattaacct gagaaatact cgtttttattt ataaatgact gagttgaaag   33240
ctgatagccc acagtaattg ctttcatggc tttgaatata aaccttactg ttacaaaaca   33300
cattttcatg aaaatgaatg tgtggtgttt ggaactagct ttaatgtttg tcttcctgtt   33360
tttccttcta gttgctataa tataataagg aattttgtat gttttttccta attgtaccca   33420
cttttctaca ttttcttaac agatctggtg aatcttcatt attaaatata attatacata   33480
taaattattg tttaataata atattaatta ttaaaaataa tataaattat taaatataaa   33540
gatacatata atattatctg ttaatttcta agttaggtgt gggttctgaa gactattata   33600
tgaatgaaca aaaagcttgc atatttgcgt ggaagctgaa agtacgaaat ttttagatac   33660
cattatacca gtatctaaag aaaaaaattca gtaccacata ggttttttaag taggagctgt   33720
atgatcatag gtcatccaga tgaaggaagg cttctgtacc agacgtacag aggtagacag   33780
tgttgtctga gtactgtctg agatctggca agaatgaatc caataaacgt agtttttctcc   33840
catgagctcc tgtcttgttt cctgtattct gtttgtattt gaaaagattt ggtgtgcata   33900
acttatttt gtcttttggc tgtcaatcaa agttattagt gtagtttttg taactcagtt   33960
ctcaagctag gagttttttgc tgtataattt taatgtttct gtttttactt tcctaagcag   34020
ataagcgtaa aaacttagac taattgatta cttattaaac gtccagcttg atattcttct   34080
ttatattatt ttagtttcag tttatataac aaatgaggtt tcttataaat aaaatttaaa   34140
```

```
atgcactaaa ggagctgtgt gaaataggaa ttctgtgtga agcttttgaa tgtgaacatt   34200
tagaacgttt cacatggtgg gaatttacta tatgattttc atcaaatgag gtactttta    34260
gtgttggtac ttaacgatac tgatttctaa aatttgtatt tctaaaaatg acgtattaca   34320
ggatctgaaa gggcaaaaac tcattgaggc tttgtatgag tcagcgtttc atggcctatt   34380
tttaattagt gaattattag catataatta gaaatgtttt tagattcttc atggctgacc   34440
taccaatgaa tgtagcactg catttaaaat atagttcacg ttatgttcat acttaattgt   34500
tgcattttgt ttgcccctct tgaaacgaag gtcacatgta aataaatata cattttctcc   34560
tactgtagga aatactctgt tagcattagt aggtttagct tttttaggtt aacaataaca   34620
aaaacaaagc tcacacaaaa taaaccaaat ttgctctatg tcccacagat gtatcttgtg   34680
attttttccag aaggtacaag gtataatcca gagcaaacaa aagtcctttc agctagtcag   34740
gcatttgctg cccaacgtgg taagtaaaaa tttgagtgtt tgaacaaata attttcaaag   34800
ataataacat ttttagtttt tcttcctgga aaagatactt ttgtttaca gttgaaggaa    34860
tgaatgtatt cattccttga attagtgtac atattatctc ttaggaaatg aagtttcttc   34920
tccttaattc actttcatgc tattattaca tatatctgag aaattaagtt gaagtgcttg    34980
ttacgataca tattcttgtg ccatggattt atttaaaatc tatctaagta catgattatg    35040
tagatggaag cttttttctac agtgtatggg ttatatgtaa tggagcttct gttttgtaag   35100
atgacagacc taagttggag tccaaactcg tacttttatt agctgtatgg ttgcaacttg    35160
gaagttgtgt aatgttgctg agcttgcttc ttcatctctt aaaagaacat atgccttata    35220
agtagatcta aatctgtgtg aggattagat tagaaaatat gtcaagtttc tattggagaa    35280
gttacacaaa gttggtccac agtgcttgga agctgttaat gtcttcaaca atggtaatgt    35340
tcttaatatc catattttag aaaattgaat aattggtaca ccaataagct atgcaattta    35400
accaaattgg gaagtataca gaaaacagtg gctatgctat gttcttagag gtgtctttga    35460
agcttgactg tgatttagtg tgtgatctcc atatgttgat agtcactcac tgagcaaata    35520
ccttgttggt gacattacag cagggcctat gacagtgctg tctaatggaa ctttctgcaa    35580
taatggtaaa gttcttcatc tgttctgtcc agtgtgctgg ctcctaccaa tgtggttttt    35640
gagcattcaa catgtgacta gtgcatgaaa ctaattttta atttattta attttagttt     35700
aattaaaaat aaggggggagt ttttacaagg tgcttacaag agcagatatg tcataggtat    35760
atgacatcat ttgtaacagt actttaaaa aatgccagtt tgttttaaa cacatgtcct     35820
attaagtaag gagtgtttca gaataggagg gttcagttgg tctccccatc tgccagctct    35880
cttttgactt tcattgcttc ctctgtctaa tagacatgac gttctgtcat ttcagttgct    35940
cttttgcaat gccattgtct cttttgccct tttcacattt attaaacaga acaaaacaaa    36000
aaccactctc gaatctgtag tctacctttg ttgtaagcac tttttccagt actcactctg    36060
ccctcaattt gttttggtct gatttgaaat tctctcccta gacttctgtg gggctgttct    36120
ccattatcct cccaactctc tggcgattac ttcctagcct ccttttccagc ctcttttctgc   36180
ttcatttctc cctgctacat gtgttatttc cagtgtcagg ttttggtgtt tgattaattt    36240
cactttttgt ttctcatggt ggccttcctc taaatccatg gctttagcca tcgtttcctt    36300
gactgctgat gactcgcaaa agcttcctcc cctccatgtc tctctgccta actctggacc    36360
catttgtaca attgtccatt agagagcttc gcttgactgg cccaaaagga tgtctcaaac    36420
tcagcatatt gaagatagaa tttatccttc catgcataca ctcatatttc ttgtcttggt    36480
aactccatca ttcagttttt ttgcctaagt tttattcaca aaaagaacaa attgatagca    36540
gttgcatacc tcttatagga aacttagaca tggaggaaga agctgttcag atggggtcct    36600
gcagaagtgc aggcactgtg gtaatattta aacttttctc agctgttcga agggtttttgt   36660
tttaactaat tttccttaga cttgttttag gtatttggct ttctaatggt tataagggat    36720
gtggaattaa atgtatctta atctgccacc tggacccatt aaagtaagcc cctatggtgg    36780
tttttttttt taattgccat ggttaaaacc atagttgcta gcgaaggtga catacttaag    36840
cttttgaac tctcttaaaa gaaaacagaa atttaatgat gtgtctataa tggcaaacca    36900
gatacctaga atttccatgt tattcatagg gtgaataaca ctggcgattg tagagatttg    36960
agagttcttt caaaacagga gaacaaaggg aataagctac aaagcaattt ttttcttgt     37020
agacttaact gaataaaaat tattttatg tctcaaacat catatgaaca aatttagttg      37080
gcaaatggca agctaataat atttataat ataggatatt aatatactta atattacaaa     37140
agtgcttcat aattagaaaa gacataaact agaaaaatgg gaaaagggca tgaataagaa    37200
attcaagaga tacaaatgac ccacacactt gaacaaatgt ttattctttc tcataatcaa    37260
agaagtagaa attaaatgaa tactttgaag ccaacttctg agaaagcata gcaaacaaga    37320
aagctagtgc tcagctttgt gtggtaacgg cactctcgct cttaagaagg tgtgtttgct    37380
ccctgtggct gctctcaggc agggccacaa acttggtggc ttaaacacc acagatttct     37440
tctcttacat ttgagaagtc tgaaatgggt cttactcagc tgaaatcaag gtgttggcag    37500
ggctgcagtc ctttgtggag gcttggggggg atcttgttct cctgtacggg gtcctgtgct    37560
tggttcgggg tcctgtgctt ggtctgggat cctgtgcttg gttcgaggtc ctgtgctggg    37620
tccagtgctc tgcttttacc accttgaagt tcatctggaa atggcactgg ctcgcccaca    37680
ccatatagct gactctggtt ctccctcctc ctcactcgct ctaaacctgt gtttttggct    37740
gatttctaat ctctctttcc ttggcccttc tgcagcttgc agggccttct gcagctcttg    37800
```

13

```
tctgccccag ccccggggtc tgcccatccc agtgctgggc tgttctgttc ctgccctgcc  37860
tttcctcagc ccttggcaac cctgtttgtt ttctcccttc cttagcagtg gagaacatcg  37920
taagatcaat gctgactgcc ttctgcagcc aagccaggcc atttcatttc agccgagcca  37980
agtctgtgtg gagcagttct tttatttttc tccttttgac tacctcatgg ttttcacgga  38040
tttttgttct cttcacattc aaggattttt tgctttcaga aagttatatt tctctggaaa  38100
gagtgcaccc aatatccctt ttgatttcaa aatcttaatg tggagtctct tgacttggat  38160
ttctttggaa gaaactgctg aagctgccat gtctaagaag aaaactttgg agaaaaattt  38220
tcttcttaga catggcaacg tcaacagttt ctaagctctt gattccgtct accctgtctc  38280
catcgttgcc tcagtcatct gccttacttc tctgcagggg tttctcccag cttgcaaatg  38340
tactccaatt ctgaaataac taagtctata gctgtgcaaa gagaagtctg ggccccttgc  38400
tttcttgtgt ttgactccat ccactctcca gaaatgaatc ccacttctca cttaaccact  38460
gacctccaaa gcatcgtatc atttgtgtca gttgtcatat ttgttaactt tcacataact  38520
tttgacatta tttatacctt tataaccagg aaataatttt aactttattg tagaaataaa  38580
caatggagta taatttttct tgttgaagat aaatatcacc tcctcttcct ttaaacatct  38640
cttccctttg tttttgtatt acattggttt cccccctttt tttatttcct gggttgtcgt  38700
attccctgtt attattttta cctttttttt tttaatgtgg atgtttccgg agtctgtatt  38760
tcttgccttt tcatcttctg ccctttatta ttctcagcca ctgccattac ttcagttatc  38820
cattcccatg gtttccacat gcttagcttc ggttgattct tgccatttta cagaccatat  38880
ttccaactac ttctagaatg ttttgttcct tcagcctcag tatgcccaat ttgaactcat  38940
gttctctctc ccccttcttt cttccttctt tctttcgctc tctctccctt ccttcttttc  39000
tttccctccc tcccttcttt ccttccctca ctcgttctct cttgcttgct tgctttctct  39060
cctctctctc ttttcttttct gcnnnnnnnn nnnattcttc tccctccctc tcttccttct  39120
ctcccccact ccccaacttc caggctaaag cagtcctcct gagtagttag gactacagac  39180
atacacgtgc caccgcgccc agctccgtgt tctctttgtt tccctgcctc ctgctcttcc  39240
acttatcttt gcatggcagg tgggtgcacg caggcatgct ctgcatgtct tcctcttggc  39300
cattcccctt ctagttatgg tgtggcttta tctacgcgtt ctggagcaga agcctagtca  39360
caaagctatt ttttttaaaac attcatgata attcatttcc ttttatgttt taaaaatact  39420
agctttctgt ctttatttcc ttactaactt acttggatgc cagtaattag ttgtttagt  39480
gaacaccaca gagtgatatt ttgaaacttt ggacttcata aagttggatg agctccagta  39540
gcaaagaagg aagtgttaac tagtttaact gacaaataaa tgcttcccag cttggtgtgc  39600
gattgagatt tttgttgcaa gtttgtgaat caatttaact gcccctgccc tggggactaa  39660
agtcagatac gtgcttgtgg gaatctttgt cttttcccaca ccaccctgcca ttttaaaacc  39720
tcttgtgtgg gacagtccca ccatgtaata gctgttcttc cttactcagc tactttcccct  39780
ccagagaggc cagtagaaaa tctagactag tttttatag tctatttttca tgtcacttat  39840
tgagagctac tgttttctgt taaattgtca gtaaatattt taatcaagga aaagggaggc  39900
aataggaagg agagaagaac aaatccttaa ccctagtagg aacctaatga atgggatttg  39960
ttctggataa ttgcagtagt cccccagcta aagaaccttt taaaaatatg tcagatatac  40020
ccaagaggat tgaaatcgta tgttcataca aaagcttgtt cacctgcagc cttcatatgc  40080
aattcctatg aatgttcata gcagcattat tcataatagc caaagtatgg atgcaaccca  40140
aatgtccatg aagcaattaa taggtaaaca aaatgtgatc tgttcacaca gtggaatact  40200
aactattcag ccataaaaag gaatgaagca ctgagtcctg cagccacaca gatgaacctc  40260
agatccatgc tgagcgaaag aagccagaaa caggaggcca tgtgctgtgt gactgtattt  40320
ctaggaaatc ttgagtcacc atgggcaaga tgctatcacc tttgttcagt ggccagaagc  40380
gagggcacta atatttaccc ttgccggggt ctactagatt gaagcgtttc cgctaggcca  40440
taaacttcca acacggtgac ttgtacatgt agatatttga tcaatatata gcaaatgaat  40500
attgatttaa acagaaaaag gcaagtgaga gtgctttcta aacttagagc cctaaatata  40560
tgaggttgtg gaattaatag attctgttgt gtgtgtttga gggaatttaa aaataattta  40620
gatgttaaac agtatattgt ggaggtgttt tgtaactaat taatgacggc actgaattga  40680
cttctaggcc ttgcagtatt aaaacatgtg ctaacaccac gaataaaggc aactcacgtt  40740
gcttttgatt gcatgaagaa ttatttagat gcaatttatg atgttacggt ggtttatgaa  40800
gggaaagacg atggagggca gcgaagagag tcaccgacca tgacgggtaa gtgtgttcac  40860
gcacctgaaa tgcctgtaca cggtatatac agtgcacatg tttatgtaga attcagtttt  40920
acaaagtagg ttaagtgtac tttttttcctc cattacattt acccggtata ttttttcaaga  40980
tgttattaag atgtaacagt ggagatttca ttagtcctgc aaagtgtggt atttcttggc  41040
tgtcgtgtga gtcctgtgga ctcaccaatt atcattaatc cagcctcttt ctactcaaag  41100
ttcacactta aaaggaaagc tctgtaaaag ggaggaagac gtgaagaagg agcacgcctg  41160
gcagtactga gtgcacgtta ttagtcagtg ctgccctttt gctgtatttt tcgtaaaata  41220
tttattaaat ttgggtgtca ttgtgacaag aagaaatgca gttaagtgtg accttttttt  41280
ttccccaaac atgttaggtt ttaagaacct ttgagctatt gtcagatata accagaaaaa  41340
aatagaattt taagtgagca ggataactta gttaaactaa ccaaacatag tgttagctgt  41400
tagagaaatg taaacatgga aataggcaaa cagggaagtg tgtggagttt ctgtttcctt  41460
```

```
ttcaaaatat ctgtttgagc tggggttgag agagaacact aggcttcatg gggttttttt    41520
gttttttcgtt ttttgttttg agacaagagt ttcgctctgt cgcccaggct ggagtgcagt   41580
ggcgcaatct tggctcactg caacctccgc ctcccacgtt cacacgattc tcctgcctta    41640
gcctcctgag tagctggaac tacatgcgtg tgccaccatg catgactaat atttgtattt    41700
ttagtagata tgggatttca ccttgttggc caggctggtc tcaaactcct tacctcaggt    41760
gatccacgca cctcggcctc ccaaatgagc tttgtgtttt tacctcatca gctgtttggg    41820
gttgagccac tatgtatgtc agtgtgcttg tatcagtagg atctactgag ggcagatgtt    41880
caaaatatga gcctccagca cgttttacat ggaaaccctc acctgaagca ttcgtctgaa    41940
gttgatgtgc cttgaaatt ttatagagta atattttaa ctacaacaaa acatttataa     42000
aagtagacat tattaaagca ttcagaagtg agcaaggata gaaattattc tgcccaacct    42060
tacacgtagg ccttctagac gtagtactgt gcaccgttac attatctaac actgtctgtg    42120
tgtcatcttt ggatgttagg gattttccca aagttcagtg agattatagt tgtcaaatga    42180
ttagtctgtt aaataatgat aagatgaggg tcactcaggt tttaaaagaa aagctctttg    42240
actgaaagag agagcagctg tctactgcag aaagttaggg agggaggctg gaggagtgag    42300
gcccagggc tagctagtat aaaaattggt tatggtcgaa ggaaaaaaaa atgtaacata    42360
tttatatctg aaagatgatt gttctcataa ttgtatataa cacagagtaa ttgtaaagta    42420
gaaaactaag gtgttttttca ttttagatgt aaatgtttag aatatgtaat gcatcagttt    42480
aaaaattaaa actgtacgaa atgcacagtg aaacgtcttc cttgctttcc accctgctac    42540
ctggccttcc cttctccttc ctagcgataa ccagtttctt taattgttg tgcgttgtat      42600
gtgcaaattt aagtatatct tcttattcta ccatccctcc cttcttacag aaaagtggca    42660
tattaatatt tttctctttt aaactatcga aggagttact tacctatttt tgcatttcaa    42720
aacagacagt tcatcaagat tgtcgttggt ttattaaaca tagtttaaga ttaaacaagt    42780
gtttataacc aatgaaaaac agatagactc cccataataa ccttgtttaa atgctgctac    42840
tttatcatg tcccctcctg tctaagaacc ccttggttca gcagagctca tgggtaaggc    42900
cagcctctgt tgcctgccat cggaggaatg cgttccagcc gtgatctctg ccttgccttc     42960
gcttcctcct gtgctgtgcc gtgaagcctc ggccgtggtg aagctggctg actgagtcct    43020
cctgcacccc atgcatattc agtagttgaa ggctttgtgt ggccaatcct gctttccaca    43080
ggaaaccacc ctctcttttg ttgcccctcat ccaaggctac tgttctccca gagtgacagg    43140
cggcaccttt cccagcatag cactgtgcct tctcctgccc ctgctcttgc agtactgctg    43200
tggcactgat ggcgtgtgtt acagtgctgg cacttagcac agggctctgc ctttctctct    43260
tcccagccgc atcataagtg ccttgaggaa gccaaaacct tctgtgagtt gcattgcctg    43320
ggttccaacc tcccactgcc ctgcttatcc tctgctacat gtgagctgac tgtggctttg    43380
gggtggtcac tgcctatgtg tattcattac aaattgtctc cttttgaaag attgacctt     43440
ctgacttacc cagataccat aaagaaaata aaatcttatc acttcagtca aggataaagt    43500
atttctgaat taaaggaaaa atacaccaga gtaaaatcaa gactgaaaga caaactggga    43560
aattatttgc aacctagatc atagaaaagg ggtcatttcc ttcttgcgta aagtgcactt    43620
acaaattgat aagaagatga ctgataacta gaaagaaaaa tgggtaaaga acaacaatag    43680
acatttcaca tttaacctca ttcatgataa ggtaagtgca aatgaaaact acaggggata    43740
ccttttttttt tttttaatcc attagattgg caaacatccc aaggtttgat cataggctca    43800
gtgggtgaga tttaagtatt atcaggcatt tttatacttt gctgttagga atgcaatgta    43860
gtacaaacct ttgtagaagt tgctttggaa atgtctctca gatgtacaaa tgcattcaca    43920
ttttagattt agcattcccg ctttctgaga cattattcaa catgtatacg tgtgcacata    43980
agatataata ataacacgtt tttccttcta gtgtgttgct tttaacctgt agcttgaaaa    44040
aactctgctt tcattgtttt ttttgttttt ctgtcactgg ctcagccctg ctttcaattg    44100
tttatatgaa ttgatgggtg ttctggtctg gttataatct actttagttt aagagtcact    44160
ttaaattata tgacatctga tataagttgt gttaggtaga aaattctgta acttggaata    44220
ctgtaagtac tttgtggcca catttcatta gtattaaata ttatctctat atatagtagg    44280
ctatttaata ttcatatttt atgatgcaat taagaaataa ttttttttctg aagttggtag    44340
attgttgata tgccatggcc cagtgtttct caaagcattc tgggggatca ctgtttgtca    44400
gaattagctg cagtgattgt tgaacatgca gggcctctgc tccactccac gttgctacca    44460
ggacgctctg caggtgagag ctgggaagct gtagaagctg cagtgctaac aaatgctaca    44520
ggaattcttg tagtcacctt catgaggtct tatgttgagg agaggcagcc agtagtgtcc    44580
cttgtccttc ccgtttatg gtgtaagttt cattttaagg gaggtataaa tcaaagccca     44640
cctgggcatt ctctcatggt tcactgcttc ttgtaatcat ggaagatgtc attgcggcag    44700
agacgaaaca gtgtagtttg attactattg attttttttt aattattttt ctgaagtggc    44760
tgttgtaatg taataaaattg tgtgcttaag acaacctttt ggtattctat ttgagtattg    44820
tgtatgatcc tagttaagtt ttttctacca gtattttcat attacaacat atttactttc     44880
catttctatt aatattttta tatttaaagt atggaggccg ggcacagtgg ctcacgcgtg    44940
taatcccagc attttgggat gctgaggcgg gtggatcaca aggtcaggag ttctagacca    45000
gcgtgaccaa cacggtgaaa tcccatctct actaaaaata caaaaattag ccgggcacag    45060
tggtaggcac ctgtaattcc agctactcag gaggctgagg taggagaatc acttgaatcc    45120
```

15

```
gggaggcagc agttgcagtg agctaagatc gtgccactgg actctagcct ggctgacaga  45180
gcaagaatcc gcctaaaaaa aaagggatca gggaagaggg gattacagat aacccaaaga  45240
agaaggaaaa atctccacaa gttcacctgt ccagcggtaa ccccaatttg gatattttcc  45300
tttaacaatt tggatatttt ccttttaaatc ctctttttta taatgtctat atgttggaga  45360
gagtatgtgc ctttacgtat tttttaaaga tgagatttct gtgtgtgtct atatctcctg  45420
ttcttcatat tttcttgtgt gttataaaca gctgtacatg tcagtatata tacttccgta  45480
actttttttt aaaggctata tagtgttcat tgatgtgatt aacagcagt tatctccccg  45540
gcttcatctt gttggaatgt gggtcctgtg tgttgccttc agagcaaatg gggcttggtt  45600
ttgcagcaag tagacctgtg acctgtacga atagttggaa gactttctct attacccaag  45660
cgtatcagta tactttagtg cctactagaa atttatgggt agaaaaacaa taatatctta  45720
gagtattttt tcctagattc cctaaggtgc tatagggtga ttttttactca tgtaacatga  45780
actatgcttc aactaagata gtttttgcaa atgtggatat ataagtactt tattaaacct  45840
ataggaagta tttataccac ttatttcctc ccttcagtgt tagaacctcc taaatggcat  45900
ttgacattga actgctttcc actttgtcgc atgctcctct cattgtccct acctgggtcc  45960
tgaaccttag ggacttggct gttatagccc caccatggct acgctgggcc ttggtcgtct  46020
ctgagactta gtttcttcat cttacaagga gataataaca gccctgcct gcgtagaatt  46080
gcagagatca aatgaaataa ttaacatact caaaagcatg ccgtaaacac attctgagca  46140
catgtacgtt ttaggaaaaa caaaggacc catgcacatt tcggagtgct tttgtctcag  46200
cagcactgcc tcttcttcca aagctgacgt cttagtagag gccctgccac gtcctgagca  46260
ctgtactcca cgaagcattc tatttctgac attcgaaatg cagtctgttc catcttcctt  46320
acaatctgta tgccagcact tgaaataccg ggtatctgca gtgttgacca ggtgattact  46380
taattatgga aatgttgagg tggagatcta gataattcag tgaaggcagg aaaattggtg  46440
tcggaatctg tctttttatg tgtcagaaat agaaataaga tagggtgaga agtaatttgt  46500
ggctaaaaca ctataatagc taacacatag tgcatactgt gtgccaagca ctcctgtagg  46560
tgcttgaaat cttctattat tattatccct actttataga cttgcaccct taggcacaga  46620
gaggcggaca gttgtccaag gttaccccag aggtggagat ccaggctacc tgactccacc  46680
atgtgtgctc ttccctaggg cacagttgtg ctgctaaaaa tactttttaa gcagttcttt  46740
gattattcag atgatagtac tgtaggaaaa ttaagacaaa aataatgaaa aattaaaatc  46800
tttatttttag tgttttgcac atgtattatt aaagccagtt tactcctgga agtgtgtaag  46860
aatacagggt attttttgatc acctaaatgc tgcatgttac taagagctcg acactgaagt  46920
caagaagagc agttgcagag agtacttagc aaaaacggga agtgtgtggg gttgaaggag  46980
caaagacaag tcttcctcgg acggtggagt gtagaattca tcatttctca gaacacgtct  47040
ttgaacgcat tttcaatttg aggccaaagg tctcagcctc ccactcggca tacctcccta  47100
ccttagtcag ctcttaaatc ttaggaatat ttctttgttc ttcaaggaac ttaaatatgt  47160
taacattctt acctgtccac agggagcccc ctacaaagaa gggagtttct agtctccgtt  47220
ctttcttgga ataaataata gcctcatacc ttgtgcaatc gaggctgaaa aagactgtct  47280
cctttttttca aataagcaag tcttagaaac tacagttgtt tacagggctc atggctattc  47340
cacagtaata attttggttc ttttaccaat tatataatat gttaaaatat ggcaagtatc  47400
aggaaagcaa ggagtggcaa tgattagaaa ccaatggcca agttagagag gaggggcaat  47460
tgctccccca agtttgttgt ggctgtgtag cagtcagtga cgagaagctg tgtgtcaggc  47520
gacaagcaaa gttgaggatt atcaggcgcc tgtgagtgcc cagctgtgtg ccaggtcagg  47580
aggtgccatc gtgagccaga ccagcttcct ctcggcccct gtggagctcg cagtctggtg  47640
gggaggcagc agtcaccatg gtgacaggtg acacactagg atggggctgg tggtggtagg  47700
catttgcggg tcccttcaga gaggtgagta tggacttaga ggaggctcca gcttcctatt  47760
cctgggctgt ctatagcact aaaagttgtc acatgaaaaa taacatttgg tactattgat  47820
ttaacttaat gacttatgta attgtagttg acttagaaat tataacatgc tcttctactt  47880
cagcttgaaa cccccaacca ccagtttata atccttttttt tttaacttttt gtttattttt  47940
cctaaggaat ctgtactttt tcttcatttt acaacttttt ttgtcctgtt accttatttt  48000
cattttact ttatatgacc atgagttcta aaatagtaaa aaaaaagaat tatttttgtt  48060
ctttgttaga atttctctgc aaagaatgtc caaaaattca tattcacatt gatcgtatcg  48120
acaaaaaaga tgtcccagaa gaacaagaac atatgagaag atggctgcat gaacgtttcg  48180
aaatcaaaga taagtgagta acaacagttc cagcacttcc ggaacttcgg ttcaactaga  48240
tttcagtata gtcaacaatt tgaaaccaat gtaaatggtt atattgtctc aagaatacat  48300
tttataaatt caaatcaaat tttatgcatg tctgatcgtg ttttaaactt tacttgtaca  48360
aatcagtcta aaagaacttg ttacagtggg occatctact tgcattgata gtatttcttg  48420
gacaatacta cgtgataaca tagcaaatta aattaaaaac aacaacaaac acacaaaaaa  48480
actttccagt gtcagatgcc cggacctacc tgtcaggtca cataaagtgg tgttactgtg  48540
tgaggtctgg ctgttgggcc agtgtgcgca gaaaagcaag ggaggggtag aggactatgc  48600
ggacgtgcag gtggacatga tgctgttata tttgttggaa atagaagggg gcagttgaca  48660
gcgttatatc caaagtgtct tctgtggtta attatattca gaaatttttag ccaattgttt  48720
tattctctaa atatgtactt tctgctcaag aaactatcat tgttcttctt ttccttgttt  48780
```

16

```
tacagtacag tgtttttaat taaccctcct gggttaactt taccaggtga aaatgattaa    48840
aagtgtaata ggttaacaat gaaactttaa gcttctattt ttcattgact cttaactgta    48900
catgatgtaa tgtattcagc gagccattca ggaccacttt ggcccatgga agaaatttaa    48960
aagtaagatc tacatgtatt gacatgaaaa tatgttctca gaaaaaagac taatgtattt    49020
aatgtcctac ttattttata agtatttaga atacctctgg acattttaaa acaatgatta    49080
ttgctagggt gtgtgattta taaagcaata gaagcgcttt ccctttctgt ttgtgtttta    49140
gattattata tcggtatgt tctgctatca taactttaca aatcttatgt aatatgggaa    49200
aatgagttaa ctttgctgtt ttccttcttt tacctgcctt tctaattctg tgggaataaa    49260
ggcgtttttg agacagccca ggtgtagtga gcagtccata tccatggatt ccacattcat    49320
ggattccacc aagcacagac caaaaatact cagaaaaaa ggggctggc tgtggtggct    49380
catgcatgta atcccagcac tttgggaggc taaggcaggc aaattgcttg agcccagaag    49440
ttcaagacag cctgggcaac atggcaaaac cctgtctcta cagaaaatac aaaaattagc    49500
caggcgtgca cctgtagtcc cagctactca ggaggccgag gtgcgaggat cacctgagcc    49560
tggaaggttg agactgcagt gagctatcat tgtgccaact ccagcctggt aacagagtgc    49620
ctttttttcaa aaaaaaaaa aaaaaaggat tgggaggat atgcatatgt tatattcaaa    49680
tacatgccat tttattcata tatcagggac ttgagcatcc tttgatcttg gtctctgccg    49740
ggtatcctgg gaccagcccc ctgtcgatac agagggaccg ctgtctaaga accgctggtc    49800
ctatctttga cttctggcgg aataggagct ccatgtaaaa aggaggagaa gctgcagcgg    49860
gttattagcc atttgtgagt caggtcactg taaaacttta tcaaaagttt aaaagacaaa    49920
aagcatcctc ataaaatgcc ttaaaaccac ctgttgaaat attacatata caattcatgt    49980
atactaatca tagagcatat taaagatatt ttagaagact agaaacttct attaaaccaa    50040
gtttctggat gtttccgtat tcatccttat tttccaggga cctgcataac ttttccagcg    50100
tgtaatagct acctgattga tattttttga attgaaatac tgaagtgact aaaatctaaa    50160
cttttttccat tctggccata ggatgcttat agaattttat gagtcaccag atccagaaag    50220
aagaaaaaga tttcctggga aaagtgttaa ttccaaatta agtatcaaga agactttacc    50280
atcaatgttg atcttaagtg gtttgactgc aggcatgctt atgaccgatg ctggaaggaa    50340
gctgtatgtg aacacctgga tatatggaac cctacttggc tgcctgtggg ttactattaa    50400
agcatagaca agtagctgtc tccagacagt gggatgtgct acattgtcta tttttggcgg    50460
ctgcacatga catcaaattg tttcctgaat ttattaagga gtgtaaataa agccttgttg    50520
attgaagatt ggataataga atttgtgacg aaagctgata tgcaatggtc ttgggcaaac    50580
atacctggtt gtacaacttt agcatcgggg ctgctggaag ggtaaaagct aaatggagtt    50640
tctcctgctc tgtccatttc ctatgaacta atgacaactt gagaaggctg ggaggattgt    50700
gtattttgca agtcagatgg ctgcattttt gagcattaat ttgcagcgta tttcactttt    50760
tctgttattt tcaatttatt acaacttgac agctccaagc tcttattact aaagtattta    50820
gtatcttgca gctagttaat atttcatctt ttgcttattt ctacaagtca gtgaaataaa    50880
ttgtatttag gaagtgtcag gatgttcaaa ggaaagggta aaaagtgttc atggggaaaa    50940
agctctgttt agcacatgat tttattgtat tgcgttatta gctgatttta ctcatttat    51000
atttgcaaaa taaatttcta atatttattg aaattgctta atttgcacac cctgtacaca    51060
cagaaaatgg tataaaatat gagaacgaag tttaaaattg tgactctgat tcattatagc    51120
agaactttaa atttcccagc tttttgaaga tttaagctac gctattagta cttccctttg    51180
tctgtgccat aagtgcttga aaacgttaag gttttctgtt ttgtttttgtt tttttaatat    51240
caaaagagtc ggtgtgaacc ttggttggac cccaagttca caagattttt aaggtgatga    51300
gagcctgcag acattctgcc tagatttact agcgtgtgcc ttttgcctgc ttctctttga    51360
tttcacagaa tattcattca gaagtcgcgt ttctgtagtg tggtggattc ccactgggct    51420
ctggtccttc ccttggatcc cgtcagtggt gctgctcagc ggcttgcacg tagacttgct    51480
aggaagaaat gcagagccag cctgtgctgc ccactttcag agttgaactc tttaagccct    51540
tgtgagtggg cttcaccagc tactgcagag gcattttgca tttgtctgtg tcaagaagtt    51600
caccttctca agccagtgaa atacagactt aattcgtcat gactgaacga atttgtttat    51660
ttcccattag gtttagtgga gctacacatt aatatgtatc gccttagagc aagagctgtg    51720
ttccaggaac cagatcacga tttttagcca tggaacaata tatcccatgg gagaagacct    51780
ttcagtgtga actgttctat ttttgtgtta taatttaaac ttcgatttcc tcatagtcct    51840
ttaagttgac atttctgctt actgctactg gattttgct gcagaaatat atcagtggcc    51900
cacattaaac ataccagttg gatcatgata agcaaaatga aacaaataat gattaaggga    51960
aaattaagtg actgtgttac actgcttctc ccatgccaga gaataaactc tttcaagcat    52020
catctttgaa gagtcgtgtg gtgtgaattg gtttgtgtac attagaatgt atgcacacat    52080
ccatggacac tcaggatata gttggcctaa taatcggggc atgggtaaaa cttatgaaaa    52140
tttcctcatg ctgaattgta attttctctt acctgtaaag taaaatttag atcaattcca    52200
tgtctttgtt aagtacaggg atttaatata tttttgaatat aatgggtatg ttctaaattt    52260
gaacttgag aggcaatact gttggaatta tgtggattct aactcatttt aacaaggtag    52320
cctgacctgc ataagatcac ttgaatgtta ggtttcatag aactatacta atcttctcac    52380
aaaaggtcta taaaatacag tcgttgaaaa aaattttgta tcaaaatgtt tggaaaatta    52440
```

```
gaagcttctc cttaacctgt attgatactg acttgaatta ttttctaaaa ttaagagccg   52500
tatacctacc tgtaagtctt ttcacatatc atttaaactt ttgtttgtat tattactgat   52560
ttacagctta gttattaatt tttctttata agaatgccgt cgatgtgcat gcttttatgt   52620
ttttcagaaa agggtgtgtt tggatgaaag taaaaaaaaa aataaaatct ttcactgtct   52680
ctaatggctg tgctgtttaa catttttttga ccctaaaatt caccaacagt ctcccagtac   52740
ataaaatagg cttaatgact ggccctgcat tcttcacaat attttttccct aagctttgag   52800
caaagtttta aaaaaataca ctaaaataat caaaactgtt aagcagtata ttagtttggt   52860
tatataaatt catctgcaat ttataagatg catggccgat gttaatttgc ttggcaattc   52920
tgtaatcatt aagtgatctc agtgaaacat gtcaaatgcc ttaaattaac taagttggtg   52980
aataaaagtg ccgatctggc taactcttac accatacata ctgatagttt ttcatatgtt   53040
tcatttccat gtgattttta aaatttagag tggcaacaat tttgcttaat atgggttaca   53100
taagctttat tttttccttt gttcataatt atattctttg aataggtctg tgtcaatcaa   53160
gtgatctaac tagactgatc atagatagaa ggaaataagg ccaagttcaa gaccagcctg   53220
ggcaacatat cgagaacctg tctacaaaaa aattaaaaaa aattagccag gcatggtggc   53280
gtacactgag tagtttgtcc cagctactcg ggaggtgag gtgggagga cgcttcagcc   53340
caggaggttg agattgcagt gagccatgga cataccactg cactacagcc taggtaacag   53400
cacgagaccc caactcttag aaaatgaaaa ggaaatatag aaatataaaa tttgcttatt   53460
atagacacac agtaactccc agatatgtac cacaaaaaat gtgaaaagag agagaaatgt   53520
ctaccaaagc agtattttgt gtgtataatt gcaagcgcat agtaaaataa ttttaacctt   53580
aatttgtttt tagtagtgtt tagattgaag attgagtgaa atattttctt ggcagatatt   53640
ccgtatctgg tggaaagcta caatgcaatg tcgttgtagt tttgcatggc ttgctttata   53700
aacaagattt tttctccctc cttttgggcc agttttcatt acgagtaact cacacttttt   53760
gattaaagaa cttgaaatta cgttatcact tagtataatt gacattatat agagactatg   53820
taacatgcaa tcattagaat caaaattagt actttggtca aaatatttac aacattcaca   53880
tacttgtcaa atattcatgt aattaactga atttaaaacc ttcaactatt atgaagtgct   53940
cgtctgtaca atcgctaatt tactcagttt agagtagcta caactcttcg atactatcat   54000
caatatttga catcttttcc aatttgtgta tgaaaagtaa atctattcct gtagcaactg   54060
gggagtcata tatgaggtca aagacatata ccttgttatt ataatatgta tactataata   54120
atagctggtt atcctgagca ggggaaaagg ttatttttag gaaaaccact tcaaatagaa   54180
agctgaagta cttctaatat actgagggaa gtataatatg tggaacaaac tctcaacaaa   54240
atgtttattg atgttgatga aacagatcag tttttccatc cggattatta ttggttcatg   54300
attttatatg tgaatatgta agatatgttc tgcaatttta taaatgttca tgtctttttt   54360
taaaaaaggt gctattgaaa ttctgtgtct ccagcaggca agaatacttg actaactctt   54420
tttgtctctt tatggtattt tcagaataaa gtctgacttg tgttttttgag attattggtg   54480
cctcattaat tcagcaataa aggaaaatat gcatctcaaa aattggtgat aaaaagttat   54540
ttcttgtata tgtgataaag tttacatgtt gtgtatatat gttgtattgc caaatacggc   54600
tattaaatac tacgtcatat tttaaaggtt cagtttgtag tgatagtaaa caagcagtgc   54660
actaagcctc ttgcgggcat catctcatct cactgtcatc acaaacccca tgccacagcg   54720
tagcttgacc actaaaagta atgcatctgc aagcatactg ccaggttttg gatagtttgt   54780
accaacagtt accttatcaa ggtaaatccc agactctaaa agagttggtg ctgtgtcact   54840
acatgcataa ctttaaataa atttcctgcc gggcgcggtg gctcacgcct gtaatcccag   54900
cagtttggga ggccgaggca agtggatcac ttgaggtcag gagtttgaga ccagcctggc   54960
caacgtggtg aaaccctgtc tctactaaaa atacaaaaat tagccaggcg tgtggtggca   55020
ggcacctgta atcccagcta cttgggagga tgaggcagga gaatcatttg aatcctgcag   55080
gcggaggttg cagtgagcca agatggcgtc attgcactcc agcctgggcg acaagagcga   55140
gactccgtat taaaaaaaaa aaaaaaaaaa aaaaaaatt cctctcctgt ttgagctttc   55200
ccttacctgt aaagaggggga gaatatgtat ttacttcaaa gagttcaggg aaatgactct   55260
cactagtttg agattctagg tataaaaata cattcttata taattttaac accaatgtga   55320
gagattatta ttcttgctaa accaattcag ttttatttgc tgtctaaaat gtgtgaataa   55380
gtaattgtcc attattttct gaagtgtttt ggaactcaac acatgattgt gaggaggatt   55440
tgttgctaaa catctttctg gttattcaag ctcgtgtata ctgtgctctg ttgagacatg   55500
cagagttact ttctgtctgg gtcacaggtc agttcttgat agttttcgga caattaacca   55560
gttttcattt gcccatgacc acctttattc ttttttcctca actgcaccca tcttttataa   55620
ggtctttcag tttattgcag agaagatggt ggagaaaagc cggaattccc acccaccgct   55680
gccatcccca tgtttatca ttggctagag tggaaaatag cagtaactac tgtgagagat   55740
catttgttta tataatggaa acaaagatga ggaaagaacc tggcttagat cagagaactg   55800
atgtatttag attctttttt tttttttttt taagacggag tgttgctctg ttgcccagac   55860
tggagtacag tggctcaatc tcggctcact gcaacctcca tttccctggt tcaagcaatt   55920
atcctgcctc agcctcccaa gtatttggga ttacaggcgt gttccaccac acctggctaa   55980
ttttttgtat ttttagtaga dacggggtttt cgccatgttg gccaggctgg tctcgaaatc   56040
ctgacctcag atgatccacc cgccttggcc tcccaaagtg ctgggattac aggcgcgagc   56100
```

```
caccgcgcct ggcccaatgt atttggattc ttaaagaaca cttttcaaatt aaatatcagt    56160
tgaagagaac tagaactaaa gaatttctgt gtcaaactgt ttagcaaatg taagtagaag    56220
ctgggagatg tgtcctggaa tgaatgaata catcagtaaa ataccatacg tatgttatga    56280
tgttattgtt ccttgcctt ggttgatttg gttttactgt gaaataattt tcaatataga    56340
attgtgatcg ttggaatttg gtcatctact agaaaatgag aaagaagtta atagctatct    56400
tccttaaaga tttctgaggt tgggattaag gtagtgttcc caaggtgttc taaaacggca    56460
gcgagagctg tgcactcact tcacaaattt gaattcctgc tctgtgttag gcgctg        56516
```

`<210> 2`
`<211> 23`
`<212> DNA`
`<213> Homo sapiens`
`<400> 2`

`ggtcgtccag cgcttggtag aag`                                              `23`

`<210> 3`
`<211> 5227`
`<212> DNA`
`<213> Homo sapiens`
`<220>`
`<221> polyA_signal`
`<222> 5180..5186`
`<223> AATAAA`
`<400> 3`

```
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc      54
                                    Met Arg Tyr Leu Leu Pro Ser Val
                                     1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg      102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
         10              15              20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac      150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25               30              35              40

gac cgg ctc tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag      198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
              45              50              55

aat tac acc ggg gtc cag ata ttg cta tat gga gat ttg cca aaa aat      246
Asn Tyr Thr Gly Val Gln Ile Leu Leu Tyr Gly Asp Leu Pro Lys Asn
              60              65              70

aaa gaa aat ata ata tat tta gca aat cat caa agc aca gtt gac tgg      294
Lys Glu Asn Ile Ile Tyr Leu Ala Asn His Gln Ser Thr Val Asp Trp
         75              80              85

att gtt gct gac atc ttg gcc atc agg cag aat gcg cta gga cat gtg      342
Ile Val Ala Asp Ile Leu Ala Ile Arg Gln Asn Ala Leu Gly His Val
         90              95              100

cgc tac gtg ctg aaa gaa ggg tta aaa tgg ctg cca ttg tat ggg tgt      390
Arg Tyr Val Leu Lys Glu Gly Leu Lys Trp Leu Pro Leu Tyr Gly Cys
105              110             115             120

tac ttt gct cag cat gga gga atc tat gta aag cgc agt gcc aaa ttt      438
Tyr Phe Ala Gln His Gly Gly Ile Tyr Val Lys Arg Ser Ala Lys Phe
              125             130             135

aac gag aaa gag atg cga aac aag ttg cag agc tac gtg gac gca gga      486
Asn Glu Lys Glu Met Arg Asn Lys Leu Gln Ser Tyr Val Asp Ala Gly
              140             145             150

act cca atg tat ctt gtg att ttt cca gaa ggt aca agg tat aat cca      534
Thr Pro Met Tyr Leu Val Ile Phe Pro Glu Gly Thr Arg Tyr Asn Pro
              155             160             165

gag caa aca aaa gtc ctt tca gct agt cag gca ttt gct gcc caa cgt      582
Glu Gln Thr Lys Val Leu Ser Ala Ser Gln Ala Phe Ala Ala Gln Arg
         170             175             180

ggc ctt gca gta tta aaa cat gtg cta aca cca cga ata aag gca act      630
Gly Leu Ala Val Leu Lys His Val Leu Thr Pro Arg Ile Lys Ala Thr
185              190             195             200
```

19

```
cac gtt gct ttt gat tgc atg aag aat tat tta gat gca att tat gat      678
His Val Ala Phe Asp Cys Met Lys Asn Tyr Leu Asp Ala Ile Tyr Asp
            205                 210                 215
gtt acg gtg gtt tat gaa ggg aaa gac gat gga ggg cag cga aga gag      726
Val Thr Val Val Tyr Glu Gly Lys Asp Asp Gly Gly Gln Arg Arg Glu
            220                 225                 230
tca ccg acc atg acg gaa ttt ctc tgc aaa gaa tgt cca aaa att cat      774
Ser Pro Thr Met Thr Glu Phe Leu Cys Lys Glu Cys Pro Lys Ile His
            235                 240                 245
att cac att gat cgt atc gac aaa aaa gat gtc cca gaa gaa caa gaa      822
Ile His Ile Asp Arg Ile Asp Lys Lys Asp Val Pro Glu Glu Gln Glu
            250                 255                 260
cat atg aga aga tgg ctg cat gaa cgt ttc gaa atc aaa gat aag atg      870
His Met Arg Arg Trp Leu His Glu Arg Phe Glu Ile Lys Asp Lys Met
265                 270                 275                 280
ctt ata gaa ttt tat gag tca cca gat cca gaa aga aga aaa aga ttt      918
Leu Ile Glu Phe Tyr Glu Ser Pro Asp Pro Glu Arg Arg Lys Arg Phe
                285                 290                 295
cct ggg aaa agt gtt aat tcc aaa tta agt atc aag aag act tta cca      966
Pro Gly Lys Ser Val Asn Ser Lys Leu Ser Ile Lys Lys Thr Leu Pro
            300                 305                 310
tca atg ttg atc tta agt ggt ttg act gca ggc atg ctt atg acc gat     1014
Ser Met Leu Ile Leu Ser Gly Leu Thr Ala Gly Met Leu Met Thr Asp
            315                 320                 325
gct gga agg aag ctg tat gtg aac acc tgg ata tat gga acc cta ctt     1062
Ala Gly Arg Lys Leu Tyr Val Asn Thr Trp Ile Tyr Gly Thr Leu Leu
            330                 335                 340
ggc tgc ctg tgg gtt act att aaa gca tag acaagtagct gtctccagac       1112
Gly Cys Leu Trp Val Thr Ile Lys Ala  *
345                 350
agtgggatgt gctacattgt ctattttttgg cggctgcaca tgacatcaaa ttgtttcctg   1172
aatttattaa ggagtgtaaa taaagccttg ttgattgaag attggataat agaatttgtg   1232
acgaaagctg atatgcaatg gtcttgggca aacatacctg gttgtacaac tttagcatcg   1292
gggctgctgg aagggtaaaa gctaaatgga gtttctcctg ctctgtccat ttcctatgaa   1352
ctaatgacaa cttgagaagg ctgggaggat tgtgtatttt gcaagtcaga tggctgcatt   1412
tttgagcatt aatttgcagc gtatttcact tttttctgtta ttttcaattt attacaactt   1472
gacagctcca agctcttatt actaaagtat ttagtatctt gcagctagtt aatatttcat   1532
cttttgctta tttctacaag tcagtgaaat aaattgtatt taggaagtgt caggatgttc   1592
aaaggaaagg gtaaaaagtg ttcatgggga aaaagctctg tttagcacat gatttttattg   1652
tattgcgtta ttagctgatt ttactcattt tatatttgca aaataaattt ctaatatttta  1712
ttgaaattgc ttaatttgca caccctgtac acacagaaaa tggtataaaa tatgagaacg   1772
aagtttaaaa ttgtgactct gattcattat agcagaactt taaatttccc agctttttga   1832
agatttaagc tacgctatta gtacttccct ttgtctgtgc cataagtgct tgaaaacgtt   1892
aaggtttttct gtttttgtttt gtttttttaa tatcaaaaga gtcggtgtga accttggttg  1952
gaccccaagt tcacaagatt tttaaggtga tgagagcctg cagacattct gcctagattt   2012
actagcgtgt gcctttttgcc tgcttctctt tgatttcaca gaatattcat tcagaagtcg   2072
cgtttctgta gtgtggtgga ttcccactgg gctctggtcc ttcccttgga tcccgtcagt   2132
ggtgctgctc agcggcttgc acgtagactt gctaggaaga aatgcagagc cagcctgtgc   2192
tgcccacttt cagagttgaa ctctttaaag cccttgtgag tgggcttcac cagctactgc   2252
agaggcattt tgcatttgtc tgtgtcaaga agttcacctt ctcaagccag tgaaatacag   2312
acttaattcg tcatgactga acgaatttgt ttatttccca ttaggttttag tggagctaca   2372
cattaatatg tatcgcctta gagcaagagc tgtgttccag gaaccagatc acgattttta   2432
gccatggaac aatatatccc atgggagaag acctttcagt gtgaactgtt ctattttttgt   2492
gttataattt aaacttcgat ttcctcatag tcctttaagt tgacatttct gcttactgct   2552
actggatttt tgctgcagaa atatatcagt ggcccacatt aaacatacca gttggatcat   2612
gataagcaaa atgaaagaaa taatgattaa gggaaaatta agtgactgtg ttacactgct   2672
tctcccatgc cagagaataa actctttcaa gcatcatctt tgaagagtcg tgtggtgtga   2732
attggtttgt gtacattaga atgtatgcac acatccatgg acactcagga tatagttggc   2792
ctaataatcg gggcatgggt aaaacttatg aaaatttcct catgctgaat tgtaatttttc   2852
tcttacctgt aaagtaaaat ttagatcaat tccatgtctt tgttaagtac agggatttaa   2912
tatattttga atataatggg tatgttctaa atttgaactt tgagaggcaa tactgttgga   2972
```

```
attatgtgga ttctaactca ttttaacaag gtagcctgac ctgcataaga tcacttgaat    3032
gttaggtttc atagaactat actaatcttc tcacaaaagg tctataaaat acagtcgttg    3092
aaaaaaattt tgtatcaaaa tgtttggaaa attagaagct tctccttaac ctgtattgat    3152
actgacttga attattttct aaaattaaga gccgtatacc tacctgtaag tcttttcaca    3212
tatcatttaa acttttgttt gtattattac tgatttacag cttagttatt aattttttctt   3272
tataagaatg ccgtcgatgt gcatgctttt atgtttttca gaaaagggtg tgtttggatg    3332
aaagtaaaaa aaaaaataaa atctttcact gtctctaatg gctgtgctgt ttaacatttt    3392
ttgaccctaa aattcaccaa cagtctccca gtacataaaa taggcttaat gactggccct    3452
gcattcttca caatattttt ccctaagctt tgagcaaagt tttaaaaaaa tacactaaaa    3512
taatcaaaac tgttaagcag tatattagtt tggttatata aattcatctg caatttataa    3572
gatgcatggc cgatgttaat ttgcttggca attctgtaat cattaagtga tctcagtgaa    3632
acatgtcaaa tgccttaaat taactaagtt ggtgaataaa agtgccgatc tggctaactc    3692
ttacaccata catactgata gttttttcata tgtttcattt ccatgtgatt tttaaaattt    3752
agagtggcaa caattttgct taatatgggt tacataagct ttatttttttc ctttgttcat   3812
aattatattc tttgaatagg tctgtgtcaa tcaagtgatc taactagact gatcatagat    3872
agaaggaaat aaggccaagt tcaagaccag cctgggcaac atatcgagaa cctgtctaca    3932
aaaaaattaa aaaaaattag ccaggcatgg tggcgtacac tgagtagttt gtcccagcta    3992
ctcgggaggg tgaggtggga ggatcgcttc agcccaggag gttgagattg cagtgagcca    4052
tggacatacc actgcactac agcctaggta acagcacgag accccaactc ttagaaaatg    4112
aaaaggaaat atagaaatat aaaatttgct tattatagac acacagtaac tcccagatat    4172
gtaccacaaa aaatgtgaaa agagagagaa atgtctacca aagcagtatt ttgtgtgtat    4232
aattgcaagc gcatagtaaa ataatttttaa ccttaatttg ttttttagtag tgtttagatt   4292
gaagattgag tgaaatattt tcttggcaga tattccgtat ctggtggaaa gctacaatgc    4352
aatgtcgttg tagttttgca tggcttgctt tataaacaag atttttttctc cctcctttttg   4412
ggccagtttt cattacgagt aactcacact ttttgattaa agaacttgaa attacgttat    4472
cacttagtat aattgacatt atatagagac tatgtaacat gcaatcatta gaatcaaaat    4532
tagtactttg gtcaaaatat ttacaacatt cacatacttg tcaaatattc atgtaattaa    4592
ctgaatttaa aaccttcaac tattatgaag tgctcgtctg tacaatcgct aatttactca    4652
gtttagagta gctacaactc ttcgatacta tcatcaatat ttgacatctt ttccaatttg    4712
tgtatgaaaa gtaaatctat tcctgtagca actggggagt catatatgag gtcaaagaca    4772
tataccttgt tattataata tgtatactat aataatagct ggttatcctg agcaggggaa    4832
aaggttattt ttaggaaaac cacttcaaat agaaagctga agtacttcta atatactgag    4892
ggaagtataa tatgtggaac aaactctcaa caaaatgttt attgatgttg atgaaacaga    4952
tcagttttttc catccggatt attattggtt catgatttta tatgtgaata tgtaagatat    5012
gttctgcaat tttataaatg ttcatgtctt tttttaaaaa aggtgctatc gaaattctgt    5072
gtctccagca ggcaagaata cttgactaac tcttttttgtc tctttatggt attttcagaa    5132
taaagtctga cttgtgtttt tgagattatt ggtgcctcat taattcagca ataaaggaaa    5192
atatgcattt caaaaanaaa aaaaaaaaa aaaaa                                5227
<210> 4
<211> 353
<212> PRT
<213> Homo sapiens
<220>
<221> HELIX
<222> 1..33
<223> Rao  and  Argos  identification  method,  potential  helix
<221> HELIX
<222> 4..20
<223> Klein,  Kanehisa  and  DeLisi  identification  method,  potential  helix
<221> HELIX
<222> 4..24
<223> Eisenberg,  Schwarz,  Komarony,  Wall  identification  method,
potential  helix
<221> MYRISTATE
<222> 12..16
<223> Prosite  match
<221> HELIX
<222> 50..70
<223> Eisenberg,  Schwarz,  Komarony,  Wall  identification  method,
potential  helix
<221> CARBOHYD
```

```
<222> 57..59
<223> Prosite  match
<221> HELIX
<222> 76..96
<223> Eisenberg,  Schwarz,  Komarony,  Wall  identification  method,
potential  helix
<221> PHOSPHORYLATION
<222> 78
<223> potential  Tyrosine  kinase  site,  Prosite  match
<221> PHOSPHORYLATION
<222> 84
<223> potential  caseine  kinase  II  site,  Prosite  match
<221> SITE
<222> 94..115
<223> potential  Leucine  zipper  site,  Prosite  match
<221> MYRISTATE
<222> 119..123
<223> potential  site,  Prosite  match
<221> PHOSPHORYLATION
<222> 133
<223> potential  protein  kinase  C,  Prosite  match
<221> PHOSPHORYLATION
<222> 147
<223> potential  caseine  kinase  II  site,  Prosite  match
<221> PHOSPHORYLATION
<222> 194
<223> potential  protein  kinase  C,  Prosite  match
<221> PHOSPHORYLATION
<222> 215
<223> potential  Tyrosine  kinase  site,  Prosite  match
<221> SULFATATION
<222> 221
<223> Prosite  match
<221> PHOSPHORYLATION
<222> 233
<223> potential  cAMP  and  cGMP  dependant  protein  kinase  site,  Prosite
match
<221> PHOSPHORYLATION
<222> 235
<223> potential  caseine  kinase  II  site,  Prosite  match
<221> PHOSPHORYLATION
<222> 306
<223> potential  protein  kinase  C,  Prosite  match
<221> HELIX
<222> 310..330
<223> Eisenberg,  Schwarz,  Komarony,  Wall  identification  method,
potential  helix
<221> MYRISTATE
<222> 319..323
<223> Prosite  match
<221> MYRISTATE
<222> 323..327
<223> Prosite  match
<221> AMIDATION
<222> 329
<223> Prosite  match
<221> HELIX
<222> 333..353
<223> Eisenberg,  Schwarz,  Komarony,  Wall  identification  method,
potential  helix
<221> MYRISTATE
```

```
<222> 341..345
<223> Prosite match
<221> PHOSPHORYLATION
<222> 350
<223> potential protein kinase C, Prosite match
<400> 4
```

| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1       5       10       15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
      20       25       30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
      35       40       45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu
      50       55       60
Leu Tyr Gly Asp Leu Pro Lys Asn Lys Glu Asn Ile Ile Tyr Leu Ala
65       70       75       80
Asn His Gln Ser Thr Val Asp Trp Ile Val Ala Asp Ile Leu Ala Ile
      85       90       95
Arg Gln Asn Ala Leu Gly His Val Arg Tyr Val Leu Lys Glu Gly Leu
      100       105       110
Lys Trp Leu Pro Leu Tyr Gly Cys Tyr Phe Ala Gln His Gly Gly Ile
      115       120       125
Tyr Val Lys Arg Ser Ala Lys Phe Asn Glu Lys Glu Met Arg Asn Lys
      130       135       140
Leu Gln Ser Tyr Val Asp Ala Gly Thr Pro Met Tyr Leu Val Ile Phe
145       150       155       160
Pro Glu Gly Thr Arg Tyr Asn Pro Glu Gln Thr Lys Val Leu Ser Ala
      165       170       175
Ser Gln Ala Phe Ala Ala Gln Arg Gly Leu Ala Val Leu Lys His Val
      180       185       190
Leu Thr Pro Arg Ile Lys Ala Thr His Val Ala Phe Asp Cys Met Lys
      195       200       205
Asn Tyr Leu Asp Ala Ile Tyr Asp Val Thr Val Val Tyr Glu Gly Lys
      210       215       220
Asp Asp Gly Gly Gln Arg Arg Glu Ser Pro Thr Met Thr Glu Phe Leu
225       230       235       240
Cys Lys Glu Cys Pro Lys Ile His Ile His Ile Asp Arg Ile Asp Lys
      245       250       255
Lys Asp Val Pro Glu Glu Gln Glu His Met Arg Arg Trp Leu His Glu
      260       265       270
Arg Phe Glu Ile Lys Asp Lys Met Leu Ile Glu Phe Tyr Glu Ser Pro
      275       280       285
Asp Pro Glu Arg Arg Lys Arg Phe Pro Gly Lys Ser Val Asn Ser Lys
      290       295       300
Leu Ser Ile Lys Lys Thr Leu Pro Ser Met Leu Ile Leu Ser Gly Leu
305       310       315       320
Thr Ala Gly Met Leu Met Thr Asp Ala Gly Arg Lys Leu Tyr Val Asn
      325       330       335
Thr Trp Ile Tyr Gly Thr Leu Leu Gly Cys Leu Trp Val Thr Ile Lys
      340       345       350
Ala

```
<210> 5
<211> 364
<212> PRT
<213> Homo sapiens
<400> 5
```

Met Leu Leu Ser Leu Val Leu His Thr Tyr Ser Met Arg Tyr Leu Leu
1       5       10       15
Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp
      20       25       30
Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln

```
              35                    40                    45
Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe
      50                    55                    60
Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu Leu Tyr Gly Asp Leu
65                    70                    75                    80
Pro Lys Asn Lys Glu Asn Ile Ile Tyr Leu Ala Asn His Gln Ser Thr
              85                    90                    95
Val Asp Trp Ile Val Ala Asp Ile Leu Ala Ile Arg Gln Asn Ala Leu
              100                   105                   110
Gly His Val Arg Tyr Val Leu Lys Glu Gly Leu Lys Trp Leu Pro Leu
              115                   120                   125
Tyr Gly Cys Tyr Phe Ala Gln His Gly Gly Ile Tyr Val Lys Arg Ser
      130                   135                   140
Ala Lys Phe Asn Glu Lys Glu Met Arg Asn Lys Leu Gln Ser Tyr Val
145                   150                   155                   160
Asp Ala Gly Thr Pro Met Tyr Leu Val Ile Phe Pro Glu Gly Thr Arg
                  165                   170                   175
Tyr Asn Pro Glu Gln Thr Lys Val Leu Ser Ala Ser Gln Ala Phe Ala
              180                   185                   190
Ala Gln Arg Gly Leu Ala Val Leu Lys His Val Leu Thr Pro Arg Ile
      195                   200                   205
Lys Ala Thr His Val Ala Phe Asp Cys Met Lys Asn Tyr Leu Asp Ala
      210                   215                   220
Ile Tyr Asp Val Thr Val Val Tyr Glu Gly Lys Asp Asp Gly Gly Gln
225                   230                   235                   240
Arg Arg Glu Ser Pro Thr Met Thr Glu Phe Leu Cys Lys Glu Cys Pro
                  245                   250                   255
Lys Ile His Ile His Ile Asp Arg Ile Asp Lys Lys Asp Val Pro Glu
              260                   265                   270
Glu Gln Glu His Met Arg Arg Trp Leu His Glu Arg Phe Glu Ile Lys
              275                   280                   285
Asp Lys Met Leu Ile Glu Phe Tyr Glu Ser Pro Asp Pro Glu Arg Arg
      290                   295                   300
Lys Arg Phe Pro Gly Lys Ser Val Asn Ser Lys Leu Ser Ile Lys Lys
305                   310                   315                   320
Thr Leu Pro Ser Met Leu Ile Leu Ser Gly Leu Thr Ala Gly Met Leu
                  325                   330                   335
Met Thr Asp Ala Gly Arg Lys Leu Tyr Val Asn Thr Trp Ile Tyr Gly
              340                   345                   350
Thr Leu Leu Gly Cys Leu Trp Val Thr Ile Lys Ala
      355                   360
```

```
<210> 6
<211> 26
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..26
<223> primer oligonucleotide GC1.5p.1
<400> 6
ctgtccctgg tgctccacac gtactc                                      26
<210> 7
<211> 26
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..26
<223> primer oligonucleotide GC1.5p.2
<400> 7
tggtgctcca cacgtactcc atgcgc                                      26
```

24

```
<210> 8
<211> 27
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..27
<223> primer oligonucleotide pg15RACT196
<400> 8
caatatctgg accccggtgt aattctc                                    27
<210> 9
<211> 34
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..34
<223> primer oligonucleotide GC1.3p
<400> 9
cttgcctgct ggagacacag aatttcgata gcac                            34
<210> 10
<211> 24
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..24
<223> primer oligonucleotide PGRT32
<400> 10
tttttttttt ttttttttttg aaat                                     24
<210> 11
<211> 6
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 160..165
<223> box2 from SEQID4,   present in AF003136,  P33333,  P26647,  U89336,
U56417,  AB005623.
<400> 11
Phe Pro Glu Gly Thr Arg
1               5
<210> 12
<211> 6
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 129..134
<223> box2  from  Z72511
<400> 12
Phe Pro Glu Gly Thr Asp
1               5
<210> 13
<211> 6
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 223..228
<223> box2  from  P38226,  Z49770
```

```
<400> 13
Phe Pro Glu Gly Thr Asn
1               5
<210> 14
<211> 6
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 90..95
<223> box2 from Z49860 and Z29518
<400> 14
Phe Val Glu Gly Thr Arg
1               5
<210> 15
<211> 9
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 211..219
<223> box3 from SEQID4, present in AF003136
<400> 15
Leu Asp Ala Ile Tyr Asp Val Thr Val
1               5
<210> 16
<211> 9
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 204..212
<223> box3 from Z72511
<400> 16
Val Glu Tyr Ile Tyr Asp Ile Thr Ile
1               5
<210> 17
<211> 9
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 271..279
<223> box3 from P38226
<400> 17
Ile Glu Ser Leu Tyr Asp Ile Thr Ile
1               5
<210> 18
<211> 9
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 265..273
<223> box3 from Z49770
<400> 18
Leu Asp Ala Ile Tyr Asp Val Thr Ile
1               5
<210> 19
<211> 9
<212> PRT
```

```
<213> Homo sapiens
<220>
<221> SITE
<222> 138..146
<223> box3   fromZ49860
<400> 19
Val Pro Ala Ile Tyr Asp Met Thr Val
1               5
<210> 20
<211> 9
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 218..226
<223> box3   from   Z29518
<400> 20
Val Pro Ala Ile Tyr Asp Thr Thr Val
1               5
<210> 21
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-123
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-123.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-123.mis2
<400> 21
tttctcatcc tcacacctca ctgcgcccct cctgaaccca ctccttt                    47
<210> 22
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-26
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-26.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-26.mis2
<400> 22
ccctgtnaga cacgtcctgt atcgttgttg agatgggaaa gtgcatc                    47
<210> 23
<211> 47
<212> DNA
<213> Homo Sapiens
```

27

```
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-14
<221> allele
<222> 24
<223> polymorphic base T
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-14.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-14.mis2
<400> 23
gcagggagca gaccagacat gatttgttct agtctagctg attcata              47
<210> 24
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-77, extracted from SEQ ID1 12057 12103
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-77.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-77.mis2
<400> 24
gctgttcaga ctaaacttgg agactacagt cagtcagaga acttgct             47
<210> 25
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-217, extracted from SEQ ID1 34469 34515
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-217.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-217.mis2
<400> 25
atatagttca cgttatgttc atacttaatt gttgcatttt gtttgcc             47
<210> 26
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-67, extracted from SEQ ID1 51612 51658
```

```
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-67.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-67.mis2
<400> 26
gccagtgaaa tacagactta attcgtcatg actgaacgaa tttgttt                    47
<210> 27
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-213
<221> allele
<222> 24
<223> polymorphic base T
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-213.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-213.mis2
<400> 27
ccttagcatt caagcccctg agctctggtg ttgtccaccc ctggggg                    47
<210> 28
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-221
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-221.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-221.mis2
<400> 28
agcttgagaa accagaaaag ccaaaaggag gctcctacca catgggt                    47
<210> 29
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-135
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
```

```
<222> 1..23
<223> potential microsequencing oligo 99-135.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-135.mis2
<400> 29
agtcactata tctatgttta atgaagatag aaagagatgc agaaatg                    47
<210> 30
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-123, variant version of SEQ ID21
<221> allele
<222> 24
<223> base T ; C in SEQ ID21
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-123.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-123.mis2
<400> 30
tttctcatcc tcacacctca ctgtgcccct cctgaaccca ctcctttt                   47
<210> 31
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-26, variant version of SEQ ID22
<221> allele
<222> 24
<223> base A ; G in SEQ ID22
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-26.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-26.mis2
<400> 31
ccctgtnaga cacgtcctgt atcattgttg agatgggaaa gtgcatc                    47
<210> 32
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-14, variant version of SEQ ID23
<221> allele
<222> 24
<223> base C ; T in SEQ ID23
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-14.mis1
<221> primer_bind
<222> 25..47
```

```
<223> complement potential microsequencing oligo 4-14.mis2
<400> 32
gcagggagca gaccagacat gatctgttct agtctagctg attcata                    47
<210> 33
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-77, variant version of SEQ ID24
<221> allele
<222> 24
<223> base G ; C in SEQ ID24
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-77.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-77.mis2
<400> 33
gctgttcaga ctaaacttgg agagtacagt cagtcagaga acttgct                    47
<210> 34
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-217, variant version of SEQ ID25
<221> allele
<222> 24
<223> base T ; C in SEQ ID25
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-217.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-217.mis2
<400> 34
atatagttca cgttatgttc atatttaatt gttgcatttt gtttgcc                    47
<210> 35
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-67, variant version of SEQ ID26
<221> allele
<222> 24
<223> base T ; C in SEQ ID26
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-67.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-67.mis2
<400> 35
gccagtgaaa tacagactta atttgtcatg actgaacgaa tttgttt                    47
<210> 36
```

31

```
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-213, variant version of SEQ ID27
<221> allele
<222> 24
<223> base C ; T in SEQ ID27
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-213.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-213.mis2
<400> 36
ccttagcatt caagcccctg agccctggtg ttgtccaccc ctggggg                  47
<210> 37
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-221, variant version of SEQ ID28
<221> allele
<222> 24
<223> base C ; A in SEQ ID28
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-221.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-221.mis2
<400> 37
agcttgagaa accagaaaag ccacaaggag gctcctacca catgggt                  47
<210> 38
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-135, variant version of SEQ ID29
<221> allele
<222> 24
<223> base G ; A in SEQ ID29
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-135.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-135.mis2
<400> 38
agtcactata tctatgttta atggagatag aaagagatgc agaaatg                  47
<210> 39
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
```

```
<221> primer_bind
<222> 1..18
<223> upstream amplification primer 99-123-PU
<400> 39                                                          18
aaagccagga ctagaagg
<210> 40
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer 4-26-PU
<400> 40                                                          18
tacagccctg taagacac
<210> 41
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer 4-14-PU
<400> 41                                                          18
tctaacctct catccaac
<210> 42
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer 4-77-PU, extracted from SEQ ID1 11930
11947
<400> 42                                                          18
tgttgattta caggcggc
<210> 43
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer 99-217-PU, extracted from SEQ ID1 34216
34234
<400> 43                                                          19
ggtgggaatt tactatatg
<210> 44
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer 4-67-PU, extracted from SEQ ID1 51596
51613
<400> 44                                                          18
aagttcacct tctcaagc
<210> 45
<211> 20
<212> DNA
```

```
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> upstream amplification primer 99-213-PU
<400> 45
atactggcag cgtgtgcttc                                         20
<210> 46
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer 99-221-PU
<400> 46
cccttttct tcactgttc                                          19
<210> 47
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer 99-135-PU
<400> 47
tggaagttgt tattgccc                                          18
<210> 48
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer 99-123-RP
<400> 48
tattcagaaa ggagtggg                                          18
<210> 49
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer 4-26-RP
<400> 49
tgaggactgc taggaaag                                          18
<210> 50
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer 4-14-RP
<400> 50
gactgtatcc tttgatgcac                                        20
<210> 51
<211> 20
<212> DNA
<213> Homo Sapiens
```

—

```
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer 4-77-RP, extracted from SEQ ID1 12339
123
58 complement
<400> 51
ggaaaggtac tcattcatag                                                      20
<210> 52
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer 99-217-RP, extracted from SEQ ID1 34625
34645 complement
<400> 52
gtttattttg tgtgagcttt g                                                    21
<210> 53
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer 4-67-RP, extracted from SEQ ID1 51996
520
15 complement
<400> 53
tgaaagagtt tattctctgg                                                      20
<210> 54
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer 99-213-RP
<400> 54
ttattgcccc acatgcttga g                                                    21
<210> 55
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> downstream amplification primer 99-221-RP
<400> 55
tcattcgtct ggctaggtc                                                       19
<210> 56
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer 99-135-RP
<400> 56
aaacacctcc cattgtgc                                                        18
```

```
<210> 57
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1482
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1482.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1482.mis2
<400> 57
agtgaagtct gagggggaaa aatcaaccct atagagggaa ggatctg                47
<210> 58
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-73, extracted from SED ID1 13657 13703
<221> allele
<222> 24
<223> polymorphic base C in PG1 (13680) SEQ ID1
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-73.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-73.mis2
<400> 58
gttttcctta tgatgttaca tggcttattt ttaaaggtaa tgaaaac                47
<210> 59
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-65, extracted from SEQ ID1 51448 51494
<221> allele
<222> 24
<223> polymorphic base T in PG1 (51471) SEQ ID1
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-65.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-65.mis2
<400> 59
ggtgctgctc agcggcttgc acgtagactt gctaggaaga aatgcag                47
<210> 60
<211> 47
<212> DNA
<213> Homo Sapiens
```

```
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1482, variant version of SEQ ID57
<221> allele
<222> 24
<223> base A ; C in SEQ ID57
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1482.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1482.mis2
<400> 60
agtgaagtct gaggggggaaa aataaaccct atagagggaa ggatctg                47
<210> 61
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-73, variant version of SEQ ID58
<221> allele
<222> 24
<223> base G ; C in SEQ ID58
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-73.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-73.mis2
<400> 61
gttttcctta tgatgttaca tgggttattt ttaaaggtaa tgaaaac           47
<210> 62
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-65, variant version of SEQ ID59
<221> allele
<222> 24
<223> base C ; T in SEQ ID59
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-65.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-65.mis2
<400> 62
ggtgctgctc agcggcttgc acgcagactt gctaggaaga aatgcag          47
<210> 63
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> upstream amplification primer 99-1482-PU
```

```
<400> 63
atcaaatcag tgaagtctga g                                              21
<210> 64
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer 4-73-PU, extracted from SEQ ID1 13547
13564
<400> 64
atcgctggaa cattctgg                                                  18
<210> 65
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> upstream amplification primer 4-65-PU, extracted from SEQ ID1 51149
51168
<400> 65
gatttaagct acgctattag                                                20
<210> 66
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer 99-1482-RP
<400> 66
acaaatctat ataaggctgg                                                20
<210> 67
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer 4-73-RP, extracted from SEQ ID1 13962
13981 complement
<400> 67
ctcttggtta aacagcagtg                                                20
<210> 68
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer 4-65-RP, extracted from SEQ ID1 51482
51499 complement
<400> 68
tggctctgca tttcttcc                                                  18
<210> 69
<211> 5226
<212> DNA
<213> Homo sapiens
<400> 69
```

38

```
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc          54
                                    Met Arg Tyr Leu Leu Pro Ser Val
                                     1               5
gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg          102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
     10              15              20
cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac          150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25              30              35              40
gac cgg ctc tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag          198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                45              50              55
aat tac acc ggg gtc cag ata ttg cta tat gga gat ttg cca aaa aat          246
Asn Tyr Thr Gly Val Gln Ile Leu Leu Tyr Gly Asp Leu Pro Lys Asn
                60              65              70
aaa gaa aat ata ata tat tta gca aat cat caa agc aca gtt gac tgg          294
Lys Glu Asn Ile Ile Tyr Leu Ala Asn His Gln Ser Thr Val Asp Trp
            75              80              85
att gtt gct gac atc ttg gcc atc agg cag aat gcg cta gga cat gtg          342
Ile Val Ala Asp Ile Leu Ala Ile Arg Gln Asn Ala Leu Gly His Val
        90              95              100
cgc tac gtg ctg aaa gaa ggg tta aaa tgg ctg cca ctg tat ggg tgt          390
Arg Tyr Val Leu Lys Glu Gly Leu Lys Trp Leu Pro Leu Tyr Gly Cys
105             110             115             120
tac ttt gct cag cat gga gga atc tat gta aag cgc agt gcc aaa ttt          438
Tyr Phe Ala Gln His Gly Gly Ile Tyr Val Lys Arg Ser Ala Lys Phe
                125             130             135
aac gag aaa gag atg cga aac aag ttg cag agc tac gtg gac gca gga          486
Asn Glu Lys Glu Met Arg Asn Lys Leu Gln Ser Tyr Val Asp Ala Gly
                140             145             150
act cca atg tat ctt gtg att ttt cca gaa ggt aca agg tat aat cca          534
Thr Pro Met Tyr Leu Val Ile Phe Pro Glu Gly Thr Arg Tyr Asn Pro
                155             160             165
gag caa aca aaa gtc ctt tca gct agt cag gca ttt gct gcc caa cgt          582
Glu Gln Thr Lys Val Leu Ser Ala Ser Gln Ala Phe Ala Ala Gln Arg
170             175             180
ggc ctt gca gta tta aaa cat gtg cta aca cca cga ata aag gca act          630
Gly Leu Ala Val Leu Lys His Val Leu Thr Pro Arg Ile Lys Ala Thr
185             190             195             200
cac gtt gct ttt gat tgc atg aag aat tat tta gat gca att tat gat          678
His Val Ala Phe Asp Cys Met Lys Asn Tyr Leu Asp Ala Ile Tyr Asp
                205             210             215
gtt acg gtg gtt tat gaa ggg aaa gac gat gga ggg tag cgaagagagt          727
Val Thr Val Val Tyr Glu Gly Lys Asp Asp Gly Gly  *
                220             225
caccgaccat gacggaattt ctctgcaaag aatgtccaaa aattcatatt cacattgatc     787
gtatcgacaa aaaagatgtc ccagaagaac aagaacatat gagaagatgg ctgcatgaac     847
gtttcgaaat caaagataag atgcttatag aattttatga gtcaccagat ccagaaagaa     907
gaaaaagatt tcctgggaaa agtgttaatt ccaaattaag tatcaagaag actttaccat     967
caatgttgat cttaagtggt ttgactgcag gcatgcttat gaccgatgct ggaaggaagc    1027
tgtatgtgaa cacctggata tatggaaccc tacttggctg cctgtgggtt actattaaag    1087
catagacaag tagctgtctc cagacagtgg gatgtgctac attgtctatt tttggcggct    1147
gcacatgaca tcaaattgtt tcctgaattt attaaggagt gtaaataaag ccttgttgat    1207
tgaagattgg ataatagaat ttgtgacgaa agctgatatg caatggtctt gggcaaacat    1267
acctggttgt acaactttag catcggggct gctggaaggg taaaagctaa atggagtttc    1327
tcctgctctg tccatttcct atgaactaat gacaacttga gaaggctggg aggattgtgt    1387
attttgcaag tcagatggct gcattttga gcattaattt gcagcgtatt tcactttttc    1447
tgttattttc aatttattac aacttgacag ctccaagctc ttattactaa agtatttagt    1507
atcttgcagc tagttaatat ttcatctttt gcttatttct acaagtcagt gaaataaatt    1567
gtatttagga agtgtcagga tgttcaaagg aaagggtaaa aagtgttcat ggggaaaaag    1627
ctctgtttag cacatgattt tattgtattg cgttattagc tgattttact cattttatat    1687
```

```
ttgcaaaata aatttctaat atttattgaa attgcttaat ttgcacaccc tgtacacaca   1747
gaaaatggta taaaatatga gaacgaagtt taaaattgtg actctgattc attatagcag   1807
aactttaaat ttcccagctt tttgaagatt taagctacgc tattagtact tcccttttgtc  1867
tgtgccataa gtgcttgaaa acgttaaggt tttctgtttt gtttttgtttt tttaatatca  1927
aaagagtcgg tgtgaacctt ggttggaccc caagttcaca agatttttaa ggtgatgaga   1987
gcctgcagac attctgccta gatttactag cgtgtgcctt ttgcctgctt ctctttgatt   2047
tcacagaata ttcattcaga agtcgcgttt ctgtagtgtg gtggattccc actgggctct   2107
ggtccttccc ttggatcccg tcagtggtgc tgctcagcgg cttgcacgta gacttgctag   2167
gaagaaatgc agagccagcc tgtgctgccc actttcagag ttgaactctt taagcccttg   2227
tgagtgggct tcaccagcta ctgcagaggc attttgcatt tgtctgtgtc aagaagttca   2287
ccttctcaag ccagtgaaat acagacttaa ttcgtcatga ctgaacgaat ttgtttatttt  2347
cccattaggt ttagtggagc tacacattaa tatgtatcgc cttagagcaa gagctgtgtt   2407
ccaggaacca gatcacgatt tttagccatg gaacaatata tcccatggga gaagacctttg  2467
cagtgtgaac tgttctattt ttgtgttata atttaaactt cgatttcctc atagtcctttt  2527
aagttgacat ttctgcttac tgctactgga ttttttgctgc agaaatatat cagtggccca  2587
cattaaacat accagttgga tcatgataag caaaatgaaa gaataatga ttaagggaaa   2647
attaagtgac tgtgttacac tgcttctccc atgccagaga ataaactctt tcaagcatca   2707
tctttgaaga gtcgtgtggt gtgaattggt ttgtgtacat tagaatgtat gcacacatcc   2767
atggacactc aggatatagt tggcctaata atcggggcat gggtaaaact tatgaaaatt   2827
tcctcatgct gaattgtaat tttctcttac ctgtaaagta aaatttagat caattccatg   2887
tctttgttaa gtacagggat ttaatatatt ttgaatataa tgggtatgtt ctaaatttga   2947
actttgagag gcaatactgt tggaattatg tggattctaa ctcattttaa caaggtagcc   3007
tgacctgcat aagatcactt gaatgttagg tttcatagaa ctatactaat cttctcacaa   3067
aaggtctata aaatacagtc gttgaaaaaa attttgtatc aaaatgtttg gaaaattaga   3127
agcttctcct taacctgtat tgatactgac ttgaattatt ttctaaaatt aagagccgta   3187
tacctacctg taagtctttt cacatatcat ttaaactttt gtttgtatta ttactgatttt  3247
acagcttagt tattaatttt tctttataag aatgccgtcg atgtgcatgc ttttatgttt   3307
ttcagaaaag ggtgtgtttg gatgaaagta aaaaaaaaaa taaaatctttt cactgtctct   3367
aatggctgtg ctgtttaaca tttttttgacc ctaaaattca ccaacagtct cccagtacat   3427
aaaataggct taatgactgg ccctgcattc ttcacaatat ttttccctaa gctttgagca   3487
aagttttaaa aaaatacact aaaataatca aaactgttaa gcagtatatt agtttggtta   3547
tataaattca tctgcaattt ataagatgca tggccgatgt taatttgctt ggcaattctg   3607
taatcattaa gtgatctcag tgaaacatgt caaatgcctt aaattaacta agttggtgaa   3667
taaaagtgcc gatctggcta actcttacac catacatact gatagttttt catatgtttc   3727
atttccatgt gatttttaaa atttagagtg gcaacaattt tgcttaatat gggttacata   3787
agctttattt tttcctttgt tcataattat attctttgaa taggtctgtg tcaatcaagt   3847
gatctaacta gactgatcat agatagaagg aaataaggcc aagttcaaga ccagcctggg   3907
caacatatcg agaacctgtc tacaaaaaaa ttaaaaaaaa ttagccaggc atggtggcgt   3967
acactgagta gtttgtccca gctactcggg agggtgaggt gggaggatcg cttcagccca   4027
ggaggttgag attgcagtga gccatggaca taccactgca ctacagccta ggtaacagca   4087
cgagacccca actcttagaa aatgaaaagg aaatatagaa atataaaatt tgcttattat   4147
agacacacag taactcccag atatgtacca caaaaaatgt gaaaagagag agaaatgtct   4207
accaaagcag tattttgtgt gtataattgc aagcgcatag taaaataatt ttaacctttaa  4267
tttgttttta gtagtgtttta gattgaagat tgagtgaaat attttcttgg cagatattcc   4327
gtatctggtg gaaagctaca atgcaatgtc gttgtagttt tgcatggctt gctttataaa   4387
caagattttt tctccctcct tttgggccag ttttcattac gagtaactca cacttttttga  4447
ttaaagaact tgaaattacg ttatcactta gtataattga cattatatag agactatgta   4507
acatgcaatc attagaatca aaattagtac tttggtcaaa atatttacaa cattcacata   4567
cttgtcaaat attcatgtaa ttaactgaat ttaaaacctt caactattat gaagtgctcg   4627
tctgtacaat cgctaatttta ctcagtttag agtagctaca actcttcgat actatcatca   4687
atatttgaca tcttttccaa tttgtgtatg aaaagtaaat ctattcctgt agcaactggg   4747
gagtcatata tgaggtcaaa gacatatacc ttgttattat aaatatgtata ctataataat   4807
agctggttat cctgagcagg ggaaaaggtt atttttagga aaaccacttc aaatagaaag   4867
ctgaagtact tctaatatac tgagggaagt ataatatgtg gaacaaactc tcaacaaaat   4927
gtttattgat gttgatgaaa cagatcagtt tttccatccg gattattatt ggttcatgat   4987
tttatatgtg aatatgtaag atatgttctg caattttata aatgttcatg tctttttttta  5047
aaaaggtgc tatcgaaatt ctgtgtctcc agcaggcaag aatacttgac taactctttt   5107
tgtctcttta tggtatttttc agaataaagt ctgacttgtg tttttgagat tattggtgcc   5167
tcattaattc agcaataaag gaaaatatgc atttcaaaaa naaaaaaaaa aaaaaaaaa    5226
<210> 70
<211> 228
```

```
<212> PRT
<213> Homo sapiens
<400> 70
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5                   10                  15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20                  25                  30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35                  40                  45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu
    50                  55                  60
Leu Tyr Gly Asp Leu Pro Lys Asn Lys Glu Asn Ile Ile Tyr Leu Ala
65                  70                  75                  80
Asn His Gln Ser Thr Val Asp Trp Ile Val Ala Asp Ile Leu Ala Ile
            85                  90                  95
Arg Gln Asn Ala Leu Gly His Val Arg Tyr Val Leu Lys Glu Gly Leu
            100                 105                 110
Lys Trp Leu Pro Leu Tyr Gly Cys Tyr Phe Ala Gln His Gly Gly Ile
        115                 120                 125
Tyr Val Lys Arg Ser Ala Lys Phe Asn Glu Lys Glu Met Arg Asn Lys
    130                 135                 140
Leu Gln Ser Tyr Val Asp Ala Gly Thr Pro Met Tyr Leu Val Ile Phe
145                 150                 155                 160
Pro Glu Gly Thr Arg Tyr Asn Pro Glu Gln Thr Lys Val Leu Ser Ala
            165                 170                 175
Ser Gln Ala Phe Ala Ala Gln Arg Gly Leu Ala Val Leu Lys His Val
            180                 185                 190
Leu Thr Pro Arg Ile Lys Ala Thr His Val Ala Phe Asp Cys Met Lys
        195                 200                 205
Asn Tyr Leu Asp Ala Ile Tyr Asp Val Thr Val Val Tyr Glu Gly Lys
    210                 215                 220
Asp Asp Gly Gly
225
<210> 71
<211> 158
<212> DNA
<213> Homo sapiens
<400> 71
gccttgcagt attaaaacat gtgctaacac cacgaataaa ggcaactcac gttgcttttg    60
attgcatgaa gaattatttta gatgcaattt atgatgttac ggtggtttat gaagggaaag   120
acgatggagg gtagcgaaga gagtcaccga ccatgacg                            158
<210> 72
<211> 1381
<212> DNA
<213> Mus musculus
<220>
<221> misc_binding
<222> 608..629
<223> amplification  primer  g34292.pu
<221> misc_binding
<222> 740..758
<223> amplification  primer  g34292.rp
<400> 72
gagccgagag gatgctgctg tccctggtgc tccacacgta ctct atg cgc tac ctg     56
                                             Met Arg Tyr Leu
                                             1
ctc ccc agc gtc ctg ttg ctg ggc tcg gcg ccc acc tac ctg ctg gcc    104
Leu Pro Ser Val Leu Leu Leu Gly Ser Ala Pro Thr Tyr Leu Leu Ala
5                   10                  15                  20
tgg acg ctg tgg cgg gtg ctc tcc gcg ctg atg ccc gcc cgc ctg tac    152
Trp Thr Leu Trp Arg Val Leu Ser Ala Leu Met Pro Ala Arg Leu Tyr
```

41

```
                     25                    30                    35
cag cgc gtg gac gac cgg ctt tac tgc gtc tac cag aac atg gtg ctc    200
Gln Arg Val Asp Asp Arg Leu Tyr Cys Val Tyr Gln Asn Met Val Leu
                     40                    45                    50
ttc ttc ttc gag aac tac acc ggg gtc cag ata ttg cta tat gga gat    248
Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu Leu Tyr Gly Asp
             55                    60                    65
ttg cca aaa aat aaa gaa aat gta ata tat cta gcg aac cat caa agc    296
Leu Pro Lys Asn Lys Glu Asn Val Ile Tyr Leu Ala Asn His Gln Ser
         70                    75                    80
aca gtt gac tgg att gtt gcg gac atg ctg gct gcc aga cag gat gcc    344
Thr Val Asp Trp Ile Val Ala Asp Met Leu Ala Ala Arg Gln Asp Ala
85                    90                    95                   100
cta gga cat gtg cgc tac gta ctg aaa gac aag tta aaa tgg ctt ccg    392
Leu Gly His Val Arg Tyr Val Leu Lys Asp Lys Leu Lys Trp Leu Pro
                 105                   110                   115
ctg tat ggg ttc tac ttt gct cag cat gga gga att tat gta aaa cga    440
Leu Tyr Gly Phe Tyr Phe Ala Gln His Gly Gly Ile Tyr Val Lys Arg
             120                   125                   130
agt gcc aaa ttt aat gat aaa gaa atg aga agc aag ctg cag agc tat    488
Ser Ala Lys Phe Asn Asp Lys Glu Met Arg Ser Lys Leu Gln Ser Tyr
         135                   140                   145
gtg aac gca gga aca ccg atg tat ctt gtg att ttc cca gag gga aca    536
Val Asn Ala Gly Thr Pro Met Tyr Leu Val Ile Phe Pro Glu Gly Thr
     150                   155                   160
agg tat aat gca aca tac aca aaa ctc ctt tca gcc agt cag gca ttt    584
Arg Tyr Asn Ala Thr Tyr Thr Lys Leu Leu Ser Ala Ser Gln Ala Phe
165                   170                   175                   180
gct gct cag cgg ggc ctt gca gta tta aaa cac gta ctg aca cca aga    632
Ala Ala Gln Arg Gly Leu Ala Val Leu Lys His Val Leu Thr Pro Arg
                 185                   190                   195
ata aag gcc act cac gtt gct ttt gat tct atg aag agt cat tta gat    680
Ile Lys Ala Thr His Val Ala Phe Asp Ser Met Lys Ser His Leu Asp
             200                   205                   210
gca att tat gat gtc aca gtg gtt tat gaa ggg aat gag aaa ggt tca    728
Ala Ile Tyr Asp Val Thr Val Val Tyr Glu Gly Asn Glu Lys Gly Ser
         215                   220                   225
gga aaa tac tca aat cca cca tcc atg act gag ttt ctc tgc aaa cag    776
Gly Lys Tyr Ser Asn Pro Pro Ser Met Thr Glu Phe Leu Cys Lys Gln
     230                   235                   240
tgc cca aaa ctt cat att cac ttt gat cgt ata gac aga aat gaa gtt    824
Cys Pro Lys Leu His Ile His Phe Asp Arg Ile Asp Arg Asn Glu Val
245                   250                   255                   260
cca gag gaa caa gaa cac atg aaa aag tgg ctt cat gag cgc ttt gag    872
Pro Glu Glu Gln Glu His Met Lys Lys Trp Leu His Glu Arg Phe Glu
                 265                   270                   275
ata aaa gat agg ttg ctc ata gag ttc tat gat tca cca gat cca gaa    920
Ile Lys Asp Arg Leu Leu Ile Glu Phe Tyr Asp Ser Pro Asp Pro Glu
             280                   285                   290
aga aga aac aaa ttt cct ggg aaa agt gtt cat tcc aga cta agt gtg    968
Arg Arg Asn Lys Phe Pro Gly Lys Ser Val His Ser Arg Leu Ser Val
         295                   300                   305
aag aag act tta cct tca gtg ttg atc ttg ggg agt ttg act gcg gtc   1016
Lys Lys Thr Leu Pro Ser Val Leu Ile Leu Gly Ser Leu Thr Ala Val
     310                   315                   320
atg ctg atg acg gag tcc gga agg aaa ctg tac atg ggc acc tgg ttg   1064
Met Leu Met Thr Glu Ser Gly Arg Lys Leu Tyr Met Gly Thr Trp Leu
325                   330                   335                   340
tat gga acc ctc ctt ggc tgc ctg tgg ttt gtt att aaa gca taa       1109
Tyr Gly Thr Leu Leu Gly Cys Leu Trp Phe Val Ile Lys Ala *
                 345                   350                   355
```

```
gcaagtagca ggctgcagtc acagtctctt attgatggct acacattgta tcacattgtt  1169
tcctgaatta aataaggagt tttcttgttg ttgttttttt tgttttgttt tgttctgttt  1229
taagccttga tgatngnncn cnnnnnnnnn ncnantcnng ngaccacagc caacatgcat  1289
ttgatttggg gcaaacacat gtggctttc aggtgctggg gttgctggag acatggaagc  1349
taagtggagt ttatgctgtt tttttttttt tt                                1381
<210> 73
<211> 15766
<212> DNA
<213> Mus musculus
<220>
<221> exon
<222> 52..121
<223> exon2
<221> exon
<222> 682..797
<223> exon3
<221> exon
<222> 2628..2717
<223> exon4
<221> exon
<222> 7834..7924
<223> exon5
<221> exon
<222> 9804..9965
<223> exon6
<221> exon
<222> 11404..11527
<223> exon7
<221> exon
<222> 13539..14035
<223> exon8
<221> misc_feature
<222> 13762..13764
<223> stop  CDS
<221> polyA_signal
<222> 13835..13839
<223> AATAAA  potential
<400> 73
ttttttttt ttaattgtca aagtcatgat tctttttgtt ttctctttta gatattgcta      60
tatggagatt tgccaaaaaa taaagaaaat gtaatatatc tagcgaatca tcaaagcaca     120
ggtttgtatt tcatttgatg aaatttgggt ttttctagaa atggtaaatg agcattaata     180
tgtacacaca catacacaca aacacacata tgtacacaca catatgtttt aaagacagga     240
tttcatgtga cccagaatgg cctcatactc tctgagtagc tgagaatgat tttaagcttg     300
tgacacacct gccttcatct ccaaggtaca ggaattgcag gtgctttctt tgnnnnnnnn     360
nntttttttt tttgagtttt ggggagggggg tatatttttt aatgtgtctg tagttggctt     420
tgttttaagc attttaatca tactttattt ttaaaaaaac taaaagcttt tttaaggcta     480
ggtcttgcta tgtggcccta gtgttcctgg gacttgctct gtacaccggg ttgactctga     540
gcctgtgcgc cttctgcctc tgcctccata gttagattct caggacatgt tacaaagact     600
gtgctgtgaa gatgagtttt tgttcctggg agggaaggtt ggagctgact tgtgaggtac     660
tgacttgggt ctgccttaca gttgactgga ttgttgcgga catgctggct gccagacagg     720
atgccctagg acatgtgcgc tacgtactga aagacaagtt aaaatggctt ccgctgtatg     780
ggttctactt tgctcaggta aactttgtct ttgccctttt atttcaaact taacaccatt     840
taatgaaact atatctgatt tttttgttta tgtgtttgtt ttatggtacc cgtgattgaa     900
catggggtca tatgtgtgct actgagtgac agccttagtt cagacatttt ttaaagcgac     960
ttttactagt attttttattt agaattctat atgtgtgcac atgcatatgt gtgcttgtgt    1020
gcacacgtgg atgcatgtga ggtcgaagga caattttcag tacaagtgtg agtgtcactt    1080
tttaggcacc ttccactctt attttgagac agtctcctag acctttgctg agttgcccag    1140
gctagccggc cagtgagccc tgggcatcta ccggtctctg cctccttacc tttacttagg    1200
ttacaagtgt gtgctgctac gcccagctgt ttactagatt ctagggatcc aaatgtgggt    1260
cctcgtaact tgtgagacaa gtactttcca aactgagcca cctccctagc tcttcttcac    1320
ggttcctgat ggtgtgtgtc tagatggctg gttgtccgta tatttaagtc cagtagcaga    1380
```

```
aatacaaata cctaggagtc caatagaaag ctacaagtgc agaattgaca atcggtaatg  1440
ttcggaaatt gattcaaaag tagttagtga gtgacagaca ggagctaaaa gcagactctg  1500
agctcagagt gtgaagtgtg gagaaatgtg ttttctcaca gttctgaagg ctgaaagtct  1560
ccccaaggtc aggatgtggg tggtactgct gtctcccaan cacccacctc tttggattat  1620
agactgcagc cttctccctg tgttctgagc cggcctttcc cacatgtgga catccttggt  1680
gggtgttcca ccagcagggc ctcagctagt gcccttattt cacttaactg taatgatttt  1740
cttaaagacc ctgtctccat acacagtcac tgtggaagct gaagcttcaa tgtaagagtt  1800
aaggggggag gggaaatttt agtccataat ggtgtcacac caatctctgt agctgagtcc  1860
atgattcagt tctttaaagg ctctgagtgt agacattatc ttaattattt tgcccattta  1920
tgtattatct ttaatttatt ttatgtaact gaatgcctgt gtatatatgt ttctggttcc  1980
tagtccatat tttaattcct taaaggatgg aggtgtagac ttttgtcttt ttaattttct  2040
atccttccct cctggcctcc tgtggcctct tttacgtatt tattacttt aatttatttt  2100
atgtgtttga gtgttttgta tctatgcatt cctggggccc atggaggtca gaaaaacaca  2160
ttaggtggcc tacaactgag ttatgggtgg tttgtgacca tggggtgctg ggacttgatc  2220
accagtctct gagaagactc gtgtctgctg agccttctct ccagtcctgg gagtgtggat  2280
atttttaagga tacttttaat tgacttggtg aatgacagta gaaaatcaat gagttaggat  2340
ccatcggaaa aagcttttga actaaatctt ttaaagagaa aatattttaa gtgctaacaa  2400
aattaaatgt gtattttcca tgatgcagtt ttacttgggc tctgtagaaa taggattttc  2460
aggtacatat tgtatatata gttggcaata tttaaatact aactgtcgct tgagttctga  2520
aatgtagttt tatgtttttt actcattagg agtacagttg ccttaataac tacggagatt  2580
agttattaaa gaataattgc tcttctttttt tcttttctgt gtaccagcat ggaggaattt  2640
atgtaaaacg aagtgccaaa tttaatgata aagaaatgag aagcaagctg cagagctatg  2700
tgaacgcagg aacaccggta agtgcgcccg cttttattcc tcaaggcagg ttaagaagtt  2760
aagttcttaa gtcattttga aaatatatta ccccatgtgg agcaatggaa ctggttcggg  2820
gttttgttga dataagctgt cctctggccg tgaggtaaga ttgctgcagg tgattgtaag  2880
gtttctcctg agtaacagtc agcatgggct cgggacgggc aagggcaggc cttagtgtgc  2940
agaggatgga gctcactgaa gccccaaaga gttagtcttc acatgagatt cagttctaga  3000
agaagttaaa ttgctttctt tctgtgtaaa tttggatttt tattgtagaa attaaagttt  3060
gttttctttt aaaacaaaca caaacccaga gcaaagagtc tcctagtgaa gagtcattcc  3120
gtgtcagtat tttacacaac tgttttttctg taaaggggga aaaagaattc aaatcttctc  3180
tttcaagaat gctgactgct gccaactgcc tctccccgtg gcccctctct gtatagacag  3240
gcatagctat ggtgaggact tgggcggctc ttgtctttct cctctctctg cttctctacc  3300
ctttctctcg tgccctccac ttaccaggcc ctgggaagct acacaccagg caacagtgac  3360
cagggcctcg gcctgggctt cgaccaatta ctagagcaga aacagcagca gctgcagtgt  3420
tgtttttgtgc tgtgcactgt attaggttgt gttttcatca cctttgggtt ttgtgatgtt  3480
ttgatgaagt cctggtacca ttctagtttt tacattctgg gtagatagag tttattcaag  3540
gtctcaaggc atatgaatgg aagagctcct ctttacagcc attcgtgtag catgcataac  3600
tgctcttctg tattctctct agtgtctttt tttttgtgtg tgaatctgat gtcttgttat  3660
tcacctacaa tgtggagtaa tggtcataaa catataaagt acttatgcct ttatctgcca  3720
aattgtattt aacttttcag cttttaatat aacttttat ataataatta atttatttta  3780
aaaaaaattg aataccagcc tgttatagtg gcatatgcct gtgttcctag cactcaggag  3840
acaaaggcag aagtgtgaga acttcagact catactcagc tatatacaag accccaaatt  3900
tgtgctagat tctgcagtac agccatgagt gtccccatct tagagggaga tcgctcatcc  3960
ttgtgctgtt ctttaagtct taccctgcaa cccactgtaa gtacactctt gctcacagtc  4020
ctttagaatc tcacactctt tctctttaca gacaccatgt cattgcccac tttattattt  4080
atctgatgtc tacaaagatt atgaaagaga aacttgtatg cattctgtgt aaagtacttg  4140
acacaaataa tagtattcaa gaatgacttc ttaaatgaac actgaatgaa tagtttgttc  4200
taattttttt gatcaacaaa tcaaaaaata tttagattaa atatctaaga tacaaagcat  4260
aataccacat gaatcattaa agtgagtaat caatcttata agtgactgac cctaaaactc  4320
atagacatta ataattgctt tcattgctta gatataaact ttattgatta atacgttctc  4380
atgaaagtgg ttcttggaag gttctggaaa cgaaaatatt tttcttactg ctttttttctt  4440
ctagtaactg attgaatttt tctgcagttc cataaagcat ctggtcaatt gctattatcc  4500
aatatgagga tatataacaa agtattgatt tttaaatttg gcggtgataa gacaagactg  4560
ggcgtgtgaa tgaggggggtc tctgtttctt gtcccttctc ttgggttctt ttccttttgt  4620
tggtttgcct tctccagctg ctatgtgatg ggttctgatt atcttattat atcttatttt  4680
gttattttc attgttatct cttagaagcc aacatgttat atcacctcca ctcccaccat  4740
taggtgtnct cacaaatacc ccaagctaaa caaccacatc atgtcatgtt nctgtatact  4800
tccataagtg ttgttaactc tactgactct tgtgagcagg cccaattggc tttatcccta  4860
gctgggtgac ctgggttcct ccccaacacc ataccgtcca tcaaactgag tccttttcca  4920
agcacacacc agatactgct catctgagga ctcttctcat ccacctaagg actgcctgct  4980
cctcggcaga aagggcctct agtcccatac ccttacgccc tcaccaatgc cttaggaaca  5040
```

```
tgtgctcaat gcccctgtgg gtcatttccg tttacagtag ggaaatttgc ctgataactt   5100
gcagcacacc tataaagagg ccttgcttgc tctcatattt agctggagaa gataatgtac   5160
tcaccaactc cactctatgc aacccagtct gctctgccca tgccagtcag acgtgaatct   5220
tacacctgga ttcagattga tgaatctaca acatcaccca ctccatgctt ccttctaaat   5280
cagcagttct agcctgaatg acagatgcta cccaagtctc atctagttag ccctgtccgg   5340
agtaaccctg accttgagga ttagaccagg atgcacatcc tgcaccagtt cccttttgtcc  5400
acctgacttc atcccacccg ggccatagcc catgctcagg ctccaccctc catgcacaaa   5460
gctggctttt ccagcttcct tcacctgtat cagacacaaa tagcaaaagg ggtccacgtg   5520
cctaggtccc atcacaagac catgtgcggt agtttggaaa acagtctcca cttgaggctc   5580
agatagnttg gaatcttggc tctcatgtag ttgtactgat tagatcagtt taggaagtat   5640
gacctttntg gaaagaacat ataactggga ggggctttga gatgtaaagg ccccacacaa   5700
ttcctagttc aaactntact gcctgctcaa agcttgaggc atgaactctc actgttcctg   5760
atgtcatggt tcctgtctgc ttccacaatt ccctatcatt aggggtccct ttccttcctg   5820
gaattttaag tataaataaa cncttctttn taaaacaaca agaacaacaa atctgacnct   5880
gataatggat tttaaggcgt cttctctgga taagaaaaaa aaaagaata: atttgcatag   5940
gtgctgtatt acttttgtca ttggtataac ctgactggaa gcaacttaaa ggaagaagaa   6000
tgtatcttga tttgtagatt aagagcacca tgactaagaa ggcatagcag cacaggtgca   6060
ccagcaagaa cataggctgc tagctcagat ctctgtagat atgggaacag ggcaggaagc   6120
tagtagtcta taaacctcag gacccatccc atggagttcc ttgtcttcca gtgatgtcct   6180
gtgtcttaaa gtttcacagt tcccacagca gcacctgccg tctgggaacc aacctgtggt   6240
ggatatttta caacgtgata ggcatatttt gtctctagcc ctgtaggttt atagccatcc   6300
tatacttcag tttatctagt ccacctcagt ctgatggtct tatagttcca acacttcaaa   6360
actacaaagt cttaagggcc atgggctcgg gtttattaga gcagtaacac ctctactagc   6420
tttctgtgtt acccactcct cttaaggtct ggttgaaatc ctaataggaa gcagcttgag   6480
aggagggttt attgtggccc atactttgtt ggtacattct atcatgcaag ggtggcactg   6540
tgatacagcc gaggccatcc gaggatggta ctgttggctt acatctggjt gggacaggaa   6600
atggtaattc tcaaggccca cctgcttggt gacttctttc agttaagccc catactctaa   6660
atcctctaca acctcccaac ataatgccac cagctgggga tcagctgttg acagtgctgg   6720
cccagggag cagtttaaat ccagaccagg ggacctgaaa acagagaact gcagaggggc   6780
tgtgggactt tataccagct ttgcagacaa atcacggcat ttctttgtga gcttggttca   6840
taaacaaata tatattctcc tataggctcc tttagtgggt gtttcatatc cacaaatttg   6900
ttcagaaaaa cactgtgttt tatgctagct gtgtaggaga taataccgct gggagtcact   6960
tgagcatgga taagtgacat agttcgtcct catgagtccc tgtcctgttt ctgtattatg   7020
tttacttgat gagtttagtt tgtcagttgg ccaccaatta aaaagtatca tttttatttt   7080
tttacaatac tcagttctca agttaggagt tttgttatta tatggcttca atattcacat   7140
tttaaccttt ccaggagtta agtataaaaa cttatatcaa ctgttgactt agtaaatatc   7200
tattacagat actatattct tcttagttta tatcatgaat atgaggttgc ttaaagtaag   7260
tgatgtaaaa tacactaggg gatgcttata aaatggaatg ttgtgagttt tttgaaacac   7320
gagtactaaa ttcataagtt tttaaatagt tacactgtta gcttcagtac tgctagatac   7380
atgtctataa tggctgaaga gtggagcttg gatattataa gtgtactctg tatattcatg   7440
cagacatata gcagattcca ctagtatgtg tggttaatat gtgctaataa aaatttaata   7500
caaaagtcat gttttattac tgggaaccag aggggttggt tgtgctgatc ttaagtcagt   7560
gactattagc atattctaag aaacagtttt naggatttta aagattggct ttaccataaa   7620
tgtagagcta tgttttacta taatccatat tatggtcggc cttaattcaa tctctgcagt   7680
ttggttactc tgctcaaagt gaaggtcatt tataaatgat acacattttc tcaccatagg   7740
aaatactacc tggccaataa cagagttaga attgctaaat tgatggtacc aacaatggac   7800
tcaacacaaa ctaaagttta tttatgccca cagatgtatc ttgtgatttt cccagaggga   7860
acaaggtata atgcaacata cacaaaactc ctttcagcca gtcaggcatt tgctgctcag   7920
cggggtaagt aaagatttaa ctgtattcag aaaaacactt ttttaagaag agtgatcttt   7980
gtttccttca gagtcatact aaagaatatg cgtttcttgt aagagctaag tgagagaata   8040
tccgatcttc tacagagtta ggtatattct tattagtctg tgtctgagag gttagagacg   8100
caggcttgct atggcacatt tcccatgctg tgaattgagt taaaaatgta ggtaaatgat   8160
atccccaaga aagtatactt ttnggagtga ctcagtataa agcctggtgt tataacataa   8220
acacgcacgt gcggatgtat atgtagcaca tatgtaaaca caggtatatg canttgtaat   8280
aagaaagtgg aggtcggggc ccactgcagg caagtctttt agtgatgctg agctaatgct   8340
gagaggtaga aagaccaaga aggctggagt tgctcattcg gcaaaggtca gagctcactg   8400
tgtgccataa ctcgagtgtt ctgtctccct tttgatacag ttttcttgtt tttaattatt   8460
agtttttaca attatcccat aaaatgtggg ctcattgtgg tcatcgtttt cataaagtcc   8520
ttcaagtata cacccagcaa gtatctaaat acactgggaa gaatcagtca gctgatggct   8580
tgaagtttca ggacatctag tgccacatca tgcttcagaa ccgacctgca cttagtcagg   8640
gtcatattca tgccacgtga agacgagagg aggccatgcc gtctgactta ggatggaaat   8700
```

```
ttccttcgag caaacacgaa cgggctaggt cttagttata ggcatagtgt ctgtggttat   8760
actaggcaga cattagtgga ctgggtgtta gaaggtacag acaggcaaga atttgctgta   8820
gatttgtttc cctcatgtgt tgacaccaca tctaacctgc tttttgagct tctagtccta   8880
ataatctcat aaaaatactg gttgaaccag aaatggtgtt gcaaagctat gatcccagct   8940
cctgggatct agggtgggag gatcataaat ttgaggccag cttgggtctg tcttagagaa   9000
aaaagaaaaa taaaaagtct ggtcaaggta acatggagcc tggaagtttc acagggtgat   9060
tctgtaaagg tcctgagaca agatggcctc tagtggcgaa tgacttagct gacaangaaa   9120
actttcccag cttggttgac ttttcagact tcatacaagt ttgtgaataa attacactcc   9180
ttctgccctt gggactgaac tcagatatgt ggttgtggga atggctttct ttcccacacc   9240
accctgcatt ttaaaaattc ttctgtagac agtcccacca tcctgtagct gttcttcctt   9300
atgtcgccac tttccctgga gagaggcagt gcagacttca acccgcttct ccctagtcgc   9360
tgttcatagc acatcgaaag acctagtgct tcctgtgaaa ttgtaagtac atcctggagt   9420
ccaggagagg aggaagccga acagagtgga gggaatgctg agttctgtcc taagaaagac   9480
tgcgtgctta gcaagatgct gctgctctcc tgtcgtgtct ttcttgtcag aacttatcaa   9540
agagaaggct cgcagtgggt cataatcttc ccaaggacca gccttcccag cttctcgcag   9600
catatctcat tcatgtagat gtttaatgga tatgtgtcaa tggggttgac ctaagtgaga   9660
tggcaatgta tgtgagcatt ctaggtgtga ggttatggca ttaaacttta atttccgtct   9720
atttgtggta gttgataagt aatttagatg ttgactttca tgtattccta attatgacca   9780
cattgaatct acctgctttc taggccttgc agtattaaaa cacgtactga caccaagaat   9840
aaaggccact cacgttgctt ttgattctat gaagagtcat ttagatgcaa tttatgatgt   9900
cacagtggtt tatgaaggga atgagaaagg ttcaggaaaa tactcaaatc caccatccat   9960
gactggtaag tccgtatttc catagaagct gaatagtaca tggtacaggt aagataaact  10020
cttgtttgtt cgctttgctt agcttggttc agtttggttt tcagtagagg gttccactat  10080
gaagctctgg ctggccggga actcactatg tagaccaagc tggccttggg ctccactaca  10140
cccagcacca atcacccact cttatncttt tatgcntttt tgttttttgct ttgagctttc  10200
tttataacat gtttgggaag gacattgtca ttatttacaa gaagaaatat ggtcttttcc  10260
caacatgcta gaatttaaag actcagaact cttgcctttg tcagtgacaa agtgagaatg  10320
gctgtgaagt gacgtggctt tgagtgagaa tagttcaggt aactatagcc acagactcaa  10380
catttgaaca tgggaacagg tgagaacgga gtgatggaag attctggccc cttttcagaga  10440
attcatttta gagagagatg agagtagtaa ggaagagaga agagagagac gtggtatttt  10500
gctgcagact aaagagatct cttataatcg cagtactaag gaggaagaag cagaagatga  10560
tgactacagg gccaggctga acaatctagt aaaatcctaa gtcaggaagt cagggctgag  10620
gtgcagctca gtaggagagt tgttgtctgc cctacacaag gcctggattt agctcccagt  10680
agcaacgaag ggaggcgagg gtgggcaaaa tcgaacactt actcttggag actccctttta  10740
tgaatattac cacactccag taaatactct ccagagattt cagatgagat tctgcttcct  10800
ggtaaacagg aggccaagaa tattatgtca cactgaacat gggatggaag acatgttctg  10860
aggaatgtct gcactccagt gtgatgaaga cttgaagttt agggacattt tccctccctg  10920
gccccactca ccccatctgt attgagtatt cccctagtgc tcatctttat ttgtatgtta  10980
actttcagga aggggaagca gattgatatt caaacccagc cagtttttctt aaatactttg  11040
tggatgggat tggctttgac agtaaatgag gaaatgtaaa atgtaaaaga ttctaatttt  11100
taatatttta aaggtgaggt tttctgttag tacgcagagt gagaggtttc ttactgatgt  11160
ctgcgtacct agaggaagga tggctacttc tccaaggctt gctgttagaa gtcagtgaca  11220
tgggcttaac aagagatatg tgctaatgag gttttaattt cagcttaata ctgcaaatca  11280
taagtgcata gctttattgt tttaaattct tttagtctta atgtttcatt tttaccataa  11340
gttactttgt ataatcacaa attctaaact agtaagacgt gaaattttct tcttctttgt  11400
tagagtttct ctgcaaacag tgcccaaaac ttcatattca ctttgatcgt atagacagaa  11460
atgaagttcc agaggaacaa gaacacatga aaaagtggct tcatgagcgc tttgagataa  11520
aagataggta agtggtaaga gctccagcat ttagaaagtg cagttcaacc aaattttact  11580
ctcagatcct gcttgaaagg agtcttttta tcttcattat ttagtaaata ctaatcatac  11640
ctgcatagac aagaccacat atacttaaat gtagcatgtt tcatggtgcg ttacccttgt  11700
ttaacaatta agtttaacat cctacatcag tttgcctgtt gatttctgta ccatgacaac  11760
tcaacacagc gatgcgttta ttccaaagtc gatagcacag caaaagtgaa actaaagtct  11820
gtattgtttc aagaatgctt tttgtgaact cgggttaaat cttattctat cctttcgtgt  11880
tcacattgta cattttcatg agtcactata aaaatcatga catggtggcc tacctgcagt  11940
gtttgctgga cagtaggctg ctgtgtgata agagcctttc ctcttcagct acacggggga  12000
cacgaggctt tggggttcaa gactgaagca cgggtgagca caacaccttt gtgttgtggg  12060
aaggaaggga attgttcttt tcataatgaa attgtcccct ttcttgagtt agtagaaagt  12120
attacaagga tagagagttg aaatgaagct ttatattaga tttatgcctt gtgttgtcac  12180
gtgtttctac ctgacataac ttttcaaccc agccgctcag gattattttg atgatgggaa  12240
caatgtaaga aggcctatgt atcggtaact cactgttgta gctctgtgga ancggntcnn  12300
caggcagtag ggacgcttct gtgctttgt gcctgtttg ctgttagaat cttacagagg  12360
```

```
aggatgaatg aatgacccatt tttattttctc ttgtctgctt ttctaatttt atgggaataa   12420
gaacttttgg taggtctctg tcactggcct cttgttgtga agagacacct tgagcaaagc   12480
aactcttctg agagaaagca tttagttggg gaattcctta cagcttcaga ggttgagttc   12540
gtttttcatca tgctgaggac agggaggcac tcaggcagga gaagtagttg agagccacat   12600
tctgatctac aggcagagag agacagactg agcctggcat gggttcttgg aacctcaaag   12660
cctctcatcc ctacccatc tcccgacccc tatacacact tcctccaaca aggctacacc   12720
ttctaatcct tcttaaagag tcaccacatc cagcgactaa gcattcagat atgtgaacct   12780
gtcggagcct ttcttactca gatcacctca ggaggaaaac tcctatgcta taagaatttc   12840
tttttctttcg catctttgaa agcttgtttt tgtgtgatta gatcctggcc tcacacatgc   12900
tcggcaatca tttactgtt gagctccagc ctcagccgtt ttcattggct tatgggatgc   12960
gagccatggg agagaagcta gaaggccttt cgtttttatga gtcgggttgg tggaaccact   13020
tacagatgga agatttacaa acaaaaatga agctgggggcc atcaaggctc agcactcgct   13080
gctcttccag agagttcagg ttcatttctc agtaaccaca tggtggcttt gtaaatgtaa   13140
cttcatattc aatgaccctg acaccctctt ctggcctctg tgggcaccag acacaatcat   13200
ggtatacaga cacacacact agccaacacc catctacata aaagtatata anacatatct   13260
ttatcttaaa aatccccgaa gtcctcatta aatatcttag atccccgccg tgttttgatt   13320
tttgtttccc acgtggtgag gatataatat catgtccaaa ctgtaaggag tgaatgccct   13380
cccgtgcctc tcggacacct ctgcactcat ccaagttttc taaggagctg tacttgctca   13440
gcaagtactc aatacctaat aaatggttta tgtttgtttc aacaccaaaa atgtccaaaa   13500
ctgaaagatc aattctgttg ttttccttct ggccataggt tgctcataga gttctatgat   13560
tcaccagatc cagaagaag aaacaaattt cctgggaaaa gtgttcattc cagactaagt   13620
gtgaagaaga ctttaccttc agtgttgatc ttggggagtt tgactgcggt catgctgatg   13680
acggagtccg gaaggaaact gtacatgggc acctggttgt atggaaccct ccttggctgc   13740
ctgtggtttg ttattaaagc ataagcaagt agcaggctgc agtcacagtc tcttattgat   13800
ggctacacat tgtatcacat tgtttcctga attaaataag gagtttttctt gttgttgttt   13860
ttttttgtttt gttttgttct gttttaagcc ttgatgattg aacactggat aaagtagagt   13920
ttgtgaccac agccaacatg catttgattt ggggcaaaca catgtggctt ttcaggtgct   13980
ggggttgctg gagacatgga agctaagtgg agtttatgct gnttttttt ttttttnaa   14040
tgttttcatg aattaatgtc cacttgtaaa gattattgga tactttctgt aattcagaag   14100
gttgtatttt aacactagtt tgcagtatgt ttcgctatat tggttatctt ccatttgact   14160
acttggcagc tcagactctt aatactaaag tatttttacat tttgaagcta tgtgatactg   14220
gtttttttgtt gttgttgttg ttgttaatttt ctgaaagtca atgaaagaca ctgtaatgat   14280
gcgttaagat gttccaagaa aaaggtgaga attattcatg gcaaaaaaga tctgtctagt   14340
gtatattttt attatattgc tctatttagc taattttctt tatatttgca aaataatgaa   14400
cattttttaat atttattaaa atgcttgatt tgcataccccc cgattctaca gagaataatg   14460
tgtaaagtgt cagaatagac ttgaagctct gctgtgactc agtctccttt gtcagagctt   14520
ctagtagccc agctactgag ctgctttgtt agtacctcca gcacctgagc cgttaagtac   14580
ttataaatgc aagggacccg ttatcttcat atcggaatag acatgaacag agctctaagg   14640
cgatgaaagt ctgccagcat cctctctgtc ctcgcacgtg ccttctgcct ggctccattt   14700
gctttggcac tgcgttcgat ctagagtgta ggtgctcact gcttatttca gccctggctc   14760
tgcggttttg tgtcctccag tggtgctgtt cactgttggg gtgcaggtgg tgctgccctg   14820
actcagaggg gcagctccct ggctcctgag ggtgagcctt cttggctact acagaagtat   14880
tgtgcgtttg tgtatggcaa gaaccatcag gattggataa atgtgttatt tctctttgat   14940
ttccatggag ccacactgtt ggtacatgtc ccctgtgaac agagctacct ttcaggagca   15000
catcatactg tcgtgagtca cggcacggtg tgtcctgtga gaagaggctt tctaacgtgt   15060
gatttgccgt gtttctatgt tgtgatttaa gcgtgattgc ctactagtca ttcaaggtaa   15120
catttctgca aatttcatac agattttgt cacaaaatta ctataccaat gatctagttg   15180
aaatagacca attgaatcac aataaataat tttttttaat tgagggaaaa tttgcttctt   15240
gttttttcaa agccagaaaa cgagccattt caaacatctt tgaagagtca tgtgctgtca   15300
cttgtttttct atgtgttagt gtctatattc atgtatggat acacatgaac atgtatattc   15360
atacacacac gccaatagaa tataacagcc taaaaacaat ccagcttgtg tatcatgtta   15420
ctgtgctgaa ttgtaatggt ttttacttac aaagtgaggc taaaatcgat ttcatgtctt   15480
tgttaaatac gtttttttca gcaatcctat tagagcttat tttgaccaga tcaaaataag   15540
tacaagttca gagactttaa atatggctga ggtctagagc gatagctcag tagttaggaa   15600
cacatgccac tctttcaagg gcttcagttc ccagcactca tatggaggct cacagaaggc   15660
tggaattcca gcttcatgga attggacaca tcctctagct tccatggatc tgtctgtctg   15720
tctctcccctt ctctctctct ctctctctct ctctct                            15766
```

&lt;210&gt; 74
&lt;211&gt; 354
&lt;212&gt; PRT
&lt;213&gt; Mus musculus

```
<400> 74
Met Arg Tyr Leu Leu Pro Ser Val Leu Leu Leu Gly Ser Ala Pro Thr
1               5                   10                  15
Tyr Leu Leu Ala Trp Thr Leu Trp Arg Val Leu Ser Ala Leu Met Pro
            20                  25                  30
Ala Arg Leu Tyr Gln Arg Val Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35                  40                  45
Asn Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu
    50                  55                  60
Leu Tyr Gly Asp Leu Pro Lys Asn Lys Glu Asn Val Ile Tyr Leu Ala
65              70                  75                  80
Asn His Gln Ser Thr Val Asp Trp Ile Val Ala Asp Met Leu Ala Ala
                85                  90                  95
Arg Gln Asp Ala Leu Gly His Val Arg Tyr Val Leu Lys Asp Lys Leu
            100                 105                 110
Lys Trp Leu Pro Leu Tyr Gly Phe Tyr Phe Ala Gln His Gly Gly Ile
        115                 120                 125
Tyr Val Lys Arg Ser Ala Lys Phe Asn Asp Lys Glu Met Arg Ser Lys
    130                 135                 140
Leu Gln Ser Tyr Val Asn Ala Gly Thr Pro Met Tyr Leu Val Ile Phe
145                 150                 155                 160
Pro Glu Gly Thr Arg Tyr Asn Ala Thr Tyr Thr Lys Leu Leu Ser Ala
                165                 170                 175
Ser Gln Ala Phe Ala Ala Gln Arg Gly Leu Ala Val Leu Lys His Val
            180                 185                 190
Leu Thr Pro Arg Ile Lys Ala Thr His Val Ala Phe Asp Ser Met Lys
        195                 200                 205
Ser His Leu Asp Ala Ile Tyr Asp Val Thr Val Val Tyr Glu Gly Asn
    210                 215                 220
Glu Lys Gly Ser Gly Lys Tyr Ser Asn Pro Pro Ser Met Thr Glu Phe
225                 230                 235                 240
Leu Cys Lys Gln Cys Pro Lys Leu His Ile His Phe Asp Arg Ile Asp
                245                 250                 255
Arg Asn Glu Val Pro Glu Glu Gln Glu His Met Lys Lys Trp Leu His
            260                 265                 270
Glu Arg Phe Glu Ile Lys Asp Arg Leu Leu Ile Glu Phe Tyr Asp Ser
        275                 280                 285
Pro Asp Pro Glu Arg Arg Asn Lys Phe Pro Gly Lys Ser Val His Ser
    290                 295                 300
Arg Leu Ser Val Lys Lys Thr Leu Pro Ser Val Leu Ile Leu Gly Ser
305                 310                 315                 320
Leu Thr Ala Val Met Leu Met Thr Glu Ser Gly Arg Lys Leu Tyr Met
                325                 330                 335
Gly Thr Trp Leu Tyr Gly Thr Leu Leu Gly Cys Leu Trp Phe Val Ile
            340                 345                 350
Lys Ala
<210> 75
<211> 22
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..22
<223> amplification oligonucleotide g34292.pu
<400> 75
attaaaacac gtactgacac ca                                          22
<210> 76
<211> 19
<212> DNA
<213> Mus Musculus
<220>
```

```
<221> misc_binding
<222> 1..19
<223> amplification oligonucleotide g34292.rp
<400> 76
agtcatggat ggtggattt                                              19
<210> 77
<211> 26
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..26
<223> amplification oligonucleotide BOXIed
<400> 77
aatcatcaaa gcacagttga ctggat                                     26
<210> 78
<211> 33
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..33
<223> amplification oligonucleotide BOXIIIer
<400> 78
ataaaccacc gtaacatcat aaattgcatc taa                             33
<210> 79
<211> 22
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..22
<223> sequencing oligonucleotide moPGrace3S473
<400> 79
gagataaaag ataggttgct ca                                         22
<210> 80
<211> 19
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..19
<223> sequencing oligonucleotide moPGrace3S526
<400> 80
aagaaacaaa tttcctggg                                             19
<210> 81
<211> 18
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..18
<223> sequencing oligonucleotide moPGrace3S597
<400> 81
tcttggggag tttgactg                                              18
<210> 82
<211> 18
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
```

```
<222> 1..18
<223> sequencing oligonucleotide moPGrace5R323
<400> 82
gaccccggtg tagttctc                                                    18
<210> 83
<211> 17
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..17
<223> sequencing oligonucleotide moPGrace5R372
<400> 83
cagtaaagcc ggtcgtc                                                     17
<210> 84
<211> 17
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..17
<223> sequencing oligonucleotide moPGrace5R444
<400> 84
caggccagca ggtaggt                                                     17
<210> 85
<211> 19
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..19
<223> sequencing oligonucleotide moPGrace5R492
<400> 85
agcaggtagc gcatagagt                                                   19
<210> 86
<211> 27
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..27
<223> amplification oligonucleotide moPG13LR2
<400> 86
ggaaacaatg tgatacaatg tgtagcc                                          27
<210> 87
<211> 18
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..18
<223> amplification oligonucleotide moPG15
<400> 87
tggcgagccg agaggatg                                                    18
<210> 88
<211> 36
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..36
```

```
<223> amplification oligonucleotide moPG15Bam1
<400> 88
cgtggatccg gaaacaatgt gatacaatgt gtagcc                              36
<210> 89
<211> 27
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..27
<223> amplification oligonucleotide moPG15Eco1
<400> 89
cgtgaattct ggcgagccga gaggatg                                        27
<210> 90
<211> 20
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..20
<223> amplification oligonucleotide moPG1RACE3.18
<400> 90
ctgccagaca ggatgcccta                                                20
<210> 91
<211> 23
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..23
<223> amplification oligonucleotide moPG1RACE3.63
<400> 91
acaagttaaa atggcttccg ctg                                            23
<210> 92
<211> 18
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..18
<223> sequencing oligonucleotide moPG1RACE3R94
<400> 92
caaatgcatg ttggctgt                                                  18
<210> 93
<211> 20
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..20
<223> amplification oligonucleotide moPG1RACE5.276
<400> 93
gcaaatgcct gactggctga                                                20
<210> 94
<211> 22
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..22
<223> amplification oligonucleotide moPG1RACE5.350
```

```
<400> 94
aatcaaaagc aacgtgagtg gc                                             22
<210> 95
<211> 20
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..20
<223> amplification oligonucleotide moPG3RACE2
<400> 95
tgggcacctg gttgtatgga                                                20
<210> 96
<211> 20
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..20
<223> amplification oligonucleotide moPG3RACE2n
<400> 96
tccttggctg cctgtggttt                                                20
<210> 97
<211> 21
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..21
<223> sequencing oligonucleotide moPG3RACES20
<400> 97
gatggctaca cattgtatca c                                              21
<210> 98
<211> 24
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..24
<223> sequencing oligonucleotide moPG3RACES5
<400> 98
tcctgaatta ataaggagt tttc                                            24
<210> 99
<211> 24
<212> DNA
<213> Mus Musculus
<220>
<221> misc_binding
<222> 1..24
<223> sequencing oligonucleotide moPG3RACES90
<400> 99
gtttgttatt aaagcataag caag                                           24
<210> 100
<211> 216
<212> DNA
<213> Homo sapiens
<400> 100
ctgctgtccc tggtgctcca cacgtactcc atgcgctacc tgctgcccag cgtcgtgctc    60
ctgggcacgg cgcccaccta cgtgttggcc tggggggtct ggcggctgct ctccgccttc   120
ctgcccgccc gcttctacca agcgctggac gaccggctgt actgcgtcta ccagagcatg   180
gtgctcttct tcttcgagaa ttacaccggg gtccag                             216
```

```
<210> 101
<211> 70
<212> DNA
<213> Homo sapiens
<400> 101
atattgctat atggagattt gccaaaaaat aaagaaaata taatatattt agcaaatcat      60
caaagcacag                                                             70
<210> 102
<211> 116
<212> DNA
<213> Homo sapiens
<400> 102
ttgactggat tgttgctgac atcttggcca tcaggcagaa tgcgctagga catgtgcgct      60
acgtgctgaa agaagggtta aaatggctgc cattgtatgg gtgttacttt gctcag         116
<210> 103
<211> 90
<212> DNA
<213> Homo sapiens
<400> 103
catggaggaa tctatgtaaa gcgcagtgcc aaatttaacg agaaagagat gcgaaacaag      60
ttgcagagct acgtggacgc aggaactcca                                       90
<210> 104
<211> 91
<212> DNA
<213> Homo sapiens
<400> 104
atgtatcttg tgattttttcc agaaggtaca aggtataatc cagagcaaac aaaagtcctt     60
tcagctagtc aggcatttgc tgcccaacgt g                                     91
<210> 105
<211> 159
<212> DNA
<213> Homo sapiens
<400> 105
gccttgcagt attaaaacat gtgctaacac cacgaataaa ggcaactcac gttgcttttg      60
attgcatgaa gaattattta gatgcaattt atgatgttac ggtggtttat gaagggaaag     120
acgatggagg gcagcgaaga gagtcaccga ccatgacgg                            159
<210> 106
<211> 124
<212> DNA
<213> Homo sapiens
<400> 106
aatttctctg caaagaatgt ccaaaaattc atattcacat tgatcgtatc gacaaaaaag      60
atgtcccaga agaacaagaa catatgagaa gatggctgca tgaacgtttc gaaatcaaag     120
ataa                                                                  124
<210> 107
<211> 4342
<212> DNA
<213> Homo sapiens
<220>
<221> polyA_signal
<222> 325..330
<223> AATAAA  potential
<221> polyA_signal
<222> 694..699
<223> AATAAA  potential
<221> polyA_signal
<222> 828..833
<223> AATAAA  potential
<221> polyA_signal
<222> 1821..1826
<223> AATAAA  potential
```

```
<221> polyA_signal
<222> 2480..2485
<223> AATAAA : potential
<221> polyA_signal
<222> 2800..2805
<223> AATAAA ¦ potential
<221> polyA_signal
<222> 4264..4269
<223> AATAAA ' potential
<221> polyA_signal
<222> 4320..4315
<223> AATAAA
<400> 107
gatgcttata gaattttatg agtcaccaga tccagaaaga agaaaaagat ttcctgggaa    60
aagtgttaat tccaaattaa gtatcaagaa gactttacca tcaatgttga tcttaagtgg   120
tttgactgca ggcatgctta tgaccgatgc tggaaggaag ctgtatgtga acacctggat   180
atatggaacc ctacttggct gcctgtgggt tactattaaa gcatagacaa gtagctgtct   240
ccagacagtg ggatgtgcta cattgtctat ttttggcggc tgcacatgac atcaaattgt   300
ttcctgaatt tattaaggag tgtaaataaa gccttgttga ttgaagattg gataatagaa   360
tttgtgacga aagctgatat gcaatggtct tgggcaaaca tacctggttg tacaacttta   420
gcatcggggc tgctggaagg gtaaaagcta aatggagttt ctcctgctct gtccatttcc   480
tatgaactaa tgacaacttg agaaggctgg gaggattgtg tattttgcaa gtcagatggc   540
tgcatttttg agcattaatt tgcagcgtat ttcacttttt ctgttatttt caatttatta   600
caacttgaca gctccaagct cttattacta aagtatttag tatcttgcag ctagttaata   660
tttcatcttt tgcttatttc tacaagtcag tgaaataaat tgtatttagg aagtgtcagg   720
atgttcaaag gaaagggtaa aaagtgttca tggggaaaaa gctctgttta gcacatgatt   780
ttattgtatt gcgttattag ctgattttac tcattttata tttgcaaaat aaatttctaa   840
tatttattga aattgcttaa tttgcacacc ctgtacacac agaaaatggt ataaaatatg   900
agaacgaagt ttaaaattgt gactctgatt cattatagca gaactttaaa tttcccagct   960
ttttgaagat ttaagctacg ctattagtac ttccctttgt ctgtgccata agtgcttgaa  1020
aacgttaagg ttttctgttt tgttttgttt ttttaatatc aaaagagtcg gtgtgaacct  1080
tggttggacc ccaagttcac aagatttta aggtgatgag agcctgcaga cattctgcct  1140
agatttacta gcgtgtgcct tttgcctgct tctctttgat ttcacagaat attcattcag  1200
aagtcgcgtt tctgtagtgt ggtggattcc cactgggctc tggtccttcc cttggatccc  1260
gtcagtggtg ctgctcagcg gcttgcacgt agacttgcta ggaagaaatg cagagccagc  1320
ctgtgctgcc cactttcaga gttgaactct ttaagcccctt gtgagtgggc ttcaccagct  1380
actgcagagg cattttgcat ttgtctgtgt caagaagttc accttctcaa gccagtgaaa  1440
tacagactta attcgtcatg actgaacgaa tttgtttatt tcccattagg tttagtggag  1500
ctacacatta atatgtatcg ccttagagca agagctgtgt tccaggaacc agatcacgat  1560
ttttagccat ggaacaatat atcccatggg agaagacctt tcagtgtgaa ctgttctatt  1620
tttgtgttat aatttaaact tcgatttcct catagtcctt taagttgaca tttctgctta  1680
ctgctactgg atttttgctg cagaaatata tcagtggccc acattaaaca taccagttgg  1740
atcatgataa gcaaaatgaa agaaataatg attaagggaa aattaagtga ctgtgttaca  1800
ctgcttctcc catgccagag aataaactct ttcaagcatc atctttgaag agtcgtgtgg  1860
tgtgaattgg tttgtgtaca ttagaatgta tgcacacatc catggacact caggatatag  1920
ttggcctaat aatcggggca tgggtaaaac ttatgaaaat ttcctcatgc tgaattgtaa  1980
ttttctctta cctgtaaagt aaaatttaga tcaattccat gtctttgtta agtacaggga  2040
tttaatatat tttgaatata atgggtatgt tctaaatttg aactttgaga ggcaatactg  2100
ttggaattat gtggattcta actcatttta acaaggtagc ctgacctgca taagatcact  2160
tgaatgttag gtttcataga actatactaa tcttctcaca aaaggtctat aaaatacagt  2220
cgttgaaaaa aattttgtat caaaatgttt ggaaaattag aagcttctcc ttaacctgta  2280
ttgatactga cttgaattat tttctaaaat taagagccgt atacctacct gtaagtcttt  2340
tcacatatca tttaaacttt tgtttgtatt attactgatt tacagcttag ttattaattt  2400
ttctttataa gaatgccgtc gatgtgcatg cttttatgtt tttcagaaaa gggtgtgttt  2460
ggatgaaagt aaaaaaaaaa ataaaatctt tcactgtctc taatggctgt gctgtttaac  2520
attttttgac cctaaaattc accaacagtc tcccagtaca taaaataggc ttaatgactg  2580
gccctgcatt cttcacaata ttttttccta agctttgagc aaagttttaa aaaaatacac  2640
taaaataatc aaaactgtta agcagtatat tagtttggtt atataaattc atctgcaatt  2700
tataagatgc atggccgatg ttaatttgct tggcaattct gtaatcatta agtgatctca  2760
gtgaaacatg tcaaatgcct taaattaact aagttggtga ataaaagtgc cgatctggct  2820
aactcttaca ccatacatac tgatagtttt tcatatgttt catttccatg tgattttta   2880
```

```
aatttagagt ggcaacaatt ttgcttaata tgggttacat aagctttatt ttttcctttg      2940
ttcataatta tattctttga ataggtctgt gtcaatcaag tgatctaact agactgatca      3000
tagatagaag gaaataaggc caagttcaag accagcctgg gcaacatatc gagaacctgt      3060
ctacaaaaaa attaaaaaaa attagccagg catggtggcg tacactgagt agtttgtccc      3120
agctactcgg gaggtgagg tgggaggatc gcttcagccc aggaggttga gattgcagtg      3180
agccatggac ataccactgc actacagcct aggtaacagc acgagacccc aactcttaga      3240
aaatgaaaag gaaatataga aatataaaat ttgcttatta tagacacaca gtaactccca      3300
gatatgtacc acaaaaaatg tgaaaagaga gagaaatgtc taccaaagca gtattttgtg      3360
tgtataattg caagcgcata gtaaaataat tttaacctta atttgttttt agtagtgttt      3420
agattgaaga ttgagtgaaa tattttcttg gcagatattc cgtatctggt ggaaagctac      3480
aatgcaatgt cgttgtagtt ttgcatggct tgctttataa acaagatttt ttctccctcc      3540
ttttgggcca gttttcatta cgagtaactc acactttttg attaaagaac ttgaaattac      3600
gttatcactt agtataattg acattatata gagactatgt aacatgcaat cattagaatc      3660
aaaattagta ctttggtcaa aatatttaca acattcacat acttgtcaaa tattcatgta      3720
attaactgaa tttaaaacct tcaactatta tgaagtgctc gtctgtacaa tcgctaattt      3780
actcagttta gagtagctac aactcttcga tactatcatc aatatttgac atctttttcca     3840
atttgtgtat gaaaagtaaa tctattcctg tagcaactgg ggagtcatat atgaggtcaa      3900
agacatatac cttgttatta taatatgtat actataataa tagctggtta tcctgagcag      3960
gggaaaaggt tattttttagg aaaaccactt caaatagaaa gctgaagtac ttctaatata     4020
ctgagggaag tataatatgt ggaacaaact ctcaacaaaa tgtttattga tgttgatgaa      4080
acagatcagt ttttccatcc ggattattat tggttcatga ttttatatgt gaatatgtaa      4140
gatatgttct gcaatttttat aaatgttcat gtcttttttt aaaaaaggtg ctattgaaat      4200
tctgtgtctc cagcaggcaa gaatacttga ctaactcttt ttgtctcttt atggtatttt      4260
cagaataaag tctgacttgt gttttttgaga ttattggtgc ctcattaatt cagcaataaa     4320
ggaaaatatg catctcaaaa at                                                4342
<210> 108
<211> 62
<212> DNA
<213> Homo sapiens
<400> 108
agattggatt cgtagattaa acttgagaaa caaaccataa aagtggaagg ccctctttaa       60
ca                                                                       62
<210> 109
<211> 86
<212> DNA
<213> Homo sapiens
<400> 109
gagatggggg tctcgctgtg ttgcccaggc tggtcttgga ctcaagcaat ctgcctgtct       60
cagcctacca aaatgctgga ttatag                                            86
<210> 110
<211> 116
<212> DNA
<213> Homo sapiens
<400> 110
gctaaagcag tcctcctgag tagttaggac tacagacata cacgtgccac cgcgcccagc       60
tccgtgttct ctttgtttcc ctgcctcctg ctcttccact tatctttgca tggcag          116
<210> 111
<211> 45
<212> DNA
<213> Homo sapiens
<400> 111
ggaaagacga tggagggcag cgaagagagt caccgaccat gacgg                       45
<210> 112
<211> 5138
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
```

```
<222> 262..264
<223> TAG
<221> polyA_signal
<222> 5111..5116
<223> AATAAA
<400> 112
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc        54
                                    Met Arg Tyr Leu Leu Pro Ser Val
                                     1               5
gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg       102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
    10              15                  20
cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac       150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25              30                  35                  40
gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag       198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                45              50                  55
aat tac acc ggg gtc cag ttg act gga ttg ttg ctg aca tct tgg cca       246
Asn Tyr Thr Gly Val Gln Leu Thr Gly Leu Leu Leu Thr Ser Trp Pro
            60              65                  70
tca ggc aga atg cgc tag gacatgtgcg ctacgtgctg aaagaagggt             294
Ser Gly Arg Met Arg  *
            75
taaaatggct gccattgtat gggtgttact ttgctcagca tggaggaatc tatgtaaagc    354
gcagtgccaa atttaacgag aaagagatgc gaaacaagtt gcagagctac gtggacgcag    414
gaactccaat gtatcttgtg attttttccag aaggtacaag gtataatcca gagcaaacaa   474
aagtcctttc agctagtcag gcatttgctg cccaacgtgg ccttgcagta ttaaaacatg    534
tgctaacacc acgaataaag gcaactcacg ttgcttttga ttgcatgaag aattatttag    594
atgcaattta tgatgttacg gtggtttatg aagggaaaga cgatggaggg cagcgaagag    654
agtcaccgac catgacggaa tttctctgca aagaatgtcc aaaaattcat attcacattg    714
atcgtatcga caaaaaagat gtcccagaag aacaagaaca tatgaagaa tggctgcatg     774
aacgtttcga aatcaaagat aagatgctta tagaatttta tgagtcacca gatccagaaa    834
gaagaaaaag atttcctggg aaaagtgtta attccaaatt aagtatcaag aagactttac    894
catcaatgtt gatcttaagt ggtttgactg caggcatgct tatgaccgat gctggaagga    954
agctgtatgt gaacacctgg atatatggaa ccctacttgg ctgcctgtgg gttactatta   1014
aagcatagac aagtagctgt ctccagacag tgggatgtgc tacattgtct atttttggcg   1074
gctgcacatg acatcaaatt gtttcctgaa tttattaagg agtgtaaata aagccttgtt   1134
gattgaagat tggataatag aatttgtgac gaaagctgat atgcaatggt cttgggcaaa   1194
catacctggt tgtacaactt tagcatcggg gctgctggaa gggtaaaagc taaatggagt   1254
ttctcctgct ctgtccattt cctatgaact aatgacaact tgagaaggct gggaggattg   1314
tgtatttttgc aagtcagatg gctgcatttt tgagcattaa tttgcagcgt atttcacttt  1374
ttctgttatt ttcaatttat tacaacttga cagctccaag ctcttattac taaagtatttt  1434
agtatcttgc agctagttaa tatttcatct tttgcttatt tctacaagtc agtgaaataa   1494
attgtatttta ggaagtgtca ggatgttcaa aggaaagggt aaaagtgtt catggggaaa    1554
aagctctgtt tagcacatga ttttattgta ttgcgttatt agctgatttt actcatttta   1614
tatttgcaaa ataaatttct aatatttatt gaaattgctt aatttgcaca ccctgtacac   1674
acagaaaatg gtataaaata tgagaacgaa gtttaaaatt gtgactctga ttcattatag   1734
cagaacttta aatttcccag cttttttgaag atttaagcta cgctattagt acttcccttt   1794
gtctgtgcca taagtgcttg aaaacgttaa ggtttttctgt tttgttttgt tttttttaata 1854
tcaaaagagt cggtgtgaac cttggttgga ccccaagttc acaagatttt taaggtgatg    1914
agagcctgca gacattctgc ctagatttac tagcgtgtgc cttttgcctg cttctctttg   1974
atttcacaga atattcattc agaagtcgcg tttctgtagt gtggtggatt cccactgggc   2034
tctggtccctt cccttggatc ccgtcagtgg tgctgctcag cggcttgcac gtagacttgc   2094
taggaagaaa tgcagagcca gcctgtgctg cccacttca gagttgaact ctttaagccc    2154
ttgtgagtgg gcttcaccag ctactgcaga ggcattttgc atttgtctgt gtcaagaagt   2214
tcaccttctc aagccagtga aatacagact taattcgtca tgactgaacg aatttgttta   2274
tttcccatta ggtttagtgg agctacacat taatatgtat cgccttagag caagagctgt   2334
gttccaggaa ccagatcacg attttttagcc atggaacaat atatcccatg ggagaagacc   2394
tttcagtgtg aactgttcta tttttgtgtt ataatttaaa cttcgatttc ctcatagtcc    2454
tttaagttga catttctgct tactgctact ggattttttgc tgcagaaata tatcagtggc   2514
```

56

```
ccacattaaa cataccagtt ggatcatgat aagcaaaatg aaagaaataa tgattaaggg   2574
aaaattaagt gactgtgtta cactgcttct cccatgccag agaataaact ctttcaagca   2634
tcatctttga agagtcgtgt ggtgtgaatt ggtttgtgta cattagaatg tatgcacaca   2694
tccatggaca ctcaggatat agttggccta ataatcgggg catgggtaaa acttatgaaa   2754
atttcctcat gctgaattgt aattttctct tacctgtaaa gtaaaattta gatcaattcc   2814
atgtctttgt taagtacagg gatttaatat attttgaata taatgggtat gttctaaatt   2874
tgaactttga gaggcaatac tgttggaatt atgtggattc taactcattt taacaaggta   2934
gcctgacctg cataagatca agtgaatgtt aggtttcata gaactatact aatcttctca   2994
caaaaggtct ataaaataca gtcgttgaaa aaaattttgt atcaaaatgt ttggaaaatt   3054
agaagcttct ccttaacctg tattgatact gacttgaatt attttctaaa attaagagcc   3114
gtatacctac ctgtaagtct tttcacatat catttaaact tttgtttgta ttattactga   3174
tttacagctt agttattaat ttttctttat aagaatgccg tcgatgtgca tgctttttatg   3234
tttttcagaa aagggtgtgt ttggatgaaa gtaaaaaaaa aaataaaatc tttcactgtc   3294
tctaatggct gtgctgttta acattttttg accctaaaat tcaccaacag tctcccagta   3354
cataaaatag gcttaatgac tggccctgca ttcttcacaa tattttccc  taagctttga   3414
gcaaagtttt aaaaaaatac actaaaataa tcaaaactgt taagcagtat attagtttgg   3474
ttatataaat tcatctgcaa tttataagat gcatggccga tgttaatttg cttggcaatt   3534
ctgtaatcat taagtgatct cagtgaaaca tgtcaaatgc cttaaattaa ctaagttggt   3594
gaataaaagt gccgatctgg ctaactctta caccatacat actgatagtt cttcatatgt   3654
ttcatttcca tgtgattttt aaaatttaga gtggcaacaa ttttgcttaa tatgggttac   3714
ataagctttta ttttttcctt tgttcataat tatattcttt gaataggtct gtgtcaatca   3774
agtgatctaa ctagactgat catagataga aggaaataag gccaagttca agaccagcct   3834
gggcaacata tcgagaacct gtctacaaaa aaattaaaaa aaattagcca ggcatggtgg   3894
cgtacactga gtagtttgtc ccagctactc gggagggtga ggtgggagga tcgcttcagc   3954
ccaggaggtt gagattgcag tgagccatgg acataccact gcactacagc ctaggtaaca   4014
gcacgagacc ccaactctta gaaaatgaaa aggaaatata gaaatataaa atttgcttat   4074
tatagacaca cagtaactcc cagatatgta ccacaaaaaa tgtgaaaaga gagagaaatg   4134
tctaccaaag cagtattttg tgtgtataat tgcaagcgca tagtaaaata attttaacct   4194
taatttgttt ttagtagtgt ttagattgaa gattgagtga aatattttct tggcagatat   4254
tccgtatctg gtggaaagct acaatgcaat gtcgttgtag ttttgcatgg cttgctttat   4314
aaacaagatt ttttctccct ccttttgggc cagttttcat tacgagtaac tcacacttt t   4374
tgattaaaga acttgaaatt acgttatcac ttagtataat tgacattata tagagactat   4434
gtaacatgca atcattagaa tcaaaattag tactttggtc aaaatattta caacattcac   4494
atacttgtca aatattcatg taattaactg aatttaaaac cttcaactat tatgaagtgc   4554
tcgtctgtac aatcgctaat ttactcagtt tagagtagct acaactcttc gatactatca   4614
tcaatatttg acatcttttc caatttgtgt atgaaaagta aatctattcc tgtagcaact   4674
ggggagtcat atatgaggtc aaagacatat accttgttat tataatatgt atactataat   4734
aatagctggt tatcctgagc aggggaaaag gttattttta ggaaaaccac ttcaaataga   4794
aagctgaagt acttctaata tactgaggga agtataatat gtggaacaaa ctctcaacaa   4854
aatgtttatt gatgttgatg aaacagatca gttttttccat ccggattatt attggttcat   4914
gattttatat gtgaatatgt aagatatgtt ctgcaatttt ataaatgttc atgtcttttt   4974
ttaaaaaagg tgctattgaa attctgtgtc tccagcaggc aagaatactt gactaactct   5034
ttttgtctct ttatggtatt ttcagaataa agtctgactt gtgtttttga gattattggt   5094
gcctcattaa ttcagcaata aaggaaaata tgcatctcaa aaat                     5138
```

```
<210> 113
<211> 5224
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 262..264
<223> TAG
<221> polyA_signal
<222> 5197..5202
<223> AATAAA
<400> 113
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc     54
                                    Met Arg Tyr Leu Leu Pro Ser Val
```

57

```
                                       1                   5
gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg      102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
    10                   15                  20
cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac      150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25                   30                  35                  40
gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag      198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                 45                  50                  55
aat tac acc ggg gtc cag ttg act gga ttg ttg ctg aca tct tgg cca      246
Asn Tyr Thr Gly Val Gln Leu Thr Gly Leu Leu Leu Thr Ser Trp Pro
                 60                  65                  70
tca ggc aga atg cgc tag gacatgtgcg ctacgtgctg aaagaagggt            294
Ser Gly Arg Met Arg  *
             75
taaaatggct gccattgtat gggtgttact ttgctcagga gatgggggtc tcgctgtgtt   354
gcccaggctg gtcttggact caagcaatct gcctgtctca gcctaccaaa atgctggatt   414
atagcatgga ggaatctatg taaagcgcag tgccaaattt aacgagaaag agatgcgaaa   474
caagttgcag agctacgtgg acgcaggaac tccaatgtat cttgtgattt ttccagaagg   534
tacaaggtat aatccagagc aaacaaaagt cctttcagct agtcaggcat ttgctgccca   594
acgtggcctt gcagtattaa aacatgtgct aacaccacga ataaaggcaa ctcacgttgc   654
ttttgattgc atgaagaatt atttagatgc aatttatgat gttacggtgg tttatgaagg   714
gaaagacgat ggagggcagc gaagagagtc accgaccatg acggaatttc tctgcaaaga   774
atgtccaaaa attcatattc acattgatcg tatcgacaaa aaagatgtcc agaagaaca    834
agaacatatg agaagatggc tgcatgaacg tttcgaaatc aaagataaga tgcttataga   894
attttatgag tcaccagatc cagaaagaag aaaaagattt cctgggaaaa gtgttaattc   954
caaattaagt atcaagaaga ctttaccatc aatgttgatc ttaagtggtt tgactgcagg  1014
catgcttatg accgatgctg gaaggaagct gtatgtgaac acctggatat atggaaccct  1074
acttggctgc ctgtgggtta ctattaaagc atagacaagt agctgtctcc agacagtggg  1134
atgtgctaca ttgtctattt ttggcggctg cacatgacat caaattgttt cctgaattta  1194
ttaaggagtg taaataaagc cttgttgatt gaagattgga taatagaatt tgtgacgaaa  1254
gctgatatgc aatggtcttg ggcaaacata cctggttgta caactttagc atcggggctg  1314
ctggaagggt aaaagctaaa tggagtttct cctgctctgt ccatttccta tgaactaatg  1374
acaacttgag aaggctgggg ggattgtgta ttttgcaagt cagatggctg catttttgag  1434
cattaatttg cagcgtattt cactttttct gttattttca atttattaca acttgacagc  1494
tccaagctct tattactaaa gtatttagta tcttgcagct agttaatatt tcatcttttg  1554
cttatttcta caagtcagtg aaataaattg tatttaggaa gtgtcaggat gttcaaagga  1614
aagggtaaaa agtgttcatg gggaaaaagc tctgtttagc acatgatttt attgtattgc  1674
gttattagct gattttactc attttatatt tgcaaaataa atttctaata tttattgaaa  1734
ttgcttaatt tgcacaccct gtacacacag aaaatggtat aaaatatgag aacgaagttt  1794
aaaattgtga ctctgattca ttatagcaga actttaaatt tcccagcttt ttgaagattt  1854
aagctacgct attagtactt cccctttgtct gtgccataag tgcttgaaaa cgttaaggtt  1914
ttctgttttg ttttgttttt ttaatatcaa aagagtcggt gtgaaccttg gttggacccc  1974
aagttcacaa gatttttaag gtgatgagag cctgcagaca ttctgcctag atttactagc  2034
gtgtgccttt tgcctgcttc tctttgattt cacagaatat tcattcagaa gtcgcgtttc  2094
tgtagtgtgg tggattccca ctgggctctg gtccttccct tggatcccgt cagtggtgct  2154
gctcagcggc ttgcacgtag acttgctagg aagaaatgca gagccagcct gtgctgccca  2214
ctttcagagt tgaactcttt aagcccttgt gagtgggctt caccagctac tgcagaggca  2274
ttttgcattt gtctgtgtca agaagttcac cttctcaagc cagtgaaata cagacttaat  2334
tcgtcatgac tgaacgaatt tgtttatttc ccattaggtt tagtggagct acacattaat  2394
atgtatcgcc ttagagcaag agctgtgttc caggaaccag atcacgattt ttagccatgg  2454
aacaatatat cccatgggag aagacctttc agtgtgaact gttctatttt tgtgttataa  2514
tttaaacttc gatttcctca tagtccttta agttgacatt tctgcttact gctactggat  2574
ttttgctgca gaaatatatc agtggcccac attaaacata ccagttggat catgataagc  2634
aaaatgaaag aaataatgat taagggaaaa ttaagtgact gtgttacact gcttctccca  2694
tgccagagaa taaactcttt caagcatcat ctttgaagag tcgtgtggtg tgaattggtt  2754
tgtgtacatt agaatgtatg cacacatcca tggacactca ggatatagtt ggcctaataa  2814
tcggggcatg ggtaaaactt atgaaaattt cctcatgctg aattgtaatt ttctcttacc  2874
tgtaaagtaa aatttagatc aattccatgt ctttgttaag tacagggatt taatatattt  2934
tgaatataat gggtatgttc taaatttgaa ctttgagagg caatactgtt ggaattatgt  2994
```

```
ggattctaac tcattttaac aaggtagcct gacctgcata agatcacttg aatgttaggt  3054
ttcatagaac tatactaatc ttctcacaaa aggtctataa aatacagtcg ttgaaaaaaa  3114
ttttgtatca aaatgtttgg aaaattagaa gcttctcctt aacctgtatt gatactgact  3174
tgaattattt tctaaaatta agagccgtat acctacctgt aagtcttttc acatatcatt  3234
taaacttttg tttgtattat tactgattta cagcttagtt attaattttt ctttataaga  3294
atgccgtcga tgtgcatgct tttatgtttt tcagaaaagg gtgtgtttgg atgaaagtaa  3354
aaaaaaaaat aaaatctttc actgtctcta atggctgtgc tgtttaacat tttttgaccc  3414
taaaattcac caacagtctc ccagtacata aaataggctt aatgactggc cctgcattct  3474
tcacaatatt tttccctaag ctttgagcaa agttttaaaa aaatacacta aaataatcaa  3534
aactgttaag cagtatatta gtttggttat ataaattcat ctgcaattta taagatgcat  3594
ggccgatgtt aatttgcttg gcaattctgt aatcattaag tgatctcagt gaaacatgtc  3654
aaatgcctta aattaactaa gttggtgaat aaaagtgccg atctggctaa ctcttacacc  3714
atacatactg atagtttttc atatgtttca tttccatgtg attttaaaa tttagagtgg  3774
caacaatttt gcttaatatg ggttacataa gctttatttt ttcctttgtt cataattata  3834
ttctttgaat aggtctgtgt caatcaagtg atctaactag actgatcata gatagaagga  3894
aataaggcca agttcaagac cagcctgggc aacatatcga gaacctgtct acaaaaaaat  3954
taaaaaaaat tagccaggca tggtggcgta cactgagtag tttgtcccag ctactcggga  4014
gggtgaggtg ggaggatcgc ttcagcccag gaggttgaga ttgcagtgag ccatggacat  4074
accactgcac tacagcctag gtaacagcac gagaccccaa ctcttagaaa atgaaaagga  4134
aatatagaaa tataaaattt gcttattata gacacacagt aactcccaga tatgtaccac  4194
aaaaaatgtg aaaagagaga gaaatgtcta ccaaagcagt attttgtgtg tataattgca  4254
agcgcatagt aaaataattt taaccttaat ttgttttag tagtgtttag attgaagatt  4314
gagtgaaata ttttcttggc agatattccg tatctggtgg aaagctacaa tgcaatgtcg  4374
ttgtagtttt gcatggcttg ctttataaac aagatttttt ctccctcctt ttgggccagt  4434
tttcattacg agtaactcac acttttgat taaagaactt gaaattacgt tatcacttag  4494
tataattgac attatataga gactatgtaa catgcaatca ttagaatcaa aattagtact  4554
ttggtcaaaa tatttacaac attcacatac ttgtcaaata ttcatgtaat taactgaatt  4614
taaaaccttc aactattatg aagtgctcgt ctgtacaatc gctaatttac tcagtttaga  4674
gtagctacaa ctttcgata ctatcatcaa tatttgacat cttttccaat ttgtgtatga  4734
aaagtaaatc tattcctgta gcaactgggg agtcatatat gaggtcaaag acatatacct  4794
tgttattata atatgtatac tataataata gctggttatc ctgagcaggg gaaaaggtta  4854
tttttaggaa aaccacttca aatagaaagc tgaagtactt ctaatatact gagggaagta  4914
taatatgtgg aacaaactct caacaaaatg tttattgatg ttgatgaaac agatcagttt  4974
ttccatccgg attattattg gttcatgatt ttatatgtga atatgtaaga tatgttctgc  5034
aattttataa atgttcatgt cttttttaa aaaaggtgct attgaaattc tgtgtctcca  5094
gcaggcaaga atacttgact aactcttttt gtctctttat ggtattttca gaataaagtc  5154
tgacttgtgt ttttgagatt attggtgcct cattaattca gcaataaagg aaaatatgca  5214
tctcaaaaat                                                         5224
```

```
<210> 114
<211> 4863
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 745..747
<223> TAG
<221> polyA_signal
<222> 4836..4841
<223> AATAAA
<400> 114
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc      54
                                  Met Arg Tyr Leu Leu Pro Ser Val
                                  1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg     102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
    10              15                  20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac     150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
```

```
       25                   30                   35                   40
gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag        198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                45                   50                   55
aat tac acc ggg gtc cag cat gga gga atc tat gta aag cgc agt gcc        246
Asn Tyr Thr Gly Val Gln His Gly Gly Ile Tyr Val Lys Arg Ser Ala
                60                   65                   70
aaa ttt aac gag aaa gag atg cga aac aag ttg cag agc tac gtg gac        294
Lys Phe Asn Glu Lys Glu Met Arg Asn Lys Leu Gln Ser Tyr Val Asp
            75                   80                   85
gca gga act cca atg tat ctt gtg att ttt cca gaa ggt aca agg tat        342
Ala Gly Thr Pro Met Tyr Leu Val Ile Phe Pro Glu Gly Thr Arg Tyr
        90                   95                   100
aat cca gag caa aca aaa gtc ctt tca gct agt cag gca ttt gct gcc        390
Asn Pro Glu Gln Thr Lys Val Leu Ser Ala Ser Gln Ala Phe Ala Ala
105                  110                  115                  120
caa cgt gaa ttt ctc tgc aaa gaa tgt cca aaa att cat att cac att        438
Gln Arg Glu Phe Leu Cys Lys Glu Cys Pro Lys Ile His Ile His Ile
                125                  130                  135
gat cgt atc gac aaa aaa gat gtc cca gaa gaa caa gaa cat atg aga        486
Asp Arg Ile Asp Lys Lys Asp Val Pro Glu Glu Gln Glu His Met Arg
            140                  145                  150
aga tgg ctg cat gaa cgt ttc gaa atc aaa gat aag atg ctt ata gaa        534
Arg Trp Leu His Glu Arg Phe Glu Ile Lys Asp Lys Met Leu Ile Glu
        155                  160                  165
ttt tat gag tca cca gat cca gaa aga aga aaa aga ttt cct ggg aaa        582
Phe Tyr Glu Ser Pro Asp Pro Glu Arg Arg Lys Arg Phe Pro Gly Lys
    170                  175                  180
agt gtt aat tcc aaa tta agt atc aag aag act tta cca tca atg ttg        630
Ser Val Asn Ser Lys Leu Ser Ile Lys Lys Thr Leu Pro Ser Met Leu
185                  190                  195                  200
atc tta agt ggt ttg act gca ggc atg ctt atg acc gat gct gga agg        678
Ile Leu Ser Gly Leu Thr Ala Gly Met Leu Met Thr Asp Ala Gly Arg
                205                  210                  215
aag ctg tat gtg aac acc tgg ata tat gga acc cta ctt ggc tgc ctg        726
Lys Leu Tyr Val Asn Thr Trp Ile Tyr Gly Thr Leu Leu Gly Cys Leu
        220                  225                  230
tgg gtt act att aaa gca tag acaagtagct gtctccagac agtgggatgt          777
Trp Val Thr Ile Lys Ala  *
        235
gctacattgt ctattttttgg cggctgcaca tgacatcaaa ttgtttcctg aatttattaa    837
ggagtgtaaa taaagccttg ttgattgaag attggataat agaatttgtg acgaaagctg      897
atatgcaatg gtcttgggca aacatacctg gttgtacaac tttagcatcg gggctgctgg      957
aagggtaaaa gctaaatgga gtttctcctg ctctgtccat ttcctatgaa ctaatgacaa     1017
cttgagaagg ctgggaggat tgtgtatttt gcaagtcaga tggctgcatt tttgagcatt     1077
aatttgcagc gtatttcact ttttctgtta ttttcaattt attacaactt gacagctcca     1137
agctcttatt actaaagtat ttagtatctt gcagctagtt aatatttcat cttttgctta     1197
tttctacaag tcagtgaaat aaattgtatt taggaagtgt caggatgttc aaaggaaagg     1257
gtaaaaagtg ttcatgggga aaaagctctg tttagcacat gattttattg tattgcgtta     1317
ttagctgatt ttactcattt tatatttgca aaataaattt ctaatatttta ttgaaattgc    1377
ttaatttgca caccctgtac acacagaaaa tggtataaaa tatgagaacg aagtttaaaa     1437
ttgtgactct gattcattat agcagaactt taaatttccc agctttttga agatttaagc     1497
tacgctatta gtacttccct ttgtctgtgc cataagtgct tgaaaacgtt aaggtttttct    1557
gttttgtttt gtttttttaa tatcaaaaga gtcggtgtga accttggttg gaccccaagt     1617
tcacaagatt tttaaggtga tgagagcctg cagacattct gcctagattt actagcgtgt     1677
gccttttgcc tgcttctctt tgatttcaca gaatattcat tcagaagtcg cgtttctgta     1737
gtgtggtgga ttcccactgg gctctggtcc ttcccttgga tcccgtcagt ggtgctgctc     1797
agcggcttgc acgtagactt gctaggaaga aatgcagagc cagcctgtgc tgcccacttt     1857
cagagttgaa ctctttaagc ccttgtgagt gggcttcacc agctactgca gaggcatttt     1917
gcatttgtct gtgtcaagaa gttcaccttc tcaagccagt gaaatacaga cttaattcgt     1977
catgactgaa cgaatttgtt tatttcccat taggtttagt ggagctacac attaatatgt     2037
```

```
atcgccttag agcaagagct gtgttccagg aaccagatca cgatttttag ccatggaaca   2097
atatatccca tgggagaaga cctttcagtg tgaactgttc tattttttgtg ttataattta   2157
aacttcgatt tcctcatagt cctttaagtt gacatttctg cttactgcta ctggattttt   2217
gctgcagaaa tatatcagtg gcccacatta aacataccag ttggatcatg ataagcaaaa   2277
tgaaagaaat aatgattaag ggaaaattaa gtgactgtgt tacactgctt ctcccatgcc   2337
agagaataaa ctctttcaag catcatcttt gaagagtcgt gtggtgtgaa ttggtttgtg   2397
tacattagaa tgtatgcaca catccatgga cactcaggat atagttggcc taataatcgg   2457
ggcatgggta aaacttatga aaatttcctc atgctgaatt gtaattttct cttacctgta   2517
aagtaaaatt tagatcaatt ccatgtcttt gttaagtaca gggatttaat atattttgaa   2577
tataatgggt atgttctaaa tttgaacttt gagaggcaat actgttggaa ttatgtggat   2637
tctaactcat tttaacaagg tagcctgacc tgcataagat cacttgaatg ttaggtttca   2697
tagaactata ctaatcttct cacaaaaggt ctataaaata cagtcgttga aaaaaatttt   2757
gtatcaaaat gtttggaaaa ttagaagctt ctccttaacc tgtattgata ctgacttgaa   2817
ttattttcta aaattaagag ccgtataccct acctgtaagt cttttcacat atcatttaaa   2877
ctttttgtttg tattattact gatttacagc ttagttatta atttttcttt ataagaatgc   2937
cgtcgatgtg catgctttta tgttttttcag aaaagggtgt gtttggatga aagtaaaaaa   2997
aaaaataaaa tctttcactg tctctaatgg ctgtgctgtt taacattttt tgaccctaaa   3057
attcaccaac agtctcccag tacataaaat aggcttaatg actggccctg cattcttcac   3117
aatattttttc cctaagcttt gagcaaagtt ttaaaaaaat acactaaaat aatcaaaact   3177
gttaagcagt atattagttt ggttatataa attcatctgc aatttataag atgcatggcc   3237
gatgttaatt tgcttggcaa ttctgtaatc attaagtgat ctcagtgaaa catgtcaaat   3297
gccttaaatt aactaagttg gtgaataaaa gtgccgatct ggctaactct tacaccatac   3357
atactgatag tttttcatat gtttcatttc catgtgattt ttaaaattta gagtggcaac   3417
aattttgctt aatatgggtt acataagctt tattttttcc tttgttcata attatattct   3477
ttgaataggt ctgtgtcaat caagtgatct aactagactg atcatagata gaaggaaata   3537
aggccaagtt caagaccagc ctgggcaaca tatcgagaac ctgtctacaa aaaaattaaa   3597
aaaaattagc caggcatggt ggcgtacact gagtagtttg tcccagctac tcgggagggt   3657
gaggtgggag gatcgcttca gcccaggagg ttgagattgc agtgagccat ggacatacca   3717
ctgcactaca gcctaggtaa cagcacgaga ccccaactct tagaaaatga aaaggaaata   3777
tagaaatata aaatttgctt attatagaca cacagtaact cccagatatg taccacaaaa   3837
aatgtgaaaa gagagagaaa tgtctaccaa agcagtattt tgtgtgtata attgcaagcg   3897
catagtaaaa taattttaac cttaatttgt ttttagtagt gtttagattg aagattgagt   3957
gaaatatttt cttggcagat attccgtatc tggtggaaag ctacaatgca atgtcgttgt   4017
agttttgcat ggcttgcttt ataaacaaga ttttttctcc ctccttttgg gccagttttc   4077
attacgagta actcacactt tttgattaaa gaacttgaaa ttacgttatc acttagtata   4137
attgacatta tatagagact atgtaacatg caatcattag aatcaaaatt agtactttgg   4197
tcaaaatatt tacaacattc acatacttgt caaatattca tgtaattaac tgaatttaaa   4257
accttcaact attatgaagt gctcgtctgt acaatcgcta atttactcag tttagagtag   4317
ctacaactct tcgatactat catcaatatt tgacatcttt tccaatttgt gtatgaaaag   4377
taaatctatt cctgtagcaa ctggggagtc atatatgagg tcaaagacat ataccttgtt   4437
attataatat gtatactata ataatagctg gttatcctga gcagggaaa aggttatttt   4497
taggaaaacc acttcaaata gaaagctgaa gtacttctaa tatactgagg gaagtataat   4557
atgtggaaca aactctcaac aaaatgttta ttgatgttga tgaaacagat cagttttttcc   4617
atccggatta ttattggttc atgatttttat atgtgaatat gtaagatatg ttctgcaatt   4677
ttataaatgt tcatgtctttt ttttaaaaaa ggtgctattg aaattctgtg tctccagcag   4737
gcaagaatac ttgactaact cttttttgtct ctttatggta ttttcagaat aaagtctgac   4797
ttgtgtttttt gagattattg gtgcctcatt aattcagcaa taaaggaaaa tatgcatctc   4857
aaaaat                                                                 4863
```

```
<210> 115
<211> 5022
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 904..906
<223> TAG
<221> polyA_signal
<222> 4995..5000
```

<223> AATAAA
<400> 115
```
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc        54
                                  Met Arg Tyr Leu Leu Pro Ser Val
                                   1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg       102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
         10              15                  20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac       150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25                  30                  35                  40

gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag       198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                 45                  50                  55

aat tac acc ggg gtc cag cat gga gga atc tat gta aag cgc agt gcc       246
Asn Tyr Thr Gly Val Gln His Gly Gly Ile Tyr Val Lys Arg Ser Ala
                 60                  65                  70

aaa ttt aac gag aaa gag atg cga aac aag ttg cag agc tac gtg gac       294
Lys Phe Asn Glu Lys Glu Met Arg Asn Lys Leu Gln Ser Tyr Val Asp
             75                  80                  85

gca gga act cca atg tat ctt gtg att ttt cca gaa ggt aca agg tat       342
Ala Gly Thr Pro Met Tyr Leu Val Ile Phe Pro Glu Gly Thr Arg Tyr
         90                  95                  100

aat cca gag caa aca aaa gtc ctt tca gct agt cag gca ttt gct gcc       390
Asn Pro Glu Gln Thr Lys Val Leu Ser Ala Ser Gln Ala Phe Ala Ala
105                 110                 115                 120

caa cgt ggc ctt gca gta tta aaa cat gtg cta aca cca cga ata aag       438
Gln Arg Gly Leu Ala Val Leu Lys His Val Leu Thr Pro Arg Ile Lys
                 125                 130                 135

gca act cac gtt gct ttt gat tgc atg aag aat tat tta gat gca att       486
Ala Thr His Val Ala Phe Asp Cys Met Lys Asn Tyr Leu Asp Ala Ile
                 140                 145                 150

tat gat gtt acg gtg gtt tat gaa ggg aaa gac gat gga ggg cag cga       534
Tyr Asp Val Thr Val Val Tyr Glu Gly Lys Asp Asp Gly Gly Gln Arg
             155                 160                 165

aga gag tca ccg acc atg acg gaa ttt ctc tgc aaa gaa tgt cca aaa       582
Arg Glu Ser Pro Thr Met Thr Glu Phe Leu Cys Lys Glu Cys Pro Lys
             170                 175                 180

att cat att cac att gat cgt atc gac aaa aaa gat gtc cca gaa gaa       630
Ile His Ile His Ile Asp Arg Ile Asp Lys Lys Asp Val Pro Glu Glu
185                 190                 195                 200

caa gaa cat atg aga aga tgg ctg cat gaa cgt ttc gaa atc aaa gat       678
Gln Glu His Met Arg Arg Trp Leu His Glu Arg Phe Glu Ile Lys Asp
                 205                 210                 215

aag atg ctt ata gaa ttt tat gag tca cca gat cca gaa aga aga aaa       726
Lys Met Leu Ile Glu Phe Tyr Glu Ser Pro Asp Pro Glu Arg Arg Lys
             220                 225                 230

aga ttt cct ggg aaa agt gtt aat tcc aaa tta agt atc aag aag act       774
Arg Phe Pro Gly Lys Ser Val Asn Ser Lys Leu Ser Ile Lys Lys Thr
             235                 240                 245

tta cca tca atg ttg atc tta agt ggt ttg act gca ggc atg ctt atg       822
Leu Pro Ser Met Leu Ile Leu Ser Gly Leu Thr Ala Gly Met Leu Met
         250                 255                 260

acc gat gct gga agg aag ctg tat gtg aac acc tgg ata tat gga acc       870
Thr Asp Ala Gly Arg Lys Leu Tyr Val Asn Thr Trp Ile Tyr Gly Thr
265                 270                 275                 280

cta ctt ggc tgc ctg tgg gtt act att aaa gca tag acaagtagct          916
Leu Leu Gly Cys Leu Trp Val Thr Ile Lys Ala *
                 285                 290

gtctccagac agtgggatgt gctacattgt ctatttttgg cggctgcaca tgacatcaaa       976
ttgtttcctg aatttattaa ggagtgtaaa taaagccttg ttgattgaag attggataat      1036
```

```
agaatttgtg acgaaagctg atatgcaatg gtcttgggca aacatacctg gttgtacaac   1096
tttagcatcg gggctgctgg aagggtaaaa gctaaatgga gtttctcctg ctctgtccat   1156
ttcctatgaa ctaatgacaa cttgagaagg ctgggaggat tgtgtatttt gcaagtcaga   1216
tggctgcatt tttgagcatt aatttgcagc gtatttcact tttctgtta ttttcaattt     1276
attacaactt gacagctcca agctcttatt actaaagtat ttagtatctt gcagctagtt   1336
aatatttcat cttttgctta tttctacaag tcagtgaaat aaaattgtatt taggaagtgt  1396
caggatgttc aaaggaaagg gtaaaaagtg ttcatgggga aaaagctctg tttagcacat   1456
gattttattg tattgcgtta ttagctgatt ttactcattt tatatttgca aaataaattt   1516
ctaatatttа ttgaaattgc ttaatttgca caccctgtac acacagaaaa tggtataaaa  1576
tatgagaacg aagtttaaaa ttgtgactct gattcattat agcagaactt taaatttccc  1636
agcttttga agatttaagc tacgctatta gtacttccct ttgtctgtgc cataagtgct    1696
tgaaaacgtt aaggttttct gtttttgtttt gttttttaa tatcaaaaga gtcggtgtga   1756
accttggttg gacccccaagt tcacaagatt tttaaggtga tgagagcctg cagacattct  1816
gcctagattt actagcgtgt gcctttttgcc tgcttctctt tgatttcaca gaatattcat  1876
tcagaagtcg cgtttctgta gtgtggtgga ttcccactgg gctctggtcc ttcccttgga  1936
tcccgtcagt ggtgctgctc agcggcttgc acgtagactt gctaggaaga aatgcagagc  1996
cagcctgtgc tgcccacttt cagagttgaa ctctttaagc ccttgtgagt gggcttcacc   2056
agctactgca gaggcatttt gcatttgtct gtgtcaagaa gttcaccttc tcaagccagt   2116
gaaatacaga cttaattcgt catgactgaa cgaatttgtt tatttcccat taggtttagt   2176
ggagctacac attaatatgt atcgccttag agcaagagct gtgttccagg aaccagatca   2236
cgatttttag ccatggaaca atatatccca tgggagaaga cctttcagtg tgaactgttc   2296
tattttgtg ttataattta aacttcgatt tcctcatagt cctttaagtt gacatttctg     2356
cttactgcta ctggatttt gctgcagaaa tatatcagtg gcccacatta aacataccag     2416
ttggatcatg ataagcaaaa tgaaagaaat aatgattaag ggaaaattaa gtgactgtgt   2476
tacactgctt cttccatgcc agagaataaa ctctttcaag catcatcttt gaagagtcgt   2536
gtggtgtgaa ttggtttgtg tacattagaa tgtatgcaca catccatgga cactcaggat   2596
atagttggcc taataatcgg ggcatgggta aaacttatga aaatttcctc atgctgaatt   2656
gtaattttct cttacctgta aagtaaaatt tagatcaatt ccatgtcttt gttaagtaca   2716
gggatttaat atattttgaa tataatgggt atgttcaaa tttgaacttt gagaggcaat    2776
actgttggaa ttatgtggat tctaactcat tttaacaagg tagcctgacc tgcataagat  2836
cacttgaatg ttaggtttca tagaactata ctaatcttct cacaaaaggt ctataaaata   2896
cagtcgttga aaaaaatttt gtatcaaaat gtttggaaaa ttagaagctt ctccttaacc   2956
tgtattgata ctgacttgaa ttatttttcta aaattaagag ccgtatacct acctgtaagt  3016
ctttttcacat atcatttaaa cttttgtttg tattattact gatttacagc ttagttatta   3076
attttttcttt ataagaatgc cgtcgatgtg catgctttta tgttttttcag aaaagggtgt  3136
gtttggatga aagtaaaaaa aaaaataaaa tctttcactg tctctaatgg ctgtgctgtt   3196
taacattttt tgaccctaaa attcaccaac agtctcccag tacataaaat aggcttaatg   3256
actggccctg cattcttcac aatatttttc cctaagcttt gagcaaagtt ttaaaaaaat   3316
acactaaaat aatcaaaact gttaagcagt atattagttt ggttatataa attcatctgc   3376
aatttataag atgcatggcc gatgttaatt tgcttggcaa ttctgtaatc attaagtgat  3436
ctcagtgaaa catgtcaaat gccttaaatt aactaagttg gtgaataaaa gtgccgatct  3496
ggctaactct tacaccatac atactgatag ttttttcatat gtttcatttc catgtgattt  3556
ttaaaattta gagtggcaac aattttgctt aatatgggtt acataagctt tatttttttcc  3616
tttgttcata attatattct ttgaataggt ctgtgtcaat caagtgatct aactagactg  3676
atcatagata gaaggaaata aggccaagtt caagaccagc ctgggcaaca tatcggagaac 3736
ctgtctacaa aaaaattaaa aaaaattagc caggcatggt ggcgtacact gagtagtttg   3796
tcccagctac tcgggagggt gaggtgggag gatcgcttca gcccaggagg ttgagattgc   3856
agtgagccat ggacatacca ctgcactaca gcctaggtaa cagcacgaga ccccaactct  3916
tagaaaatga aaaggaaata tagaaatata aaatttgctt attatagaca cacagtaact   3976
cccagatatg tatccacaaaa aatgtgaaaa gagagagaaa tgtctaccaa agcagtattt 4036
tgtgtgtata attgcaagcg catagtaaaa taattttaac cttaatttgt ttttagtagt   4096
gtttagattg aagattgagt gaaatatttt cttggcagat attccgtatc tggtggaaag   4156
ctacaatgca atgtcgttgt agttttgcat ggcttgcttt ataaacaaga ttttttctcc  4216
ctccttttgg gccagttttc attacgagta actcacactt tttgattaaa gaacttgaaa   4276
ttacgttatc acttagtata attgacatta tatagagact atgtaacatg caatcattag   4336
aatcaaaatt agtactttgg tcaaaatatt tacaacattc acatacttgt caaatattca   4396
tgtaattaac tgaatttaaa accttcaact attatgaagt gctcgtctgt acaatcgcta   4456
atttactcag tttagagtag ctacaactct tcgatactat catcaatatt tgacatcttt   4516
tccaatttgt gtatgaaaag taaatctatt cctgtagcaa ctggggagtc atatatgagg   4576
tcaaagacat ataccttgtt attataatat gtatactata ataatagctg gttatcctga   4636
gcaggggaaa aggttatttt taggaaaacc acttcaaata gaaagctgaa gtacttctaa  4696
```

```
tatactgagg gaagtataat atgtggaaca aactctcaac aaaatgttta ttgatgttga    4756
tgaaacagat cagttttccc atccggatta ttattggttc atgattttat atgtgaatat    4816
gtaagatatg ttctgcaatt ttataaatgt tcatgtcttt ttttaaaaaa ggtgctattg    4876
aaattctgtg tctccagcag gcaagaatac ttgactaact ctttttgtct ctttatggta    4936
ttttcagaat aaagtctgac ttgtgttttt gagattattg gtgcctcatt aattcagcaa    4996
taaaggaaaa tatgcatctc aaaaat                                         5022
<210> 116
<211> 4932
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 814..816
<223> TAG
<221> polyA_signal
<222> 4905..4910
<223> AATAAA
<400> 116
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc     54
                                 Met Arg Tyr Leu Leu Pro Ser Val
                                  1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg    102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
         10              15              20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac    150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
 25              30              35              40

gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag    198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
             45              50              55

aat tac acc ggg gtc cag atg tat ctt gtg att ttt cca gaa ggt aca    246
Asn Tyr Thr Gly Val Gln Met Tyr Leu Val Ile Phe Pro Glu Gly Thr
             60              65              70

agg tat aat cca gag caa aca aaa gtc ctt tca gct agt cag gca ttt    294
Arg Tyr Asn Pro Glu Gln Thr Lys Val Leu Ser Ala Ser Gln Ala Phe
         75              80              85

gct gcc caa cgt ggc ctt gca gta tta aaa cat gtg cta aca cca cga    342
Ala Ala Gln Arg Gly Leu Ala Val Leu Lys His Val Leu Thr Pro Arg
         90              95              100

ata aag gca act cac gtt gct ttt gat tgc atg aag aat tat tta gat    390
Ile Lys Ala Thr His Val Ala Phe Asp Cys Met Lys Asn Tyr Leu Asp
105              110              115              120

gca att tat gat gtt acg gtg gtt tat gaa ggg aaa gac gat gga ggg    438
Ala Ile Tyr Asp Val Thr Val Val Tyr Glu Gly Lys Asp Asp Gly Gly
             125              130              135

cag cga aga gag tca ccg acc atg acg gaa ttt ctc tgc aaa gaa tgt    486
Gln Arg Arg Glu Ser Pro Thr Met Thr Glu Phe Leu Cys Lys Glu Cys
             140              145              150

cca aaa att cat att cac att gat cgt atc gac aaa aaa gat gtc cca    534
Pro Lys Ile His Ile His Ile Asp Arg Ile Asp Lys Lys Asp Val Pro
         155              160              165

gaa gaa caa gaa cat atg aga aga tgg ctg cat gaa cgt ttc gaa atc    582
Glu Glu Gln Glu His Met Arg Arg Trp Leu His Glu Arg Phe Glu Ile
         170              175              180

aaa gat aag atg ctt ata gaa ttt tat gag tca cca gat cca gaa aga    630
Lys Asp Lys Met Leu Ile Glu Phe Tyr Glu Ser Pro Asp Pro Glu Arg
185              190              195              200

aga aaa aga ttt cct ggg aaa agt gtt aat tcc aaa tta agt atc aag    678
```

```
Arg Lys Arg Phe Pro Gly Lys Ser Val Asn Ser Lys Leu Ser Ile Lys
                205               210               215
aag act tta cca tca atg ttg atc tta agt ggt ttg act gca ggc atg    726
Lys Thr Leu Pro Ser Met Leu Ile Leu Ser Gly Leu Thr Ala Gly Met
              220               225               230
ctt atg acc gat gct gga agg aag ctg tat gtg aac acc tgg ata tat    774
Leu Met Thr Asp Ala Gly Arg Lys Leu Tyr Val Asn Thr Trp Ile Tyr
              235               240               245
gga acc cta ctt ggc tgc ctg tgg gtt act att aaa gca tag            816
Gly Thr Leu Leu Gly Cys Leu Trp Val Thr Ile Lys Ala  *
          250               255               260
acaagtagct gtctccagac agtgggatgt gctacattgt ctatttttgg cggctgcaca  876
tgacatcaaa ttgtttcctg aatttattaa ggagtgtaaa taaagccttg ttgattgaag  936
attggataat agaatttgtg acgaaagctg atatgcaatg gtcttgggca aacatacctg  996
gttgtacaac tttagcatcg gggctgctgg aagggtaaaa gctaaatgga gtttctcctg  1056
ctctgtccat ttcctatgaa ctaatgacaa cttgagaagg ctgggaggat tgtgtatttt  1116
gcaagtcaga tggctgcatt tttgagcatt aatttgcagc gtatttcact tttctgtta   1176
ttttcaattt attacaactt gacagctcca agctcttatt actaaagtat ttagtatctt  1236
gcagctagtt aatatttcat cttttgctta tttctacaag tcagtgaaat aaattgtatt  1296
taggaagtgt caggatgttc aaaggaaagg gtaaaaagtg ttcatgggga aaaagctctg  1356
tttagcacat gattttattg tattgcgtta ttagctgatt ttactcattt tatatttgca  1416
aaataaattt ctaatattta ttgaaattgc ttaatttgca caccctgtac acacagaaaa  1476
tggtataaaa tatgagaacg aagtttaaaa ttgtgactct gattcattat agcagaactt  1536
taaatttccc agcttttga  agatttaagc tacgctatta gtacttccct ttgtctgtgc   1596
cataagtgct tgaaaacgtt aaggtttct  gttttgtttt gtttttttaa tatcaaaaga  1656
gtcggtgtga accttggttg gaccccaagt tcacaagatt tttaaggtga tgagagcctg  1716
cagacattct gcctagattt actagcgtgt gccttttgcc tgcttctctt tgatttcaca  1776
gaatattcat tcagaagtcg cgtttctgta gtgtggtgga ttcccactgg gctctggtcc  1836
ttcccttgga tcccgtcagt ggtgctgctc agcggcttgc acgtagactt gctaggaaga  1896
aatgcagagc cagcctgtgc tgcccacttt cagagttgaa ctctttaagc ccttgtgagt  1956
gggcttcacc agctactgca gaggcatttt gcatttgtct gtgtcaagaa gttcaccttc  2016
tcaagccagt gaaatacaga cttaattcgt catgactgaa cgaatttgtt tatttcccat  2076
taggtttagt ggagctacac attaatatgt atcgccttag agcaagagct gtgttccagg  2136
aaccagatca cgattttttag ccatggaaca atatatccca tgggagaaga cctttcagtg  2196
tgaactgttc tattttttgtg ttataattta aacttcgatt tcctcatagt cctttaagtt  2256
gacatttctg cttactgcta ctggatttt  gctgcagaaa tatatcagtg gcccacatta  2316
aacataccag ttggatcatg ataagcaaaa tgaaagaaat aatgattaag ggaaaattaa  2376
gtgactgtgt tacactgctt ctcccatgcc agagaataaa ctctttcaag catcatcttt  2436
gaagagtcgt gtggtgtgaa ttggtttgtg tacattagaa tgtatgcaca catccatgga  2496
cactcaggat atagttggcc taataatcgg ggcatgggta aaacttatga aaatttcctc  2556
atgctgaatt gtaattttct cttacctgta aagtaaaatt tagatcaatt ccatgtcttt  2616
gttaagtaca gggatttaat atattttgaa tataatgggt atgttctaaa tttgaacttt  2676
gagaggcaat actgttggaa ttatgtggat tctaactcat tttaacaagg tagcctgacc  2736
tgcataagat cacttgaatg ttaggtttca tagaactata ctaatcttct cacaaaaggt  2796
ctataaaata cagtcgttga aaaaaatttt gtatcaaaat gtttggaaaa ttagaagctt  2856
ctccttaacc tgtattgata ctgacttgaa ttattttcta aaattaagag ccgtatacct  2916
acctgtaagt cttttcacat atcatttaaa cttttgtttg tattattact gatttacagc  2976
ttagttatta atttttctttt ataagaatgc cgtcgatgtg catgctttta tgttttttcag  3036
aaaagggtgt gtttggatga aagtaaaaaa aaaaataaaa tctttcactg tctctaatgg  3096
ctgtgctgtt taacattttt tgaccctaaa attcaccaac agtctcccag tacataaaat  3156
aggcttaatg actggccctg cattcttcac aatatttttc cctaagcttt gagcaaagtt  3216
ttaaaaaaat acactaaaat aatcaaaact gttaagcagt atattagttt ggttatataa  3276
attcatctgc aatttataag atgcatggcc gatgttaatt tgcttggcaa ttctgtaatc  3336
attaagtgat ctcagtgaaa catgtcaaat gccttaaatt aactaagttg gtgaataaaa  3396
gtgccgatct ggctaactct tacaccatac atactgatag ttttttcatat gtttcatttc  3456
catgtgattt ttaaaattta gagtggcaac aattttgctt aatatgggtt acataagctt  3516
tattttttcc tttgttcata attatattct ttgaataggt ctgtgtcaat caagtgatct  3576
aactagactg atcatagata gaaggaaata aggccaagtt caagaccagc ctgggcaaca  3636
tatcgagaac ctgtctacaa aaaaattaaa aaaaattagc caggcatggt ggcgtacact  3696
gagtagtttg tcccagctac tcgggagggt gaggtgggag gatcgcttca gcccaggagg  3756
ttgagattgc agtgagccat ggacatacca ctgcactaca gcctaggtaa cagcacgaga  3816
```

```
ccccaactct tagaaaatga aaaggaaata tagaaatata aaatttgctt attatagaca    3876
cacagtaact cccagatatg taccacaaaa aatgtgaaaa gagagagaaa tgtctaccaa    3936
agcagtattt tgtgtgtata attgcaagcg catagtaaaa taattttaac cttaatttgt    3996
ttttagtagt gtttagattg aagattgagt gaaatatttt cttggcagat attccgtatc    4056
tggtggaaag ctacaatgca atgtcgttgt agttttgcat ggcttgcttt ataaacaaga    4116
ttttttctcc ctccttttgg gccagttttc attacgagta actcacactt tttgattaaa    4176
gaacttgaaa ttacgttatc acttagtata attgacatta tatagagact atgtaacatg    4236
caatcattag aatcaaaatt agtactttgg tcaaaatatt tacaacattc acatacttgt    4296
caaatattca tgtaattaac tgaatttaaa accttcaact attatgaagt gctcgtctgt    4356
acaatcgcta atttactcag tttagagtag ctacaactct tcgatactat catcaatatt    4416
tgacatcttt tccaatttgt gtatgaaaag taaatctatt cctgtagcaa ctggggagtc    4476
atatatgagg tcaaagacat ataccttgtt attataatat gtatactata ataatagctg    4536
gttatcctga gcaggggaaa aggttatttt taggaaaacc acttcaaata gaaagctgaa    4596
gtacttctaa tatactgagg gaagtataat atgtggaaca aactctcaac aaaatgttta    4656
ttgatgttga tgaaacagat cagttttttcc atccggatta ttattggttc atgattttat    4716
atgtgaatat gtaagatatg ttctgcaatt ttataaatgt tcatgtcttt ttttaaaaaa    4776
ggtgctattg aaattctgtg tctccagcag gcaagaatac ttgactaact cttttttgtct    4836
ctttatggta ttttcagaat aaagtctgac ttgtgttttt gagattattg gtgcctcatt    4896
aattcagcaa taaaggaaaa tatgcatctc aaaaat                              4932
```

```
<210> 117
<211> 4682
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 301..303
<223> TGA
<221> polyA_signal
<222> 4655..4660
<223> AATAAA
<400> 117
```

```
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc    54
                                   Met Arg Tyr Leu Leu Pro Ser Val
                                   1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg    102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
    10              15                  20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac    150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25              30                  35                  40

gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag    198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                45                  50                  55

aat tac acc ggg gtc cag aat ttc tct gca aag aat gtc caa aaa ttc    246
Asn Tyr Thr Gly Val Gln Asn Phe Ser Ala Lys Asn Val Gln Lys Phe
                60                  65                  70

ata ttc aca ttg atc gta tcg aca aaa aag atg tcc cag aag aac aag    294
Ile Phe Thr Leu Ile Val Ser Thr Lys Lys Met Ser Gln Lys Asn Lys
            75                  80                  85

aac ata tga gaagatggct gcatgaacgt ttcgaaatca aagataagat             343
Asn Ile *
        90
```

```
gcttatagaa ttttatgagt caccagatcc agaaagaaga aaaagatttc ctgggaaaag    403
tgttaattcc aaattaagta tcaagaagac tttaccatca atgttgatct taagtggttt    463
gactgcaggc atgcttatga ccgatgctgg aaggaagctg tatgtgaaca cctggatata    523
tggaacccta cttggctgcc tgtgggttac tattaaagca tagacaagta gctgtctcca    583
gacagtggga tgtgctacat tgtctatttt tggcggctgc acatgacatc aaattgtttc    643
ctgaatttat taaggagtgt aaataaagcc ttgttgattg aagattggat aatagaattt    703
```

```
gtgacgaaag ctgatatgca atggtcttgg gcaaacatac ctggttgtac aactttagca    763
tcggggctgc tggaagggta aaagctaaat ggagtttctc ctgctctgtc catttcctat    823
gaactaatga caacttgaga aggctgggag gattgtgtat tttgcaagtc agatggctgc    883
attttttgagc attaatttgc agcgtatttc acttttttctg ttattttcaa tttattacaa    943
cttgacagct ccaagctctt attactaaag tatttagtat cttgcagcta gttaatattt   1003
catcttttgc ttatttctac aagtcagtga aataaattgt atttaggaag tgtcaggatg   1063
ttcaaaggaa agggtaaaaa gtgttcatgg ggaaaaagct ctgtttagca catgatttta   1123
ttgtattgcg ttattagctg attttactca ttttatattt gcaaaataaa tttctaatat   1183
ttattgaaat tgcttaattt gcacaccctg tacacacaga aaatggtata aaatatgaga   1243
acgaagttta aaattgtgac tctgattcat tatagcagaa ctttaaattt cccagctttt   1303
tgaagattta agctacgcta ttagtacttc cctttgtctg tgccataagt gcttgaaaac   1363
gttaaggttt tctgtttttgt tttgttttttt taatatcaaa agagtcggtg tgaaccttgg   1423
ttggacccca agttcacaag atttttaagg tgatgagagc ctgcagacat tctgcctaga   1483
tttactagcg tgtgcctttt gcctgcttct ctttgatttc acagaatatt cattcagaag   1543
tcgcgtttct gtagtgtggt ggattcccac tgggctctgg tccttcccct ggatcccgtc   1603
agtggtgctg ctcagcggct tgcacgtaga cttgctagga agaaatgcag agccagcctg   1663
tgctgcccac tttcagagtt gaactcttta agcccttgtg agtgggcttc accagctact   1723
gcagaggcat tttgcatttg tctgtgtcaa gaagttcacc ttctcaagcc agtgaaatac   1783
agacttaatt cgtcatgact gaacgaattt gtttatttcc cattaggttt agtggagcta   1843
cacattaata tgtatcgcct tagagcaaga gctgtgttcc aggaaccaga tcacgatttt   1903
tagccatgga acaatatatc ccatgggaga agacctttca gtgtgaactg ttctattttt   1963
gtgttataat ttaaacttcg atttcctcat agtcctttaa gttgacattt ctgcttactg   2023
ctactggatt tttgctgcag aaatatatca gtggcccaca ttaaacatac cagttggatc   2083
atgataagca aaatgaaaga aataatgatt aagggaaaat taagtgactg tgttacactg   2143
cttctcccat gccagagaat aaactctttc aagcatcatc tttgaagagt cgtgtggtgt   2203
gaattggttt gtgtacatta gaatgtatgc acacatccat ggacactcag gatatagttg   2263
gcctaataat cggggcatgg gtaaaactta tgaaaatttc ctcatgctga attgtaattt   2323
tctcttacct gtaaagtaaa atttagatca attccatgtc tttgttaagt acagggattt   2383
aatatatttt gaatataatg ggtatgttct aaatttgaac tttgagaggc aatactgttg   2443
gaattatgtg gattctaact cattttaaca aggtagcctg acctgcataa gatcacttga   2503
atgttaggtt tcatagaact atactaatct tctcacaaaa ggtctataaa atacagtcgt   2563
tgaaaaaaat tttgtatcaa aatgtttgga aaaattagaag cttctcctta acctgtattg   2623
atactgactt gaattatttt ctaaaattaa gagccgtata cctacctgta agtcttttca   2683
catatcattt aaacttttgt ttgtattatt actgatttac agcttagtta ttaatttttc   2743
tttataagaa tgccgtcgat gtgcatgctt ttatgtttttt cagaaaaggg tgtgtttgga   2803
tgaaagtaaa aaaaaaaata aaatctttca ctgtctctaa tggctgtgct gtttaacatt   2863
ttttgaccct aaaattcacc aacagtctcc cagtacataa aataggctta atgactggcc   2923
ctgcattctt cacaatattt ttccctaagc tttgagcaaa gtttttaaaaa aatacactaa   2983
aataatcaaa actgttaagc agtatattag tttggttata taaattcatc tgcaatttat   3043
aagatgcatg gccgatgtta atttgcttgg caattctgta atcattaagt gatctcagtg   3103
aaacatgtca aatgccttaa attaactaag ttggtgaata aaagtgccga tctggctaac   3163
tcttacacca tacatactga tagttttttca tatgtttcat ttccatgtga ttttttaaaat   3223
ttagagtggc aacaattttg cttaatatgg gttacataag cttttatttt tcctttgttc   3283
ataattatat tctttgaata ggtctgtgtc aatcaagtga tctaactaga ctgatcatag   3343
atagaaggaa ataaggccaa gttcaagacc agcctgggca acatatcgag aacctgtcta   3403
caaaaaaatt aaaaaaaatt agccaggcat ggtggcgtac actgagtagt ttgtcccagc   3463
tactcgggag ggtgaggtgg gaggatcgct tcagcccagg aggttgagat tgcagtgagc   3523
catggacata ccactgcact acagcctagg taacagcacg agaccccaac tcttagaaaa   3583
tgaaaaggaa atatagaaat ataaaatttg cttattatag acacacagta actcccagat   3643
atgtaccaca aaaatgtga aaagagagag aaatgtctac caaagcagta ttttgtgtgt   3703
ataattgcaa gcgcatagta aaataatttt aaccttaatt tgttttttagt agtgtttaga   3763
ttgaagattg agtgaaatat tttcttggca gatattccgt atctggtgga aagctacaat   3823
gcaatgtcgt tgtagttttg catggcttgc tttataaaca agattttttc tccctccttt   3883
tgggccagtt ttcattacga gtaactcaca ctttttgatt aaagaacttg aaattacgtt   3943
atcacttagt ataattgaca ttatatagag actatgtaac atgcaatcat tagaatcaaa   4003
attagtactt tggtcaaaat atttacaaca ttcacatact tgtcaaatat tcatgtaatt   4063
aactgaattt aaaaccttca actattatga agtgctcgtc tgtacaatcg ctaatttact   4123
cagtttagag tagctacaac tcttcgatac tatcatcaat atttgacatc ttttccaatt   4183
tgtgtatgaa aagtaaatct attcctgtag caactgggga gtcatatatg aggtcaaaga   4243
catatacctt gttattataa tatgtatact ataataatag ctggttatcc tgagcagggg   4303
aaaaggttat ttttaggaaa accacttcaa atagaaagct gaagtacttc taatatactg   4363
```

67

```
agggaagtat aatatgtgga acaaactctc aacaaaatgt ttattgatgt tgatgaaaca   4423
gatcagtttt tccatccgga ttattattgg ttcatgattt tatatgtgaa tatgtaagat   4483
atgttctgca attttataaa tgttcatgtc tttttttaaa aaaggtgcta ttgaaattct   4543
gtgtctccag caggcaagaa tacttgacta actctttttg tctctttatg gtattttcag   4603
aataaagtct gacttgtgtt tttgagatta ttggtgcctc attaattcag caataaagga   4663
aaatatgcat ctcaaaaat                                                4682
```

<210> 118
<211> 4558
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 235..237
<223> TGA
<221> polyA_signal
<222> 4531..4536
<223> AATAAA

<400> 118

```
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc       54
                                    Met Arg Tyr Leu Leu Pro Ser Val
                                    1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg      102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
    10              15                  20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac      150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25              30                  35                  40

gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag      198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
            45                  50                  55

aat tac acc ggg gtc cag gat gct tat aga att tta tga gtcaccagat        247
Asn Tyr Thr Gly Val Gln Asp Ala Tyr Arg Ile Leu  *
                    60                  65

ccagaaagaa gaaaagatt tcctgggaaa agtgttaatt ccaaattaag tatcaagaag    307
actttaccat caatgttgat cttaagtggt ttgactgcag gcatgcttat gaccgatgct    367
ggaaggaagc tgtatgtgaa cacctggata tatggaaccc tacttggctg cctgtgggtt    427
actattaaag catagacaag tagctgtctc cagacagtgg gatgtgctac attgtctatt    487
tttggcggct gcacatgaca tcaaattgtt tcctgaattt attaaggagt gtaaataaag    547
ccttgttgat tgaagattgg ataatagaat ttgtgacgaa agctgatatg caatggtctt    607
gggcaaacat acctggttgt acaactttag catcggggct gctggaaggg taaaagctaa    667
atggagtttc tcctgctctg tccatttcct atgaactaat gacaacttga gaaggctggg    727
aggattgtgt atttgcaag tcagatggct gcattttga gcattaattt gcagcgtatt      787
tcacttttc tgttattttc aatttattac aacttgacag ctccaagctc ttattactaa    847
agtatttagt atcttgcagc tagttaatat ttcatctttt gcttatttct acaagtcagt    907
gaaataaatt gtatttagga agtgtcagga tgttcaaagg aaagggtaaa aagtgttcat    967
ggggaaaaag ctctgtttag cacatgattt tattgttattg cgttattagc tgattttact   1027
cattttatat ttgcaaaata aattctaat atttattgaa attgcttaat ttgcacaccc    1087
tgtacacaca gaaaatggta taaaatatga gaacgaagtt taaaattgtg actctgattc    1147
attatagcag aactttaaat ttcccagctt tttgaagatt taagctacgc tattagtact    1207
tcccttttgtc tgtgccataa gtgcttgaaa acgttaaggt tttctgtttt gttttgtttt   1267
tttaatatca aaagagtcgg tgtgaacctt ggttggaccc caagttcaca agattttaa    1327
ggtgatgaga gcctgcagac attctgccta gatttactag cgtgtgcctt ttgcctgctt    1387
ctctttgatt tcacagaata ttcattcaga agtcgcgttt ctgtagtgtg gtggattccc    1447
actgggctct ggtccttccc ttggatcccg tcagtggtgc tgctcagcgg cttgcacgta    1507
gacttgctag gaagaaatgc agagccagcc tgtgctgccc actttcagag ttgaactctt    1567
taagcccttg tgagtgggct tcaccagcta ctgcagaggc attttgcatt tgtctgtgtc    1627
aagaagttca ccttctcaag ccagtgaaat acagacttaa ttcgtcatga ctgaacgaat    1687
ttgtttattt cccattaggt ttagtggagc tacacattaa tatgtatcgc cttagagcaa    1747
```

```
gagctgtgtt ccaggaacca gatcacgatt tttagccatg gaacaatata tcccatggga    1807
gaagaccttt cagtgtgaac tgttctattt ttgtgttata atttaaactt cgatttcctc    1867
atagtccttt aagttgacat ttctgcttac tgctactgga tttttgctgc agaaatatat    1927
cagtggccca cattaaacat accagttgga tcatgataag caaaatgaaa gaaataatga    1987
ttaagggaaa attaagtgac tgtgttacac tgcttctccc atgccagaga ataaactctt    2047
tcaagcatca tctttgaaga gtcgtgtggt gtgaattggt ttgtgtacat tagaatgtat    2107
gcacacatcc atggacactc aggatatagt tggcctaata atcggggcat gggtaaaact    2167
tatgaaaatt tcctcatgct gaattgtaat tttctcttac ctgtaaagta aaatttagat    2227
caattccatg tctttgttaa gtacagggat ttaatatatt ttgaatataa tgggtatgtt    2287
ctaaatttga actttgagag gcaatactgt tggaattatg tggattctaa ctcattttaa    2347
caaggtagcc tgacctgcat aagatcactt gaatgttagg tttcatagaa ctatactaat    2407
cttctcacaa aaggtctata aaatacagtc gttgaaaaaa attttgtatc aaaatgtttg    2467
gaaaattaga agcttctcct taacctgtat tgatactgac ttgaattatt ttctaaaatt    2527
aagagccgta tacctacctg taagtctttt cacatatcat ttaaactttt gtttgtatta    2587
ttactgattt acagcttagt tattaatttt tctttataag aatgccgtcg atgtgcatgc    2647
ttttatgttt ttcagaaaag ggtgtgtttg gatgaaagta aaaaaaaaaa taaaatcttt    2707
cactgtctct aatggctgtg ctgtttaaca ttttttgacc ctaaaattca ccaacagtct    2767
cccagtacat aaaataggct taatgactgg ccctgcattc ttcacaatat ttttccctaa    2827
gctttgagca aagtttaaa aaaatacact aaaataatca aaactgttaa gcagtatatt    2887
agtttggtta tataaattca tctgcaattt ataagatgca tggccgatgt taatttgctt    2947
ggcaattctg taatcattaa gtgatctcag tgaaacatgt caaatgcctt aaattaacta    3007
agttggtgaa taaaagtgcc gatctggcta actcttacac catacatact gatagttttt    3067
catatgtttc atttccatgt gatttttaaa atttagagtg gcaacaattt tgcttaatat    3127
gggttacata agctttattt tttcctttgt tcataattat attctttgaa taggtctgtg    3187
tcaatcaagt gatctaacta gactgatcat agatagaagg aaataaggcc aagttcaaga    3247
ccagcctggg caacatatcg agaacctgtc tacaaaaaaa ttaaaaaaaa ttagccaggc    3307
atggtggcgt acactgagta gtttgtccca gctactcggg agggtgaggt gggaggatcg    3367
cttcagccca ggaggttgag attgcagtga gccatggaca taccactgca ctacagccta    3427
ggtaacagca cgagacccca actcttagaa aatgaaaagg aaatatagaa atataaaatt    3487
tgcttattat agacacacag taactcccag atatgtacca caaaaaatgt gaaaagagag    3547
agaaatgtct accaaagcag tattttgtgt gtataattgc aagcgcatag taaaataatt    3607
ttaaccttaa tttgtttta gtagtgttta gattgaagat tgagtgaaat attttcttgg    3667
cagatattcc gtatctggtg gaaagctaca atgcaatgtc gttgtagttt tgcatggctt    3727
gctttataaa caagattttt tctccctcct tttgggccag ttttcattac gagtaactca    3787
cacttttttga ttaaagaact tgaaattacg ttatcactta gtataattga cattatatag    3847
agactatgta acatgcaatc attagaatca aaattagtac tttggtcaaa atatttacaa    3907
cattcacata cttgtcaaat attcatgtaa ttaactgaat ttaaaacctt caactattat    3967
gaagtgctcg tctgtacaat cgctaattta ctcagtttag agtagctaca actcttcgat    4027
actatcatca atatttgaca tcttttccaa tttgtgtatg aaaagtaaat ctattcctgt    4087
agcaactggg gagtcatata tgaggtcaaa gacatatacc ttgttattat aatatgtata    4147
ctataataat agctggttat cctgagcagg ggaaaaggtt attttttagga aaaccacttc    4207
aaatagaaag ctgaagtact tctaatatac tgagggaagt ataatatgtg gaacaaactc    4267
tcaacaaaat gtttattgat gttgatgaaa cagatcagtt tttccatccg gattattatt    4327
ggttcatgat tttatatgtg aatatgtaag atatgttctg caattttata aatgttcatg    4387
tcttttttta aaaaggtgc tattgaaatt ctgtgtctcc agcaggcaag aatacttgac    4447
taactctttt tgtctctttta tggtattttc agaataaagt ctgacttgtg tttttgagat    4507
tattggtgcc tcattaattc agcaataaag gaaaatatgc atctcaaaaa t    4558
```

```
<210> 119
<211> 5270
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 229..231
<223> TAG
<221> polyA_signal
<222> 5243..5248
<223> AATAAA
```

69

```
<400> 119
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc        54
                                 Met Arg Tyr Leu Leu Pro Ser Val
                                  1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg       102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
     10              15              20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac       150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25              30              35              40

gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag       198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                 45              50              55

aat tac acc ggg gtc cag aga ttg gat tcg tag attaaacttg agaaacaaac     251
Asn Tyr Thr Gly Val Gln Arg Leu Asp Ser  *
             60              65

cataaaagtg gaaggccctc tttaacaata ttgctatatg gagatttgcc aaaaaataaa     311
gaaaatataa tatatttagc aaatcatcaa agcacagttg actggattgt tgctgacatc     371
ttggccatca ggcagaatgc gctaggacat gtgcgctacg tgctgaaaga agggttaaaa     431
tggctgccat tgtatgggtg ttactttgct cagcatggag gaatctatgt aaagcgcagt     491
gccaaattta acgagaaaga gatgcgaaac aagttgcaga gctacgtgga cgcaggaact     551
ccaatgtatc ttgtgatttt tccagaaggt acaaggtata atccagagca aacaaaagtc     611
ctttcagcta gtcaggcatt tgctgcccaa cgtggccttg cagtattaaa acatgtgcta     671
acaccacgaa taaaggcaac tcacgttgct tttgattgca tgaagaatta tttagatgca     731
atttatgatg ttacggtggt ttatgaaggg aaagacgatg gagggcagcg aagagagtca     791
ccgaccatga cggaatttct ctgcaaagaa tgtccaaaaa ttcatattca cattgatcgt     851
atcgacaaaa aagatgtccc agaagaacaa gaacatatga aagatggct gcatgaacgt       911
ttcgaaatca aagataagat gcttatagaa ttttatgagt caccagatcc agaaagaaga     971
aaaagatttc ctgggaaaag tgttaattcc aaattaagta tcaagaagac tttaccatca    1031
atgttgatct tagtggttt gactgcaggc atgcttatga ccgatgctgg aaggaagctg      1091
tatgtgaaca cctggatata tggaacccta cttggctgcc tgtgggttac tattaaagca    1151
tagacaagta gctgtctcca gacagtggga tgtgctacat tgtctatttt tggcggctgc    1211
acatgacatc aaattgtttc ctgaatttat taaggagtgt aaataaagcc ttgttgattg    1271
aagattggat aatagaattt gtgacgaaag ctgatatgca atggtcttgg gcaaacatac    1331
ctggttgtac aactttagca tcggggctgc tggaagggta aaagctaaat ggagtttctc    1391
ctgctctgtc catttcctat gaactaatga caacttgaga aggctgggag gattgtgtat    1451
tttgcaagtc agatggctgc attttttgagc attaatttgc agcgtatttc acttttttctg   1511
ttattttcaa tttattacaa cttgacagct ccaagctctt attactaaag tatttagtat    1571
cttgcagcta gttaatattt catcttttgc ttatttctac aagtcagtga aataaattgt    1631
atttaggaag tgtcaggatg ttcaaaggaa agggtaaaaa gtgttcatgg ggaaaaagct    1691
ctgtttagca catgatttta ttgtattgcg ttattagctg attttactca ttttatattt    1751
gcaaaataaa tttctaatat ttattgaaat tgcttaattt gcacaccctg tacacacaga    1811
aaatggtata aaatatgaga acgaagttta aaattgtgac tctgattcat tatagcagaa    1871
ctttaaattt cccagctttt tgaagattta agctacgcta ttagtacttc cctttgtctg    1931
tgccataagt gcttgaaaac gttaaggttt tctgtttttgt tttgtttttt taatatcaaa   1991
agagtcggtg tgaaccttgg ttggacccca agttcacaag attttaagg tgatgagagc      2051
ctgcagacat tctgcctaga tttactagcg tgtgccttt gcctgcttct ctttgatttc      2111
acagaatatt cattcagaag tcgcgtttct gtagtgtggt ggattcccac tggcctctgg    2171
tccttccctt ggatcccgtc agtggtgctg ctcagcggct tgcacgtaga cttgctagga    2231
agaaatgcag agccagcctg tgctgcccac tttcagagtt gaactcttta agcccttgtg    2291
agtgggcttc accagctact gcagaggcat tttgcatttg tctgtgtcaa gaagttcacc    2351
ttctcaagcc agtgaaatac agacttaatt cgtcatgact gaacgaattt gtttatttcc    2411
cattaggttt agtggagcta cacattaata tgtatcgcct tagagcaaga gctgtgttcc    2471
aggaaccaga tcacgatttt tagccatgga acaatatatc ccatgggaga agacctttca    2531
gtgtgaactg ttctattttt gtgttataat ttaaacttcg atttcctcat agtcctttaa    2591
gttgacattt ctgcttactg ctactggatt tttgctgcag aaatatatca gtggcccaca    2651
ttaaacatac cagttggatc atgataagca aaatgaaaga ataatgatt aagggaaaat     2711
taagtgactg tgttacactg cttctcccat gccagagaat aaactctttc aagcatcatc    2771
tttgaagagt cgtgtggtgt gaattggttt gtgtacatta gaatgtatgc acacatccat    2831
ggacactcag gatatagttg gcctaataat cggggcatgg gtaaaactta tgaaaatttc    2891
ctcatgctga attgtaattt tctcttacct gtaaagtaaa atttagatca attccatgtc    2951
```

70

```
tttgttaagt acagggattt aatatatttt gaatataatg ggtatgttct aaatttgaac   3011
tttgagaggc aatactgttg gaattatgtg gattctaact cattttaaca aggtagcctg   3071
acctgcataa gatcacttga atgttaggtt tcatagaact atactaatct tctcacaaaa   3131
ggtctataaa atacagtcgt tgaaaaaaat tttgtatcaa aatgtttgga aaattagaag   3191
cttctcctta acctgtattg atactgactt gaattatttt ctaaaattaa gagccgtata   3251
cctacctgta agtcttttca catatcattt aaacttttgt ttgtattatt actgatttac   3311
agcttagtta ttaatttttc tttataagaa tgccgtcgat gtgcatgctt ttatgttttt   3371
cagaaaaggg tgtgtttgga tgaaagtaaa aaaaaaata aaatctttca ctgtctctaa   3431
tggctgtgct gtttaacatt ttttgaccct aaaattcacc aacagtctcc cagtacataa   3491
aataggctta atgactggcc ctgcattctt cacaatattt ttccctaagc tttgagcaaa   3551
gttttaaaaa aatacactaa aataatcaaa actgttaagc agtatattag tttggttata   3611
taaattcatc tgcaatttat aagatgcatg gccgatgtta atttgcttgg caattctgta   3671
atcattaagt gatctcagtg aaacatgtca aatgccttaa attaactaag ttggtgaata   3731
aaagtgccga tctggctaac tcttacacca tacatactga tagttttca tatgtttcat   3791
ttccatgtga tttttaaaat ttagagtggc aacaattttg cttaatatgg gttacataag   3851
ctttattttt tcctttgttc ataattatat tctttgaata ggtctgtgtc aatcaagtga   3911
tctaactaga ctgatcatag atagaaggaa ataaggccaa gttcaagacc agcctgggca   3971
acatatcgag aacctgtcta caaaaaaatt aaaaaaaatt agccaggcat ggtggcgtac   4031
actgagtagt ttgtcccagc tactcgggag ggtgaggtgg gaggatcgct tcagcccagg   4091
aggttgagat tgcagtgagc catggacata ccactgcact acagcctagg taacagcacg   4151
agaccccaac tcttagaaaa tgaaaggaa atatagaaat ataaaattg cttattatag    4211
acacacagta actcccagat atgtaccaca aaaatgtga aaagagagag aaatgtctac    4271
caaagcagta ttttgtgtgt ataattgcaa gcgcatagta aaataatttt aaccttaatt   4331
tgtttttagt agtgtttaga ttgaagattg agtgaaatat tttcttggca gatattccgt   4391
atctggtgga aagctacaat gcaatgtcgt tgtagttttg catggcttgc tttataaaca   4451
agattttttc tccctccttt tgggccagtt ttcattacga gtaactcaca cttttttgatt  4511
aaagaacttg aaattacgtt atcacttagt ataattgaca ttatatagag actatgtaac   4571
atgcaatcat tagaatcaaa attagtactt tggtcaaaat atttacaaca ttcacatact   4631
tgtcaaatat tcatgtaatt aactgaattt aaaaccttca actattatga agtgctcgtc   4691
tgtacaatcg ctaatttact cagtttagag tagctacaac tcttcgatac tatcatcaat   4751
atttgacatc ttttccaatt tgtgtatgaa aagtaaatct attcctgtag caactgggga   4811
gtcatatatg aggtcaaaga catatacctt gttattataa tatgtatact ataataatag   4871
ctggttatcc tgagcagggg aaaaggttat ttttaggaaa accacttcaa atagaaagct   4931
gaagtacttc taatatactg agggaagtat aatatgtgga acaaactctc aacaaaatgt   4991
ttattgatgt tgatgaaaca gatcagtttt tccatccgga ttattattgg ttcatgatttt  5051
tatatgtgaa tatgtaagat atgttctgca attttataaa tgttcatgtc tttttttaaa   5111
aaaggtgcta ttgaaattct gtgtctccag caggcaagaa tacttgacta actctttttg   5171
tctctttatg gtatttttcag aataaagtct gacttgtgtt tttgagatta ttggtgcctc   5231
attaattcag caataaagga aaatatgcat ctcaaaaat                          5270
```

```
<210> 120
<211> 5002
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 322..324
<223> TAA
<221> polyA_signal
<222> 4975..4980
<223> AATAAA
<400> 120
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc   54
                                   Met Arg Tyr Leu Leu Pro Ser Val
                                    1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg   102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
 10          15                  20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac  150
```

```
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25              30              35              40
gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag     198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                45              50              55
aat tac acc ggg gtc cag ata ttg cta tat gga gat ttg cca aaa aat     246
Asn Tyr Thr Gly Val Gln Ile Leu Leu Tyr Gly Asp Leu Pro Lys Asn
            60              65              70
aaa gaa aat ata ata tat tta gca aat cat caa agc aca gat gta tct     294
Lys Glu Asn Ile Ile Tyr Leu Ala Asn His Gln Ser Thr Asp Val Ser
        75              80              85
tgt gat ttt tcc aga agg tac aag gta taa tccagagcaa acaaaagtcc       344
Cys Asp Phe Ser Arg Arg Tyr Lys Val  *
        90              95
tttcagctag tcaggcattt gctgcccaac gtggccttgc agtattaaaa catgtgctaa   404
caccacgaat aaaggcaact cacgttgctt ttgattgcat gaagaattat ttagatgcaa   464
tttatgatgt tacggtggtt tatgaaggga aagacgatgg agggcagcga agagagtcac   524
cgaccatgac ggaatttctc tgcaaagaat gtccaaaaat tcatattcac attgatcgta   584
tcgacaaaaa agatgtccca gaagaacaag aacatatgag aagatggctg catgaacgtt   644
tcgaaatcaa agataagatg cttatagaat tttatgagtc accagatcca gaaagaagaa   704
aaagatttcc tgggaaaagt gttaattcca aattaagtat caagaagact ttaccatcaa   764
tgttgatctt aagtggtttg actgcaggca tgcttatgac cgatgctgga aggaagctgt   824
atgtgaacac ctggatatat ggaaccctac ttggctgcct gtgggttact attaaagcat   884
agacaagtag ctgtctccag acagtgggat gtgctacatt gtctattttt ggcggctgca   944
catgacatca aattgtttcc tgaatttatt aaggagtgta aataaagcct tgttgattga  1004
agattggata atagaatttg tgacgaaagc tgatatgcaa tggtcttggg caaacatacc  1064
tggttgtaca actttagcat cggggctgct ggaagggtaa aagctaaatg gagtttctcc  1124
tgctctgtcc atttcctatg aactaatgac aacttgagaa ggctgggagg attgtgtatt  1184
ttgcaagtca gatggctgca tttttgagca ttaatttgca gcgtatttca ctttttctgt  1244
tattttcaat ttattacaac ttgacagctc caagctctta ttactaaagt atttagtatc  1304
ttgcagctag ttaatatttc atcttttgct tatttctaca agtcagtgaa ataaattgta  1364
tttaggaagt gtcaggatgt tcaaaggaaa gggtaaaaag tgttcatggg gaaaaagctc  1424
tgtttagcac atgatttttat tgtattgcgt tattagctga ttttactcat tttatatttg  1484
caaaataaat ttctaatatt tattgaaatt gcttaatttg cacaccctgt acacacagaa  1544
aatggtataa aatatgagaa cgaagtttaa aattgtgact ctgattcatt atagcagaac  1604
tttaaatttc ccagcttttt gaagatttaa gctacgctat tagtacttcc ctttgtctgt  1664
gccataagtg cttgaaaacg ttaaggtttt ctgttttgtt ttgttttttt aatatcaaaa  1724
gagtcggtgt gaaccttggt tggaccccaa gttcacaaga tttttaaggt gatgagagcc  1784
tgcagacatt ctgcctagat ttactagcgt gtgccttttg cctgcttctc tttgatttca  1844
cagaatattc attcagaagt cgcgtttctg tagtgtggtg gattcccact gggctctggt  1904
ccttcccttg gatcccgtca gtggtgctgc tcagcggctt gcacgtagac ttgctaggaa  1964
gaaatgcaga gccagcctgt gctgcccact ttcagagttg aactctttaa gcccttgtga  2024
gtgggcttca ccagctactg cagaggcatt ttgcatttgt ctgtgtcaag aagttcacct  2084
tctcaagcca gtgaaataca gacttaattc gtcatgactg aacgaatttg tttatttccc  2144
attaggttta gtggagctac acattaatat gtatcgcctt agagcaagag ctgtgttcca  2204
ggaaccagat cacgatttt agccatggaa caatatatcc catgggagaa gacctttcag  2264
tgtgaactgt tctatttttg tgttataatt taaacttcga tttcctcata gtcctttaag  2324
ttgacatttc tgcttactgc tactggattt ttgctgcaga aatatatcag tggcccacat  2384
taaacatacc agttggatca tgataagcaa aatgaaagaa ataatgatta agggaaaatt  2444
aagtgactgt gttacactgc ttctcccatg ccagagaata aactctttca agcatcatct  2504
ttgaagagtc gtgtggtgtg aattggtttg tgtacattag aatgtatgca cacatccatg  2564
gacactcagg atatagttgg cctaataatc ggggcatggg taaaacttat gaaaatttcc  2624
tcatgctgaa ttgtaatttt ctcttacctg taaagtaaaa tttagatcaa ttccatgtct  2684
ttgttaagta cagggattta atatattttg aatataatgg gtatgttcta aatttgaact  2744
ttgagaggca atactgttgg aattatgtgg attctaactc attttaacaa ggtagcctga  2804
cctgcataag atcacttgaa tgttaggttt catagaacta tactaatctt ctcacaaaag  2864
gtctataaaa tacagtcgtt gaaaaaaatt ttgtatcaaa atgtttggaa aattagaagc  2924
ttctccttaa cctgtattga tactgacttg aattattttc taaaattaag agccgtatac  2984
ctacctgtaa gtcttttcac atatcattta aacttttgtt tgtattatta ctgatttaca  3044
gcttagttat taattttttct ttataagaat gccgtcgatg tgcatgcttt tatgtttttc  3104
agaaaagggt gtgtttggat gaaagtaaaa aaaaaaataa aatctttcac tgtctctaat  3164
```

```
ggctgtgctg tttaacattt tttgacccta aaattcacca acagtctccc agtacataaa      3224
ataggcttaa tgactggccc tgcattcttc acaatatttt tccctaagct ttgagcaaag      3284
ttttaaaaaa atacactaaa ataatcaaaa ctgttaagca gtatattagt ttggttatat      3344
aaattcatct gcaatttata agatgcatgg ccgatgttaa tttgcttggc aattctgtaa      3404
tcattaagtg atctcagtga aacatgtcaa atgccttaaa ttaactaagt tggtgaataa      3464
aagtgccgat ctggctaact cttacaccat acatactgat agttttcat atgtttcatt       3524
tccatgtgat tttaaaatt tagagtggca acaattttgc ttaatatggg ttacataaₒc      3584
tttattttt cctttgttca taattatatt ctttgaatag gtctgtgtca atcaagtgₒt       3644
ctaactagac tgatcataga tagaaggaaa taaggccaag ttcaagacca gcctgggcaa      3704
catatcgaga acctgtctac aaaaaaatta aaaaaaatta gccaggcatg gtggcgtaca      3764
ctgagtagtt tgtcccagct actcgggagg gtgaggtggg aggatcgctt cagcccagga      3824
ggttgagatt gcagtgagcc atggacatac cactgcacta cagcctaggt aacagcacga      3884
gaccccaact cttagaaaat gaaaaggaaa tatagaaata taaaatttgc ttattataga      3944
cacacagtaa ctcccagata tgtaccacaa aaaatgtgaa aagagagaga aatgtctacc      4004
aaagcagtat tttgtgtgta taattgcaag cgcatagtaa aataatttta accttaattt      4064
gtttttagta gtgtttagat tgaagattga gtgaaatatt ttcttggcag atattccgta      4124
tctggtggaa agctacaatg caatgtcgtt gtagttttgc atggcttgct ttataaacaa      4184
gatttttct ccctcctttt gggccagttt tcattacgag taactcacac tttttgatta       4244
aagaacttga aattacgtta tcacttagta taattgacat tatatagaga ctatgtaaca      4304
tgcaatcatt agaatcaaaa ttagtacttt ggtcaaaata tttacaacat tcacatactt      4364
gtcaaatatt catgtaatta actgaattta aaaccttcaa ctattatgaa gtgctcgtct      4424
gtacaatcgc taatttactc agtttagagt agctacaact cttcgatact atcatcaata      4484
tttgacatct tttccaattt gtgtatgaaa agtaaatcta ttcctgtagc aactggggag      4544
tcatatatga ggtcaaagac atataccttg ttattataat atgtatacta taataatagc      4604
tggttatcct gagcagggga aaaggttatt tttaggaaaa ccacttcaaa tagaaagctg      4664
aagtacttct aatatactga gggaagtata atatgtggaa caaactctca acaaaatgtt      4724
tattgatgtt gatgaaacag atcagttttt ccatccggat tattattggt tcatgatttt      4784
atatgtgaat atgtaagata tgttctgcaa ttttataaat gttcatgtct tttttaaaa       4844
aaggtgctat tgaaattctg tgtctccagc aggcaagaat acttgactaa ctctttttgt      4904
ctctttatgg tattttcaga ataaagtctg acttgtgttt ttgagattat tggtgcctca      4964
ttaattcagc aataaaggaa aatatgcatc tcaaaaat                              5002
<210> 121
<211> 4958
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 577..579
<223> TGA
<221> polyA_signal
<222> 4931..4936
<223> AATAAA
<400> 121
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc      54
                                    Met Arg Tyr Leu Leu Pro Ser Val
                                    1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg      102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
    10              15                  20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac      150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25              30                  35                  40

gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag      198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                45                  50                  55

aat tac acc ggg gtc cag ata ttg cta tat gga gat ttg cca aaa aat      246
Asn Tyr Thr Gly Val Gln Ile Leu Leu Tyr Gly Asp Leu Pro Lys Asn
                60                  65                  70
```

73

```
aaa gaa aat ata ata tat tta gca aat cat caa agc aca gtt gac tgg      294
Lys Glu Asn Ile Ile Tyr Leu Ala Asn His Gln Ser Thr Val Asp Trp
         75              80              85
att gtt gct gac atc ttg gcc atc agg cag aat gcg cta gga cat gtg      342
Ile Val Ala Asp Ile Leu Ala Ile Arg Gln Asn Ala Leu Gly His Val
     90              95              100
cgc tac gtg ctg aaa gaa ggg tta aaa tgg ctg cca ttg tat ggg tgt      390
Arg Tyr Val Leu Lys Glu Gly Leu Lys Trp Leu Pro Leu Tyr Gly Cys
105              110              115              120
tac ttt gct cag cat gga gga atc tat gta aag cgc agt gcc aaa ttt      438
Tyr Phe Ala Gln His Gly Gly Ile Tyr Val Lys Arg Ser Ala Lys Phe
             125              130              135
aac gag aaa gag atg cga aac aag ttg cag agc tac gtg gac gca gga      486
Asn Glu Lys Glu Met Arg Asn Lys Leu Gln Ser Tyr Val Asp Ala Gly
         140              145              150
act cca aat ttc tct gca aag aat gtc caa aaa ttc ata ttc aca ttg      534
Thr Pro Asn Phe Ser Ala Lys Asn Val Gln Lys Phe Ile Phe Thr Leu
         155              160              165
atc gta tcg aca aaa aag atg tcc cag aag aac aag aac ata tga         579
Ile Val Ser Thr Lys Lys Met Ser Gln Lys Asn Lys Asn Ile *
         170              175              180
gaagatggct gcatgaacgt ttcgaaatca aagataagat gcttatagaa ttttatgagt      639
caccagatcc agaaagaaga aaaagatttc ctgggaaaag tgttaattcc aaattaagta      699
tcaagaagac tttaccatca atgttgatct taagtggttt gactgcaggc atgcttatga      759
ccgatgctgg aaggaagctg tatgtgaaca cctggatata tggaacccta cttggctgcc      819
tgtgggttac tattaaagca tagacaagta gctgtctcca gacagtggga tgtgctacat      879
tgtctatttt tggcggctgc acatgacatc aaattgtttc ctgaatttat taaggagtgt      939
aaataaagcc ttgttgattg aagattggat aatagaattt gtgacgaaag ctgatatgca      999
atggtcttgg gcaaacatac ctggttgtac aactttagca tcggggctgc tggaagggta     1059
aaagctaaat ggagtttctc ctgctctgtc catttcctat gaactaatga caacttgaga     1119
aggctgggag gattgtgtat tttgcaagtc agatggctgc attttgagc attaatttgc      1179
agcgtatttc acttttctg ttattacaa cttgacagct ccaagctctt                  1239
attactaaag tatttagtat cttgcagcta gttaatatttt catcttttgc ttatttctac    1299
aagtcagtga aataaattgt atttaggaag tgtcaggatg ttcaaaggaa agggtaaaaa     1359
gtgttcatgg ggaaaaagct ctgtttagca catgatttta ttgtattgcg ttattagctg     1419
atttactca ttttatattt gcaaaataaa tttctaatat ttattgaaat tgcttaattt      1479
gcacaccctg tacacacaga aaatggtata aaatatgaga acgaagttta aaattgtgac     1539
tctgattcat tatagcagaa ctttaaattt cccagctttt tgaagattta agctacgcta     1599
ttagtacttc cctttgtctg tgccataagt gcttgaaaac gttaaggttt tctgttttgt     1659
tttgtttttt taatatcaaa agagtcggtg tgaaccttgg ttggacccca agttcacaag     1719
attttttaagg tgatgagagc ctgcagacat tctgcctaga tttactagcg tgtgcctttt    1779
gcctgcttct ctttgatttc acagaatatt cattcagaag tcgcgtttct gtagtgtggt     1839
ggattcccac tgggctctgg tccttccctt ggatccgtc agtggtgctg ctcagcggct       1899
tgcacgtaga cttgctagga agaaatgcag agccagcctg tgctgcccac tttcagagtt     1959
gaactcttta agcccttgtg agtgggcttc accagctact gcagaggcat tttgcatttg     2019
tctgtgtcaa gaagttcacc ttctcaagcc agtgaaatac agacttaatt cgtcatgact     2079
gaacgaattt gtttatttcc cattaggttt agtggagcta cacattaata tgtatcgcct     2139
tagagcaaga gctgtgttcc aggaaccaga tcacgatttt tagccatgga acaatatatc     2199
ccatgggaga agaccttca gtgtgaactg ttctatttt gtgttataat ttaaacttcg        2259
atttcctcat agtcctttaa gttgacattt ctgcttactg ctactggatt tttgctgcag     2319
aaatatatca gtggcccaca ttaaacatac cagttggatc atgataagca aaatgaaaga     2379
aataatgatt aagggaaaat taagtgactg tgttacactg cttctcccat gccagagaat     2439
aaactctttc aagcatcatc tttgaagagt cgtgtggtgt gaattggttt gtgtacatta     2499
gaatgtatgc acacatccat ggacactcag gatatagttg gcctaataat cggggcatgg     2559
gtaaaactta tgaaaatttc ctcatgctga attgtaattt tctcttacct gtaaagtaaa     2619
atttagatca attccatgtc tttgttaagt acagggattt aatatatttt gaatataatg     2679
ggtatgttct aaatttgaac tttgagaggc aatactgttg gaattatgtg gattctaact     2739
cattttaaca aggtagcctg acctgcataa gatcacttga atgttaggtt tcatagaact     2799
atactaatct tctcacaaaa ggtcatataaa atacagtcgt tgaaaaaaat tttgtatcaa     2859
aatgtttgga aaattagaag cttctcctta acctgtattg atactgactt gaattatttt     2919
ctaaaattaa gagccgtata cctacctgta agtcttttca catatcattt aaacttttgt     2979
```

```
ttgtattatt actgatttac agcttagtta ttaatttttc tttataagaa tgccgtcgat   3039
gtgcatgctt ttatgttttt cagaaaaggg tgtgtttgga tgaaagtaaa aaaaaaaata   3099
aaatctttca ctgtctctaa tggctgtgct gtttaacatt ttttgaccct aaaattcacc   3159
aacagtctcc cagtacataa aataggctta atgactggcc ctgcattctt cacaatattt   3219
ttccctaagc tttgagcaaa gttttaaaaa aatacactaa aataatcaaa actgttaagc   3279
agtatattag tttggttata taaattcatc tgcaatttat aagatgcatg gccgatgtta   3339
atttgcttgg caattctgta atcattaagt gatctcagtg aaacatgtca aatgccttaa   3399
attaactaag ttggtgaata aaagtgccga tctggctaac tcttacacca tacatactga   3459
tagtttttca tatgtttcat ttccatgtga tttttaaaat ttagagtggc aacaattttg   3519
cttaatatgg gttacataag ctttattttt tcctttgttc ataattatat tctttgaata   3579
ggtctgtgtc aatcaagtga tctaactaga ctgatcatag atagaaggaa ataaggccaa   3639
gttcaagacc agcctgggca acatatcgag aacctgtcta caaaaaaatt aaaaaaaatt   3699
agccaggcat ggtggcgtac actgagtagt ttgtcccagc tactcgggag ggtgaggtgg   3759
gaggatcgct tcagcccagg aggttgagat tgcagtgagc catggacata ccactgcact   3819
acagcctagg taacagcacg agaccccaac tcttagaaaa tgaaaaggaa atatagaaat   3879
ataaaatttg cttattatag acacacagta actcccagat atgtaccaca aaaaatgtga   3939
aaagagagag aaatgtctac caaagcagta ttttgtgtgt ataattgcaa gcgcatagta   3999
aaataatttt aaccttaatt tgttttttagt agtgtttaga ttgaagattg agtgaaatat   4059
tttcttggca gatattccgt atctggtgga aagctacaat gcaatgtcgt tgtagttttg   4119
catggcttgc tttataaaca agatttttttc tccctccttt tgggccagtt ttcattacga   4179
gtaactcaca ctttttgatt aaagaacttg aaattacgtt atcacttagt ataattgaca   4239
ttatatagag actatgtaac atgcaatcat tagaatcaaa attagtactt tggtcaaaat   4299
atttacaaca ttcacatact tgtcaaatat tcatgtaatt aactgaattt aaaaccttca   4359
actattatga agtgctcgtc tgtacaatcg ctaatttact cagtttagag tagctacaac   4419
tcttcgatac tatcatcaat atttgacatc ttttccaatt tgtgtatgaa aagtaaatct   4479
attcctgtag caactgggga gtcatatatg aggtcaaaga catatacctt gttattataa   4539
tatgtatact ataataatag ctggttatcc tgagcagggg aaaaggttat ttttaggaaa   4599
accacttcaa atagaaagct gaagtacttc taatatactg agggaagtat aatatgtgga   4659
acaaactctc aacaaaatgt ttattgatgt tgatgaaaca gatcagtttt tccatccgga   4719
ttattattgg ttcatgattt tatatgtgaa tatgtaagat atgttctccag atttttataaa   4779
tgttcatgtc tttttttaaa aaaggtgcta ttgaaattct gtgtctccag caggcaagaa   4839
tacttgacta actcttttg tctctttatg gtattttcag aataaagtct gacttgtgtt   4899
tttgagatta ttggtgcctc attaattcag caataaagga aaatatgcat ctcaaaaat   4958
```

<210> 122
<211> 5094
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 976..978
<223> TAG
<221> polyA_signal
<222> 5067..5072
<223> AATAAA
<400> 122

```
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc      54
                                    Met Arg Tyr Leu Leu Pro Ser Val
                                     1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg     102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
     10                  15                  20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac     150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
 25                  30                  35                  40

gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag     198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                 45                  50                  55

aat tac acc ggg gtc cag ata ttg cta tat gga gat ttg cca aaa aat     246
```

```
Asn Tyr Thr Gly Val Gln Ile Leu Leu Tyr Gly Asp Leu Pro Lys Asn
             60                  65                  70
aaa gaa aat ata ata tat tta gca aat cat caa agc aca gtt gac tgg      294
Lys Glu Asn Ile Ile Tyr Leu Ala Asn His Gln Ser Thr Val Asp Trp
         75                  80                  85
att gtt gct gac atc ttg gcc atc agg cag aat gcg cta gga cat gtg      342
Ile Val Ala Asp Ile Leu Ala Ile Arg Gln Asn Ala Leu Gly His Val
         90                  95                 100
cgc tac gtg ctg aaa gaa ggg tta aaa tgg ctg cca ttg tat ggg tgt      390
Arg Tyr Val Leu Lys Glu Gly Leu Lys Trp Leu Pro Leu Tyr Gly Cys
105                 110                 115                 120
tac ttt gct cag cat gga gga atc tat gta aag cgc agt gcc aaa ttt      438
Tyr Phe Ala Gln His Gly Gly Ile Tyr Val Lys Arg Ser Ala Lys Phe
                 125                 130                 135
aac gag aaa gag atg cga aac aag ttg cag agc tac gtg gac gca gga      486
Asn Glu Lys Glu Met Arg Asn Lys Leu Gln Ser Tyr Val Asp Ala Gly
                 140                 145                 150
act cca atg tat ctt gtg att ttt cca gaa ggt aca agg tat aat cca      534
Thr Pro Met Tyr Leu Val Ile Phe Pro Glu Gly Thr Arg Tyr Asn Pro
             155                 160                 165
gag caa aca aaa gtc ctt tca gct agt cag gca ttt gct gcc caa cgt      582
Glu Gln Thr Lys Val Leu Ser Ala Ser Gln Ala Phe Ala Ala Gln Arg
         170                 175                 180
ggg aaa gac gat gga ggg cag cga aga gag tca ccg acc atg acg gaa      630
Gly Lys Asp Asp Gly Gly Gln Arg Arg Glu Ser Pro Thr Met Thr Glu
185                 190                 195                 200
ttt ctc tgc aaa gaa tgt cca aaa att cat att cac att gat cgt atc      678
Phe Leu Cys Lys Glu Cys Pro Lys Ile His Ile His Ile Asp Arg Ile
                 205                 210                 215
gac aaa aaa gat gtc cca gaa gaa caa gaa cat atg aga aga tgg ctg      726
Asp Lys Lys Asp Val Pro Glu Glu Gln Glu His Met Arg Arg Trp Leu
             220                 225                 230
cat gaa cgt ttc gaa atc aaa gat aag atg ctt ata gaa ttt tat gag      774
His Glu Arg Phe Glu Ile Lys Asp Lys Met Leu Ile Glu Phe Tyr Glu
             235                 240                 245
tca cca gat cca gaa aga aga aaa aga ttt cct ggg aaa agt gtt aat      822
Ser Pro Asp Pro Glu Arg Arg Lys Arg Phe Pro Gly Lys Ser Val Asn
         250                 255                 260
tcc aaa tta agt atc aag aag act tta cca tca atg ttg atc tta agt      870
Ser Lys Leu Ser Ile Lys Lys Thr Leu Pro Ser Met Leu Ile Leu Ser
265                 270                 275                 280
ggt ttg act gca ggc atg ctt atg acc gat gct gga agg aag ctg tat      918
Gly Leu Thr Ala Gly Met Leu Met Thr Asp Ala Gly Arg Lys Leu Tyr
                 285                 290                 295
gtg aac acc tgg ata tat gga acc cta ctt ggc tgc ctg tgg gtt act      966
Val Asn Thr Trp Ile Tyr Gly Thr Leu Leu Gly Cys Leu Trp Val Thr
             300                 305                 310
att aaa gca tag acaagtagct gtctccagac agtgggatgt gctacattgt      1018
Ile Lys Ala  *
             315
           ctatttttgg cggctgcaca tgacatcaaa ttgtttcctg aatttattaa ggagtgtaaa    1078
           taaagccttg ttgattgaag attggataat agaatttgtg acgaaagctg atatgcaatg    1138
           gtcttgggca aacatacctg gttgtacaac tttagcatcg gggctgctgg aagggtaaaa    1198
           gctaaatgga gtttctcctg ctctgtccat ttcctatgaa ctaatgacaa cttgagaagg    1258
           ctgggaggat tgtgtatttt gcaagtcaga tggctgcatt tttgagcatt aatttgcagc    1318
           gtatttcact ttttctgtta ttttcaattt attacaactt gacagctcca agctcttatt    1378
           actaaagtat ttagtatctt gcagctagtt aatatttcat cttttgctta tttctacaag    1438
           tcagtgaaat aaattgtatt taggaagtgt caggatgttc aaaggaaagg gtaaaaagtg    1498
           ttcatgggga aaaagctctg tttagcacat gattttattg tattgcgtta ttagctgatt    1558
           ttactcattt tatatttgca aaataaattt ctaatattta ttgaaattgc ttaatttgca    1618
           caccctgtac acacagaaaa tggtataaaa tatgagaacg aagtttaaaa ttgtgactct    1678
```

```
gattcattat agcagaactt taaatttccc agcttttga agatttaagc tacgctatta    1738
gtacttccct ttgtctgtgc cataagtgct tgaaaacgtt aaggttttct gttttgtttt   1798
gttttttaa tatcaaaaga gtcggtgtga accttggttg gaccccaagt tcacaagatt    1858
tttaaggtga tgagagcctg cagacattct gcctagattt actagcgtgt gccttttgcc  1918
tgcttctctt tgatttcaca gaatattcat tcagaagtcg cgtttctgta gtgtggtgga   1978
ttcccactgg gctctggtcc ttcccttgga tcccgtcagt ggtgctgctc agcggcttgc   2038
acgtagactt gctaggaaga aatgcagagc cagcctgtgc tgcccacttt cagagttgaa   2098
ctctttaagc ccttgtgagt gggcttcacc agctactgca gaggcatttt gcatttgtct   2158
gtgtcaagaa gttcaccttc tcaagccagt gaaatacaga cttaattcgt catgactgaa   2218
cgaatttgtt tatttcccat taggtttagt ggagctacac attaatatgt atcgccttag   2278
agcaagagct gtgttccagg aaccagatca cgatttttag ccatggaaca atatatccca   2338
tgggagaaga cctttcagtg tgaactgttc tattttgtg ttataattta aacttcgatt    2398
tcctcatagt cctttaagtt gacatttctg cttactgcta ctggattttt gctgcagaaa   2458
tatatcagtg gcccacatta aacataccag ttggatcatg ataagcaaaa tgaaagaaat   2518
aatgattaag ggaaaattaa gtgactgtgt tacactgctt ctcccatgcc agagaataaa   2578
ctctttcaag catcatcttt gaagagtcgt gtggtgtgaa ttggtttgtg tacattagaa   2638
tgtatgcaca catccatgga cactcaggat atagttggcc taataatcgg ggcatgggta   2698
aaacttatga aaatttcctc atgctgaatt gtaattttct cttacctgta aagtaaaatt   2758
tagatcaatt ccatgtcttt gttaagtaca gggatttaat atatttcgaa cataatgggt   2818
atgttctaaa tttgaacttt gagaggcaat actgttggaa ttatgtggat tctaactcat   2878
tttaacaagg tagcctgacc tgcataagat cacttgaatg ttaggtttca tagaactata   2938
ctaatcttct cacaaaaggt ctataaaata cagtcgttga aaaaaatttt gtatcaaaat   2998
gtttggaaaa ttagaagctt ctccttaacc tgtattgata ctgacttgaa ttatttcta    3058
aaattaagag ccgtatacct acctgtaagt cttttcacat atcatttaaa cttttgtttg   3118
tattattact gatttacagc ttagttatta attttctttt ataagaatgc cgtcgatgtg   3178
catgctttta tgttttcag aaaagggtgt gtttggatga aagtaaaaaa aaaaataaaa    3238
tctttcactg tctctaatgg ctgtgctgtt taacattttt tgaccctaaa attcaccaac   3298
agtctcccag tacataaaat aggcttaatg actggccctg cattcttcac aatatttttc   3358
cctaagcttt gagcaaagtt ttaaaaaaat acactaaaat aatcaaaact gttaagcagt   3418
atattagttt ggttatataa attcatctgc aatttataag atgcatggcc gatgttaatt   3478
tgcttggcaa ttctgtaatc attaagtgat ctcagtgaaa catgtcaaat gccttaaatt   3538
aactaagttg gtgaataaaa gtgccgatct ggctaactct tacaccatac atactgatag   3598
tttttcatat gtttcatttc catgtgattt ttaaaattta gagtggcaac aattttgctt   3658
aatatgggtt acataagctt tattttttcc tttgttcata attatattct ttgaataggt   3718
ctgtgtcaat caagtgatct aactagactg atcatagata gaaggaaata aggccaagtt   3778
caagaccagc ctgggcaaca tatcgagaac ctgtctacaa aaaaattaaa aaaaattagc   3838
caggcatggt ggcgtacact gagtagtttg tcccagctac tcgggagggt gaggtgggag   3898
gatcgcttca gcccaggagg ttgagattgc agtgagccat ggacatacca ctgcactaca   3958
gcctaggtaa cagcacgaga ccccaactct tagaaaatga aaaggaaata tagaaatata   4018
aaatttgctt attatagaca cacagtaact cccagatatg taccacaaaa aatgtgaaaa   4078
gagagagaaa tgtctaccaa agcagtattt tgtgtgtata attgcaagcg catagtaaaa   4138
taattttaac cttaatttgt ttttagtagt gtttagattg aagattgagt gaaatatttt   4198
cttggcagat attccgtatc tggtggaaag ctacaatgca atgtcgttgt agttttgcat   4258
ggcttgcttt ataaacaaga ttttttctcc ctccttttgg gccagttttc attacgagta   4318
actcacactt ttgattaaa gaacttgaaa ttacgttatc acttagtata attgacatta    4378
tatagagact atgtaacatg caatcattag aatcaaaatt agtactttgg tcaaaatatt   4438
tacaacattc acatacttgt caaatattca tgtaattaac tgaatttaaa accttcaact   4498
attatgaagt gctcgtctgt acaatcgcta atttactcag tttagagtag ctacaactct   4558
tcgatactat catcaatatt tgacatcttt tccaatttgt gtatgaaaag taaatctatt   4618
cctgtagcaa ctggggagtc atatatgagg tcaaagacat ataccttgtt attataatat   4678
gtatactata ataagctg gttatcctga gcaggggaaa aggttatttt taggaaaacc    4738
acttcaaata gaaagctgaa gtacttctaa tatactgagg gaagtataat atgtggaaca   4798
aactctcaac aaaatgttta ttgatgttga tgaaacagat cagttttttcc atccggatta  4858
ttattggttc atgatttat atgtgaatat gtaagatatg ttctgcaatt ttataaatgt    4918
tcatgtcttt tttaaaaaaa ggtgctattg aaattctgtg tctccagcag gcaagaatac   4978
ttgactaact cttttttgtct ctttatggta ttttcagaat aaagtctgac ttgtgttttt  5038
gagattattg gtgcctcatt aattcagcaa taaaggaaaa tatgcatctc aaaaat       5094
```

<210> 123
<211> 5049
<212> DNA
<213> Homo sapiens

```
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 931..933
<223> TAG
<221> polyA_signal
<222> 5022..5027
<223> AATAAA
<400> 123
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc      54
                                  Met Arg Tyr Leu Leu Pro Ser Val
                                  1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg     102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
10                  15                  20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac     150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
25                  30                  35                  40

gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag     198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                45                  50                  55

aat tac acc ggg gtc cag ata ttg cta tat gga gat ttg cca aaa aat     246
Asn Tyr Thr Gly Val Gln Ile Leu Leu Tyr Gly Asp Leu Pro Lys Asn
            60                  65                  70

aaa gaa aat ata ata tat tta gca aat cat caa agc aca gtt gac tgg     294
Lys Glu Asn Ile Ile Tyr Leu Ala Asn His Gln Ser Thr Val Asp Trp
        75                  80                  85

att gtt gct gac atc ttg gcc atc agg cag aat gcg cta gga cat gtg     342
Ile Val Ala Asp Ile Leu Ala Ile Arg Gln Asn Ala Leu Gly His Val
    90                  95                  100

cgc tac gtg ctg aaa gaa ggg tta aaa tgg ctg cca ttg tat ggg tgt     390
Arg Tyr Val Leu Lys Glu Gly Leu Lys Trp Leu Pro Leu Tyr Gly Cys
105                 110                 115                 120

tac ttt gct cag cat gga gga atc tat gta aag cgc agt gcc aaa ttt     438
Tyr Phe Ala Gln His Gly Gly Ile Tyr Val Lys Arg Ser Ala Lys Phe
                125                 130                 135

aac gag aaa gag atg cga aac aag ttg cag agc tac gtg gac gca gga     486
Asn Glu Lys Glu Met Arg Asn Lys Leu Gln Ser Tyr Val Asp Ala Gly
            140                 145                 150

act cca atg tat ctt gtg att ttt cca gaa ggt aca agg tat aat cca     534
Thr Pro Met Tyr Leu Val Ile Phe Pro Glu Gly Thr Arg Tyr Asn Pro
        155                 160                 165

gag caa aca aaa gtc ctt tca gct agt cag gca ttt gct gcc caa cgt     582
Glu Gln Thr Lys Val Leu Ser Ala Ser Gln Ala Phe Ala Ala Gln Arg
    170                 175                 180

gaa ttt ctc tgc aaa gaa tgt cca aaa att cat att cac att gat cgt     630
Glu Phe Leu Cys Lys Glu Cys Pro Lys Ile His Ile His Ile Asp Arg
185                 190                 195                 200

atc gac aaa aaa gat gtc cca gaa gaa caa gaa cat atg aga aga tgg     678
Ile Asp Lys Lys Asp Val Pro Glu Glu Gln Glu His Met Arg Arg Trp
                205                 210                 215

ctg cat gaa cgt ttc gaa atc aaa gat aag atg ctt ata gaa ttt tat     726
Leu His Glu Arg Phe Glu Ile Lys Asp Lys Met Leu Ile Glu Phe Tyr
                220                 225                 230

gag tca cca gat cca gaa aga aga aaa aga ttt cct ggg aaa agt gtt     774
Glu Ser Pro Asp Pro Glu Arg Arg Lys Arg Phe Pro Gly Lys Ser Val
        235                 240                 245

aat tcc aaa tta agt atc aag aag act tta cca tca atg ttg atc tta     822
Asn Ser Lys Leu Ser Ile Lys Lys Thr Leu Pro Ser Met Leu Ile Leu
```

```
        250              255              260
agt ggt ttg act gca ggc atg ctt atg acc gat gct gga agg aag ctg   870
Ser Gly Leu Thr Ala Gly Met Leu Met Thr Asp Ala Gly Arg Lys Leu
265                   270              275              280
tat gtg aac acc tgg ata tat gga acc cta ctt ggc tgc ctg tgg gtt   918
Tyr Val Asn Thr Trp Ile Tyr Gly Thr Leu Leu Gly Cys Leu Trp Val
                     285              290              295
act att aaa gca tag acaagtagct gtctccagac agtgggatgt gctacattgt   973
Thr Ile Lys Ala *
                 300
    ctattttttgg cggctgcaca tgacatcaaa ttgtttcctg aatttattaa ggagtgtaaa   1033
    taaagccttg ttgattgaag attggataat agaatttgtg acgaaagctg atatgcaatg   1093
    gtcttgggca aacatacctg gttgtacaac tttagcatcg gggctgctgg aagggtaaaa   1153
    gctaaatgga gtttctcctg ctctgtccat ttcctatgaa ctaatgacaa cttgagaagg   1213
    ctgggaggat tgtgtatttt gcaagtcaga tggctgcatt tttgagcatt aatttgcagc   1273
    gtatttcact ttttctgtta ttttcaattt attacaactt gacagctcca agctcttatt   1333
    actaaagtat ttagtatctt gcagctagtt aatatttcat ctttttgctta tttctacaag   1393
    tcagtgaaat aaattgtatt taggaagtgt caggatgttc aaaggaaagg gtaaaaagtg   1453
    ttcatgggga aaaagctctg tttagcacat gattttattg tattgcgtta ttagctgatt   1513
    ttactcattt tatatttgca aaataaattt ctaatattta ttgaaattgc ttaatttgca   1573
    caccctgtac acacagaaaa tggtataaaa tatgagaacg aagtttaaaa ttgtgactct   1633
    gattcattat agcagaactt taaatttccc agcttttttga agatttaagc tacgctatta   1693
    gtacttccct ttgtctgtgc cataagtgct tgaaaacgtt aaggttttct gttttgtttt   1753
    gttttttttaa tatcaaaaga gtcggtgtga accttggttg daccccaagt tcacaagatt   1813
    tttaaggtga tgagagcctg cagacattct gcctagattt actagcgtgt gccttttgcc   1873
    tgcttctctt tgatttcaca gaatattcat tcagaagtcg cgtttctgta gtgtggtgga   1933
    ttcccactgg gctctggtcc ttcccttgga tcccgtcagt ggtgctgctc agcggcttgc   1993
    acgtagactt gctaggaaga aatgcagagc cagcctgtgc tgcccacttt cagagttgaa   2053
    ctctttaagc ccttgtgagt gggcttcacc agctactgca gaggcatttt gcatttgtct   2113
    gtgtcaagaa gttcaccttc tcaagccagt gaaatacaga cttaattcgt catgactgaa   2173
    cgaatttgtt tatttcccat taggtttagt ggagctacac attaatatgt atcgccttag   2233
    agcaagagct gtgttccagg aaccagatca cgattttttag ccatggaaca atatatccca   2293
    tgggagaaga cctttcagtg tgaactgttc tatttttgtg ttataatttta aacttcgatt   2353
    tcctcatagt cctttaagtt gacatttctg cttactgcta ctggattttt gctgcagaaa   2413
    tatatcagtg gcccacatta aacataccag ttggatcatg ataagcaaaa tgaaagaaat   2473
    aatgattaag ggaaaattaa gtgactgtgt tacactgctt ctcccatgcc agagaataaa   2533
    ctctttcaag catcatcttt gaagagtcgt gtggtgtgaa ttggtttgtg tacattagaa   2593
    tgtatgcaca catccatgga cactcaggat atagttggcc taataatcgg ggcatgggta   2653
    aaacttatga aaatttcctc atgctgaatt gtaatttttct cttacctgta aagtaaaatt   2713
    tagatcaatt ccatgtcttt gttaagtaca gggatttaat atatttttgaa tataatgggt   2773
    atgttctaaa tttgaacttt gagaggcaat actgttggaa ttatgtggat tctaactcat   2833
    tttaacaagg tagcctgacc tgcataagat cacttgaatg ttaggtttca tagaactata   2893
    ctaatcttct cacaaaaggt ctataaaata cagtcgttga aaaaaatttt gtatcaaaat   2953
    gtttggaaaa ttagaagctt ctccttaacc tgtattgata ctgacttgaa ttattttcta   3013
    aaattaagag ccgtatacct acctgtaagt cttttcacat atcatttaaa cttttgtttg   3073
    tattattact gatttacagc ttagttatta attttttcttt ataagaatgc cgtcgatgtg   3133
    catgctttta tgtttttcag aaaagggtgt gtttggatga aagtaaaaaa aaaaataaaa   3193
    tctttcactg tctctaatgg ctgtgctgtt taacatttttt tgaccctaaa attcaccaac   3253
    agtctcccag tacataaaat aggcttaatg actggccctg cattcttcac aatatttttc   3313
    cctaagcttt gagcaaagtt ttaaaaaaat acactaaaat aatcaaaact gttaagcagt   3373
    atattagttt ggttatataa attcatctgc aatttataag atgcatggcc gatgttaatt   3433
    tgcttggcaa ttctgtaatc attaagtgat ctcagtgaaa catgtcaaat gccttaaatt   3493
    aactaagttg gtgaataaaa gtgccgatct ggctaactct tacaccatac atactgatag   3553
    ttttttcatat gtttcatttc catgtgattt ttaaaattta gagtggcaac aattttgctt   3613
    aatatgggtt acataagctt tatttttttcc tttgttcata attatattct ttgaataggt   3673
    ctgtgtcaat caagtgatct aactagactg atcatagata gaaggaaata aggccaagtt   3733
    caagaccagc ctgggcaaca tatcgagaac ctgtctacaa aaaaattaaa aaaaattagc   3793
    caggcatggt ggcgtacact gagtagtttg tcccagctac tcgggagggt gaggtgggag   3853
    gatcgcttca gcccaggagg ttgagattgc agtgagccat ggacatacca ctgcactaca   3913
    gcctaggtaa cagcacgaga ccccaactct tagaaaatga aaggaaata tagaaatata   3973
    aaatttgctt attatagaca cacagtaact cccagatatg taccacaaaa aatgtgaaaa   4033
```

```
gagagagaaa tgtctaccaa agcagtattt tgtgtgtata attgcaagcg catagtaaaa    4093
taattttaac cttaatttgt ttttagtagt gtttagattg aagattgagt gaaatatttt    4153
cttggcagat attccgtatc tggtggaaag ctacaatgca atgtcgttgt agttttgcat    4213
ggcttgcttt ataaacaaga ttttttctcc ctccttttgg gccagttttc attacgagta    4273
actcacactt tttgattaaa gaacttgaaa ttacgttatc acttagtata attgacatta    4333
tatagagact atgtaacatg caatcattag aatcaaaatt agtactttgg tcaaaatatt    4393
tacaacattc acatacttgt caaatattca tgtaattaac tgaatttaaa accttcaact    4453
attatgaagt gctcgtctgt acaatcgcta atttactcag tttagagtag ctacaactct    4513
tcgatactat catcaatatt tgacatcttt tccaatttgt gtatgaaaag taaatctatt    4573
cctgtagcaa ctggggagtc atatatgagg tcaaagacat ataccttgtt attataatat    4633
gtatactata ataatagctg gttatcctga gcaggggaaa aggttatttt taggaaaacc    4693
acttcaaata gaaagctgaa gtacttctaa tatactgagg gaagtataat atgtggaaca    4753
aactctcaac aaaatgttta ttgatgttga tgaaacagat cagttttttcc atccggatta    4813
ttattggttc atgattttat atgtgaatat gtaagatatg ttctgcaatt ttataaatgt    4873
tcatgtcttt ttttaaaaaa ggtgctattg aaattctgtg tctccagcag gcaagaatac    4933
ttgactaact cttttgtct ctttatggta ttttcagaat aaagtctgac ttgtgttttt    4993
gagattattg gtgcctcatt aattcagcaa taaaggaaaa tatgcatctc aaaaat        5049
```
<210> 124
<211> 5324
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> 31..33
<223> ATG
<221> misc_feature
<222> 586..588
<223> TAA
<221> polyA_signal
<222> 5297..5302
<223> AATAAA
<400> 124

```
ctgctgtccc tggtgctcca cacgtactcc atg cgc tac ctg ctg ccc agc gtc         54
                                 Met Arg Tyr Leu Leu Pro Ser Val
                                  1               5

gtg ctc ctg ggc acg gcg ccc acc tac gtg ttg gcc tgg ggg gtc tgg        102
Val Leu Leu Gly Thr Ala Pro Thr Tyr Val Leu Ala Trp Gly Val Trp
 10              15                  20

cgg ctg ctc tcc gcc ttc ctg ccc gcc cgc ttc tac caa gcg ctg gac       150
Arg Leu Leu Ser Ala Phe Leu Pro Ala Arg Phe Tyr Gln Ala Leu Asp
 25                  30                  35                  40

gac cgg ctg tac tgc gtc tac cag agc atg gtg ctc ttc ttc ttc gag       198
Asp Arg Leu Tyr Cys Val Tyr Gln Ser Met Val Leu Phe Phe Phe Glu
                     45                  50                  55

aat tac acc ggg gtc cag ata ttg cta tat gga gat ttg cca aaa aat      246
Asn Tyr Thr Gly Val Gln Ile Leu Leu Tyr Gly Asp Leu Pro Lys Asn
                 60                  65                  70

aaa gaa aat ata ata tat tta gca aat cat caa agc aca gtt gac tgg      294
Lys Glu Asn Ile Ile Tyr Leu Ala Asn His Gln Ser Thr Val Asp Trp
             75                  80                  85

att gtt gct gac atc ttg gcc atc agg cag aat gcg cta gga cat gtg      342
Ile Val Ala Asp Ile Leu Ala Ile Arg Gln Asn Ala Leu Gly His Val
         90                  95                  100

cgc tac gtg ctg aaa gaa ggg tta aaa tgg ctg cca ttg tat ggg tgt      390
Arg Tyr Val Leu Lys Glu Gly Leu Lys Trp Leu Pro Leu Tyr Gly Cys
105                 110                 115                 120

tac ttt gct cag cat gga gga atc tat gta aag cgc agt gcc aaa ttt      438
Tyr Phe Ala Gln His Gly Gly Ile Tyr Val Lys Arg Ser Ala Lys Phe
                 125                 130                 135

aac gag aaa gag atg cga aac aag ttg cag agc tac gtg gac gca gga      486
Asn Glu Lys Glu Met Arg Asn Lys Leu Gln Ser Tyr Val Asp Ala Gly
```

```
          140                  145                  150
act cca atg tat ctt gtg att ttt cca gaa ggt aca agg tat aat cca      534
Thr Pro Met Tyr Leu Val Ile Phe Pro Glu Gly Thr Arg Tyr Asn Pro
          155                  160                  165
gag caa aca aaa gtc ctt tca gct agt cag gca ttt gct gcc caa cgt      582
Glu Gln Thr Lys Val Leu Ser Ala Ser Gln Ala Phe Ala Ala Gln Arg
          170                  175                  180
ggc taa agcagtcctc ctgagtagtt aggactacag acatacacgt gccaccgcgc      638
Gly  *
185
ccagctccgt gttctctttg tttccctgcc tcctgctctt ccacttatct ttgcatggca    698
ggccttgcag tattaaaaca tgtgctaaca ccacgaataa aggcaactca cgttgctttt    758
gattgcatga agaattattt agatgcaatt tatgatgtta cggtggttta tgaagggaaa    818
gacgatggag ggcagcgaag agagtcaccg accatgacgg aatttctctg caaagaatgt    878
ccaaaaattc atattcacat tgatcgtatc gacaaaaaag atgtcccaga agaacaagaa    938
catatgagaa gatggctgca tgaacgtttc gaaatcaaag ataagatgct tatagaattt    998
tatgagtcac cagatccaga aagaagaaaa agatttcctg ggaaaagtgt taattccaaa   1058
ttaagtatca agaagacttt accatcaatg ttgatcttaa gtggtttgac tgcaggcatg   1118
cttatgaccg atgctggaag gaagctgtat gtgaacacct ggatatatgg aaccctactt   1178
ggctgcctgt gggttactat taaagcatag acaagtagct gtctccagac agtgggatgt   1238
gctacattgt ctatttttgg cggctgcaca tgacatcaaa ttgtttcctg aatttattaa   1298
ggagtgtaaa taaagccttg ttgattgaag attggataat agaatttgtg acgaaagctg   1358
atatgcaatg gtcttgggca aacatacctg gttgtacaac tttagcatcg gggctgctgg   1418
aagggtaaaa gctaaatgga gtttctcctg ctctgtccat ttcctatgaa ctaatgacaa   1478
cttgagaagg ctgggaggat tgtgtatttt gcaagtcaga tggctgcatt tttgagcatt   1538
aatttgcagc gtatttcact tttttctgtta ttttcaattt attacaactt gacagctcca   1598
agctcttatt actaaagtat ttagtatctt gcagctagtt aatatttcat cttttgctta   1658
tttctacaag tcagtgaaat aaattgtatt taggaagtgt caggatgttc aaaggaaagg   1718
gtaaaaagtg ttcatgggga aaaagctctg tttagcacat gattttattg tattgcgtta   1778
ttagctgatt ttactcattt tatatttgca aaataaattt ctaatatttta ttgaaattgc   1838
ttaatttgca caccctgtac acacagaaaa tggtataaaa tatgagaacg aagtttaaaa   1898
ttgtgactct gattcattat agcagaactt taaatttccc agcttttttga agatttaagc   1958
tacgctatta gtacttccct ttgtctgtgc cataagtgct tgaaaacgtt aaggtttttct   2018
gttttgtttt gttttttttaa tatcaaaaga gtcggtgtga accttggttg gaccccaagt   2078
tcacaagatt tttaaggtga tgagagcctg cagacattct gcctagattt actagcgtgt   2138
gccttttgcc tgcttctctt tgatttcaca gaatattcat tcagaagtcg cgtttctgta   2198
gtgtggtgga ttcccactgg gctctggtcc ttcccttgga tcccgtcagt ggtgctgctc   2258
agcggcttgc acgtagactt gctaggaaga aatgcagagc cagcctgtgc tgcccacttt   2318
cagagttgaa ctctttaagc ccttgtgagt gggcttcacc agctactgca gaggcatttt   2378
gcatttgtct gtgtcaagaa gttcaccttc tcaagccagt gaaatacaga cttaattcgt   2438
catgactgaa cgaatttgtt tatttcccat taggtttagt ggagctacac attaatatgt   2498
atcgccttag agcaagagct gtgttccagg aaccagatca cgattttag ccatggaaca   2558
atatatccca tgggagaaga cctttcagtg tgaactgttc tattttttgtg ttataatttta   2618
aacttcgatt tcctcatagt ccttttaagtt gacatttctg cttactgcta ctggattttt   2678
gctgcagaaa tatatcagtg gcccacatta aacataccag ttggatcatg ataagcaaaa   2738
tgaaagaaat aatgattaag ggaaaattaa gtgactgtgt tacactgctt ctcccatgcc   2798
agagaataaa ctctttcaag catcatcttt gaagagtcgt gtggtgtgaa ttggtttgtg   2858
tacattagaa tgtatgcaca catccatgga cactcaggat atagttggcc taataatcgg   2918
ggcatgggta aaacttatga aaatttcctc atgctgaatt gtaattttct cttacctgta   2978
aagtaaaatt tagatcaatt ccatgtcttt gttaagtaca gggatttaat atattttgaa   3038
tataatgggt atgttctaaa tttgaacttt gagaggcaat actgttggaa ttatgtggat   3098
tctaactcat tttaacaagg tagcctgacc tgcataagat cacttgaatg ttaggtttca   3158
tagaactata ctaatcttct cacaaaaggt ctataaaata cagtcgttga aaaaaatttt   3218
gtatcaaaat gtttggaaaa ttagaagctt ctccttaacc tgtattgata ctgacttgaa   3278
ttattttcta aaattaagag ccgtatacct acctgtaagt cttttcacat atcatttaaa   3338
cttttgtttg tattattact gatttacagc ttagttatta atttttcttt ataagaatgc   3398
cgtcgatgtg catgctttta tgttttttcag aaaagggtgt gtttggatga aagtaaaaaa   3458
aaaaataaaa tctttcactg tctctaatgg ctgtgctgtt aacatttttt tgaccctaaa   3518
attcaccaac agtctcccag tacataaaat aggcttaatg actggccctg cattcttcac   3578
aatatttttc cctaagcttt gagcaaagtt ttaaaaaaat acactaaaat aatcaaaact   3638
gttaagcagt atattagttt ggttatataa attcatctgc aatttataag atgcatggcc   3698
```

```
gatgttaatt tgcttggcaa ttctgtaatc attaagtgat ctcagtgaaa catgtcaaat    3758
gccttaaatt aactaagttg gtgaataaaa gtgccgatct ggctaactct tacaccatac    3818
atactgatag tttttcatat gtttcatttc catgtgattt ttaaaattta gagtggcaac    3878
aattttgctt aatatgggtt acataagctt tattttttcc tttgttcata attatattct    3938
ttgaataggt ctgtgtcaat caagtgatct aactagactg atcatagata gaaggaaata    3998
aggccaagtt caagaccagc ctgggcaaca tatcgagaac ctgtctacaa aaaaattaaa    4058
aaaaattagc caggcatggt ggcgtacact gagtagtttg tcccagctac tcgggagggt    4118
gaggtgggag gatcgcttca gcccaggagg ttgagattgc agtgagccat ggacatacca    4178
ctgcactaca gcctaggtaa cagcacgaga ccccaactct tagaaaatga aaaggaaata    4238
tagaaatata aaatttgctt attatagaca cacagtaact cccagatatg taccacaaaa    4298
aatgtgaaaa gagagagaaa tgtctaccaa agcagtattt tgtgtgtata attgcaagcg    4358
catagtaaaa taattttaac cttaatttgt ttttagtagt gtttagattg aagattgagt    4418
gaaatatttt cttggcagat attccgtatc tggtggaaag ctacaatgca atgtcgttgt    4478
agttttgcat ggcttgcttt ataaacaaga ttttttctcc ctccttttgg gccagttttc    4538
attacgagta actcacactt tttgattaaa gaacttgaaa ttacgttatc acttagtata    4598
attgacatta tatagagact atgtaacatg caatcattag aatcaaaatt agtactttgg    4658
tcaaaatatt tacaacattc acatacttgt caaatattca tgtaattaaa tgaatttaaa    4718
accttcaact attatgaagt gctcgtctgt acaatcgcta atttactcag tttagagtag    4778
ctacaactct tcgatactat catcaatatt tgacatcttt tccaatttgt gtatgaaaag    4838
taaatctatt cctgtagcaa ctggggagtc atatatgagg tcaaagacat ataccttgtt    4898
attataatat gtatactata ataatagctg gttatcctga gcaggggaaa aggttatttt    4958
taggaaaacc acttcaaata gaaagctgaa gtacttctaa tatactgagg gaagtataat    5018
atgtggaaca aactctcaac aaaatgttta ttgatgttga tgaaacagat cagttttttcc    5078
atccggatta ttattggttc atgatttttat atgtgaatat gtaagatatg ttctgcaatt    5138
ttataaatgt tcatgtcttt ttttaaaaaa ggtgctattg aaattctgtg tctccagcag    5198
gcaagaatac ttgactaact cttttttgtct ctttatggta ttttcagaat aaagtctgac    5258
ttgtgttttt gagattattg gtgcctcatt aattcagcaa taaaggaaaa tatgcatctc    5318
aaaaat                                                                5324
```

<210> 125
<211> 77
<212> PRT
<213> Homo sapiens
<400> 125

```
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5                  10                  15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20                  25                  30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35                  40                  45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Leu Thr
    50                  55                  60
Gly Leu Leu Leu Thr Ser Trp Pro Ser Gly Arg Met Arg
65                  70                  75
```

<210> 126
<211> 238
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 98..103
<223> Box  II
<400> 126

```
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5                  . 10                  15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20                  25                  30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35                  40                  45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln His Gly
    50                  55                  60
Gly Ile Tyr Val Lys Arg Ser Ala Lys Phe Asn Glu Lys Glu Met Arg
```

```
65                    70                    75                    80
Asn Lys Leu Gln Ser Tyr Val Asp Ala Gly Thr Pro Met Tyr Leu Val
                85                    90                    95
Ile Phe Pro Glu Gly Thr Arg Tyr Asn Pro Glu Gln Thr Lys Val Leu
            100                   105                   110
Ser Ala Ser Gln Ala Phe Ala Ala Gln Arg Glu Phe Leu Cys Lys Glu
            115                   120                   125
Cys Pro Lys Ile His Ile His Ile Asp Arg Ile Asp Lys Lys Asp Val
        130                   135                   140
Pro Glu Glu Gln Glu His Met Arg Arg Trp Leu His Glu Arg Phe Glu
145                   150                   155                   160
Ile Lys Asp Lys Met Leu Ile Glu Phe Tyr Glu Ser Pro Asp Pro Glu
                165                   170                   175
Arg Arg Lys Arg Phe Pro Gly Lys Ser Val Asn Ser Lys Leu Ser Ile
            180                   185                   190
Lys Lys Thr Leu Pro Ser Met Leu Ile Leu Ser Gly Leu Thr Ala Gly
        195                   200                   205
Met Leu Met Thr Asp Ala Gly Arg Lys Leu Tyr Val Asn Thr Trp Ile
    210                   215                   220
Tyr Gly Thr Leu Leu Gly Cys Leu Trp Val Thr Ile Lys Ala
225                   230                   235
```

<210> 127
<211> 291
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 98..103
<223> Box II
<221> SITE
<222> 149..157
<223> Box III
<400> 127

```
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5                   10                    15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20                    25                    30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35                    40                    45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln His Gly
    50                    55                    60
Gly Ile Tyr Val Lys Arg Ser Ala Lys Phe Asn Glu Lys Glu Met Arg
65                    70                    75                    80
Asn Lys Leu Gln Ser Tyr Val Asp Ala Gly Thr Pro Met Tyr Leu Val
                85                    90                    95
Ile Phe Pro Glu Gly Thr Arg Tyr Asn Pro Glu Gln Thr Lys Val Leu
            100                   105                   110
Ser Ala Ser Gln Ala Phe Ala Ala Gln Arg Gly Leu Ala Val Leu Lys
            115                   120                   125
His Val Leu Thr Pro Arg Ile Lys Ala Thr His Val Ala Phe Asp Cys
        130                   135                   140
Met Lys Asn Tyr Leu Asp Ala Ile Tyr Asp Val Thr Val Val Tyr Glu
145                   150                   155                   160
Gly Lys Asp Asp Gly Gly Gln Arg Arg Glu Ser Pro Thr Met Thr Glu
                165                   170                   175
Phe Leu Cys Lys Glu Cys Pro Lys Ile His Ile His Ile Asp Arg Ile
            180                   185                   190
Asp Lys Lys Asp Val Pro Glu Glu Gln Glu His Met Arg Arg Trp Leu
        195                   200                   205
His Glu Arg Phe Glu Ile Lys Asp Lys Met Leu Ile Glu Phe Tyr Glu
    210                   215                   220
```

```
Ser Pro Asp Pro Glu Arg Arg Lys Arg Phe Pro Gly Lys Ser Val Asn
225             230             235             240
Ser Lys Leu Ser Ile Lys Lys Thr Leu Pro Ser Met Leu Ile Leu Ser
            245             250             255
Gly Leu Thr Ala Gly Met Leu Met Thr Asp Ala Gly Arg Lys Leu Tyr
            260             265             270
Val Asn Thr Trp Ile Tyr Gly Thr Leu Leu Gly Cys Leu Trp Val Thr
            275             280             285
Ile Lys Ala
        290
<210> 128
<211> 261
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 68..73
<223> Box II
<221> SITE
<222> 119..127
<223> Box III
<400> 128
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5               10              15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20              25              30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
            35              40              45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Met Tyr
        50              55              60
Leu Val Ile Phe Pro Glu Gly Thr Arg Tyr Asn Pro Glu Gln Thr Lys
65              70              75              80
Val Leu Ser Ala Ser Gln Ala Phe Ala Ala Gln Arg Gly Leu Ala Val
            85              90              95
Leu Lys His Val Leu Thr Pro Arg Ile Lys Ala Thr His Val Ala Phe
            100             105             110
Asp Cys Met Lys Asn Tyr Leu Asp Ala Ile Tyr Asp Val Thr Val Val
        115             120             125
Tyr Glu Gly Lys Asp Asp Gly Gly Gln Arg Arg Glu Ser Pro Thr Met
        130             135             140
Thr Glu Phe Leu Cys Lys Glu Cys Pro Lys Ile His Ile His Ile Asp
145             150             155             160
Arg Ile Asp Lys Lys Asp Val Pro Glu Glu Gln Glu His Met Arg Arg
            165             170             175
Trp Leu His Glu Arg Phe Glu Ile Lys Asp Lys Met Leu Ile Glu Phe
            180             185             190
Tyr Glu Ser Pro Asp Pro Glu Arg Arg Lys Arg Phe Pro Gly Lys Ser
        195             200             205
Val Asn Ser Lys Leu Ser Ile Lys Lys Thr Leu Pro Ser Met Leu Ile
        210             215             220
Leu Ser Gly Leu Thr Ala Gly Met Leu Met Thr Asp Ala Gly Arg Lys
225             230             235             240
Leu Tyr Val Asn Thr Trp Ile Tyr Gly Thr Leu Leu Gly Cys Leu Trp
            245             250             255
Val Thr Ile Lys Ala
            260
<210> 129
<211> 90
<212> PRT
<213> Homo sapiens
<400> 129
```

```
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5               10              15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20              25              30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35              40              45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Asn Phe
    50              55              60
Ser Ala Lys Asn Val Gln Lys Phe Ile Phe Thr Leu Ile Val Ser Thr
65              70              75              80
Lys Lys Met Ser Gln Lys Asn Lys Asn Ile
            85              90
```

```
<210> 130
<211> 68
<212> PRT
<213> Homo sapiens
<400> 130
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5               10              15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20              25              30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35              40              45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Asp Ala
    50              55              60
Tyr Arg Ile Leu
65
```

```
<210> 131
<211> 66
<212> PRT
<213> Homo sapiens
<400> 131
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5               10              15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20              25              30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35              40              45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Arg Leu
    50              55              60
Asp Ser
65
```

```
<210> 132
<211> 97
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 81..83
<223> Box  I
<400> 132
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5               10              15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20              25              30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35              40              45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu
    50              55              60
Leu Tyr Gly Asp Leu Pro Lys Asn Lys Glu Asn Ile Ile Tyr Leu Ala
65              70              75              80
```

```
Asn His Gln Ser Thr Asp Val Ser Cys Asp Phe Ser Arg Arg Tyr Lys
            85                  90                  95
Val
<210> 133
<211> 182
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 81..83
<223> Box  I
<400> 133
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5                   10                  15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20                  25                  30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35                  40                  45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu
        50                  55                  60
Leu Tyr Gly Asp Leu Pro Lys Asn Lys Glu Asn Ile Ile Tyr Leu Ala
65                  70                  75                  80
Asn His Gln Ser Thr Val Asp Trp Ile Val Ala Asp Ile Leu Ala Ile
            85                  90                  95
Arg Gln Asn Ala Leu Gly His Val Arg Tyr Val Leu Lys Glu Gly Leu
            100                 105                 110
Lys Trp Leu Pro Leu Tyr Gly Cys Tyr Phe Ala Gln His Gly Gly Ile
            115                 120                 125
Tyr Val Lys Arg Ser Ala Lys Phe Asn Glu Lys Glu Met Arg Asn Lys
        130                 135                 140
Leu Gln Ser Tyr Val Asp Ala Gly Thr Pro Asn Phe Ser Ala Lys Asn
145                 150                 155                 160
Val Gln Lys Phe Ile Phe Thr Leu Ile Val Ser Thr Lys Lys Met Ser
            165                 170                 175
Gln Lys Asn Lys Asn Ile
            180
<210> 134
<211> 315
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 81..83
<223> Box  I
<221> SITE
<222> 160..165
<223> Box  II
<400> 134
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5                   10                  15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20                  25                  30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35                  40                  45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu
        50                  55                  60
Leu Tyr Gly Asp Leu Pro Lys Asn Lys Glu Asn Ile Ile Tyr Leu Ala
65                  70                  75                  80
Asn His Gln Ser Thr Val Asp Trp Ile Val Ala Asp Ile Leu Ala Ile
            85                  90                  95
Arg Gln Asn Ala Leu Gly His Val Arg Tyr Val Leu Lys Glu Gly Leu
```

```
                  100              105              110
Lys Trp Leu Pro Leu Tyr Gly Cys Tyr Phe Ala Gln His Gly Gly Ile
        115              120              125
Tyr Val Lys Arg Ser Ala Lys Phe Asn Glu Lys Glu Met Arg Asn Lys
    130              135              140
Leu Gln Ser Tyr Val Asp Ala Gly Thr Pro Met Tyr Leu Val Ile Phe
145              150              155              160
Pro Glu Gly Thr Arg Tyr Asn Pro Glu Gln Thr Lys Val Leu Ser Ala
            165              170              175
Ser Gln Ala Phe Ala Ala Gln Arg Gly Lys Asp Asp Gly Gly Gln Arg
            180              185              190
Arg Glu Ser Pro Thr Met Thr Glu Phe Leu Cys Lys Glu Cys Pro Lys
        195              200              205
Ile His Ile His Ile Asp Arg Ile Asp Lys Lys Asp Val Pro Glu Glu
    210              215              220
Gln Glu His Met Arg Arg Trp Leu His Glu Arg Phe Glu Ile Lys Asp
225              230              235              240
Lys Met Leu Ile Glu Phe Tyr Glu Ser Pro Asp Pro Glu Arg Arg Lys
            245              250              255
Arg Phe Pro Gly Lys Ser Val Asn Ser Lys Leu Ser Ile Lys Lys Thr
            260              265              270
Leu Pro Ser Met Leu Ile Leu Ser Gly Leu Thr Ala Gly Met Leu Met
        275              280              285
Thr Asp Ala Gly Arg Lys Leu Tyr Val Asn Thr Trp Ile Tyr Gly Thr
    290              295              300
Leu Leu Gly Cys Leu Trp Val Thr Ile Lys Ala
305              310              315
```

```
<210> 135
<211> 300
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 81..83
<223> Box  I
<221> SITE
<222> 160..165
<223> Box  II
<400> 135
```

```
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5               10              15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
        20              25              30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
        35              40              45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu
    50              55              60
Leu Tyr Gly Asp Leu Pro Lys Asn Lys Glu Asn Ile Ile Tyr Leu Ala
65              70              75              80
Asn His Gln Ser Thr Val Asp Trp Ile Val Ala Asp Ile Leu Ala Ile
            85              90              95
Arg Gln Asn Ala Leu Gly His Val Arg Tyr Val Leu Lys Glu Gly Leu
            100              105              110
Lys Trp Leu Pro Leu Tyr Gly Cys Tyr Phe Ala Gln His Gly Gly Ile
        115              120              125
Tyr Val Lys Arg Ser Ala Lys Phe Asn Glu Lys Glu Met Arg Asn Lys
    130              135              140
Leu Gln Ser Tyr Val Asp Ala Gly Thr Pro Met Tyr Leu Val Ile Phe
145              150              155              160
Pro Glu Gly Thr Arg Tyr Asn Pro Glu Gln Thr Lys Val Leu Ser Ala
            165              170              175
```

```
Ser Gln Ala Phe Ala Ala Gln Arg Glu Phe Leu Cys Lys Glu Cys Pro
            180                 185                 190
Lys Ile His Ile His Ile Asp Arg Ile Asp Lys Lys Asp Val Pro Glu
            195                 200                 205
Glu Gln Glu His Met Arg Arg Trp Leu His Glu Arg Phe Glu Ile Lys
    210                 215                 220
Asp Lys Met Leu Ile Glu Phe Tyr Glu Ser Pro Asp Pro Glu Arg Arg
225                 230                 235                 240
Lys Arg Phe Pro Gly Lys Ser Val Asn Ser Lys Leu Ser Ile Lys Lys
            245                 250                 255
Thr Leu Pro Ser Met Leu Ile Leu Ser Gly Leu Thr Ala Gly Met Leu
            260                 265                 270
Met Thr Asp Ala Gly Arg Lys Leu Tyr Val Asn Thr Trp Ile Tyr Gly
    275                 280                 285
Thr Leu Leu Gly Cys Leu Trp Val Thr Ile Lys Ala
    290                 295                 300
<210> 136
<211> 185
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> 81..83
<223> Box  I
<221> SITE
<222> 160..165
<223> Box  II
<400> 136
Met Arg Tyr Leu Leu Pro Ser Val Val Leu Leu Gly Thr Ala Pro Thr
1               5                   10                  15
Tyr Val Leu Ala Trp Gly Val Trp Arg Leu Leu Ser Ala Phe Leu Pro
            20                  25                  30
Ala Arg Phe Tyr Gln Ala Leu Asp Asp Arg Leu Tyr Cys Val Tyr Gln
            35                  40                  45
Ser Met Val Leu Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu
    50                  55                  60
Leu Tyr Gly Asp Leu Pro Lys Asn Lys Glu Asn Ile Ile Tyr Leu Ala
65                  70                  75                  80
Asn His Gln Ser Thr Val Asp Trp Ile Val Ala Asp Ile Leu Ala Ile
            85                  90                  95
Arg Gln Asn Ala Leu Gly His Val Arg Tyr Val Leu Lys Glu Gly Leu
            100                 105                 110
Lys Trp Leu Pro Leu Tyr Gly Cys Tyr Phe Ala Gln His Gly Gly Ile
    115                 120                 125
Tyr Val Lys Arg Ser Ala Lys Phe Asn Glu Lys Glu Met Arg Asn Lys
    130                 135                 140
Leu Gln Ser Tyr Val Asp Ala Gly Thr Pro Met Tyr Leu Val Ile Phe
145                 150                 155                 160
Pro Glu Gly Thr Arg Tyr Asn Pro Glu Gln Thr Lys Val Leu Ser Ala
                165                 170                 175
Ser Gln Ala Phe Ala Ala Gln Arg Gly
            180                 185
<210> 137
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..19
<223> amplification oligonucleotide PG1ASe13
<400> 137
```

```
accggggtcc agttgactg                                              19
<210> 138
<211> 17
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..17
<223> amplification oligonucleotide PG1ASe14
<400> 138
cggggtccag catggag                                                17
<210> 139
<211> 16
<212> DNA
<213> Homo Sapiens
<220>          ;
<221> misc_binding
<222> 1..16
<223> amplification oligonucleotide PG1ASe15
<400> 139
ccggggtcca ggcctt                                                 16
<210> 140
<211> 16
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..16
<223> amplification oligonucleotide PG1ASe16
<400> 140
cggggtccag gccttg                                                 16
<210> 141
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..21
<223> amplification oligonucleotide PG1ASe17
<400> 141
accggggtcc agaatttctc t                                           21
<210> 142
<211> 19
<212> DNA
<213> Homo Sapiens
<220>          !
<221> misc_binding
<222> 1..19
<223> amplification oligonucleotide PG1ASe18
<400> 142
cggggtccag gatgcttat                                              19
<210> 143
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..23
<223> amplification oligonucleotide PG1ASe24
<400> 143
aatcatcaaa gcacagcatg gag                                         23
```

```
<210> 144
<211> 28
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..28
<223> amplification oligonucleotide PG1ASe25
<400> 144
caaatcatca aagcacagat gtatcttg                                    28
<210> 145
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..20
<223> amplification oligonucleotide PG1ASe26
<400> 145
atcaaagcac aggccttgca                                             20
<210> 146
<211> 26
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..26
<223> amplification oligonucleotide PG1ASe27
<400> 146
agcaaatcat caaagcacag aatttc                                      26
<210> 147
<211> 28
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..28
<223> amplification oligonucleotide PG1ASe28
<400> 147
atcatcaaag cacaggatgc ttatagaa                                    28
<210> 148
<211> 31
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..31
<223> amplification oligonucleotide PG1ASe35
<400> 148
gtgttacttt gctcagatgt atcttgtgat t                                31
<210> 149
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..23
<223> amplification oligonucleotide PG1ASe36
<400> 149
tactttgctc aggccttgca gta                                         23
<210> 150
```

```
<211> 27
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..27
<223> amplification oligonucleotide PG1ASe37
<400> 150
gggtgttact ttgctcagaa tttctct                                    27
<210> 151
<211> 29
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..29
<223> amplification oligonucleotide PG1ASe38
<400> 151
ggtgttactt tgctcaggat gcttataga                                  29
<210> 152
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..20
<223> amplification oligonucleotide PG1ASe46
<400> 152
caggaactcc agccttgcag                                            20
<210> 153
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..23
<223> amplification oligonucleotide PG1ASe47
<400> 153
caggaactcc aaatttctct gca                                        23
<210> 154
<211> 25
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..25
<223> amplification oligonucleotide PG1ASe48
<400> 154
cgcaggaact ccagatgctt ataga                                      25
<210> 155
<211> 22
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..22
<223> amplification oligonucleotide PG1ASe57
<400> 155
ctgcccaacg tgaatttctc tg                                         22
<210> 156
<211> 22
```

```
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..22
<223> amplification oligonucleotide PG1ASe58
<400> 156
gcccaacgtg gatgcttata ga                                              22
<210> 157
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..23
<223> amplification oligonucleotide PG1ASe68
<400> 157
cgaccatgac gggatgctta tag                                             23
<210> 158
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..19
<223> amplification oligonucleotide PG1ASe1X
<400> 158
ccggggtcca gagattgga                                                  19
<210> 159
<211> 26
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..26
<223> amplification oligonucleotide PG1ASeX2
<400> 159
aaagtggaag gccctcttta acaata                                          26
<210> 160
<211> 25
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..25
<223> amplification oligonucleotide PG1Ae1b3
<400> 160
gccctcttta acattgactg gattg                                           25
<210> 161
<211> 24
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..24
<223> amplification oligonucleotide PG1Ae1b4
<400> 161
gccctcttta acacatggag gaat                                            24
<210> 162
<211> 28
<212> DNA
```

```
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..28
<223> amplification oligonucleotide PG1Ae1b5
<400> 162
ggccctcttt aacaatgtat cttgtgat                              28
<210> 163
<211> 25
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..25
<223> amplification oligonucleotide PG1Ae1b6
<400> 163
gccctcttta acagccttgc agtat                                 25
<210> 164
<211> 25
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..25
<223> amplification oligonucleotide PG1Ae1b7
<400> 164
ggccctcttt aacaaatttc tctgc                                 25
<210> 165
<211> 28
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..28
<223> amplification oligonucleotide PG1Ae1b8
<400> 165
gaaggccctc tttaacagat gcttatag                              28
<210> 166
<211> 26
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..26
<223> amplification oligonucleotide PG1Ae3b4
<400> 166
atgctggatt atagcatgga ggaatc                                26
<210> 167
<211> 31
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..31
<223> amplification oligonucleotide PG1Ae3b5
<400> 167
caaaatgctg gattatagat gtatcttgtg a                          31
<210> 168
<211> 23
<212> DNA
<213> Homo Sapiens
```

```
<220>
<221> misc_binding
<222> 1..23
<223> amplification oligonucleotide PG1Ae3b6
<400> 168
tgctggatta taggccttgc agt                                    23
<210> 169
<211> 28
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..28
<223> amplification oligonucleotide PG1Ae3b7
<400> 169
tgctggatta tagaatttct ctgcaaag                               28
<210> 170
<211> 30
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..30
<223> amplification oligonucleotide PG1Ae3b8
<400> 170
ccaaaatgct ggattatagg atgcttatag                             30
<210> 171
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..21
<223> amplification oligonucleotide PG1Ae5b6
<400> 171
tatctttgca tggcagcctt g                                      21
<210> 172
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..23
<223> amplification oligonucleotide PG1Ae5b7
<400> 172
ctttgcatgg caaatttctc tgc                                    23
<210> 173
<211> 27
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..27
<223> amplification oligonucleotide PG1Ae5b8
<400> 173
ttatctttgc atggcagatg cttatag                                27
<210> 174
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
```

94

```
<221> misc_binding
<222> 1..20
<223> amplification oligonucleotide PG1Ae56b
<400> 174
ctgcccaacg tgggaaagac                                                20
<210> 175
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..21
<223> amplification oligonucleotide PG1Ae46b
<400> 175
gcaggaactc caggaaagac g                                              21
<210> 176
<211> 25
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..25
<223> amplification oligonucleotide PG1Ae36b
<400> 176
tgttactttg ctcagggaaa gacga                                          25
<210> 177
<211> 22
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..22
<223> amplification oligonucleotide PG1Ae26b
<400> 177
atcaaagcac agggaaagac ga                                             22
<210> 178
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> misc_binding
<222> 1..19
<223> amplification oligonucleotide PG1Ae16b
<400> 178
ccggggtcca gggaaagac                                                 19
<210> 179
<211> 56520
<212> DNA
<213> Homo sapiens
<220>
<221> exon
<222> 2001..2216
<223> exon1
<221> exon
<222> 18196..18265
<223> exon2
<221> exon
<222> 23716..23831
<223> exon3
<221> exon
<222> 25570..25659
```

```
<223> exon4
<221> exon
<222> 34668..34758
<223> exon5
<221> exon
<222> 40685..40843
<223> exon6
<221> exon
<222> 48067..48190
<223> exon7
<221> exon
<222> 50179..54519
<223> exon8
<221> polyA_signal
<222> 54493..54498
<223> AATAAA
<221> primer_bind
<222> 1991..2008
<223> upstream amplification primer 5-63
<221> primer_bind
<222> 2505..2525
<223> downstream amplification primer 5-63 , complement
<221> primer_bind
<222> 4091..4111
<223> downstream amplification primer 99-622
<221> primer_bind
<222> 4528..4546
<223> upstream amplification primer 99-622 , complement
<221> primer_bind
<222> 5475..5495
<223> downstream amplification primer 99-621
<221> primer_bind
<222> 5927..5947
<223> upstream amplification primer 99-621 , complement
<221> primer_bind
<222> 8127..8144
<223> downstream amplification primer 99-619
<221> primer_bind
<222> 8560..8578
<223> upstream amplification primer 99-619 , complement
<221> primer_bind
<222> 11622..11639
<223> upstream amplification primer 4-76
<221> primer_bind
<222> 12018..12037
<223> downstream amplification primer 4-76 , complement
<221> primer_bind
<222> 11930..11947
<223> upstream amplification primer 4-77
<221> primer_bind
<222> 12339..12358
<223> downstream amplification primer 4-77 , complement
<221> primer_bind
<222> 12915..12932
<223> upstream amplification primer 4-71
<221> primer_bind
<222> 13317..13334
<223> downstream amplification primer 4-71 , complement
<221> primer_bind
<222> 13216..13233
<223> upstream amplification primer 4-72
```

```
<221> primer_bind
<222> 13617..13636
<223> downstream amplification primer 4-72 , complement
<221> primer_bind
<222> 13547..13564
<223> upstream amplification primer 4-73
<221> primer_bind
<222> 13962..13981
<223> downstream amplification primer 4-73 , complement
<221> primer_bind
<222> 15994..16011
<223> downstream amplification primer 99-610
<221> primer_bind
<222> 16463..16480
<223> upstream amplification primer 99-610 , complement
<221> primer_bind
<222> 17304..17324
<223> downstream amplification primer 99-609
<221> primer_bind
<222> 17814..17832
<223> upstream amplification primer 99-609 , complement
<221> primer_bind
<222> 18008..18027
<223> upstream amplification primer 4-90
<221> primer_bind
<222> 18423..18442
<223> downstream amplification primer 4-90 , complement
<221> primer_bind
<222> 18699..18716
<223> downstream amplification primer 99-607
<221> primer_bind
<222> 19164..19182
<223> upstream amplification primer 99-607 , complement
<221> primer_bind
<222> 22589..22609
<223> downstream amplification primer 99-602
<221> primer_bind
<222> 23111..23129
<223> upstream amplification primer 99-602 , complement
<221> primer_bind
<222> 25098..25118
<223> downstream amplification primer 99-600
<221> primer_bind
<222> 25657..25674
<223> upstream amplification primer 99-600 , complement
<221> primer_bind
<222> 26537..26557
<223> downstream amplification primer 99-598
<221> primer_bind
<222> 27022..27040
<223> upstream amplification primer 99-598 , complement
<221> primer_bind
<222> 32262..32281
<223> downstream amplification primer 99-592
<221> primer_bind
<222> 32823..32841
<223> upstream amplification primer 99-592 , complement
<221> primer_bind
<222> 34215..34233
<223> upstream amplification primer 99-217
<221> primer_bind
```

```
<222> 34624..34644
<223> downstream amplification primer 99-217 , complement
<221> primer_bind
<222> 34473..34491
<223> upstream amplification primer 5-47
<221> primer_bind
<222> 34916..34936
<223> downstream amplification primer 5-47 , complement
<221> primer_bind
<222> 34702..34722
<223> downstream amplification primer 99-589
<221> primer_bind
<222> 35182..35200
<223> upstream amplification primer 99-589 , complement
<221> primer_bind
<222> 39591..39611
<223> upstream amplification primer 99-12899
<221> primer_bind
<222> 39971..39991
<223> downstream amplification primer 99-12899 , complement
<221> primer_bind
<222> 40531..40549
<223> upstream amplification primer 4-12
<221> primer_bind
<222> 40932..40950
<223> downstream amplification primer 4-12 , complement
<221> primer_bind
<222> 40629..40649
<223> downstream amplification primer 99-582
<221> primer_bind
<222> 41058..41078
<223> upstream amplification primer 99-582 , complement
<221> primer_bind
<222> 45729..45746
<223> downstream amplification primer 99-576
<221> primer_bind
<222> 46186..46203
<223> upstream amplification primer 99-576 , complement
<221> primer_bind
<222> 47879..47896
<223> upstream amplification primer 4-13
<221> primer_bind
<222> 48217..48236
<223> downstream amplification primer 4-13 , complement
<221> primer_bind
<222> 48902..48922
<223> upstream amplification primer 99-12903
<221> primer_bind
<222> 49331..49351
<223> downstream amplification primer 99-12903 , complement
<221> primer_bind
<222> 49830..49848
<223> upstream amplification primer 5-56
<221> primer_bind
<222> 50271..50290
<223> downstream amplification primer 5-56 , complement
<221> primer_bind
<222> 50172..50189
<223> upstream amplification primer 4-61
<221> primer_bind
<222> 50573..50591
```

```
<223> downstream amplification primer 4-61 , complement
<221> primer_bind
<222> 50541..50560
<223> upstream amplification primer 4-62
<221> primer_bind
<222> 50940..50959
<223> downstream amplification primer 4-62 , complement
<221> primer_bind
<222> 50555..50572
<223> upstream amplification primer 4-63
<221> primer_bind
<222> 50964..50983
<223> downstream amplification primer 4-63 , complement
<221> primer_bind
<222> 50774..50792
<223> upstream amplification primer 4-64
<221> primer_bind
<222> 51183..51202
<223> downstream amplification primer 4-64 , complement
<221> primer_bind
<222> 51146..51165
<223> upstream amplification primer 4-65
<221> primer_bind
<222> 51479..51496
<223> downstream amplification primer 4-65 , complement
<221> primer_bind
<222> 51593..51610
<223> upstream amplification primer 4-67
<221> primer_bind
<222> 29734..29744
<223> upstream amplification primer 4-67 , complement
<221> primer_bind
<222> 51167..51185
<223> upstream amplification primer 5-50
<221> primer_bind
<222> 51667..51687
<223> downstream amplification primer 5-50 , complement
<221> primer_bind
<222> 51387..51403
<223> upstream amplification primer 5-71
<221> primer_bind
<222> 51826..51843
<223> downstream amplification primer 5-71 , complement
<221> primer_bind
<222> 51772..51789
<223> upstream amplification primer 5-30
<221> primer_bind
<222> 52199..52217
<223> downstream amplification primer 5-30 , complement
<221> primer_bind
<222> 51850..51867
<223> upstream amplification primer 5-58
<221> primer_bind
<222> 52382..52400
<223> downstream amplification primer 5-58 , complement
<221> primer_bind
<222> 52507..52527
<223> upstream amplification primer 5-53
<221> primer_bind
<222> 52997..53017
<223> downstream amplification primer 5-53 , complement
```

```
<221> primer_bind
<222> 52703..52721
<223> upstream amplification primer 5-60
<221> primer_bind
<222> 53142..53162
<223> downstream amplification primer 5-60 , complement
<221> primer_bind
<222> 53001..53018
<223> upstream amplification primer 5-68
<221> primer_bind
<222> 53521..53538
<223> downstream amplification primer 5-68 , complement
<221> primer_bind
<222> 53459..53476
<223> upstream amplification primer 5-66
<221> primer_bind
<222> 53920..53940
<223> downstream amplification primer 5-66 , complement
<221> primer_bind
<222> 54202..54220
<223> upstream amplification primer 5-62
<221> primer_bind
<222> 54681..54701
<223> downstream amplification primer 5-62 , complement
<400> 179
gtggatctgt gactgttcgc aggaagagag gagcgggagc aggacagaca ataactgata    60
gtcaggagct gggtttggag ataaagaggg aacaagagaa agttaagttc tgtgtttca   120
tggcaaacat tgcacaaaag tttacaactt cgtgactaac agtaatctgg ggtgattcac   180
aacaaattta cacataaaca catatttact gactttatac acagcaatcc taacgtgaac   240
acagaacctg ctttatcttt tcgcacactg ttctagtgta gagatgtctg tctcagttta   300
aagaaagcat aaggagcatt agttgtgcac actgtccaca cccgtgactt ttttccacca   360
gtactaaacc tagtgcttct tacagtacag ggcaatgaca gccacagaaa gagagaagct   420
cctttactg tgtaatgctt cctgctggcc ttcaaatact tgttacttga gagatctcca   480
ttcacctggc tttgtcccca aaggtcatca tctaccaatg atgttgttat ttgatgttaa   540
tcatgtataa agaaagtagc taccatcctg gccctgatta gaacttccca ctgaaatacc   600
gtcctgccta aaggtagcac aggtttccat tatggtggtg gtggggaggg ggcgggaata   660
tatatatata tatatatata tatatatg gtaaagcatt cggcattctt ttaaagtaca   720
actatccttg aaaagggtta catattaaac cattttacc acagccaaag gggaggagaa   780
agatccaaaa gtcctgtgga tctgctttaa catcaataaa acagttatcc accttcgta   840
gcttttagtg aaggctacaa aagtatgctt tttatggatt acacatgtgc acgcaactac   900
tttaattact acagaaaaaa acgaggctcc ttattaaaaa aaaatcagaa acaagtccaa   960
cagactctga ggaaatgaag caagagtgaa ttctgaaaag gtctaataaa cagtatggaa  1020
atatccttgt gggattgttc ttcagctatg cataaacatg taattatcat cattactgtg  1080
atgggaaaa acacggaccc taattctgaa acaccctggt agcgagagac gggcaggagg  1140
ggctgctgcg cactcagaga ggaggctgag gaggcggcgt cccccttgcaa aggactggca  1200
gtgagcagat ggggacactc gagctgcccc gcgacctggg ccgagctgcc tacaacctgg  1260
gcccaggtgc ctgcaagaat tagacctccg ataacgttaa cacccacttt ctcactgctc  1320
taattgtgtg catcccggcg cccagggggct tgtgagcagc aggtgcgcgt tccaggcagc  1380
tccagcgacc cttaaacctg accgcgcgca cgtccggccc gagggagcag aacaagaggc  1440
acccggaccc tcctccggcc agcacccacc ttcacccagt tccgtcagtc gccaccacct  1500
cccttcccgc gtccgcagcc ggcccagctg gggagcatgc gcagtggccg gagccgggtt  1560
gcccgcgcca cagcaggtag ctgtactgca actgtcggcc caaaccaacc aatcaagaga  1620
cgtgttattg ccgccgaggt ggaactatgg caacgggcga ccaatcagaa ggcgcgttgt  1680
tgccgcggag cccctgccc cggcaggggg atgtggcgat gggtgagggt catggggtgt  1740
gagcatccct gagccatcga tccgggaggg ccgcgggttc ccttgctttg ccgccgggag  1800
cggcgcacgc agccccgcac tcgcctaccc ggccccgggc ggcggcgcgg cccatgcggc  1860
tgggggcgga ggctgggagc gggtggcggg cgcggcggcc cgggcccggg cggtgattgg  1920
ccgcctgctg gccgcgactg aggcccggga ggcgggcggg gagcgcaggc ggagctcgct  1980
gccgccgagc tgagaagatg ctgctgtccc tggtgctcca cacgtactcc atgcgctacc  2040
tgctgcccag cgtcgtgctc ctgggcacgg cgcccaccta cgtgttggcc tgggggggtct  2100
ggcggctgct ctccgccttc ctgcccgccc gcttctacca agcgctggac gaccggctgt  2160
```

```
actgcgtcta ccagagcatg gtgctcttct tcttcgagaa ttacaccggg gtccaggtga   2220
gccgcctccc gctcccgggt ctcggcgtcc acccgagctc ccggggggcgc ggacctctcc   2280
gctcccccac agctggcgag ggtcacccgg ccggcccggc ggacccagca cggagagcac   2340
gtgccgcctc cccgccttcc tctccgcatg cttcctgccg ttctgccgag atcgctctct   2400
aggaagctgt ggctgcgtcg tcctgaggct acgagtggga cccgccgccc ctttccccgc   2460
ccctcgcctg ggtctgatgc tgcttagcaa agtgggtgca gatgcacgtt ttaaataata   2520
gggcacgcgt ttagcagttt ctggcctttg gtccaaagag gtggtcatgt tggaacagat   2580
cggagacgtc tacactccga agtgcgcttt tacagtgacc tcttgaaaca gaagtacaat   2640
tcggtcttgt gttctttccc ctggacaagt gaaagctggg cgaagaaatg aatacatttg   2700
ttaaccgtag aagcctaact agatacaatt cttgccaact ttaactgggc ttgaatgtgt   2760
gggtgatctg ttgtctgatt actttctttc tgttactgtt tctctgtaga gattggattc   2820
gtagattaaa cttgagaaac aaaccataaa agtggaaggc cctctttaac agtaggtatt   2880
tgaagtgtta taaaaaaaaa aaaggtgaat ttttctttta tttctcagtt tgaaagaaca   2940
gctttattct tggttattcc taatgtccac ctagtcctct tttacttttc ttggtagggt   3000
tagggtggca tggggaaatg ggacggtatc atttttgtctt tttaactttt ttttttttcca   3060
cctacagcag ctgttttac cctgtggtca gtcaggtact atatttagtt tgcagttgca   3120
ctgctgatcg acccttgatg gccccagttg gaagttgttt gggggggaagg aactaggaga   3180
ggccagggcc tccatttaaa ccagtgtctg taagtgtctc cttggaagga aaaaaagata   3240
ctgttccagg tcatggtttc ctggtagttg acgtttaaaa tgggcctcat ttaaaaattt   3300
caataattca ggctaatttt ttcccttttat atggtaactc caccaagttt gtctaaatgt   3360
atgattttta tcatgattaa gttttttactt ccacatcatg tgacaactgg cctgggatgg   3420
gatataagct cagaacacaa agtcattcac ctgttaaaaa aataattcta tctgtggcgg   3480
gttatgttat ttttgttcaa agaggacaca atatgatgca gaatacacca ttgaaggatt   3540
ttttggtttg gcaagttctt atttttttaa atggctgtaa aacctagcag tgtttctgaa   3600
attgcatacc ttacctgatg ttcagagatc cgatttactt cttgatttcc cagcaagtga   3660
ttttgaaaac atttaatcta atcattcccc ccaccgtctg ttcaaatcaa aggaagtggc   3720
atccagcact aatttcatg catttatgaa aggatgcctg aggacccta agtataattc   3780
aaaattttgt ttaatgtgtg ttccttgatg aagttcttta ggagtcgtag aacgaactga   3840
ttgcccactg atcatcaaat gcaagttatg aacatttaat aaaaatttaa aaccaagagt   3900
ttcttgttcc tgcattttta tttttattgt atggagggga caaataatta ttttctgttt   3960
agtaacagag cagggtattg tgaatttatt agggtctttt tctgcagtct gggtttcctg   4020
tgtacacaaa gctaccttc aatatttttt attgtttctg ttaagattaa atcaatagag   4080
gaataaatag ctatcttcaa acataagacc caaaggaaaa agatttatag tgatgttctg   4140
tcaccttatt ttttacctgt gactttgtac cattaactt gtcactgaga tgttttgatt   4200
aaaatttta gcttgctttt cttgttttgt taggacactc ttttttttctt gaattgtttt   4260
tatcagcttt cgtttgcaag gctagtgatg attctcttgt tctgtataaa gtattgttga   4320
ctcatttctg aagggagttt tagtaattta agaggttata agtttttaaa taaaaggttt   4380
attaatttat atatattaaa gaggcatttt aaaataaaat ttttttaaa tgacattttt   4440
acacctttca actctaggtt taaaaaataa gtggttcaca gtagttcttg cagaagaata   4500
ttttctttta catagaattt ttaagctgaa gagaagtagt agtaggtcca tgagatttat   4560
gatctgtgct tggcaggtaa acctgcttcc aacaaattta gttggatttt tcttggattc   4620
tgggtaaata ccttttttctt ccccagtttc actactttat tttcatatgt atctctgaga   4680
tagagaaata tttcagtcag tgctgctaaa attgttcctt ataactcgtt tatcctttta   4740
ggtccttcca gaatctctca ttggtactga aactcaaatg ggtactttct tcaccattta   4800
tttctttaga ataagtaata agaatttat aagctttttt atatttcacg taatttgaga   4860
ctattgaaaa tccagttaag tctctctact gtgttgagag gcattgattc aagtacctgt   4920
gttactttcc tgtgctgcca aaacagatca cctcaaaacta agcggcttaa aataatagaa   4980
cttaagttct cgtgattctg gaggccagca ctttgaaatc aaggtgtagg ctcaatttta   5040
ctccctctgg aggccctagg gggaatctgt tcttgtgggt ttcaacttct ggtgactggt   5100
ggcattcctt ggcttggggc cccatcactt caacctctgc cttacagtcc ttgctgccac   5160
ctcttctgtc tcacatctca ctctcccttt ctcttagaag gatgcttgtc attgggttta   5220
gagcccacct ggatattccg ggatgatctc ttcatctcaa gatccttaat tataactgca   5280
aagagccttt ttccaaataa gaaaacattc acaggttcca gggcttagga tgtggacaca   5340
tttttttgagg ggctgccctt cattcccccca caacaatgaa ctccatagtt ctgcctattc   5400
agtatttgt agttatttcg tagtttaact tgccttattt ctttaggtat ttacgtatta   5460
aagcattttg gtctctgctt tctttaacag agaacctggt ttttctgtaat aagtttactt   5520
actttcccat aatcttttag tttcttattt acagatttac cttcacatat cccttaagta   5580
gaacatttga ttaactgttt tattttcgga acaaatctgc attctgtata ataaccaact   5640
tattcatatt tcggtattct tttaattctt atctgattct gaattacca tcttgtgatt   5700
atatatatat atatatggaa ataactgaaa tcttgataaa ttaaaggtga tataacttct   5760
aagacaatta attatgtatg atgtggtgaa tatactggtg tttggtttgt ttgccactta   5820
```

```
aaagccctat ctataggata ggaagtaact tgaatgtgga atgcttagag actcagagta   5880
agaggccgta tatatatcct tgagctggag tttaaggaaa acttatggga aattaaaagg   5940
aaagttggag tactgacaga ggattgcgta ggactcatga aaaaggaatg aagttacctt   6000
aaattctatc atcgtgagtt aacgtgaaac tagatttatg ttagtttata gcctagaatt   6060
ctatcctagg aatctagata tatcctaaat gttgagatag ctgcataaac aataactgta   6120
atcgttatga taaataatga caaatctttt tagcatgttt tgtgaagctg ataaatgtta   6180
atacgatgtc ttcaaatgtc agaattcttt tttctttgct tcttttttaa aaaatttctt   6240
ttcaccatt cctatgcaat acactgaaaa ctgatcattg aaatttgtag gccaaaaaat   6300
taatcaacac gtaatagatt ggggtttggg ttttttttgag tcagggtctt cttctgtcac   6360
ccaggctctg gtgcggtggc accatcatgg ctcattgcag ccttgaatgc ctgggttcaa   6420
gtgatcctcc ggagtagctg ccgtgccatt atttctagct aattttttaaa agttttttgta   6480
gaaatggggt ctttctgtgt tgcccaggct ggtcttgaat tcctggcctc aggtgatcct   6540
tctgccttgg cctcccaaag tgctgggatt acaggtgtga gccaccatgc ctagccccta   6600
ataaatattc taattaccga tttatcttgc ttaaatcagt tggtaacact tggaatttac   6660
ttcagaatat attttacatt agtggctctg actgctaatt cccccttctc caaatgctaa   6720
tgtaatataa caataaaatg cacagttctt aagtttatat aaaataaaca ggttttcagt   6780
tgacctgctt taagtgtaaa atagtgtgaa aaacacaaga aagaagataa agaatttaag   6840
attttgacat ttctctaata tgcccttaac ttctccaagg attcatactt ttttttgtaa   6900
gacagaatct cacactgttg cccaaaccag aggtgcagtg gtgcagtctc cactcactgc   6960
aacctctgcc cccgggctca agcggtcctc ccacctcagc ctcctgagta gctgggacta   7020
caggtacaca gcaccatgcc cagctaattt ttttttttgg tatttttag tggggggtaga   7080
gacgagattt tgccatattg cccagtctgg ttttgagctc ctgggctcaa gtgatccgtc   7140
cttgatccac catgcttagc tgattcatac tcttaactga aacattgttc caagtttctc   7200
agaaacagtc aaggctttt atctagagaa catttataac tggatctttc tttgtgtagc   7260
actgattcat caaactaatc ctaaactcct aatgagttaa atttatattc tgaatcttgc   7320
tgtaaaagca gccattcatt agaatgaaac atgtttactt agaattggag aagggagctt   7380
ataagtcatc tagtctactc cctttttatga cacttctaca ttctttctgc acttctgcca   7440
aaatgttgcc cagcgtcgtc tctgatacct atagtcctaa caagaatatg aatcatacct   7500
tgtatcctta attttactct tctctgctta tttgccattc atgtgaagac cttaaataga   7560
tcttaaattg cttccttcac tttagctgag agtgacagga ctgtgtaggt gtgggtgtgt   7620
ttctgcattt gcttatttaa gcaggataat aaaaactttt actataggaa attaaacatt   7680
tcccaatcaa atacaattcc agtctaacac aattaaattc tggttaggga actgcttaac   7740
ttactagact tataggaaaa tactaaaaaa atgtaactag aactctattt ttacacttta   7800
taaaatataaa cctctgtgaa caaaccagtt atttcaggtt gcattgtgt atagttttt   7860
aatgcctgat ttttctattt taaaatcaca gatgcaatta tacattcaaa cactgccaca   7920
atactttgag aaagttaaag tttcccctac tcctacactg cgtacacctt tcctaggtac   7980
atcccagttt ggtgtgtaac tttagatttc ttccaagagc ttttgagtaa gtgtttgaat   8040
tgtgggaagg ttctttagtt aaatgaactt cttacagatc agttttttag tacagtagca   8100
cgaaatatac ctgcatacct atggggatac ctctgtgcca ttacgatgga aggcacggga   8160
aaacagcact ccgtatatac ctagtttact ttccctcttt tgtatatttg tctgattttg   8220
tggagctgat gcttctcaag tggaatcaga agttaacttt tcctttacta ttttctcatt   8280
ttattatggt ttcttaacta gaggttgatg ttagtggttg gaccattcaa tagtaagtaa   8340
tgactttca gtaagggatc tctagaaccc agatcccctta attcctgcaa tattcccgtg   8400
tgtacattgt tccaggtgct gtcctgggta ccaagggata caatgtttga tagacaatgt   8460
acctgccatt atggaggtca cattctagtg tgggaagaca aacaataaca agaaaatgaa   8520
aatttactgt gccatgccag gttgtttagc ctggtgggtg agaggtaggg gtttggaaaa   8580
tcttactgag caagtgacat ttgtgtggag ctctgtaaaa gggccagctt ggaaggtaat   8640
gtagtcatcc aggtgagaaa tgatggttag gggagtggaa agagtggatg ttaagattga   8700
aaagaattcc aaatctattt tagtggtagc tgatagggct ttgtgattga atgtggagga   8760
aaaagaagag ggtgggttag taacacactc agtcgcagtt agtgagtgct gctgtgtgca   8820
agtattgttc tattatgtaa ataattccat ctttacaaag taggcaccat tcttcctctt   8880
ttacagacaa ggaaaaggga acacccatgg ttcacatctg tagtagccta gccaggagtt   8940
tcaggcactt attttctgaa gatgctctgc ctggcaatgt ggttatattg gttgaaatga   9000
gacccctac tttcaaggta ttcatctagg aaagacatga actgccaatt acaatatagg   9060
ataacactga aattagagac gtgtttatta actttgccat acagaggtaa agtaactctt   9120
taaagtaact ctttgcttgg gttagtggag aaggctataa aaattacttg gagttttttac   9180
tttgaacatg cgtaattaac atggaatgtt tagggaaaag aggtttttcaa ttgataacat   9240
aataaacatg aggagtttga agcatggcat tcaaggtttt ctaaattctg ccccggttaa   9300
cttttccatt cgttggtttc attctagtct agctttttcct tctgggccgc ccctcccac   9360
attagaccgc tcctctctgg aattccaact caagcccttg cttttctcca tctgtcatga   9420
tgttacccca tctcattgtc agggtaactt ttatgtaata ttaacatata taatactgat   9480
```

```
ataacattag catattttaa tgtatggatc atctcctctg caacattgta acctcttgga   9540
gatggcaata atgggaagaa tgacttgatt ttactttttc ttttaacaaa aatggtggag   9600
tagtctgggc acggtgtggc tcatgcctgt aatcccagca ttttgggagg ccaaggaggg   9660
tggatcactt gaggtcaggc attcgagacc agtctggcca acattgtgaa accccatctc   9720
taccaaaaaa atacaaacac ttactgggca tggtggtgtg tgcctgtagt cctagctact   9780
caggaggctg aggtgggaga atcacttgaa catgggaggt agaggctcca gcttgggcga   9840
cagagtgaga ccctgtctca aaagaaaaaa aaggtaaaag ggccaggtgc ggaggctcac   9900
gctggtaatc caagcacttt gggaggctga ggcaatggat cacctgaggt cgggagttcg   9960
agatcagcct gaccaacatg gagaaacccc ttctctacta aaaatacaaa attagccggg   10020
cgtggtggtg cctgcctgta atctaagcta catgggaggc tgaggcagga gaatcacttg   10080
aacccaggag acagaggttg tggtgagcca agatggcacc attgcactcc cgactgggca   10140
acaagagcga aattccgtct caaaacaaac aaacaaacaa aacaaacag agagaaaagg   10200
cagagtactc tagggaattc tagtctgtgt ttctgtggaa atgtatatga atctcacttt   10260
taagggatgg agattttttga atggcataac tagttgataa gttttgctct aacagggtac   10320
ccaagtctag tgagtccgat tcattctttc cttaaataga tgaaggagga agaaacatga   10380
ctccaccctc aagagtaagg cagaatgagc aaagtcagag aagttaaaaa agaattctca   10440
cgcagccagc agtgcagaga aaccttggtt tagttgtgaa tcaaaaccag tactttttgt   10500
aattttttgag cctatgcaat tctccaaggt tttatgttgt ttcttctgtt tctctgtagg   10560
caccagaaat caaaacccca aataagaaag tgttacttga agattttaga gtacttattt   10620
gtgtataagt gtaagtgata tttggaagac gactttactg cgctcctcca gcttggcatg   10680
agaattccag gggcggaaag aaaggagggt gatggtacct ggaaaggaga gtcatgttaa   10740
gtcccagcca catattaagt gctaaccacc tactgttaaa aggtgtaatg ttctagactg   10800
acaaaataca tagtctctac cgtaaagtaa cacataattt agcagtgcag aaagatgtca   10860
cttaaaagaa aacttgaata tatgctgaga tagttcacaa attaaagaaa tgaacaaaga   10920
actgaggaaa taaaggagga atacaactgt gtccaaatga atacttaact gggtgggagc   10980
tgttgcatat gtaagcaggt ggttcaccta aaagttggat gtaacgtagt taacgccagc   11040
tcttggtgca cttacatatt gcattgcttc cgggcttaat ttgtgttcat ataggaataa   11100
atttttttgtt ggttttttaat tttactcctt gtaattccgt ggttgatatt caaagtgaaa   11160
aaaattacat aagcttctaa tatatgagaa gtcttctcac ttgacatttt ttatttggaa   11220
tttttgcaga gagtagtttt gtcacagtca aaagattttg ggatcttgca gtgagaaacc   11280
taggtgtaat tcctattttct ctgccattcc gtatgtcatc tggattaagt gtcaacttct   11340
cagtctcaag attctcgtcc ttaaatggaa tacttttgt catgctattt tgaagacaaa   11400
atgagataat acgtgaaact gcctagctca gtgaatggta catcatagat actcagaaaa   11460
aacacaccct ctaaaataag aacagtacca aaagacagga tgtaaaataa gggcagtacc   11520
aaaagacaca tgcatgctga gtgtatgaga aagaactttg tggccttctt gggtggcaca   11580
ggccatggca gttccacagc atgacgtggt tgctgtgggt ggtagagcag acatgccgct   11640
ccccgtcact gcctggcttt gatgcttgct ttcttcagct gagaggacgc agctgtgata   11700
tgaaggtctt gtgtgtacag tcgtgacctc acatttccaa tttcctgctg gcagaaccca   11760
cagtctacaa cgtacgagca ccagagttga cgtgagacag acagcataca gaggcttgta   11820
acatccttct ggaaaacact gtgtaagctt tcagtgcgaa taaacatgat cagtggcaag   11880
ttctgttaga tgtagtctgc aagcatcctg attttactgg gcaagactat gttgatttac   11940
aggcggctga tgattccatg gatagcccac tactagtatt ttcacaaatt tcacaagaca   12000
ttcttactgg aagattgccc tgttcttatg atactgctgc cctttttagct tcatttgctg   12060
ttcagactaa acttggagac tacagtcagt cagagaactt gctaggccac ctctcaggtt   12120
attctttcat tcctgatcat cctcaaaaat ttgaaaaaga aattgtaaaa attacatcag   12180
caacatatag gcttatgtcc ttgagaagca gcagttaatt acctaaacac agcaagtacc   12240
ttagaactct gtgggagtta attgcactat gcaagggatc aagtaacaat aaaaattatga   12300
ttggaatgat gtcaagagga attctgattt ataacaggct atgaatgagt accttttccat   12360
ggtcgaagat tgtaaaaatt tgttttaagt gcaaacagtt ttttattcag ctttgaaaat   12420
gacttgcata aatctggaga aagattatca ggatttaata tggtgaatta tatggcatgt   12480
aaacatttgt ggaaagcaag tttagaacat cacatattct tctgtttgga cagaccactt   12540
ccaactagaa agaatttttt tgcacattat tttacattag gttcaaaatt cctaatgcat   12600
ggtgggagaa ctgaagttca gttagttcag tatggcaaag aaaaggcaaa taaagacaga   12660
ctacttgcag gatcctcaag taagccattg acgtggaaat taatagtttg ggaagtagta   12720
ggcaggaatt caatatctga tgaaaagatt agaaacataa agccttccat cacaattccc   12780
acccggaaca ggaattccta ctcatcaaaa ttctgcattc atacaagagg gaacctgatt   12840
atgaccatct tctgttggtc atttggtaga ttatgtggtt cacacttctt ccaaatatttt   12900
gcaaatcaga catcaccatt atcagcacaa gctaatagca tcattctgga atcatcacta   12960
ttacaggaca ccctggaga tgggtagcct ccagctttac cacccaaaca agctaagaaa   13020
aactgttgga actaaattca ttatttacat tttcaacaag atctggaaga tcatattaat   13080
gaaacgttga tgttctatct tctcttaaaa aatctgctcc taatggtggt attctacatg   13140
```

```
ataatcgtgt tctaatccga gtgaacctga cgaaaatgga aggtttggag tcaatgcaaa 13200
gggggatatg atcagaagat gtctgtgatc gtgtcctgag aagcaccagg aacacctttg 13260
acctcagtga ctctcgattg aagagaagac caagttgtat tgatcagtgg ttgggacttt 13320
acagaacaca cccatgattg ggttgtcctg cttttaaag ccaactgtga gagacattct 13380
ggggaactca tgcttctagt tctacctatg ctgcatatga tgtagtggaa gaagtgctag 13440
aaaatgagac agacttccag tacattctgg agaaagcccc actagatagt gtccaccagg 13500
atgaccatgt gctgtgggag tcagtgatcc agctaaccga gggcttatcg ctggaacatt 13560
ctggacacaa tttgatcaac ttatcaaaaa aaaacttgga atgacaattt ctggtgccag 13620
attaccttag aacctttgca aaaatagata gagatagttt tccttatgat gttacatggc 13680
ttattttaa aggtaatgaa aactacatca gtgtaattcc agcatcataa gtcagaacag 13740
tgcttgtcaa ggggcgttac cacacacttg aacagatttt tggcagatga cttgggaaca 13800
aggctcctcc atgtttgtaa tgttgaccac acaagttgaa tgtggcagag ttaaatgacc 13860
ccaatattgg ccagaaccca caggaagttc atcctatgga tgctaccaag ccttctgcca 13920
ctgagaagaa ggaagcactg tctttatctt caggaagatc acactgctgt ttaaccaaga 13980
gaaaaattag agagtcatca atcacgcaga tccagtacag agggtggcct gaccatggag 14040
accctgatga ttcagtgact ttctggattt tgttttcat atgcaaaata agagggctag 14100
caaggaaaaa cccccttgttg tttcttgcag tgctggagtt ggaagaacca gcgttcttaa 14160
tactatggaa acagccatgt gtctcattga tctcattgaa tgcagtcagc cagtttattc 14220
actagacatg gtaagaacaa tgagagagca gtgagccgtg atggtccaaa cacctagtca 14280
ttacagtttt gcgtgtgaag tactattttg aaagcttatg aagaaggctt tgctgaagaa 14340
agcaaaagga aaaaaagaac tttgtcatct gttaggttcc atttattgca tgataattgt 14400
gtttgtattg attattgggc aagtagctgt ttgctatttt gatcttattt cagaagggca 14460
taataatttt actattcaat gaaacgtttt aaacggggta gaaaaagact agttttgta 14520
tgctttacag cagaaatctt ataatgatta actggtaata tatttcgttg gcataaaaat 14580
acatttaaaa gttcaagtaa ttataaacat tgtaaattgt atatgtaatc atattgaaat 14640
tgaaattctt tatagctgta cttctgtgta atcaaagact ggggagagat agactagcta 14700
gctctttctc ttatccatta atcacttaac agagtttga ataaaaagtt ccatttcatg 14760
ggataagaat aatgacaggt taacctattt tagttggtta ctatgttcta ggtgttgtat 14820
gaagtagttt acatagtttc actgatttca ctacaatccc aggaggagta gttactatta 14880
ttacactcat tttacaggca aagaaatagg tttggagggg ttgggtgttt tgcccaagtt 14940
ctcatcgtaa aatgacagat gaggattcaa attcaagtct taattgaagt ccattacttt 15000
agaacctacc tcttagtggc tcttatgtta cagtataagg gagagcagac tgttcctta 15060
cccttgtagg gtagctaggg cttgtgaatt aagagactga ttaacaggag aagaggcata 15120
cacattttat tgacgttagt attttacat gcacagggaa ggagggtttt attttattt 15180
ttattttat ctttattta aagagacagg ggtcttgctg tgttgccagg gctggactca 15240
aactcctgaa gccaagcgat tcttctgctt gagattcctg agtagcaggg actataggtg 15300
tgctcctctg tgcttggcta aagaaggggt ttgtatgtga tttttaacaa aggctgataa 15360
attgtgaaga agtgactagt caaaggagaa gaggatttca gctcccaggg gtggtaaatt 15420
gtgggaagat gactaggaaa tgtatagtaa taaggtttgc tatgcaggtt tattttgcca 15480
gtttctggtc tcctaataag ggacagggaa acacctttac agatggaaat tcatatcacc 15540
tttccacagg gaaatttatg tcctgcctta ggcagttagg ggaagggcag agaattcttc 15600
ctgtatctgc tgtgtctcag gtgccttcag ctcaaaataa tccttatgcc aaagtagcat 15660
atttgggtgt ggcatattct ctgatctctt tcaacagcat catctatact taacaacagc 15720
aaaagttttt tttaaaaaat catgtttcaa gatttgcatg tggaagacaa atggacatga 15780
ttgagataaa tgaagaatat atatttttta acaaagaatg ctgtatattt atgtctctgt 15840
gacattgtgt tatggaggct aaggtgttaa gcatgtgatt actttagatg ccgtatgact 15900
acctgttttt aagattaaaa aagaatcaat aggcagttta tatgcatggg agcaagttaa 15960
aaacaacaca gatgtgatga aggcgaggtg aaactggtcc gcatctaatt caggccttct 16020
cctgaaagcc agtgtgtgca agataaataa gtttgtttga cgaaagcaga ataactagtt 16080
tgtcctttgt gatgaagata gttattcaga aatcattttt attggctacc tctgaattaa 16140
taaatgaaaa gagaaatttt tttttctgta ggggatgtct gatgagttct taaaaagtgg 16200
atgaacctga aattatcatg aacaagcaat tataatgaac ttaaaattac ttaaagagtt 16260
atgaaaaaca aaaagaaaag ccgtatgttt cttgtgcct tattttgaag tgacaaatta 16320
tttgcagggt acatttgtag acggaactaa tgtgatttaa aaaatgagta ctagatttac 16380
agaatgatgc ctttaaaaag tcactggtgc actttaatta ttttatttat gtttattctg 16440
aaactacctt tattttgaaa atgaggtata gctttgccta ctggtgacaa aagtgtaaat 16500
aattcagtaa acatctgtta aaaaccagct tggtgctagg ctcttggggt agaaaactga 16560
tcaggccatt gaggagctca tagtccctaa ggggctgggg acttgtcatt aggtgtgcag 16620
tgtgttctgg atgctcctga aggagtgtgg gcaggtgcgc accaccatgc ctggctaatc 16680
ttttttataat tatgtagaga cagggtctgg ctgtgctgcc catgctgggt ttgaacttct 16740
gggcttaaga gatcttccct ccctgcccct accgacccg cccgcccact ccacctcagc 16800
```

```
ctccccaaag cactgggatt gcaggcatgg gccactatgc ctgggctgtg caaaacttttt   16860
aaatcagtgc atactcaatg gtcttgatgc aattctggct tgttggtaag agaatggggа   16920
tttactcaca agccacgatg tcacttttaa ctctgaacag atcaagctat tggtattact   16980
catttatgtc atcgataaac tttatgaata aaaactcatt gtgcaaatat ttaaacatac   17040
tacatacata gcactgtgca gtttctaagg aaagtaatgg aaacctttgt cacatccctg   17100
gcttccagaa ctttatgtta tctaagtgca tttgtctgca aagttgttgg gttaattgcc   17160
cctttctttc ttctcttttt aagatattaa taaatagtgt catgaccaaa agataatcct   17220
tatggacaag atagatctaa aaagccttag ctaatttata atcttgcata atccatgatg   17280
acaagatgca gaaacaaaaa tgcccagaat aaaaacttag caccattagc agccatttcc   17340
ttttaagtct ttacaagtat actcccagtt tcttgaaaaa tttattctaa aatatgtaag   17400
acacacaaaa cagcagaagg actaatacag gtacatcgaa cacctgtgtg cctaccgccc   17460
agtttaaaaa taaactggaa tgatgtttct ctcatactta cagaataaag tttttaatctt   17520
tagcatggaa ttcaaaagac ttctgccatt ccagttcaga gccacccttc tggtctcctt   17580
gctcctcagc cgcgacactg cccatgtacc caacaggcct ccagggttac tgcttccatt   17640
cgttcttatt ctcatgaaca ttttccttca tctcatctgc cagaatccta cctaataata   17700
ctcctgctct gcagtttaca gttctttaaa attaaaaaag gttgtgtacc ctttagtgtc   17760
ctgaaaaaag aaaaaacaaa tttaaaacct taaaaaggta ccatattttc atagtatttg   17820
cgttatgtct cattacagtt cctgtggaca tgtctgtctc ttttactaga ttgattgtgg   17880
gctctttgaa ggaagatata tcttatgaac agtgtttttat atattgttag caatcaatga   17940
atgcttgcta tattttttctc atgaggatat tgattattct attttaattt attaccgtta   18000
acctgtacta tacataactg ctttctgtac ctgagctatt tatgatctct gaggctcctg   18060
tgagaaatct aatttttgtt aatcatggat ggaaatattc acaacatcat tcgtcagttt   18120
cttcacattg tcttcctttg tatattacag atgtttttaaa atatcaaagt aatgtttttt   18180
tgttttatct tttagatatt gctatatgga gatttgccaa aaaataaaga aaatataata   18240
tatttagcaa atcatcaaag cacaggtttg tatttcattt gcatgaaacc taggtttttc   18300
tacagatggc acatgggcat tcaaaatacc gttcttatat ttaaatgaag tgggttttttt   18360
aaaacagcaa ttttctgtgc agatattaca cctgttcttg tattttttgtg atttttacttt   18420
ttggaaagtc agaaacttga aagctatgaa ttttcctaaa cttaccttct ccctctgttg   18480
gatgtaagta agctatcttc ttacttgctt gctttgtttt tcctttgtgt agctctttaa   18540
agagtgtatt cattcttttt gtaagtgatg tttctagaag tagcattggt gggtcgaagt   18600
gtgtatacat tttacatttt tgattgctaa gctgcagaaa agctgtattg gtatgtaagt   18660
actcgtttcc ttactatgct cgtcatttct agtgtctgct cttcctttcc ttcttcaaat   18720
gggtttggtt taattctagt tgctactgtt ccatcagagg aattgcagag aactggtctt   18780
caaaacagtg cagtatatac tttaggtgaa gatacttcta aaaacctttg tatttttgagg   18840
taattctaga gtcccaagaa tttgcaaaaa gagtacattg tcagcaatat ttttcccaat   18900
ggtgacatct taatataact gtagcacagt agcagaatca ggaaattgtc attgggtaag   18960
gtacttttta attctccaaa taattcagcc ctccaaaaaa atcccacttc ttatgttttc   19020
aaacctgtag ctactttttga tgcgtacttc ctaaattgca ttttttattac tttaaaaaaat   19080
ataataccta gaagctcaaa gctggaaaca gcctgatcaa tatagtactc ttaagctaaa   19140
aacaacctga tcaatatagt actcttaggg aaatcactta tgcctgtggc tttttttttaaa   19200
ttttcttcct gtcagctgtc tcttcatgat tttgtggttt ttattactgc ttataccata   19260
gatgaggtat agaaagtaaa agaagttaaa atgcatttttt ctcaatttag tgaattaatg   19320
attacattca gatttatagg acaagggttg aagctacaag gggttgatag gaatcttgat   19380
gtatctgagt attttccca actttattac atgactggtt cagactattt tatctaatta   19440
catttcactc ttggcagaaa tagcaaaaca gtcaaccaat ggtcaatgct gctgagaact   19500
ctggcctgtg cagacatatt ggctgtttta cttctaatac cattctgctt ttcctgtcct   19560
gctgctgatg gatgtttctt ccaggtttta aatatcaaac aaaagggatc tgtgggccca   19620
gtacagggaa tggctcttga tagatttgat tttcctgcat ttcctttatt ttgatccagt   19680
gttaatttca tgtagagttg tctgtttaac aggattctct taaaattcct tcttcagttt   19740
acctgccagc tttctcttgt ccaggtttca gtatgaactc cactcgatta atagagctct   19800
ctagtagtga cttgtggagt gggttctctg aacatttctg gaagtgttgc tgatagtgat   19860
aatattgatc actagtactg ttaatttgtg tgcttactac atgttggctt ttatatgtat   19920
tccttcagat taaggacttc tagaaaacat ccatgaaaaa acagattaaa aaaaacaatt   19980
ctgcatgtat ttgggactag aaggtactat gggaaggata atcttcatac tcagaccata   20040
ctgacctgaa tttcatttat cagtttagag aaccacttcc ccttcccttc accctacctc   20100
cgagtgcctg tgactttgta tcaccgctct ggcaccacat cctcatccca gcaggatttg   20160
ggaaggctgc tttttgaaag cctttttaaaa ttctgtaagt tgagaaaata ctaggggaat   20220
gattttaaat ttctttagaa ttacaggctt tagtcagtat atgacagagc cttttcctag   20280
aaaaatgtgc atataaaaat ttgcatgtag ttttagggtt tcagagaccc ctaaagccta   20340
tccatagacg tggttcattg tctgattgtg tttaggtacc cttctaaaac cctttttgaga   20400
tgttaggaat cacaacagag tatctctgaa aatgtaatta gcggaaagaa catttcaaag   20460
```

105

```
actgttgttc tgcttagact ttctagtttg tcttctgcca ggcttgccgg aataaatgag   20520
tttcctggcc tgatactcaa aagaattgac atttaaatta gtctctctct tcccttgttt   20580
tcgcttgaca catccttgtc tctacattct gtctctgtct ctgttagctt atttctctct   20640
cgagtcagca ggatatagtg gctgttattt cttcccctta tccttcaacg atctactttt   20700
gacaacactt tgcctttttt tttttgagat ggagtttcac tcttgttgcc caggctgggt   20760
gtaatggtgc aatctcagct cactgcaacc tttgcctccc gggttcaagc cattttcctg   20820
cctcagcctc ccgagtagct gggattacag acatgcacca ccacgcctgg ctaattttgt   20880
attttcagta gagatggggt ttcaccatgt tggtcaggct ggtcttgaac tcctgacctc   20940
aggtgatctg cctgcctcgg cctcccaaag tgcagggatt acaggcgtga gccactgtgc   21000
cctgcctgct atttgccttt ttaatctcat gaaatgttct cttttcttgg ctgaagtgtc   21060
acttttcttg ttgaacagca tgcgtggtga gtagaatgtt ataaaaaggg atggactttg   21120
gagttagaga gacccaggtt cctgttcggc attgcagaaa tgctgttctg caataggctg   21180
tgtgtcagtg ggcaaattac ttatctctca gagccttatt ggtaaggtgt gagtgatagc   21240
tcctttcagg caccttacag aggctgtctc ctaatcctgg tagcgtacct ggctcataga   21300
tggcatttaa aagtggttgt gatgacagtc atagctcacc attagcatag cgctggatcc   21360
atggcaggga agcgctgcac atgcagtatc tcttggacta cacagggccc tcatgaatta   21420
ggaactgctg tttcatgagg atagggatga ggaaattaga cttgctgccc ctcactgcct   21480
tccactcctc tcctccaagt taatgggaac tatgactctg ctttggcttg attgccatgg   21540
aagattctca cacagccaaa tttattgcta tcttagttaa attatgccag aacacaaaat   21600
atgaagttat tgtcaaagta atataatctc agctgtaact gagatagtca gaaactgtct   21660
gtaatctgat gtcctatctg aaaggtagct gagaataaac aagaaataaa gagaattcag   21720
tagcaaatat tggtgacaca aagctttat attttgacta gttaagctag ttcttaaatg   21780
tttccactaa aatattcaag tttaagggca tagcccaggg cagcttatta tgaacatgat   21840
gtattttgga aatcttacac tttctcttaa aagttcttgg gaggggcatg tgaggccata   21900
atataaccat aaaaccattt gttttaaaat aaaacccatt tttaaaattc ttccaaataa   21960
aaaaattatt gcaggaaaaa atgctaaacc tggttttaa ctttgtacgc caactatatt   22020
tccaagatgt gctgtagcct ggtaaccata cagaaccata cagaattagt tctcagaatt   22080
tattgtctgc ttacttttgc atttggtaca ggtataacag ggtcgattat atggtttcta   22140
agacatgact agaaagaaat atgtttatca gttattattt cttccatcta aattagaagg   22200
ggctagggag agggcttcaa caggaattta tatactttag agaaaagtga tcattgatag   22260
cccaatagta tagatatctc aacccaataa cacaggttgt gtctgtctct gggatcatac   22320
actgtagggg agaatctttg caagcaacat tctacttata gggagccata acaaaagttt   22380
catatgtata ataattataa gtcttaagtc atcaagaaaa agttaacttg tgaatgataa   22440
tccctgatta aaaagagaga tgtataataa tggataagag attttttcttg gttaattttt   22500
agtattaaaa tggctaaatc ttctttggga tattctgact agtatggtgc attgtctaat   22560
agatttccca tagctgagag ctaatcatct tgtaatctgt ggaaaactgt cctctttggc   22620
taaaacttta ttgtaattcc tctaaatcct cagctttat tttctacaga ctttttttt   22680
tttttaacat ttccttcctc tgactcactc cttttgttct cattttcatg gcctgagaac   22740
atgggtgatg atagaattat tcttttcaca gattaacagt tttcttttcg agtatcgttg   22800
agctcatgtg tgtattaact agagaagtct cccttacatt tcattttat gttttctttc   22860
tcatcaggag atagtttgta gccatttact ttcaaatcca agtttctgcg gttcttaaga   22920
cctgtatcat ttgtctcctg aatttcactt catttcctct ttaaaccatg tcctctgttt   22980
cccatcttct gcacccactt tgccacttcc tgtttgttta attggcaagg gccactctct   23040
gtgttggaaa ttttttcttt ttgaaagctc aactaacaac ttctaggaag tttttattg   23100
ctactgttat caattcatac catcttaccc ttgttttgc aaccctttgt taataacata   23160
tttatttaac tatagttatt agcagtctga gatcatttta cttggttaca taaggagcac   23220
atatatctac ccagcatcat tgtaaggcat gtgagacctt tgtttgattg ctgtcctaac   23280
ctagtaccga gtcctaaaaa ctcattagta gaagatgaag tgtccttgcc ttttgctgaa   23340
catatatata cacactgaat atttagtggc aattcatagt tgcatttggc cattttttgt   23400
ttataatttc ccctttctca ttaaaaaaac tttgttttct agactttagg atttagagaa   23460
gctcattttg ttccatacac atgctgctgt tggattattt aggtattttg tgactgtatt   23520
ttatctttga aataaaaagc ctttcaagaa atgcaaaaaa aaaaagctca aaaaacagaa   23580
aatgtatatt ttttaaatat ctcagataga tttaaagaaa ttttaaacat cctaatcata   23640
gtacttttga agcccattca tagtacaacc tgtgaagagc ctcatgtacg cgctaactgg   23700
gtcctgtctc tgcagttgac tggattgttg ctgacatctt ggccatcagg cagaatgcgc   23760
taggacatgt gcgctacgtg ctgaagaag ggttaaaatg gctgccattg tatgggtgtt   23820
actttgctca ggtaacttgt ttccatgctt ttctctctat atatgtagtt tataaatttt   23880
ttttttttt tttggagaca gtctcacttt attgctcagg ctgagtgcag tggtgtgaac   23940
acagctcact gcagccttga cctctggggc tcaagtgaac ctcctgcctc tgcctcccaa   24000
gtagttggga ccgtagtgcc caccatcatg cccggctaaa ttttctattt tttgtagaga   24060
tgggggtctc gctgtgttgc ccaggctggt cttggactca agcaatctgc ctgtctcagc   24120
```

```
ctaccaaaat gctggattat aggtgtgaac tgccataccc aaccctataa aaatgttata   24180
ttttaaaatt taacaatata cttcatgtga atgtatggtt tttaaaatgg gtttaatagt   24240
ttattctcag ttgaagtaat tttgtttggc attttttagtg gtgtgtattt atatacgtct   24300
gattatccat atgcggtttt ccttcagcat ctgtgggggat tggtttttaga accaccacag   24360
ataccaaaat ctaaggtgtt caagaccctc atatagaatg ggatagtatt tgcatataac   24420
ctgtgcacta cttttaaatca tctctagatt acttataaata tctaatacat tataaatgcc   24480
atgtaaatgg ttgttatact ttatttttta tttgtattat trccattgtt atattattttt   24540
taatttttat ttgttcacat atttttgatc tgtgatttgt tgaacctgca gatgtggaac   24600
tcatggatgt gaagggccag ctgcagtaaa atgaaagagc aaaaatgcaa atgtacaaag   24660
ttcaaacaaa taggaaattt aaaggcatag aatttgatag gcaattacat taaactgttg   24720
ataacagtaa ttagtgatct gtatgatatt aaaaaaaaaa agcaaactgt atatataaaa   24780
cttactttct ccagttctgg aggctagaca tccaagatca aggtgttgac agggttagtt   24840
tctcccaagg cctctctccc aggcttgcag acagcatcct tcttcctgtg tcctcaggtg   24900
gttttttttcc ctgtgcccaa gcacccctgg cactgcttcc tcttcttaga aggactagtt   24960
acactggatg actaatcctt ctacagagac tgctaaggtc ccactctgag gccctttttt   25020
aaccttaatt accacctcta agtccctctc tctgaataca gtcacagtgg gaactattag   25080
ggctttagta gactgatttg ggggaacaca cttctgtccg taacagtgcc acataaatat   25140
ctttagcagg attgattttt taaaatccct aaagatcgtg agtattgaca tgttaaggac   25200
gcttttttagt gactctgtaa taagtgggtg gaagaattgg gagttaaatc catctgatgg   25260
atcaggtttt ttattttttaa aaatgtgtat ttaagaaaga aagcattttc attttaactg   25320
ccaacaaaac taaacttcat gtgtttttcca atacagtgtc acatgcagtt tttttgaatt   25380
atgttgagac aaggcaattt tcagctaaat gttctttaga agctaatgtt tgaagatatt   25440
aaatatagat taaattctga aatgtagttt tcattctgta cttttttgcaa gagaagttgc   25500
cttttttgatg actctggcca attgttatttt taaaagtaaa tgctcttttct cccgatttga   25560
ttgtggcagc atggaggaat ctatgtaaag cgcagtgcca aatttaacga gaaagagatg   25620
cgaaacaagt tgcagagcta cgtggacgca ggaactccag taagagccta cccgtttttta   25680
tttttcttac cagctctcag tttctaaatt taagaattaa attaaaatct aagaattgtt   25740
ttgacaatgt atttttcccat gtgtaattac taattcaggg ttatgctgag gtaacagaaa   25800
ccctctatgt acaggtaggc aggtttttca gccatcagaa agattgctgt aaacaactag   25860
gtcctttgct ggtcagtgga ccttaaagag gaataaaaag agcatttggt gtcgttcaga   25920
gtctataaat agaactaact gcattttaac ctgacattta agctagttta caagctcatc   25980
ttacttcttg tcttctttag tatcagattt ggtttttagaa gcagcaactg tttttctgtta   26040
gtgcaaattt tgaatgtctt acatgtacag aaaaaccaaa aaaggatgaa tctctacaaa   26100
tgttaaatca ttcagtgtaa ataatatttt ataaaactttt attccacaaa agtggggaga   26160
gttcaatctg ctttgtatag aatgctgatt gctgccaaag gctttttcccc tggttccctc   26220
cggagacaaa gcaccatgat caccgggggcg acttgggctt tctctttcag tacatgacat   26280
gtgctcagaa gcttagctcg tgtgcacagg ctttcccttt cctttctggc tccctccctc   26340
tgtcttccct cctctcctct tgccctcccc tcaccagggg tcctgggcag cagctggagc   26400
tcatggtgaa ggaagaattc ttcatggtca gctggcgaag tgcctggtgt gagcattgtt   26460
tattcacatg cctcttctag gtgtttttac attagaacat tgcatctgtt ttgggcatgt   26520
gttgggtgac agaagcagaa tggaatgaga tgaacagtga cccttttatcc tgttatagct   26580
aaccccttgag aaccaagctt ggtgtcttca aagggtctgt ttagtctgaa acagtgtggt   26640
gaatttgggc agaattgtgg tcattgcatg taggtctcca aaagacagaa taagttggta   26700
atatggttta tcgactttt acaaaaaaaa tttaaaaatc atgaatttat accttaaaat   26760
gtccatccca cttctctccc agctgtccag tcacccccagc aatggatgac tgctgtggag   26820
ttccttctgt gtcctgctgt gggcattgta tatatgaagc aaatgaagat agctgccttt   26880
tgggtgatgt tggcatccta tgcacagtgg tcccttgctt ttttgcccccc atgaatatag   26940
ctgccagtgg cgctagggct gaaaaaatca gctctttaca cttgtcatgt gtcttgttta   27000
tgtggctgcc ttcgtgagtt tcttcttgtt tttggtttgc agcagtttaa gtatcatata   27060
tctgagtgtc atttaaaaat ttttacctgg attggtcctc tgagcttgga tctatgattt   27120
ggtgtctgtt attaattttg gaaatttctt tgctcttatt tccttaaata ttattcctac   27180
cccagtctttt cttctccagt tatgtttgtg ttggttcatt tctcgctgtt ctttagttct   27240
tagatgcatt attcgttttt tgttggtttt tttttaaatt ttttttttta cgccccctcc   27300
cttttttttctt tttgtgttac attttggata atttctgttg acccacccttt gagttcatgg   27360
attcttcctt tggctgtgtt gagtctactg gtgagccagt ttaaggcact cttcatctct   27420
gctactgcgt gtttcattcc tcacatttcc ctttgacact gtttcatagt ttccatctct   27480
gtgctagtgt atctatctga tcataaagct tagtcacgtt ttccagttga acctttatca   27540
ttttattata cttgcagttc tcttaaattc cctgcttgat aattccaaca tctgggccat   27600
atctgagtct gcaaattttg attactttat ctcttcagat tgtgctttat cttgcctttg   27660
tcatacttcc taagattttg cctaacgctg ggcctttttt gtaagacagg agaaatggag   27720
gcaagttgtc ttgatacctg gaaatggata gacttgtctt tctgcttggc ttttagtgtt   27780
```

```
gaggagtgga gtcagtccac tgaggaggtg cactgcattt gggttttgct catgtgcttt   27840
ttctcacagc ttcaggtttc tgtagaactc attactttgt ttgtaggttg gggatgtcct   27900
cccgctagag cttttcctca gtgtctattt cacactcagc gttttcacat agcaccttgg   27960
agtggctctc ttctttatgc ctttccccac tatacttctt ggatacttgt tactgaactc   28020
tcgctagttt ggtggtagaa ggagagggaa gggaagtgtc ttttcattct tagggagaat   28080
ctcaggggtg gagccttctc tgatcctgcc ttgcttctgg ctgtaagtct gtgcccagta   28140
tgtattcctg cctttactaa gagttttttcc ctgttctctt cacccagcct catcgagtat   28200
tcatccgtgc cccatgggta gcagggtttt gttgccctg ttcatcagtt tcaggctgct    28260
gttccatagg aaaggtagaa agaaggatgt gggctgggcc ctgagccctt cccacagggc   28320
tgcttttccc tcccacaagc ctacatccag tcttccctga ccgcagtgtg ttttcttttt   28380
tctttgtctt gtgagtacac aggaggtctg tgggtcgagc ctgtgaaatg tgctgcattc   28440
tccttgtgtc tgtagcccag gggttcgtct gttccacttg ctcatacttg gctttctgca   28500
aaattgataa aatttttagc taaattcttt ttactggtat ctgttacatt ggcccccaac   28560
taaacaacca cttgcatctt gtttctcctt tgagtttttcc atctttccttt agactttttgg   28620
gttagttggt tgccttgcaa ccttgcagct ctctgaaggg tttaagaaaa gtcatgaatc   28680
tacagcttgt cagtgttgtt gttgttgtag ggttggcagt agtattccttt cagcattcta   28740
catacttaat ggaagccgcc tcccattttt ggttaataaa tttcaaaact tggaacaatg   28800
ttagatttac aaaaacgtca gaaagaacag agtgttcctg tttattcttt atatagcttt   28860
ttttttttttt tttttttttg agttggagtc tcggtctgtc acccaggctg gagtgcagtg   28920
gcacgatctt ggctcactgc aacctctgcc tcacgggttc aagcaatctc ctgcctcagc   28980
ctcctgagta gctgggatta caggcgtgca ccgccatgcc cggctaattt ttgtattttt   29040
agtagagaca gggtttcacc atgttggcca ggctggtctc gaactcctga cctcttgatc   29100
cgcccgcctc ggcccccac agtgctggga ttataggtgt gagccaccac gcccagcctt    29160
cttcatctag ctttaacatc taatgttgac atcttacata acatggtata tatttgtcaa   29220
aactaagaaa taaacattgg taccacacta ttaattgtac tacagatttt tattcagact   29280
ttaccaggtt ttccactaat gtcctttttc tgttctaaaa tacaatccag aatagataca   29340
aatccattca acttcagtgt tttaaattat tgttttttcat tatatgaagt gctgtgtggt   29400
ttttgtcaaa tctgttattt tggtttttaat cttcaagctt gtctttgttt ctttaagtga   29460
taaaggcata atttaaaagg tgtgttgggt tatttcagtg cctaaagtct tgtctgagtc   29520
acttgttttc tgctgttctt gcttatggta ctttctttcc ttgtttgctt tgttatcttc   29580
ctttgctgct ggctgtgttt ggttaagtta tttgtggaaa tcagttgaag cctcaggtgg   29640
gagtgtcttt ctccggagaa catttctacc tgtttttagct gggcccctta aggctcctct   29700
agcgtgggcc ccacccaaac gagattctga gttgaaggtg aactgagcca ttcaggcagt   29760
gcagccaggg ttgcagatgc acgtgagacc tgctcacctc tcatttactt tcaccctgag   29820
agtagagcct ttggtgtttc gttcacttgt ctgattctct cttcacagtt ctattagaag   29880
gtccatgggt tttggtttct gtgcccttca tcttatgagt cttgtaaatc aaagttctgt   29940
tttatgctta cttctgcttt actgtgtttg cttaatttca gtcttaacat cttgccaact   30000
cttgggtact tttaaaataa tgttatatcc agcttttttaa gttgtttttca gtaggaaggt   30060
tgattcaaat aacctagtct ggttatgggc tacgagaata gcctccctgt tttttgtggg   30120
caaaattcca gccttttatg ttcctagcgc agtgtggata acagactggc aggttcaaga   30180
ggccgtgctg agcagctttc actgtaaggt cactgtccca ggtcgggttt ctaagaatct   30240
ggatggttgt ttcatttctt aatatgtacg ccctgtgaga gcggatacat cttgctcagg   30300
ttcttatgat tcttttgttt ctgaaggtga attaagtaag tgacatggta gaatatgtta   30360
agtcaacttt cgtgtggctt actagttctc atgaatctat tccatgattg tatcagttct   30420
tattcagtat tagtatttaa gaaatgcaga attttgtttc aaaaaatata tttgtattat   30480
aagttgtgaa gaaatacatc tccataatta ttgctgggac aatacagtat tttcttaagg   30540
aacttattgg ttgtggatgc aaatgaagca tatttgtgat aaaaataact aatagaagtc   30600
attttgttag actatgagct agtaaaactt atggcacaaa catggagact taacactttt   30660
tcttccagct ttcacttaag ttccttttca gataggaggc agcctggtgg ataagagtat   30720
tggttttgaa attagattca ggtttaaatc ccagatcttc tgtttaatct ttattttatt   30780
tcaggtagat tttctggata acttgctata gcttatacgt cagtacttgc cacttcaatt   30840
ttatgttatg gagagacggc ttctttcctt aaacctcacg aaccaacctc tgctagcttc   30900
taagtttttt cctgccactt ctttacctct ctcagccttc agagaattaa agggagttag   30960
ggccttgctc tggattagga tttgctttaa gggagtgttg tggctggttt gatgtttttat   31020
ctagagcact caaactttct ccatatcagc aataaggctg ttttgctttc taatcattca   31080
tgtgttcagt gaagtagcac ttttaattct ctttaagaac ttttcctttg catccgcaac   31140
ttggctgttt agtggaaagg acctagcttt tgacctacct tggctttcaa catacctttcc   31200
tcactaagcc atttctagct attgatgtaa agtgagagac atgcaactct tcctttcact   31260
ggaacgctta gcagccattg tagggttatt aattggccta atttcaatat tgttgtgtct   31320
cagggaatag ggaaacccaa ggggcggtag agagaaagag agacaggaga acaggccatc   31380
attggagcag tcagaacaca cacgacattt atcaattaaa ttgtcatct tatatgggtg    31440
```

aggcaatccg aagatggttg catctgggtg gtttggaaag aagagatcct 18600
caaaccca ctcctggtg accctccca atccctaaa ccagacgtac 18660
acatgagc sagaaccga aactttca ggacagat tccataaat 18720
ataaccg gacacagga ggcttctga tcgtctgg accatagt 18780
gagctacc ctagagat ttgtgccaa gagggtgag cgaataat 18840
tatttaact gaggtctt tggagact cagaccct aggataaa 18900
sataggct gtgtatga gacctgct ccagacgg accttagg 18960
cattataac ctagacatt gagctttt ggtccaga gaaacct 19020
agtcgatc atctaccat gcagcatg tcctacc gaaatcg 19080
saccagata gctagtt actaacat tcatcct agacagga 19140
sagaggt gttggacta atcagatg gcacagc aaacctc 19200
acctattat atcgaaca cagaggt aaccatga ctcagac 19260
sacacgaga atcaacatt gagaagc ctgaagc agccgaca 19320
cataagtt gcagacga atgaacac ctcagctt tgacatcc 19380
saccgagac ataatcagc gataagt atctctct agacatcag 19440
sagcaata gataatct gataaacg gataaagt aaaccgata 19500
caggtccac agtaatatt gtcaaag ctgtaatc aaaggtaga 19560
ttttctct gagagctt gtgctcagt caccagaga cagactag 19620
tattctaa acaatctc agagctgga taatcaac atcagactat 19680
tttactcc acatctca aacattct acaccggaa acacctacg 19740
accaagtca agtcgtta acatttct accagggaa atacacct 19800
aaaattggt gtcagggac cgattcggt ccagagggac aaagatagt 19860
acaacacaga atccaccctt cagcactt gagactta aagaaacac 19920
agattcaac gctcccagag aaacactt tagctcaga agagcgga 19980
tctccaga acagtacca ggtcagat ctcctgga agatcgtca 20040
cagggcatct cagaacata ctacaga acatcgta gatacgggac 20100
gtagcagga gatactct gggagaaa atcagtgt acatctcg 20160
atcacaaggt gttggagaga gagaaatt aatctaat gacaccatg 20220
atacacaag gagaaacagt gataaactt gataaacag gacagcaa 20280
cagagacaga gatgaacatt cttttctcg gaacacagga cacaggagag 20340
ccaatacagt gatctagagg ggatacaaa tcattatg ctacagctaa 20400
atacaagaga ttgtacttc gatcgtatt ctgattat tgctcagaca 20460
ccacagaca agccacatt aaaagtatc acctcataa aagggctacg 20520
cagagacacg aaatcggta gcagaact aacatctc gatataccg 20580
cagaggatt aaggacatct ccagagact acacagcg aaagctacac 20640
acgtcacaggc catctctg gactagcaa caagctct aacgagcat 20700
cagaacagag catctatct ctgtatgt ataccgac aacagaaag 20760
aatcaggt gtatcaca ctataacct ccagacatt aagaacacct 20820
cagcgagag gaacataca aaacatat ccacacata acgtacgcac 20880
acgaattgta aacacaca agggttt gtacagcat aaaacagt 20940
gaacgattc aacatgagt cggctcac acaccctct ggatctgg 21000
caaaacaga agagaaaaa ctgtcctt aaaacaaa agaaacata 21060
aagacagt gattacaca agctgagga ggagtcgta acacacct 21120
cagagactt ccagagtct gataaactt ctatataac gtagcagat 21180
aatcatga tataacta gttttccta cacagatct gacttaacg 21240
aataccag tatctctct cacacagga acaccaact acagtcaa 21300
acatacga cacaccaca gcagactct gatactct ataacatcc 21360
sagagacac ggatctcgg aatacaac gtaaccct ctcagacat 21420
saaacacat gcaaacaca gctcaagc gcagaacca aggagacac 21480
saacacacga gtacacaca gcacacag atcataca accaatat 21540
atactggac tcacacaca gctctctg tcagaggac ctagacagta 21600
cagagacaa tccagaact cacagctt gacagacgg cagaagct 21660
cagagcaact cacatctg ggaacagat accacgaa gacacactag 21720
acacacaga aagacacca cttaacaac gacacccc aatccacac 21780
cctccagac agaacacgt gcagacacg gaacacctg gcacacacg 21840
sacttagac gaaacacact gcagacat catcaacct ccagacagga 21900
sagactagct gcacacag gcagacaca acacaacga gacacacct 21960
atccacagg acacaacga acacctgg gacacacct gcaagcacg 22020
sactacag gagacacag ggactagc actaacagc gcaacacac 22080
saagacacga gatcacagc agggacagc ccacacagac gcaagacaca 22140
ccaacctat tttgcctact gactctgac ttttggttt cctgttggg 22200

123

159

```
<223> polymorphic fragment 4-43-328, variant version of SEQ ID202
<221> allele
<222> 24
<223> base T ; C in SEQ ID202
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-43-328.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-43-328.mis2
<400> 279
agaattctgt gttctggcca aagtttaaac ccacagagcc agtttaa                    47
<210> 280
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-43-70, variant version of SEQ ID203
<221> allele
<222> 24
<223> base C ; G in SEQ ID203
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-43-70.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-43-70.mis2
<400> 280
atcgcctcca ttattctcaa aaacaccatg ggacacaaca caagaag                    47
<210> 281
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-50-209, variant version of SEQ ID204
<221> allele
<222> 24
<223> base T ; C in SEQ ID204
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-50-209.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-50-209.mis2
<400> 281
atatagagtg tgcatccctg acattgaaac tgaaggcttt atggttt                    47
<210> 282
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-50-293, variant version of SEQ ID205
<221> allele
<222> 24
<223> base T ; G in SEQ ID205
```

```
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-50-293.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-50-293.mis2
<400> 282
cctgagtccc agggggctga cagtggacag tttaaaacat tgatgaa                47
<210> 283
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-50-323, variant version of SEQ ID206
<221> allele
<222> 24
<223> base T ; C in SEQ ID206
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-50-323.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-50-323.mis2
<400> 283
tttaaaacat tgatgaatct ttattactac aaaagggttc gatttag                47
<210> 284
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-50-329, variant version of SEQ ID207
<221> allele
<222> 24
<223> base T ; C in SEQ ID207
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-50-329.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-50-329.mis2
<400> 284
acattgatga atctttatta ctataaaagg gttcgattta ggctagc                47
<210> 285
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-50-330, variant version of SEQ ID208
<221> allele
<222> 24
<223> base T ; A in SEQ ID208
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-50-330.mis1
<221> primer_bind
```

```
<222> 25..47
<223> complement potential microsequencing oligo 4-50-330.mis2
<400> 285
cattgatgaa tctttattac tactaaaggg ttcgatttag gctagcc                47
<210> 286
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-52-163, variant version of SEQ ID209
<221> allele
<222> 24
<223> base C ; A in SEQ ID209
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-52-163.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-52-163.mis2
<400> 286
gaacaggata ttcttaacta ccacagaatt ttacacatct attgttt               47
<210> 287
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-52-88, variant version of SEQ ID210
<221> allele
<222> 24
<223> base T ; C in SEQ ID210
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-52-88.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-52-88.mis2
<400> 287
tccatgtcat tattattcaa aagtttaaaa aatacacaag gtgaaaa               47
<210> 288
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-53-258, variant version of SEQ ID211
<221> allele
<222> 24
<223> base G ; A in SEQ ID211
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-53-258.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-53-258.mis2
<400> 288
gagaaatcat gcagagagaa tgcgttctca ctcaaatttt aacctaa               47
```

```
<210> 289
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-54-283, variant version of SEQ ID212
<221> allele
<222> 24
<223> base T ; A in SEQ ID212
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-54-283.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-54-283.mis2
<400> 289
aagtagtttt tcacactttc tctttgatac aatcgatggc ttaatct                47
<210> 290
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-54-388, variant version of SEQ ID213
<221> allele
<222> 24
<223> base C ; A in SEQ ID213
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-54-388.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-54-388.mis2
<400> 290
ctctctatcg tatacatctt tacccacgct gcagcgccaa gactcca                47
<210> 291
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-55-70, variant version of SEQ ID214
<221> allele
<222> 24
<223> base T ; A in SEQ ID214
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-55-70.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-55-70.mis2
<400> 291
tattaagaac ctaggtttta aaatactctc tatcgtatac atcttta                47
<210> 292
<211> 47
<212> DNA
<213> Homo Sapiens
```

```
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-55-95, variant version of SEQ ID215
<221> allele
<222> 24
<223> base C ; A in SEQ ID215
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-55-95.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-55-95.mis2
<400> 292
ctctctatcg tatacatctt tacccacgct gcagcgccaa gactcca          47
<210> 293
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-56-159, variant version of SEQ ID216
<221> allele
<222> 24
<223> base T ; C in SEQ ID216
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-56-159.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-56-159.mis2
<400> 293
aagttttcct tctcttctgt agatgtctcc atgttacagt caactat          47
<210> 294
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-56-213, variant version of SEQ ID217
<221> allele
<222> 24
<223> base G ; A in SEQ ID217
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-56-213.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-56-213.mis2
<400> 294
atggctcatg ttcactctgg ttcgccttca gaggagtttg atatttt          47
<210> 295
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-58-289, variant version of SEQ ID218
```

164

```
<221> allele
<222> 24
<223> base C ; G in SEQ ID218
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-58-289.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-58-289.mis2
<400> 295
catacctgca gcctgctttt ggtcaggggt gactacttta cctgcaa                47
<210> 296
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-58-318, variant version of SEQ ID219
<221> allele
<222> 24
<223> base C ; A in SEQ ID219
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-58-318.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-58-318.mis2
<400> 296
tgactacttt acctgcaata tttctttgca agtttatttc ttccttt                47
<210> 297
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-60-266, variant version of SEQ ID220
<221> allele
<222> 24
<223> base T ; G in SEQ ID220
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-60-266.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-60-266.mis2
<400> 297
aacaggacca agacactgca ttatataaag tttcagtatt tcttagc                47
<210> 298
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-60-293, variant version of SEQ ID221
<221> allele
<222> 24
<223> base T ; C in SEQ ID221
<221> primer_bind
```

```
<222> 1..23
<223> potential microsequencing oligo 4-60-293.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-60-293.mis2
<400> 298
aagtttcagt atttcttagc agatgaagcc agcaggaagt cctccta                47
<210> 299
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-84-241, variant version of SEQ ID222
<221> allele
<222> 24
<223> base T ; G in SEQ ID222
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-84-241.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-84-241.mis2
<400> 299
gaaaaaaaaa tagtgactgc cactgtgaat aattcagttc ttcagaa                47
<210> 300
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-84-262, variant version of SEQ ID223
<221> allele
<222> 24
<223> base G ; A in SEQ ID223
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-84-262.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-84-262.mis2
<400> 300
acggtgaata attcagttct tcagaagcag caacatgatc tcatgga                47
<210> 301
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-86-206, variant version of SEQ ID224
<221> allele
<222> 24
<223> base G ; A in SEQ ID224
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-86-206.mis1
<221> primer_bind
<222> 25..47 .
```

<223> complement potential microsequencing oligo 4-86-206.mis2
<400> 301
gtattcaaat caggacacac cacgaatggc atctacacgt taacatt                    47
<210> 302
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-86-309, variant version of SEQ ID225
<221> allele
<222> 24
<223> base T ; A in SEQ ID225
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-86-309.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-86-309.mis2
<400> 302
tggctctagg caggccactt tagtgagtga ggaaccagag agcagaa                    47
<210> 303
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-88-349, variant version of SEQ ID226
<221> allele
<222> 24
<223> base C ; G in SEQ ID226
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-88-349.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-88-349.mis2
<400> 303
gaaactaaaa gacaatattc agtctgagat tttccaagtt ctttatg                    47
<210> 304
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-89-87, variant version of SEQ ID227
<221> allele
<222> 24
<223> base T ; C in SEQ ID227
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-89-87.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-89-87.mis2
<400> 304
ttcttccctg aacgctggtt tcatatagtt tttgtgttga gaataga                    47
<210> 305

```
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-123-184, variant version of SEQ ID228
<221> allele
<222> 24
<223> base C ; G in SEQ ID228
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-123-184.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-123-184.mis2
<400> 305
ccagcccaga acattcacca gctcggccaa gagttctgct gggtttt                47
<210> 306
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-128-202, variant version of SEQ ID229
<221> allele
<222> 24
<223> base C ; A in SEQ ID229
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-128-202.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-128-202.mis2
<400> 306
aatgtctgtt tcttagagaa ctgcaacaca cacacataca tacacac              47
<210> 307
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-128-275, variant version of SEQ ID230
<221> allele
<222> 24
<223> base G ; A in SEQ ID230
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-128-275.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-128-275.mis2
<400> 307
acacccctac ctcacatgtg taggcaaatg tatgcatata tgtctct              47
<210> 308
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
```

```
<221> allele
<222> 1..47
<223> polymorphic fragment 99-128-313, variant version of SEQ ID231
<221> allele
<222> 24
<223> base G ; A in SEQ ID231
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-128-313.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-128-313.mis2
<400> 308
tatgtctcta gacagatata catgagattc tatttggcat agaaaaa                    47
<210> 309
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-128-60, variant version of SEQ ID232
<221> allele
<222> 24
<223> base T ; C in SEQ ID232
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-128-60.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-128-60.mis2
<400> 309
gcactgtgac ccaggcgcta ggttcctctt acagtgacac tccgaca                    47
<210> 310
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-12907-295, variant version of SEQ ID233
<221> allele
<222> 24
<223> base G ; A in SEQ ID233
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-12907-295.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-12907-295.mis2
<400> 310
gctatatggc attatatctc cacggggcag acctgatgta caagatg                    47
<210> 311
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-130-58, variant version of SEQ ID234
<221> allele
```

```
<222> 24
<223> base T ; C in SEQ ID234
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-130-58.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-130-58.mis2
<400> 311
aaagcaaaag agcttcaaaa atatttcagg agtgtgcata tggcgag                47
<210> 312
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-134-362, variant version of SEQ ID235
<221> allele
<222> 24
<223> base T ; G in SEQ ID235
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-134-362.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-134-362.mis2
<400> 312
caaaacactc atgttagtta gattattatt cctattacaa agataag                47
<210> 313
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-140-130, variant version of SEQ ID236
<221> allele
<222> 24
<223> base T ; C in SEQ ID236
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-140-130.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-140-130.mis2
<400> 313
tgttcaaaag cagctacaga ccatatgtaa acaattgagc atggctg                47
<210> 314
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1462-238, variant version of SEQ ID237
<221> allele
<222> 24
<223> base C ; G in SEQ ID237
<221> primer_bind
<222> 1..23
```

170

```
<223> potential microsequencing oligo 99-1462-238.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1462-238.mis2
<400> 314
ccctttcaag gttagtaact catctgctgt gtttctgctt cagaagg          47
<210> 315
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-147-181, variant version of SEQ ID238
<221> allele
<222> 24
<223> base G ; A in SEQ ID238
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-147-181.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-147-181.mis2
<400> 315
gtgtcatgaa aaagagcatg atagaaagaa aaacttaaat ctttata          47
<210> 316
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1474-156, variant version of SEQ ID239
<221> allele
<222> 24
<223> base T ; G in SEQ ID239
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1474-156.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1474-156.mis2
<400> 316
cttgtactca taagttaaat atttataaca agaagaaata tggactt          47
<210> 317
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1474-359, variant version of SEQ ID240
<221> allele
<222> 24
<223> base G ; A in SEQ ID240
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1474-359.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1474-359.mis2
```

```
<400> 317
aaaaaaaatc aaattattgt accgaattcc ctaatatcag atgtgta                    47
<210> 318
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1479-158, variant version of SEQ ID241
<221> allele
<222> 24
<223> base T ; C in SEQ ID241
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1479-158.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1479-158.mis2
<400> 318
tttaaaaatc cacttgtaat cgctgctaat tggagtgtat attcagg                    47
<210> 319
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1479-379, variant version of SEQ ID242
<221> allele
<222> 24
<223> base G ; A in SEQ ID242
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1479-379.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1479-379.mis2
<400> 319
gtagagctgt gtactgaggt cagggaagca gctcatggta cagcctt                    47
<210> 320
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-129, variant version of SEQ ID243
<221> allele
<222> 24
<223> base G ; A in SEQ ID243
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-129.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-129.mis2
<400> 320
ttcatatcta tacaaataat tttgaattta atacataggg ctgcaaa                    47
<210> 321
<211> 47
```

172

```
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-132, variant version of SEQ ID244
<221> allele
<222> 24
<223> base T ; C in SEQ ID244
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-132.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-132.mis2
<400> 321
atatctatac aaataatttt gaatttaata catagggctg caaaaca                    47
<210> 322
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-139, variant version of SEQ ID245
<221> allele
<222> 24
<223> base T ; C in SEQ ID245
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-139.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-139.mis2
<400> 322
tacaaataat tttgaattta atatataggg ctgcaaaaca aggttga                    47
<210> 323
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-140, variant version of SEQ ID246
<221> allele
<222> 24
<223> base G ; A in SEQ ID246
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-140.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-140.mis2
<400> 323
acaaataatt ttgaatttaa tacgtagggc tgcaaaacaa ggttgat                    47
<210> 324
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
```

```
<222> 1..47
<223> polymorphic fragment 99-148-182, variant version of SEQ ID247
<221> allele
<222> 24
<223> base G ; A in SEQ ID247
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-182.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-182.mis2
<400> 324
ttgatgttga tatgggcaac tgtgtgttgg atggtcccaa agcattc                    47
<210> 325
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-366, variant version of SEQ ID248
<221> allele
<222> 24
<223> base T ; G in SEQ ID248
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-366.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-366.mis2
<400> 325
tccttgtcaa aggtctctcc ctgttgctca cggctgccgc ctcaaag                    47
<210> 326
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-76, variant version of SEQ ID249
<221> allele
<222> 24
<223> base T ; C in SEQ ID249
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-76.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-76.mis2
<400> 326
tgatagaatg ccttcctgaa ttattactct tgatggcttc ataaaac                    47
<210> 327
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1480-290, variant version of SEQ ID250
<221> allele
<222> 24
```

```
<223> base T ; G in SEQ ID250
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1480-290.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1480-290.mis2
<400> 327
tgcaccatct tcaccacaac ccctggcaac cactgatcct tttactg                     47
<210> 328
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1481-285, variant version of SEQ ID251
<221> allele
<222> 24
<223> base T ; G in SEQ ID251
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1481-285.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1481-285.mis2
<400> 328
tcccataacc tgttttgctt ctctctctaa cctcaagatg gtataaa                     47
<210> 329
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1484-101, variant version of SEQ ID252
<221> allele
<222> 24
<223> base C ; A in SEQ ID252
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1484-101.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1484-101.mis2
<400> 329
aaaaagatca aatataagca tgtcactcct ctccttaaaa tctcagt                     47
<210> 330
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1484-328, variant version of SEQ ID253
<221> allele
<222> 24
<223> base C ; G in SEQ ID253
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1484-328.mis1
```

```
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1484-328.mis2
<400> 330
ggacacgtgg tcatgaggag tttcaaggga ttcagttttc agatccc                47
<210> 331
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1485-251, variant version of SEQ ID254
<221> allele
<222> 24
<223> base T ; G in SEQ ID254
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1485-251.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1485-251.mis2
<400> 331
gattgccttg atatatgctc ccatagaacc aagaatgtcc cctttc                 47
<210> 332
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1490-381, variant version of SEQ ID255
<221> allele
<222> 24
<223> base T ; C in SEQ ID255
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1490-381.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1490-381.mis2
<400> 332
tgcacagtgg aaataccatg tcatggtacg ctactgtgca tctcttc                47
<210> 333
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1493-280, variant version of SEQ ID256
<221> allele
<222> 24
<223> base G ; A in SEQ ID256
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1493-280.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1493-280.mis2
<400> 333
```

```
ggatgacaga gtattgttgg agggatgggg tttggctgct tgttttt              47
<210> 334
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-151-94, variant version of SEQ ID257
<221> allele
<222> 24
<223> base G ; A in SEQ ID257
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-151-94.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-151-94.mis2
<400> 334
attgagatca ttgataagga aatgttctaa aatttcaaaa tctatat              47
<210> 335
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-211-291, variant version of SEQ ID258
<221> allele
<222> 24
<223> base G ; A in SEQ ID258
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-211-291.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-211-291.mis2
<400> 335
ctggttatat cagactgacc ttcgtgtttt caacaggtca atgcctt              47
<210> 336
<211> 46
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..46
<223> polymorphic fragment 99-213-37, variant version of SEQ ID259
<221> allele
<222> 23
<223> base GC ; T in SEQ ID259
<221> primer_bind
<222> 1..22
<223> potential microsequencing oligo 99-213-37.mis1
<221> primer_bind
<222> 24..46
<223> complement potential microsequencing oligo 99-213-37.mis2
<400> 336
gtgcttccgg ctgcaggact gtgcggagga ctccagtgtc tgacag             46
<210> 337
<211> 47
<212> DNA
```

```
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-221-442, variant version of SEQ ID260
<221> allele
<222> 24
<223> base C ; A in SEQ ID260
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-221-442.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-221-442.mis2
<400> 337
tgcctttgta gatatgcatg ggacttccat gacctagcca gacgaat                 47
<210> 338
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-222-109, variant version of SEQ ID261
<221> allele
<222> 24
<223> base T ; C in SEQ ID261
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-222-109.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-222-109.mis2
<400> 338
caggtgagga gtgctggatt ggctacgata tgaatttctt cagcagt                 47
<210> 339
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 185, SEQ 262, SEQ 186, SEQ 263,
SEQ 187, SEQ 264
<400> 339
tctaacctct catccaac                                                 18
<210> 340
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 188, SEQ 265, SEQ 189, SEQ 266
<400> 340
gttatcgtga gacttttc                                                 19
<210> 341
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
```

```
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 190, SEQ 267, SEQ 191, SEQ 268
<400> 341
tgctggtgct gtgataac                                                    18
<210> 342
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 192, SEQ 269, SEQ 193, SEQ 270
<400> 342
tacagccctg taagacac                                                    18
<210> 343
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 194, SEQ 271
<400> 343
cagtatgttc aatgcacag                                                   19
<210> 344
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 195, SEQ 272, SEQ 196, SEQ 273
<400> 344
aaaacatcga catgggac                                                    18
<210> 345
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 197, SEQ 274, SEQ 198, SEQ 275,
SEQ 199, SEQ 276
<400> 345
agcatttcga gtcatgtg                                                    18
<210> 346
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 200, SEQ 277, SEQ 201, SEQ 278
<400> 346
ccctctttcc tcatgtag                                                    18
<210> 347
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
```

```
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 202, SEQ 279, SEQ 203, SEQ 280
<400> 347                                                           19
taactcgtaa acagagaac
<210> 348
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 204, SEQ 281, SEQ 205, SEQ 282,
SEQ 206, SEQ 283, SEQ 207, SEQ 284, SEQ 208, SEQ 285
<400> 348                                                           18
gcgtattgaa gctctttg
<210> 349
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 209, SEQ 286, SEQ 210, SEQ 287
<400> 349                                                           18
aacacgggga ttttaggc
<210> 350
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 211, SEQ 288
<400> 350                                                           19
cacatactaa ggctaatgg
<210> 351
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 212, SEQ 289, SEQ 213, SEQ 290
<400> 351                                                           18
gttgctggaa cctatttg
<210> 352
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 214, SEQ 291, SEQ 215, SEQ 292
<400> 352                                                           18
tcgatggctt aatctacc
<210> 353
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
```

180

```
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 216, SEQ 293, SEQ 217, SEQ 294
<400> 353
aaagaggagt aaatgggg                                              18
<210> 354
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 218, SEQ 295, SEQ 219, SEQ 296
<400> 354
tccccacagc taagagcc                                             18
<210> 355
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 220, SEQ 297, SEQ 221, SEQ 298
<400> 355
atacctaatt tcaggggg                                            18
<210> 356
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 222, SEQ 299, SEQ 223, SEQ 300
<400> 356
ttaacagagt accttggag                                           19
<210> 357
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 224, SEQ 301, SEQ 225, SEQ 302
<400> 357
gtacagcctt ttgcttac                                            18
<210> 358
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 226, SEQ 303
<400> 358
aacgtgtcat agaaagcc                                            18
<210> 359
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
```

```
<222> 1..19
<223> upstream amplification primer for SEQ 227, SEQ 304
<400> 359
gctgatgagt tagataacc                                                    19
<210> 360
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 228, SEQ 305
<400> 360
aaagccagga ctagaagg                                                     18
<210> 361
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 229, SEQ 306, SEQ 230, SEQ 307,
SEQ 231, SEQ 308, SEQ 232, SEQ 309
<400> 361
gaccagggtt taagttag                                                     18
<210> 362
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 233, SEQ 310
<400> 362
tctgttagga cctgtgag                                                     18
<210> 363
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 234, SEQ 311
<400> 363
ccataacagc tagtacaac                                                    19
<210> 364
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 235, SEQ 312
<400> 364
tggaaaggta ctcagaag                                                     18
<210> 365
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
```

<222> 1..19
<223> upstream amplification primer for SEQ 236, SEQ 313
<400> 365
agagcatagt ataaagcag                                              19
<210> 366
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 237, SEQ 314
<400> 366
ctagaagtag ctttaacag                                              19
<210> 367
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 238, SEQ 315
<400> 367
gcagccaatc ttatatttc                                              19
<210> 368
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 239, SEQ 316, SEQ 240, SEQ 317
<400> 368
aaggttgtag agtagaaag                                              19
<210> 369
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 241, SEQ 318, SEQ 242, SEQ 319
<400> 369
caactgacac tataaccc                                               18
<210> 370
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 243, SEQ 320, SEQ 244, SEQ 321,
SEQ 245, SEQ 322, SEQ 246, SEQ 323, SEQ 247, SEQ 324, SEQ 248, SEQ 325, SEQ
249, SEQ 326
<400> 370
cagtggagtg tttatgtg                                               18
<210> 371
<211> 19
<212> DNA
<213> Homo Sapiens
<220>

```
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 250, SEQ 327
<400> 371                                                          19
ttgcacaaaa ggtatagag
<210> 372
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 251, SEQ 328
<400> 372                                                          19
aggctcccct tttgagttg
<210> 373
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 252, SEQ 329, SEQ 253, SEQ 330
<400> 373                                                          18
atcctttcta gctgggag
<210> 374
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> upstream amplification primer for SEQ 254, SEQ 331
<400> 374                                                          20
gtttaagaat gtgtgatggg
<210> 375
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 255, SEQ 332
<400> 375                                                          19
aaggcaacag cgttgtgac
<210> 376
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 256, SEQ 333
<400> 376                                                          18
ttttgggggt tttcagtg
<210> 377
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
```

```
<222> 1..18
<223> upstream amplification primer for SEQ 257, SEQ 334
<400> 377
aacacaacag caaatccc                                                   18
<210> 378
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> upstream amplification primer for SEQ 258, SEQ 335
<400> 378
tccttacttg taacccccc                                                  18
<210> 379
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> upstream amplification primer for SEQ 259, SEQ 336
<400> 379
atactggcag cgtgtgcttc                                                 20
<210> 380
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> upstream amplification primer for SEQ 260, SEQ 337
<400> 380
cccttttct tcactgttc                                                   19
<210> 381
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> upstream amplification primer for SEQ 261, SEQ 338
<400> 381
aggggagatg agggaagttg                                                 20
<210> 382
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer for SEQ 185, SEQ 262, SEQ 186, SEQ 263,
SEQ 187, SEQ 264
<400> 382
gactgtatcc tttgatgcac                                                 20
<210> 383
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
```

```
<222> 1..20
<223> downstream amplification primer for SEQ 188, SEQ 265, SEQ 189, SEQ 266
<400> 383
gcataattgt gcttgactgg                                                    20
<210> 384
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 190, SEQ 267, SEQ 191, SEQ 268
<400> 384
tgctgagagg agcttttg                                                      18
<210> 385
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 192, SEQ 269, SEQ 193, SEQ 270
<400> 385
tgaggactgc taggaaag                                                      18
<210> 386
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer for SEQ 194, SEQ 271
<400> 386
acaaaatcag gaacaatggg                                                    20
<210> 387
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 195, SEQ 272, SEQ 196, SEQ 273
<400> 387
ttgcattttc cccccaac                                                      18
<210> 388
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 197, SEQ 274, SEQ 198, SEQ 275,
SEQ 199, SEQ 276
<400> 388
accatttgga caatgggg                                                      18
<210> 389
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
```

<222> 1..20
<223> downstream amplification primer for SEQ 200, SEQ 277, SEQ 201, SEQ 278
<400> 389
gctcttaaac tggctctgtg                                              20
<210> 390
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 202, SEQ 279, SEQ 203, SEQ 280
<400> 390
ggcatgactt cacgtttc                                                18
<210> 391
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 204, SEQ 281, SEQ 205, SEQ 282,
SEQ 206, SEQ 283, SEQ 207, SEQ 284, SEQ 208, SEQ 285
<400> 391
aggatcttct acagtcac                                                18
<210> 392
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer for SEQ 209, SEQ 286, SEQ 210, SEQ 287
<400> 392
tggtagcgtt tgaaatcatc                                              20
<210> 393
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer for SEQ 211, SEQ 288
<400> 393
tataagcaca aataggttcc                                              20
<210> 394
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 212, SEQ 289, SEQ 213, SEQ 290
<400> 394
gaataactga ggggagtg                                                18
<210> 395
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind

```
<222> 1..19
<223> downstream amplification primer for SEQ 214, SEQ 291, SEQ 215, SEQ 292
<400> 395
gtgaatctcc ttttccaag                                              19
<210> 396
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 216, SEQ 293, SEQ 217, SEQ 294
<400> 396
ctaaggtgtt gtagacag                                               18
<210> 397
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer for SEQ 218, SEQ 295, SEQ 219, SEQ 296
<400> 397
cacctcgata aatcaagtcc                                             20
<210> 398
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer for SEQ 220, SEQ 297, SEQ 221, SEQ 298
<400> 398
gttcacttaa ttctgttgag                                             20
<210> 399
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 222, SEQ 299, SEQ 223, SEQ 300
<400> 399
cgccttttct gaaaggtg                                               18
<210> 400
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 224, SEQ 301, SEQ 225, SEQ 302
<400> 400
attttctgca cagcagcg                                               18
<210> 401
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
```

```
<223> downstream amplification primer for SEQ 226, SEQ 303
<400> 401
tattttctag ctcttctgg                                            19
<210> 402
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> downstream amplification primer for SEQ 227, SEQ 304
<400> 402
agcaagagtg attgtaaag                                            19
<210> 403
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 228, SEQ 305
<400> 403
tattcagaaa ggagtggg                                             18
<210> 404
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 229, SEQ 306, SEQ 230, SEQ 307,
SEQ 231, SEQ 308, SEQ 232, SEQ 309
<400> 404
agagcgttct tgcctttc                                             18
<210> 405
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer for SEQ 233, SEQ 310
<400> 405
ggtaaccta aaatgttatc                                            20
<210> 406
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer for SEQ 234, SEQ 311
<400> 406
agaaaccata agggtatatt g                                         21
<210> 407
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
```

```
<223> downstream amplification primer for SEQ 235, SEQ 312
<400> 407
acagtgcaaa ggttatatc                                           19
<210> 408
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer for SEQ 236, SEQ 313
<400> 408
gaacaacctt gaattagctt g                                        21
<210> 409
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer for SEQ 237, SEQ 314
<400> 409
gattccagaa gtccatttca g                                        21
<210> 410
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer for SEQ 238, SEQ 315
<400> 410
aggtaagaat gagcaaaaag g                                        21
<210> 411
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> downstream amplification primer for SEQ 239, SEQ 316, SEQ 240, SEQ 317
<400> 411
gcttgtgttt gttcaattc                                           19
<210> 412
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 241, SEQ 318, SEQ 242, SEQ 319
<400> 412
cttgaaatac tcccagcc                                            18
<210> 413
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
```

<223> downstream amplification primer for SEQ 243, SEQ 320, SEQ 244, SEQ 321,
SEQ 245, SEQ 322, SEQ 246, SEQ 323, SEQ 247, SEQ 324, SEQ 248, SEQ 325, SEQ
249, SEQ 326
<400> 413
ccatgaactg agaactttg                                                19
<210> 414
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 250, SEQ 327
<400> 414
ggtgacaggt aaagaaac                                                 18
<210> 415
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer for SEQ 251, SEQ 328
<400> 415
attcaggcac agaagtcata c                                             21
<210> 416
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer for SEQ 252, SEQ 329, SEQ 253, SEQ 330
<400> 416
agggcagcac aatgtagtaa g                                             21
<210> 417
<211> 18
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..18
<223> downstream amplification primer for SEQ 254, SEQ 331
<400> 417
cctctttatc tccaaacc                                                 18
<210> 418
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> downstream amplification primer for SEQ 255, SEQ 332
<400> 418
gaaaacaatc aagctctgg                                                19
<210> 419
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind

```
<222> 1..19
<223> downstream amplification primer for SEQ 256, SEQ 333
<400> 419
cctttatatc cttggagtc                                              19
<210> 420
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer for SEQ 257, SEQ 334
<400> 420
tattacacgt tccaactctt c                                          21
<210> 421
<211> 20
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..20
<223> downstream amplification primer for SEQ 258, SEQ 335
<400> 421
ctgtgtttaa gtgactgctg                                            20
<210> 422
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer for SEQ 259, SEQ 336
<400> 422
ttattgcccc acatgcttga g                                          21
<210> 423
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> downstream amplification primer for SEQ 260, SEQ 337
<400> 423
tcattcgtct ggctaggtc                                             19
<210> 424
<211> 21
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..21
<223> downstream amplification primer for SEQ 261, SEQ 338
<400> 424
gaaacagact gaagcaagga c                                          21
<210> 425
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
```

192

```
<223> potential microsequencing oligo for 4-14-107.mis1
<400> 425
acaaccacca aatgcatac                                                    19
<210> 426
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-14-317.mis1
<400> 426
acatgcaagg tgggcaaga                                                    19
<210> 427
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-14-35.mis1
<400> 427
aacacagaaa ccgctaaaa                                                    19
<210> 428
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-20-149.mis1
<400> 428
tttttgctgt gtcttcaaag tga                                               23
<210> 429
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-20-77.mis1
<400> 429
acatgaagat tctgaaggg                                                    19
<210> 430
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-22-174.mis1
<400> 430
ggattgtgca gaagttgcct ttc                                               23
<210> 431
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-22-176.mis1
```

```
<400> 431
tgcagaagtt gcctttcat                                    19
<210> 432
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-26-60.mis1
<400> 432
ggaaagtgca tcttaagac                                    19
<210> 433
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-26-72.mis1
<400> 433
ttaagacagt tagcaggcc                                    19
<210> 434
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-3-130.mis1
<400> 434
gggcctaaaa cagtattct                                    19
<210> 435
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-38-63.mis1
<400> 435
agttataaga aaatcaggc                                    19
<210> 436
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-38-83.mis1
<400> 436
gaggctaaac ttttttttt                                    19
<210> 437
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-4-152.mis1
<400> 437
```

```
ttcccattgt tcctgactt                                              19
<210> 438
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-4-187.mis1
<400> 438
tataaacaga aacatggatg agt                                         23
<210> 439
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-4-288.mis1
<400> 439
catcaactaa ttttcacaa                                              19
<210> 440
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-42-304.mis1
<400> 440
tttaaaacta tttatgtaa                                              19
<210> 441
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-42-401.mis1
<400> 441
taagaaagaa ttctgtgttc tgg                                         23
<210> 442
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-43-328.mis1
<400> 442
ttctgtgttc tggccaaag                                              19
<210> 443
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-43-70.mis1
<400> 443
atcgcctcca ttattctcaa aaa                                         23
```

```
<210> 444
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-50-209.mis1
<400> 444
atatagagtg tgcatccctg aca                                    23
<210> 445
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-50-293.mis1
<400> 445
cctgagtccc aggggctga cag                                     23
<210> 446
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-50-323.mis1
<400> 446
tttaaaacat tgatgaatct tta                                    23
<210> 447
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-50-329.mis1
<400> 447
acattgatga atctttatta cta                                    23
<210> 448
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-50-330.mis1
<400> 448
gatgaatctt tattactac                                         19
<210> 449
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-52-163.mis1
<400> 449
gaacaggata ttcttaacta cca                                    23
<210> 450
```

```
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-52-88.mis1
<400> 450
tccatgtcat tattattcaa aag                                    23
<210> 451
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-53-258.mis1
<400> 451
aatcatgcag agagaatgc                                         19
<210> 452
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-54-283.mis1
<400> 452
aagtagtttt tcacactttc tct                                    23
<210> 453
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-54-388.mis1
<400> 453
ctatcgtata catctttac                                         19
<210> 454
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-55-70.mis1
<400> 454
aagaacctag gttttaaaa                                         19
<210> 455
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-55-95.mis1
<400> 455
ctctctatcg tatacatctt tac                                    23
<210> 456
<211> 23
```

```
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-56-159.mis1
<400> 456
aagttttcct tctcttctgt aga                                    23
<210> 457
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-56-213.mis1
<400> 457
ctcatgttca ctctggttc                                         19
<210> 458
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-58-289.mis1
<400> 458
catacctgca gcctgctttt ggt                                    23
<210> 459
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-58-318.mis1
<400> 459
tgactacttt acctgcaata ttt                                    23
<210> 460
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-60-266.mis1
<400> 460
aacaggacca agacactgca tta                                    23
<210> 461
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-60-293.mis1
<400> 461
aagtttcagt atttcttagc aga                                    23
<210> 462
<211> 19
<212> DNA
```

198

```
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-84-241.mis1
<400> 462
aaaaaatagt gactgccac                                              19
<210> 463
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-84-262.mis1
<400> 463
tgaataattc agttcttca                                             19
<210> 464
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-86-206.mis1
<400> 464
tcaaatcagg acacaccac                                             19
<210> 465
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-86-309.mis1
<400> 465
tctaggcagg ccactttag                                             19
<210> 466
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-88-349.mis1
<400> 466
ctaaaagaca atattcagt                                             19
<210> 467
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-89-87.mis1
<400> 467
ttcttccctg aacgctggtt tca                                        23
<210> 468
<211> 19
<212> DNA
<213> Homo Sapiens
```

```
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-123-184.mis1
<400> 468
cccagaacat tcaccagct                                           19
<210> 469
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-128-202.mis1
<400> 469
tctgtttctt agagaactg                                           19
<210> 470
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-128-275.mis1
<400> 470
ccctacctca catgtgtag                                           19
<210> 471
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-128-313.mis1
<400> 471
tctctagaca gatatacat                                           19
<210> 472
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 99-128-60.mis1
<400> 472
cactgtgacc caggcgctag cgt                                      23
<210> 473
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing qligo for 99-12907-295.mis1
<400> 473
tatggcatta tatctccac                                           19
<210> 474
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
```

```
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-130-58.mis1
<400> 474
caaaagagct tcaaaaata                                            19
<210> 475
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-134-362.mis1
<400> 475
acactcatgt tagttagat                                            19
<210> 476
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-140-130.mis1
<400> 476
caaaagcagc tacagacca                                            19
<210> 477
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-1462-238.mis1
<400> 477
ttcaaggtta gtaactcat                                            19
<210> 478
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-147-181.mis1
<400> 478
catgaaaaag agcatgata                                            19
<210> 479
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1474-156.mis1
<400> 479
tactcataag ttaaatatt                                            19
<210> 480
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
```

```
<222> 1..19
<223> potential microsequencing oligo for 99-1474-359.mis1
<400> 480
aaaatcaaat tattgtacc                                                    19
<210> 481
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-1479-158.mis1
<400> 481
aaaatccact tgtaatcgc                                                    19
<210> 482
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1479-379.mis1
<400> 482
agctgtgtac tgaggtcag                                                    19
<210> 483
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-129.mis1
<400> 483
tatctataca aataatttt                                                    19
<210> 484
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-132.mis1
<400> 484
ctatacaaat aattttgaa                                                    19
<210> 485
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-139.mis1
<400> 485
aataattttg aatttaata                                                    19
<210> 486
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
```

```
<223> potential microsequencing oligo for 99-148-140.mis1
<400> 486
ataattttga atttaatac                                             19
<210> 487
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-182.mis1
<400> 487
tgttgatatg ggcaactgt                                             19
<210> 488
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-366.mis1
<400> 488
tgtcaaaggt ctctccctg                                             19
<210> 489
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-76.mis1
<400> 489
agaatgcctt cctgaatta                                             19
<210> 490
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1480-290.mis1
<400> 490
ccatcttcac cacaacccc                                             19
<210> 491
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1481-285.mis1
<400> 491
ataacctgtt ttgcttctc                                             19
<210> 492
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1484-101.mis1
```

```
<400> 492
agatcaaata taagcatgt                                                19
<210> 493
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-1484-328.mis1
<400> 493
acgtggtcat gaggagttt                                                19
<210> 494
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1485-251.mis1
<400> 494
gccttgatat atgctccca                                                19
<210> 495
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-1490-381.mis1
<400> 495
cagtggaaat accatgtca                                                19
<210> 496
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1493-280.mis1
<400> 496
gacagagtat tgttggagg                                                19
<210> 497
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-151-94.mis1
<400> 497
agatcattga taaggaaat                                                19
<210> 498
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-211-291.mis1
<400> 498
```

```
ttatatcaga ctgaccttc                                          19
<210> 499
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-213-37.mis1
<400> 499
cttccggctg caggactgt                                          19
<210> 500
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-221-442.mis1
<400> 500
tttgtagata tgcatggga                                          19
<210> 501
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 99-222-109.mis1
<400> 501
caggtgagga gtgctggatt ggc                                     23
<210> 502
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-14-107.mis2
<400> 502
ctatcaggca tttgcctggt tgc                                     23
<210> 503
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-14-317.mis2
<400> 503
tcatgacctg tgcccacctc ttt                                     23
<210> 504
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-14-35.mis2
<400> 504
tctctgcaga cagcttctgc ctg                                     23
```

```
<210> 505
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-20-149.mis2
<400> 505
agcaggcaat aaaccaaga                                                    19
<210> 506
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-20-77.mis2
<400> 506
gtgttctcag acaacaaag                                                    19
<210> 507
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-22-174.mis2
<400> 507
aaattaacat ttttgaaca                                                    19
<210> 508
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-22-176.mis2
<400> 508
acaaattaac atttttgaa                                                    19
<210> 509
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-26-60.mis2
<400> 509
aagtcgctcc tcggcctgct aac                                               23
<210> 510
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-26-72.mis2
<400> 510
accctttaaa gtcgctcct                                                    19
<210> 511
```

```
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-3-130.mis2
<400> 511
agttaatacc aatttaagct tta                                    23
<210> 512
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-38-63.mis2
<400> 512
aaaaaaaaag tttagcctc                                         19
<210> 513
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-38-83.mis2
<400> 513
atattctcaa cagcattgcc aaa                                    23
<210> 514
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-4-152.mis2
<400> 514
tgtttatata taggataac                                         19
<210> 515
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-4-187.mis2
<400> 515
tttttttttt tttttttt                                          19
<210> 516
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-4-288.mis2
<400> 516
tgaaatcaaa acataggta                                         19
<210> 517
<211> 19
```

```
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-42-304.mis2
<400> 517
aaaaacccct gaaaataag                                              19
<210> 518
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-42-401.mis2
<400> 518
tctgtgggtt taaactttg                                             19
<210> 519
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-43-328.mis2
<400> 519
actggctctg tgggtttaa                                             19
<210> 520
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-43-70.mis2
<400> 520
ttgtgttgtg tcccatggt                                             19
<210> 521
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-50-209.mis2
<400> 521
cataaagcct tcagtttca                                             19
<210> 522
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-50-293.mis2
<400> 522
tcaatgtttt aaactgtcc                                             19
<210> 523
<211> 19
<212> DNA
```

```
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-50-323.mis2
<400> 523
atcgaaccct tttgtagta                                         19
<210> 524
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-50-329.mis2
<400> 524
gcctaaatcg aacccttt                                          19
<210> 525
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-50-330.mis2
<400> 525
agcctaaatc gaacccttt                                         19
<210> 526
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-52-163.mis2
<400> 526
aatagatgtg taaaattct                                         19
<210> 527
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-52-88.mis2
<400> 527
caccttgtgt atttttttaa                                        19
<210> 528
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-53-258.mis2
<400> 528
ttaggttaaa atttgagtga gaa                                    23
<210> 529
<211> 19
<212> DNA
<213> Homo Sapiens
```

209

```
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-54-283.mis2
<400> 529
taagccatcg attgtatca                                              19
<210> 530
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-54-388.mis2
<400> 530
gtcttggcgc tgcagcgtg                                              19
<210> 531
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-55-70.mis2
<400> 531
taaagatgta tacgatagag agt                                         23
<210> 532
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-55-95.mis2
<400> 532
gtcttggcgc tgcagcgtg                                              19
<210> 533
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-56-159.mis2
<400> 533
ttgactgtaa catggagac                                              19
<210> 534
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-56-213.mis2
<400> 534
tatcaaactc ctctgaagg                                              19
<210> 535
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
```

```
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-58-289.mis2
<400> 535
aggtaaagta gtcacccct                                              19
<210> 536
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-58-318.mis2
<400> 536
gaagaaataa acttgcaaa                                              19
<210> 537
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-60-266.mis2
<400> 537
agaaatactg aaactttat                                             19
<210> 538
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-60-293.mis2
<400> 538
aggacttcct gctggcttc                                             19
<210> 539
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 4-84-241.mis2
<400> 539
ttctgaagaa ctgaattatt cac                                        23
<210> 540
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-84-262.mis2
<400> 540
tgagatcatg ttgctgctt                                             19
<210> 541
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
```

```
<222> 1..23
<223> microsequencing oligo for 4-86-206.mis2
<400> 541
aatgttaacg tgtagatgcc att                                          23
<210> 542
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-86-309.mis2
<400> 542
gctctctggt tcctcactc                                               19
<210> 543
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-88-349.mis2
<400> 543
aagaacttgg aaaatctca                                               19
<210> 544
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 4-89-87.mis2
<400> 544
ttctcaacac aaaaactat                                               19
<210> 545
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-123-184.mis2
<400> 545
cccagcagaa ctcttggcc                                               19
<210> 546
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-128-202.mis2
<400> 546
gtatgtatgt gtgtgtgtt                                               19
<210> 547
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
```

212

```
<223> potential microsequencing oligo for 99-128-275.mis2
<400> 547
acatatatgc atacatttg                                                    19
<210> 548
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-128-313.mis2
<400> 548
tctatgccaa atagaatct                                                    19
<210> 549
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-128-60.mis2
<400> 549
ggagtgtcac tgtaagagg                                                    19
<210> 550
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-12907-295.mis2
<400> 550
ttgtacatca ggtctgccc                                                    19
<210> 551
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 99-130-58.mis2
<400> 551
ctcgccatat gcacactcct gaa                                               23
<210> 552
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-134-362.mis2
<400> 552
tctttgtaat aggaataat                                                    19
<210> 553
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-140-130.mis2
```

```
<400> 553
catgctcaat tgtttacat                                               19
<210> 554
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1462-238.mis2
<400> 554
ctgaagcaga aacacagca                                               19
<210> 555
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 99-147-181.mis2
<400> 555
tataaagatt taagtttttc ttt                                          23
<210> 556
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-1474-156.mis2
<400> 556
ccatatttct tcttgttat                                               19
<210> 557
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1474-359.mis2
<400> 557
catctgatat tagggaatt                                               19
<210> 558
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1479-158.mis2
<400> 558
aatatacact ccaattagc                                               19
<210> 559
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1479-379.mis2
<400> 559
```

```
ctgtaccatg agctgcttc                                                    19
<210> 560
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-129.mis2
<400> 560
cagccctatg tattaaatt                                                    19
<210> 561
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-132.mis2
<400> 561
ttgcagcccT atgtattaa                                                    19
<210> 562
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-139.mis2
<400> 562
ccttgttttg cagccctat                                                    19
<210> 563
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-140.mis2
<400> 563
accttgtttt gcagcccta                                                    19
<210> 564
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 99-148-182.mis2
<400> 564
gaatgctttg ggaccatcca aca                                               23
<210> 565
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-366.mis2
<400> 565
gaggcggcag ccgtgagca                                                    19
```

```
<210> 566
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-148-76.mis2
<400> 566
tatgaagcca tcaagagta                                              19
<210> 567
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-1480-290.mis2
<400> 567
aaaaggatca gtggttgcc                                              19
<210> 568
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-1481-285.mis2
<400> 568
taccatcttg aggttagag                                              19
<210> 569
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1484-101.mis2
<400> 569
agattttaag gagaggagt                                              19
<210> 570
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1484-328.mis2
<400> 570
tctgaaaact gaatccctt                                              19
<210> 571
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-1485-251.mis2
<400> 571
aggggacatt cttggttct                                              19
<210> 572
```

```
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-1490-381.mis2
<400> 572
agatgcacag tagcgtacc                                                19
<210> 573
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> microsequencing oligo for 99-1493-280.mis2
<400> 573
acaagcagcc aaaccccat                                                19
<210> 574
<211> 23
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..23
<223> microsequencing oligo for 99-151-94.mis2
<400> 574
atatagattt tgaaatttta gaa                                           23
<210> 575
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-211-291.mis2
<400> 575
cattgacctg ttgaaaaca                                                19
<210> 576
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-213-37.mis2
<400> 576
tcagacactg gagtcctcc                                                19
<210> 577
<211> 19
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-221-442.mis2
<400> 577
gtctggctag gtcatggaa                                                19
<210> 578
<211> 19
```

217

```
<212> DNA
<213> Homo Sapiens
<220>
<221> primer_bind
<222> 1..19
<223> potential microsequencing oligo for 99-222-109.mis2
<400> 578
ctgaagaaat tcatatcgt                                          19
```

| Intei | Application No |
|---|---|
| PCT/1B 98/02133 | |

..(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ʾ | Citation of document. with indication,where appropriate. of the relevant passages | Relevant to claim No. |
|---|---|---|
| X | EMBL Database Entry HS1184481<br>Accession number AA280082;20 June 1997<br>National Cancer Institute, Cancer Genome<br>Anatomy Project (CGAP): "zs93h09.r1<br>NCI_CGAP_GCB1 Homosapiens cDNA clone<br>IMAGE: 705089 5'."100% overlap in 170bp p<br>with Seq ID Nos 121 and 69; & 100% overlap<br>in 237bp with ID No 112."<br>XP002109142<br>"100% overlap in 170bp with Seq ID no 3."<br>Additionally, an 100% overlap in 100 and<br>101 amino acids with polypeptides having<br>Seq ID Nos 135 and 134 respectively."<br>--- | 1-3,5-9,<br>16-18 |
| A | ICHIKAWA T ET AL: "Metastasis supressor<br>genes for prostate cancer"<br>PROSTATE,<br>vol. 28, no. 3 suppl 6, 1966, pages 31-35,<br>XP002109139<br>the whole document<br>--- | 1-3,5-38 |
| A | G S BOVA ET AL: "Homozygous deletion and<br>frequent allelic loss of cchromosome 8p22<br>loci in human prostate cancer"<br>CANCER RESEARCH,<br>vol. 53, 1 September 1993 (1993-09-01),<br>pages 3869-3873, XP002084748<br>ISSN: 0008-5472<br>the whole document<br>--- | 1-3,5-38 |
| A | WU C ET AL: "Deletion mapping defines<br>three discrete areas of allelic imbalance<br>on chromosome arm 8p in oral and<br>oropharangeal squamous cell carcinomas"<br>GENES, CHROMOSOMES AND CANCER,<br>vol. 20, no. 4, December 1997 (1997-12),<br>pages 347-53, XP002109140<br>page 352, paragraph 3<br>--- | 1-3,5-38 |
| A | WO 96 20288 A (CTRC RES FOUNDATION ;UNIV<br>MICHIGAN (US)) 4 July 1996 (1996-07-04)<br>the whole document<br>--- | 1-3,5-38 |
| A | WO 97 46702 A (UNIV CALIFORNIA)<br>11 December 1997 (1997-12-11)<br>the whole document<br>--- | 1-3,5-38 |
| A | WO 97 36535 A (UNIV TEXAS) ⸴<br>9 October 1997 (1997-10-09)<br>the whole document<br>--- | 1-3,5-38 |

-/--

.3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

VSDOCID: <WO___9932644A3_J_>

# PCT

WORLD INTELLECTUAL PROPERTY ORGANIZA'
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| (51) International Patent Classification <sup>6</sup> : C12N 15/85, 9/10, C07K 16/30, 16/40, C12Q 1/68, A01K 67/027, C07K 14/47 | A3 | (11) International Publication Number: WO 99/32644 |
|---|---|---|
| | | (43) International Publication Date: 1 July 1999 (01.07.99) |

(21) International Application Number: PCT/IB98/02133

(22) International Filing Date: 2? December 1998 (22.12.98)

(30) Priority Data:
08/996,306    22 December 1997 (22.12.97)    US
60/099,658    9 September 1998 (09.09.98)    US

(71) Applicant (for all designated States except US): GENSET [FR/FR]; 24, rue Royale, F-75008 Paris (FR).

(72) Inventors; and
(75) Inventors/Applicants (for US only): COHEN, Daniel [FR/FR]; 5, avenue Odette, F-94210 Fontenay-sous-Bois (FR). BLUMENFELD, Marta [FR/FR]; 5, rue Tagore, F-75013 Paris (FR). CHUMAKOV, Ilya [FR/FR]; 196, rue des Chèvrefeuilles, F-77000 Vaux-le-Pénil (FR). BOUGUEL-ERET, Lydie [FR/FR]; 108, avenue Victor-Hugo, F-92170 Vanves (FR).

(74) Agents: MARTIN, Jean-Jacques et al.; Cabinet Regimbeau, 26, avenue Kléber, F-75116 Paris (FR).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(54) Title: PROSTATE CANCER GENE

(57) Abstract

The present invention relates to PG1, a gene associated with prostate cancer. The invention provides polynucleotides including biallelic markers derived from PG1 and from flanking genomic regions. Primers hybridizing to these biallelic markers and regions flanking are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and prostate cancer and between a haplotype and prostate cancer. The invention also relates to diagnostic methods of determining whether an individual is at risk for developing prostate cancer, and whether an individual suffers from prostate concer as a result of a mutation in the PG1 gene.

# INTERNATIONAL SEARCH REPORT

**A. CLASSIFICATION OF SUBJECT MATTER**
IPC 6  C12N15/85  C12N9/10  C07K16/30  C07K16/40  C12Q1/68
       A01K67/027  C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)
IPC 6  C12Q  C07K  C12N  A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| X | EMBL Database Entry HS164152<br>Accession Number H06164; 23 June 1995<br>Hillier L et al.: "y177g12.r1 Homosapiens<br>cDNA clone 44264 5'."<br>100% identity in 169pb overlap with Seq ID<br>No 118.<br>XP002109141<br>see database entry<br>___<br><div align="center">-/--</div> | 1-3 |

[X] Further documents are listed in the continuation of box C.　　[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|---|
| 15 July 1999 | 29/07/1999 |

| Name and mailing address of the ISA | Authorized officer |
|---|---|
| European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,<br>Fax: (+31-70) 340-3016 | Osborne, H |

3

Form PCT/ISA/210 (second sheet) (July 1992)

page 1 of 3

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document. with indication,where appropriate. of the relevant passages | Relevant to claim No. |
|---|---|---|
| A | KRUGLYAK L: "THE USE OF A GENETIC MAP OF BIALLELIC MARKERS IN LINKAGE STUDIES" NATURE GENETICS, vol. 17, no. 1, 1 September 1997 (1997-09-01), pages 22-24, XP002050647 ISSN: 1061-4036 the whole document | 19-38 |
| A | WANG D ET AL: "TOWARD A THIRD GENERATION GENETIC MAP OF THE HUMAN GENOME BASED ON BI-ALLELIC POLYMORPHISMS" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 59, no. 4, 1 October 1996 (1996-10-01), page A03 XP002050641 ISSN: 0002-9297 the whole document | 19-38 |
| A | SCHORK N J ET AL: "Linkage disequilibrium mapping for quantitative traits within case/control settings" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 61, no. 4, SUPPL, 1 January 1997 (1997-01-01), page A293 XP002089399 ISSN: 0002-9297 | 19-38 |

# INTERNATIONAL SEARCH REPORT

**Box I    Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.:        4, 39
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II    Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

FURTHER INFORMATION CONTINUED FROM    PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.:  4 and 39

Present claims 4 and 39 relate to an extremely large number of possible
polynucleotide sequences. In the present case, a meaningful search over
the whole of the claimed scope is impossible. Consequently, the search
has been carried out for those parts of the claims which appear to be
related to the PG1 gene per se., and their utility in the claimed
diagnostic methods.

The applicant's attention is drawn to the fact that claims relating to
inventions in respect of which no international search report has been
established need not be the subject of an international preliminary
examination (Rule 66.1(e) PCT). The applicant is advised that the EPO
policy when acting as an International Preliminary Examining Authority is
normally not to carry out a preliminary examination on matter which has
not been searched. This is the case irrespective of whether or not the
claims are amended following receipt of the search report or during any
Chapter II procedure.

| Patent document cited in search report | | Publication date | Patent family member(s) | | Publication date |
|---|---|---|---|---|---|
| WO 9620288 | A | 04-07-1996 | US<br>AU | 5658730 A<br>4473596 A | 19-08-1997<br>19-07-1996 |
| WO 9746702 | A | 11-12-1997 | NONE | | |
| WO 9736535 | A | 09-10-1997 | US<br>AU<br>EP | 5861248 A<br>2601797 A<br>0904405 A | 19-01-1999<br>22-10-1997<br>31-03-1999 |

127

```
cagtgtcact aagcctgtag ttcactgatg aagctagagt gcccactagt gagccactat 33240
cactagtgag cacactagta atagtgtgaa agaaagtgac ttccactgtc ccatgaacac 33300
acccaccttc atctcctcta ccttgcacct ggttcagatt tcggcagatg cagtgagcat 33360
ggtgcttaag aagtctgaag gatagctctg ggggatggtg gcacatgaag gtcacatctt 33420
tttttaatta ggtgatttaa atgggtttgt gcacatgagt gcaacaccca tacaggccag 33480
aagggggcat aagatccccg gctctagagt gtcaggctgt tgtgaactgc ctggaatagg 33540
tgttgggaac tgatcttggg tcccctggaa gagcattgag tacatgtcat cactatctct 33600
ccagcctcac actcttatcg gtatgtctca tttgtggggg caatttgggg agtcccacct 33660
ctggatcagg tactgtgaaa tatggagttg gcggggctgg atccctgtct tgccaccagc 33720
cagctgagga aagctgtcaa ttgtcttcct gtgtctgcct cagtttccta gaaactagaa 33780
aggaaaaatg gatggtatca ctaagttcag ccttccattg taaggatcca ttgaagtagt 33840
tggtgtgatg tactcacgct ggtgcccctc cccttctgag ctgcaagcat cagctgttgg 33900
acccagcagt tctgtgctcc gacaggaagc agtgggaaac tgggctgcaa gatgatccca 33960
gttctagcat ttgctgcaac cccctttgct cacatctgtt tccacatttt atttcatcct 34020
tgagcacata acctttcat tttgatacat gcttttcttt acatagcctg ggccagcctt 34080
gaactcatgc tcctcctgcc ataattcctt aaggactgac aatgacagtg gacatgcacc 34140
gccaggtccc actgctccta gtactttgt tatgggtctt ctatgctggt ctaatgtgga 34200
atgtgacact gcacaccagg cattgtggga tgaagtagaa catgttcatg cacacaaaga 34260
tcaatcccaa acagcatctg cccaccccct ccctctgccc cttcccccgg tggatgttag 34320
cattctcttg tgtagtgctg ggtcggcccc ttctctgtct ctaaacattg aaacaagggg 34380
aacagaccca tacataactc caacacagcg atctggtcca agtctggatg tagaaccctt 34440
ggctctgctc ttttctcctc ttcccagagc tgtcccagtc gcctccctt ctaattggct 34500
ggtgctcatc taacttgatg tatatgtttc tttcctggtc tgttttatga ctggcctgct 34560
ccagtcatta gtgcatctgg tgttagaagc taagctcaac ttggcctcac agtcttgatg 34620
ttcaggacac atggggttat ggctggatcc tgtgtcaagc acatcacttc tttctgaacc 34680
cacacatctt aagacatggg cattgtcaca tggctgacag cagtacattc ttgtatgtag 34740
ttttctctca agtgttttgg ttacatggcc ctaaagccta ggactgtctg tcttcaatca 34800
tgtctgccac ctgctgccca gcaagcccaa gttgtggttc ttcctgtcta atctgcctct 34860
tttatcttta gccctcctcc ataagcctct tttccactga gctctgggtt attcagatta 34920
cagctcccta ctgctttcct gagaccctaa gccgctccac gatgcacagc agcactttcc 34980
agcagtccta tggagatgca gtgtcgagat gatatgagct gtgctgtata tgtaaaatgc 35040
atggtagaat ctgaaaacca agcacaaaaa aataaaaaaa aagttcatta atatttatag 35100
caatcatgta atgttttgaa aatacgtgcc taataaaatt attttcacct ttttaaaaat 35160
gtgggtacta tgatgtttaa tagcgcatat tcatgtggca tatttacctc aatggggcat 35220
ggaaaacaag acgacaaagg gtgggatatt tctctcaact ttcctagctg caacttgtga 35280
taatttgtga gacacattaa gcactcaaga agggtttgat tctgtagaca aaacccgggg 35340
tcagacagtc cacagcttca gcatagtgtg ttcactatat ctaaagtagg ttttacttct 35400
ttaagattaa ttttgttctt agacagtttc ccacatgcag cacaaagcag ttatgtttta 35460
attttatagg ctacaatgac ggtatttcaa aaagtaagat gtgggagtta caccttgaat 35520
gatcacccaa ggattgttgg ccatcagcac tgaatggccc agaaccaatc tacagcaaat 35580
ctgagagagc agagacatgc tgctccactg tctgagggcc cttgcccatg gtggttgcta 35640
ttgacatctt gacaggatct aaaatcacct aggtgtgctc tgggcacctc tggacatatc 35700
tgggagtctc tagactggat tgcctgaggt tgatttaaaa accctaactg ggcagcacca 35760
ttcattggga tggggtcctg gcgtggataa agattggagg atgagggagc accaggttcc 35820
acctctctgc ctcctgactg gatgcagcat gatcagctcc ctctcctgct gtgacacaat 35880
ctctgtaccc tcaaactgaa caaaacaagc tcactcgaaa gttgctttcg ttagtcactt 35940
tgtcacagct ttgtcacagt gatgagaaaa ataacacaca cccccccaaat gaggattgga 36000
tcgaggccct gggcatgctg ggtaaactct tcaccactaa gctatattcc taaccctttt 36060
tactttgaat agggtcttaa ttgcccagat tggccttaaa atgataattc tcctgtcttc 36120
agcttcccaa gcagctggaa ttacaaatgc gagcactagt atgtatatgt agtatataaa 36180
taatatattg tacatatatt cacatgtgtg tgtacatgtg tgtacacaat tacaaatggg 36240
agccccagaa tgatgtatac acatacatat aagtaggtaa ttaatatata catatttaca 36300
catattatac tagtgtgtat atatagaata tataatatgt attgcacata tattccacata 36360
tgtgtgtaca tgtccatgtc acattgtgat tgctagttaa ataccacttt tccctgctct 36420
ctaatccaag tagcaattga acctgtgaat tatggtaaac ttcaggggat tgaaaagcct 36480
gacctccaca gaatcagcta acgttagctg ctactatgat tccaagcagt agttactgga 36540
agtgtttgct cctgtattct cttggaagga agaactagat tgttagtcat cagttcacag 36600
tcggttatgg tcccctgtt ggcctcatag accagaaagt agagttgcat ggtttgattg 36660
taaagtgacc cacctcccac aggttcacat gcttgaacac tgggtcccca gatgatggag 36720
ctcttggggg aggttgtgga gaccatctag gaggttagct tacctggagg aaatgggctt 36780
ctaggggaca gacattgaag atgataggtt ttccctgttt ctgccctggg aatatatcca 36840
```

```
aattcctcac tcgaatgcca cagccctgag atgagccttc cccttcacag tggactctac    36900
cctcaaaccc tgagccagag tagatccttc gtcctttgct agatgtttgg tcacggcagt    36960
gaggtaaagt accgagcaca gcatcattgt tcccatttta cggatgggaa aactgagcct    37020
tgggagatgc ccaaggctgt cagccttgag tgtttaaaag ctgcaaggat tggatgcatt    37080
tgtcctatat cagggaaaca tgatggggat ggagtctggg tgctgaggca ctgagttggc    37140
aagagggaag gcctggtgtt cactcaaagt cattaaggac caattgtgtc tgcaatcctg    37200
tgccctccct tgaacaatag gtaagggtca gtgtgagccc tgattactcc cagcagaagg    37260
atacatctgc tttggagacc aaagtccctt cactgtagaa actaggtcct tcaaggtctc    37320
agataaaaag acaatgggtt ttgtgctaat ttccacccaa tgggtgtgtg ggtcacacta    37380
ctcactgggc caacatggtg gtctggacag tcacacagga tgaagtgagg aaaggcaagt    37440
ctccccggca cctcccctat cgtcactgca aggccaccct gactaagagt cccctcttca    37500
atgctggccc tacgaatatc ttatcactct tcgtgtttac aagatttctc tccttggaag    37560
gtgtgatgtg gacagtgaag ctctcaacaa cccctactca cctaagacct agacaagaga    37620
gtctgggatg gccatgtatg tactccttca gtaattgaca gccattttct ttgtctagga    37680
agtcttccta caagcttccg caccataacg gtatcggctg tcctgattta cagacatgtc    37740
attgggactg atatctgcaa caaagagcag atctccagtc actcatctca ctccagcttg    37800
ttcacagaac aaaaaggagt tgaagggagg tcttcatcat tgggtgttcc cttccatgga    37860
gcataggaca ggcatggtgc ccagaacctg cccagcttct agctctccaa gcctcatgct    37920
ttcctgtctc naaaaaaaaa aaaaaaaaaa                                     37950
```

<210> 184
<211> 1381
<212> DNA
<213> Mus musculus

<400> 184

```
gagccgagag gatgctgctg tccctggtgc tccacacgta ctct atg cgc tac ctg        56
                                                   Met Arg Tyr Leu
                                                    1

ctc ccc agc gtc ctg ttg ctg ggc tcg gcg ccc acc tac ctg ctg gcc         104
Leu Pro Ser Val Leu Leu Leu Gly Ser Ala Pro Thr Tyr Leu Leu Ala
5                   10                  15                  20

tgg acg ctg tgg cgg gtg ctc tcc gcg ctg atg ccc gcc cgc ctg tac         152
Trp Thr Leu Trp Arg Val Leu Ser Ala Leu Met Pro Ala Arg Leu Tyr
                25                  30                  35

cag cgc gtg gac gac cgg ctt tac tgc gtc tac cag aac atg gtg ctc         200
Gln Arg Val Asp Asp Arg Leu Tyr Cys Val Tyr Gln Asn Met Val Leu
                40                  45                  50

ttc ttc ttc gag aac tac acc ggg gtc cag ata ttg cta tat gga gat         248
Phe Phe Phe Glu Asn Tyr Thr Gly Val Gln Ile Leu Leu Tyr Gly Asp
            55                  60                  65

ttg cca aaa aat aaa gaa aat gta ata tat cta gcg aat cat caa agc         296
Leu Pro Lys Asn Lys Glu Asn Val Ile Tyr Leu Ala Asn His Gln Ser
            70                  75                  80

aca gtt gac tgg att gtt gcg gac atg ctg gct gcc aga cag gat gcc         344
Thr Val Asp Trp Ile Val Ala Asp Met Leu Ala Ala Arg Gln Asp Ala
85                  90                  95                  100

cta gga cat gtg cgc tac gta ctg aaa gac aag tta aaa tgg ctt ccg         392
Leu Gly His Val Arg Tyr Val Leu Lys Asp Lys Leu Lys Trp Leu Pro
                105                 110                 115

ctg tat ggg ttc tac ttt gct cag cat gga gga att tat gta aaa cga         440
Leu Tyr Gly Phe Tyr Phe Ala Gln His Gly Gly Ile Tyr Val Lys Arg
                120                 125                 130

agt gcc aaa ttt aat gat aaa gaa atg aga agc aag ctg cag agc tat         488
Ser Ala Lys Phe Asn Asp Lys Glu Met Arg Ser Lys Leu Gln Ser Tyr
                135                 140                 145

gtg aac gca gga aca ccg atg tat ctt gtg att ttc cca gag gga aca         536
Val Asn Ala Gly Thr Pro Met Tyr Leu Val Ile Phe Pro Glu Gly Thr
                150                 155                 160

agg tat aat gca aca tac aca aaa ctc ctt tca gcc agt cag gca ttt         584
Arg Tyr Asn Ala Thr Tyr Thr Lys Leu Leu Ser Ala Ser Gln Ala Phe
165                 170                 175                 180

gct gct cag cgg ggc ctt gca gta tta aaa cac gta ctg aca cca aga         632
Ala Ala Gln Arg Gly Leu Ala Val Leu Lys His Val Leu Thr Pro Arg
```

129

```
Ala Ala Gln Arg Gly Leu Ala Val Leu Lys His Val Leu Thr Pro Arg
                185                 190                 195
ata aag gcc act cac gtt gct ttt gat tct atg aag agt cat tta gat    680
Ile Lys Ala Thr His Val Ala Phe Asp Ser Met Lys Ser His Leu Asp
                200                 205                 210
gca att tat gat gtc aca gtg gtt tat gaa ggg aat gag aaa ggt tca    728
Ala Ile Tyr Asp Val Thr Val Val Tyr Glu Gly Asn Glu Lys Gly Ser
                215                 220                 225
gga aaa tac tca aat cca cca tcc atg act gag ttt ctc tgc aaa cag    776
Gly Lys Tyr Ser Asn Pro Pro Ser Met Thr Glu Phe Leu Cys Lys Gln
                230                 235                 240
tgc cca aaa ctt cat att cac ttt gat cgt ata gac aga aat gaa gtt    824
Cys Pro Lys Leu His Ile His Phe Asp Arg Ile Asp Arg Asn Glu Val
245                 250                 255                 260
cca gag gaa caa gaa cac atg aaa aag tgg ctt cat gag cgc ttt gag    872
Pro Glu Glu Gln Glu His Met Lys Lys Trp Leu His Glu Arg Phe Glu
                265                 270                 275
ata aaa gat agg ttg ctc ata gag ttc tat gat tca cca gat cca gaa    920
Ile Lys Asp Arg Leu Leu Ile Glu Phe Tyr Asp Ser Pro Asp Pro Glu
                280                 285                 290
aga aga aac aaa ttt cct ggg aaa agt gtt cat tcc aga cta agt gtg    968
Arg Arg Asn Lys Phe Pro Gly Lys Ser Val His Ser Arg Leu Ser Val
                295                 300                 305
aag aag act tta cct tca gtg ttg atc ttg ggg agt ttg act gcg gtc   1016
Lys Lys Thr Leu Pro Ser Val Leu Ile Leu Gly Ser Leu Thr Ala Val
                310                 315                 320
atg ctg atg acg gag tcc gga agg aaa ctg tac atg ggc acc tgg ttg   1064
Met Leu Met Thr Glu Ser Gly Arg Lys Leu Tyr Met Gly Thr Trp Leu
325                 330                 335                 340
tat gga acc ctc ctt ggc tgc ctg tgg ttt gtt att aaa gca taa       1109
Tyr Gly Thr Leu Leu Gly Cys Leu Trp Phe Val Ile Lys Ala *
                345                 350                 355
gcaagtagca ggctgcagtc acagtctctt attgatggct acacattgta tcacattgtt  1169
tcctgaatta aataaggagt tttcttgttg ttgttttttt tgttttgttt tgttctgttt  1229
taagccttga tgattgaaca ctggataaag tcgagtcttg tgaccacagc caacatgcat  1289
ttgatttggg gcaaacacat gtggcttttc aggtgctggg gttgctggag acatggaagc  1349
taagtggagt ttatgctgtt tttttttttt tt                                1381
<210> 185
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-14-107
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-14-107.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-14-107.mis2
<400> 185
ctaaacaacc accaaatgca tacagcaacc aggcaaatgc ctgatag                  47
<210> 186
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
```

```
<221> allele
<222> 1..47
<223> polymorphic fragment 4-14-317
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-14-317.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-14-317.mis2
<400> 186
cataacatgc aaggtgggca agaaaaagag gtgggcacag ctcatga                47
<210> 187
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-14-35
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-14-35.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-14-35.mis2
<400> 187
atccaacaca gaaaccgcta aaaccaggca gaagctgtct gcagaga             47
<210> 188
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-20-149
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-20-149.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-20-149.mis2
<400> 188
tttttgctgt gtcttcaaag tgactcttgg tttattgcct gctaagg             47
<210> 189
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-20-77
<221> allele
```

```
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-20-77.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-20-77.mis2
<400> 189
tgcaacatga agattctgaa gggactttgt tgtctgagaa cacatct                    47
<210> 190
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-22-174
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-22-174.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-22-174.mis2
<400> 190
ggattgtgca gaagttgcct ttcatgttca aaaatgttaa tttgttt                    47
<210> 191
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-22-176
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-22-176.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-22-176.mis2
<400> 191
attgtgcaga agttgccttt catattcaaa aatgttaatt tgtttgt                    47
<210> 192
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-26-60
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
```

132

```
<223> potential microsequencing oligo 4-26-60.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-26-60.mis2
<400> 192
gatgggaaag tgcatcttaa gacagttagc aggccaagga gcgactt                    47
<210> 193
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-26-72
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-26-72.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-26-72.mis2
<400> 193
catcttaaga cagttagcag gccaaggagc gactttaaag ggtgagc                    47
<210> 194
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-3-130
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-3-130.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-3-130.mis2
<400> 194
tattgggcct aaaacagtat tctataaagc ttaaattggt attaact                    47
<210> 195
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-38-63
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-38-63.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-38-63.mis2
```

```
<400> 195
tataagttat aagaaaatca ggcagaggct aaactttttt tttgttt                47
<210> 196
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-38-83
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-38-83.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-38-83.mis2
<400> 196
ggcagaggct aaactttttt tttgtttggc aatgctgttg agaatat                47
<210> 197
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-4-152
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-4-152.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-4-152.mis2
<400> 197
tactttccca ttgttcctga cttcgttatc ctatatataa acagaaa                47
<210> 198
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-4-187
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-4-187.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-4-187.mis2
<400> 198
tataaacaga aacatggatg agtaaaaaaa aaaaaaaaaa aaaaaaa                47
<210> 199
<211> 47
```

134

```
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-4-288
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-4-288.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-4-288.mis2
<400> 199
ctgtcatcaa ctaattttca caagtaccta tgttttgatt tcatgta                              47
<210> 200
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-42-304
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-42-304.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-42-304.mis2
<400> 200
attatttaaa actatttatg taaccttatt ttcaggggtt tttaatt                              47
<210> 201
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-42-401
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-42-401.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-42-401.mis2
<400> 201
taagaaagaa ttctgtgttc tggacaaagt ttaaacccac agagcca                              47
<210> 202
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
```

```
<222> 1..47
<223> polymorphic fragment 4-43-328
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-43-328.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-43-328.mis2
<400> 202
agaattctgt gttctggcca aagcttaaac ccacagagcc agtttaa                47
<210> 203
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-43-70
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-43-70.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-43-70.mis2
<400> 203
atcgcctcca ttattctcaa aaagaccatg ggacacaaca caagaag                47
<210> 204
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-50-209
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-50-209.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-50-209.mis2
<400> 204
atatagagtg tgcatccctg acactgaaac tgaaggcttt atggttt                47
<210> 205
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-50-293
<221> allele
<222> 24
```

```
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-50-293.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-50-293.mis2
<400> 205
cctgagtccc agggggctga caggggacag tttaaaacat tgatgaa                    47
<210> 206
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-50-323
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-50-323.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-50-323.mis2
<400> 206
tttaaaacat tgatgaatct ttactactac aaaagggttc gatttag                    47
<210> 207
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-50-329
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-50-329.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-50-329.mis2
<400> 207
acattgatga atctttatta ctacaaaagg gttcgattta ggctagc                    47
<210> 208
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-50-330
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-50-330.mis1
```

```
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-50-330.mis2
<400> 208
cattgatgaa tctttattac tacaaaaggg ttcgatttag gctagcc                    47
<210> 209
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-52-163
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-52-163.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-52-163.mis2
<400> 209
gaacaggata ttcttaacta ccaaagaatt ttacacatct attgttt                    47
<210> 210
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-52-88
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-52-88.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-52-88.mis2
<400> 210
tccatgtcat tattattcaa aagcttaaaa aatacacaag gtgaaaa                     47
<210> 211
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-53-258
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-53-258.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-53-258.mis2
<400> 211
```

```
gagaaatcat gcagagagaa tgcattctca ctcaaatttt aacctaa              47
<210> 212
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-54-283
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-54-283.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-54-283.mis2
<400> 212
aagtagtttt tcacactttc tctatgatac aatcgatggc ttaatct             47
<210> 213
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-54-388
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-54-388.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-54-388.mis2
<400> 213
ctctctatcg tatacatctt tacacacgct gcagcgccaa gactcca             47
<210> 214
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-55-70
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-55-70.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-55-70.mis2
<400> 214
tattaagaac ctaggtttta aaaactctc tatcgtatac atcttta             47
<210> 215
<211> 47
<212> DNA
```

```
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-55-95
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-55-95.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-55-95.mis2
<400> 215
ctctctatcg tatacatctt tacacacgct gcagcgccaa gactcca                47
<210> 216
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-56-159
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-56-159.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-56-159.mis2
<400> 216
aagttttcct tctcttctgt agacgtctcc atgttacagt caactat        47
<210> 217
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-56-213
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-56-213.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-56-213.mis2
<400> 217
atggctcatg ttcactctgg ttcaccttca gaggagtttg atatttt       47
<210> 218
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
```

```
<223> polymorphic fragment 4-58-289
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-58-289.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-58-289.mis2
<400> 218
catacctgca gcctgctttt ggtgaggggt gactacttta cctgcaa              47
<210> 219
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-58-318
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-58-318.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-58-318.mis2
<400> 219
tgactacttt acctgcaata tttatttgca agtttatttc ttccttt              47
<210> 220
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-60-266
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-60-266.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-60-266.mis2
<400> 220
aacaggacca agacactgca ttagataaag tttcagtatt tcttagc              47
<210> 221
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-60-293
<221> allele
<222> 24
<223> polymorphic base C
```

```
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-60-293.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-60-293.mis2
<400> 221
aagtttcagt atttcttagc agacgaagcc agcaggaagt cctccta                47
<210> 222
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-84-241
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-84-241.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-84-241.mis2
<400> 222
gaaaaaaaaa tagtgactgc cacggtgaat aattcagttc ctcagaa                47
<210> 223
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-84-262
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-84-262.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-84-262.mis2
<400> 223
acggtgaata attcagttct tcaaaagcag caacatgatc tcatgga                47
<210> 224
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-86-206
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-86-206.mis1
<221> primer_bind
```

142

```
<222> 25..47
<223> complement potential microsequencing oligo 4-86-206.mis2
<400> 224
gtattcaaat caggacacac cacaaatggc atctacacgt taacatt                    47
<210> 225
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-86-309
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-86-309.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-86-309.mis2
<400> 225
tggctctagg caggccactt tagagagtga ggaaccagag agcagaa                    47
<210> 226
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-88-349
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-88-349.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-88-349.mis2
<400> 226
gaaactaaaa gacaatattc agtgtgagat tttccaagtt ctttatg                    47
<210> 227
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-89-87
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-89-87.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-89-87.mis2
<400> 227
ttcttccctg aacgctggtt tcacatagtt tttgtgttga gaataga                    47
```

```
<210> 228
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-123-184
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-123-184.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-123-184.mis2
<400> 228
ccagcccaga acattcacca gctgggccaa gagttctgct gggtttt                47
<210> 229
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-128-202
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-128-202.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-128-202.mis2
<400> 229
aatgtctgtt tcttagagaa ctgaaacaca cacacataca tacacac              47
<210> 230
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-128-275
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-128-275.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-128-275.mis2
<400> 230
acacccctac ctcacatgtg tagacaaatg tatgcatata tgtctct             47
<210> 231
<211> 47
<212> DNA
<213> Homo Sapiens
```

```
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-128-313
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-128-313.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-128-313.mis2
<400> 231
tatgtctcta gacagatata cataagattc tatttggcat agaaaaa                     47
<210> 232
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-128-60
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-128-60.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-128-60.mis2
<400> 232
gcactgtgac ccaggcgcta ggtccctctt acagtgacac tccgaca                     47
<210> 233
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-12907-295
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-12907-295.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-12907-295.mis2
<400> 233
gctatatggc attatatctc cacagggcag acctgatgta caagatg                     47
<210> 234
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-130-58
```

```
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-130-58.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-130-58.mis2
<400> 234
aaagcaaaag agcttcaaaa atacttcagg agtgtgcata tggcgag                        47
<210> 235
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-134-362
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-134-362.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-134-362.mis2
<400> 235
caaaacactc atgttagtta gatgattatt cctattacaa agataag                        47
<210> 236
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-140-130
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-140-130.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-140-130.mis2
<400> 236
tgttcaaaag cagctacaga ccacatgtaa acaattgagc atggctg                        47
<210> 237
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1462-238
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
```

```
<222> 1..23
<223> potential microsequencing oligo 99-1462-238.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1462-238.mis2
<400> 237
ccctttcaag gttagtaact catgtgctgt gtttctgctt cagaagg                47
<210> 238
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-147-181
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-147-181.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-147-181.mis2
<400> 238
gtgtcatgaa aaagagcatg ataaaaagaa aaacttaaat ctttata                47
<210> 239
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1474-156
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1474-156.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1474-156.mis2
<400> 239
cttgtactca taagttaaat attgataaca agaagaaata tggactt                47
<210> 240
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1474-359
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1474-359.mis1
<221> primer_bind
<222> 25..47
```

```
<223> complement potential microsequencing oligo 99-1474-359.mis2
<400> 240
aaaaaaaatc aaattattgt accaaattcc ctaatatcag atgtgta                     47
<210> 241
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1479-158
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1479-158.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1479-158.mis2
<400> 241
tttaaaaatc cacttgtaat cgccgctaat tggagtgtat attcagg                     47
<210> 242
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1479-379
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1479-379.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1479-379.mis2
<400> 242
gtagagctgt gtactgaggt cagagaagca gctcatggta cagcctt                     47
<210> 243
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-129
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-129.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-129.mis2
<400> 243
ttcatatcta tacaaataat tttaaattta atacataggg ctgcaaa                     47
<210> 244
```

148

```
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-132
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-132.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-132.mis2
<400> 244
atatctatac aaataatttt gaacttaata catagggctg caaaaca                 47
<210> 245
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-139
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-139.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-139.mis2
<400> 245
tacaaataat tttgaattta atacatagggg ctgcaaaaca aggttga               47
<210> 246
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-140
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-140.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-140.mis2
<400> 246
acaaataatt ttgaatttaa tacatagggc tgcaaaacaa ggttgat              47
<210> 247
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
```

```
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-182
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-182.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-182.mis2
<400> 247
ttgatgttga tatgggcaac tgtatgttgg atggtcccaa agcattc              47
<210> 248
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-366
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-366.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-366.mis2
<400> 248
tccttgtcaa aggtctctcc ctggtgctca cggctgccgc ctcaaag              47
<210> 249
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-148-76
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-148-76.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-148-76.mis2
<400> 249
tgatagaatg ccttcctgaa ttactactct tgatggcttc ataaaac             47
<210> 250
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1480-290
<221> allele
```

150

```
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1480-290.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1480-290.mis2
<400> 250
tgcaccatct tcaccacaac cccgggcaac cactgatcct tttactg                    47
<210> 251
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1481-285
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1481-285.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1481-285.mis2
<400> 251
tcccataacc tgttttgctt ctcgctctaa cctcaagatg gtataaa                    47
<210> 252
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1484-101
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1484-101.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1484-101.mis2
<400> 252
aaaaagatca aatataagca tgtaactcct ctccttaaaa tctcagt                    47
<210> 253
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1484-328
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
```

<223> potential microsequencing oligo 99-1484-328.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1484-328.mis2
<400> 253
ggacacgtgg tcatgaggag tttgaaggga ttcagttttc agatccc                    47
<210> 254
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1485-251
<221> allele
<222> 24
<223> polymorphic base G
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1485-251.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1485-251.mis2
<400> 254
gattgccttg atatatgctc ccagagaacc aagaatgtcc cctttc                     47
<210> 255
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1490-381
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1490-381.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1490-381.mis2
<400> 255
tgcacagtgg aaataccatg tcacggtacg ctactgtgca tctcttc                    47
<210> 256
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-1493-280
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-1493-280.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-1493-280.mis2

152

```
<400> 256
ggatgacaga gtattgttgg aggaatgggg tttggctgct tgttttt                    47
<210> 257
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-151-94
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-151-94.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-151-94.mis2
<400> 257
attgagatca ttgataagga aatattctaa aatttcaaaa tctatat                    47
<210> 258
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-211-291
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-211-291.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-211-291.mis2
<400> 258
ctggttatat cagactgacc ttcatgtttt caacaggtca atgcctt                    47
<210> 259
<211> 45
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..45
<223> polymorphic fragment 99-213-37
<221> allele
<222> 23
<223> polymorphic base T
<221> primer_bind
<222> 1..22
<223> potential microsequencing oligo 99-213-37.mis1
<221> primer_bind
<222> 24..45
<223> complement potential microsequencing oligo 99-213-37.mis2
<400> 259
gtgcttccgg ctgcaggact gttggaggac tccagtgtct gacag                      45
<210> 260
<211> 47
```

```
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-221-442
<221> allele
<222> 24
<223> polymorphic base A
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-221-442.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-221-442.mis2
<400> 260
tgcctttgta gatatgcatg ggaattccat gacctagcca gacgaat                  47
<210> 261
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 99-222-109
<221> allele
<222> 24
<223> polymorphic base C
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 99-222-109.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 99-222-109.mis2
<400> 261
caggtgagga gtgctggatt ggccacgata tgaatttctt cagcagt                  47
<210> 262
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
<222> 1..47
<223> polymorphic fragment 4-14-107, variant version of SEQ ID185
<221> allele
<222> 24
<223> base G ; A in SEQ ID185
<221> primer_bind
<222> 1..23
<223> potential microsequencing oligo 4-14-107.mis1
<221> primer_bind
<222> 25..47
<223> complement potential microsequencing oligo 4-14-107.mis2
<400> 262
ctaaacaacc accaaatgca tacggcaacc aggcaaatgc ctgatag                  47
<210> 263
<211> 47
<212> DNA
<213> Homo Sapiens
<220>
<221> allele
```